"","analysisId","nctId","pValue","statisticalMethod","studyType","EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","outcomeTitle","outcomeType","groupDescription","conditionIds","briefTitle","has_less_than","N","model","I","R","C","JAB"
"1","000b15fd0f89314c7a8a6d517f05f580","NCT01695863",0.042,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Renal Function Pre and Post Bowel Prep (mg/dL)","SECONDARY","Sodium","D015179","Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep",FALSE,128,"t-test",NA,NA,NA,1.45436033935212
"2","00217bfeac2a793d634de9d6304b4337","NCT00910689",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change in Quality of Life at Month 16","SECONDARY","Post-test contrast. Mean difference in change.","D008881; D006261","Drug and Non-Drug Treatment Of Severe Migraine",FALSE,108,"t-test",NA,NA,NA,1.00825566060259
"3","0049049023adbbc782eb3eb8fa2e7687","NCT01056718",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Resting Systolic BP","PRIMARY","Nebivolol treatment group refers to 50 patients that completed 10 weeks of open label nebivolol treatment. Results were compared using paired T-tests in a pre - post study design before and after 10 weeks of treatment. Each subject served as his/her own control.","D006973; D054160","Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function",TRUE,50,"t-test",NA,NA,NA,1.07648023860356
"4","0059cb3359eae93692edcc9e8020bce1","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Specific Perceived Healthfulness","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1750,"linear_regression",NA,NA,NA,6.13526752012651
"5","005a1ae8196e41c451233629925ff0f5","NCT02939131",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Depression Outcomes: Quick Inventory of Depression Symptomatology Self-Report (QIDS-SR) Response to Treatment Over 48 Weeks, Defined as a Decrease in QIDS-SR Score by > 50%","SECONDARY","We tested the null hypothesis that the treatment group means were equal vs. not.","D003863; D003866","IMPAACT 2002: Cognitive Behavioral Therapy and Medication Management for Treatment of Depression in US Youth With HIV",FALSE,126,"t-test",NA,NA,NA,1.66971913113983
"6","006fd0cb04bfd97ec1eb48be8ac17ba9","NCT03163264",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Mean Weight Change in Kg","PRIMARY",NA,"D050177","The Peer Assisted Lifestyle Intervention",FALSE,281,"mann_whitney",NA,NA,NA,2.47263222241364
"7","00a1e2b752f343dfa84d48bb74aac05c","NCT02528253",0.0235,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 4, \>=50%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1011,"logistic_regression",NA,NA,NA,2.45053077955471
"8","00a3a149908704414eb388ceecbfeefb","NCT00591578",0.015,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg.","SECONDARY",NA,"D006973; D000075222","Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension",FALSE,633,"logistic_regression",NA,NA,NA,1.31215998662274
"9","00ac46f4b74c3526b34aae4d6589e3fc","NCT01945034",0.043,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","SECONDARY","At Rest Day 4(AM): The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms. Upper limit of 95% CI \< 0 for Ibuprofen treatment significantly better than combined Placebo.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,219,"anova",2,NA,NA,1.92742522970739
"10","00b982f501b22671ec77df342f94ccaa","NCT03670810",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Pain Freedom, Pain Relief, Freedom From MBS, and No Disability Postdose During First Attack","SECONDARY","Freedom from MBS 1 Hour 200 mg","D008881","A Study of Lasmiditan (LY573144) Over Four Migraine Attacks",FALSE,877,"logistic_regression",NA,NA,NA,2.81874643634291
"11","00dff307c271f65d9e080c41bcfe6591","NCT01219959",0.029,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline of Nutritional Status Determined by Albumin and Total Protein (Labs) at Month 3 and 6","SECONDARY","Estimate of Least Square Means Comparing Treatment Groups for Albumin-Month 6","D007676","Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients",FALSE,251,"anova",2,NA,NA,1.47464458060979
"12","00ef12715d23258b506781f6cc97e174","NCT02528253",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants Who Responded for Chronic Low Back Pain Responder Index at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56","SECONDARY","Week 2: OR and 95% CI estimated from logistic regression model. Logistic regression model included treatment as fixed effect and baseline average LBPI, baseline PGA, and baseline RMDQ as covariates.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1009,"logistic_regression",NA,NA,NA,3.0223812983612
"13","00fe50cdb725fc49ef264f1684e0f1f4","NCT01245439",0.048,"Wilcoxon","INTERVENTIONAL",0,0,0,1,0,"Mean Number of Tender and Swollen Joints","SECONDARY","Change in Swollen Joints from Visit 7 to Visit 8","D001168; D001172","A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis",FALSE,65,"wilcoxon",NA,NA,NA,1.1761865868564
"14","01039b760aa9a4f5e97da02d5f732f01","NCT00443872",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Beck Depression Inventory for All Subjects","SECONDARY",NA,"D010300","Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists",FALSE,60,"mann_whitney",NA,NA,NA,1.17169922891753
"15","010ae36fac752441c8fb52130fab79b1","NCT05893862",0.0282,"Two-sample t-test","INTERVENTIONAL",0,1,0,0,0,"Change From Baseline in QT Interval Corrected for Heart Rate (QTc) Following Moxifloxacin Treatment","SECONDARY",NA,"D012559","A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019)",FALSE,168,"t-test",NA,NA,NA,1.18342806774251
"16","011bcefd17641cf871ca64734cab72e6","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Fasting Plamsa Glucagon","SECONDARY","Difference in treatment effect between the 2 groups","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",FALSE,50,"t-test",NA,NA,NA,1.07648023860356
"17","011d72e608817eff8f8beb417f187a35","NCT03279458",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Tidal Volume of Each Breath Was Measured Using the Same Breathing Mask CPAP Apparatus Combined With Respiratory Monitoring Device Allowing for Simultaneous Recording.","PRIMARY",NA,NA,"Non-invasive Tidal Volume Monitoring Using the Linshom Respiratory Monitoring Device",TRUE,60,"linear_regression",NA,NA,NA,1.17169922891753
"18","012616c24811584ede671489139063a6","NCT00408876",0.044,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Vital Signs - Pulse Rate","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,166,"t-test",NA,NA,NA,1.71588941288951
"19","0137e396a3fa7c160156bbd227f90ff5","NCT01049373",0.0465,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change in Pain Score (SES), Subscale ""Sensoric Pain""","SECONDARY",NA,"D001416; D017116","Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain",FALSE,185,"mann_whitney",NA,NA,NA,1.89495545737712
"20","0139466486b0cddf00bb52c76f24a7d4","NCT00663923",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Correction of Astigmatism","PRIMARY",NA,"D001251","Comparison of Cross-cylinder and Conventional Photorefractive Keratectomy(PRK) in Correcting Medium-high Astigmatism",TRUE,96,"t-test",NA,NA,NA,1.46440978390488
"21","0140151d169e1dd8f9fe8e245c6277cc","NCT00245219",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Physical Health (as Measured With the SF36) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the peer support condition and control condition at Time 3, among both late and early stage patients. The full regression model consisted of 3 steps: The 1st step contained the baseline measure of the dependent variable. The 2nd step contained two dummy coded variables contrasting each condition with control. The 3rd step contained the interaction between the peer support condition and cancer stage. Patients in the education condition were excluded from this analysis.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"linear_regression",NA,NA,NA,1.79957957739554
"22","0141f77f24e593b6edaf1138228ab488","NCT00475904",0.0441,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change in Pain Scores Comparing NP-1 Cream vs. Placebo Cream for Treatment of the Pain of Post Herpetic Neuralgia(PHN)From Baseline to 28 Days.","PRIMARY","In the initial analysis, the efficacy of the test treatment NP-1 cream was compared with placebo using an analysis of variance (ANOVA). The analysis was conducted using the ITT population to compare the mean changes in pain scores from baseline to endpoint for the 2 treatments; the LOCF approach was employed for patients who did not complete the trial.","D009437; D051474","A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)",FALSE,211,"anova",2,NA,NA,1.93318366859218
"23","014d4247c570575faad9bda39c300a2d","NCT04833777",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Post-operative Pain","PRIMARY",NA,"D002349","Does a Different Local Anesthetic Improve Pain After Carpal Tunnel Release?",TRUE,139,"mann_whitney",NA,NA,NA,1.75124288073831
"24","015bd20d4a1846498beba5e9d029ffc2","NCT04172701",0.0103,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Adjusted All-cause Costs: Hospitalization Costs (Per Person Per Month)","SECONDARY",NA,"D029424","A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)",FALSE,4888,"t-test",NA,NA,NA,2.60338427775782
"25","01613b31745a34b62c0eff1c23b9adae","NCT00070707",0.038,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in AM and PM Chest Tightness Symptom Score","SECONDARY","Change at Week 1 (AM)","D012220; D001249; D006255; D065631","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",FALSE,187,"anova",2,NA,NA,1.60729714845832
"26","01741ad1eaf35a97721faf806cf057d0","NCT03597464",0.045,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Renal Flare as Adjudicated by the Clinical Endpoints Committee (CEC).","SECONDARY","Number of subjects with adequate renal response. This model is based on a logistic regression with terms for treatment, baseline urine protein creatinine ratio (UPCR), biopsy class, mycophenolate mofetil (MMF) use at baseline and region. An odds ratio \< unity indicates benefit for voclosporin.","D009393; D008181","Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin",FALSE,216,"logistic_regression",NA,NA,NA,1.98897982111762
"27","01889f4df66de4f3b6e7e2ecc7f3eedb","NCT02303704",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Pharmacologic Inotropic Support (Adrenaline)","SECONDARY",NA,NA,"Myocardial Protection With Multiport Antegrade Cold Blood Cardioplegia",TRUE,434,"t-test",NA,NA,NA,3.06552394865376
"28","018a91adce533ac19d7220fbe05bf66c","NCT00150969",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Percent Change in Bone Mineral Density (BMD) at the Total Hip Between Treatment Arms.","PRIMARY",NA,"D010024; D001851; D015663","Vitamin K Supplementation in Post-Menopausal Osteopenia",TRUE,440,"t-test",NA,NA,NA,3.08645519783843
"29","018b6e55bd0bf5b7c5ddd47af1a6365a","NCT02697422",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Low Density Lipoprotein Cholesterol (LDL-c).","SECONDARY",NA,"D002318; D006949","Veteran Peer Coaches Optimizing and Advancing Cardiac Health",FALSE,264,"linear_regression",NA,NA,NA,2.39772562409599
"30","01a6ae05b082fcf6fcf50191fe8b8642","NCT01014910",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Length of Stay in the Hospital","PRIMARY","Differences in LOS were compared between study arms using the Mann-Whitney U-test and the Kaplan-Meier method. Statistical analyses were performed using Stata version 13.1 for Windows (StataCorp). All patients enrolled in the study, including those who subsequently had consent for the intervention withdrawn, were included for analysis (intention to treat).","D001988; D000860","Intermittent Versus Continuous Pulse Oximetry Monitoring of Infants Admitted for Bronchiolitis",TRUE,161,"mann_whitney",NA,NA,NA,1.88118663862499
"31","01bb6a3c4be819748c85c9b0de4ad075","NCT02481596",0.024,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Supportive Family Behaviors","SECONDARY","3 months. Multiply imputed data (m=20) using chained equations.","D003920; D003924","FAMS Mobile Health Intervention for Diabetes Self-care Support",FALSE,379,"linear_regression",NA,NA,NA,1.53445158002198
"32","01c17cfeb723adf3fdc12dc75238acbb","NCT03064113",0.048,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Peak Expiratory Flow Rate (PEFR) From 25% to 75% of Vital Capacity (FEF25-75), as Related to FEV1","SECONDARY","Tx Difference of LS Mean 24 hr","D008171; D008173; D029424","Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",FALSE,64,"t-test",NA,NA,NA,1.16765253868256
"33","01e5960d67c236101d62224a3936aef7","NCT00174915",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change in the Total Number of Tophi at Week 28 in the Subset of Subjects With Palpable Tophi at the Screening Visit.","SECONDARY",NA,"D006073","Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.",FALSE,60,"mann_whitney",NA,NA,NA,1.17169922891753
"34","01f74e6f302db5eb4fd00cd2b47b11f9","NCT00234104",0.0459,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Body Weight","PRIMARY",NA,"D006333; D004487","A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)",FALSE,61,"t-test",NA,NA,NA,1.10017879043895
"35","0213d492acef588a1d989886ad5d84eb","NCT04076020",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Self-reported Adherence","PRIMARY","Difference in self-reported adherence reported across baseline, 4-, 8-, and 12-month visits using generalized estimating equations and adjusted for trial stratification factors.","D001281; D006331; D001145; D010335","Atrial Fibrillation Health Literacy and Information Technology Trial in Rural Pennsylvania Counties",TRUE,270,"logistic_regression",NA,NA,NA,2.42442742178718
"36","02157a7c5c0636a6da8e758670c73f4c","NCT01060059",0.026,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Factor of Greater Height Associated With Treatment Choice at Baseline","SECONDARY","Logistic regression analysis was used to determine if greater height (1 cm higher) was associated with treatment choice at baseline. Odds ratios were determined and if the odds ratio was greater than 1, it indicated it is more likely to initiate exenatide treatment. Covariates with more than 30% observations missing were omitted in this analysis. Missing values for remaining numeric covariates were replaced with means, and for categorical ones - with modes.","D003920; D003924","Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes",FALSE,881,"logistic_regression",NA,NA,NA,2.49760460754097
"37","0215fc87c4bd5f51d2d96d2e16c48d18","NCT00212134",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Parenting Stress","SECONDARY","ITT comparison of mean PSI scores","D002386; D001035","Infant Aphakia Treatment Study (IATS)",FALSE,81,"t-test",NA,NA,NA,1.3501394396673
"38","023027062f27b089cc4da77e7994316c","NCT03676465",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Mean Glucose by CGM","SECONDARY",NA,"D003920; D003922; D002908","CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management",FALSE,43,"t-test",NA,NA,NA,1.00454908915455
"39","02344a2d86149b66a0f4bb556c05f915","NCT01910116",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,1,0,"AUSCAN Function Change at 16 Weeks From Baseline","SECONDARY",NA,"D010003","Efficacy of Shinabro in Hand Osteoarthritis",FALSE,215,"mann_whitney",NA,NA,NA,2.1673890251257
"40","0242664aa7af594ba23b3415b25126b0","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Fasting Glycogenolysis","PRIMARY","Difference in treatment effect between groups was evaluated","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",FALSE,50,"t-test",NA,NA,NA,1.07648023860356
"41","02508db05bc9a1dff41c52238dbb6b3f","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in HbA1C","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,109,"anova",2,NA,NA,1.55669642807029
"42","025663f58347aad8c73945b4e156bc1f","NCT00105989",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Acute and Continuation Phases (Females)","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,286,"t-test",NA,NA,NA,2.49423565648373
"43","028f8681fc49134a2d9a0a3b5944c333","NCT00433290",0.042,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Statisically Significant Change From Baseline to 13 Week Endpoint in Chloride","SECONDARY",NA,"D010003; D020370","Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain",FALSE,246,"anova",2,NA,NA,2.0006428538477
"44","029199510479bb57a4c67e23b9ccc6da","NCT02528253",0.0101,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 16, \>=50%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,810,"logistic_regression",NA,NA,NA,1.04499808857622
"45","02cc05fa0df7844558083059adf822fa","NCT04445792",0.0119,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Sleep Disturbance as Measured by PROMIS (Patient-Reported Outcomes Measurement Information System)","SECONDARY",NA,"D059350; D059787; D003863; D003866","A Depression and Opioid Pragmatic Trial in Pharmacogenetics (DCRI Coordinating Center)",FALSE,1112,"mann_whitney",NA,NA,NA,1.41474353449606
"46","02d0a24f5769f31c6dd22bb85731edca","NCT01134783",0.049,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Prevalence of Overweight/Obese","SECONDARY",NA,NA,"Choosing Healthy Options in College Environments and Settings",FALSE,179,"logistic_regression",NA,NA,NA,1.94807427189901
"47","02d0a2960472a30543990df94d608d4e","NCT01131299",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Small LDL Particle Number (by NMR Spectrometry of Lipoproteins) After 12-14 Weeks Intervention, Compared to Baseline for Alpha-cyclodextrin (a-CD) and Placebo Groups After 12-14 Weeks, Compared to Baseline","SECONDARY",NA,"D002318","Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol",FALSE,150,"t-test",NA,NA,NA,1.5074733457683
"48","02fffd264db23cc01def0cdb0b0ebafd","NCT03726489",0.048,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Physician Global Assessment Times Body Surface Area (PGAxBSA)","SECONDARY","Overall analysis adjusted for all skin phototypes","D011565","Light Treatment Effectiveness (LITE) Study",FALSE,472,"linear_regression",NA,NA,NA,3.088354660063
"49","0304161403521e9920d7b2728c92025c","NCT02037776",0.038,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Patient's Evaluation of Symptomatic Improvement by Overall Treatment Efficacy (OTE)","PRIMARY","Comparison between groups in Rikkunshito Placebo and Rikkunshito, based on the count of participants categorized in 1 (Significantly improved) through 7 (Much worse), using the Wilcoxon (Mann-Whitney).","D004415","The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia",FALSE,125,"mann_whitney",NA,NA,NA,1.32163006558525
"50","030ea8badce454e5b62f6659a64ac8ea","NCT03773978",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving PedACR90 Responder Index","SECONDARY","at week 20","D001168; D001171","A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis",FALSE,163,"logistic_regression",NA,NA,NA,1.22958247273945
"51","0340c411fd4b6d9354231212bc487c2a","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Alkaline Phosphatase Value at Baseline and After Treatment Completion","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"52","0376c51af402155ce928d000d41d3aa5","NCT02559609",0.024,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Longest Duration of Alcohol Abstinence (Days) (Physiological Measure)","SECONDARY","Group A/C (contrast -1) compared to Group B/D (contrast 1) to test Aim 1.",NA,"Interventions for Unemployed Hazardous Drinkers",FALSE,234,"mann_whitney",NA,NA,NA,1.21073826660967
"53","03a1f58c7d84e9a2501b04dcbdb453b2","NCT01138124",0.0337,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","PRIMARY",NA,"D010190; D002292; D007680; D010386; D010195; D050500; D012148","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",FALSE,30026,"logistic_regression",NA,NA,NA,18.1751377246872
"54","03ae94ccfb4d2207885f191051b32932","NCT00245219",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Depressive Symptoms (as Measured With the CES-D) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the education condition and the control condition at Time 3. The full regression model included 2 dummy coded variables, 1 contrasting the education and control condition, and 1 contrasting the peer support and control condition. The baseline measure of the outcome variable was included, in order to examine changes in the outcomes over time. This model tested the main effects of the conditions among patients with early stage cancer, late stage patients were excluded.","D001943","Understanding Shared Psychobiological Pathways",FALSE,131,"logistic_regression",NA,NA,NA,1.70153588988359
"55","03b87fa3a9cfac3f4d3a028c047b1210","NCT02572401",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Proportion Condom-protected Intercourse","SECONDARY","The primary analysis tested the efficacy of the HIV risk reduction intervention by comparing the HIV Risk Reduction Only and HIV Risk Reduction and Text Messaging Arms to the Text Messaging Only and No-Intervention No Text Message Control Arms. This is a test of the main effect of the HIV risk reduction intervention.","D000163; D015658; D012749; D007153","Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men",TRUE,268,"linear_regression",NA,NA,NA,2.41555960484265
"56","03ce9a18b303380e14c571babb4ccea0","NCT00256750",0.0276,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire","SECONDARY","Physical Functioning, Month 24","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,424,"anova",2,NA,NA,1.82969463226566
"57","03d486eaf1bf050dc3d5ece28b2eca9c","NCT00684060",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Regional Left Ventricular Function (Border Zone Wall Motion)","PRIMARY","Comparison of change in border zone wall motion in the active group minus change in global LVEF in the control group. 80 percent power based on BOOST results","D018754; D018487","Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)",TRUE,76,"t-test",NA,NA,NA,1.30984657914153
"58","03db1b4cc38680ec345c1d7f8bdc603d","NCT00116584",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change in Modified Wood's Clinical Bronchiolitis Score (MWCBS) Between Oxygen and Heliox Groups at Various Times","SECONDARY",NA,"D001988","Heliox-Driven Racemic Epinephrine in Treatment of Bronchiolitis in Pediatric ED Patients",TRUE,69,"mann_whitney",NA,NA,NA,1.25127183253256
"59","03f4ae1b35f0678e43f82a2de2fe4f40","NCT00256750",0.016,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire","SECONDARY","Vitality, Month 12","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,424,"anova",2,NA,NA,1.13913896833781
"60","0408fcde3db4476aa0a5c9a8de0c70a6","NCT00386425",0.047,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Mean Change in Protein C Level From Study Day 1 to Study Day 7 in Patients With Moderate and Severe Protein C Deficiency","SECONDARY",NA,"D018805; D014115","Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)",FALSE,433,"t-test",NA,NA,NA,2.90731649600765
"61","040be5f878727960b42ee3b6f299f564","NCT02347787",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants With 30 Day Hospital Readmissions","SECONDARY",NA,"D002908; D014029","A Multi-center Trial of IMPaCT CHW Support for Chronically-ill Patients",FALSE,176,"logistic_regression",NA,NA,NA,1.62951484633317
"62","041422c5443cbebb2b90d48b767293f5","NCT03687762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in Pain Intensity (Macro-level)","SECONDARY",NA,"D059350","Back on Track to Healthy Living Study",FALSE,302,"anova",3,NA,NA,1.03237942189705
"63","041f7693a1d591c1fd1aff5a479b2d50","NCT00105989",0.035,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Alanine Aminotransferase (ALT) - Maintenance Phase","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,276,"anova",2,NA,NA,1.81423831177251
"64","04258de1293191c732a3470bf3a2e90b","NCT02528253",0.0179,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 48, \>=70%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1010,"logistic_regression",NA,NA,NA,1.93222696415266
"65","043ae49a7a7bddf150f9e7586dc12745","NCT00767806",0.019,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to 12 Week Endpoint in Total Protein","SECONDARY","Tested was the null hypothesis that there is no difference between placebo and duloxetine groups in change of total protein during 12 weeks of treatment.","D001416; D017116","A Study for Patient With Chronic Low Back Pain",FALSE,384,"anova",2,NA,NA,1.26077541508344
"66","044fa2b56e66a2186ab4d6895da01aea","NCT02697773",0.0335,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants Who Withdrew Due to Lack of Efficacy","SECONDARY","Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,465,"logistic_regression",NA,NA,NA,2.26111427448128
"67","0454cf5700d29df86d53d096ee8e4e28","NCT03035916",0.045,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Anesthesia Recovery: Number of Participants With Prolonged Hospitalization","SECONDARY",NA,NA,"Transversus Abdominis Plane Block on Stress Response",FALSE,59,"t-test",NA,NA,NA,1.06556506237742
"68","0489d1d467c34040c9037ec4c2a56309","NCT04302545",0.021,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Composite Micturition Problems During Hospital Stay","SECONDARY",NA,"D014947","Cystoinflation to Prevent Bladder Injury in Obstetrics and Gynaecology Surgery",FALSE,207,"linear_regression",NA,NA,NA,1.01595583273406
"69","049c999281ddef2e130a7a21da4170a7","NCT01640197",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Chronic Modulation of Cerebral Blood Flow","PRIMARY",NA,NA,"Chronic Resveratrol Supplementation in Healthy Humans",FALSE,46,"anova",2,NA,NA,1.03597838019194
"70","049d36f354765e828f7ac0bfbbf77468","NCT01098747",0.044,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Sum of Pain Relief Rating and Pain Intensity Difference (PRID)","SECONDARY","7 hours: Treatment difference \[Ibuprofen sodium - Ibuprofen (Advil + Motrin IB)\] and corresponding 95% CI were calculated based on LS means from the ANOVA model.","D014098","Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain",FALSE,268,"anova",2,NA,NA,2.17011639212768
"71","049ee5f84f396876d120d53055cffe1b","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Total Energy Intake at Follow-up","SECONDARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,97,"anova",2,NA,NA,1.47171356596352
"72","04b202f20a750323d975dbfff90e2688","NCT04876482",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Tongue Elevation Muscle Strength","PRIMARY","We hypothesized that the improvements in the tongue elevation muscle strength would be more in patients who underwent TORS combined with OPR than in those who underwent only TORS and those who received conservative treatment (controls).","D001049; D012891; D020181","Myofunctional Training for Obstructive Sleep Apnea Patients After Transoral Robotic Surgery",TRUE,74,"linear_regression",NA,NA,NA,1.2933799900503
"73","04bf997f5f564387600960f4150c120c","NCT01945034",0.04,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","SECONDARY","At Rest Day 4 Mid-day: The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,152,"anova",2,NA,NA,1.51720918816802
"74","04c3a528cded1bfde0fe42bc5556d467","NCT03645954",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Postoperative Pain Intensity and Pain Control","PRIMARY",NA,NA,"Femoral Triangle and Adductor Canal Blocks Versus Femoral Nerve Block for Total Knee Arthroplasty",FALSE,77,"t-test",NA,NA,NA,1.31800316623017
"75","04d3639459d3d4494cfd9e25b0037f80","NCT02912650",0.018,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Relief Rating (PRR) Score","OTHER_PRE_SPECIFIED","8 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,347,"anova",2,NA,NA,1.14413791910448
"76","04e3ec56c1f146b4bef6233c150a0c95","NCT04427501",0.034,"Logistic regression","INTERVENTIONAL",0,0,1,1,0,"Phase 2: Percentage of Participants Demonstrating Symptom Resolution","SECONDARY",NA,"D000086382","A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness",FALSE,253,"logistic_regression",NA,NA,NA,1.69592035150336
"77","04f12f40d697f230c771ed57f2337d4d","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Health Warning Label","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1750,"linear_regression",NA,NA,NA,6.13526752012651
"78","04f8529e63a017fda3a52d14db4d11d2","NCT00023595",0.009,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"H01: KCCQ Symptom Stability","SECONDARY",NA,"D006333; D002318; D006331; D003327","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",FALSE,1194,"mann_whitney",NA,NA,NA,1.14336521708696
"79","050a49aac7b67356e1c1bf6ecc2acb27","NCT00270998",0.048,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"No Bothersome Stress Incontinence Symptoms at 3 Months","PRIMARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",FALSE,299,"logistic_regression",NA,NA,NA,2.46395374770415
"80","0563369005452307ab6b60228d5ca777","NCT02980276",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Birth Weight >4000g","SECONDARY",NA,"D016640; D003920","RCT Metformin for Reduction of Gestational Diabetes Mellitus Effects",FALSE,524,"logistic_regression",NA,NA,NA,1.53720010503454
"81","05655271e137f3dec569ed8ba703827b","NCT00046475",0.026,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in The OHSA Items 2 Through 6 Scores","SECONDARY","Analysis of Item 5","D007024; D007022","A Study for Patients With Neurogenic Orthostatic Hypotension",FALSE,206,"anova",2,NA,NA,1.21891099786522
"82","05698f2e0d768002b054750a645eb837","NCT00452426",0.028,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Area Under the Curve for Oxygen Desaturation (AUCDesat)","PRIMARY",NA,NA,"Safety and Effectiveness of a Computer-Assisted Personalized Sedation (CAPS) Device for Propofol Delivery During Endoscopy",FALSE,977,"anova",2,NA,NA,2.80297255014578
"83","058602444455053356157c18991fed94","NCT01899144",0.0488,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Baseline-Adjusted Area-Under-The- Forced Expiratory Volume In 1 Second (FEV1) Versus Time Curve Over 6 Hours Post-Dose (FEV1 AUC0-6)","SECONDARY","Pre-specified, exploratory analysis","D001249","Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients",FALSE,118,"anova",2,NA,NA,1.58515559040288
"84","05870cbc4e509cba6181955bc11e9514","NCT01225822",0.0401,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Venous Thromboembolic (VTE) Events","PRIMARY","BIBR 1048 150 mg bid vs. Enoxaparin 40 mg qd comparison. Secondary analysis, active control used as reference. The statistical model was a logistic regression which included treatment and centre.","D013923; D054556","BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery",FALSE,757,"logistic_regression",NA,NA,NA,3.35563333179277
"85","058f21caa95b79fe74f64bae6fbaf63d","NCT02323204",0.0286,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Conduct Problems (SDQ Subscale) Through the First and Last Survey Administered Post-Baseline","PRIMARY","A Generalized Linear Mixed Model (GLMM) with log link and gamma distribution was fit to five imputed data sets. Obtained estimates and standard errors were adjusted accordingly.

A comparison of intervention efficacy was made through the intervention-time interaction effect included in the model. Statistical significance of the interaction effect is indicative of a difference in effect between interventions over time.","D014947; D000067073","PCORI-1306-02918 Evaluation of Parent-based Programs to Support Children After Traumatic Injury",FALSE,247,"t-test",NA,NA,NA,1.44575010033605
"86","05906de31abd4838716b36933141bac5","NCT05170841",0.042,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Total Pain Relief (TOTPAR) at 48h After the First Dose - Multiple Dose Phase - Dexketoprofen/Tramadol vs Tramadol","SECONDARY",NA,"D001416; D017116","Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain",FALSE,499,"t-test",NA,NA,NA,2.83727600960804
"87","059c1d6603af4a79bf8be32e03503758","NCT03480022",0.049,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"10% Body Weight Loss From Baseline","SECONDARY",NA,"D011085; D011236; D013577; D001835","Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS",TRUE,67,"mann_whitney",NA,NA,NA,1.21359894006401
"88","05ab6f367ed2083eda56d77abeced196","NCT00456092",0.028,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in the Functional Assessment of Chronic Illness Therapy for Fatigue (FACIT-F) at Week 12","SECONDARY",NA,"D001168; D015535","Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis",FALSE,131,"anova",2,NA,NA,1.04288685455502
"89","05b37d9d1bb2f19a17a5def88184effc","NCT02814565",0.0262,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Physician's Clinical Global Assessment on Days 7 and 15 of Treatment","SECONDARY","Day 15. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.","D013035; D001416; D019547; D017116","Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin",FALSE,180,"mann_whitney",NA,NA,NA,1.14892049429464
"90","05b71b4ec752cf12f39185cf46323a58","NCT04283994",0.023,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"EHR Documentation of Goals of Care Discussions","PRIMARY","A total sample size of 600 (200 per arm) would give 80% power to detect a difference in proportions of 0.16 for each of the 3 pairwise comparisons assuming an overall 0.5 significance threshold, a Bonferroni adjustment for the 3 comparisons, and variance based on a proportion of 0.54.","D009369; D009362; D008175; D008103; D008171; D029424; D017563; D051437; D007676; D006333; D014652; D016491; D058729; D002908","Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)",FALSE,414,"linear_regression",NA,NA,NA,1.54484346303315
"91","05baebe0fb52353f03ad4d6572b62a63","NCT05302414",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Knowledge of Teamwork Assessment","PRIMARY","For follow-up test at the 16 weeks.",NA,"The Learning Outcome of Resuscitation Teamwork Training in Postgraduate Year Doctors and Nurses",FALSE,64,"kruskal_wallis",2,NA,NA,1.20770700959599
"92","05bbf20a4308fdde29bb7a225a39b604","NCT01638000",0.009,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12","SECONDARY","Week 12 (≥1 point improvement) Odds Rato vs. Mirabegron","D053201; D014570; D001745","A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.",FALSE,1747,"logistic_regression",NA,NA,NA,1.381772317663
"93","05c05c3640766261d6ef65f2d8f0b47b","NCT01522755",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Impedance Measurements During and Post Implant of the CapsureFix MRI Lead Model 5086","PRIMARY",NA,"D001919","Predictive Factors of a Successful Implant of the CapsureFix MRI Model 5086",TRUE,409,"t-test",NA,NA,NA,2.97672685958764
"94","05dd05787534b7bbcc5169a24f9b71e0","NCT02267538",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Incidence of Non-delirium Complications After Surgery","SECONDARY",NA,"D003693; D011183","Dexmedetomidine and Delirium in Patients After Cardiac Surgery",FALSE,285,"logistic_regression",NA,NA,NA,2.48992995915375
"95","05e52cb6ea1ef3b9b8ae5515fd783e57","NCT02900378",0.0301,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Mean Daily Light Non-sedentary Daytime Physical Activity","SECONDARY","Change from BL at Week 4","D006333","randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure",FALSE,604,"mann_whitney",NA,NA,NA,2.34877718818499
"96","05ee280debc594fde8fb2abc13c80604","NCT05194956",0.0439,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Relative Speed of Impression","SECONDARY",NA,NA,"Orthodontic Patient Experience of Intraoral Scans Versus Alginate Impressions",FALSE,84,"anova",2,NA,NA,1.23290794063991
"97","05ff534033e7e1f9c4474050ea3d1fb0","NCT01236053",0.0138,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,20382,"logistic_regression",NA,NA,NA,6.88659951043447
"98","060189ea41389cef044e2459e7c8b6ee","NCT02858713",0.047,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Lattice-System Physician's Global Assessment (LS-PGA)","SECONDARY","LS-PGA: Change from baseline to week 4","D011565","Adherence in Topical Treatment of Psoriasis",FALSE,134,"linear_regression",NA,NA,NA,1.63386316143171
"99","0633eb96e75d684e02e9e8ce4181902b","NCT00453999",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Scores of Symptoms of Influenza","SECONDARY","Fatigue: change from Baseline at Days 2, 3, 4, 5, 10, 14","D007251","Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza",FALSE,122,"mann_whitney",NA,NA,NA,1.64382327798156
"100","063432339262c1944e1d8cd203b24a79","NCT04332614",0.0248,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Email Opened: Control vs. Less-is-better vs. Social Proof vs. Endowment","PRIMARY",NA,NA,"Email Campaign to Increase Uptake of myGeisinger",FALSE,8501,"logistic_regression",NA,NA,NA,7.42881999000529
"101","063818a1251f8fcc1adf50eb2e8e7f23","NCT03855189",0.04,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Response To Therapy At Day 8 (Participant-Evaluated)","SECONDARY","Pairwise treatment comparison based on t-test from an analysis of variance (ANOVA).","D012220; D065631; D006255","Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)",FALSE,223,"anova",2,NA,NA,1.82960616278853
"102","0655ca5f7ac30058030ebd08501aa65e","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Environment)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1754,"linear_regression",NA,NA,NA,6.14225987828851
"103","065673c665ffad05acf29fe2559c8015","NCT02312154",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Erythema Index","PRIMARY","The change in each of the biophysical parameters was calculated as the pretreatment value minus the posttreatment value for each visit, and these pre- vs posttreatment changes were used in the statistical analysis to minimize the intraindividual variation between the two cheeks. The Wilcoxon rank-sum test was performed to compare the week-by-week changes in parameters of the right and left cheeks (i.e., treated vs untreated).",NA,"Changing in Skin Physiology After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces",TRUE,48,"mann_whitney",NA,NA,NA,1.05642048349345
"104","065f7917ad2c58403157b5f1551a6ac0","NCT05919082",0.0438,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Physician's Global Assessment of Disease Severity (PGA) Score of 0 (Clear) or 1 (Almost Clear) at Day 29, With at Least a 2-point Reduction From Baseline","PRIMARY",NA,"D011565","A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis",FALSE,604,"logistic_regression",NA,NA,NA,3.23175074037193
"105","067606e72d1495f6b57ebaccfd0279d3","NCT02912650",0.038,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Relief Rating (PRR) Score","OTHER_PRE_SPECIFIED","10 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,228,"anova",2,NA,NA,1.77110309175734
"106","069072107caffd695b4f906f933020df","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Total Urinary Isoflavones","SECONDARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,98,"anova",2,NA,NA,1.47898140162831
"107","069b68fdca37c072446d901e1aff7014","NCT01368042",0.02,"Wilcoxon","OBSERVATIONAL",0,0,0,0,0,"Change From Enrollment to 6 Months in Parathyroid Hormone (PTH) Levels (pg/mL)","SECONDARY",NA,"D007674; D051436; D006961; D006962","Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous",FALSE,254,"wilcoxon",NA,NA,NA,1.07613213202089
"108","06a58250eaeb879d9ff835c6180842bf","NCT01638000",0.026,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Normalization of Micturitions at Weeks 4, 8, 12 and Final Visit","SECONDARY","Week 8 Odds ratio vs. Mirabegron","D053201; D014570; D001745","A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.",FALSE,1833,"logistic_regression",NA,NA,NA,3.59734865821954
"109","06ba4f3c94c3af6180d51f770bbf4e8a","NCT02732145",0.0412,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Various Characteristics and Duration of Vulvar Discomfort in Patients With Vulvar Dermatosis and Vulvodynia","SECONDARY","Parameter: The difference in the incidence of vulvar sticking versus paper-cuts pain in patients with vulvodynia who had sharp vulvar pain.","D056650; D008010; D018459; D012871; D009450","Diagnostic Accuracy of ""Three Rings Vulvoscopy"" for Detection of Vulvar Dermatosis",FALSE,82,"t-test",NA,NA,NA,1.15591010655605
"110","06c7795a87e29f0cf24a3b42bc9b75db","NCT05182840",0.0348,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Multiple Imputation","SECONDARY","The odds ratio, 95% confidence interval, and p-value were calculated based on logistic regression of binary outcome adjusting for treatment, and stratification factors as covariates.

Randomisation stratification was used, which is based on estimated glomerular filtration rate (eGFR) and urine albumin creatinine ratio (UACR) levels at screening.","D007674; D051436","A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease",FALSE,127,"logistic_regression",NA,NA,NA,1.23633578870849
"111","06e3dd47d9b387db57ab3ee8d50cec95","NCT03203512",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Ex Vivo Agonist-stimulated Platelet Activation Detected by Plate-based Platelet Aggregation Assay (CRP-XL Log EC50)","SECONDARY","Null hypothesis is that there was no difference in change of platelet function in affecting LogEC50 values in response to CRP-XL between fish oil and placebo capsules. Comparisons of this parameter after each intervention were drawn using 2-way ANOVA with the Turkey multiple comparisons test.","D001768","Fish Oil-derived N-3 Polyunsaturated Fatty Acids and Extracellular Vesicles",FALSE,80,"anova",2,NA,NA,1.34217713699512
"112","06e847e65a32cdd47f8cddb801eb83a3","NCT03982368",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Patient Global Impression of Change (PGIC) - Per Protocol Set","SECONDARY","at week 12 (FUP)","D015352; D007638","A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye",FALSE,152,"mann_whitney",NA,NA,NA,1.82914240849702
"113","06f1a8df74d8742cb398aa351057a455","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Systolic Blood Pressure at Screening/Visit 1, Visit 2, and Visit 3","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"114","06fcff60314abccf977fb549b27fa4f6","NCT00270998",0.0492,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"No Bothersome Stress Incontinence Symptoms at 12 Months.","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",TRUE,299,"logistic_regression",NA,NA,NA,2.51540237553809
"115","070dc4112a8f0d1caa3d7c18cb0a5097","NCT03192176",0.0359,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 3 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 3","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.03563343281231
"116","070ee5d9857ce8710fe5717eecacd0df","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Tax","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1770,"linear_regression",NA,NA,NA,6.17015007090058
"117","073408dc0c5be3b1dd31a44c8f101cca","NCT03733301",0.022,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)","SECONDARY",NA,"D003876; D003872; D004485","A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis",FALSE,220,"logistic_regression",NA,NA,NA,1.089635791202
"118","073cb31af4dfe1bd7e2853ba05f464d1","NCT02633358",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Interleukin-6/Soluble Interleukin-6 Receptor Complex - the Plasma Level of Participants","OTHER_PRE_SPECIFIED",NA,"D006323; D012770; D007035","Anti-inflammatory Effect of Therapeutic Hypothermia in Out-hospital Cardiac Arrest Patients With Cardiogenic Shock",TRUE,141,"t-test",NA,NA,NA,1.76345107862741
"119","075c333e6c9593a4cef9cbcf81243a99","NCT02259127",0.0435,"Logistic regression","INTERVENTIONAL",0,0,1,1,0,"HIV-1 RNA <50c/ml at 96 Weeks","SECONDARY","Statistical Analysis Title: Adjusted Difference (ODYSSEY B \>=14kg)

Number of subjects included in analysis: 381

Analysis Specification: Pre-specified","D007239; D015658; D000163","ODYSSEY (PENTA 20)",FALSE,381,"logistic_regression",NA,NA,NA,2.55695300502333
"120","0762d788d30bea044e9f39b55989b6f5","NCT02528188",0.006,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 4: \>=70% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,1.02602381662469
"121","07677b438902f30086647427bab32f00","NCT00550147",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"CGI-S: Clinical Global Improvement Scale","SECONDARY","This was a repeated-measures analysis, using a single group of subjects who were administered quetiapine in addition to OROS mph. Results reported here are for the augmentation period (Visit 5-10). See Kronenberger et al. (2007, Journal of Child and Adolescent Psychopharmacology) for additional information.","D001289; D000374","Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.",TRUE,48,"t-test",NA,NA,NA,1.05642048349345
"122","0768c8cca42451627ae4844705900b7c","NCT03726489",0.0127,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cumulative Dose of Phototherapy Received","SECONDARY","Analysis for Phototypes V/VI","D011565","Light Treatment Effectiveness (LITE) Study",FALSE,541,"linear_regression",NA,NA,NA,1.04836935152761
"123","0780933d35c540f8fac9ec86bad6e6eb","NCT01484912",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change in Total Exercise Time","PRIMARY","T-test was used to compare the change in total exercise time between the treatment groups. The change in total exercise time (△) was defined as the total exercise time at end-point visit minus the total exercise time at baseline. Let △T be the change in total exercise time for treatment group (STA-2) and △C be the change in total exercise time for control group (Placebo). The hypothesis testing for the superiority of STA-2 to Placebo was H0：△T-△C≦0 with H1：△T-△C﹥0.","D000787; D060050","Phase II Study of STA-2 in Patients With Chronic Stable Angina",FALSE,77,"t-test",NA,NA,NA,1.31800316623017
"124","07925708293e496b64d5d3f0ecb3191a","NCT00550147",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"RAAPP: Rating of Aggression Against People and/or Property Scale","PRIMARY","This was a repeated-measures analysis, using a single group of subjects who were administered quetiapine in addition to OROS mph. See Kronenberger et al. (2007, Journal of Child and Adolescent Psychopharmacology) for additional information.","D001289; D000374","Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.",TRUE,48,"t-test",NA,NA,NA,1.05642048349345
"125","079e25c5fa0d4770351b4722417bbbe3","NCT02528188",0.0059,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Meeting Outcome Measures in Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Responder Index at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 4","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1998,"logistic_regression",NA,NA,NA,1.0116180724855
"126","07a7243bdd273d22e480da004af7af4d","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient-Reported Outcomes Measurement Information System (PROMIS Short Forms 8a - Pediatrics v. 2.0) is a Set of Person-centered Measures That Evaluates and Monitors Physical, Mental, and Social Health in Children and Adolescents.","SECONDARY","These are the 12 month outcomes for Emotional distress - anxiety. See earlier comments.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,126,"t-test",NA,NA,NA,1.66971913113983
"127","07acb3f2a017bad8f2000c231ef2185d","NCT00930943",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Spatial Recognition Memory (SRM) Test Percentage of Correct Hits","SECONDARY",NA,"D059350","Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning",FALSE,60,"anova",2,NA,NA,1.17169922891753
"128","07acfb66c1a5f15d3204fc4f478a75e2","NCT02431247",0.033,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) at Week 48","SECONDARY",NA,"D007153","A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects",FALSE,665,"mann_whitney",NA,NA,NA,2.66558039974539
"129","07b91b1362516d8b2124e37210bbe98f","NCT02005627",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Delta Peak Nasal Inspiratory Flow in L/Min","SECONDARY",NA,"D012220; D065631","Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study",TRUE,46,"t-test",NA,NA,NA,1.03597838019194
"130","07c7c4a1a1f7e8f5c6ab446f45be8bb4","NCT05457647",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Endothelial Cell Density","SECONDARY","Assessment of change of ECD value at 12-months follow-up visit.","D007640","Theranostic Guided Riboflavin/UV-A Corneal Cross-linking",TRUE,47,"mann_whitney",NA,NA,NA,1.04624856756472
"131","07da94c524424e1dfcf9a3b1755854d6","NCT02738580",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"SERUM PROGSTERONE CONCENTRATION","PRIMARY",NA,"D007246","Follicular Steroid Genesis in Controlled Ovarian Stimulation",TRUE,104,"t-test",NA,NA,NA,1.52186200926557
"132","07df2d4389265599d7692ff78c03f01e","NCT01956240",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Pectoralis Minor Length After Pectoralis Minor Stretching Protocol","PRIMARY",NA,"D020069","Effects of a Pectoralis Minor Muscle Stretching Protocol",TRUE,97,"anova",2,NA,NA,1.47171356596352
"133","07e794c66cb3069ec1abf9f265bd71a4","NCT02528253",0.035,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 40, \>=50%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1012,"logistic_regression",NA,NA,NA,3.45371543079873
"134","07eba5e796a1480a25842ff527282c8f","NCT04490109",0.0228,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Proportion of Subjects With Investigator's Global Assessment (IGA) of Clear or Almost Clear and ≥2 Point Improvement","OTHER_PRE_SPECIFIED","Responder rates for IGA and EASI will be summarized using descriptive statistics and analyzed using a logistic regression model at each respective timepoints.","D003876; D003872; D004485; D011537","B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis",FALSE,337,"logistic_regression",NA,NA,NA,1.38526705841991
"135","08054b5c1df7855e8eff13146db01495","NCT00056316",0.05,"Two-sample t-test","INTERVENTIONAL",0,1,1,0,0,"Secondary Outcome: Negative Affect Scale (Watson, Clark & Tellegen, 1988)","SECONDARY",NA,"D003704; D003863; D003866","Reducing Depression in Dementia Caregivers",FALSE,74,"t-test",NA,NA,NA,1.2933799900503
"136","080590c410322473b0c5ddb09f0f7018","NCT00070707",0.037,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in AM and PM Rhinorrhea Symptom Score","SECONDARY","Change at Final Week (AM)","D012220; D001249; D006255; D065631","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",FALSE,187,"anova",2,NA,NA,1.57142139631477
"137","080ceee84ee7a7e7a6c64b19d4959a5d","NCT00699907",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Colony Stimulating Factor (CSF-1) Expression in Ovarian Stroma","PRIMARY",NA,"D010051; D000077216","Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer",FALSE,88,"mann_whitney",NA,NA,NA,1.40461812327938
"138","0828134a8d581cf881868de4c63b6735","NCT00453999",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change in Amount of Influenza Virus in Nose and Throat (Influenza A and B Combined)","SECONDARY","Change from Baseline at 72 hours","D007251","Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza",FALSE,112,"mann_whitney",NA,NA,NA,1.57722881888439
"139","083d880690166b161ef20d48047e5952","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in 120-minutes Postload Plasma Glucose","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,110,"anova",2,NA,NA,1.56357043896758
"140","08421e20e6ece7bff7380a5524873e57","NCT03228680",0.035,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportions of Participants With Early OHSS (Including OHSS of Moderate/Severe Grade) and/or Preventive Interventions for Early OHSS","SECONDARY","Proportion of participants with early OHSS (moderate/severe).","D007246","Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese Women",FALSE,347,"logistic_regression",NA,NA,NA,2.03090188313393
"141","0842d255794e10148abcf8bdbba3b864","NCT04218864",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Personal Progress Scale-Revised (PPS-R)","OTHER_PRE_SPECIFIED","Statistical analysis strategy is identical to that for primary outcome.",NA,"Strength for U in Relationship Empowerment",FALSE,121,"linear_regression",NA,NA,NA,1.63728545358366
"142","084b6609986e8512f5a7ed8d5c77319f","NCT03458702",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Low-frequency Band (LFNU) Assessed at Baseline, Post-Condition and Post-Exposure","PRIMARY",NA,"D001008","The Effects of Emotional Exposure on State Anxiety",FALSE,80,"anova",2,NA,NA,1.34217713699512
"143","0867d37cdfc725100a9dff2b40698a84","NCT01070550",0.0258,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for HCV RNA at BL in log10(IU/mL). The logistic regression analysis for relapse 24 weeks after EOT was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,227,"logistic_regression",NA,NA,NA,1.26964116624856
"144","086cc24f4cc3dbd7a731fbfa18ece6f6","NCT02649634",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Self-efficacy for Engaging in Physical Activity After the Second Motivational Interviewing or Attention Control Interview, Week 12","SECONDARY","Self-efficacy was analyzed via an independent sample t-test comparing the groups on mean self efficacy rating on the ESE.","D009765; D050177; D015431","Does Motivational Interviewing Improve Behavioral Weight Loss Outcomes for Obesity?",FALSE,129,"t-test",NA,NA,NA,1.68888097915129
"145","087ef90e9bf2446214496ea63fb35dea","NCT01960907",0.038,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Difference of Hospitalization Rate","POST_HOC",NA,"D008173; D029424; D012891; D006333","Clinical Trials for Elderly Patients With Multiple Disease",FALSE,129,"mann_whitney",NA,NA,NA,1.34189292830794
"146","088d4a255b3cfc524e4add2c4f2101be","NCT02836496",0.036,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Change From Baseline in Fatigue Severity Based on Brief Fatigue Inventory (BFI) in Item 3 (Worst Level of Fatigue During Past 24 Hours) at Week 32 by Category","SECONDARY",NA,"D017681; D013577","Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)",FALSE,108,"mann_whitney",NA,NA,NA,1.17688398839666
"147","089b55d712103c0df0a25a372384f293","NCT04445792",0.0205,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Depression as Measured by PROMIS (Patient-Reported Outcomes Measurement Information System)","SECONDARY",NA,"D059350; D059787; D003863; D003866","A Depression and Opioid Pragmatic Trial in Pharmacogenetics (DCRI Coordinating Center)",FALSE,905,"mann_whitney",NA,NA,NA,2.05963837343046
"148","08a6b48b0466cb9617e909e03bfb3b34","NCT05127304",0.021,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"All-cause Health Care Resource Utilization: Pharmacy Fills","PRIMARY",NA,"D029424","A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",FALSE,11316,"linear_regression",NA,NA,NA,7.41737828165696
"149","08bcf7d0e1f2e93b91cb1aba27cf73bf","NCT02528253",0.0308,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Low Back Pain From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/ Last Observation CF (LOCF)","SECONDARY","Week 2: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline PGA of low back pain, baseline average LBPI, and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1012,"logistic_regression",NA,NA,NA,3.09599249567414
"150","08ca1e41912309813db09416da50ab48","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Health)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1770,"linear_regression",NA,NA,NA,6.17015007090058
"151","08dff38eb8bc2e477d3e8cac58360210","NCT03676465",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Low Blood Glucose Episodes Per Week","SECONDARY",NA,"D003920; D003922; D002908","CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management",FALSE,43,"mann_whitney",NA,NA,NA,1.00454908915455
"152","08fc9cfe8a28f7ca0dafd90c1354a77d","NCT00683878",0.0496,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])","SECONDARY",NA,"D003924","Add-on to Thiazolidinedione (TZD) Failures",FALSE,278,"logistic_regression",NA,NA,NA,2.4431274080813
"153","08fd531190922eb1474a907864ffbc02","NCT01843023",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"HIV Sex Risk Behaviors","SECONDARY",NA,"D019966","Extended Release Naltrexone for Opioid-Dependent Youth",TRUE,220,"t-test",NA,NA,NA,2.19200127568343
"154","090a0900f7f632c0e5d21b271c9e7967","NCT00408876",0.045,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Athens Insomnia Scale","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,208,"t-test",NA,NA,NA,1.95249779897531
"155","09111ac615d773b2094b6084e040abca","NCT00855738",0.0433,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline to Month 6 in the Hospital Anxiety and Depression Scale (HADS)","SECONDARY","Anxiety domain: P-value vs baseline.","D004827; D004828","A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice",FALSE,92,"t-test",NA,NA,NA,1.27285511313328
"156","0915091be5ab6f1426decc17c8395037","NCT00090584",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Satisfaction","SECONDARY","Null hypothesis: no difference in satisfaction at 10 weeks","D014549; D004775","Behavior Enhances Drug Reduction of Incontinence (BE-DRI)",FALSE,272,"logistic_regression",NA,NA,NA,1.11282536249767
"157","091a20bba8f4378da2e63d921983ded1","NCT00270998",0.0492,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"75% Reduction in Weekly Urinary Incontinence Episodes at 12 Months","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",TRUE,296,"logistic_regression",NA,NA,NA,2.50291558562827
"158","091f78e794b8ac0e2b9bf2686ca317ed","NCT00640653",0.03,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Self-report of Ever Having Sexual Intercourse","PRIMARY","With alpha = .05, 2-tailed, and 37.4% of the control group initiating sexual intercourse by 24-month follow-up, a total sample size of 563 participants completing the trial was projected to provide power of 80% to detect a difference of 16.8% in self-reported sexual intercourse between an HIV intervention condition and the health promotion control condition.","D012749","Efficacy of an Abstinence-Only HIV Risk-Reduction Intervention for Young African-American Adolescents",FALSE,183,"linear_regression",NA,NA,NA,1.30077972312385
"159","092ce615e9a5c5d05b5ec75bca590ffb","NCT02487745",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"The Percentage of Opiate- and Cocaine-negative Urine Samples","PRIMARY",NA,"D019966; D015819","The Long-Term Treatment of Drug Addiction and Unemployment",FALSE,91,"logistic_regression",NA,NA,NA,1.42733241699876
"160","093eb2b060bfee7bcbdac717df542d6f","NCT00305253",0.05,"Two-sample t-test","INTERVENTIONAL",0,1,1,0,0,"Emergency Hysterectomy","SECONDARY","Relative risks and confidence intervals were computed for emergency hysterectomy.","D006470; D012769; D020896","Efficacy Study of the Non-Pneumatic Anti-Shock Garment (NASG) in Egypt",TRUE,674,"t-test",NA,NA,NA,3.81421696491443
"161","09435f92652e598cc7047b0ac4e1b40d","NCT00927368",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Opioid Consumption","PRIMARY","The primary analysis for opioid was a linear regression model comparing stimulating catheter to ultrasound alone on the log of cumulative opioid consumption score for a patient in the first 48 hours.",NA,"Comparison of 3 Techniques for Ultrasound-guided Femoral Nerve Catheter Insertion",FALSE,285,"t-test",NA,NA,NA,1.61584878634499
"162","09598d1bd73aed68c89f6da8d45596fc","NCT02155738",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Cumulative Narcotic Consumption Over the First 24 Hours","PRIMARY","1b) We will use equianalgesic dosage tables to convert intra- and postoperative narcotics into morphine equivalents to compare narcotic requirements for the first week after surgery. We hypothesize that those patients receiving preemptive IV acetaminophen will have lower postoperative VAS scores and reduced narcotic requirements compared to placebo.","D010149; D011391; D056887","IV Acetaminophen for Postoperative Pain After Pelvic Organ Prolapse Repair",TRUE,202,"t-test",NA,NA,NA,2.10204987545228
"163","095a2cb39dcb4c9509cedfafd8e4f6b3","NCT03426787",0.0463,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Decisional Conflict Scale","PRIMARY",NA,"D006526; D006505; D007674; D051436","Helping Empower Liver and Kidney Patients",FALSE,109,"t-test",NA,NA,NA,1.46018741594715
"164","095bc12fd04556124d64f00d92501b6f","NCT00070707",0.027,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in AM and PM Nasal Itching Symptom Score","SECONDARY","Change at Week 4 (AM)","D012220; D001249; D006255; D065631","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",FALSE,187,"anova",2,NA,NA,1.20108562230388
"165","095e0658d435e33b85c39f327f8e6369","NCT04910165",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Outpatient Opioid Use","PRIMARY",NA,"D010149","Exparel Use in Adductor Canal Block After Total Knee Arthroplasty",TRUE,100,"mann_whitney",NA,NA,NA,1.49341131573029
"166","0974eb3d78fb3d1f92ad792baa5c8419","NCT00245219",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mental Health (as Measured With the SF-36) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The interaction between the peer support condition and cancer stage at Time 2. The full regression model consisted of 3 steps: The 1st step contained the baseline measure of the dependent variable. The 2nd step contained two dummy coded variables contrasting each condition with control. The 3rd step contained the interaction between the peer support condition and cancer stage. Patients in the education condition were excluded from this analysis.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"linear_regression",NA,NA,NA,1.79957957739554
"167","09849bb1050ec614b64341845acbdbe3","NCT00672737",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Experimental Cold-induced Pain - IGFBP-1","PRIMARY","Beta for SaO2: for every 1-%-absolute decrease in the nadir SaO2 the cold pain threshold will additionally increase by 0.9694 seconds for every 1-mcg/mL increase in the plasma level of remifentanil.","D001049; D012891; D020181","Study of Pain Processing in Subjects Suffering From Obstructive Sleep Apnea",FALSE,48,"linear_regression",NA,NA,NA,1.05642048349345
"168","0986d7aa1ea9d05259eeaa7fc5a77726","NCT02057068",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Mean Sleep Efficiency","SECONDARY",NA,NA,"Improving Sleep in Veterans and Their CGs",FALSE,96,"anova",2,NA,NA,1.46440978390488
"169","0999f50b444c2c8a9b5087ca74c05ce5","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Daytime Brachial Diastolic Pressure","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"170","099c5b4d3a4e1260c011784a560be8f4","NCT00112151",0.05,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Fat Free Mass (kg)","SECONDARY","As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in fat free mass measured by dual x-ray absorptiometry (DXA) with any T to placebo in subjects assigned to PRT.",NA,"TEAM: Testosterone Supplementation and Exercise in Elderly Men",TRUE,71,"linear_regression",NA,NA,NA,1.26828177971868
"171","09b1a977e3dfd34ac24e3e41b72d8a66","NCT04267614",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Change From Baseline in CDAI Score at Month 12","OTHER_PRE_SPECIFIED",NA,"D001168; D001172","This Study is to Investigate the Effect of Etanercept in Early Versus Delayed Referral for Management of Rheumatoid Arthritis Patients.",TRUE,979,"t-test",NA,NA,NA,4.59283895163754
"172","09ce4e19d155a367f4e46fa39478a3db","NCT04003142",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate, and Severe VMS From Baseline to Each Study Week Up to Week 12","SECONDARY","Week 8","D019584","A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2",FALSE,334,"logistic_regression",NA,NA,NA,1.74712959829196
"173","09e27ea1bbe62e85ed8611e912271e86","NCT03192176",0.0494,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 3 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 4","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.37543656888442
"174","09f28692846ac2c20809f21666229b6f","NCT00420927",0.043,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Number of Subjects Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 78","SECONDARY",NA,"D001168; D001172","Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis",FALSE,207,"logistic_regression",NA,NA,NA,1.87489115786306
"175","09f8b4bce731cfecd2eed25692fc0b2d","NCT00964366",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Skin Hydration","SECONDARY",NA,"D000152","Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications",FALSE,52,"anova",2,NA,NA,1.09617796589869
"176","0a0929b81bfae254e8df496db22365d9","NCT01969201",0.02,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Total Number of Oocytes Retrieved","SECONDARY",NA,"D007246","FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)",FALSE,683,"anova",2,NA,NA,1.75288336572169
"177","0a10afc1081b3fa29c79e9b98889bc31","NCT04593940",0.045,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Mean Change in the 8-point Ordinal Scale From Day 0 to Day 21","SECONDARY",NA,"D000086382","Immune Modulators for Treating COVID-19",FALSE,1004,"t-test",NA,NA,NA,4.25695965336694
"178","0a19c515b3e0ad71e50f0894500d3072","NCT03036800",0.023,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Weight Loss of ≥15% From Baseline (Complete Cases)","SECONDARY","A logistic regression with a binary outcome of weight loss of ≥32% from baseline at 16 weeks was fitted. The main covariate was randomised arm, with the model also being adjusted for the stratification variables: site and baseline body mass index (≥45kg/m2; \<45kg/m2).","D009765; D015431","Saxenda in Obesity Services (STRIVE Study)",FALSE,287,"logistic_regression",NA,NA,NA,1.28980741448669
"179","0a32fa51bc0422a42af4c8f817e1f8cc","NCT04667338",0.0396,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Stigma Scale for Chronic Illness 8-item Version (SSCI-8) Total Score","SECONDARY",NA,"D009290","A Study to Collect Information of People With Narcolepsy in Spain",FALSE,207,"t-test",NA,NA,NA,1.74912948023893
"180","0a3488de7d30f4e10a56c20d6e4bf25c","NCT01972841",0.012,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours at Weeks 4, 8, 12 and EoT","SECONDARY","Odds ratio from a logistic regression model including treatment group, sex, age group (\<65, \>=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.","D053201; D014570; D001745","This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",FALSE,1238,"logistic_regression",NA,NA,NA,1.50341694487259
"181","0a34a850402370ec78d1a2849d448828","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Intention to Reduce","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1753,"linear_regression",NA,NA,NA,6.14051253521365
"182","0a531c77126d77da54def02339b7d58f","NCT06053541",0.03,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Total Costs Associated With Chronic Obstructive Pulmonary Disease (COPD) Hospitalizations","PRIMARY","For the evaluation of statistical significance, considering that the data do not follow a normal distribution and that the two samples are independent and not paired, the Mann-Whitney test was applied and a p value \< 0.05 was considered.","D008171; D008173; D029424","Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change",FALSE,6030000,"mann_whitney",NA,NA,NA,233.103614326504
"183","0a702ba808693e88a65e41f0ed8fa95c","NCT00120627",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Short-Form (SF)-12v2 Health Quality of Life (Mental Health Component Score)","SECONDARY","Intent to treat analysis using Expectation-Maximization (EM) algorithm in SPSS, a maximum-likelihood method based on group assignment, demographic variables and clinical variables.","D013313","Mantram Repetition to Manage PTSD in Veterans",TRUE,146,"anova",2,NA,NA,1.79360862376457
"184","0a8896f6c002c7014149dbb21cf371a9","NCT00789074",0.04,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change in Pre-quit Ratings of Cigarette Satisfaction","SECONDARY",NA,"D014029","Use of Varenicline for 4-weeks Prior to Quitting",TRUE,78,"anova",2,NA,NA,1.10125434205372
"185","0aa217de381651d80dd8934302521cf1","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cancer Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1753,"linear_regression",NA,NA,NA,6.14051253521365
"186","0aa5d1d6843089d893f99490b46b47bf","NCT03331978",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Internalized HIV Stigma","SECONDARY","Tested with repeated measures logistic regression where both post-intervention responses were stacked together such that each participant could contribute up to 2 records. Standard errors were adjusted for clustering on participant, and weights for follow-up response were used. Fixed effects were an intervention indicator and baseline stigma. Model included all participants with responses (a) at baseline and (b) at least one of the two follow-up surveys.","D000163; D015658","A Randomized Controlled Trial of an Antiretroviral Treatment Adherence Intervention for HIV+ African Americans",FALSE,190,"logistic_regression",NA,NA,NA,2.03988152031571
"187","0abafa07c758c105e429bb35e8dafb37","NCT03192176",0.0462,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 2 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 1","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.3010040465196
"188","0abc244983e18ccfea63b6bcfd133c9c","NCT02122887",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Changes in Empathy as a Function of Perspective Taking","SECONDARY",NA,NA,"Peace-Building Interventions for Israeli and Palestinian Youth",FALSE,79,"anova",2,NA,NA,1.33416755946001
"189","0ac5ac01d873024a61a2f625b57eaab5","NCT03582813",0.046,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants With Employment","SECONDARY","This mixed effects random regression analysis tested whether intervention participants would report greater likelihood of employment that would be maintained longitudinally","D001523","Efficacy of Mental Health Self-Directed Care Financing",FALSE,216,"logistic_regression",NA,NA,NA,2.02599031722651
"190","0acf40fff3184ab5e983e9b8ecc1b22c","NCT01590433",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change in Body Weight","PRIMARY",NA,"D015431","Weight Loss With Exenatide Treatment",TRUE,108,"t-test",NA,NA,NA,1.54979200994087
"191","0ad15b1b1e776580eaf291c5c772d062","NCT03982368",0.029,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Schirmer I Test (Without Anesthesia) vs Week 4 - Per Protocol Set","PRIMARY",NA,"D015352; D007638","A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye",FALSE,151,"anova",2,NA,NA,1.15098719988299
"192","0ae399a91c112d4927ebb25b7f100cb7","NCT05302414",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Resuscitation Knowledge Scale","SECONDARY","For posttest right after intervention at the 4 weeks.",NA,"The Learning Outcome of Resuscitation Teamwork Training in Postgraduate Year Doctors and Nurses",FALSE,64,"kruskal_wallis",2,NA,NA,1.20770700959599
"193","0afcbac469055d21ebf4bc549516af82","NCT02406677",0.026,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Patients With Long Term Non-persistence to P2Y12 Receptor Inhibitor","PRIMARY",NA,"D009203; D054058; D007238","Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study",FALSE,10102,"logistic_regression",NA,NA,NA,8.43576351581061
"194","0b007803a2f9616cdeb9c2dec3601fde","NCT03810417",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Renal Function","PRIMARY",NA,"D058186","Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI",FALSE,125,"linear_regression",NA,NA,NA,1.66328288934253
"195","0b0f9f0c997e9f65fb72bb582b026af4","NCT02886728",0.017,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 24","PRIMARY","Filgotinib 100 mg + MTX vs MTX Monotherapy at Week 24","D001168; D001172","Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy",FALSE,623,"logistic_regression",NA,NA,NA,1.45304024639415
"196","0b140db98bc9f55581483df211bfbc31","NCT00803114",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Maternal Visual Analogue Scale (VAS) Score at Time of Request for First Additional Analgesic","SECONDARY",NA,NA,"Epidural Morphine Following Vaginal Delivery",FALSE,228,"t-test",NA,NA,NA,2.2308164865578
"197","0b18375f525d6c4591b4ed32bd134d00","NCT05170841",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Percentage of Patients Achieving at Least 50% of Maximum TOTPAR at 6 Hours After the First Dose - Single Dose Phase - Dexketoprofen/Tramadol vs Placebo","SECONDARY",NA,"D001416; D017116","Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain",FALSE,204,"t-test",NA,NA,NA,1.75147038541087
"198","0b1f0e221b32b27c9824245097ee469c","NCT00464568",0.0448,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Mean Messenger Ribonucleic Acid (mRNA) Concentrations as a Measure of Gene Expression","PRIMARY","NR4A2; Placebo vs GSK256066 1 mcg","D012220; D006255; D065631","A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis",FALSE,61,"anova",2,NA,NA,1.07827432985975
"199","0b2da9b717dc0b77066f0adc29a100cd","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in High Density Lipoprotein Cholesterol","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,111,"anova",2,NA,NA,1.5704144397227
"200","0b2fe58700374c94705472c1681f8e7e","NCT00884065",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Active extensión Movement After Intervention Minus Baseline","PRIMARY",NA,"D020069","Effectiveness of Diacutaneous Fibrolysis in Painful Shoulder",FALSE,50,"t-test",NA,NA,NA,1.07648023860356
"201","0b3f1214d2ad8c0811336ca13c7791ac","NCT00244374",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Viral Transmission Risk Behavior Association With Travel","SECONDARY","Adjusted odds with 95% confidence intervals for travel as a risk factor for each behavior.","D006506; D006526; D006509; D006505; D019966; D015819","A Randomized Trial of Vaccine Adherence in Young Injection Drug Users",FALSE,355,"logistic_regression",NA,NA,NA,2.77524765919219
"202","0b4d493451ed72b588c7e69e37b6220f","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Pizza Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1749,"linear_regression",NA,NA,NA,6.13351818505813
"203","0b574a5416ff07879169f01d625c5a97","NCT01921517",0.0481,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Distal Tibia Bone Quality","PRIMARY",NA,NA,"Micromechanical Modeling Using Low Magnitude Mechanical Stimulation",FALSE,80,"t-test",NA,NA,NA,1.2997664725163
"204","0b66dd42ac4a1f051e05b492eac36498","NCT00762528",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Dental Plaque Index (PI)","SECONDARY","The null hypothesis states that there is no difference between groups.","D005891","Compare Anti-inflammatory Dentifrices",TRUE,49,"anova",2,NA,NA,1.06649684228356
"205","0b6afb28828d0a3b90ed5bbecad01a57","NCT01589445",0.039,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Comparison of Changes in Fasting Serum Insulin (FSI)With Pioglitazone and Metformin","PRIMARY","FSI","D003920; D003924","Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects",TRUE,80,"anova",2,NA,NA,1.09112577033862
"206","0b7c14d79ea52575f54d7216f96aa204","NCT02440854",0.043,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Patient-rated Total Lung Cancer Symptom Scale (LCSS) Score","SECONDARY","Baseline vs 30-month post-baseline.","D002289","Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings",FALSE,76,"t-test",NA,NA,NA,1.15558769509454
"207","0b7c6a4bc40bec14ef5b8863af00115b","NCT01049373",0.04443,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change in Pain Score (SES), Subscale ""Sensoric Pain""","SECONDARY",NA,"D001416; D017116","Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain",FALSE,132,"mann_whitney",NA,NA,NA,1.54748644035646
"208","0b7cf45ce18dd8e8d33e911cfcbfa87a","NCT02395120",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants With Receipt of Dental Care-restoration or Extraction of at Least One Tooth at Final Exam","PRIMARY",NA,"D003731","Family Access to Dentist Study",TRUE,597,"logistic_regression",NA,NA,NA,3.5910564987254
"209","0b8927d3fe168cbd960394a741d4e6ea","NCT00069160",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Geometric Mean of Area Under Curve (AUC0)-24","PRIMARY",NA,"D009369; D002583; D008175; D010051; D007680","Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer",FALSE,76,"t-test",NA,NA,NA,1.30984657914153
"210","0b974d6b6dbccea07d5e068010608b17","NCT01236053",0.0115,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,22537,"mann_whitney",NA,NA,NA,6.1620763747626
"211","0bb7479448d4df1d17d927c7a1eb9280","NCT03655951",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Contraception Self-efficacy From Pretest to Posttest","SECONDARY",NA,NA,"Birds and Bees Research Study",FALSE,261,"linear_regression",NA,NA,NA,2.38426263739808
"212","0bc2f6fbff08ee9336cd0cf8de6593f9","NCT00331773",0.037,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"EQ-5D Scores","SECONDARY","Baseline VAS score","D011471","Radiation Therapy in Treating Patients With Stage II Prostate Cancer",FALSE,857,"mann_whitney",NA,NA,NA,3.33359484547026
"213","0bc5b50c6286f2489833da8747c662b6","NCT04445792",0.0292,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Overall Wellbeing as Measured by PROMIS (Patient-Reported Outcomes Measurement Information System)","SECONDARY",NA,"D059350; D059787; D003863; D003866","A Depression and Opioid Pragmatic Trial in Pharmacogenetics (DCRI Coordinating Center)",FALSE,1111,"mann_whitney",NA,NA,NA,3.09799946015437
"214","0bd103cea79c963cb10569b4c8972458","NCT01848054",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Retention in Treatment in the Full Analysis Population","SECONDARY",NA,"D009293","Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence",TRUE,310,"t-test",NA,NA,NA,2.59543112524924
"215","0beabffcc70ff24cd736dae3745af4ec","NCT03676465",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"My-Q","SECONDARY",NA,"D003920; D003922; D002908","CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management",FALSE,43,"t-test",NA,NA,NA,1.00454908915455
"216","0beda42dab5598f4543a6c6395ad350d","NCT01986647",0.0324,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Attendance Rates","OTHER_PRE_SPECIFIED",NA,NA,"On the Move: Optimizing Participation in Group Exercise",FALSE,298,"logistic_regression",NA,NA,NA,1.76406981022274
"217","0bf00bd1e6ad59abe483c523538c66eb","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in 120-minutes Postload Plasma Glucose","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,109,"anova",2,NA,NA,1.55669642807029
"218","0c3868fa82d23d84b094ed938ce4f5df","NCT00927472",0.0386,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Proportion of Index Subjects Free of Any of Lice 14 Days After Their Last Treatment.","PRIMARY",NA,"D010373","Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice",FALSE,95,"t-test",NA,NA,NA,1.17382023910888
"219","0c3a2705f288d0bd1fee7dfbdc7dab61","NCT04249336",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Percent Change in Mean Score of Pain Response From Baseline on Schiff Cold Air Sensitivity Scale Using Air Blast Stimulus","PRIMARY","It was calculated that 140 participants randomized in a 1:1:1:1 fashion between the four arms would have at least 80 % power to detect a difference of 0.20 mean scores between four treatments from baseline to week 4. Sample size was determined using PAS V.11, two independent sample t-test with 95% confidence interval.","D003807; D006967","Clinical Efficacy Of BioMin F, Colgate Sensitive Pro-Relief And Sensodyne Rapid Action Dentifrices In DH",TRUE,64,"anova",2,NA,NA,1.20770700959599
"220","0c3cbc9eef5e89925bbed576522c7ac7","NCT04436744",0.0433,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Relative Percent Change in Ki67 Scores From Baseline to Week 2","PRIMARY",NA,"D001943","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)",FALSE,201,"t-test",NA,NA,NA,1.85890061063191
"221","0c536f161188c6e3906e0c7315b67ca1","NCT01089582",0.0137,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Change From Baseline in the Caregiver's Assessment for Quality of Life for Alzheimer's Dementia (QoL-AD) Overall and Subscale Scores at Week 12","PRIMARY","The effect of possible prognostic factors on response: primary diagnosis severity.","D000544","Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets",FALSE,564,"linear_regression",NA,NA,NA,1.14421186612429
"222","0c5605462eac0ff708591b124720a986","NCT00162266",0.0418,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"ACR Numeric Values (ACR-N)","SECONDARY","Day 15 Treatment Comparison","D001168; D001172","Abatacept With Methotrexate- Phase IIB",FALSE,224,"anova",2,NA,NA,1.90299580630991
"223","0c68ae4928e4d14819a597d7f8699a47","NCT02596126",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Efficacy Endpoints","SECONDARY","Patient satisfaction is measured at visit 1 (6 months) and visit 3 (2 years) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument comprising of four domains: effectiveness (questions 1 to 3), side effects (questions 4 to 8), convenience (questions 9 to 11) and global satisfaction (questions 12 to 14).","D009362; D002318; D009203; D007238","Secondary Prevention of Cardiovascular Disease in the Elderly Trial",TRUE,2466,"t-test",NA,NA,NA,7.28069129722027
"224","0c7899487f9b7c316126c2c964c697ee","NCT02260492",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"FEV1 Trough","PRIMARY","Same as the Day 1 analyses","D001249","Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma",TRUE,801,"anova",2,NA,NA,4.15619078273321
"225","0c8633a205224b6ca94fceff9c958d2f","NCT00487084",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Verbal Rating Score (0 to 10) for Pain (VRPS)","SECONDARY",NA,"D000377","Effect of Timing on Efficacy of Morphine Analgesia After 2-chloroprocaine Anesthesia",TRUE,58,"kruskal_wallis",2,NA,NA,1.15327776573523
"226","0c904219905246023cb88e313e0049b7","NCT01049334",0.0435,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe","SECONDARY",NA,"D010612","A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis",FALSE,135,"anova",2,NA,NA,1.53695150119865
"227","0c9042ba4f70e50c44b58c7ecebbd5c9","NCT01115673",0.043,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 75 Minutes","SECONDARY","The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.","D014098","To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery",FALSE,480,"anova",2,NA,NA,2.83901747307063
"228","0c9ef13d8fee57932139c200d6cad65e","NCT02214186",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Renal Function in Severe Preeclampsia With Restrictive Fluid Therapy","PRIMARY",NA,"D004461; D011225","Restrictive Fluid Therapy in Severe Preeclampsia",TRUE,46,"mann_whitney",NA,NA,NA,1.03597838019194
"229","0cd96437af2e2d152548aae955d78c26","NCT01779375",0.05,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"ß-cell Function Measured by Hyperglycemic Clamp Techniques at M12","SECONDARY","Analyses were completed on a log scale and re-exponentiated for display.","D011236","RISE Pediatric Medication Study",FALSE,86,"linear_regression",NA,NA,NA,1.38926982128357
"230","0cdd4deeabe21aed3fae29dbe0e8a45b","NCT00110461",0.043,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change in General Behavior Inventory Scale (GBI) Total Parent/Guardian Version Depression Score at Week 4","SECONDARY","Analyses were performed by fitting an ANCOVA model with treatment as factor, and baseline score as covariate. Two pair-wise comparisons, aripiprazole 10 mg target dose versus placebo and aripiprazole 30 mg target dose versus placebo, were performed within the ANCOVA or ANOVA model.","D001714","Aripiprazole in Children and Adolescents With Bipolar I Disorder",FALSE,186,"t-test",NA,NA,NA,1.77923130277515
"231","0cdf34c2fd8cfc18e1a1a2e776e98920","NCT02912650",0.023,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Time-weighted Sum of Pain Intensity Difference Scores on 4-Point Categorical Scale (SPID4) From 0 to 2 Hours, 0 to 6 Hours, 0 to 8 Hours, 0 to 12 Hours and 6 to 8 Hours Post-dose","OTHER_PRE_SPECIFIED","6-8 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,347,"anova",2,NA,NA,1.4160300936537
"232","0ce354300b4d07aa4bb8dd0d1e9eb676","NCT03802396",0.025,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Number of Adverse Events (AEs) of Grade II or Higher Per Patient","PRIMARY",NA,"D000069544; D003693; D000071257; D004660; D007249; D000079690; D060825","Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction",FALSE,186,"mann_whitney",NA,NA,NA,1.12124010972644
"233","0cedebdf8504ab161232ad99c05d7a1d","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in High Density Lipoprotein Cholesterol","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,109,"anova",2,NA,NA,1.55669642807029
"234","0cf689bf33764a60d56d07e5f1a1045f","NCT06899737",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Intention Scores From Pretest to Posttest","OTHER_PRE_SPECIFIED",NA,NA,"Monitoring and Outreach for Maternal Safety Postpartum",FALSE,94,"t-test",NA,NA,NA,1.44969222080406
"235","0cff9e60992ba6e29b8b1d94c3a5412c","NCT02391363",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Hospital Admissions at 6 Months","SECONDARY","We expected to reject the null hypothesis of no treatment group difference in 6 month hospital admissions, controlling for baseline hospital admissions.

Race/ethnicity and ERS-expectancies significantly differed between groups at baseline and were included as covariates.

A total of 134 participants allowed for 80% power to detect moderate group differences (d=.49) in primary and secondary outcomes given a 2-tailed type 1 error rate",NA,"Calmer Life: Treating Worry Among Older Adults In Underserved, Low-income, Minority Communities",FALSE,134,"logistic_regression",NA,NA,NA,1.42720213865968
"236","0d1e80cbee552d9e3017d2fdd9677d4b","NCT01489891",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Rate of Administration of Propofol 1% Required to Obtain Uniform Sedation During Endoscopy","PRIMARY",NA,NA,"Usefulness of Lidocaine as Topical Pharyngeal Anaesthesia in Esophagogastroduodenoscopy Under Sedation With Propofol",TRUE,119,"t-test",NA,NA,NA,1.62413102595047
"237","0d284e97cee4c7eb70f12bd64b318d70","NCT04003142",0.044,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate, and Severe VMS From Baseline to Each Study Week Up to Week 12","SECONDARY","Week 5","D019584","A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2",FALSE,334,"logistic_regression",NA,NA,NA,2.41901950359631
"238","0d2f1c712c795263180e5dc2b61aad9d","NCT00119158",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in the m-EASI (Eczema Area Severity Index) Score.","PRIMARY",NA,"D003876; D003872; D004485","Combination Therapy for Atopic Dermatitis",TRUE,45,"t-test",NA,NA,NA,1.02560707988412
"239","0d2f2786f3d5a66715e2f9a5923e0c42","NCT04697264",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Correlation Between the Markers and Study Patients' Obesity Status","PRIMARY","The impact of BMI on biomarker levels was assessed by categorising the population into two groups-normal weight and overweight/obese-for straightforward comparison.

Here, we present the association between IL6, TNFα, IGF1, and IGF2 and the BMI of the study population at baseline.","D016889; D009765","Adipocytokines in Endometrial Cancer",FALSE,50,"linear_regression",NA,NA,NA,1.07648023860356
"240","0d3af48de8c6b0811f7c0d829e519924","NCT00392379",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Prolonged Smokeless Tobacco Abstinence at 3 Months","PRIMARY","Based upon previous research, we hypothesized that the end-of-treatment abstinence rate for subjects receiving placebo would be 35% and the abstinence rate for subjects receiving the 4-mg nicotine lozenge would be 53%. A resulting power calculation indicated that 270 subjects (135 per group) were required in order to have 85% power to detect a significant difference (two-sided, α = 0.05 level test).","D016739","Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction",TRUE,270,"logistic_regression",NA,NA,NA,2.42442742178718
"241","0d3d5231134d7794d87453cf1543ec8f","NCT01340027",0.038,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Major Improvement in PPBC","SECONDARY",NA,"D053201; D014570; D001745; D020924","A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder",FALSE,222,"logistic_regression",NA,NA,NA,1.7480897186845
"242","0d4511bedea519ec34ac4aff319f3e85","NCT00297882",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Cure Rate on Day 28","PRIMARY","Sample Size will be determined by N = {\[(Zα/2)/E\]\*2}pq where Where: n=sample size; Zα/2= Z value of a two-tailed test with 95% confidence level=1.96; p represents cure rate, q=1-p, which represents treatment failure rate of; E=precision of 5%","D008288","Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon",FALSE,816,"t-test",NA,NA,NA,4.19474101824876
"243","0d6941e19b10b90c1847a3df3aa1749a","NCT02223377",0.04,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Mean Dose of Analgesic Used","SECONDARY",NA,"D014839; D020250","Satisfactory Analgesia Minimal Emesis in Day Surgeries",FALSE,401,"anova",2,NA,NA,2.44317305635809
"244","0d773f2d20bd2a195eda1803459602e7","NCT00661999",0.0424,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,1,0,"Transferrin Saturation at Baseline, Week 7 and Week 16","SECONDARY",NA,"D008223; D007938; D009101; D054219; D010954; D011230; D000740; D008232","Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer",FALSE,490,"kruskal_wallis",3,NA,NA,1.08261287196333
"245","0d7f429724a5493a0476f496cb4be579","NCT00562159",0.022,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Participant Average Weekly Rhinoconjunctivitis Quality-of-Life Questionnaire With Standardized Activities (RQLQ(S)) Total Score Over the Entire GPS","SECONDARY",NA,"D012220; D003231","Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)",FALSE,391,"anova",2,NA,NA,1.44508686944304
"246","0d9665b5c025261d0b134ee96d1d6e11","NCT01225822",0.0472,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Major Bleeding Events (MBE)","PRIMARY","BIBR 1048 50 mg bid vs. Enoxaparin 40 mg qd, same methodology as for primary endpoint","D013923; D054556","BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery",FALSE,781,"logistic_regression",NA,NA,NA,3.91058293440426
"247","0db8fca4eec8130daaa4e02d824f5611","NCT04697264",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Correlation Between Circulating Levels of These Markers and Demographic Characteristics.","PRIMARY","The influence of age on leptin levels was analysed by dividing the population into binary groups (\<60years and \>/=60years) to facilitate comparison.","D016889; D009765","Adipocytokines in Endometrial Cancer",FALSE,100,"linear_regression",NA,NA,NA,1.49341131573029
"248","0dc9268fea929332996692eace3a81dc","NCT01621009",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"7-day Point Prevalence Abstinence From Smoking at 6 Months","PRIMARY",NA,"D014029","Bupropion SR Plus Counseling for Smoking Cessation",FALSE,226,"logistic_regression",NA,NA,NA,2.22117623685084
"249","0dcfde6ad93b871e72cc08eac0bd70d9","NCT00354159",0.033,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Characterize Intracardiac Pressure","SECONDARY","Null hypothesis: Average daily median ePAD is the same between the Treatment and Control arms.

Alternative hypothesis: Average daily median ePAD is the different between the Treatment and Control arms.","D006333","Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (HF) (REDUCEhf)",FALSE,372,"t-test",NA,NA,NA,1.99904040094699
"250","0ddc16280478e22f73ce2c0cbd92ee27","NCT02344290",0.02,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"For Mechanistic Substudy: HsCRP Level","SECONDARY","Comparison of hsCRP Levels at Month 24","D002318","Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults",FALSE,804,"mann_whitney",NA,NA,NA,1.90069198985338
"251","0df7ad085734cf80c99f06f300c957cf","NCT00449644",0.035,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"The Percentage of Participants With Sputum Culture Conversion (Stage 2)","SECONDARY","Week 120","D014376","TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).",FALSE,132,"logistic_regression",NA,NA,NA,1.26573271550508
"252","0df9d10351476fa25b40dc8a0cd1a412","NCT02537678",0.032,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Child Behavior Checklist Internalizing Symptoms","SECONDARY",NA,"D013313","Stepped Care for Children After Trauma: Optimizing Treatment",FALSE,183,"t-test",NA,NA,NA,1.37445710454267
"253","0e3cdc7c0fed523b8575350a066a49b5","NCT02528188",0.0079,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 4: \>=50% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1998,"logistic_regression",NA,NA,NA,1.31483938037962
"254","0e53759e74fc4c5dd218b8f1eeff0013","NCT02874144",0.05,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"TOTAL POLYP SCORE (TPS)","PRIMARY","We used baseline scores to track change to follow-up scores and used a difference-in-differences (D-I-D) statistical approach to compare the change over time compare relative rate of change over time between scores within the treatment group (AZD1981 plus INCS) and within the to scores within the placebo group (INCS treatment only)..","D012852; D009298","Anti-Inflammatory Agent in Sinusitis",TRUE,43,"linear_regression",NA,NA,NA,1.00454908915455
"255","0e6d6d3fc10b573456dcbe568a771d53","NCT01387815",0.037,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"PtGA of Disease Activity Based on a VAS: Change From Baseline to Month 24","SECONDARY",NA,"D011565","Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis",FALSE,284,"t-test",NA,NA,NA,1.9288817426765
"256","0e72f5c63d40bad0655790b59c4362b6","NCT00472797",0.036,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"SF-36 Physical and Mental Component Scores","OTHER_PRE_SPECIFIED","Physical Component - Change from Baseline to Exisit Visit LOCF","D009103; D012598","Rebif New Formulation (RNF) Quality of Life (QOL) Study",FALSE,232,"t-test",NA,NA,NA,1.70624130312717
"257","0e97a2b8b37502070131a98d0932dd44","NCT02337361",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Reporting Heavy Alcohol Use","PRIMARY",NA,NA,"Computerized Tool for Preventing Prenatal Drinking",TRUE,86,"t-test",NA,NA,NA,1.38926982128357
"258","0ea024f44d85ab294b53fd36dd86017c","NCT02528188",0.0425,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 2: \>=70% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1989,"logistic_regression",NA,NA,NA,5.70383113378003
"259","0ea53baf42cf83b1c2b16a82f5ebd2be","NCT01256944",0.05,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"BMI","PRIMARY",NA,"D011085; D002318; D024821; D013577","To Study Polycystic Ovary Syndrome in Taiwanese Women",TRUE,290,"anova",2,NA,NA,2.51138465397077
"260","0eccaa7e6b5d14bf4b608abf60688789","NCT04258709",0.0474,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Breastfeeding Exclusivity","PRIMARY",NA,NA,"PRenatal Video-Based Education and PostPARtum Effects",FALSE,268,"logistic_regression",NA,NA,NA,2.31003159717025
"261","0ed5131c7a94b142a43678fce208908d","NCT00043186",0.049,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36","SECONDARY",NA,"D001851","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",FALSE,60,"mann_whitney",NA,NA,NA,1.15233499097851
"262","0edd82e153f682f7f381353aa19da378","NCT06899737",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Knowledge Scores From Pretest to Posttest","OTHER_PRE_SPECIFIED",NA,NA,"Monitoring and Outreach for Maternal Safety Postpartum",FALSE,93,"t-test",NA,NA,NA,1.44227732582979
"263","0ede1e33856acccdc9fb19d62d999ee2","NCT03546413",0.029,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of LEAP Participants, Younger Siblings and Older Siblings With at Least One Peanut-related Adverse Event","SECONDARY",NA,"D006967; D021183","Follow up of LEAP Participants and Their Families",FALSE,508,"logistic_regression",NA,NA,NA,2.0878327112716
"264","0ee0c874fa0c8c7448138453070ddfb1","NCT01066793",0.0418,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for age per 10 years. The logistic regression analysis for mSVR was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2b.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,960,"logistic_regression",NA,NA,NA,3.91174106233395
"265","0ee92e13f4634d01b148f2122962b3dd","NCT00094302",0.01,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Potassium","SECONDARY","Since the p-value for the preceding test (Statistical Analysis 1) was not significant at the 0.05 level, another generalized linear model was fit, omitting the interaction between treatment group and month of visit. This tests whether the value of the post-baseline laboratory parameter differs by treatment group, taking into account that measurements in the same subject over time may be correlated.","D006333; D002318; D006331","Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function",TRUE,3445,"linear_regression",NA,NA,NA,2.12942984619502
"266","0ef1c8c97db4c1ebbbaaa6412d55a233","NCT00551135",0.0325,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Numeric Rating Scale (NRS): Current Pain With Movement - Coughing","SECONDARY","Day 2 PS; LS Means from ANOVA model with terms of treatment, pooled center and baseline pain from coughing (for baseline visit ANOVA model with terms of treatment and pooled center). Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,202,"anova",2,NA,NA,1.46153509839396
"267","0f25072416fcbde03fe25953c26832c3","NCT00408876",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Vital Signs - Pulse Rate","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,224,"t-test",NA,NA,NA,1.83362641390184
"268","0f2c012ae3a8684923d65b910e97fa07","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Specific Perceived Healthfulness","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1771,"linear_regression",NA,NA,NA,6.17188902328434
"269","0f42d22d5dd12f087fe55bf4a89616d9","NCT01535014",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Average Relative Change in Body Weight After 24 Weeks of Treatment","PRIMARY",NA,NA,"Clinical Trial of Safety and Efficacy of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients",FALSE,257,"t-test",NA,NA,NA,1.53580391362835
"270","0f4455a179d76f63900a879b4cf394a5","NCT00739674",0.026,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Change in Diastolic Blood Pressure From Baseline to Week 10","SECONDARY",NA,"D006973","SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)",FALSE,769,"linear_regression",NA,NA,NA,2.334408273138
"271","0f66af3ac99b6d636698683f1c736792","NCT03428100",0.037,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)","SECONDARY",NA,"D003876; D003872; D004485","A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable",FALSE,278,"logistic_regression",NA,NA,NA,1.90871295766336
"272","0f78adc65bdcf2eaa510af71331c7c65","NCT01817530",0.041,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With ≥ 25% Reduction From Baseline in Uterine Volume at Month 3, Month 6, and Final Visit","SECONDARY","Month 3","D007889; D047708; D014592; D008595; D006470","Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)",FALSE,130,"logistic_regression",NA,NA,NA,1.43594242428047
"273","0f7a518eb73542bc31dd82f540ec1145","NCT00635492",0.0141,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Higher Random Glucose Associated With Treatment Choice at Baseline","SECONDARY","Random blood glucose - 1 mmol/L higher","D003920; D003924","CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy",FALSE,2492,"logistic_regression",NA,NA,NA,2.45675058836521
"274","0f9a3015e13560d4b19564b31fe2614a","NCT04766333",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Who Complete COVID-19 Testing","PRIMARY",NA,NA,"New Jersey Healthcare Essential Worker Outreach and Education Study - Testing Overlooked Occupations",TRUE,1100,"logistic_regression",NA,NA,NA,4.867349004839
"275","0fb7c917424ee05a1f37dd613b8d04a1","NCT03203512",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Ex Vivo Agonist-stimulated Platelet Activation Detected by Plate-based Platelet Aggregation Assay","SECONDARY","Null hypothesis is that there was no difference in change of platelet function in affecting LogEC50 values in response to ADP between fish oil and placebo capsules. Comparisons of this parameter after each intervention were drawn using 2-way ANOVA with the Turkey multiple comparisons test.","D001768","Fish Oil-derived N-3 Polyunsaturated Fatty Acids and Extracellular Vesicles",FALSE,80,"anova",2,NA,NA,1.34217713699512
"276","0fbd6baec27178049c0e5901e354b893","NCT00337727",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Patients Who Reported Complete Response","SECONDARY",NA,"D009325; D014839","Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)",TRUE,832,"logistic_regression",NA,NA,NA,1.04964838595516
"277","0fccae580acef6476750c037ee977bec","NCT00531661",0.0236,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Quality of Life - Minnesota Living With Heart Failure Questionnaire (MLHFQ)","SECONDARY",NA,"D006333","CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients",FALSE,550,"t-test",NA,NA,NA,1.8179716962974
"278","0fd2075d594407a7d4aa5f9c1e9f4bcc","NCT02442206",0.0437,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change in Left and Right Ventricular End-systolic Volume","SECONDARY","LV ESV","D008171; D008173; D029424","Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients",FALSE,116,"anova",2,NA,NA,1.43371974866633
"279","0fe84d3e300e8a114647f41a37a3c821","NCT02697773",0.0175,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >= 30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 8, \>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,463,"logistic_regression",NA,NA,NA,1.2868519959001
"280","0ff7062e8a9776b73150a0aafbc1e646","NCT01520363",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change in Mullen, Expressive Language Sub-scale Scores, Pre- and Post-Intervention","PRIMARY",NA,"D015518; D013577","Placebo Controlled Trial of Dextromethorphan in Rett Syndrome",FALSE,46,"t-test",NA,NA,NA,1.03597838019194
"281","103a4acf40b229d6c0b3207487526f39","NCT01415232",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Correlation Between Actual Epidural Needle Depth (ND) and Estimated Epidural Depth (Est-D)","PRIMARY","Clinical epidural needle depth","D009765","A Novel Way to Estimate Epidural Depth in Morbidly Obese Parturient",FALSE,160,"t-test",NA,NA,NA,1.87547517894336
"282","1077f160bce278a8d68ffa14d9127bd6","NCT03192176",0.0359,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 2","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,87,"logistic_regression",NA,NA,NA,1.05900292387223
"283","10861773325b0893fbb7f67267deb86f","NCT01236053",0.0144,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,2067,"logistic_regression",NA,NA,NA,2.27996374323798
"284","108d96006a34a040bc1abb48ae11d275","NCT00571064",0.0431,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in NPI-8 Total Score by Visit","SECONDARY","Week 12/ET (Visit 4)","D000544","The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility",FALSE,93,"t-test",NA,NA,NA,1.27450662941382
"285","1091e90846af7c47b858e3b6231331ca","NCT00472199",0.0179,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Short Form-36 (SF-36) Dimension Bodily Pain After 26 Weeks","SECONDARY",NA,"D011595; D012148; D013577","Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)",FALSE,309,"mann_whitney",NA,NA,NA,1.07550130924103
"286","109fed42c595995a3b8dbafd892cf7a1","NCT01628523",0.05,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"The Incidence of ARDS in Mechanically Ventilated Emergency Department Patients, and Risk Factors Associated With Progression to ARDS","SECONDARY",NA,"D012131; D055370; D055371","Mechanical Ventilation in the Emergency Department: A Prospective Cross-Sectional Study",TRUE,204,"logistic_regression",NA,NA,NA,2.11223351769391
"287","10a1dc4033f93639f1ece91622873848","NCT00482170",0.045,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Influence of Participant's Assessment of General Health on Participant Satisfaction With Injection Device","SECONDARY","Statistical analysis was carried out between all categories, by 10 unit increment. Univariate model in which all continuous variables were considered continuous and mean centered was used.","D011565","Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept",FALSE,417,"linear_regression",NA,NA,NA,2.75121289718629
"288","10c9841c8a202d025365fb5b4f27f664","NCT05127304",0.024,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Pneumonia-related Health Care Resource Utilization","PRIMARY","Inpatient visits","D029424","A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",FALSE,11316,"linear_regression",NA,NA,NA,8.33026576749005
"289","10e73f9c867203340c168ecd2e9594ab","NCT00405964",0.035,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Total Rhinoconjunctivitis Quality of Life Questionnaire-Standarized Version (RQLQ-S) After 29 Days of Treatment","SECONDARY",NA,"D012220; D065631","Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)",FALSE,602,"anova",2,NA,NA,2.66774396661302
"290","10fddaa665be5473e7975002a9009495","NCT03781167",0.0324,"One-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Average Daily Normalized ""On"" Time With Troublesome Dyskinesia: Change From Baseline to End of Study","SECONDARY","Week 6 vs Baseline","D010300","A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)",FALSE,110,"t-test",NA,NA,NA,1.08593631488663
"291","11052175734cc6a84a54644c9365937e","NCT00556374",0.007,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With New or Worsening Vertebral Fractures","SECONDARY",NA,"D001943","Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy",FALSE,1644,"logistic_regression",NA,NA,NA,1.07054865380522
"292","11094e97e3b2176c27abbddde5c192e2","NCT01945034",0.023,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","SECONDARY","At Rest Day 4 Mid-day: The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms. Upper limit of 95% CI \< 0 for Ibuprofen treatment significantly better than combined Placebo.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,219,"anova",2,NA,NA,1.12984849536433
"293","1138071f7bdd3cd41e2ff6213db950f8","NCT01245439",0.047,"Wilcoxon","INTERVENTIONAL",0,0,0,1,0,"Participant's (PT) and Investigator's (IN) Assessment of Disease Activity","SECONDARY","PT assessment Visit 7 to Visit 8","D001168; D001172","A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis",FALSE,65,"wilcoxon",NA,NA,NA,1.15586447451685
"294","113e4e28667776461cdb659fcc2d93a2","NCT03975790",0.0345,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Total RA Related Monthly Health Care Cost","SECONDARY","8 months before index date","D001168; D001172","Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX",FALSE,431,"t-test",NA,NA,NA,2.23303891802309
"295","114e6ced91a010d55b13e4b197e866ea","NCT03868930",0.0345,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"State-Trait Anger Expression Inventory (STAXI-2) (Change)","PRIMARY","Hypothesis 1: Participants randomized into the STEP-Home Intervention will show improvement on anger as measured by the State-Trait Anger Expression Inventory (STAXI).

Hypothesis 2: Treatment effects will be maintained at follow-up for both groups","D001930; D000070642; D019966; D040921; D001008; D013405; D013313","Multisite RCT of STEP-Home: A Transdiagnostic Skill-based Community Reintegration Workshop",FALSE,83,"t-test",NA,NA,NA,1.00147163136022
"296","11603e3e91228e44ac31dfd3877640a6","NCT00388453",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Decrease in pH From Baseline to <4","PRIMARY",NA,"D005764; D007818","Efficacy of Dx-pH Probe in Diagnosing Extra-esophageal Reflux Disease",FALSE,47,"mann_whitney",NA,NA,NA,1.04624856756472
"297","118f1e14a7c8b5b11e370195c6aae47f","NCT02528188",0.0077,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 8: \>=70% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,1.28370859508888
"298","119a09467a852ad90424f48926a2fb7f","NCT00707447",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Glucose Tolerance","SECONDARY",NA,"D003920","Evaluation of a Primary Type 2 Diabetes Prevention Programme",TRUE,166,"t-test",NA,NA,NA,1.90948799930043
"299","119ebb4e0ad9975df21167952bda1065","NCT05034328",0.05,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"AUC (Area Under Curve) of the Wisconsin Upper Respiratory Symptoms Survey for Kids (WURSS-K) During the 10-day Treatment Period","PRIMARY",NA,"D003139","Symbiofilm Trial in Allergic Kids (SYMBIOFILM-TAK)",TRUE,186,"mann_whitney",NA,NA,NA,2.01873369003327
"300","11a940350a196ae26fd83d3cb05d77e0","NCT00510146",0.047,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in Glucose and Lipids (Cholesterol, Triglycerides, HDL Cholesterol, LDL Cholesterol) (Open-Label Phase)","SECONDARY",NA,"D001714","Olanzapine Treatment of Patients With Bipolar I Disorder",FALSE,380,"t-test",NA,NA,NA,2.72531134478895
"301","11a9a232839ac453e8d2c972e882c93a","NCT03114969",0.041,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants Making at Least One Critical Error at Visit 2-Primary Device Comparisons","SECONDARY",NA,"D008171; D029424","Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs",FALSE,97,"logistic_regression",NA,NA,NA,1.24716614495594
"302","11b7717a67a21d048ed0fc6baf0c2dd8","NCT00424476",0.0252,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percent of Subjects Whose Average Prednisone Dose Has Been Reduced by ≥ 25% From Baseline to ≤ 7.5 mg/Day During Weeks 40 Through 52","SECONDARY",NA,"D008180","A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)",FALSE,396,"logistic_regression",NA,NA,NA,1.63556461438486
"303","11b80be122bd6cd3325caa3a151560c5","NCT00930943",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Spatial Recognition Memory (SRM) Test Response Latency","SECONDARY",NA,"D059350","Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning",FALSE,60,"anova",2,NA,NA,1.17169922891753
"304","11c09cf1a4a5eab5cfe3829e64e433db","NCT02922634",0.025,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Delirium by Body Mass Index","PRIMARY",NA,"D060825","Preoperative Cognitive Screening in Older Spinal Surgical Patients",FALSE,219,"mann_whitney",NA,NA,NA,1.2141725682839
"305","11c6fb012c8a3108560ff2fbbe8656cf","NCT03130699",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Healthy Eating Behaviors; 12 Months From Enrollment","SECONDARY","Analyses controlled for income.","D003920; D003924","Dulce Digital-Me: An Adaptive mHealth Intervention for Underserved Hispanics With Diabetes",FALSE,170,"logistic_regression",NA,NA,NA,1.93183092008029
"306","11cac9991de8cc97f27cd6c686d7c396","NCT00468845",0.0387,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Integrated Analgesic Score","SECONDARY","48-72 Hours PS","D010149","Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy",FALSE,296,"anova",2,NA,NA,2.04501525708877
"307","11dcf5fb1e2e225b982f506428862bb4","NCT01236053",0.0162,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,188924,"logistic_regression",NA,NA,NA,24.1442893274603
"308","11e4547e7a269113b740276aeaa7e766","NCT03769090",0.028,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Asthma Quality of Life Questionnaire for Participants Aged 12 Years and Older (AQLQ+12) - Number of Participants Who Were Responders at Week 24","SECONDARY","Logistic regression model with baseline AQLQ-12 as a continuous covariate and age group, region and number of severe exacerbations in the 12 months prior to randomization as categorical covariates. A sequential testing strategy is used for secondary endpoints. A null hypothesis can only be rejected if all preceding null hypotheses are also rejected.","D001249","A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma",FALSE,1987,"logistic_regression",NA,NA,NA,3.99231724141739
"309","1213331acf448fd6bedc5fcd07ae12e6","NCT04525222",0.04,"Logistic regression","INTERVENTIONAL",0,1,0,0,0,"Biochemically Confirmed 7-day PPA From Smoking","SECONDARY",NA,NA,"mHealth Mood Management Tool (Actify) to Improve Population-Level Smoking Cessation",FALSE,242,"logistic_regression",NA,NA,NA,1.90454132764031
"310","1221907b9663868594d16ab84ece319f","NCT02790138",0.047,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Weeks 14, 22, and 34","SECONDARY","Change from Baseline at Week 34","D019449","A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis",FALSE,101,"mann_whitney",NA,NA,NA,1.42532183052047
"311","124cdee420300eb7f95fc50fba594b02","NCT03950167",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Gallbladder (GB) Volume","PRIMARY",NA,"D006939","Gallbladder Functions & Serum Cholecystokinin Levels in Women Diagnosed With Hyperemesis Gravidarum",FALSE,46,"t-test",NA,NA,NA,1.03597838019194
"312","1271d7d5bb2534461028f88a34c9f5bb","NCT02730455",0.031,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Composite Global Measure of Functional Disability Excellent Outcome at Day 90","PRIMARY","Composite Measure: The global odds ratio was based on a linear logistic regression model with baseline NIHSS category (score 5-15, 16-23), age (\<60, 60-69, 70-80), tPA use (yes/no), treatment window (\<=9, \>9 and \<=24hours), thrombectomy (yes/no) and region (Spain, UK/Germany, USA) as covariates and unstructured working correlation structure","D020521; D000083242; D002544; D007511","Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke",FALSE,179,"logistic_regression",NA,NA,NA,1.32340595068332
"313","1275bf5f32a561db3fa165ddcb342e6b","NCT05012163",0.002,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Flu Vaccination at Appointment","PRIMARY","Null hypothesis: There is no difference in vaccination rates between patients sent messages offering $1 cash in exchange for vaccination and those sent no study messages; Alternative hypothesis: the vaccination rate is higher in patients sent messages offering $1 cash compared to those who were not sent messages.","D007251","Lottery Incentive Nudges to Increase Influenza Vaccinations",FALSE,28792,"linear_regression",NA,NA,NA,1.43236139635449
"314","12769d9e3a6eab57a1b753e7d8ddfb12","NCT03022370",0.032,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Any Past Year Physical Intimate Partner Violence Perpetration (Men) and Experience (Women)","PRIMARY",NA,NA,"Stepping Stones and Creating Futures Intervention Trial",FALSE,505,"logistic_regression",NA,NA,NA,2.26502031125575
"315","127a836fb624c88498d0c3850a699293","NCT01280617",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Rates of Acute Cellular Rejection Between Study Group","PRIMARY",NA,"D058186","Low Dose Thymoglobin in Renal Transplant Patients",TRUE,43,"t-test",NA,NA,NA,1.00454908915455
"316","127e5be07539634026185f74fc3d0d7b","NCT01347580",0.0307,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Definite Stent Thrombosis","SECONDARY",NA,"D009203; D000072657; D007238","A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)",FALSE,1858,"logistic_regression",NA,NA,NA,4.17892679929268
"317","12aae763899a2fe519ebb30873a7226c","NCT00245219",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Physical Health (as Measured With the SF36) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The interaction between the peer support condition and breast cancer stage at Time 3. The full regression model consisted of 3 steps: The 1st step contained the baseline measure of the dependent variable. The 2nd step contained two dummy coded variables contrasting each condition with control. The 3rd step contained the interaction between the peer support condition and cancer stage. Patients in the education condition were excluded from this analysis.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"linear_regression",NA,NA,NA,1.79957957739554
"318","12c39ad027cd8c291916c45be6f7ca37","NCT02110758",0.013,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Change in Patient Experience From Baseline to Follow up","PRIMARY","To estimate exposure to the intervention on the Shared Decision-Making composite score, we used a difference-in-differences model with fixed effects for practices. The dependent variable was the composite score. The intervention effects were represented by the coefficient estimates for survey time period (pre or post) interacted with status (pilot or comparison).","D009369","Evaluating the Impact of Patient-Centered Oncology Care",FALSE,866,"logistic_regression",NA,NA,NA,1.3511408977339
"319","12d9fc31dd48c9b41e428e7b4360c625","NCT03718832",0.0442418,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Proportion of Participants Filing Outpatient Insurance Claims With Insurance","SECONDARY","Unadjusted mean difference, 6 months after trial enrollment",NA,"Fresh Food Farmacy: A Randomized Controlled Trial",FALSE,465,"t-test",NA,NA,NA,2.86255857962017
"320","12e7af8ba33cd7bbded1ba32c4827bcf","NCT04333420",0.0293,"Logistic regression","INTERVENTIONAL",0,0,1,1,0,"Phase III: 28-day All-cause Mortality (FAS)","PRIMARY","Sensitivity analysis; 369 patients were included in this analysis including the patient that was randomized in error and not treated. Missing values were imputed by multiple imputation.","D000086382; D011014","Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia",FALSE,368,"logistic_regression",NA,NA,NA,1.79596992399397
"321","12ebe3f1c4559797ed7143162cf29d46","NCT01236053",0.0049,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,17853,"logistic_regression",NA,NA,NA,2.55280962895913
"322","12ff118a7bff19c9d4f131c9ce6fe6d5","NCT03192176",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 12","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.36592548755136
"323","1307513f51e132e5a71b050efeed5d91","NCT04954326",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pharmacokinetics Measurement","PRIMARY","Cmax was natural log-transformed and analyzed using an analysis of variance (ANOVA) with fixed effect for formulation. The two one-sided tests procedures were performed on the geometric mean ratio (GMR) between test (S95014 lyophilizate) and reference (S95014 liquid formulation) treatments. The 90% confidence interval for the ratio was obtained within the framework of the ANOVA.","D007938; D054198; D007945","A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL)",FALSE,81,"anova",2,NA,NA,1.3501394396673
"324","1324f542c6915110a85b1fb0f443d499","NCT04428411",0.02,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Month 12","PRIMARY",NA,"D011565","Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).",FALSE,422,"t-test",NA,NA,NA,1.38122065206443
"325","13296a4842d20a1c232516131fd39ad6","NCT04823494",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Quick Speech in Noise Test (QuickSIN)","SECONDARY","For the QuickSIN, aided performance after each wear period was compared between SELF-FIT and PRO-FIT.

* Null hypothesis: Mean (QuickSIN SELF-FIT - QuickSIPRO-FIT) ≥ 1.5 dB
* Alternative hypothesis: Mean (QuickSIN SELF-FIT - QuickSIN PRO-FIT) \< 1.5 dB

Power calculations were based on the primary outcome measured, the aided APHAB global score, (see information for that outcome measure). With the minimum required N of 32 based on the APHAB global score, the power for QuickSIN exceeded 80%.","D034381; D003638; D006319","Wear-Time Trial for Self-Fitting Hearing Aid",TRUE,74,"t-test",NA,NA,NA,1.2933799900503
"326","134459009534e3cb16c612d8abf67c22","NCT00771537",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants Who Accepted Rapid HIV Testing.","PRIMARY",NA,NA,"HIV Testing & Womens Attitudes on HIV Vaccine Trials",FALSE,1029,"logistic_regression",NA,NA,NA,4.708213589095
"327","1354e381ac9da5f1223239107c498197","NCT04231318",0.0298,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score","PRIMARY",NA,"D010003; D020370","Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain",FALSE,198,"anova",2,NA,NA,1.34401081478898
"328","137a374fcaa39fc81981c75cc06c8b0b","NCT00975923",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"CLABSI and VAP Rates","PRIMARY","Infection rates were analyzed using hierarchical negative binomial regression models to model infection rate changes over time and account for clustering of ICUs within hospitals and adjusting for baseline covariates. Power was calculated a priori with a 1-tailed alpha of 0.05 and group size of 30; a 50% decrease in infection rates in the Collaborative group and 15% for the Tool Kit group, yielding power ranging from 82% to 91% for testing group differences.","D053717; D018805","Safe Critical Care: Testing Improvement Strategies",TRUE,59,"linear_regression",NA,NA,NA,1.16252463235142
"329","1392598cab592d08fe851b294e983690","NCT01836445",0.043,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mean Score of Motivation and Behavioral Skills at Baseline and 12 Months","SECONDARY","Analysis for Motivation items","D006069","Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men",FALSE,762,"linear_regression",NA,NA,NA,3.57140646457763
"330","1393731f7527f3a035ac7ab501e779a0","NCT01272921",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Duration of Motor and Sensory Block of the Sciatic With 0.5% Bupivacaine and Ropivacaine After Ultrasound-guided Nerve-stimulator-Assisted Needle Positioning Beneath the CIEL","PRIMARY","The sample selected for this study,70 per drug group (or 10 in each of the 7 groups), achieves 88% power to detect a minimal difference of 4 hours in duration at a significance level (α) of 0.05 and a standard deviation of 3 hours using Williams test. We chose a difference of 4 hours as this was the interval used for assessment in the postoperative period at night. We sought to detect a difference that was equal to 1 observation period difference.",NA,"The Use of Bupivacaine and Ropivacaine for Sciatic Nerve Block",FALSE,70,"mann_whitney",NA,NA,NA,1.2598053214673
"331","13a173dcab4785f8a8e6a9dc9970ba71","NCT00270998",0.0492,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"""Much Better"" or ""Very Much Better"" on PGI-I at 12 Months","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",TRUE,296,"logistic_regression",NA,NA,NA,2.50291558562827
"332","13a7498b0f505a4a51b43e5718d64528","NCT02195583",0.0325,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Surface Microhardness Recovery (% SMHR)","PRIMARY",NA,NA,"The Effect of Experimental Dentifrices on Remineralization of Caries Lesions In-situ",FALSE,114,"anova",2,NA,NA,1.10759207289787
"333","13c1bcb574f8436f580f94b842f3dfd3","NCT00735709",0.026,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants in MADRS Remission at Week 8","SECONDARY",NA,"D003866; D003863; D003865","Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder",FALSE,278,"logistic_regression",NA,NA,NA,1.4115873324377
"334","13cbc8099722207b149693de4cd3f858","NCT01179568",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Responder Status Based on Complicated Grief Clinical Global Impression-Improvement (CGI-I) Scale","PRIMARY","Our prespecified primary analysis was cross-sectional, comparing treatment response rates for CIT vs PLA at week 12 (aim 1), based on the intention-to-treat principle including all randomized participants. With 10% of 440 target enrollment lost to follow-up we had a power of 76-83% to detect predicted between-group difference in response (CGT with PLA, 40%; CGT with CIT, 60%; CIT 40%; and PLA 20%)",NA,"A Study of Medication With or Without Psychotherapy for Complicated Grief",TRUE,200,"logistic_regression",NA,NA,NA,2.09181669397075
"335","13dc45550418fa544c5c8686a7a55a3d","NCT01715896",0.048,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Who Achieved Simplified Disease Activity Index (SDAI) Remission at Day 169","SECONDARY",NA,"D001168; D001172; D009336","A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis",FALSE,138,"logistic_regression",NA,NA,NA,1.68674478331257
"336","13ec533e40e3cdab8b30f00a5d75abd5","NCT01361568",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Total Pain Relief Within the First 2 Hours (TOTPAR 0-2) Following Postoperative Study Drug Treatment Using LOCF","SECONDARY",NA,"D010149","Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery",TRUE,142,"t-test",NA,NA,NA,1.7695236426303
"337","1414d98aa8e660469dd25945cc9a58d8","NCT00855582",0.027,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Uroflowmetry Parameters - Peak Urine Flow Rate (Qmax) at Week 12 Endpoint","SECONDARY",NA,"D007172; D011470; D006965","A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia",FALSE,300,"anova",2,NA,NA,1.51382124324515
"338","1415c47892eb8b22c6d944f92dc692b7","NCT02688400",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Patient's Global Assessment of Disease Activity","SECONDARY",NA,"D010003; D020370","Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis",FALSE,370,"mann_whitney",NA,NA,NA,2.83265165361863
"339","141eb02ef0aee39f7c81996099338422","NCT05302414",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Resuscitation Knowledge Scale","SECONDARY","For follow-up test at the 16 weeks.",NA,"The Learning Outcome of Resuscitation Teamwork Training in Postgraduate Year Doctors and Nurses",FALSE,64,"kruskal_wallis",2,NA,NA,1.20770700959599
"340","14234134ffd918a2c16da04246de887d","NCT00458406",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Change in ESS From Month 1 to Month 3","SECONDARY","Mann-Whitney test. We hypothesized that Bi-Flex would result in improved adherence but similar efficacy to CPAP.

The study sample size of 45 in the Bi-Flex group and 15 in the CPAP group had 80% power to detect an effect size ≥ 0.85 with a 0.05 two-sided significance level. In addition, with this sample size, the 95% CI for the difference between the 2 means had a range of 1.282 SD.","D001049; D012891; D020181","Evaluation of Adherence and Therapeutic Effectiveness of Bi-Flex Versus CPAP in Children With OSA",FALSE,56,"mann_whitney",NA,NA,NA,1.13456029943022
"341","1428a182d0a4f05aef1057ffc7f200de","NCT02690649",0.03,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Atrial Fibrillation Knowledge","SECONDARY",NA,"D001281","Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence",FALSE,149,"linear_regression",NA,NA,NA,1.17718974224181
"342","146fb109b8c9cccf740bd6350b287d5b","NCT03655951",0.03,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Parent Reported Parent-child Communication Quality From Pretest to Posttest","SECONDARY",NA,NA,"Birds and Bees Research Study",FALSE,293,"linear_regression",NA,NA,NA,1.63800086900411
"343","148353be7b605e562729aa5c216fb458","NCT05127304",0.037,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"COPD or Pneumonia-attributable Health Care Resource Utilization: Pharmacy Fills","PRIMARY",NA,"D029424","A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",FALSE,11316,"linear_regression",NA,NA,NA,12.0850943643871
"344","14906df2420fbbab468c6057fb04f0ed","NCT05226884",0.05,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Non-inferiority of Distance Corrected Binocular Intermediate Visual Acuity","PRIMARY",NA,"D019591","Intermediate Vision in Patients With Clareon IOLs Compared to Eyhance IOLs",TRUE,310,"mann_whitney",NA,NA,NA,2.59543112524924
"345","149418c0bf3bf2efbc3d23e1b7bc5d4c","NCT00321854",0.0282,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 9","SECONDARY",NA,"D010300","Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)",FALSE,406,"mann_whitney",NA,NA,NA,1.82432127051625
"346","14a74334e17619b4b16079a93f617dd6","NCT03203512",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Pro-thrombotic Activities of Platelet-derived Extracellular Vesicles (PDEVs) Prepared From the Supernatants of Stimulated Platelets (Endpoint and Maximum of Thrombus Formation)","SECONDARY","Null hypothesis is that there was no difference in change of pro-thrombotic activity of PDEVs in affecting endpoint for ex vivo thrombus formation between fish oil and placebo capsules. A general linear model with fixed factors of treatment and period was conducted to determine the differences in the effect of two treatments and two periods on the pro-thrombotic activity of PDEVs.","D001768","Fish Oil-derived N-3 Polyunsaturated Fatty Acids and Extracellular Vesicles",FALSE,80,"anova",2,NA,NA,1.34217713699512
"347","14d913afaba3bfb80dd431d7a9605e95","NCT03192176",0.0472,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 2 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 6","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.32438475117263
"348","14e88b1e2a2f97f874217560bafb64bb","NCT05293314",0.05,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"The Ability of the Breath Test Model to Distinguish Bronchiectasis From Healthy People","PRIMARY","Evaluate the ability of the breath test model to distinguish bronchiectasis from healthy individuals by measuring the area under the receiver operating characteristic (ROC) curves. The maximum value in the area below the receiver is 1. The closer the value is to 1, the higher the prediction accuracy of the model.","D001987","Assessment of an Exhaled Breath Test to Detect Bronchiectasis",TRUE,436,"mann_whitney",NA,NA,NA,3.07251687284502
"349","14f457be2ca2aab7736ad416404c1c29","NCT02697422",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Number of Outpatient Clinic/Primary Care Visits","SECONDARY",NA,"D002318; D006949","Veteran Peer Coaches Optimizing and Advancing Cardiac Health",FALSE,264,"linear_regression",NA,NA,NA,2.39772562409599
"350","14fd39bb3dec177c68c42a361940efe5","NCT02677701",0.043,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Change in Sputum Pseudomonas Aeruginosa Bacterial Density","OTHER_PRE_SPECIFIED",NA,"D003550; D005355","Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)",FALSE,64,"linear_regression",NA,NA,NA,1.06581078191614
"351","150c93a0f650263224ad829664a9d6b7","NCT01279343",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Time From Start of Labor Induction to Vaginal Delivery","PRIMARY",NA,NA,"Cervical Foley Plus Vaginal Misoprostol for Labor Induction",FALSE,117,"t-test",NA,NA,NA,1.04766724848982
"352","152bf35734e2e6ebce90b5224572672c","NCT03372369",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Effective Contraception Preference Score","PRIMARY","The null hypothesis is that the patient-centered poster does not produce a larger increase in the effective contraception preference score between baseline and followup than the CDC poster.",NA,"Testing the Impact of Two Posters on Contraceptive Knowledge, Contraceptive Preferences, and Perceived Pregnancy Risk",FALSE,936,"t-test",NA,NA,NA,2.04981899054956
"353","154c037a1b76e7a2c87072458f864a83","NCT02867709",0.0129,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose","PRIMARY",NA,"D008881","Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine",FALSE,919,"logistic_regression",NA,NA,NA,1.38212302222286
"354","155d4cd7a09536d5410fb25d802811f7","NCT00551135",0.0487,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Total Cumulative Dose of Opioids and Tramadol Used During and After Surgery","SECONDARY","Day 6 PS; LS Means from ANOVA model with terms of treatment, pooled center. Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,203,"anova",2,NA,NA,2.0613097101377
"355","1561d6966687b2e50db3a3d2053e7df7","NCT02496156",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"SURE Test","SECONDARY",NA,"D003920; D003922","Shared Medical Decision Making in Pediatric Diabetes",FALSE,115,"anova",2,NA,NA,1.59749798944782
"356","15623dae458375a7b39c6bff841a7a2b","NCT05194956",0.0355,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Chairside Time Taken to Complete Impression Method","SECONDARY",NA,NA,"Orthodontic Patient Experience of Intraoral Scans Versus Alginate Impressions",FALSE,84,"anova",2,NA,NA,1.03173541224505
"357","1563b33a2934e2363c58ad65f90ac27b","NCT00394901",0.0353,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Patients Not Reporting Hyperalgesia","SECONDARY","Hypothesis testing was conducted using two-sided tests with significance level of 0.05.","D009437; D051474","A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia",FALSE,182,"logistic_regression",NA,NA,NA,1.49014435532393
"358","1567868878b917d462003ffff97f7c96","NCT01504438",0.04,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Pain and Function Following a Total Ankle Replacement as Measured by the American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Rating System","PRIMARY",NA,"D010003","Prospective Randomized Evaluation of a Two and Three Piece Total Ankle Replacement",FALSE,74,"anova",2,NA,NA,1.07421425939155
"359","158f70ad82d5219cd9e678440a0bc09b","NCT02270671",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Anxiety Related Disorders at 4-week Post-intervention and 12-week Follow-up","SECONDARY",NA,"D003863","Attention Bias Modification Training for Young People",FALSE,120,"anova",2,NA,NA,1.63072147479452
"360","159e59038bd7c13bd8e250ffb6a8dc7e","NCT00684060",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Global Left Ventricular Function","PRIMARY","Comparison of change in global LVEF in the active group minus change in global LVEF in the control group. 80 percent power based on BOOST results","D018754; D018487","Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)",TRUE,81,"t-test",NA,NA,NA,1.3501394396673
"361","15a810b89cf97daa91b774391f249c50","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Nighttime Central Diastolic Pressure","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"362","15b5563846d677ea6a53282d5b3bb809","NCT01945034",0.03,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","SECONDARY","At Rest 3 hour Day 1: The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,152,"anova",2,NA,NA,1.18861079960632
"363","15dccfa02d9348d1abfa530177a1d84c","NCT00270998",0.0492,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Satisfaction With Treatment at 12 Months","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",TRUE,296,"logistic_regression",NA,NA,NA,2.50291558562827
"364","15ddc8ae5a3eed5f38d1e7cbe7e264f3","NCT00105989",0.021,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in Sheehan Disability Scale (SDS) - Maintenance Phase","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,245,"t-test",NA,NA,NA,1.10307743494356
"365","15e52311a6c81c2bc850e2525a63effb","NCT01672892",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Urinary Toxicity, as Measured by Change in EPIC Urinary Domain","SECONDARY","Week 3 of RT","D002583; D016889; D011183","Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer",FALSE,279,"t-test",NA,NA,NA,2.04259800589513
"366","15fedf6c9513d2dc5a1bc463cb89383d","NCT00043186",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Serum CTX Percent Change From Baseline at Month 48","SECONDARY",NA,"D001851","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",FALSE,43,"mann_whitney",NA,NA,NA,1.00454908915455
"367","162b0b74b521757289fff7d64b6abcf9","NCT00267111",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Visual Analogue Scale","SECONDARY","We hypothesized that parents and nurses will report lower pain scores as assessed by visual analogue scale in topical amethocaine gel 4% compared to placebo group. This was a secondary outcome and no power calculation was performed.",NA,"Topical Amethocaine Gel for Intramuscular Injection in Term Neonates",TRUE,109,"t-test",NA,NA,NA,1.55669642807029
"368","1635f5357c89e2d196855374ef66f846","NCT01445951",0.0156,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Incidence of Severe Hypoglycemia","OTHER_PRE_SPECIFIED",NA,"D003920; D003922","Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period",FALSE,345,"logistic_regression",NA,NA,NA,1.00656348809843
"369","16448e93398ce9e5bd11b890f2bce4b8","NCT03399318",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Area-under-the-curve (AUC) of Fever ≥ 38.5°C (Best)","SECONDARY","A secondary efficacy measure included fever exposure as measured by the area under 214 the temperature × time curve for T≥38.5°C during the 72-hour follow-up period, categorized as 215 0, \> 0 and \< 2, and ≥ 2 degree-hours.","D008288; D018512; D012640; D005334; D000084462","Aggressive Antipyretics for Fever Reduction in CNS Malaria",TRUE,256,"logistic_regression",NA,NA,NA,2.36165385862108
"370","165285e269636bb278952f67dfd97a39","NCT03769090",0.033,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Asthma Control Questionnaire-5 (ACQ-5) - Number of Participants Who Were Responders at Week 24","SECONDARY","Logistic regression model with baseline ACQ-5 as a continuous covariate and age group, region and number of severe exacerbations in the 12 months prior to randomization as categorical covariates. A sequential testing strategy is used for secondary endpoints. A null hypothesis can only be rejected if all preceding null hypotheses are also rejected.","D001249","A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma",FALSE,2027,"logistic_regression",NA,NA,NA,4.6431257892256
"371","165c8ecf0aeadc076d42702db8c34efa","NCT02709486",0.0201,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 24, \>=30%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,563,"logistic_regression",NA,NA,NA,1.59974493546501
"372","165d7aea6639a4bec9ad8f7c8dee7d74","NCT02626819",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Weight Change (kg)","PRIMARY",NA,"D009765","Improving Weight Management at the VA",TRUE,43,"mann_whitney",NA,NA,NA,1.00454908915455
"373","166cc3fc78dffd135e7e70150874733b","NCT03192176",0.0451,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 4","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,85,"logistic_regression",NA,NA,NA,1.26806811704172
"374","167b2f24dc7d3e4155f638dbedff5f40","NCT01378299",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Percent Change in Hematocrit According to re1062033 Polymorphism of the CYP19A1 Gene","SECONDARY","Analysis by intention to treat with the last value carry forward.","D007006","CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy",TRUE,52,"anova",2,NA,NA,1.09617796589869
"375","167f6b5caf68e0bc811396540efa3fcb","NCT02537678",0.048,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Child Behavior Checklist Externalizing Symptoms","SECONDARY",NA,"D013313","Stepped Care for Children After Trauma: Optimizing Treatment",FALSE,183,"t-test",NA,NA,NA,1.93563056662706
"376","168083650cf7ad6847aba05dc78af793","NCT04697264",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Correlation Between Circulating Levels of These Markers and Demographic Characteristics.","PRIMARY","The influence of age on IGF1 and 2 levels were analysed by dividing the population into binary groups (\<60years and \>/=60years) to facilitate comparison.","D016889; D009765","Adipocytokines in Endometrial Cancer",FALSE,50,"linear_regression",NA,NA,NA,1.07648023860356
"377","16aba643149075715834625baf876135","NCT03373383",0.041,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"75 % Responder Rate Over the 12 Week Maintenance Period","SECONDARY","PSL dose/Placebo was calculated using logistic regression with categorical factors for treatment group, Region (Europe, Non-Europe), Baseline SV2A use (0, 1) and log-transformed Baseline seizure frequency as a continuous covariate.","D004827; D012640; D000069279","Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy",FALSE,162,"logistic_regression",NA,NA,NA,1.59788304581029
"378","16b33168ef70cc041dd17ff37fa4a6e2","NCT00530842",0.0482,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Post-dose TGV(FRC) (After 8 Weeks)","PRIMARY",NA,"D029424","Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD",FALSE,618,"anova",2,NA,NA,3.54274763907608
"379","16b89f90193158ac84097e1ec2e4d8c0","NCT01256944",0.05,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"Impaired Glucose Tolerance","PRIMARY",NA,"D011085; D002318; D024821; D013577","To Study Polycystic Ovary Syndrome in Taiwanese Women",TRUE,160,"anova",2,NA,NA,1.87547517894336
"380","16b9b997b6e9dc4fdbe85b9d723199fd","NCT01187550",0.041,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Lipid Profile at Week 4","SECONDARY","For LDL-cholesterol: Wilcoxon rank sum test was used to calculate p-value.","D004392; D004393; D010900","Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®",FALSE,204,"mann_whitney",NA,NA,NA,1.78834011912328
"381","16bf8c23d20b6b5ac0bb06fec7b1df41","NCT00443872",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Mini Mental State Examination (MMSE) Scores for All Subjects","SECONDARY",NA,"D010300","Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists",TRUE,60,"t-test",NA,NA,NA,1.17169922891753
"382","16c1e68f5a80c351f0973efbb29b18ac","NCT04910165",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Inpatient Opioid Use","PRIMARY",NA,"D010149","Exparel Use in Adductor Canal Block After Total Knee Arthroplasty",TRUE,100,"mann_whitney",NA,NA,NA,1.49341131573029
"383","16ca896e796055a64bb1ed31e55eac54","NCT01236053",0.0158,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,2067,"logistic_regression",NA,NA,NA,2.47400323627304
"384","16d0cc64acf96d402ca8da6f9474d118","NCT00255190",0.042,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Change From Baseline to Month 12 for Hemoglobin Values","PRIMARY",NA,"D005764","Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn",FALSE,316,"anova",2,NA,NA,2.26327312901033
"385","16d177a4bc47aa4f9fc2f8b98d8281d2","NCT01066819",0.0255,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for On-treatment response (cEVR vs NO RVR/EVR). The logistic regression analysis for relapse was performed for association between treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,264,"logistic_regression",NA,NA,NA,1.35340153480285
"386","16d18eb1d6d3a48a2eec3237466b0646","NCT01778127",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Differences in Change in Muscular Strength Between Groups Over 24 Weeks: Dorsiflexion at 60 Degrees/Second","SECONDARY",NA,NA,"A Web-Based Physical Activity Intervention in Adolescent Survivors of Childhood Cancer",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"387","16d4c291ca9437a9b58e95a4b2c44438","NCT00508183",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"ASES Score","SECONDARY",NA,"D000070636","Types of Fixation in Arthroscopic Rotator Cuff Repair",FALSE,73,"t-test",NA,NA,NA,1.28506804726186
"388","16db3325a9945be3a98c62bef2ba5b13","NCT01421342",0.018,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Rate of Protocol Remission of Symptoms of Major Depressive Disorder","PRIMARY","Co-primary hypothesis: After ordering results form largest p-value to smallest (Hochberg approach) the comparison of Augmentation Antidepressant + Aripiprazole with Switching to Bupropion-SR was performed at the 0.025 significance level.","D003863; D003866; D003865","VA Augmentation and Switching Treatments for Improving Depression Outcomes",FALSE,1016,"logistic_regression",NA,NA,NA,1.94739730056856
"389","17247d6d1beba06822a6dad66f6c5b2a","NCT01236053",0.0309,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,20382,"logistic_regression",NA,NA,NA,13.9024228981453
"390","1765f37af2471bf8e79547af754ed149","NCT02820038",0.0377,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mean Knowledge of the Risks and Benefits Associated With DMARD Therapy at 6 Months Adjusted for Baseline","SECONDARY","The investigators hypothesized that participants would exhibit a greater increase in knowledge between baseline and the 6-month follow-up if they were assigned to receive gist reasoning training, delivered via the SMART Program, compared to those who were not assigned to receive this training.","D001168; D001172","Enhancing Patient Ability to Understand and Utilize Complex Information Concerning Medication Self-management",FALSE,127,"linear_regression",NA,NA,NA,1.32292124286088
"391","17799fd128782ce2dec7c448417d95c3","NCT00779246",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Acquisition of Methicillin-resistant Staph Aureus (MRSA) Colonization or Infection","PRIMARY","Null hypothesis was that ASC and CHG would be no different in preventing acquisition of MRSA.","D007239; D003141; D013203","Cost-Effectiveness Study Comparing Chlorhexidine Bathing With Active Surveillance Cultures to Prevent Methicillin-resistant Staphylococcus Aureus & Other Hospital Infections",FALSE,687,"logistic_regression",NA,NA,NA,3.85061762427125
"392","178730604a2d680afa4432a77761d620","NCT04714320",0.047,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit","SECONDARY","Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 64","D006973","A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure",FALSE,58,"logistic_regression",NA,NA,NA,1.09585976056121
"393","17875b3cc3ea4ac97ed1b770c1491476","NCT00939029",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,1,0,"End of Treatment (Week 8) Point Prevalence Abstinence","PRIMARY",NA,NA,"Highdose Nicotine Patch Therapy for Smokeless Tobacco Use",FALSE,52,"logistic_regression",NA,NA,NA,1.09617796589869
"394","17a2a92a5d7db8c119c6b5222c0b2046","NCT00458406",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Apnea Hypopnea Index (AHI; Number of Apneas and Hypopneas Per Hour of Sleep) From Month 1 to Month 3","SECONDARY","Two-sided t-test. We hypothesized that Bi-Flex would result in improved adherence but similar efficacy to CPAP.

The study sample size of 45 in the Bi-Flex group and 15 in the CPAP group had 80% power to detect an effect size ≥ 0.85 with a 0.05 two-sided significance level. In addition, with this sample size, the 95% CI for the difference between the 2 means had a range of 1.282 SD.","D001049; D012891; D020181","Evaluation of Adherence and Therapeutic Effectiveness of Bi-Flex Versus CPAP in Children With OSA",TRUE,56,"t-test",NA,NA,NA,1.13456029943022
"395","17a763dc9ddb2cac979f169c81e18075","NCT01832961",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Exhaled Nitric Oxide (FeNO)","SECONDARY",NA,"D008171; D008173; D029424","Acute Effects of a Flutter Device in COPD",TRUE,45,"t-test",NA,NA,NA,1.02560707988412
"396","17c2d4e36520405d62673ba8aaf87499","NCT02649634",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Self-efficacy for Engaging in Physical Activity After the First Motivational Interviewing or Attention Control Interview, Week 1- 2","SECONDARY","Self-efficacy was analyzed via an independent sample t-test comparing the groups on mean self efficacy rating on the ESE.","D009765; D050177; D015431","Does Motivational Interviewing Improve Behavioral Weight Loss Outcomes for Obesity?",FALSE,135,"t-test",NA,NA,NA,1.7265679672307
"397","17c823c462fa219a385b1d60620967a2","NCT00105989",0.032,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Leukocyte Count - Continuation Phase","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,386,"t-test",NA,NA,NA,1.98303169230429
"398","17cfed6f8f7c618c83eb5b3a21292023","NCT02572401",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Proportion Condom-protected Intercourse","SECONDARY","The analysis tested whether text messaging enhanced the effects of the HIV risk reduction intervention by comparing the HIV Risk Reduction and Text Messaging and No-Intervention No Text Message Arms to the Text Messaging Only and HIV Risk Reduction Only Arms. This is a test of the interaction between the two types of interventions.","D000163; D015658; D012749; D007153","Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men",TRUE,268,"linear_regression",NA,NA,NA,2.41555960484265
"399","17d39901cc26ec607749b397c678888c","NCT04026555",0.045,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Mortality Rate","SECONDARY","IPTW log-binomial regression models were used to model the secondary and ad hoc outcomes. Treatment effect is expressed as adjusted relative risk (RR).","D000075902","Realtime Streaming Clinical Use Engine for Medical Escalation",FALSE,2740,"logistic_regression",NA,NA,NA,7.02355972277979
"400","17e3fe6456aba1f04784627de36418f3","NCT03192176",0.0422,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 10","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,85,"logistic_regression",NA,NA,NA,1.19963908172612
"401","17e5c50f73262c41d73514f494712af6","NCT02547779",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"30-day In-hospital Mortality","SECONDARY",NA,"D058186; D016638","Isotonic Solutions and Major Adverse Renal Events Trial in the Non-Medical Intensive Care Unit (SMART-SURG)",TRUE,10421,"logistic_regression",NA,NA,NA,14.9579666321604
"402","17e8e0b540d6b86e7fe3f7be24bdb99b","NCT00256750",0.0174,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire","SECONDARY","General Health, Month 12","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,411,"anova",2,NA,NA,1.20730540750468
"403","17f986db2c171f85c395813bb0c6c847","NCT04864249",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Mean Arterial Pressure","SECONDARY",NA,"D004461; D011225; D046110; D006973","Neonatal Sleep Intervention to Improve Postpartum Hypertension",FALSE,102,"t-test",NA,NA,NA,1.2513463072596
"404","17fba2c76ebcd8961813a6c5ed0a7806","NCT01197508",0.037,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 12, Week 14, and End of Treatment (Week 16)","SECONDARY","Logistic regression model including treatment and pooled center as fixed effects and the randomization MADRS total score as a covariate.","D003866; D003863; D003865","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.",FALSE,343,"logistic_regression",NA,NA,NA,2.11700226917923
"405","180bc8d64ab2ff519778875062a582c8","NCT01187550",0.033,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Lipid Profile at Week 4","SECONDARY","For HDL-cholesterol: Wilcoxon rank sum test was used to calculate p-value.","D004392; D004393; D010900","Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®",FALSE,204,"mann_whitney",NA,NA,NA,1.48782010665858
"406","1812811451c08e2faf3be4f83a45bc1c","NCT02160977",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Proprioception of the Knee Post Operation","PRIMARY",NA,"D010003","Proprioception of the Knee Post MIS TKA and MIS-QS TKA",TRUE,84,"t-test",NA,NA,NA,1.37375080866169
"407","18195f193aef4d7f57ddddeba5729a2e","NCT05127304",0.017,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"COPD and/or Pneumonia-related Health Care Resource Utilization","PRIMARY","Ambulatory visits","D029424","A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",FALSE,11316,"linear_regression",NA,NA,NA,6.166005718102
"408","181af0a520d07ab644ef471bc994a330","NCT05438576",0.032,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Left Ventricular Ejection Fraction (LVEF) <50%","PRIMARY",NA,"D009202","Screening for Pregnancy Related Heart Failure in Nigeria",FALSE,1195,"logistic_regression",NA,NA,NA,3.47511069757978
"409","18237c97b0417433dc4dacc3065be9a1","NCT03192176",0.0428,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week","SECONDARY","Week 14","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.20021032028455
"410","182d1d7464c3bad95d169f9939f90437","NCT00240487",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Mean PaO2/FiO2 Ratio","PRIMARY","Differences in mean PaO2/FiO2 ratios between the two groups will help to determine whether order of therapy (immediate treatment with nitric oxide versus delayed treatment with nitric oxide) impacts outcomes.","D012128; D012127; D055371; D013577","Nitric Oxide Administration for Acute Respiratory Distress Syndrome",FALSE,52,"t-test",NA,NA,NA,1.09617796589869
"411","183ef5ff37f8dfb41b7e07a78c649ed5","NCT00902330",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Means and Standard Deviations of Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).","SECONDARY","Spearman correlation coefficients were computed for the biomarkers. P-Values shown are not adjusted for multiple comparisons. The a priori threshold for statistical significance was P less than 0.05. This information applies to all rows listed in the table.","D001943; D012893; D020447; D005221; D003863; D001008","Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer",TRUE,152,"t-test",NA,NA,NA,1.82914240849702
"412","1858d085d6d6740c480910925df5e96c","NCT03158311",0.013,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Patients Achieving the Minimally Clinically Important Difference (MCID) Change From Baseline AQLQ ≥ 0.5","SECONDARY",NA,"D001249","Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium",FALSE,895,"logistic_regression",NA,NA,NA,1.37341911923278
"413","186ae52f6754475a6f313dff364ed301","NCT00442546",0.0284,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Interference With General Activity as Measured by the m-BPI-sf","SECONDARY","Discharge","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,166,"anova",2,NA,NA,1.18370875214069
"414","1887738fc6caffda50b61538369071f8","NCT02868216",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Difference in Flow-mediated Dilation in the Brachial Artery in the Base and After the Treatment.","PRIMARY",NA,"D009203; D007238","Management of Anger in Patients With Acute Myocardial Infarction (MAPAMI)",FALSE,76,"anova",2,NA,NA,1.30984657914153
"415","188d78dba67681c49f0f274da322ece5","NCT00717977",0.04,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Daytime (6:00 a.m. - Midnight) Mean Sensor Glucose by Age Group","PRIMARY","The associations of mean sensor glucose and glucose variability measures with age were assessed using least-squares regression models adjusting for device type.","D003922","Continuous Glucose Sensor Profiles in Non-Diabetic Subjects",FALSE,74,"linear_regression",NA,NA,NA,1.07421425939155
"416","188efdbad05a1807bb0d2a794ec343f5","NCT01539070",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Children´s Consumption of Foods From Baseline to 3 Months by Intervention Assignment","PRIMARY","In intent-to-treat analyses, we used unadjusted and adjusted multivariate regression models, to examine differences from baseline to 3 months between the intervention and usual care groups. For continuous outcomes, we used linear regression models, and for dichotomous outcomes, we used logistic regression models. To account for clustering by practices, we performed generalized linear mixed models. The Estimator (Est) and Confidence Interval 95% (95% CI)are reported.","D009765; D063766","Intervention for the Prevention of Obesity in Preschool",TRUE,306,"linear_regression",NA,NA,NA,2.5788408992482
"417","18b41bd320651649568b656c3d53ab1c","NCT04881760",0.029,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction","SECONDARY",NA,"D009765; D050177","A Study of LY3437943 in Participants Who Have Obesity or Are Overweight",FALSE,137,"logistic_regression",NA,NA,NA,1.09810262366075
"418","18bd1e035fe23887ab80014008dd1478","NCT03192176",0.0454,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 2 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 3","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.28221861783766
"419","18da14e0783be0f0ad42d87671e415fc","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Urea Nitrogen Value at Baseline and After Treatment Completion","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"420","1915e4e2c6b54a0840f10acb359e5ccc","NCT01216163",0.037,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Sum of Pain Relief Rating and Pain Intensity Difference (PRID)","SECONDARY","6 hours: Treatment difference (Ibuprofen sodium - Acetaminophen) and corresponding 95% CI were calculated based on LS means from the ANOVA model.","D014098","Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain",FALSE,173,"anova",2,NA,NA,1.51287735990295
"421","1918733abb24cc048fc0349541b6bb71","NCT01329029",0.0175,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Rate of Severe COPD Exacerbations Per Patient Per Year","SECONDARY",NA,"D008171; D008173; D029424","Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)",FALSE,1935,"linear_regression",NA,NA,NA,2.61857116755189
"422","191e7203f026e133d56a95e983cc0854","NCT00286468",0.046,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Glycosylated Hemoglobin ≤ 7.0%.","SECONDARY",NA,"D003920","Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.",FALSE,302,"logistic_regression",NA,NA,NA,2.38931884054946
"423","19235a2c1dfbbdbc2464f819d86df0a1","NCT02485483",0.034,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"WHO-5 Index at Baseline: VADERA I","PRIMARY","Number of participants analyzed (N) = 222","D001168; D001172; D003863","Study for Validation of Standardized Questionnaires on Depression and Investigation of the Frequency of Depression in Rheumatoid Arthritis (RA) Participants",FALSE,224,"t-test",NA,NA,NA,1.59760217169233
"424","19257a5c21d932c1c019410bd34ee8a8","NCT01236053",0.0333,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,2067,"logistic_regression",NA,NA,NA,4.72505074842544
"425","192a0f8b0b4d3bf70245886979556fb5","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Saturated Fat","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1765,"linear_regression",NA,NA,NA,6.1614479472587
"426","1935d6b7ef318790c867f3a80d2a0514","NCT00416572",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mental Health (Measured With the SF-36) at Baseline, Post-intervention (4-months Post-intervention) and Final Follow-up (13-months Post-intervention)","PRIMARY","Comparison between nutrition education intervention and the control condition at 4 months post-intervention. The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome.","D001943","Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer",FALSE,154,"linear_regression",NA,NA,NA,1.84083479148392
"427","19460bc010e83e05b2cdc3ce97d50972","NCT00390949",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Reporting More Than One Casual Partner in the Past 3 Years","SECONDARY",NA,"D015658","Scientific Evaluation of Peer Education and STD Treatment to Reduce the Spread of HIV in Zimbabwe",TRUE,4749,"logistic_regression",NA,NA,NA,10.0998413233167
"428","19802b09cdc1a4c9de628cce6de98dca","NCT00105989",0.019,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in Hamilton Depression Rating Scale Subscales, Including the Core, Maier, Anxiety/Somatization, Retardation/Somatization, and Sleep Subscales, and the Depressed Mood Item - Acute and Continuation Phases","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,412,"t-test",NA,NA,NA,1.30529687286858
"429","198a25a99a741c35ac215137ce513e98","NCT00338884",0.045,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Ctrough Stratified by Tumor Response (CR or PR or [SD > = 12 Weeks] Versus PD) for Total Drug (Sunitinib + SU012662)","SECONDARY","Day 1, Week 7 (CR or PR or \[SD \> = 12 Weeks\] Versus PD)","D002292","Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer",FALSE,88,"mann_whitney",NA,NA,NA,1.28683000126716
"430","19a43ae57ea35d61fc31110ed79e6424","NCT01672892",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Urinary Toxicity, as Measured by Change in EPIC Urinary Domain","SECONDARY","Week 5 of RT","D002583; D016889; D011183","Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer",FALSE,279,"t-test",NA,NA,NA,1.5990334601552
"431","19bf3e43057be0fda81bb2f49ce7fa28","NCT02033889",0.023,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)","SECONDARY",NA,"D003920; D003924","A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).",FALSE,416,"logistic_regression",NA,NA,NA,1.54852400071779
"432","19ced305275d18330a043a0d0f86b7ea","NCT01138995",0.022,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Berg Balance Scale (BBS) Score","SECONDARY",NA,"D020521; D010291; D020427; D020233","Clinical Study of the L300 Versus Ankle-foot Orthosis (AFO) on Post-Stroke Subjects With Foot Drop",TRUE,197,"mann_whitney",NA,NA,NA,1.03254180235995
"433","19d809fa7d23fbfddbfec305554aeedc","NCT00536471",0.045,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Statistically Significant Changes in Baseline to 9 Month Endpoint Laboratory Values - Hemoglobin","SECONDARY",NA,"D003866; D003863; D003865","A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients",FALSE,264,"anova",2,NA,NA,2.19518396887831
"434","19dccecb9ee38e5112f3aa2dc3b46dce","NCT03258645",0.01,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Previous Modified Rankin Scale (mRS) at First Ever Ischaemic Stroke According to Dabigatran Initiation Time Period","SECONDARY","Univariate linear regression with the continuous dependent variable of time-to-initiation for dabigatran in days and independent variable of Modified Rankin Scale (mRS) at index date was applied.","D001281","This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke",FALSE,1240,"linear_regression",NA,NA,NA,1.27974442537769
"435","19e4bb0f7c90dd0143d97807e219627b","NCT01559259",0.039,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Intensity Difference on 4-Point Categorical Scale (PID4)","SECONDARY","0.5 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,185,"anova",2,NA,NA,1.63437425337792
"436","19e5e4821cb9f0c9d6ede0aeac7bdf61","NCT03183908",0.0435,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Quality of Life - Late Life Function & Disability Instrument - Ages 65 - 79","SECONDARY","Social Roles Changes from Day 1 to Day 3 Group Comparisons","D000075662; D064420","FLUAD® vs. Fluzone® High-Dose Study",FALSE,239,"mann_whitney",NA,NA,NA,2.03160559771789
"437","19e678e0f716ab35f7c7580cc117cc9f","NCT02373813",0.037,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in SDAI Score at All Measured Timepoints","SECONDARY","Change at Week 36","D001168; D001172","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",FALSE,152,"t-test",NA,NA,NA,1.42055118922827
"438","19eef806574d2578a623c3a26f583e0b","NCT03521115",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Count of Teens Who Were Drunk or Very, Very High During the Past 6 Months","PRIMARY","12 month follow-up. Among those assigned to intervention, dosage was assigned as 0 for no exposure, 1 for completing only the communication, and 2 for completing the alcohol component. A probit analysis predicting completion was conducted from baseline measures and an instrumental variable, inverse Mills' ratio (IMR) representing the underlying selection processes was included as a covariate accounting for factors related to program completion. All controls were assigned 0 dosage.","D019973; D000435; D000374; D000428; D064829","Family Based Prevention of Alcohol and Risky Sex for Older Teens",TRUE,400,"linear_regression",NA,NA,NA,2.94410447224363
"439","19fa108d54609438228f3bf4a649960c","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Environmental Warning Label","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1770,"linear_regression",NA,NA,NA,6.17015007090058
"440","1a0983774d5920833d45dd10c432b141","NCT01070550",0.0147,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for ALT ratio at BL (\> 1 - 3 vs \> 3). The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including total cumulative dose of peginterferon and ribavirin), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,2981,"logistic_regression",NA,NA,NA,2.78701049165799
"441","1a0d8db93e34d3654c0f81a76be90ee0","NCT05170841",0.027,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Percentage of Maximum TOTPAR (%Max TOTPAR) at 72 Hours After the First Dose- Multiple Dose Phase - Dexketoprofen/Tramadol vs Tramadol","SECONDARY",NA,"D001416; D017116","Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain",FALSE,499,"t-test",NA,NA,NA,1.94604313586797
"442","1a0e388ebe5f3378397149e519bed861","NCT03192176",0.0394,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 12","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,85,"logistic_regression",NA,NA,NA,1.13260360037906
"443","1a2f2e28e943bca0664521dc36f48c1b","NCT01236053",2e-04,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,1.29789263256815
"444","1a3f8ee50f4406ba0eaaa37c5e97c8d0","NCT00455533",0.0276,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]), to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR","SECONDARY","RRM1 201477_s_at","D001943","Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer",FALSE,295,"logistic_regression",NA,NA,NA,1.53000732159602
"445","1a4cb824dc60966550f3750973c4b82f","NCT02178995",0.045,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Neuropsychiatric Questionnaires","OTHER_PRE_SPECIFIED","AES visit 1 vs visit 5 epilepsy","D004827; D001289; D003072; D060825","Methylphenidate Treatment of Attention Deficits in Epilepsy",FALSE,56,"t-test",NA,NA,NA,1.0400167301957
"446","1a5172b324ac33cc08d0de9652b602dc","NCT02539394",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Degree of Dysphagia Patients Experience (Mental)","PRIMARY","The distribution of POD1 SWAL-QOL - Mental is the same across the 2 arms","D007405; D055959; D003680; D013118","Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion",FALSE,109,"mann_whitney",NA,NA,NA,1.29185573846819
"447","1a5346394adce486fda824932da6430c","NCT04837807",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"IDEEL (Impact of Dry Eye on Daily Life) Quality of Life - Work Subsection","PRIMARY","Each participant in the study was asked to complete the IDEEL work at their baseline, week 1 and week 2 visits. The IDEEL work is graded on a scale to 100 with higher numbers being deemed as ""better"" scores thus representing more comfort than previous weeks.","D015352","Digital Device Users Who Are Treated With Systane Hydration PF",TRUE,60,"anova",2,NA,NA,1.17169922891753
"448","1a580384d956dda93fb672a6a76bc98d","NCT03334422",0.044,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving SCORAD90","SECONDARY",NA,"D003876; D003872; D004485","Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis",FALSE,367,"logistic_regression",NA,NA,NA,2.53432334269055
"449","1a593cef6a037ee1dbd73e4e0c350b59","NCT01559259",0.031,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Intensity Difference on 11-Point Numerical Scale (PID11)","SECONDARY","1 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, baseline numerical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,182,"anova",2,NA,NA,1.33416400439747
"450","1a5ac4f36696f4edcf350047cc750508","NCT05127304",0.007,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"COPD or Pneumonia-attributable Health Care Resource Utilization","PRIMARY","Other medical visits","D029424","A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",FALSE,11316,"linear_regression",NA,NA,NA,2.80337301464238
"451","1a74b186365495cfe727435310512be9","NCT01669902",0.0357,"Wilcoxon","OBSERVATIONAL",0,0,0,0,0,"Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Months 3 and 6","SECONDARY","Change at Month 6","D001168; D001172","An Observational Study of RoActemra/Actemra (Tocilizumab) in Monotherapy in Patients With Rheumatoid Arthritis",FALSE,82,"wilcoxon",NA,NA,NA,1.02487378231496
"452","1a89a4a410eccf96be53d3b6c6f0da4a","NCT04452331",0.03,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Glycated Hemoglobin (Access vs. Non-access)","SECONDARY",NA,"D006973","Assessing Open Access Audio",FALSE,673,"linear_regression",NA,NA,NA,2.47125290894845
"453","1a9be6b224fc5216c5709ce01ea2d6b5","NCT03547531",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Gingival Condition at 1 Month","PRIMARY","null hypotesis: there is no difference of mean of gingival index between groups","D003773; D009066","Comparison of Modified Circular and Natural Tooth Brushing Methods in Effectiveness of Dental Plaque Removal",TRUE,118,"t-test",NA,NA,NA,1.61751378500378
"454","1abe3aa341ff5aece485e5968742dbd9","NCT05170841",0.035,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Percentage of Maximum TOTPAR (%Max TOTPAR) at 96 Hours After the First Dose- Multiple Dose Phase - Dexketoprofen/Tramadol vs Tramadol","SECONDARY",NA,"D001416; D017116","Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain",FALSE,500,"t-test",NA,NA,NA,2.43308902722911
"455","1ae25e1491adbc47a7bd021fba1a79e0","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Fasting Plasma Total Glucose-dependent Insulinotropic Peptide (GIP)","SECONDARY","Difference in treatment effect between the 2 groups","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",TRUE,50,"t-test",NA,NA,NA,1.07648023860356
"456","1ae761dd50d08432d40cbe4c665c2766","NCT02528253",0.0164,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 40, \>=70%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1010,"logistic_regression",NA,NA,NA,1.78955692324257
"457","1af43d7c959f5ba0ecd1921c336e81df","NCT01817530",0.032,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With ≥ 25% Reduction From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit","SECONDARY","Final Visit","D007889; D047708; D014592; D008595; D006470","Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)",FALSE,155,"logistic_regression",NA,NA,NA,1.26781882577224
"458","1afb59b94db65ba098b507eb94272674","NCT01298531",0.0498,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Number of Participants With Patient Acceptable Symptom State (PASS) at Week 8","OTHER_PRE_SPECIFIED","Logistic regression with baseline morning stiffness score and treatment group included as covariates. Week 8 was analyzed using a logistic regression to assess treatment effect.","D013166; D025241; D000089183","A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis",FALSE,80,"logistic_regression",NA,NA,NA,1.33773035331594
"459","1b034cebe3c183ce9706fdba4ede5209","NCT02697773",0.0141,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >= 30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 16, \>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,463,"logistic_regression",NA,NA,NA,1.06458045826851
"460","1b26bb6780f26d2961147971430793e0","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Environmental Warning Label","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1732,"linear_regression",NA,NA,NA,6.10370278152778
"461","1b29a9dda22fb45fbe7cc0d3ead9192b","NCT03855228",0.02,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Total Symptom Score (Assessed by Participant)","PRIMARY","This analysis compares Change From Baseline values.","D012220; D065631; D006255","Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)",FALSE,340,"anova",2,NA,NA,1.24170354272197
"462","1b2ca2e4744e72ab28eafc2a9602fbba","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Healthfulness","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1752,"linear_regression",NA,NA,NA,6.13876469477842
"463","1b4ab7ae01a807e22f379468dc8b44ee","NCT02967510",0.043,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline to Week 12 in the Severity of Petechiae","SECONDARY",NA,"D001284","Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy",FALSE,139,"mann_whitney",NA,NA,NA,1.54383188853036
"464","1ba94bfc1a56b874a8e4f088c97f9906","NCT01234649",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Diastolic Blood Pressure","SECONDARY","Factorial repeated measures ANOVA","D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",FALSE,72,"anova",2,NA,NA,1.27670232702116
"465","1bc6c853ea793b7967c7ffe388c3ce77","NCT00408876",0.048,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Laboratory Assessment - Bicarbonate, HCO3","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,161,"t-test",NA,NA,NA,1.81820917240153
"466","1c04f1881064c7c09b27807593ea5110","NCT01459653",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Modeling FN Episode: Cycle Level","SECONDARY","History of anaemia at enrollment as patient-level predictor for FN episode","D009101; D009503; D064147; D000084462; D005334","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",FALSE,1273,"logistic_regression",NA,NA,NA,1.29657154396284
"467","1c06c80a505ae301f7d58854ecc5d664","NCT00408876",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Severity (BPI-S) - Least Pain Score","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,164,"t-test",NA,NA,NA,1.23323979816842
"468","1c273b33baca02d59fcd7aca62cee21b","NCT00070707",0.043,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in AM and PM Rhinorrhea Symptom Score","SECONDARY","Change at Final Week (PM)","D012220; D001249; D006255; D065631","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",FALSE,187,"anova",2,NA,NA,1.78390274545123
"469","1c3ea7e0b28198aa6af56edc2ad887d9","NCT03810417",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Renal Function","PRIMARY",NA,"D058186","Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI",TRUE,125,"logistic_regression",NA,NA,NA,1.66328288934253
"470","1c58d1f619a66a073eb507979ff70eca","NCT03947333",0.018,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Diabetes Self-Care (Specific Diet)","SECONDARY",NA,"D003920; D003924","Evaluation of a Patient Portal Intervention for Diabetes: A Pilot Randomized Controlled Trial",FALSE,269,"t-test",NA,NA,NA,1.00972992377719
"471","1c59cb1ffaf7cd68eeeb8cc8120cf535","NCT02986139",0.048,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Injection Site Pain","PRIMARY","A mixed effects analysis of variance model was used to assess injection site pain with the new formulation of etanercept as the test treatment and the commercial formulation of etanercept as the reference treatment. Treatment, study period, sequence, and disease indication were evaluated as fixed effect covariates, and subject within sequence was included as a random effect.","D001168; D001172; D015535","Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis",FALSE,208,"anova",2,NA,NA,2.06096659584265
"472","1c66680cd21daf6480a0276f74e61387","NCT03978871",0.048,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Mean Change From Baseline to 4 Months in Emotional Self-efficacy Vignettes Scores","SECONDARY","We are reporting the p-value for the group (Growth Mindset vs. Brain Education) by time effect (pre-manipulation and post-manipulation) on emotional self-efficacy vignette scores from time 1 to time 3. This is a test of between by within-subjects interaction effect.",NA,"Effect of Emotion Mindsets on Emotion Processing",FALSE,139,"anova",2,NA,NA,1.69267262325643
"473","1c68f74c04e81e25f4588e74ba7d0043","NCT00023595",0.023,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"H01: KCCQ Symptom Stability","SECONDARY",NA,"D006333; D002318; D006331; D003327","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",FALSE,1194,"mann_whitney",NA,NA,NA,2.61285621058988
"474","1c699e377761541ab0937ccad76e80f0","NCT04593940",0.0354,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Mortality Through 14 Days","SECONDARY",NA,"D000086382","Immune Modulators for Treating COVID-19",FALSE,1049,"logistic_regression",NA,NA,NA,3.55024820373261
"475","1c74c26290f79327c064aaa2c9c5cf84","NCT01640197",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Number of Participants With Modulated Mood","SECONDARY",NA,NA,"Chronic Resveratrol Supplementation in Healthy Humans",FALSE,54,"anova",2,NA,NA,1.11553228437488
"476","1c79d6a1a3663b1822aee2de730c057a","NCT02109107",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Body Weight","SECONDARY",NA,NA,"Study of Low Level Laser Light Therapy on Circumference Reduction",TRUE,54,"t-test",NA,NA,NA,1.11553228437488
"477","1c9a056bac917de87ed964c2d9ed7544","NCT04833777",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Post-operative Analgesia Requirements","PRIMARY",NA,"D002349","Does a Different Local Anesthetic Improve Pain After Carpal Tunnel Release?",TRUE,139,"mann_whitney",NA,NA,NA,1.75124288073831
"478","1c9b3b2ef47f33ceffdf3d6f4ce3176c","NCT01070550",0.0255,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for sex (male vs female). The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,665,"logistic_regression",NA,NA,NA,2.13580071514031
"479","1c9e4bbce560feab4ef9ec30a4d4197c","NCT01361568",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Total Morphine Consumption in the First 24 Hours Following Postoperative Study Drug Treatment","PRIMARY",NA,"D010149","Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery",TRUE,91,"t-test",NA,NA,NA,1.42733241699876
"480","1ca08fbf8ad12413cb5b8c30771e47a2","NCT03007745",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Client Satisfaction Questionnaire (CSQ-8)","SECONDARY","Between group comparison of Client Satisfaction Questionnaire (CSQ-8) at 3 months (LOCF applied using 1-month data)","D001049; D012891","Remote Diagnosis and Management of Obstructive Sleep Apnea",FALSE,92,"t-test",NA,NA,NA,1.4348242556313
"481","1ca2e24de533d033c3e34a2ae4a4bc83","NCT01236053",0.0158,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,2067,"logistic_regression",NA,NA,NA,2.47400323627304
"482","1cb0c526e2fa10e6933462d2aaf930a5","NCT03855189",0.04,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Response To Therapy At Day 22 (Physician-Evaluated)","SECONDARY","Pairwise treatment comparison based on t-test from an analysis of variance (ANOVA).","D012220; D065631; D006255","Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)",FALSE,214,"anova",2,NA,NA,1.79301862839811
"483","1cd31cd45f779eea08df0d6d08ea11c3","NCT00755222",0.046,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Peyronie's Disease Questionnaire (PDQ) Peyronie's Disease Symptom Bother","PRIMARY",NA,"D010411","The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease",FALSE,134,"anova",2,NA,NA,1.60476826759773
"484","1cd61115676ea39910831b675dba8b83","NCT01316419",0.0197,"One-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Psychological Domain","SECONDARY",NA,"D006973","Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension",FALSE,1490,"t-test",NA,NA,NA,2.54962933237101
"485","1cea6743d7be3b2ffbf4b0518f8882e9","NCT05970861",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Antiphospholipid Antibodies","PRIMARY","Null hypothesis: No statistically significant difference exists between antiphospholipid antibody levels before and after the mare's milk administration.

Alternate hypothesis: Statistically significant difference exists between antiphospholipid antibody levels before and after the mare's milk administration.","D000086382","Effect of Natural Food on Gut Microbiome and Phospholipid Spectrum of Immune Cells in COVID-19 Patients",FALSE,60,"mann_whitney",NA,NA,NA,1.17169922891753
"486","1ceae1776330593ac7fe48ee92873044","NCT00964366",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Sebum Measurements","SECONDARY",NA,"D000152","Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications",FALSE,52,"anova",2,NA,NA,1.09617796589869
"487","1cf37b57c3bfc31d3465f7d431416123","NCT04047121",0.0193,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean of Rheumatoid Arthritis Related Total Health Care Cost During 12 Months Pre-index Date","SECONDARY",NA,"D001168; D001172","A Study to Evaluate Patient Characteristics and Treatment Patterns Among Rheumatoid Arthritis Patients",FALSE,374,"t-test",NA,NA,NA,1.2616026192406
"488","1cf94411e31d5fe670fe5dc8cd859235","NCT01048866",0.0322,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Took Rescue Pain Medication","SECONDARY",NA,"D010612","A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis",FALSE,198,"logistic_regression",NA,NA,NA,1.43592665483976
"489","1cfc66e71c14d44310048d2317575cfa","NCT00869349",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"RADAI Disease Activity Score","PRIMARY","Treatment effects are reported as mean between-group differences from baseline to 21 months using t-tests to determine the differential effect of the intervention versus the education group.","D001168; D001172","Living Well With Rheumatoid Arthritis",FALSE,68,"t-test",NA,NA,NA,1.03233725989138
"490","1d0dd745d3574652948ac4afac4afd36","NCT02504671",0.039,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Achieving Categorical DAS28(CRP) Response (Moderate/Good [European League Against Rheumatism] EULAR Response) at All Assessment Time Points","SECONDARY",NA,"D001168; D001172","Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis",FALSE,74,"logistic_regression",NA,NA,NA,1.05167952381391
"491","1d19b8803a17e29cd9968ab54474849c","NCT02872909",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Patient Satisfaction","SECONDARY",NA,"D012878","Randomized Comparison of Low and Conventional Irradiance PDT for Skin Cancer",TRUE,50,"mann_whitney",NA,NA,NA,1.07648023860356
"492","1d296be1a39a2fd83b055f8f8832792d","NCT02994108",0.025,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Who Initiated the HPV Vaccine Series","PRIMARY",NA,NA,"txt2protect: Using Text Messaging to Increase HPV Vaccination Among Young Sexual Minority Men",FALSE,148,"logistic_regression",NA,NA,NA,1.00364224862066
"493","1d4805ab6dd918d23f1af3d56e10ad56","NCT00733499",0.0327,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Comparative Evaluation of Any Variability in Functional Recovery Using the Oxford Knee Score Between Subjects Receiving LCS Complete Duofix™ and Porocoat® Knee Systems at 60 Months.","SECONDARY",NA,"D010003","A Study to Determine the Difference in Low Contact Stress (LCS) Duofix Versus Low LCS Porocoat Knee Systems",FALSE,155,"t-test",NA,NA,NA,1.29138864019516
"494","1d4aaafa0c0c8369efde6bf3917ad1f9","NCT02140593",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Surgical Rating Score","PRIMARY",NA,"D005770","The Laparotomy Study",TRUE,128,"mann_whitney",NA,NA,NA,1.68251789784767
"495","1d4b5a2b15326efeb9e10d2188d11728","NCT01601847",0.0185,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Number of Infants With Recurrent Wheezing","PRIMARY",NA,"D012135","Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy",FALSE,269,"logistic_regression",NA,NA,NA,1.03415262224566
"496","1d56c1a3e81603ae612440ae2c6dd32f","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Healthfulness","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1750,"linear_regression",NA,NA,NA,6.13526752012651
"497","1d87206e4d35a8ecc515e641d78380cd","NCT04218123",0.05,"ANOVA","INTERVENTIONAL",0,0,1,1,0,"Number of Vertigo Episodes","PRIMARY",NA,"D008575","Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes",TRUE,80,"anova",2,NA,NA,1.34217713699512
"498","1d8c47c2963c359d377ccddd4e559137","NCT00790335",0.02,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Change in Leg Pain Severity","SECONDARY",NA,"D013927; D013923; D054556; D020246; D054070; D011186; D013577","Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis",FALSE,642,"linear_regression",NA,NA,NA,1.69988704947583
"499","1d973d76e0c98f32505cf9d17fa6ed5e","NCT01765920",0.0174,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,1,0,"Average Duration of Fever.","PRIMARY",NA,"D007239; D003141; D012141","Clinical Trial of Safety and Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adults",FALSE,333,"kruskal_wallis",2,NA,NA,1.08847449489529
"500","1dc4c0afa51e3af27d863d01534ffbbf","NCT02891070",0.0241,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Duration in Surgery (Minutes)","SECONDARY",NA,"D065634","Efficacy and Safety of FS VH S/D 500 S-apr (Tisseel) as an Adjunct to Sutured Dural Repair in Cranial Surgery",FALSE,184,"mann_whitney",NA,NA,NA,1.08067049160081
"501","1dc77f1d8788330dbd6b4118461fe212","NCT01894230",0.0482,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Low Density Lipoprotein Cholesterol (LDLc) at Baseline, Month 3 and Month 8","SECONDARY",NA,"D006937","Genetically Guided Statin Therapy",FALSE,159,"linear_regression",NA,NA,NA,1.81344124910664
"502","1dd6a7c7438b61e6e0d40e87bed10e5e","NCT00458406",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Change in Apnea Hypopnea Index (AHI; Number of Apneas and Hypopneas Per Hour of Sleep) From Month 1 to Month 3","SECONDARY","Mann-Whitney test. We hypothesized that Bi-Flex would result in improved adherence but similar efficacy to CPAP. The study sample size of 45 in the Bi-Flex group and 15 in the CPAP group had 80% power to detect an effect size ≥ 0.85 with a 0.05 two-sided significance level. In addition, with this sample size, the 95% CI for the difference between the 2 means had a range of 1.282 SD.","D001049; D012891; D020181","Evaluation of Adherence and Therapeutic Effectiveness of Bi-Flex Versus CPAP in Children With OSA",FALSE,56,"mann_whitney",NA,NA,NA,1.13456029943022
"503","1ddd6dbdd7dc3fbe9bbcfea1f2e0b3fb","NCT02727478",0.039,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Change in Dual Task Interference During the Timed Up and Go (TUG) Test From Baseline at 1 Week Post Intervention.","SECONDARY",NA,"D010300","Effectiveness and Implementation of the HiBalance Program in Clinical Practice",FALSE,108,"mann_whitney",NA,NA,NA,1.25905078626544
"504","1de1f781a8e06c4489c5b05697dfd276","NCT00253890",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Sleep Quality, as Measured by Total Sleep Time","PRIMARY","Change in sleep quality was assessed by calculating gain scores. We used a 2-sided t-test to report mean change.","D009293","Insomnia and Drug Relapse Risk",FALSE,134,"t-test",NA,NA,NA,1.72034403504361
"505","1de2542a6f9fa89f7544d74cd376cd98","NCT01115673",0.027,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 15 Minutes","SECONDARY","The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.","D014098","To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery",FALSE,299,"anova",2,NA,NA,1.5113373033839
"506","1de4d5ec9650b4a402cb600ac586dccf","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cancer Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1735,"linear_regression",NA,NA,NA,6.10897489711546
"507","1df1011958b8aff3ab44d86a45771585","NCT06150573",0.04,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Adjusted Mean MLSI (Intensity) Score at 12 and 24 Weeks After Tooth Bleaching","SECONDARY","Week 12","D003807","A Study Assessing the Effects of an Experimental Dentifrice in Maintaining Tooth Color Following Tooth Bleaching",FALSE,159,"anova",2,NA,NA,1.55080413807822
"508","1e001a57a1829dcc9ab1ea9adf563cc6","NCT04231669",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Intention to Migrate","PRIMARY",NA,NA,"Intervention to Improve Developmental and Health Outcomes for Female Adolescents",FALSE,97,"linear_regression",NA,NA,NA,1.47171356596352
"509","1e0bbd200b1e79cb60ae66ae4dcbf94f","NCT00967330",0.0354,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ - C30) at Baseline, Post-Baseline (up to Month 30)","SECONDARY","Pain. ANOVA included all post-baseline data (Months 3 through 21).","D005909","A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma",FALSE,170,"anova",2,NA,NA,1.44488235094821
"510","1e1dc3be83181ba1b92f3035a7d4597e","NCT00261443",0.027,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Adjusted Mean Change in CGI-BP From Preceding Phase (Mania) Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 40 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,1.57703172391936
"511","1e3a0142fec482f616a94def478f741f","NCT02889796",0.009,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With no Radiographic Progression From Baseline at Week 24","SECONDARY","Filgotinib 200 mg vs Placebo at Week 24 for change in mTSS ≤ 0.","D001168; D001172","Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate",FALSE,950,"logistic_regression",NA,NA,NA,1.02061821357177
"512","1e5b1e87fe4b8bf8a42e0d2a97fae762","NCT03114969",0.05,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants Making at Least One Critical Error at Visit 1-Primary Device Comparisons","PRIMARY",NA,"D008171; D029424","Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs",FALSE,100,"logistic_regression",NA,NA,NA,1.49341131573029
"513","1e64d1a183451c11542e240ee664a022","NCT04976530",0.042,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Chest Tube Drainage, i-CABG PP Population","SECONDARY",NA,"D006470; D016063; D019106","Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)",FALSE,111,"mann_whitney",NA,NA,NA,1.35769722521339
"514","1e675c7bb4cfa1d1265fda5801adf360","NCT01001234",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Pain Freedom at 2 Hours Post Dose in Participants Between 6 and 17 Years of Age","SECONDARY","The comparison of rizatriptan versus placebo with respect to pain freedom at 2 hours post Stage 2 dose for participants between 6 and 17 years of age was conducted using a logistic regression model with factors for treatment, Stage 2 baseline pain severity (moderate or severe), age (6 to 11 years old or 12 to 17 years old), and region (US or ex-US). Model-derived odds ratio and a two-sided p-value were provided. An odds ratio \>1 is in favor of the rizatriptan group.","D008881","A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)",FALSE,770,"logistic_regression",NA,NA,NA,1.01010605604897
"515","1e824670d159b3dfae13d57ae3d387a3","NCT01221623",0.0248,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Penile Length","SECONDARY",NA,"D010411","Study of AA4500 in the Treatment of Peyronie's Disease",FALSE,309,"anova",2,NA,NA,1.42749847783574
"516","1e85835fac7452db0bc3347630e4b30e","NCT03906136",0.029,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Patients Achieving ASAS Partial Remission","SECONDARY","Week 12","D013166; D025241; D000089183","AScalate: Treat-to-target in Axial Spondyloarthritis",FALSE,292,"logistic_regression",NA,NA,NA,1.5884106319469
"517","1ea8050ed1c7e26854df67056c5c1c5e","NCT01672892",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Quality of Life, as Measured by Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G) and FACT-Cx (Cervix) Subscale","SECONDARY","Physical subscale score - 5 weeks","D002583; D016889; D011183","Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer",FALSE,279,"t-test",NA,NA,NA,1.5990334601552
"518","1ebbdb6a8f8e3251832c172f6528f942","NCT00424476",0.0189,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percent of Subjects With a ≥ 4 Point Reduction From Baseline in SELENA SLEDAI Score at Wk 52.","SECONDARY",NA,"D008180","A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)",FALSE,575,"logistic_regression",NA,NA,NA,1.53204694889141
"519","1ed9ea57e370bd8a8d31778a2980369e","NCT00949884",0.0347,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Participants Achieving Blood Pressure Goals at Week 8","OTHER_PRE_SPECIFIED","Percentage of participants achieving systolic blood pressure goal of \<130 mmHg","D006973","Olmesartan Comparison to Losartan in Hypertensive Subjects",FALSE,810,"logistic_regression",NA,NA,NA,3.0689384835502
"520","1eff3bed06c940670089d449b5e61fad","NCT00286455",0.029,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.5%.","SECONDARY",NA,"D003920","Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes",FALSE,195,"logistic_regression",NA,NA,NA,1.303323733992
"521","1f1cde929acf1acae4fdda663af7b5fd","NCT04003155",0.037,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate, and Severe VMS From Baseline to Each Study Week Up to Week 12","SECONDARY","Week 10","D019584","A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause",FALSE,348,"logistic_regression",NA,NA,NA,2.13218220326467
"522","1f22fd5c7b26b5307cdbd7a6ea0a2213","NCT01945034",0.021,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Sum of Pain Intensity Difference Scores at Rest Over 3 Days","SECONDARY","At Rest Over 3 Days: The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms. Upper limit of 95% CI \< 0 for Ibuprofen treatment significantly better than combined Placebo.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,219,"anova",2,NA,NA,1.0442525046957
"523","1f340e31069d7debcddcce13228947d3","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Platelet Count at Baseline and After Treatment Completion","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"524","1f442d31786e959cd5ee89a679540d3f","NCT01313767",0.0429,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"MAS(Modified Ashworth Score) of Elbow Flexor","SECONDARY","Difference between groups in change from baseline to week 12 in elbow flexor MAS score was compared using two sample t-test.","D009128","MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity",FALSE,181,"t-test",NA,NA,NA,1.75225494838335
"525","1f4481297a103c1a17f38bf0b5fd41b7","NCT00416572",0.04,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Physical Health (Measured With SF-36) at Baseline, Post-intervention (4-months Post-intervention) and Final Follow-up (13-months Post-intervention)","PRIMARY","Comparison between nutrition education intervention and the control condition at 4 months post-intervention. The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome.","D001943","Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer",FALSE,154,"linear_regression",NA,NA,NA,1.52688305382348
"526","1f46ffec23676d74a4480678cc5d90d3","NCT01115673",0.041,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Intensity Difference (PID) at 75 Minutes","SECONDARY","The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.","D014098","To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery",FALSE,480,"anova",2,NA,NA,2.72709140496984
"527","1f60b5f7c4bea4277082d7e9343f6c7c","NCT00996632",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Drainage Volume","PRIMARY","null hypothesis is that drainage volumes are not different","D001943","The Use of a High-frequency Ultrasonic Knife in Breast Cancer Surgery",TRUE,94,"mann_whitney",NA,NA,NA,1.44969222080406
"528","1f6bf96f1dfae5ed8d88cfd52e40b42a","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Specific Perceived Healthfulness","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1753,"linear_regression",NA,NA,NA,6.14051253521365
"529","1f6e58ef7422dd973e45a9b49d04679c","NCT01969240",0.013,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Test if the Decision Aid Has an Effect on Healthcare Utilization Within 30 Days After Enrollment.","SECONDARY",NA,"D054058; D004630; D002637","Shared Decision Making in the Emergency Department: Chest Pain Choice Trial",TRUE,898,"t-test",NA,NA,NA,1.37570317380646
"530","1f78652261fc469b907797679519bbc2","NCT05493787",0.027,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Number of Patients Who Self-scheduled a Flu Shot","PRIMARY","Null hypothesis: Protect Yourself - Frequent messages and Waiting for You messages are equally effective at promoting flu shot self-scheduling; Alternative hypothesis: There is a difference in effectiveness between Protect Yourself - Frequent and Waiting for You messages. Analysis combines across November and December send dates.",NA,"Nudging Flu Vaccination by Making it Easy for Patients to Schedule a Flu Shot",FALSE,46573,"linear_regression",NA,NA,NA,18.7095693569314
"531","1f7d79a3a3a572269c98f714ea866ce3","NCT02697422",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Health-Related Quality of Life (HRQoL), Mental Component Summary Score","SECONDARY",NA,"D002318; D006949","Veteran Peer Coaches Optimizing and Advancing Cardiac Health",FALSE,264,"linear_regression",NA,NA,NA,2.39772562409599
"532","1fa660a110d401a3d48002eac57c9ba7","NCT03192176",0.043,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 5","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.22541928867971
"533","1fb9e88394bff571f8452f92b91e7a8e","NCT01667406",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Oocyte Maturation","PRIMARY","Phase 3","D007246","The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment",TRUE,62,"logistic_regression",NA,NA,NA,1.18983814919554
"534","1fe0f4ced1d312b6ee4cde7efc679867","NCT04148989",0.005,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Antibiotic Utilization'","OTHER_PRE_SPECIFIED","Differences-in-differences analysis using multivariable logistic regression to estimate the change in outcome after versus before intervention implementation at the intervention site adjusted for the change observed at control sites and for prespecified covariates.","D018805; D014115; D004630","Effects of Code Sepsis Implementation on Emergency Department (ED) Sepsis Care",FALSE,180402,"logistic_regression",NA,NA,NA,8.26288695498596
"535","1fec2a5396544c72f10baa5601ceddf7","NCT00256750",0.0417,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of Physical and Mental Components Using SF-36 Questionnaire","SECONDARY","Physical Component Score; Month 24","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,421,"anova",2,NA,NA,2.59236959427136
"536","1fed72927bb3fb867f4165b1f260dd27","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Healthfulness","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1755,"linear_regression",NA,NA,NA,6.14400672442735
"537","1fef5bebf9f889aae811db8769252b75","NCT01070550",0.0267,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for weight per 10 kg. The logistic regression analysis for relapse 24 weeks after EOT was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,227,"logistic_regression",NA,NA,NA,1.3076571987454
"538","1ff599842735f42e16e4c5df88106a91","NCT01115673",0.037,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Intensity Difference (PID) at 15 Minutes","SECONDARY","The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.","D014098","To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery",FALSE,299,"anova",2,NA,NA,1.97840478351401
"539","1ffef575554088dc6deca11b7e7512d1","NCT01318538",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Group Stability","OTHER_PRE_SPECIFIED",NA,"D019966; D019973","Women's Recovery Group (WRG) Study - A Randomized Controlled Stage II Trial",FALSE,100,"t-test",NA,NA,NA,1.49341131573029
"540","20022be62e622a6bc14f06d189eba6e8","NCT02422797",0.042,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase","SECONDARY",NA,"D015658","Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)",FALSE,516,"mann_whitney",NA,NA,NA,2.88480776409264
"541","200b00568cf00840ecf78fe067deac52","NCT00110461",0.0296,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change in General Behavior Inventory Scale (GBI) Total Subject Version Mania Score at Week 4","SECONDARY","Analyses were performed by fitting an ANCOVA model with treatment as factor, and baseline score as covariate. Two pair-wise comparisons, aripiprazole 10 mg target dose versus placebo and aripiprazole 30 mg target dose versus placebo, were performed within the ANCOVA or ANOVA model.","D001714","Aripiprazole in Children and Adolescents With Bipolar I Disorder",FALSE,187,"t-test",NA,NA,NA,1.29955337259016
"542","200f1029859f099c7cdb220fc4689339","NCT02912650",0.016,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Relief Rating (PRR) Score","OTHER_PRE_SPECIFIED","8 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,340,"anova",2,NA,NA,1.02180369467945
"543","202cd6bb9adf8c3b428435fa1ae6ab2b","NCT02867202",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"the AFS Score at Second-look Hysteroscopy","PRIMARY","Data analysis was performed with SPSS version 22.0, using two-sided test, and a p value \< 0.05 was considered statistically significant.","D006175","Adjuvant Therapy for Intrauterine Adhesions Between Two Groups",TRUE,118,"t-test",NA,NA,NA,1.61751378500378
"544","202f7f26b5792cf48a9aca0078322111","NCT01236053",0.0224,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,20382,"logistic_regression",NA,NA,NA,10.5287467950524
"545","2033a80d1f2c2be28a1ad0fc0efd7410","NCT02498067",0.049,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Contraceptive Effectiveness Knowledge","SECONDARY","Paired samples t-test comparison of proportion of participants who provided correct answers to whether pills or condoms are more effective at preventing pregnancy, before and 3 months after engaging in rPlan","D012749","rPlan Multimedia Dual Protection Intervention to Reduce Health Disparities",FALSE,70,"t-test",NA,NA,NA,1.23893499432688
"546","203569856312723178a6d140db5942ce","NCT01185522",0.036,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Participants With Clinically Significant Improvement in Fatigue at Month 4 With Respect to Predictive Factors","PRIMARY","Comparison between time since initial diagnosis: \>= 10 years and \< 10 years","D001168; D001172","An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS)",FALSE,264,"logistic_regression",NA,NA,NA,1.81802378674032
"547","2040774a7f7bc0989e40288d88d1ef8d","NCT03192176",0.046,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 11","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.29631447895437
"548","204b71a058107abde10d8a986a681d61","NCT01780298",0.0357,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Impulse Oscillometry (IOS) Measurements: Resonant Frequency (Fres)","PRIMARY",NA,"D007249","Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study",FALSE,120,"t-test",NA,NA,NA,1.22929128178827
"549","20544df50544920316b5afb6539b3100","NCT01843842",0.0364,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,1,0,"Severity of the Disease Within 6 Days Was Assessed Using the ""Area Under the Curve"" for the Total Symptom Score (TSS)","SECONDARY","All symptoms (Days 1-5, patient diary data)","D007239; D003141; D012141","Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children",FALSE,293,"kruskal_wallis",2,NA,NA,1.93174650085771
"550","206384746d360021ad7642445d1b86d3","NCT03334396",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2 mg, or 4 mg Baricitinib)","PRIMARY",NA,"D003876; D003872; D004485","A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis",FALSE,372,"logistic_regression",NA,NA,NA,1.29793399186526
"551","2079ccb2dd535841c7fd5b97d9b29e4e","NCT04662086",0.05,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Time to First Resolution","SECONDARY",NA,"D000086382","COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol",FALSE,120,"linear_regression",NA,NA,NA,1.63072147479452
"552","20981eb451a73b3ee6bf6c08a97cf20f","NCT02662985",0.0327,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Spondyloarthritis Research Consortium of Canada (SPARCC)","SECONDARY","SPARCC","D001168; D015535","Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)",FALSE,164,"logistic_regression",NA,NA,NA,1.3272793834183
"553","209ba4fc5b45c119753a4c0f5a47176c","NCT05302414",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Knowledge of Teamwork Assessment","PRIMARY","For posttest right after intervention at the 4 weeks.",NA,"The Learning Outcome of Resuscitation Teamwork Training in Postgraduate Year Doctors and Nurses",FALSE,64,"kruskal_wallis",2,NA,NA,1.20770700959599
"554","20c618d1170411aa54d56998b8de9359","NCT00517933",0.04,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Change in St. George's Respiratory Questionnaire (Activity Score) Adjusted Value","SECONDARY",NA,"D011658; D054990; D006976; D006973; D005355","Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis",FALSE,180,"linear_regression",NA,NA,NA,1.64748927508577
"555","20cf39bc9b865aba599a217088ac8871","NCT04523831",0.03,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Number of Patients With Early Clinical Improvement","PRIMARY",NA,"D000086382","Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection",TRUE,363,"linear_regression",NA,NA,NA,1.82037390469617
"556","20d08741b0757b02af272d7a77e10cb2","NCT04118348",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Lipid Panel Screening","PRIMARY","Passive control was set as the reference group.","D006938; D006937; D006949","Evaluating the Efficacy of Pediatric Lipid Screening Alerts",FALSE,6857,"logistic_regression",NA,NA,NA,7.8633279744356
"557","20d3033b5240ccbf3d02e47f61e18fd7","NCT02697773",0.0404,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >= 30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 2, \>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,463,"logistic_regression",NA,NA,NA,2.64559799918968
"558","20e1f602681dfc4dc608bb3d05106f93","NCT04030026",0.0374,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Mean Change From Baseline in E-RS Breathlessness Score at Days 9, 16, and 22","SECONDARY","Change from baseline at Day 16","D011658; D054990; D005355","A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough",FALSE,76,"t-test",NA,NA,NA,1.02820608551892
"559","20ee66963549f09c6ca56d345932c932","NCT02566902",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in FEV1 (% Predicted)","PRIMARY",NA,"D001249","Comparison of Breath-Enhanced and T-Piece Nebulizers in Children With Acute Asthma",FALSE,107,"t-test",NA,NA,NA,1.2804119528737
"560","20f6cdcf1998e2f1c07933c297e90307","NCT00551135",0.0406,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Total Cumulative Dose of Opioids and Tramadol Used During and After Surgery","SECONDARY","Day 7 PS; LS Means from ANOVA model with terms of treatment, pooled center. Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,202,"anova",2,NA,NA,1.7650787041701
"561","20fdaf9a9c1c2ee4ba5eeb048beaa76b","NCT02912650",0.045,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Relief Rating (PRR) Score","OTHER_PRE_SPECIFIED","10 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,231,"anova",2,NA,NA,2.05564044948276
"562","21006dab236877a492d438ac15b9795d","NCT04736628",0.0476,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Patients Achieving UACR Decreases in 10-hour Urine of at Least 20% From Baseline After 20 Weeks of Trial Treatment","SECONDARY","Treatment and sodium-glucose co-transporter-2 inhibitor (SGLT2i) use at randomization were used as covariates in the logistic regression model.","D007674; D051436","A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease",FALSE,126,"logistic_regression",NA,NA,NA,1.60269442205522
"563","2101962950e71ca68de5ee0ccb0a2a8b","NCT02618772",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Intention to Treat (ITT): Faces Pain Scale-Revised/ FLACC Scale","SECONDARY",NA,"D022125; D001008","Intranasal Midazolam for Treatment of Anxiety in Children Undergoing Suturing in the Pediatric Emergency Department",TRUE,78,"t-test",NA,NA,NA,1.32610986002301
"564","210eb18d36867b42fee23a428da80cb1","NCT02697422",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Framingham Cardiovascular Risk Score (FRS)","SECONDARY",NA,"D002318; D006949","Veteran Peer Coaches Optimizing and Advancing Cardiac Health",FALSE,264,"linear_regression",NA,NA,NA,2.39772562409599
"565","2120942fa31de82172eedf3fbe9266c9","NCT02854800",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,1,0,"Percentage of Days on Which Participants Experienced Each Reason for Attrition","PRIMARY","A separate t-test for each row was used to compare dropouts and completers.","D009293","Smoking Cessation & Opioid Dependence Treatment Integration",TRUE,74,"t-test",NA,NA,NA,1.2933799900503
"566","2120a7b229ae65f128276bae46044c91","NCT00859898",0.0165,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percent Adjusted for Baseline HbA1c of Participants Achieving a Therapeutic Glycemic Response at Week 24 (LOCF) - Randomized, Treated Participants","SECONDARY","The probability of response was modeled using a logistic regression model with baseline HbA1c as the covariate. Treatment group estimates of response rate were then obtained by integrating each group's modeled probability of response over the observed distribution of baseline covariate (combined across groups).","D003920; D003924","Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes",FALSE,405,"logistic_regression",NA,NA,NA,1.1441303860062
"567","21280ecb2b992018d7263f89fdf50060","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Health)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1735,"linear_regression",NA,NA,NA,6.10897489711546
"568","2135f349baa0010328295335789c3ae1","NCT00922194",0.05,"Wilcoxon","INTERVENTIONAL",0,0,0,0,0,"Change in Waist Circumference From Baseline at 12 Months or More","PRIMARY","Analysis of difference between 12 months and baseline values","D003920; D003924; D050177","Metformin in Overweight Type 2 Diabetes Mellitus",TRUE,102,"wilcoxon",NA,NA,NA,1.50770356720122
"569","213e597c82eb26921c5d12fc12efd813","NCT00692198",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Sleep Quality","SECONDARY",NA,"D008171; D008173; D029424","Long-term Oxygen Treatment Trial",FALSE,514,"t-test",NA,NA,NA,2.16202770329848
"570","2155a873e9c93b4ca816864bc66175ff","NCT02389816",0.0418,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"MADRS Remission at Week 8 (LOCF)","SECONDARY",NA,"D003866; D003863; D003865","A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder",FALSE,328,"logistic_regression",NA,NA,NA,2.29602815889838
"571","217764ab1ef1b0ccdb5a7610cc728da5","NCT03707912",0.032,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms.","PRIMARY",NA,"D007239; D003141; D014777","Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections",FALSE,203,"mann_whitney",NA,NA,NA,1.44582613953215
"572","217f05e0e0a6f5e7f903b6225d8188b9","NCT03480022",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Diastolic Blood Pressure (BP)","SECONDARY","Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect","D011085; D011236; D013577; D001835","Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS",FALSE,67,"anova",2,NA,NA,1.23402909436682
"573","218404a39fd2bcf2e1846b5be5d8eafa","NCT00608426",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Self-reported, Smoking Abstinence Rate: 6-month Prolonged Abstinence","PRIMARY",NA,NA,"Proactive Tobacco Treatment for Veterans",FALSE,3307,"logistic_regression",NA,NA,NA,3.84498379848281
"574","2186ba580829a95d70adaeb548aac58b","NCT03879772",0.04,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Total Nasal Symptom Score (TNSS) on Day 29 as Assessed by Investigator","SECONDARY","Pairwise comparisons were performed using least square means from two-way ANOVA.","D012220; D065631; D006255","Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)",FALSE,269,"anova",2,NA,NA,2.0062219570789
"575","218dd5ccb23325ca2dc37d1aec93b7dd","NCT01378299",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Percent Change in Bone Turnover Markers According to the rs700518 Polymorphism of the CYP19A1 Gene","SECONDARY","Analysis was by intention to treat with the last value carry forward. Those who had at least one follow-up from baseline and with acceptable assay coefficient of variability were included in the analysis. The data of 79 subjects were analyzed; 15 in the GG, 43 in the GA and 21 in the AA genotype.","D007006","CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy",TRUE,58,"anova",2,NA,NA,1.15327776573523
"576","219256811c1158dd38a1aac8a9154511","NCT01728246",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in ODI Score at Week 4","PRIMARY",NA,"D010003","An Efficacy, Safety and Effects on Quality of Life of Tramadol/Paracetamol as Add-on Therapy in Chronic Osteoarthritis",TRUE,473,"t-test",NA,NA,NA,3.19913039915235
"577","21a4de7939050efde69e181a99f884d4","NCT04196777",0.013,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Excessive Post-procedural Antimicrobial Duration (Mean)","SECONDARY","The median duration of post-procedural antimicrobial prescriptions at site 1 were compared using the Wilcoxon rank-sum test.Type of statistical test","D014570; D064420","Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists",FALSE,860,"mann_whitney",NA,NA,NA,1.34648559536908
"578","21b7c3391179e1580f587f23e3aabcfb","NCT03265210",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Pain-related Disability, as Measured by the Roland-Morris Disability Questionnaire (RMDQ)","PRIMARY","Domain 1, 12 weeks","D059350; D003863; D003866","A Behavioral Intervention for Depression and Chronic Pain in Primary Care",FALSE,73,"t-test",NA,NA,NA,1.28506804726186
"579","21ba6c9b3f8c478013dcf7d878d26577","NCT01049334",0.0459,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline at 24 Hours in the Tonsillo-Pharyngitis Assessment (TPA) Scores in Participants With Baseline TPA Scores >=8","SECONDARY",NA,"D010612","A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis",FALSE,162,"mann_whitney",NA,NA,NA,1.75675446979615
"580","21cfbfb3ae35901209c6cdfd37475755","NCT01087905",0.029,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"7-Day Point Prevalence Abstinence From Smoking by Nicotine Replacement Therapy (NRT) Group","PRIMARY","Null hypothesis: No difference in abstinence rates for participants receiving Two Weeks of Nicotine Replacement Therapy (NRT) Monotherapy (Nicotine Patch Only) versus Two Weeks of Combination NRT (Patch+Gum). We hypothesized that Two Weeks of Combination NRT would result in statistically significantly higher abstinence rates compared to Two Weeks of NRT Monotherapy.

The study was originally powered to detect at least a 6.4% increase in the abstinence rate due to an enhanced intervention.",NA,"Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines",FALSE,490,"logistic_regression",NA,NA,NA,2.05086344716113
"581","21e1fe81b7d93e6e8796f5110768d77c","NCT01199601",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Correct Breastfeeding Practices to 1 Year","SECONDARY",NA,"D006509","Blood-borne Infection Screening in an Afghan Antenatal Population",TRUE,697,"linear_regression",NA,NA,NA,3.87838567678856
"582","21f5998028025b67f6fd4a654aff4c25","NCT02912650",0.022,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Intensity Difference on 4-Point Categorical Scale (PID4)","OTHER_PRE_SPECIFIED","11 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,228,"anova",2,NA,NA,1.10880651042333
"583","21f701a526a30a95a3262e4de6137a07","NCT00377858",0.018,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"30-Day Adjusted Rates of Self-Reported Hypoglycemic Episodes (Including Nocturnal and Non-Nocturnal)","SECONDARY",NA,"D003920; D003924","Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)",FALSE,479,"anova",2,NA,NA,1.3412704065296
"584","22057c18a3305ac2d8d46013aa65eda1","NCT00395850",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Cocaine Use Over Time","PRIMARY","Used placebo group as contrast to determine whether slopes of disulfiram groups differed from slope of placebo group data","D019970","Disulfiram for Cocaine Abuse",TRUE,80,"logistic_regression",NA,NA,NA,1.34217713699512
"585","220a0801fd081a7e79112f0ea8661025","NCT01256944",0.05,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"Two Hour Glucose","PRIMARY",NA,"D011085; D002318; D024821; D013577","To Study Polycystic Ovary Syndrome in Taiwanese Women",TRUE,290,"anova",2,NA,NA,2.51138465397077
"586","2224c4553bd4f324d3beaa40be69e951","NCT01236053",0.002,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,20382,"logistic_regression",NA,NA,NA,1.20522964988748
"587","222aa59cf2cb76b4327a59799782ec91","NCT01166230",0.041,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Median Time to Recurrence","OTHER_PRE_SPECIFIED",NA,"D001749; D012008","Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB",FALSE,261,"mann_whitney",NA,NA,NA,2.01829437623942
"588","2235b84dfd13c3490e9d30c158cab814","NCT01891396",0.0227,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"OMERACT-OARSI Responder Index Comparing Cingal® to Saline (PP)","SECONDARY",NA,"D010003; D020370","Cingal Study for Knee Osteoarthritis",FALSE,200,"anova",2,NA,NA,1.06873765133598
"589","22722cd1e0c21151eba96c89ed51b7d3","NCT03239665",0.0246,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Mean Change in Knowledge and Awareness About Vaccine-Preventable Diseases","PRIMARY","Testing total knowledge score change between groups from post-intervention to one-month follow-up","D003141; D007239; D018410","Vaccination Education Through Pharmacists and Senior Centers (VEPSC)",FALSE,287,"mann_whitney",NA,NA,NA,1.36701452322919
"590","22834e1db692e7494819da2cba21e1a8","NCT01910402",0.016,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"HIVTSQs Total Score at Indicated Timepoints","SECONDARY",NA,"D007239; D003141; D015658; D000163; D007153","A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)",FALSE,495,"mann_whitney",NA,NA,NA,1.22961771079809
"591","2287f0805d8536d761d76f73a0540e1c","NCT02160977",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"HSS(Hospital for Special Surgery) Score of the Knee Joint","SECONDARY",NA,"D010003","Proprioception of the Knee Post MIS TKA and MIS-QS TKA",TRUE,84,"t-test",NA,NA,NA,1.37375080866169
"592","22896646f7c00da645f67b6e2b8898c0","NCT00706849",0.042,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Percent Change From Baseline in Triglycerides at the Primary Efficacy Time Point","OTHER_PRE_SPECIFIED",NA,"D003324; D017202; D003327; D006938; D006937","Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease",FALSE,123,"mann_whitney",NA,NA,NA,1.42660836172024
"593","228c17ccadb81acafc220333cd1360ae","NCT00227903",0.04,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Proportion of Participants (Without a Baseline Diagnosis of Drug Abuse or Dependence) Abstinent From Both Drugs and Alcohol According to Combined Self-report and Urine","SECONDARY",NA,"D002189; D000437; D019970","Therapeutic Substance Abuse Treatment in Pregnancy - 1",FALSE,79,"logistic_regression",NA,NA,NA,1.10791193525359
"594","22989a3e0883d8bb3b08c0af32904e7c","NCT01207453",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Thumbnail Pain Threshold","SECONDARY","The difference between the change measured during placebo versus the change during milnacipran treatment. Calculated using Wilcoxon signed-rank tests.","D001168; D001172","Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis",FALSE,64,"mann_whitney",NA,NA,NA,1.00345743424713
"595","22a52e43439989a06c6381f09da131e1","NCT03194503",0.015,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Number of Participants With Tracheal Intubation Associated Events (TIAEs) in the NICU Over 2 Years","PRIMARY","This statistical analysis applies to all three rows in the post-intervention column. ITT analysis: Multivariable analysis for Any TIAEs, Severe TIAEs, and Severe desaturation(\>20%)",NA,"Tracheal Intubation Coaching in NICUs",FALSE,1512,"t-test",NA,NA,NA,2.02246454594492
"596","22b22ac0afba4e5f220b3efa0666fad6","NCT03337399",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Patient-reported Quality of Life","PRIMARY","The difference in week 24 means between groups was estimated using a linear regression model adjusted for baseline FACT-L score.","D008175","Stepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced Lung Cancer",TRUE,507,"linear_regression",NA,NA,NA,3.3112127512036
"597","22cae929e81ae26757615a65b9c62ed5","NCT00775463",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Physician Global Assessment of Digital Ulcer Severity VAS","SECONDARY","The VAS-global assessments were recorded in centimeters, with possible values ranging from 0.0 to 15.0. The recorded value was divided by 15, then multiplied by 100 to convert it to the VAS-Global scale, with values ranging from 0 (no disease activity) to 100 (very severe disease). The difference between treatment groups for the change from Baseline was tested using the Wilcoxon rank-sum test.","D012595; D045743; D012594","Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine",FALSE,146,"mann_whitney",NA,NA,NA,1.48781087340431
"598","22eb8346cce3f276b705c94f16f177b5","NCT03499600",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Satisfaction With Intake Questionnaire","PRIMARY","A power analysis assuming an alpha level = 0.05, beta = 0.2, and power = 0.8, identified a sample ≥82 participants was needed to identify small-to-medium effects (i.e., OR\~2.5).Intent-to-treat analyses were employed. This linear regressions tested condition effects on provider satisfaction with the intake.","D000066553","Improving Satisfaction, Engagement and Outcomes Among Traditionally Underserved Children Through Cultural Formulation",TRUE,89,"linear_regression",NA,NA,NA,1.41222998379373
"599","230ed7b3b5157ea3e3b1c4c8975ea307","NCT02954848",0.0478,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Percentage of Days Without Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) at Week 2","SECONDARY","Statistical analysis for criteria 1, improved response","D005764; D004942","Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)",FALSE,483,"mann_whitney",NA,NA,NA,3.1129203376625
"600","23237e12089ec25c6822aee21f77e320","NCT02528188",0.0154,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 2: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline PGA of OA scale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade, NSAID and treatment.","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1989,"logistic_regression",NA,NA,NA,2.3728912912825
"601","2354d5552bb8645ffe3c9095ffbd87db","NCT00755807",0.047,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Bicarbonate (HCO3) at Week 6 (Acute Phase)","OTHER_PRE_SPECIFIED",NA,"D009103; D012598","Duloxetine for Multiple Sclerosis Pain",FALSE,226,"anova",2,NA,NA,2.10918577585876
"602","236030fb6a80c492a0c5addb3226a4ba","NCT02849509",0.0174,"One-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Perception of Anticoagulant Treatment Questionnaire, Part 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second Assessment Compared to Baseline Assessment","PRIMARY","Satisfaction dimension score of PACT-Q2 at the second assessment (Visit 2) were compared with the baseline assessment (Visit 1). There was no (confirmatory) hypothesis testing foreseen in a strict statistical sense. Analyses were descriptive in nature and p-values from statistical models were used for exploratory purposes.","D001281","Patient Convenience Study- NIS RELATE",FALSE,379,"t-test",NA,NA,NA,1.16002708560349
"603","2389c613c7722f35cf42e8b4cbeabe2f","NCT00000378",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"HAMILTON Rating Scale for DEPRESSION Range","PRIMARY","logistic regression and mixed effects model","D003863; D003866","Antidepressant Treatment of Melancholia in Late Life",TRUE,110,"logistic_regression",NA,NA,NA,1.56357043896758
"604","23a0fa923b6982ecca59f85cac36d9e7","NCT04796909",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Level of Perceptions of Health Care Practitioners' Autonomy Support","OTHER_PRE_SPECIFIED",NA,"D002658","Occupational Performance Coaching With Parents of Young Children With Developmental Disability",FALSE,50,"t-test",NA,NA,NA,1.07648023860356
"605","23a71a9b9005e72d07a172bf91647a4e","NCT02528253",0.0088,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 12, \>=70%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1011,"logistic_regression",NA,NA,NA,1.0317486938692
"606","23ba3964a181031f74657e9287e751e4","NCT01787461",0.027,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Investigator Assessment of Decolletage and Back of Hands at Weeks 12 and 24","SECONDARY","Change at Week 24, Back of Hands - Mottled Hyperpigmentation: Analysis was performed using an ANOVA model with treatment, Glogau cassification of photoaging, site, baseline and treatment-by-baseline interaction (if applicable) terms.",NA,"A Study to Assess the Effects of an Oral Dietary Supplement on Overall Facial Appearance Among Healthy Adult Women With Existing Skin Damage From Sun Exposure",FALSE,190,"anova",2,NA,NA,1.21043171014778
"607","23bfec74f90a2d4bbcc54e5baea09cfb","NCT01283139",0.044,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With a Cutaneous Lupus Erythematosus Disease Activity and Severity Index (CLASI) Activity Score Greater Than or Equal to (>=) 10 at Baseline Who Achieved a >= 4-point Reduction","SECONDARY",NA,"D008180","A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus",FALSE,68,"logistic_regression",NA,NA,NA,1.1177308611713
"608","23d4abf648caa29057cbf5fea9491087","NCT01881373",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Prevalence of Acanthosis Nigricans","PRIMARY","intervention vs control. The children from each community recruited each time were NOT the same children. The number of communities is consistent across time.","D000052; D009765; D056128","Children's Healthy Living Community Randomized Trial",TRUE,3987,"logistic_regression",NA,NA,NA,2.29052474927477
"609","23e8da3ff1ca8167127bbe47e0b23b52","NCT03953508",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Number of Clicks for Menthol Cigarette Puffs on the Behavioral Choice Task","SECONDARY",NA,NA,"Perceptions of Cigarette Smoking in Young Adults",TRUE,107,"anova",2,NA,NA,1.54285677868397
"610","23e94b75c045aa80165394d3c7566aec","NCT00548249",0.049,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Hemoglobin (Hgb)","SECONDARY","Each dose was compared to placebo using an ANOVA model with treatment as the effect","D007674; D007676","Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis",FALSE,55,"anova",2,NA,NA,1.10652059811465
"611","240117e954ed5f45c3965d7490f3f1dd","NCT01817530",0.049,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With ≥ 25% Reduction From Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit","SECONDARY","Month 6","D007889; D047708; D014592; D008595; D006470","Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)",FALSE,155,"logistic_regression",NA,NA,NA,1.81581992984799
"612","243a8322ee1688d83f8a4eab2958e1d1","NCT00790335",0.03,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Venous Clinical Severity Score","SECONDARY",NA,"D013927; D013923; D054556; D020246; D054070; D011186; D013577","Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis",FALSE,449,"linear_regression",NA,NA,NA,2.02204529442074
"613","244632e7f1b1359c47c6cb8217b20565","NCT01070550",0.0247,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for BMI in kg/m\^2. The logistic regression analysis for relapse 24 weeks after EOT was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including total cumulative dose of peginterferon and ribavirin), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,227,"logistic_regression",NA,NA,NA,1.22285507246175
"614","24601eee0e584616f8d75cc6fc1e568e","NCT01193127",0.0314,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Postoperative Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade, Day 7","SECONDARY",NA,"D002386","Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)",FALSE,111,"anova",2,NA,NA,1.06199112156877
"615","24879734fe0e4c1b2bed7692bd213e21","NCT04858802",0.041,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Inflammation Score in the Frontal Recess/FSO by Clinical Investigators","SECONDARY","Day 180","D000096825","A Clinical Evaluation of PROPEL® Contour Sinus Implant",FALSE,160,"t-test",NA,NA,NA,1.58824480219701
"616","2496f5c575e7dfde7b74f9b8bae6fbef","NCT02528253",0.017,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 24, \>=50%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1011,"logistic_regression",NA,NA,NA,1.84776703562164
"617","249dc4a0a937fe1066d7a8bb06bdeabd","NCT02223364",0.043,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Maximum Pain POD 1 (24 Hours)","SECONDARY",NA,NA,"Peripheral Nerve Blocks vs Periarticular Local Anesthetic Injection for Total Knee Arthroplasty (TKA)",FALSE,102,"mann_whitney",NA,NA,NA,1.32957699604834
"618","24a3488a5182d6a0e5e8e50134554ad8","NCT00105989",0.046,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Total Protein - Continuation Phase","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,392,"t-test",NA,NA,NA,2.71804331819882
"619","24a724ae834ce77d5dabbb0509d485d5","NCT02921776",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Number of Participants That Responded ""Yes"" to Having Communication Difficulty at Extubation or ICU Discharge","SECONDARY",NA,"D016638","Vidatalk Communication Application: Usability, Acceptability and Efficacy Study",FALSE,48,"t-test",NA,NA,NA,1.05642048349345
"620","24b0ddf8bf808ace02d48e68b004ee52","NCT05502081",0.027,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,1,"Platelets at Day 7","SECONDARY",NA,"D000086382","Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients",FALSE,158,"kruskal_wallis",2,NA,NA,1.10668521692669
"621","24d8e7f1ee554f07ff5d155c874e0eea","NCT04512482",0.044,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Composite Plaque Score","PRIMARY","A power analysis determined that a sample size of forty-five (45) subjects would possess 90% power to detect an effect size of 0.5 between the intervention and control legs of the crossover design. With 43 total subjects the study had between 85 and 90% power.","D003731; D003773","Evaluation of Oral Plaque Removal Utilizing an Adjunct Enzyme Pre-rinse",FALSE,86,"anova",2,NA,NA,1.24916760091218
"622","24e749fc26ec6c9df168161dbdc543a4","NCT00416572",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mental Health (Measured With the SF-36) at Baseline, Post-intervention (4-months Post-intervention) and Final Follow-up (13-months Post-intervention)","PRIMARY","Comparison between education intervention and the control condition at final follow-up (13 months post-intervention). The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome.","D001943","Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer",FALSE,146,"linear_regression",NA,NA,NA,1.79360862376457
"623","24fb4487c94163217496b2896247927a","NCT01779375",0.05,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"M/I","PRIMARY","Analyses were completed on a log scale and re-exponentiated for presentation.","D011236","RISE Pediatric Medication Study",FALSE,84,"linear_regression",NA,NA,NA,1.37375080866169
"624","24fb7dcfd04ff2ebcac5a24844d94fa5","NCT01539070",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Children´s Time of Physical Activity From Baseline to 3 Months by Intervention Assignment","PRIMARY","In intent-to-treat analyses, we used unadjusted and adjusted multivariate regression models, to examine differences from baseline to 3 months between the intervention and usual care groups. For continuous outcomes, we used linear regression models, and for dichotomous outcomes, we used logistic regression models. To account for clustering by practices, we performed generalized linear mixed models. The Estimator (Est) and Confidence Interval 95% (95% CI)are reported.","D009765; D063766","Intervention for the Prevention of Obesity in Preschool",TRUE,306,"linear_regression",NA,NA,NA,2.5788408992482
"625","250eb58fdd1d15d7e666cfed3238bb59","NCT01142726",0.045,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria at Month 12 and at Both Months 12 and 18","PRIMARY","Conditional on statistical significance of the 1st coprimary efficacy analysis (CEA), a sample of 116 patients per arm would provide 98% power for the 2nd CEA comparison of the percentage of patients in DAS28-CRP remission at Months 12 and 18 between the abatacept (ABA)+methotrexate (MTX) arm and the MTX monotherapy arm for intent-to treat population. This sample size calculation assumed 30% remission in the ABA+MTX arm and 8% in the monotherapy arm at Month 18 and a 2-sided alpha level of 5%.","D001168; D001172","Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis",FALSE,235,"logistic_regression",NA,NA,NA,2.07305486249094
"626","2519bd38aa312dbcafeef244667efacc","NCT02265796",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks","PRIMARY","between group comparison for all SAQ domains","D000787","Ranolazine Among Unrevascularized Chronic Stable Angina Patients",FALSE,46,"t-test",NA,NA,NA,1.03597838019194
"627","2546574178cc7232e8633ded4ffebd6c","NCT03932799",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Satisfaction With Pain-related Treatment","SECONDARY","* Primary predictor is binary (1 for Washington, 0 for Ohio)
* Models survey weighted
* Robust variance estimates","D009293","Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing",FALSE,2295,"logistic_regression",NA,NA,NA,1.73888007679412
"628","255fd5aa110345118859d157d3475b8a","NCT00554294",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Overweight","PRIMARY","adjusted for overweight at baseline, age at baseline,sex and clustering by school","D050177","Promoting Water Consumption for Prevention of Overweight in School Children in a Controlled Intervention Trial",TRUE,2950,"logistic_regression",NA,NA,NA,7.96217265351951
"629","25610a546e74d94f1a7ba34e4acb6033","NCT05018689",0.025,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Change in University of Michigan Depression Center Peer-to-Peer Depression Awareness Assessment Knowledge Scores From Baseline (4 of 4)","PRIMARY","Feeling tired or less energetic",NA,"Evaluation of the Aevidum Curriculum and Club",FALSE,2557,"logistic_regression",NA,NA,NA,4.10552764988755
"630","25657feb8e7d358a6d3ad1d8770ce6cd","NCT03468868",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Modified Fatigue Impact Scale (MFIS)","SECONDARY","MFIS Physical","D009103; D012598","Comparative Effectiveness Study Telerehab Versus Conventional",FALSE,379,"t-test",NA,NA,NA,2.37593323206142
"631","256e786665fe033e7340d93e7225758f","NCT03694418",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Number of Protected Acts of Vaginal and/or Anal Sex in the Past 30 Days.","PRIMARY",NA,NA,"We Are Here Now: a Multi-level, Multicomponent Sexual and Reproductive Health Intervention for American Indian Youth",TRUE,453,"mann_whitney",NA,NA,NA,3.13132636371691
"632","257cd2403f2b5eace0177b9434897e59","NCT00718549",0.045,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With CR or PR Assessed According to the NCI Revised Guidelines for the Diagnosis and Treatment of CLL According to Clinical and Biochemical Factors at Week 29","SECONDARY","Univariate Comparison: Beta-2-Microglobulin \>/= Median Value versus Beta-2-Microglobulin \<Median Value","D007938; D007945; D015451","A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)",FALSE,97,"logistic_regression",NA,NA,NA,1.34817303752635
"633","25985e74678ce451f9889e94e2779024","NCT00472446",0.028,"Two-sample t-test","INTERVENTIONAL",0,0,1,1,0,"Post-operative Pain Measured by Visual Analogue Scale","PRIMARY","null hypothesis: no difference in outcome measure between superficial cervical block and placebo treatment (irrespective of timing of treatment)","D013959","Superficial, Cervical Block in Thyroid Surgery, a Randomized Controlled Trial",FALSE,159,"t-test",NA,NA,NA,1.14522484920267
"634","25a53746ac3186cb697e890acf2ce1f0","NCT03855189",0.02,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 4 (Physician-Evaluated)","SECONDARY","Pairwise treatment comparison based on t-test from an analysis of variance (ANOVA).","D012220; D065631; D006255","Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)",FALSE,229,"anova",2,NA,NA,1.02299044795298
"635","25a93d282625cda7176f126a98fbe5e6","NCT00245219",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mental Health (as Measured With the SF-36) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The interaction between the peer support condition and cancer stage at Time 3. The full regression model consisted of 3 steps: The 1st step contained the baseline measure of the dependent variable. The 2nd step contained two dummy coded variables contrasting each condition with control. The 3rd step contained the interaction between the peer support condition and cancer stage. Patients in the education condition were excluded from this analysis.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"linear_regression",NA,NA,NA,1.79957957739554
"636","25ba035ae8c12c45bc1f22454c30172e","NCT02609828",0.0455,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Cumulative Reduction of >=30, 50, 70 and 90 Percent (%) From Baseline in Daily Average Pain Intensity NRS Score in the Index Bone Metastasis Cancer Pain Site at Weeks 1, 2, 4, 6, 8, 12, 16 and 24","SECONDARY","Week 4 Reduction \>=70%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","D009362; D001859; D001855; D000072716","Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy",FALSE,144,"logistic_regression",NA,NA,NA,1.64672865213099
"637","25bcc75ca888e7f8ee6358820375d9cd","NCT04910165",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"WOMAC Score","PRIMARY",NA,"D010149","Exparel Use in Adductor Canal Block After Total Knee Arthroplasty",TRUE,88,"mann_whitney",NA,NA,NA,1.40461812327938
"638","25e54f499c0ab81713b2c368ec5caeea","NCT01416194",0.03,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Selected Ocular Events","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",FALSE,7777,"logistic_regression",NA,NA,NA,8.37389908386674
"639","25e5b0ae2eda878e4042014be6aec643","NCT01888874",0.0435,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12","PRIMARY","Pairwise comparisons of each group vs. the placebo group using a logistic regression model with factors treatment group, geographical region, and prior use of biologics.","D001168; D001172","Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)",FALSE,171,"logistic_regression",NA,NA,NA,1.72429321634767
"640","25fcef67e67a20147baec635bcbe6d2b","NCT01335477",0.0218,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)","SECONDARY","Logistic regression with terms treatment, baseline SGRQ total score","D011658; D054990; D005355","Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II",FALSE,548,"logistic_regression",NA,NA,NA,1.69401222227232
"641","263537a3dda2360b31b92fc852f66b58","NCT00261443",0.017,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Mean Baseline and Adjusted Mean Change From Baseline in Young-Mania Rating Scale (Y-MRS) Total Score Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 16 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,1.0554830773903
"642","26425bada8c87ce5ef9fe8327bd5d55c","NCT03547531",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Plaque Level at 1 Month","PRIMARY","null hypotesis: there is no difference of mean of plaque index between groups","D003773; D009066","Comparison of Modified Circular and Natural Tooth Brushing Methods in Effectiveness of Dental Plaque Removal",TRUE,118,"t-test",NA,NA,NA,1.61751378500378
"643","264ca84b0ee4ead7571ecf3e449f7128","NCT03962738",0.044,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Health-Related Quality of Life (HRQoL) Total Score as Measured by the 24-Hour Migraine Quality of Life Questionnaire (MQoLQ)","SECONDARY","Migraine Symptoms","D008881","A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine",FALSE,339,"anova",2,NA,NA,2.43684040369896
"644","265000392474dfb9e01a2d4c992ecad6","NCT02106403",0.0357,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Participant-perceived Cooling Sensation at 15 Min","PRIMARY","The null and alternative hypotheses were: H0: product difference was null vs. Ha: product difference was not null.",NA,"A Study to Evaluate the Cooling Sensation and Consumer Liking of a Skin Disinfectant Spray",FALSE,100,"anova",2,NA,NA,1.12631718204853
"645","2651e01bc189824725faeaf014330832","NCT00840996",0.049,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants With Any Major 30-day Post Operative Complications","SECONDARY",NA,NA,"Perioperative Intravenous Lidocaine or Epidural Anesthesia on Outcomes in Complex Spine Surgery",FALSE,115,"logistic_regression",NA,NA,NA,1.57088451450169
"646","265e64fd941fbeeb725a8a3f0d3576b8","NCT00798161",0.049,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Use of Rescue Therapy","SECONDARY",NA,"D003924","Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design",FALSE,278,"logistic_regression",NA,NA,NA,2.41839485366732
"647","266aec131f104777cbe4ba02b3f04c06","NCT00112151",0.05,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Upper Body Muscle Strength (1-RM, kg)","SECONDARY","As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in average upper body strength with any T to placebo in subjects assigned to no PRT.",NA,"TEAM: Testosterone Supplementation and Exercise in Elderly Men",TRUE,72,"linear_regression",NA,NA,NA,1.27670232702116
"648","26774d97da069ed9682f51881af0b3ca","NCT02373813",0.049,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Disease Activity Score (28 Joint) Calculated Using the Erythrocyte Sedimentation Rate Formula (DAS28-ESR) at All Measured Timepoints","SECONDARY","Week 12","D001168; D001172","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",FALSE,152,"t-test",NA,NA,NA,1.79860533855173
"649","2684ee743446fe24618e7cec25c4d5ec","NCT01381406",0.013,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Incidence Rate Per 100 Person Years of Hospitalization or Emergency Department (ED) Visit Related to Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)","PRIMARY",NA,"D008171; D008173; D029424","Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations",FALSE,3333,"logistic_regression",NA,NA,NA,2.64371347241917
"650","2691910a85919f2ccae9f8bd14436356","NCT00408876",0.035,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Severity (BPI-S) - Average Pain Score","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,221,"t-test",NA,NA,NA,1.6266956333314
"651","26d254c2cf53ef58ee2577f296440640","NCT04876482",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Computer Tomography (CT)_Volume","PRIMARY","We hypothesized that the improvements in the upper airway volume would be higher in patients who underwent TORS combined with OPR than in those who underwent only TORS and those who received conservative treatment (controls).","D001049; D012891; D020181","Myofunctional Training for Obstructive Sleep Apnea Patients After Transoral Robotic Surgery",TRUE,74,"linear_regression",NA,NA,NA,1.2933799900503
"652","26e8bb0b77c2ad9e6030a512a5f9cd12","NCT03975790",0.0199,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Total RA Related Monthly Health Care Cost","SECONDARY","9 months before index date","D001168; D001172","Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX",FALSE,431,"t-test",NA,NA,NA,1.38960520400192
"653","27131dac5f9bbf9bbf2104ecf5172042","NCT00885664",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"IL-10","SECONDARY",NA,"D007239; D003141; D015658; D000163","Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection",FALSE,60,"mann_whitney",NA,NA,NA,1.17169922891753
"654","271d6c2b893412d5a294f975085d9f75","NCT00408876",0.042,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Laboratory Assessment - Chloride","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,162,"t-test",NA,NA,NA,1.63061793601119
"655","272a46ffbe8c9bcf9c2df4b999bc573e","NCT00608985",0.0186,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 1&2 in the Self-reported WASO (sWASO)","PRIMARY","Change from baseline to week 1\&2 compared with placebo","D007319","Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia",FALSE,354,"mann_whitney",NA,NA,NA,1.18898849910313
"656","275f48b0a3e4ea3022812d6ff80bc6b1","NCT02072174",0.0242,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,1,"Average Illness Duration","PRIMARY",NA,"D007239; D003141; D007251; D014777","Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children",FALSE,498,"kruskal_wallis",2,NA,NA,1.76876217998711
"657","276c48ed4ddf6837494d384a28d112a5","NCT03646305",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Self-Ratings of Thought Appraisals (Avoidance)","PRIMARY","Paired sample t-tests was conducted to measure differences in avoidance of target thought from post-intervention to follow-up. Null hypothesis: there would be no significant differences in avoidance from post-intervention to follow-up.",NA,"Singing Your Negative Body-Related Thoughts",TRUE,122,"t-test",NA,NA,NA,1.64382327798156
"658","277250ea7dc3167d655872b6a3ce32e1","NCT04332614",0.0286,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Email Opened: Control vs. Less-is-better vs. Social Proof vs. Endowment","SECONDARY",NA,NA,"Email Campaign to Increase Uptake of myGeisinger",FALSE,8403,"logistic_regression",NA,NA,NA,8.35359349227427
"659","277829a1bcd17085be4c6dc41f27c887","NCT01070550",0.0255,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for sex (male vs female). The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including total cumulative dose of peginterferon and ribavirin), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,665,"logistic_regression",NA,NA,NA,2.13580071514031
"660","2782066e97cba46d0379a4eef102f829","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Health)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1754,"linear_regression",NA,NA,NA,6.14225987828851
"661","2793a2dff1e27709c63d1ed8f3ff7f36","NCT03334396",0.032,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)","SECONDARY",NA,"D003876; D003872; D004485","A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis",FALSE,376,"logistic_regression",NA,NA,NA,1.9574862775043
"662","2793ba1dbdfa1f6e118419945165c815","NCT03687762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in Pain Intensity (Micro-level)","SECONDARY",NA,"D059350","Back on Track to Healthy Living Study",FALSE,302,"anova",3,NA,NA,1.03237942189705
"663","27a785dc996aeffd8c34d0baa0090cd6","NCT03847896",0.039,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With a Clinically Meaningful Difference on the Asthma Control Questionnaire 7-item Version (ACQ-7) at Week 12.","SECONDARY","Comparison is not type-I error controlled.","D001249","A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma",FALSE,320,"logistic_regression",NA,NA,NA,2.13909821239441
"664","27b3517351120204a5201863545f486f","NCT03655951",0.03,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Willingness to Engage in Unwanted Sexual Activity From Pretest to Posttest","SECONDARY",NA,NA,"Birds and Bees Research Study",FALSE,268,"linear_regression",NA,NA,NA,1.56773728461108
"665","27b9deec0fb479cca1233a19ce64bcc3","NCT05529173",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change in S. Aureus/MRSA Colony Forming Units (CFU) in Nasal Swab Specimen After Treatment in Patients Who Presented With a Positive for S. Aureus/MRSA Pre-interventional Nasal Swab Specimen.","PRIMARY",NA,"D014946; D013530; D000072836","Povidone-Iodine for Nasal Decolonization",TRUE,89,"mann_whitney",NA,NA,NA,1.41222998379373
"666","27cac7bbda31a7aceecce341837a4958","NCT00453999",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Scores of Symptoms of Influenza","SECONDARY","Feeling Feverish: change from Baseline at Days 2, 3, 4, 5, 10, 14","D007251","Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza",FALSE,122,"mann_whitney",NA,NA,NA,1.64382327798156
"667","27d2d30357d5a45a15b47c2862bffe95","NCT02407132",0.038,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Glycemic Control, Measured by Change in Adjusted Mean HbA1c (%) From Baseline to Immediate Post-intervention, 6 Months Post-intervention, and 12 Months Post-intervention.","PRIMARY","The outcome variable for these analyses is Change in mean HbA1c from baseline to immediate post-intervention, 6 months post-intervention, and 12 months post-intervention.","D003920","Family Model of Diabetes Self-Management Education in the Marshallese Community",FALSE,221,"linear_regression",NA,NA,NA,1.74422465913534
"668","27d74e2106a1e946e154c8aa9e38720f","NCT05170841",0.029,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Percentage of Maximum TOTPAR (%Max TOTPAR) at 48 Hours After the First Dose- Multiple Dose Phase - Dexketoprofen/Tramadol vs Tramadol","SECONDARY",NA,"D001416; D017116","Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain",FALSE,499,"t-test",NA,NA,NA,2.06943061999492
"669","27e8077a7811e92cabb5fa15dbd0de03","NCT03203512",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Ex Vivo Agonist-stimulated Platelet Activation Detected by Plate-based Platelet Aggregation Assay","SECONDARY","Null hypothesis is that there was no difference in change of platelet function in affecting LogEC50 values in response to U46619 between fish oil and placebo capsules. Comparisons of this parameter after each intervention were drawn using 2-way ANOVA with the Turkey multiple comparisons test.","D001768","Fish Oil-derived N-3 Polyunsaturated Fatty Acids and Extracellular Vesicles",FALSE,80,"anova",2,NA,NA,1.34217713699512
"670","27ec6d885dd94464894fa313cd358158","NCT01945034",0.02,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","SECONDARY","At Rest Day 1(PM): The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms. Upper limit of 95% CI \< 0 for Ibuprofen treatment significantly better than combined Placebo.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,219,"anova",2,NA,NA,1.00094501898898
"671","280052535d0f68ad477c21fb14ff71f8","NCT01472432",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"HIF-1α","SECONDARY","p-values from multiple comparisons: placebo at baseline vs. placebo at 3 months; placebo at 3 months vs. Vildagliptin at 3 months; Vildagliptin at baseline vs. Vildagliptin at 3 months.","D016523; D003924; D014456","DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes",TRUE,106,"t-test",NA,NA,NA,1.53589031932405
"672","2828aa15694934e977a66ae338aafd1e","NCT00565812",0.032,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Decrease in Total Analgesic Medication Use","SECONDARY","Month 24; Odds ratio, 95 percent CI and P-values were obtained from a logistic regression model, with treatment group, (collapsed) KLG, geographic region, and gender as factors, age and body mass index as covariates.","D010003; D020370","A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee",FALSE,971,"logistic_regression",NA,NA,NA,3.13391398150506
"673","284ad23186ccb0aa42d92b480a2206fa","NCT00245219",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Physical Health (as Measured With the SF36) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the education condition and the control condition at Time 3. The full regression model included 2 dummy coded variables, 1 contrasting the education and control condition, and 1 contrasting the peer support and control condition. The baseline measure of the outcome variable was included, in order to examine changes in the outcomes over time. This model tested the main effects of the conditions among patients with early stage cancer, late stage patients were excluded.","D001943","Understanding Shared Psychobiological Pathways",FALSE,131,"linear_regression",NA,NA,NA,1.70153588988359
"674","285369dd9c4f642a6da7e9652fca64ac","NCT00930943",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Rapid Visual Information Processing (RVP) Response Latency","PRIMARY",NA,"D059350","Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning",FALSE,60,"anova",2,NA,NA,1.17169922891753
"675","2853baedf71b4a9ff74ceedde3a80eb6","NCT01943435",0.03,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Sense Wear Armband","OTHER_PRE_SPECIFIED","This secondary analysis consisted of a between-groups comparison of means using linear regression with physical activity as the dependent variable (average number of minutes spent daily in activities \>1.5 METs), while adjusting for randomization stratification factors.","D013130; D003251","Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)",FALSE,172,"linear_regression",NA,NA,NA,1.26211756568296
"676","286a588d731cf075a7dbc39272dcaeb2","NCT00733499",0.0485,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Comparative Evaluation of Any Variability in Quality of Life Assessed by SF-12 (Physical Composite) Questionnaire Between Subjects Receiving LCS Complete Duofix™ and Porocoat® Knee Systems at 60 Months.","SECONDARY",NA,"D010003","A Study to Determine the Difference in Low Contact Stress (LCS) Duofix Versus Low LCS Porocoat Knee Systems",FALSE,137,"t-test",NA,NA,NA,1.69538403950934
"677","28a4a7ed6b2e2e132078b6452a7096c2","NCT03655951",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Change in Awareness of Family Having Rules About Media Use - Child Report From Pretest to Posttest","SECONDARY",NA,NA,"Birds and Bees Research Study",FALSE,270,"logistic_regression",NA,NA,NA,1.10880825088059
"678","28ac4ac544f3126fef39e4165f3ec57d","NCT03855189",0.03,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 4 (Participant-Evaluated)","SECONDARY","Pairwise treatment comparison based on t-test from an analysis of variance (ANOVA).","D012220; D065631; D006255","Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)",FALSE,229,"anova",2,NA,NA,1.45135438024678
"679","28c69dc3faaedbef275a5e13546b28a2","NCT01191255",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"ESA Analysis","SECONDARY",NA,"D051437; D054559","A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis",TRUE,414,"mann_whitney",NA,NA,NA,2.99469688545461
"680","28d8b9f9a59e7a0e09bf06d6562fb919","NCT03687762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in Mood (Micro-level)","SECONDARY",NA,"D059350","Back on Track to Healthy Living Study",FALSE,302,"anova",3,NA,NA,1.03237942189705
"681","28ea1d6a5ea183207ec5d0ed9df1d28e","NCT02559609",0.028,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Longest Duration of Alcohol Abstinence (Samples) (Physiological Measure)","PRIMARY","Group A/C (contrast -1) compared to Group B/D (contrast 1) to test Aim 1",NA,"Interventions for Unemployed Hazardous Drinkers",FALSE,234,"mann_whitney",NA,NA,NA,1.38256881724902
"682","29292e4058b40e0710a2903949056e47","NCT03962738",0.017,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With No Disability","SECONDARY",NA,"D008881","A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine",FALSE,377,"logistic_regression",NA,NA,NA,1.13370446810975
"683","2942b2a778484a9923c89548706b62c8","NCT03192176",0.0426,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week","SECONDARY","Week 8","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.21588657859219
"684","295a9cd0ef453d9e54a80066c27fe364","NCT00474175",0.031,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Pain Relief Combined With Pain Intensity Difference (PRID) Scores","SECONDARY","5 minutes: P-value was calculated using ANOVA which was adjusted for treatment, site and baseline DPS. Treatment difference (Benzocaine 20% - Benzocaine 10%) and corresponding 95% C.I. were calculated based on least-squares means from the ANOVA model with treatment, site, and baseline DPS effects.","D014098","Benzocaine Gel Toothache Dose-Response Study",FALSE,461,"anova",2,NA,NA,2.10699822529353
"685","2961c1853ef5c9cf7fc0fa2a1bb83e81","NCT04357795",0.0323,"One-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Mean Change in Baseline for Tear Osmolarity Score for Both Eyes","SECONDARY",NA,"D015352; D007638; D005128","Effect of Cequa™ in Subjects With Dry Eye Disease",FALSE,125,"t-test",NA,NA,NA,1.15169568369151
"686","296877a1a4f3371372b3599174a13dba","NCT01718522",0.04,"Wilcoxon","OBSERVATIONAL",0,0,0,0,0,"Sensor Wearing Time (Sensor Days/Calendar Week) at Baseline and 3 Months","SECONDARY",NA,"D003922","Registry of Use and Application of Sensor Augmented Pump (SAP) Therapy Under Daily Life Conditions",FALSE,67,"wilcoxon",NA,NA,NA,1.02519287579014
"687","29927a4934c0d2282cef2b5da88f9609","NCT02481596",0.015,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Diabetes Self-efficacy","SECONDARY","3 months. Multiply imputed data (m=20) using chained equations.","D003920; D003924","FAMS Mobile Health Intervention for Diabetes Self-care Support",FALSE,379,"linear_regression",NA,NA,NA,1.01850872872381
"688","299febde522200e117d87a9090ec820c","NCT05170841",0.045,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Total Pain Relief (TOTPAR) at 24h After the First Dose - Multiple Dose Phase - Dexketoprofen/Tramadol vs Tramadol","SECONDARY",NA,"D001416; D017116","Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain",FALSE,494,"t-test",NA,NA,NA,2.99221959645013
"689","29ac6480c7638a33551d5c6028d2637c","NCT03950167",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Blood Cholecystokinin (CCK) Levels","PRIMARY",NA,"D006939","Gallbladder Functions & Serum Cholecystokinin Levels in Women Diagnosed With Hyperemesis Gravidarum",FALSE,46,"t-test",NA,NA,NA,1.03597838019194
"690","29afaee84b00c59b126cd4b751c9ad74","NCT02593032",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Percent of Participants With Adherence at Month 6","PRIMARY",NA,"D006973; D003920; D006949; D006951","Effects of Use of a Connected Pillbox On Medication Adherence",TRUE,50,"t-test",NA,NA,NA,1.07648023860356
"691","29d70d17926c0c9dfb94f17985f7af80","NCT00556374",0.0088,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With New Vertebral Fractures","SECONDARY",NA,"D001943","Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy",FALSE,1644,"logistic_regression",NA,NA,NA,1.31395862272312
"692","2a17d9ead79c6136fa6e5b2c38ade581","NCT00116584",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change in Respiratory Distress Assessment Instrument (RDAI) Scores in Oxygen and Heliox Groups at Different Times","SECONDARY",NA,"D001988","Heliox-Driven Racemic Epinephrine in Treatment of Bronchiolitis in Pediatric ED Patients",TRUE,69,"mann_whitney",NA,NA,NA,1.25127183253256
"693","2a2d85245c1343253a4b9ac304e82541","NCT01850446",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Average Duration of Fever.","SECONDARY",NA,"D007251","Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza",FALSE,184,"t-test",NA,NA,NA,1.66526992555918
"694","2a31b137846b80985ac25d8bb0fab550","NCT02697773",0.0322,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >= 30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 8, \>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,465,"logistic_regression",NA,NA,NA,2.18593427023585
"695","2a39e7488cf3467cd8df6640670bc7ce","NCT00588692",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in Peak Oxygen Uptake (VO2) During Maximal Effort Exercise Stress Test According to Ejection Fraction Subgroups","PRIMARY","35-49% Ejection Fraction Subgroup","D006333","Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure",TRUE,50,"anova",2,NA,NA,1.07648023860356
"696","2a6cc9d2c1782f9574cae8edfc0ec70f","NCT05457647",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Corneal Topography","SECONDARY","Assessment of change of Kmax value at 12-months follow-up visit.","D007640","Theranostic Guided Riboflavin/UV-A Corneal Cross-linking",TRUE,47,"mann_whitney",NA,NA,NA,1.04624856756472
"697","2a6de7a2c16aa40553900339ba299f16","NCT01011556",0.029,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Percent Change From Baseline in Procollagen Type 1 N-Terminal Propeptide (P1NP)","SECONDARY",NA,"D010024","A Study for the Transdermal Application of Teriparatide",FALSE,114,"mann_whitney",NA,NA,NA,1.00521666000469
"698","2a85f1e6c0bc597b84f24abacf11eef5","NCT02136680",0.022,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mental Health: Rosenberg Self-Esteem Scale","PRIMARY","Change in Self-Esteem from Baseline to Second Follow-up: Intervention Group vs. Control Group","D000163; D015658","CASA: Care and Support Access in HIV Disease",FALSE,197,"linear_regression",NA,NA,NA,1.03254180235995
"699","2ac478ed3d8428b63347510629ffdde2","NCT02487745",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"The Percentage of Participants Who Are Employed","PRIMARY",NA,"D019966; D015819","The Long-Term Treatment of Drug Addiction and Unemployment",FALSE,91,"logistic_regression",NA,NA,NA,1.42733241699876
"700","2ae345e02e5bb4fb5923933fb46b37ee","NCT03779048",0.033,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Phase 1: Baseline Delay Discounting (Computer Task), Area Under the Curve Representing the Ratio of Immediate Reward Size to Time Delay","SECONDARY",NA,"D015431","Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment",FALSE,139,"linear_regression",NA,NA,NA,1.234540839031
"701","2aea431719a92886d1ab412ab8b923cd","NCT01116986",0.041,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Self-Reported 7-Day Point-Prevalence Abstinence","PRIMARY","The logistic regression model effects consisted of six treatment main effects and 15 two-way treatment interactions. The main effects provide direct tests of the primary aim of the study, i.e., determining whether or not more intensive treatments (compared to less intensive treatments; e.g., No Counseling Before the Quit Attempt vs. Counseling Before the Quit Attempt) would result in significantly higher abstinence at 16 weeks post-quit.","D014029","Identifying Optimal Smoking Cessation Intervention Components (Cessation)",FALSE,637,"logistic_regression",NA,NA,NA,3.13821842653033
"702","2af4220681382ac2265377712ebf6eba","NCT01236053",0.0157,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,2067,"logistic_regression",NA,NA,NA,2.46023151484407
"703","2af42e57b0cbd199813888fac9e5d461","NCT00363311",0.039,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Number of Participants With the Indicated Change From Baseline in Gleason Score on Repeat Biopsy at Years 0-3","SECONDARY",NA,"D011471","Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men",FALSE,276,"mann_whitney",NA,NA,NA,1.98870890456469
"704","2b538e676f17fc705c06a6f0aefe723a","NCT03504852",0.0498,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Subjects Who Achieve Investigator Global Assessment (IGA Modified 2011) Score of 0 or 1 - Week 16 (Full Analysis Set)","SECONDARY",NA,"D011565","Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis",FALSE,331,"logistic_regression",NA,NA,NA,2.6718793935732
"705","2b5af3167024ef21d44b1913664825ff","NCT00256750",0.0164,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire","SECONDARY","Role-Physical, Month 24","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,424,"anova",2,NA,NA,1.1640701215531
"706","2b5c3d4d85b7b4f262abd2b99dc35f9e","NCT00351533",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change in BALF Leukotriene B4","SECONDARY",NA,"D012128; D012127; D055371; D055370; D013577; D014947","A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)",FALSE,66,"mann_whitney",NA,NA,NA,1.0179988089863
"707","2b6f7fa2ee10b9d36108ef1dde1288cb","NCT03151551",0.036,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Participants Simultaneously Achieving American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI100)","PRIMARY","After data lock and initial analysis run, a medical inconsistency in baseline PASI data was identified (PASI=0 but BSA≥3%). The scenario was not anticipated or described in protocol or SAP. The inconsistency was resolved using medical judgment. The impacted participants had met baseline criteria for active psoriasis. Therefore, in the primary analysis, participants with baseline PASI=0 \& BSA≥3% were considered PASI100 responders if, and only if, PASI=0 \& BSA=0 achieved at week 24.","D001168; D015535","A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis",FALSE,566,"logistic_regression",NA,NA,NA,2.65018403715581
"708","2b74823607b1cfa1dd32cd96810a7b3e","NCT02373813",0.021,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Disease Activity Score (28 Joint) Using the C-Reactive Protein Formula (DAS28-CRP) at All Measured Timepoints","SECONDARY","Week 48","D001168; D001172","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",FALSE,202,"t-test",NA,NA,NA,1.00393051424065
"709","2b79fc2f450b462bd153abdc628b668f","NCT05370157",0.03,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Teamwork Knowledge From Baseline to 3-month Follow-up","PRIMARY","Intent-to-treat analyses tested changes in knowledge from baseline to follow-up using linear mixed models. Mixed models analyses were conducted in R using the lme4 package and restricted maximum likelihood estimation (REML). Models included fixed effects of time (baseline vs. follow-up), intervention condition, and their interaction as well as random effects for person and team. We used the clubSandwich package to calculate cluster robust standard errors.",NA,"TeamTRACS Pilot (CTSI)",FALSE,165,"linear_regression",NA,NA,NA,1.23688632821815
"710","2b9cf5ebd242f32205f78d6232902da4","NCT01066819",0.0205,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response Over Time by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for Ethnic origin (ASIAN vs WHITE/CAUCASIAN). The logistic regression analysis for mSVR was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,674,"logistic_regression",NA,NA,NA,1.77925476772405
"711","2ba2cc2c35e3043e10c074e8bacdd160","NCT03480022",0.042,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Corrected First Phase Insulin Secretion (IGI/HOMA-IR)","SECONDARY","Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect","D011085; D011236; D013577; D001835","Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS",TRUE,67,"anova",2,NA,NA,1.06780372312506
"712","2be859008d0d36cbc5e5bce1e0e6732d","NCT02037776",0.036,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Hospital Anxiety and Depression Scale (HAD)","SECONDARY","Change from baseline in overall point score of HAD","D004415","The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia",FALSE,125,"mann_whitney",NA,NA,NA,1.26262509907286
"713","2c1c6ca6147c4e1f6329bc6875fa5771","NCT02912650",0.045,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Intensity Difference on 4-Point Categorical Scale (PID4)","OTHER_PRE_SPECIFIED","8 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,347,"anova",2,NA,NA,2.51213548253568
"714","2c1f77c83ca702ec9828b1155d855ec4","NCT00094302",0.01,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Quality of Life, as Measured by the Kansas City Cardiomyopathy Questionnaire.","SECONDARY","Since the p-value for the preceding test (Statistical Analysis 1) was not significant at the 0.05 level, another generalized linear model was fit, omitting the interaction between treatment group and month of visit. This tests whether the value of the post-baseline quality of life parameter differs by treatment group, taking into account that measurements in the same subject over time may be correlated.","D006333; D002318; D006331","Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function",TRUE,3445,"linear_regression",NA,NA,NA,2.12942984619502
"715","2c23b4c8ebfabca4ce225cf660ca654c","NCT04445792",0.0441,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Ability to Participant in Social Roles and Activities as Measured by PROMIS (Patient-Reported Outcomes Measurement Information System)","SECONDARY",NA,"D059350; D059787; D003863; D003866","A Depression and Opioid Pragmatic Trial in Pharmacogenetics (DCRI Coordinating Center)",FALSE,1113,"mann_whitney",NA,NA,NA,4.40554216747209
"716","2c258ceb720cd677263c603ada1ce488","NCT03450629",0.0291,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Mean Intraocular Pressure","PRIMARY",NA,"D005901; D005902; D009798; D006973","Evaluation of Safety and Efficacy of PDP-716",FALSE,523,"t-test",NA,NA,NA,2.12442065118015
"717","2c29efb1232c0559f0b9e591de9529c4","NCT00684060",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Left Ventricular Mass","SECONDARY","Comparison of change in the active group minus change in global LVEF in the control group.","D018754; D018487","Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)",TRUE,81,"t-test",NA,NA,NA,1.3501394396673
"718","2c2d734072db6f6dd7e410c3b24a249a","NCT00509392",0.0457,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change in CIVIQ QOL","SECONDARY",NA,"D005764","ClosureFAST vs. Laser Ablation for the Treatment of GSV Disease: A Multicenter, Single-Blinded, Randomized Study.",FALSE,69,"t-test",NA,NA,NA,1.16145807304632
"719","2c3a46fb142be6cccb66d5c7d21cfbcf","NCT00550147",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Attention Deficit/Hyperactivity Disorder Rating Scale -IV- Parent Version (ADHDRS-IV-Parent Version)","SECONDARY","This was a repeated-measures analysis, using a single group of subjects who were administered quetiapine in addition to OROS mph. Results reported here are for the augmentation period (Visit 5-10). See Kronenberger et al. (2007, Journal of Child and Adolescent Psychopharmacology) for additional information.","D001289; D000374","Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.",TRUE,48,"t-test",NA,NA,NA,1.05642048349345
"720","2c599e2d9e277d49d7427b29403c0e7b","NCT00071513",0.05,"Two-sample t-test","INTERVENTIONAL",0,1,0,0,0,"Change in Short Moods and Feelings Questionnaire (SMFQ)","PRIMARY","Mean changes in Short Moods and Feelings measure of depression was the unit of analysis.","D019966; D003863; D003866","Middle School to High School Transition Project: Depression and Substance Abuse Prevention",TRUE,480,"t-test",NA,NA,NA,3.22252483067495
"721","2c5c28bf6feb7e8c2449c4b2f1874cfd","NCT01640197",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Number of Participants With Significant Modulation of CBF in MCA","SECONDARY",NA,NA,"Chronic Resveratrol Supplementation in Healthy Humans",FALSE,46,"anova",2,NA,NA,1.03597838019194
"722","2c6d36de7ad044ef6bdb07593726e3ad","NCT01333969",0.043,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Overall Epidural Volume","SECONDARY",NA,"D007511; D010149","Ischemic Preconditioning in Total Knee Arthroplasty",FALSE,60,"t-test",NA,NA,NA,1.03417040936323
"723","2c6f5102dfd7d5c7676f238acfba2b00","NCT03676465",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Glucose Time in Range 70-180 mg/dL, Overall","SECONDARY",NA,"D003920; D003922; D002908","CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management",FALSE,43,"t-test",NA,NA,NA,1.00454908915455
"724","2c734f9910dbad161747433909686cff","NCT02697773",0.0476,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Osteoarthritis","SECONDARY","Week 12: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline PGA of osteoarthritis, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,463,"logistic_regression",NA,NA,NA,3.03762147719266
"725","2c83d0b6bc65dc0c91f5dec54bde5928","NCT02900378",0.0123,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Mean Daily Non-sedentary Daytime Activity in Two-weekly Intervals","SECONDARY","Change from BL at Week 4","D006333","randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure",FALSE,604,"mann_whitney",NA,NA,NA,1.07618563246589
"726","2cb7cb439191a59e4963c46dd2585885","NCT05136170",0.046,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Cornea and Conjunctiva Vital Staining With Fluorescein (National Eye Institute [NEI] Scales) at Week 2","OTHER_PRE_SPECIFIED",NA,"D015352; D007638; D005128","Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease",FALSE,79,"mann_whitney",NA,NA,NA,1.24498895706906
"727","2cde2fff79b2b89b53715a465e8d3813","NCT02528188",0.0108,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 4: \>=30% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,1.73604931298562
"728","2d1a2abcbfb707ce32ecdf91b71d7861","NCT01144182",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"General Quality of Life From the Standardized Physical Component Score","PRIMARY",NA,"D006333","Veterans Affairs Lowering Readmission in Heart Failure",FALSE,96,"mann_whitney",NA,NA,NA,1.46440978390488
"729","2d1e7261c98450a6e13209170f1d29c5","NCT00755807",0.033,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Creatinine at Week 6 (Acute Phase)","OTHER_PRE_SPECIFIED",NA,"D009103; D012598","Duloxetine for Multiple Sclerosis Pain",FALSE,225,"anova",2,NA,NA,1.56089964897883
"730","2d2fa52cfcf199312eba465581a0f71d","NCT03595332",0.026,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Intention to Engage in Physical Activity From Baseline to 10 Weeks","SECONDARY",NA,"D009765; D063766","Addressing Health Disparities in Childhood Obesity, One Summer at a Time",FALSE,182,"linear_regression",NA,NA,NA,1.14752719152965
"731","2d40e05f130bcff05a0815d52a5c246b","NCT01728246",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in VAS-pain Score at Week 4","PRIMARY",NA,"D010003","An Efficacy, Safety and Effects on Quality of Life of Tramadol/Paracetamol as Add-on Therapy in Chronic Osteoarthritis",TRUE,473,"t-test",NA,NA,NA,3.19913039915235
"732","2d4b436ba9356abfaeea4778867abe2f","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Glucose Value at Baseline and After Treatment Completion","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"733","2d5646c1161651e1880f6f731cf3df08","NCT03136861",0.0264,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With a Spinal Pain Numerical Rating Scale (NRS) Score Below 4 at Week 8 (Treatment Period 1)","PRIMARY","Average Spinal Pain Score \<4 at Week 8","D013166; D025241; D000089183","SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis",FALSE,371,"logistic_regression",NA,NA,NA,1.64860706996693
"734","2d5c3e4882dd4217b5a6a1c81b6ae12f","NCT01939002",0.0464,"One-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Mean Change From 4-Week Run-In Period at Week 4 for TSQM, Global Satisfaction Scale Factor: Between FLS Management Arms","SECONDARY","change at Week 4","D009103; D012598","Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)",FALSE,94,"t-test",NA,NA,NA,1.36239176581899
"735","2d709879ee497da99a1e0953584b8638","NCT05777785",0.037,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Adult ADHD Self-Report Scale (ASRS) - Inattentiveness Subscale Score at Baseline and 2 Months Follow up","PRIMARY",NA,"D001289","A Novel Device for the Management of ADHD",FALSE,95,"t-test",NA,NA,NA,1.1327286790019
"736","2d7cfea7105f66da50d64b9344546a62","NCT02494401",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Change in Fatigue Scale on the PROMIS® 29 Profile v 2.0 Outcome Measure","SECONDARY",NA,"D012595; D045743; D012598","Taking Charge of Systemic Sclerosis",FALSE,247,"mann_whitney",NA,NA,NA,1.92377634803955
"737","2d8a141e79c040285b057e3ebd7e36c3","NCT01236053",0.0261,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Anal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,2067,"logistic_regression",NA,NA,NA,3.83217730189031
"738","2d8ccaa408eefef8eba9b6df8f9a6c32","NCT03857230",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Area Under the Serum Concentration of Follicle Stimulating Hormone (FSH) - Time Curve (AUC(0-192))","PRIMARY","Statistical comparison of the obtained results comprised the calculation of parametric bilateral 90 % CIs for the ratios of the corresponding mean values of the pharmacokinetic parameters of the study and comparator drug. The equivalence of the pharmacokinetics of the drug products will be proven if the limits of the evaluated CIs for the ratios of the mean values are in the range of 80.00-125.00%.",NA,"The Safety and Pharmacokinetics of Primapur and Gonal-f",FALSE,48,"anova",2,NA,NA,1.05642048349345
"739","2d979a6e08a300a78b44938bd67b6fd4","NCT05870956",0.026,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"Total All-cause Medical Costs","PRIMARY",NA,"D011658; D054990; D005355","Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients",FALSE,1036,"anova",2,NA,NA,2.70727797130438
"740","2d9aaf04ddc316d87b11342899a8e85e","NCT01183689",0.02,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Insulin Resistance","SECONDARY","2 degree of freedom F-test to compare mean 2 year differences among 3 arms","D015430","Study of Novel Approaches for Prevention",FALSE,312,"anova",2,NA,NA,1.19032607967294
"741","2dc6f1c64b0f636b72483fa5b9444bc6","NCT01066793",0.0211,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for Gamma-Glutamyl Transferase (Gamma-GT) in log10 international units per liter (IU/L) at BL. The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week \[Wk\]12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,960,"logistic_regression",NA,NA,NA,2.1748937133046
"742","2dc7c7973aba77fc2a7408f74300d277","NCT02020967",0.0196,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With the Most Pathognomonic Subjective and Objective Signs for Tracing Acromegaly","SECONDARY","Predictor variable: Lips enlargement","D000172","Programme of Acromegaly Screening in Patients With Associated Somatic Disorders",FALSE,329,"logistic_regression",NA,NA,NA,1.20047813870526
"743","2ddc48cd17677f83f19eeff8ba1dbc83","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in Low Density Lipoprotein Cholesterol","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,109,"anova",2,NA,NA,1.55669642807029
"744","2de263c0dcee1fb665c331d82d35def1","NCT03131687",0.036,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With 10% or Greater Body Weight Loss From Baseline","SECONDARY",NA,"D003920; D003924","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus",FALSE,106,"logistic_regression",NA,NA,NA,1.16638390709256
"745","2ded309ae36fb2e838cce03758d417a1","NCT00508183",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Constant Score","SECONDARY",NA,"D000070636","Types of Fixation in Arthroscopic Rotator Cuff Repair",FALSE,73,"t-test",NA,NA,NA,1.28506804726186
"746","2e03e1701e38f60a32ae96c4d255b27d","NCT00966875",0.031,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Dose-Response Relationship Measured by the Percentage of Participants With American College of Rheumatology (ACR) 20 Response in bDMARD-Naive Population","PRIMARY",NA,"D001168; D001172","A Study in Patients With Rheumatoid Arthritis",FALSE,260,"logistic_regression",NA,NA,NA,1.58852751254504
"747","2e3c5e06646560867f6cdfd588ce4b18","NCT02688400",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Global Assessment of Response to Therapy","SECONDARY",NA,"D010003; D020370","Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis",FALSE,370,"mann_whitney",NA,NA,NA,2.83265165361863
"748","2e4b8e2a4432870b0c38a4d78c26d036","NCT00708097",0.0382,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Enamel Fluoride Uptake (Sound Enamel Specimens)","SECONDARY","Null hypothesis considered population means of the treatments in comparison, to be equal with respect to EFU. Statistical tests were 2-sided with a significance level of 0.05.",NA,"In Situ Caries Efficacy of Fluoride Toothpastes",FALSE,105,"anova",2,NA,NA,1.22065853797107
"749","2e4e34a9f89edfee3c3c67a002335528","NCT04867785",0.044,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participant Reaching HbA1c <7.0%","SECONDARY",NA,"D003920; D003924","A Study of LY3437943 in Participants With Type 2 Diabetes",FALSE,89,"logistic_regression",NA,NA,NA,1.26975879643604
"750","2e58cba4d6ac0174bc8de95b84f0f99b","NCT00935818",0.03,"Logistic regression","INTERVENTIONAL",0,0,1,1,0,"Prolonged Smoking Abstinence Rates at 12 Weeks in Cigarettes Smokers.","PRIMARY","Logistic regression with covariate included for study site.",NA,"Varenicline and Bupropion for Smoking Cessation",FALSE,506,"logistic_regression",NA,NA,NA,2.14529197508637
"751","2e8489d85487253598924fad520f3df7","NCT02528188",0.0239,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 4: \>=30% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,3.4878690294922
"752","2e8a501f2d01ccf4328d81ade237c5f7","NCT03533491",0.044,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Adolescent Use of Cigarettes","PRIMARY",NA,"D019966","The Rewire Study (Mindfulness Mobile App to Reduce Adolescent Substance Use)",FALSE,58,"t-test",NA,NA,NA,1.03760063507558
"753","2e8dd8c4eb6b8b64cce1ba0b41baaadc","NCT00455533",0.025,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]), to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR","SECONDARY","GTSE1 204317_at","D001943","Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer",FALSE,295,"logistic_regression",NA,NA,NA,1.40503139235167
"754","2e910ceb223289c84698ee11242ea0db","NCT02605174",0.009,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free","PRIMARY",NA,"D008881","Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",FALSE,1026,"logistic_regression",NA,NA,NA,1.06037546625596
"755","2e9365fbe6bd4270450eeea4b76937f0","NCT02553629",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Respiration","SECONDARY",NA,"D004194","Effect of Deep Neuromuscular Block on Surgical Conditions in Morbidly Obese Patients",FALSE,100,"t-test",NA,NA,NA,1.49341131573029
"756","2eaf414817928c00e03a72f919e78fd1","NCT03321019",0.034,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"Cough Peak Flow Rate","SECONDARY","Healthy controls were compared to PD participants across each of the 3 visits. PD participants were compared between visits 1, 2 and 3.","D010300","Airway Protective Mechanisms in PD (R01)",FALSE,119,"anova",2,NA,NA,1.17479665439429
"757","2eb9a3c1d40a000df4752065010d261e","NCT00803959",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change in Quality of Life as Measured by the SF-12","SECONDARY","Null hypothesis is that the 2 arms do not differ according to mean change in SF-12 scores.","D014549; D004775","Value of Urodynamic Evaluation",FALSE,538,"t-test",NA,NA,NA,1.55739056538896
"758","2ec0928fc5b5dc9ce04eb3dd3fd46fe2","NCT05170841",0.029,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Percentage of Maximum TOTPAR (%Max TOTPAR) at 6 Hours After the First Dose- Single Dose Phase - Dexketoprofen/Tramadol vs Placebo","SECONDARY",NA,"D001416; D017116","Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain",FALSE,204,"t-test",NA,NA,NA,1.33234242503758
"759","2efdf20debcba89abc7f10e6ff4f15ba","NCT00135356",0.0385,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Mean Percent Change From Baseline in Total Body Fat by DEXA and in Total Adipose Tissue (TAT) Area by CT Scans","SECONDARY","Week 48 Total Body Fat","D039682; D008060; D013577","Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome",FALSE,200,"t-test",NA,NA,NA,1.6794534231169
"760","2effc540d61e557f56acba418c93bb34","NCT00455533",0.0284,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]) to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR/RCB1","SECONDARY","GTSE1 204315_s_at","D001943","Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer",FALSE,295,"logistic_regression",NA,NA,NA,1.56802881302072
"761","2f03c062642295264bc89353c16856df","NCT03065283",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Thoracic Mobility","PRIMARY","A paired t-test was used for intragroup analysis, and an independent Student's t-test was used for intergroup analysis. Data are represented in mean between-group difference with a 95% CI, and analysis was by intention to treat.",NA,"Effects of Diaphragm-releasing Techniques on the Lumbar Spine and Diaphragmatic Function in Healthy Women",FALSE,75,"t-test",NA,NA,NA,1.301639172202
"762","2f2778467d8a7d265a384c2de922f429","NCT02307682",0.0159,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Central Subfield Thickness (CSFTtot) at Each Post-baseline Visit - Study Eye","SECONDARY","Week 16","D008268; D057135; D020256; D009389","Efficacy and Safety of RTH258 Versus Aflibercept - Study 1",FALSE,718,"anova",2,NA,NA,1.47010486729527
"763","2f3bcdbd17b4757dc3da9b2345dd5cf1","NCT04591015",0.0496,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Glycosylated Hemoglobin (HbA1c) - Change From Baseline to 90 Days","PRIMARY","Only includes participants who completed a 90-day lab","D000086382; D003920; D003924","Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19",FALSE,56,"t-test",NA,NA,NA,1.1270796663428
"764","2f62aae09904d3267000a4bbf9919aba","NCT01559259",0.034,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (PRID4)","SECONDARY","10 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,123,"anova",2,NA,NA,1.19364463758821
"765","2f841237c48b53d6c0135672e98a6370","NCT00778622",0.0232,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Mean Change From Baseline at Week 16 (95% Confidence Interval) in Glycosated Hemoglobin A1c (HbA1c) (Last Observation Carried Forward) - Full Analysis Set (FAS)","PRIMARY",NA,"D003924; D001835","Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients",FALSE,223,"t-test",NA,NA,NA,1.14844286256385
"766","2f990c0143785487c400e6d2594e280c","NCT01345682",0.0353,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Disease Control (DC)","SECONDARY",NA,"D002277; D006258; D002294","LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy",FALSE,483,"logistic_regression",NA,NA,NA,2.40919468905417
"767","2f9d875ad7fb830475c346452e16a007","NCT03718832",0.0484944,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Systolic Blood Pressure","SECONDARY","Unadjusted mean difference, 12 months after trial enrollment",NA,"Fresh Food Farmacy: A Randomized Controlled Trial",FALSE,378,"t-test",NA,NA,NA,2.79047444844519
"768","2f9faaa306b9afa7a7b60c5a67666209","NCT00536471",0.033,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Bilirubin, Creatinine, Uric Acid","SECONDARY",NA,"D003866; D003863; D003865","A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients",FALSE,330,"anova",2,NA,NA,1.88427718653366
"769","2fb354093dec3f0942db1038a126e05d","NCT00551135",0.0347,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Total Cumulative Dose of Opioids and Tramadol Used During and After Surgery","SECONDARY","Day 7 PS; LS Means from ANOVA model with terms of treatment, pooled center. Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,203,"anova",2,NA,NA,1.54906187309312
"770","2fc5691a284b4103231ba2288be37859","NCT03687762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in Mood (Macro-level)","SECONDARY",NA,"D059350","Back on Track to Healthy Living Study",FALSE,302,"anova",3,NA,NA,1.03237942189705
"771","2fc67f72aeff31cfd356dd2b333270cd","NCT00070707",0.025,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Weekly Average Nighttime Awakenings Due to Asthma","SECONDARY","Change at Week 1","D012220; D001249; D006255; D065631","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",FALSE,187,"anova",2,NA,NA,1.12416896570947
"772","2fe23e23eacf542db9081d31aea7c92b","NCT02713490",0.0381,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Area Under The Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores From 12 to 48 Hours","PRIMARY",NA,NA,"Local Infiltration Analgesia With and Without EXPAREL Following Total Knee Arthroplasty",FALSE,138,"anova",2,NA,NA,1.38948398757435
"773","3039128a2c25a33ea89288bbe4584539","NCT03975790",0.028,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Number of Biologic Disease Modifying Antirheumatic Drug (bDMARD) Received During Variable Length Pre-Index Period","PRIMARY",NA,"D001168; D001172","Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX",FALSE,316,"t-test",NA,NA,NA,1.60235871969984
"774","304ea03d9aca4a6a38b99f4fab7ec627","NCT04697264",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Adipose Tissue","SECONDARY","Expression of adiponectin receptors were studied in endometrial cancer tissue and fat tissue using qRT-PCR.","D016889; D009765","Adipocytokines in Endometrial Cancer",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"775","3053c63ed5f71ae3dac0327e56c51ba6","NCT01106833",0.039,"Two-sample t-test","INTERVENTIONAL",0,0,1,1,0,"SF-36 Physical Component Summary","SECONDARY","The null hypothesis is that the mean PCS scores at 6 months are equal for those receiving either Sirolimus, Calcineurin Inhibitor, and Prednisone or Sirolimus and Prednisone for treatment of chronic GVHD.","D000092122; D006086","Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)",FALSE,138,"t-test",NA,NA,NA,1.41712618721709
"776","3058850052b5e036ff36cc2e095e4886","NCT01951885",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Percentage of Severe (Grade 3-4) Mucositis Graded According to the World Health Organization (WHO) Grading Scale","PRIMARY",NA,"D007938; D009101; D054198; D015451; D007951; D015464; D006689; D015456; D009190; D009196","Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention",FALSE,96,"mann_whitney",NA,NA,NA,1.46440978390488
"777","306832c62f0e39fcfc3a883dea41ae6f","NCT01910116",0.021,"Mann-Whitney","INTERVENTIONAL",0,0,1,1,0,"Patient Global Assessment, Change From Baseline","SECONDARY",NA,"D010003","Efficacy of Shinabro in Hand Osteoarthritis",FALSE,215,"mann_whitney",NA,NA,NA,1.03490613824908
"778","307aab3bac9c90a55926cd339f7bc746","NCT00038467",0.047,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Total Functional Assessment of Cancer Therapy - General Breast and Endocrine (FACT-GBE) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study","SECONDARY","6 months: p-value was estimated using 2-sided t-test.","D001943","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",FALSE,504,"t-test",NA,NA,NA,3.13462001520375
"779","3084283ec5df757b0e557ff1acf58527","NCT03468309",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Clinical Global Impression","PRIMARY",NA,NA,"Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population",TRUE,50,"t-test",NA,NA,NA,1.07648023860356
"780","308fc87079460106ad1cee681528ba65","NCT02887404",0.025,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Secondary Outcome: 24h Time-weighted Average Pain Score","POST_HOC",NA,NA,"Evaluation of Spine Surgery Analgesic Pathway",FALSE,299,"linear_regression",NA,NA,NA,1.41436383086993
"781","30a19558c569e851b658e83b34fdc65b","NCT01236053",0.0144,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,2067,"logistic_regression",NA,NA,NA,2.27996374323798
"782","30b55c9641fc6c5261e1ae4edcfd9704","NCT01459653",0.025,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Modeling FN Episode: Cycle Level","SECONDARY","Under- vs. over-prophylacted as patient-level predictor for FN episode","D009101; D009503; D064147; D000084462; D005334","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",FALSE,1273,"logistic_regression",NA,NA,NA,2.89966714365888
"783","30be12e89248261815f7215d1504635a","NCT00408876",0.033,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Interference (BPI-I) Score - Relations With Other People","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,215,"t-test",NA,NA,NA,1.52653584392657
"784","30c679ba5d77a7ce8b2c0752a5e91fb7","NCT02672176",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Perceived Stress Measured by PSS","SECONDARY",NA,"D003920","Improving Health in Diabetes Project",FALSE,285,"mann_whitney",NA,NA,NA,2.48992995915375
"785","30cc6e196a649093b13798338f4a96f3","NCT04593940",0.0229,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Mortality Through 28 Days","SECONDARY",NA,"D000086382","Immune Modulators for Treating COVID-19",FALSE,1061,"logistic_regression",NA,NA,NA,2.45440752911542
"786","30d0f421b228a143c8a613f70e79cdce","NCT02845440",0.013,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Effect of Varenicline Use on Number of Participants Who Are Abstinence at the Intervention Year 2 Assessment in Cohorts 1 and 2","SECONDARY","Missing abstinence rates at year 2 of intervention were imputed using MICE based on baseline characteristics and abstinence rates at year 1 of intervention. The statistical model was a mixed effects logistic regression with terms for the factorial design (TAU, AD, CHW, and cohort) as well as varenicline use and a clinic-varying random intercept. Regression coefficients and mediation analysis estimates were pooled using Rubin's rule over 10 imputation runs.","D012559; D003866; D001714; D001523; D003865","Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness",FALSE,901,"logistic_regression",NA,NA,NA,1.37798344284865
"787","30d55b79ecfa5ab77556da7121c80000","NCT02979353",0.02,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Drug Burden Index (DBI): Anticholinergic and Sedative Drug","SECONDARY","Statistical Analysis 1 applies to the Hospital Discharge time point (occurred, on average, 3 days after study enrollment)",NA,"A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy",FALSE,355,"linear_regression",NA,NA,NA,1.26837184443411
"788","30d6d1b3835fe9d779bd5a19f17cacc4","NCT01066793",0.0341,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for Weight per 10 kg. The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Wk 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,427,"logistic_regression",NA,NA,NA,2.200770969765
"789","30e5e2184cd4eb6e44d04e02b62fe55f","NCT00390949",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Reporting Cessation of Sexually Transmitted Infection Symptoms","SECONDARY",NA,"D015658","Scientific Evaluation of Peer Education and STD Treatment to Reduce the Spread of HIV in Zimbabwe",TRUE,551,"logistic_regression",NA,NA,NA,3.45086143619372
"790","30fbc0e86270380ee6d0811981b74894","NCT05268055",0.046,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Healthcare Provider Cultural Competency","PRIMARY","Group comparison of participants age 33 and greater.",NA,"Sign Here: How to Conduct Informed Consent With Deaf Individuals",FALSE,52,"t-test",NA,NA,NA,1.02337827642435
"791","30fe6d2b9b129d8970bea9cb144d3a24","NCT00684060",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Regional Left Ventricular Function (Infarct Zone Wall Motion)","PRIMARY","Comparison of change in infarct zone wall motion in the active group minus change in global LVEF in the control group. 80 percent power based on BOOST results","D018754; D018487","Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)",TRUE,80,"t-test",NA,NA,NA,1.34217713699512
"792","3100f157cc23115a586422fc7a079c00","NCT01472432",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Full Epithelialization of the Wound","PRIMARY","* Vildagliptin vs Placebo at 3 months.
* Placebo baseline versus placebo 3 months.
* Vildagliptin baseline versus Vildagliptin 3 months.","D016523; D003924; D014456","DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes",TRUE,106,"t-test",NA,NA,NA,1.53589031932405
"793","3103c1cdf8db340528907f371feaf0b0","NCT05493787",0.003,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Number of Patients Who Self-scheduled a Flu Shot","PRIMARY","Null hypothesis: Flu shot self-scheduling does not differ between those sent an Active Control message and those not sent a message (i.e., those in the Passive Control group); Alternative hypothesis: Sending an Active Control message increases self-scheduling compared with sending no message. Analysis combines across November and December send dates.",NA,"Nudging Flu Vaccination by Making it Easy for Patients to Schedule a Flu Shot",FALSE,46510,"linear_regression",NA,NA,NA,2.63813386516389
"794","3109e368271af40f6ab5ef4c3bbd5eb9","NCT02371759",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Duration of Intraoral Local Anesthesia","PRIMARY","In order to detect 20% difference in intraoral anesthesia duration between healthy and diabetic participants, with 80 % statistical power at a two-tailed significance level of 0.05 using Mann Whitney U test, it was calculated that at least 24 participants must be included in each group","D003920; D003924","Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2",TRUE,220,"mann_whitney",NA,NA,NA,2.19200127568343
"795","310b8399614e250a7432a7f620761d37","NCT02697773",0.0251,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >= 30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 2, \>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,463,"logistic_regression",NA,NA,NA,1.76084632710179
"796","311570a6d0432c62b731a3cbba47a615","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Ham Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1767,"linear_regression",NA,NA,NA,6.16493027072232
"797","311c24286ff89c0b2ad3448d1fcc7e7c","NCT01340027",0.043,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With a Symptom Bother Response","SECONDARY",NA,"D053201; D014570; D001745; D020924","A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder",FALSE,218,"logistic_regression",NA,NA,NA,1.92310216252777
"798","314c46d59c3c8923c52717bc2c9c2af6","NCT01817530",0.036,"Kruskal-Wallis","INTERVENTIONAL",0,0,1,0,0,"Mean Percentage Change From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit","SECONDARY","Month 3","D007889; D047708; D014592; D008595; D006470","Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)",FALSE,130,"kruskal_wallis",2,NA,NA,1.28675924535962
"799","315996fda2d5deac6e3069cf615340ee","NCT02050373",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Level of Inflammatory Mediators","SECONDARY",NA,"D052016; D013280","Low-level Laser Therapy on Inflammatory Mediators During Chemotherapy-induced Oral Mucositis",TRUE,51,"mann_whitney",NA,NA,NA,1.08637315449684
"800","315f40869a7de35bccb3292c365ee9cd","NCT01643876",0.05,"Mann-Whitney","INTERVENTIONAL",0,1,0,0,0,"Candida Species Count","SECONDARY","Null Hypothesis: in individuals with denture stomatitis, there are no difference in the number of Candida Colony-Forming Units (CFUs), before and 3 months after palatal brushing.","D013280; D013282","The Effect of Palatal Brushing on Denture Stomatitis",TRUE,48,"mann_whitney",NA,NA,NA,1.05642048349345
"801","31642a36a68eca92118fff7375c4563d","NCT03855189",0.03,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Response To Therapy At Day 29 (Participant-Evaluated)","SECONDARY","Pairwise treatment comparison based on t-test from an analysis of variance (ANOVA).","D012220; D065631; D006255","Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)",FALSE,204,"anova",2,NA,NA,1.37157025694467
"802","31a421a9967eb87cf95c60751d905aeb","NCT01005719",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"The Difference in the Onset of Action Based on Median pH Values Between the Two Active Treatments Compared to No Treatment on Day 1 and Day 7","SECONDARY",NA,NA,"Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)",TRUE,118,"mann_whitney",NA,NA,NA,1.61751378500378
"803","31ac130f3113f713acb2d8e02ea0ed35","NCT03375489",0.04,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Patient-reported Quality of Life","PRIMARY","The difference in week-24 means between groups was estimated using a linear regression model with a main effect for group assignment and controlling for baseline Functional Assessment of Cancer Therapy - Lung Questionnaire scores.","D008175","Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Lung Cancer",FALSE,620,"linear_regression",NA,NA,NA,3.03229259334757
"804","31ba1a567d4e08ba5b38b358c937a99e","NCT02694640",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Physical Activity","PRIMARY","A series of longitudinal mixed effects models with subject-specific intercepts were used to examine between-group differences in mean min/week of self reported moderate-to-vigorous physical activity (MVPA).","D001943","Peers Promoting Exercise Adoption and Maintenance Among Cancer Survivors",TRUE,161,"linear_regression",NA,NA,NA,1.88118663862499
"805","31c69ca0024f98afdc55a54a63df67f3","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Fasting Plasma C-peptide","SECONDARY","Difference in treatment effect between the 2 groups","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",FALSE,49,"t-test",NA,NA,NA,1.06649684228356
"806","31c72f02060f289a55fceb75c6fca2f1","NCT01165684",0.046,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Mean Plasma Glucose Increment Over 3 Meals (Breakfast, Lunch and Dinner) at Week 32","SECONDARY",NA,"D003920; D003924","Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen",FALSE,352,"linear_regression",NA,NA,NA,2.57712395397424
"807","31d0b1da38ac6937d04f1a6199b87f8e","NCT00434759",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in Liebowitz Social Anxiety Scale (LSAS)","PRIMARY",NA,"D010698; D000072861","Social Phobia Intervention Study of Mannheim",TRUE,89,"anova",2,NA,NA,1.41222998379373
"808","31d323a55e8eef007f8f8ea0178cf1cd","NCT01945034",0.027,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","SECONDARY","At Rest 5 hour Day 1: The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,152,"anova",2,NA,NA,1.0861321990959
"809","321923cfd33c8cd93aeca0867e9776b6","NCT01345123",0.0106,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Knowledge","SECONDARY",NA,"D001168","Supporting Decision Making for Musculoskeletal Preference-Sensitive Care",FALSE,823,"anova",2,NA,NA,1.09950407698283
"810","32249b7eda80ff72bc594ec1fb5f0a83","NCT01859793",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Brachial Artery Flow Mediated Dilation","PRIMARY","Primary and secondary outcome variables were compared across measurement periods by repeated measures ANOVA and post hoc analyses using Tukey's test were applied if significant differences were detected. A priori sample size calculation demonstrated our study design has 80% power to detect a 1.5% absolute increase in FMD% with 30 subjects completing the entire study protocol at α=0.05.","D050197; D003920","Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy",TRUE,60,"anova",2,NA,NA,1.17169922891753
"811","323dfe80b88728c81b568faa047ee9ae","NCT02912650",0.031,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Intensity Difference on 4-Point Categorical Scale (PID4)","OTHER_PRE_SPECIFIED","0.25 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,228,"anova",2,NA,NA,1.48943276633294
"812","3241c8d407a16420da2a7ffb18fa82c4","NCT03192176",0.0467,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 2","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.2906815878418
"813","324bed2169f01ab909841ed71b96005d","NCT00256750",0.045,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire","SECONDARY","General Health, Month 36","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,411,"anova",2,NA,NA,2.73154042297551
"814","326e2b905c6b7568f8ba256e06d6cd1e","NCT00023595",0.008,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"H01: All-cause Mortality Within 30 Days After Randomization","SECONDARY",NA,"D006333; D002318; D006331; D003327","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",FALSE,1212,"logistic_regression",NA,NA,NA,1.03684043806229
"815","326f72b3fbf6883da698b7ef246d7a54","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Intention to Reduce","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1750,"linear_regression",NA,NA,NA,6.13526752012651
"816","3287893f4fdeca72b410bfb9256625e9","NCT01512108",0.0458,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change in FPG From Baseline to Week 52","SECONDARY",NA,"D003920; D003924","Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone",FALSE,359,"anova",2,NA,NA,2.59282816101168
"817","3291916454097fafd14c030ee38fc954","NCT00270998",0.0492,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Satisfaction With Treatment at 12 Months","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",TRUE,299,"logistic_regression",NA,NA,NA,2.51540237553809
"818","32a682768053c14b5a2862e0f9b6c04d","NCT00673387",0.0409,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"LS Mean Change in Waist Circumference From Baseline to Week 12 and Week 28 - Evaluable Population","SECONDARY","Change at Week 28 based on a general linear model with factors for treatment group, sex, baseline BMI category, and baseline value as a covariate.","D050177; D001835","Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects",FALSE,90,"t-test",NA,NA,NA,1.20087593705248
"819","32fc53a09618e90df5ea0c5a49e2f9ee","NCT03467685",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Numeric Rating Score","PRIMARY",NA,"D059787","Variable Perception of Cutaneous Stimulation",TRUE,101,"t-test",NA,NA,NA,1.50057440421219
"820","3325c324d78d8f866d5e093727a07baf","NCT01211145",0.032,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Pain-free Status at 24 Hours Post-treatment","SECONDARY",NA,"D008881; D006261","Zomig - Treatment of Acute Migraine Headache in Adolescents",FALSE,331,"logistic_regression",NA,NA,NA,1.83814535142638
"821","3331b9565e557e891fd5c888751b3c59","NCT02709486",0.0211,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >=30%, >=50%, >=70% and >=90% Response","SECONDARY","Week 8, \>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,565,"logistic_regression",NA,NA,NA,1.67173600317214
"822","3344ade0f0a0b2a6679c5f3f87947185","NCT02615470",0.048,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Number of Strategies Implemented to Promote Immunization Activities","SECONDARY",NA,"D006562; D011008","Enhancing a Sustainable Pharmacy-based Immunization Program in Two States",FALSE,50,"mann_whitney",NA,NA,NA,1.04093402528413
"823","3348dc0fd37b748b8ade083265a60c4e","NCT03119766",0.041,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Changes in Severity of Functional Dyspepsia Symptoms","PRIMARY","Mean changes of GIS scores after 8 weeks of treatment were compared.","D004415","Clinical Trial of Efficacy and Safety of Kolofort in Functional Dyspepsia Patients",FALSE,309,"anova",2,NA,NA,2.19332903829859
"824","336f9419854b688e827e00ea7701e520","NCT02191046",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"the Effect of Squeezable Bottle and Syringe on Clinical Effectiveness in Sinusitis Children","PRIMARY","satisfaction score between two groups at 2 weeks after treatment","D012852","Effect of Squeezable Bottle Nasal Irrigation Device in Children With Sinusitis",TRUE,74,"t-test",NA,NA,NA,1.2933799900503
"825","3398f8be2e6ec8cacb17f1acd43f9576","NCT01360996",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Cardiometabolic Measures","SECONDARY",NA,"D011085; D017588; D013577","Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism",FALSE,53,"anova",2,NA,NA,1.10589694869732
"826","33abbf5733da781907f39a25aaa9f52d","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Tax","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1756,"linear_regression",NA,NA,NA,6.1457530740539
"827","33c04ceefb7840cc751d6a2b0dce610d","NCT02539394",0.042,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Degree of Dysphagia Patients Experience (Mental)","PRIMARY","The distribution of POD2 SWAL-QOL - Mental is the same across the 2 arms","D007405; D055959; D003680; D013118","Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion",FALSE,109,"mann_whitney",NA,NA,NA,1.34587003352236
"828","33c563e2ea6ede6641a53dbd09eb232f","NCT03192176",0.0493,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 6","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.37312732445703
"829","33ca63872eb7e07f4d09bf5735a1f5bf","NCT01266161",0.042,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Time-weighted Sum of Pain Intensity Difference (SPID) Scores","SECONDARY","For SPID 44-48.","D014098","Multiple Dose Dental Pain Study Of Ibuprofen Extended Release",FALSE,106,"anova",2,NA,NA,1.32793237660092
"830","33e715ca60613e9b03e40abaa0e4ae6b","NCT00536198",0.02,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Inventory of Depression Symptoms (IDS-C)","PRIMARY","Group by time: comparison of rates of change","D065446","Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder",FALSE,252,"anova",2,NA,NA,1.07197765048643
"831","340285650a504fa0890a44b4d93625d1","NCT00120627",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"PTST Checklist (PCL) Civilian Version","PRIMARY","2 group (treatment vs control) by 2 time (pre-intervention and post-intervention) ANOVA","D013313","Mantram Repetition to Manage PTSD in Veterans",TRUE,146,"anova",2,NA,NA,1.79360862376457
"832","3427022d31b20ca956b836e3cadad5de","NCT01056718",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Mitral Valve Inflow (E) Velocity","SECONDARY","Nebivolol treatment group refers to 50 patients that completed 10 weeks of open label nebivolol treatment. Results were compared using paired T-tests in a pre - post study design before and after 10 weeks of his/her treatment. Each subject served as own control.","D006973; D054160","Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function",TRUE,50,"t-test",NA,NA,NA,1.07648023860356
"833","343171d12e0e7c264e3f1c9dd93adccc","NCT00551135",0.0401,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Numerical Rating Scale (NRS): Current Pain at Rest","SECONDARY","1 h PS; LS Means from ANOVA model with terms of treatment, pooled center and baseline pain catastrophizing total score. Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,203,"anova",2,NA,NA,1.75094774381302
"834","343494a6f2a400acc75c6ab0a43a51d7","NCT01539070",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Children´s Time of Physical Activity From Baseline to 3 Months by Intervention Assignment","PRIMARY","In intent-to-treat analyses, we used unadjusted and adjusted multivariate regression models, to examine differences from baseline to 3 months between the intervention and usual care groups. For continuous outcomes, we used linear regression models, and for dichotomous outcomes, we used logistic regression models. To account for clustering by practices, we performed generalized linear mixed models. The Estimator (Est) and Confidence Interval 95% (95% CI)are reported.","D009765; D063766","Intervention for the Prevention of Obesity in Preschool",TRUE,168,"linear_regression",NA,NA,NA,1.92069191306857
"835","34458b0bb3aea0667f33479d13ce0258","NCT00644969",0.0457,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With 7-day Point Prevalence of Non-smoking at Week 12","SECONDARY",NA,"D012559; D011618","Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder",FALSE,127,"logistic_regression",NA,NA,NA,1.55504334471309
"836","3450545eadf5f9141c2e8e31e6d90eac","NCT00560417",0.041,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Body Weight at Endpoint (LOCF)","SECONDARY",NA,"D003920; D003924","Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide",FALSE,167,"t-test",NA,NA,NA,1.62172840822993
"837","34618841bc27e4705ed697b7014e8b6b","NCT02008890",0.0411,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With ppPASI 75 Response at Week 16 (Period 1)","PRIMARY",NA,"D011565","Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab",FALSE,157,"logistic_regression",NA,NA,NA,1.57690750474068
"838","34725e5e5328ffb8551fefd8beb6e4ca","NCT02528253",0.027,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 4, \>=90%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,811,"logistic_regression",NA,NA,NA,2.47624627179095
"839","34750d379b6c5ca8e4e51061a95f06fa","NCT00986453",0.0428,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Operative Time","SECONDARY",NA,NA,"PEAK PlasmaBlade 4.0 in Bilateral Breast Reduction",FALSE,86,"t-test",NA,NA,NA,1.22065533766972
"840","3476d1142eb944a5d35c52c92d5f3fc8","NCT02891226",0.032,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Achieving Endoscopic Remission at Week 12","SECONDARY",NA,"D003424","A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease",FALSE,96,"logistic_regression",NA,NA,NA,1.00689983990285
"841","347ef6f115ed33d78fe41cb358770c56","NCT03241459",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in 6-Minute Walk Test (6MWT)","SECONDARY",NA,"D058729; D016491; D014652","Safety and Efficacy of the SurVeil™ Drug-Coated Balloon",FALSE,343,"t-test",NA,NA,NA,2.26159756207
"842","34906c3a326e188ce7d8fe618085cb3e","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Aspartate Aminotransferase (AST) Value at Baseline and After Treatment Completion","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"843","3491575166c618ec426e5a0ffcaa789b","NCT03855189",0.02,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the TNSS At Day 29 (Physician-Evaluated)","SECONDARY","Pairwise treatment comparison based on t-test from an analysis of variance (ANOVA).","D012220; D065631; D006255","Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)",FALSE,227,"anova",2,NA,NA,1.01861948606577
"844","34a1b7d8d499f8da6bb666d3f0b2c0bf","NCT01066819",0.017,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response Over Time by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for Ethnic origin (OTHER vs WHITE/CAUCASIAN). The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including total cumulative dose of peginterferon and ribavirin), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,674,"logistic_regression",NA,NA,NA,1.51082211110097
"845","34a5b2664dd5017d09114ab5d4238f8d","NCT01712009",0.0411,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Maximum Patient-reported Bone Pain by Cycle and Across Cycles","SECONDARY","Difference across all treatment cycles","D001943","NOLAN: Naproxen or Loratadine and Neulasta",FALSE,391,"anova",2,NA,NA,2.46883199033149
"846","34b3ccedac29bf31000a6848c4448d45","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cancer Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1756,"linear_regression",NA,NA,NA,6.1457530740539
"847","34bf42c3174e98bea5d99fe6f1fa9bc8","NCT00762762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"IL-6 (Interleukin - 6)","PRIMARY","Means and standard deviations. 1 factor ANOVA to balance treatment groups to show no difference between groups. The null hypothesis states that there is no difference between groups.","D010518","Effectiveness of a Triclosan Containing Toothpaste in Maintaining Periodontal Health in a Type 2 Diabetic Population",FALSE,60,"anova",2,NA,NA,1.17169922891753
"848","34d3307e1165dd354a7a72766c7e5580","NCT00162266",0.0451,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"ACR Numeric Values (ACR-N)","SECONDARY","Day 180 Treatment Comparison","D001168; D001172","Abatacept With Methotrexate- Phase IIB",FALSE,224,"anova",2,NA,NA,2.02858145429274
"849","34ebea1a3e1c033d8188ccefd94cbb17","NCT00408876",0.039,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Laboratory Assessment - Bilirubin, Total","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,170,"t-test",NA,NA,NA,1.56830814327171
"850","34ff9de565eaac65db89cb74bb1c0d2e","NCT01416194",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Clinical Fractures","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",TRUE,7777,"logistic_regression",NA,NA,NA,3.19773018380892
"851","350efcde2e6d788d1a222cab7efadd2f","NCT02373813",0.044,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Disease Activity Score (28 Joint) Using the C-Reactive Protein Formula (DAS28-CRP) at All Measured Timepoints","SECONDARY","Week 12","D001168; D001172","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",FALSE,152,"t-test",NA,NA,NA,1.64378796652281
"852","351040ca6c8fcceabf2cef4d24381f53","NCT01539070",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Children´s Consumption of Foods From Baseline to 3 Months by Intervention Assignment","PRIMARY","In intent-to-treat analyses, we used unadjusted and adjusted multivariate regression models, to examine differences from baseline to 3 months between the intervention and usual care groups. For continuous outcomes, we used linear regression models, and for dichotomous outcomes, we used logistic regression models. To account for clustering by practices, we performed generalized linear mixed models. The Estimator (Est) and Confidence Interval 95% (95% CI)are reported.","D009765; D063766","Intervention for the Prevention of Obesity in Preschool",TRUE,306,"linear_regression",NA,NA,NA,2.5788408992482
"853","3513dad3030b15e541825641607c9b16","NCT02886728",0.029,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With no Radiographic Progression From Baseline at Weeks 24, and 52","SECONDARY","Filgotinib 200 mg Monotherapy vs MTX Monotherapy at Week 24 for Change in mTSS \<= 0.5","D001168; D001172","Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy",FALSE,626,"logistic_regression",NA,NA,NA,2.31561769419694
"854","352c3dbdb02a539478838ec4edc6738f","NCT02709486",0.015,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >=30%, >=50%, >=70% and >=90% Response","SECONDARY","Week 8, \>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,563,"logistic_regression",NA,NA,NA,1.23820194598447
"855","354c145b019c5d11fbf7fc1cb80aa85d","NCT02755831",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Hospital Costs at Time of Delivery","SECONDARY",NA,"D001049; D012891; D020181","Targeted CPAP Therapy for Obstructive Sleep Apnea in Pregnancy",TRUE,187,"t-test",NA,NA,NA,2.02404134451695
"856","355450da17631b282d7b10c32bb21b3f","NCT03239496",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Seroconversion Non Inferiority of 3 Doses f-IPV ID vs 2 Doses IPV IM","SECONDARY","The group sizes are chosen to provide ≥ 80% power for each of the primary objectives, for the individual statistical tests of each serotype, as well as across both serotypes simultaneously. Power of ≥80% is also available for all secondary objectives, except for the comparison of the f-IPV regimen administered at weeks 14 and 36 to the 3-dose IPV regimen, which has power of 62% for individual serotypes, and 39% for the combined serotypes.","D011051","A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV",FALSE,319,"t-test",NA,NA,NA,2.63237698970192
"857","3556de3d6027be4c155802f61e9c110f","NCT00620191",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change in Total Recall Score in the Selective Reminding Test","PRIMARY",NA,"D060825","Metformin in Amnestic Mild Cognitive Impairment",FALSE,80,"t-test",NA,NA,NA,1.34217713699512
"858","355ac712c879abb1ac42032e93cef989","NCT00150969",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms.","PRIMARY",NA,"D010024; D001851; D015663","Vitamin K Supplementation in Post-Menopausal Osteopenia",TRUE,440,"t-test",NA,NA,NA,3.08645519783843
"859","35cf1d1abafc5db700610c30a438d445","NCT05356533",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Alcohol Use-Peak Drinks","PRIMARY",NA,"D000428","Coping Skills for Alcohol Use",FALSE,104,"anova",2,NA,NA,1.52186200926557
"860","35d9d3f40522f8e3aaf86c3aa862439c","NCT01319721",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Eye Movement Amplitude (EMA)","SECONDARY",NA,"D011625; D012008","Recurrent Pterygium Surgery Using Mitomycin C With Limbal Conjunctival or Amniotic Membrane",TRUE,87,"t-test",NA,NA,NA,1.39696496123414
"861","360c59e7bddaa023397b5b7c396dc89f","NCT03192176",0.0414,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week","SECONDARY","Week 10","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.18717193734328
"862","361acaadcf68174731c3dd564827fbf0","NCT00297427",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Characteristics of Responders Based on Glasses/Cups Per Day of Non-caffeinated Fluids (Including Water)","SECONDARY",NA,"D014549; D004775","Acupuncture for Urinary Incontinence",FALSE,100,"t-test",NA,NA,NA,1.23952993364171
"863","364fe8d89598c68dba37ebcb746bbbe5","NCT00822172",0.048,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Peak Walking Time at Day 180","SECONDARY",NA,"D058729; D016491; D014652; D007383","Evaluation of Cilostazol in Combination With L-Carnitine",FALSE,118,"t-test",NA,NA,NA,1.56348467902489
"864","366799947415379c86aaa1584fa05522","NCT01459653",0.0103,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"EP2006 Day of Initiation by Prophylaxis Type: Cycle Level","PRIMARY",NA,"D009101; D009503; D064147; D000084462; D005334","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",FALSE,1423,"anova",2,NA,NA,1.40697751268693
"865","367dc0d73ffe011023067191300b4aab","NCT02440854",0.048,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"EQ-VAS Score","SECONDARY","Baseline vs 24-month post-baseline.","D002289","Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings",FALSE,76,"mann_whitney",NA,NA,NA,1.26629752911656
"866","3685369700d03d693382502630296d0e","NCT01323010",0.042,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Albuterol Determination in the Plasma","SECONDARY",NA,"D012135","Efficacy and Safety of Increasing Doses of Inhaled Albuterol in Children With Acute Wheezing Episodes",FALSE,103,"mann_whitney",NA,NA,NA,1.30974989899619
"867","368b68b04802b941496890aa3da27b15","NCT04249336",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Percent Change in Mean Score of Pain Response From Baseline on Schiff Cold Air Sensitivity Scale Using Air Blast Stimulus","PRIMARY",NA,"D003807; D006967","Clinical Efficacy Of BioMin F, Colgate Sensitive Pro-Relief And Sensodyne Rapid Action Dentifrices In DH",TRUE,64,"anova",2,NA,NA,1.20770700959599
"868","36945d05337356c4dce811ba107f2086","NCT00755131",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Heart Rate Recovery at Baseline and 6 Months","OTHER_PRE_SPECIFIED",NA,"D009203; D007238","Effects of Cardiac Rehabilitation on High Mobility Group Box-1 Levels After Acute Myocardial Infarction",TRUE,75,"t-test",NA,NA,NA,1.301639172202
"869","369cfe02d62ed982e06bf56e20b18f50","NCT01263015",0.016,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Plasma Human Immunodeficiency Virus -1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 96 and Week 144","SECONDARY",NA,"D000163; D015658","A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)",FALSE,833,"mann_whitney",NA,NA,NA,1.59131844824663
"870","36a00d730d294eedc0563984714ce9b4","NCT01635218",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in 17-item Hamilton Rating Scale for Depression at 6 Weeks.","PRIMARY",NA,"D003863; D003866","Homeopathic Treatment for Depression in Peri- and Postmenopausal Women",TRUE,87,"anova",2,NA,NA,1.39696496123414
"871","36c65db497a75f803032aed201b2c7d8","NCT02649634",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Readiness for Change Ratings After the Second Motivational Interviewing or Attention Control Interview, Week 12","SECONDARY","Readiness for Change ratings were analyzed via an independent sample t-test comparing the groups on mean Readiness for Change ratings on the 11-point visual analogue scales","D009765; D050177; D015431","Does Motivational Interviewing Improve Behavioral Weight Loss Outcomes for Obesity?",FALSE,129,"t-test",NA,NA,NA,1.68888097915129
"872","36cd2c42b20bc270bdaf7c0020d5db5b","NCT01892865",0.024,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Difference Between the Actual and Predicted Length of Operative Day (in Minutes)","PRIMARY","The null hypothesis was that there would be no difference in predictive imprecision for the end of the operative day between the two arms",NA,"Use of Predictive Modeling to Improve Operating Room Scheduling Efficiency",FALSE,207,"t-test",NA,NA,NA,1.14036576666913
"873","36d7aee2ba64005b8f87920cf671b41b","NCT03039621",0.031,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Time to Normalization of Body Temperature.","SECONDARY",NA,"D007239; D003141; D014777","Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children",FALSE,282,"mann_whitney",NA,NA,NA,1.65321543995212
"874","3720659669e76ee396a26bb478da1580","NCT00070707",0.036,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in AM and PM Nasal Sneezing Symptom Score","SECONDARY","Change at Final Week (AM)","D012220; D001249; D006255; D065631","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",FALSE,187,"anova",2,NA,NA,1.53535089517922
"875","375983781f6bfc11480081715387d36e","NCT01945034",0.035,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","SECONDARY","At Rest Day 2(AM): The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,152,"anova",2,NA,NA,1.35523514414799
"876","37602e51bdd6475ac3c83f12d9359413","NCT01197508",0.034,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)","SECONDARY","Logistic regression model including treatment and pooled center as fixed effects and the randomization MADRS total score as a covariate.","D003866; D003863; D003865","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.",FALSE,344,"logistic_regression",NA,NA,NA,1.97289467771628
"877","376243f80629a29d1986b510ebbad883","NCT01529385",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Ankle Edema","PRIMARY",NA,"D004487","Mild Compression Sock for Control of Lower Extremity Edema in Individuals With Diabetes",TRUE,77,"anova",2,NA,NA,1.31800316623017
"878","37782ed247c756d312e47845d07de4fc","NCT00681538",0.0234,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Subject Global Impressions of Change at End of Treatment (Phase B).","SECONDARY",NA,"D009128; D009103; D012598","A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)",FALSE,238,"logistic_regression",NA,NA,NA,1.19440575580178
"879","377d45b0973298b843972e750d853f0d","NCT00468845",0.0463,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Total Clinically Meaningful Event (CME) Score","SECONDARY","Day 7","D010149","Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy",FALSE,301,"anova",2,NA,NA,2.39846217154945
"880","378487d82b94f8366f793ced3271db8c","NCT01066793",0.0244,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for Weight per 10 kg. The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including total cumulative dose of peginterferon and ribavirin), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,427,"logistic_regression",NA,NA,NA,1.65092775731804
"881","379c74c80216d8f3a8fe138ec9b650a3","NCT01115673",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Relief (PAR) Scores at 75 Minutes","SECONDARY","The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.","D014098","To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery",FALSE,480,"anova",2,NA,NA,3.22252483067495
"882","37c231b9719bac4aef333273cf31c645","NCT02886728",0.016,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved ACR20 Response at Weeks 2, 4, 12, 36, and 52","SECONDARY","Filgotinib 200 mg + MTX vs MTX Monotherapy at Week 36","D001168; D001172","Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy",FALSE,832,"logistic_regression",NA,NA,NA,1.59036964624208
"883","37c6a2571470336ca5fdfc62a600bc5c","NCT02485561",0.024,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Identification With the Character","SECONDARY",NA,"D009369; D003110; D015179; D005770; D004067; D003108","Evaluating Strategies to Present Colon Cancer Screening Information",FALSE,314,"t-test",NA,NA,NA,1.39862939262273
"884","37cd2941dd5dd4642f23b44adf214ca1","NCT01321177",0.0145,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mean Heinrichs-Carpenter Quality of Life Scale Scores Over Time","PRIMARY",NA,"D012559; D001523; D011618","An Integrated Program for the Treatment of First Episode of Psychosis",FALSE,404,"linear_regression",NA,NA,NA,1.02019205119057
"885","37d0ff3adffacbdd4a43c8024256b390","NCT04904744",0.049,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Who Scheduled an Adolescent Well-care Appointment","SECONDARY",NA,"D000079263","Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination",FALSE,823,"logistic_regression",NA,NA,NA,4.14190541398182
"886","37d3d97e568a63d53767bd6715d9fea2","NCT05127304",0.036,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"COPD and/or Pneumonia-related Health Care Resource Utilization","PRIMARY","Inpatient visits","D029424","A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",FALSE,11316,"linear_regression",NA,NA,NA,11.8062426731356
"887","37e27a7a7b7f284e296c0b530b17d29e","NCT00551135",0.0348,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Daily Sleep Interference Rating Scale (DSIRS) Score","SECONDARY","Day 3 PS; LS Means from ANOVA model with terms of treatment, pooled center. Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,202,"anova",2,NA,NA,1.54910944654498
"888","37e8730ce1fa7d49eccc95008d008543","NCT01839331",0.0442,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change in Knee Function","SECONDARY",NA,"D010003; D020370","An Efficacy and Safety Study of Two Doses of Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee",FALSE,329,"anova",2,NA,NA,2.41024789892814
"889","37febdf11606335bb20dcbd4c84c8b68","NCT02709486",0.0399,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants Who Took Rescue Medication During Weeks 2, 4, 8, 12, 16 and 24","SECONDARY","Week 16: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,565,"logistic_regression",NA,NA,NA,2.88949959857439
"890","382aeb1c3b32a1dddc2572376189ed1e","NCT02222181",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Triglycerides","SECONDARY",NA,"D000544","Impact of Pharmacotherapy Management in Patients With Alzheimer's Disease",FALSE,55,"t-test",NA,NA,NA,1.12508606526115
"891","382d21af36a5afc8236fc12a3f282db2","NCT00551135",0.0493,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Numeric Rating Scale (NRS): Current Pain With Movement - Coughing","SECONDARY","Day 5 PS; LS Means from ANOVA model with terms of treatment, pooled center and baseline pain from coughing (for baseline visit ANOVA model with terms of treatment and pooled center). Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,200,"anova",2,NA,NA,2.06734898234759
"892","382e64cda876a0b5d79e2755109c8b65","NCT01972841",0.023,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 3 Diary Days at Weeks 4, 8, 12 and EoT","SECONDARY","Odds ratio from a logistic regression model including treatment group, sex, age group (\<65, \>=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.","D053201; D014570; D001745","This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",FALSE,1238,"logistic_regression",NA,NA,NA,2.66035909566302
"893","38577ec7ab0b2401bcf4b00b92611fa9","NCT01138657",0.036,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change in VFQ-25 Near Vision Subscore From Best State Achieved Prior to Week 6 to the Final/Early Termination Visit","SECONDARY","The statistical test for the ranked secondary variables was carried out in hierarchical order at the significance level of 5%.","D014605","Efficacy and Safety of Adalimumab in Patients With Active Uveitis",FALSE,203,"anova",2,NA,NA,1.59820476100445
"894","385f669c9b25b16323b9de33215891d4","NCT00884221",0.024,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Number of Follicles of >= 12mm, 12-14 mm, 15-16 mm and >= 17 mm in Each Participant, Intention-to-treat (ITT) Analysis Set","SECONDARY","Comparison between treatment groups of the average number of follicles 12-14 mm on the last stimulation day","D007246","MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer",FALSE,749,"mann_whitney",NA,NA,NA,2.14997074447696
"895","38658b4697b4b63f75c48a84817b5b03","NCT02697773",0.0132,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >= 30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 8, \>=30%:Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,465,"logistic_regression",NA,NA,NA,1.00659167195579
"896","3875dd5db3337d0570adbe4615a160e0","NCT03687762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in Pain Catastrophizing (i.e., Cognitive Content Mechanism; Micro-level)","OTHER_PRE_SPECIFIED",NA,"D059350","Back on Track to Healthy Living Study",FALSE,302,"anova",3,NA,NA,1.03237942189705
"897","387f7c1eadf70b5084aea02301b7ade4","NCT05013008",0.044,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Mean Change in Plasma Biomarker Levels After 36 Months of Treatment Versus 4 Months of Treatment in a Set of 27 Pre-defined Biomarkers","PRIMARY","The NPX difference (corresponding to log-transformed ratio to baseline) of CCN family member 4 (O95388) was analyzed.","D007674; D051436; D003924","An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants",FALSE,921,"t-test",NA,NA,NA,4.00142832243753
"898","387fadd439bf318651f6b587e530ca94","NCT04858802",0.031,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"CT FSO Minimum Diameter by Blinded Reviewer","SECONDARY","Day 45","D000096825","A Clinical Evaluation of PROPEL® Contour Sinus Implant",FALSE,160,"t-test",NA,NA,NA,1.25313209043777
"899","3889a154b86a85372c82dc990ae01a94","NCT00244374",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Viral Transmission Risk Behavior Association With Travel","SECONDARY","Adjusted odds with 95% confidence intervals for travel as a risk factor for each behavior.","D006506; D006526; D006509; D006505; D019966; D015819","A Randomized Trial of Vaccine Adherence in Young Injection Drug Users",FALSE,355,"logistic_regression",NA,NA,NA,2.3003407940737
"900","388fb32589ad0f6f5529a09a3aa58b62","NCT02137512",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"HBGI - Main Phase, Night Only","SECONDARY",NA,"D003922","Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use",FALSE,58,"t-test",NA,NA,NA,1.15327776573523
"901","38ab3ff7658598329d6a304bb3ae49cf","NCT03372369",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Mean Accuracy of Perceived Pregnancy Risk Score","POST_HOC","The null hypothesis is that the change in the accuracy of perceived pregnancy risk score for the CDC poster between baseline and followup is 0.",NA,"Testing the Impact of Two Posters on Contraceptive Knowledge, Contraceptive Preferences, and Perceived Pregnancy Risk",FALSE,466,"t-test",NA,NA,NA,1.45056386784607
"902","38b112f3f19e2904c1a6deec678aaf81","NCT01361568",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Total Pain Relief Within the First 2 Hours (TOTPAR 0-2) Following Postoperative Study Drug Treatment Using LOCF","SECONDARY",NA,"D010149","Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery",TRUE,91,"t-test",NA,NA,NA,1.42733241699876
"903","38b9198089b30d9b0d4919562a6fc59a","NCT01444430",0.004,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Percent of Nights With Awakening(s) Due to Asthma","SECONDARY",NA,"D001249","A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents",FALSE,11580,"anova",2,NA,NA,1.71081104782295
"904","38bb2ca7b531a731334bde07997933ae","NCT02072174",0.0484,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,1,"Severity of Clinical Manifestations of Influenza / Acute Respiratory Viral Infection by Total Symptom Score.","SECONDARY","Day 4 (patient diary data)","D007239; D003141; D007251; D014777","Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children",FALSE,498,"kruskal_wallis",2,NA,NA,3.19373351728736
"905","38d57a7675f667458688de4bd9a344a3","NCT00755807",0.025,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Uric Acid at Week 6 (Acute Phase)","OTHER_PRE_SPECIFIED",NA,"D009103; D012598","Duloxetine for Multiple Sclerosis Pain",FALSE,226,"anova",2,NA,NA,1.23298640532064
"906","38d5edd0de1045eea743a0fef70c6d92","NCT04172701",0.0093,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Costs: Outpatient Medical Costs (Per Person Per Month)","SECONDARY",NA,"D029424","A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)",FALSE,4888,"t-test",NA,NA,NA,2.3769471949384
"907","38d7b079e14b7d75277b4ee04df48774","NCT00733226",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Mean Rate of Wheezing Attacks","PRIMARY","The sample size was computed to prove that a 30% decrease of the rate of virus provoked wheezing attacks in the OM-85 group compared with placebo is statistically significant. Approximately 29 analyzable participants in each group were required, with α=0.05 and β=0.10 (ie, with a power of 90%), respectively. The difference of 30% was taken from both pilot study and clinical experience. Sample size estimation was performed by using NCSS and PASS 2000 software.","D012135","Effect of OM-85 BV on Wheezing Related Morbidity in Children With Recurrent Wheezing",FALSE,75,"mann_whitney",NA,NA,NA,1.301639172202
"908","38d959a9a97f0ebc8445f313b3923038","NCT02270450",0.04,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"MDASI-GI Symptom Assessment","SECONDARY","A linear regression model was applied to the combined data from the randomized and Patient Choice (non-randomized) pathways, using the intention to treat principle with a treatment indicator variable (surgical vs non-surgical management) based on assignment. The model compares the MDASI-GI Symptom Assessment score for bloating severity between patients assigned to surgery and patients and patients assigned to non-surgical management.","D007415; D003248","S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and Bowel Obstruction",FALSE,94,"linear_regression",NA,NA,NA,1.20338768890662
"909","390a550e2ef54bbdf9e671cea98158b8","NCT01098747",0.022,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Relief Rating (PRR)","SECONDARY","1.5 hours: Treatment difference \[Ibuprofen sodium - Ibuprofen (Advil + Motrin IB)\] and corresponding 95% CI were calculated based on LS mean from the ANOVA model.","D014098","Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain",FALSE,268,"anova",2,NA,NA,1.20007960805925
"910","391226cfb0c0dfac54e264c0a0bd33d3","NCT01070550",0.0088,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for BMI in kg/m\^2. The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including total cumulative dose of peginterferon and ribavirin), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,2981,"logistic_regression",NA,NA,NA,1.76768632301629
"911","392859fe7a68badbe8be57d387feb046","NCT01225822",0.036,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Proximal DVT","SECONDARY","BIBR 1048 225 mg bid vs. BIBR 1048 50 mg bid, same methodology as primary endpoint.","D013923; D054556","BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery",FALSE,753,"logistic_regression",NA,NA,NA,3.05384061501746
"912","39369a3e35988c9aabe9fea0a0bc3f1d","NCT01236053",0.0459,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,188924,"logistic_regression",NA,NA,NA,59.2597483998631
"913","39414ea366275cf7c4367984a61433e2","NCT02539394",0.049,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Degree of Dysphagia Patients Experience (Food Selection)","PRIMARY","The distribution of POD2 SWAL-QOL - Food selection is the same across the 2 arms","D007405; D055959; D003680; D013118","Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion",FALSE,109,"mann_whitney",NA,NA,NA,1.53077510312965
"914","39a385db9a4675d6faeef3d7a9b50db5","NCT00408993",0.044,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Statistically Significant Change From Baseline to 12 Week Endpoint in Laboratory Measures - Chloride, High Density Lipoprotein, Sodium, and Triglycerides","SECONDARY",NA,"D009437; D003929","Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China",FALSE,203,"anova",2,NA,NA,1.89328538991761
"915","39b6a3720c1561040ce503ceea0626f1","NCT04490109",0.0467,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Proportion of Subjects With ≥4 Point Improvement in Worst Itch Numeric Rating Scale (WI-NRS)","SECONDARY","The frequency and rate of WI-NRS and AI-NRS responders will be reported and compared between treatment groups using a logistic regression model. Generalized estimating equations to account for repeated measures and within-subject variability may also be applied.","D003876; D003872; D004485; D011537","B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis",FALSE,344,"logistic_regression",NA,NA,NA,2.58051473774954
"916","39cea48f3385397e6442556dfb78b94f","NCT00673231",0.0427,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of Participants With Calculated Mean Daily Insulin Dose Reduction","SECONDARY","H0: proportion(treat) minus proportion(placebo) = 0 versus the alternative HA: proportion(treat) minus proportion(placebo) =/= 0","D003920; D003924","Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin",FALSE,391,"logistic_regression",NA,NA,NA,2.54972664754819
"917","39da5278e16016e43fe5b78b602daedc","NCT05302414",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Interprofessional Collaboration Scale","SECONDARY","For posttest right after intervention at the 4 weeks.",NA,"The Learning Outcome of Resuscitation Teamwork Training in Postgraduate Year Doctors and Nurses",FALSE,64,"kruskal_wallis",2,NA,NA,1.20770700959599
"918","39dfe9d55c3961350adbb87293c72dff","NCT02912650",0.028,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference Scores on 4-Point Categorical Scale (SPRID4) Over 2, 6, 8, 12 and 6 to 8 Hours Post-dose","OTHER_PRE_SPECIFIED","6-8 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,221,"anova",2,NA,NA,1.34443099262638
"919","39f0af953e907459fea9a94bc1d87762","NCT01972841",0.035,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 3 Diary Days at Weeks 4, 8, 12 and EoT","SECONDARY","Odds ratio from a logistic regression model including treatment group, sex, age group (\<65, \>=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.","D053201; D014570; D001745","This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",FALSE,1242,"logistic_regression",NA,NA,NA,3.82455103751447
"920","39fd77bdb5805eb71819458f97cbeb92","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Calories","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1740,"linear_regression",NA,NA,NA,6.11775166016043
"921","3a0272b9b051a9e8794846d7993bcb08","NCT02547779",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Major Adverse Kidney Event Within 30 Days","PRIMARY",NA,"D058186; D016638","Isotonic Solutions and Major Adverse Renal Events Trial in the Non-Medical Intensive Care Unit (SMART-SURG)",TRUE,10421,"logistic_regression",NA,NA,NA,14.9579666321604
"922","3a1a3dd4a12a265836d6b7f429a411d6","NCT00913627",0.048,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Relief Combined With Pain Intensity Difference (PRID) Score","SECONDARY","15 minutes","D014098","Study Evaluating Ibuprofen 600 mg Extended Release (ER) For Dental Pain",FALSE,87,"anova",2,NA,NA,1.35044246726388
"923","3a399af7284e58cf59a919a0575e1cbe","NCT03192176",0.0355,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 7","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.04330704255697
"924","3a459538d7e8daf08cc371416801f850","NCT00762528",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Interleukin - 1 Beta (IL-ß)","PRIMARY","The null hypothesis states that there is no difference between groups.","D005891","Compare Anti-inflammatory Dentifrices",TRUE,49,"anova",2,NA,NA,1.06649684228356
"925","3a545db24427d383050be37a468d0831","NCT04448678",0.0401,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Changes in Efficacy- Health Insurance Literacy","SECONDARY",NA,NA,"Improving Health Insurance Experiences for Adolescent and Young Adult Cancer Patients",FALSE,72,"t-test",NA,NA,NA,1.06265477556749
"926","3a5bac0b57b91851eece3dc58030014e","NCT00453999",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Scores of Symptoms of Influenza","SECONDARY","Headache: change from Baseline at Days 2, 3, 4, 5, 10, 14","D007251","Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza",FALSE,122,"mann_whitney",NA,NA,NA,1.64382327798156
"927","3a70a1783adb3a146cde87816e6b2711","NCT00279201",0.043,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c","SECONDARY",NA,"D003920; D003924","The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)",FALSE,466,"anova",2,NA,NA,2.7976672967473
"928","3a9b8f1833cff9f051499f294b9f41a5","NCT00337662",0.034,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Body Mass Index","SECONDARY",NA,"D012559; D011618","Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia",FALSE,327,"anova",2,NA,NA,1.92418160419667
"929","3aa4e31e4f48c4ca624fd64962876f10","NCT02276807",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in the Level of Intensity of Suicidal Ideation at 12 Weeks","OTHER_PRE_SPECIFIED",NA,"D003863; D003866","Improving Mood in Veterans in Primary Care",TRUE,118,"anova",2,NA,NA,1.61751378500378
"930","3ab89c077b8036788450a4dfbdfd189c","NCT01225822",0.0113,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Proximal DVT","SECONDARY","BIBR 1048 225 mg bid vs. Enoxaparin 40 mg qd, same methodology as primary endpoint.","D013923; D054556","BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery",FALSE,763,"logistic_regression",NA,NA,NA,1.12083684605261
"931","3ac7932de202807a6ef41298c01366e1","NCT00261443",0.039,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Baseline and Adjusted Mean Change From Baseline in Clinical Global Impression Scale for Bipolar Disorder (CGI-BP) Severity of Illness Score (Mania) Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 40 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,2.15879458692739
"932","3acbb3ee2fa4b823d3dd567b4b9533eb","NCT01529385",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Calf Edema","PRIMARY",NA,"D004487","Mild Compression Sock for Control of Lower Extremity Edema in Individuals With Diabetes",TRUE,77,"anova",2,NA,NA,1.31800316623017
"933","3ad60e3cef3a742e676897e6072b2dbf","NCT03192176",0.044,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 4 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 8","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.2282329662253
"934","3ae0c3387e6355c45f8e511a4dd6ca66","NCT04218864",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Composite Abuse Scale (CAS)","PRIMARY","Linear Mixed regression models (LMM) have been used to identify any difference between the intervention and the control groups over time with regards to the continuous outcomes. Group (intervention vs. control), a 5-category time (baseline, 6 week, 3 month, 6 month, 12 month) and group-by-time interaction are covariates in the model. A random subject intercept is used to account for clustering within subject.",NA,"Strength for U in Relationship Empowerment",FALSE,121,"linear_regression",NA,NA,NA,1.63728545358366
"935","3b0c1893299a0a28971b7003631d75d0","NCT00922194",0.05,"Wilcoxon","INTERVENTIONAL",0,0,0,0,0,"Change in Waist (Cms) /Height (Meters) Ratio From Baseline at 12 Months or More","PRIMARY","Analysis of difference between 12 months and baseline values","D003920; D003924; D050177","Metformin in Overweight Type 2 Diabetes Mellitus",TRUE,102,"wilcoxon",NA,NA,NA,1.50770356720122
"936","3b28b861f17d23eb8fd0b8fccf871fda","NCT04239911",0.043,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Change in Preventable 911 Calls","OTHER_PRE_SPECIFIED","Preventable 911 calls if had been able to reach the doctor. Dichotomized into ""agree"", ""strongly agree"", and ""very strongly"" vs. all other responses. We used logistic mixed regression model to compare trajectory of all outcomes between and within study arms. Mixed effects included a fixed effects categorical variable for time point (baseline/90days), and indicator for study arm (enhanced usual care/intervention), a study arm by time point interaction and subject specific random intercept.","D006333","Leveraging Home Health Aides to Improve Outcomes in Heart Failure",FALSE,102,"logistic_regression",NA,NA,NA,1.32957699604834
"937","3b2cac0062081963be9b278526db299f","NCT04238247",0.032,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants With Age- and Size-Appropriate Child Passenger Restraint System Use at 6 Months","POST_HOC",NA,NA,"Tiny Cargo, Big Deal! An ED-Based Study of Child Passenger Safety Behaviors",FALSE,396,"logistic_regression",NA,NA,NA,2.0082522833499
"938","3b47f1dc030d1811c6356d624e83a6c1","NCT01559259",0.031,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Relief Rating Score (PRR)","SECONDARY","11 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,182,"anova",2,NA,NA,1.33416400439747
"939","3b4be6cb552d2c2dd23863c38186818e","NCT02528253",0.0399,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 32, \>=30%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1012,"logistic_regression",NA,NA,NA,3.86075218415434
"940","3b4e8a102831c2b23b064021bfdb00be","NCT01185522",0.021,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Mean Clinically Significant Improvement in Tender Joints and Swollen Joints as Predictive Factors After 4 Months of Tocilizumab Treatment","PRIMARY","Predictive factor : Swollen joint","D001168; D001172","An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS)",FALSE,264,"logistic_regression",NA,NA,NA,1.14415572291942
"941","3b6ca21a9df80f8b6995e7c9e3efb524","NCT01794923",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Muscle Soreness With Movement at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 30, 36, 48, 54, 60 and 72 Hours Post-Dose 1","SECONDARY","9 Hours: Analysis was performed using an ANOVA model with treatment, baseline categorical PSR, sex, and baseline MSM terms.",NA,"Topical Ibuprofen for Delayed Onset Mulscle Soreness",FALSE,122,"anova",2,NA,NA,1.64382327798156
"942","3b6f45de34063f7526b155f13aefa8aa","NCT02206061",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Average Number of Days Without Asthma Symptoms (Symptom Free Days) During Post-intervention Follow-up Interviews (3, 5 and 7 Months)","PRIMARY",NA,"D001249","School-based Asthma Care for Teens (SB-ACT)",TRUE,377,"linear_regression",NA,NA,NA,2.85904586732926
"943","3b8267e33f5ead19cde9dd68b6c99e0d","NCT03435497",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Change in Sexual Risk Behavior Among Alters","SECONDARY",NA,NA,"Pilot Intervention to Empower HIV Clients as Prevention Advocates in Uganda",FALSE,56,"logistic_regression",NA,NA,NA,1.13456029943022
"944","3b90d1f548cd62b9319dba85ec0e7c98","NCT04445792",0.0483,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Fatigue as Measured by PROMIS (Patient-Reported Outcomes Measurement Information System)","SECONDARY",NA,"D059350; D059787; D003863; D003866","A Depression and Opioid Pragmatic Trial in Pharmacogenetics (DCRI Coordinating Center)",FALSE,904,"mann_whitney",NA,NA,NA,4.2879687510794
"945","3b9365d8192605dcde0cbb8ea090afaa","NCT00884065",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Active External Rotation After Intervention Minus Baseline","PRIMARY",NA,"D020069","Effectiveness of Diacutaneous Fibrolysis in Painful Shoulder",FALSE,50,"t-test",NA,NA,NA,1.07648023860356
"946","3b93a6e565f4e3b1c6eccab4bc330f5e","NCT03953508",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Highest Trial Competed for a Menthol Cigarette Puff in the Choice Task (Relative Reinforcing Value for Menthol Cigarettes)","PRIMARY",NA,NA,"Perceptions of Cigarette Smoking in Young Adults",TRUE,107,"anova",2,NA,NA,1.54285677868397
"947","3ba5f0402caa4000b98ac4191e1e0fef","NCT01945034",0.036,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","SECONDARY","At Rest Day 5(AM): The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms. Upper limit of 95% CI \< 0 for Ibuprofen treatment significantly better than combined Placebo.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,219,"anova",2,NA,NA,1.65868081224329
"948","3bab6591db14973dd759bec533e9a998","NCT01708902",0.0343,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"The Frequency of Patients With Use of Rescue Therapy During 24 Week Treatment Period in Main Group","SECONDARY","Comparison of 'Main: Linagliptin 2.5mg / Metformin 500mg BID' / 'Main: Linagliptin 5mg QD'.

The logistic regression includes treatment and continuous baseline HbA1c. The validity of the model is questionable as there is possibly a quasi-complete separation of data points, the results shown are based on the last maximum likelihood iteration.","D003924","Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients",FALSE,283,"logistic_regression",NA,NA,NA,1.80542231968722
"949","3bdd3cb5af06c876fd034fd2b5702e3f","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"24-hour Brachial Diastolic BP","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"950","3bf39213bf849154c1bdeb759a4daf3c","NCT00416572",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Depressive Symptoms (Measured With an Abbreviated 10-item CES-D) at Baseline, Post-intervention (4-months Post-intervention) and Final Follow-up (13-months Post-intervention).","PRIMARY","Comparison between education intervention and the control condition at 4 months post-intervention. The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome.","D001943","Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer",FALSE,146,"linear_regression",NA,NA,NA,1.79360862376457
"951","3bf3ed677f84b18a800179104b422d69","NCT02321462",0.0249,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean BBPS Score by Segment and Globally (ITT Population)","SECONDARY","Treatment difference for Right Colon BBPS Score.",NA,"Efficacy, Safety and Tolerability of Eziclen in Adult Subjects Undergoing Colonoscopy",FALSE,282,"anova",2,NA,NA,1.36951920928501
"952","3bfa0f6f6535fe6c09ce63b95af288b8","NCT02539394",0.037,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Degree of Dysphagia Patients Experience (Communication)","PRIMARY","The distribution of Pre-operative SWAL-QOL - Communication is the same across the 2 arms","D007405; D055959; D003680; D013118","Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion",FALSE,109,"mann_whitney",NA,NA,NA,1.2097625378439
"953","3bfc45e4c828da5149fcb5e6a711b702","NCT02709486",0.0373,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >=30%, >=50%, >=70% and >=90% Response","SECONDARY","Week 16, \>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,565,"logistic_regression",NA,NA,NA,2.72895840969303
"954","3c016df31563d6c631d5a374df1aeba6","NCT03625115",0.049,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"An Evaluation of Parent/Family Engagement in the Early Intervention Process","OTHER_PRE_SPECIFIED","Analysis of factor 3 items from the parent engagement questionnaire.

Factor 3 (Knowledge/Self-Efficacy):

I know how to get EI for my child. I understand how the EI process works. If I have questions about EI, I know who to call. 12. I know my child's rights to EI under the law.",NA,"The Opening Doors to Early Intervention Study",FALSE,333,"t-test",NA,NA,NA,2.64379005251025
"955","3c0434f12b9ecd4a281742de1db0917d","NCT02962908",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Severity of Symptoms in RT-PCR Influenza-confirmed Subjects.","OTHER_PRE_SPECIFIED",NA,"D007251","A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine",FALSE,77,"mann_whitney",NA,NA,NA,1.31800316623017
"956","3c04dd213eadad0c3d3246f3e01f036b","NCT00320112",0.02,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Insulin Starts at 6 Months","SECONDARY",NA,NA,"Improving Insulin Therapy With Enhanced Care Management",FALSE,244,"linear_regression",NA,NA,NA,1.05519633034059
"957","3c13094b845aba118e2c1261085496b0","NCT00768053",0.043,"One-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Sensitivity to Change of the EULAR-RAID Score: Change From Baseline to Week 12","PRIMARY","Comparison of change from baseline between EULAR-RAID score and Emotional well-being NRS value","D001168; D001172","Evaluation of EULAR-RAID Score in Rheumatoid Arthritis Patients",FALSE,108,"t-test",NA,NA,NA,1.36659841683154
"958","3c547bc35e1b8ebfe54db104a249deed","NCT02059993",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change of Daytime Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Pre-treatment and Post-treatment","PRIMARY","The sample size was calculated to assess a minimum reduction of 5 ± 5 mm Hg in systolic BPafter CPAP treatment, assuming an alpha error of 5% and a statistical power of 80%.","D012891; D020181; D006973; D006331; D003327; D003324; D017202; D008659","The Effects of Obstructive Sleep Apnea and Its Intervention on Coronary Heart Disease",TRUE,73,"t-test",NA,NA,NA,1.28506804726186
"959","3c86135281122d8b7070de423cb3cfa9","NCT01257503",0.02,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Overall Symptom Severity","SECONDARY","cold score day 1 assessment 1","D012141","Homeopathic Cold Remedy for Children Study",FALSE,240,"mann_whitney",NA,NA,NA,1.04670488635223
"960","3c881dbc737355f370c2cf956e366650","NCT00270998",0.0492,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"75% Reduction in Weekly Urinary Incontinence Episodes at 3 Months","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",TRUE,295,"logistic_regression",NA,NA,NA,2.49873946067788
"961","3cace7ec2ff2ae0636006b19eb89325c","NCT00099359",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Risk Factors for Perinatal HIV-1 Transmission","SECONDARY",NA,"D015658; D000163","Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission",FALSE,1591,"logistic_regression",NA,NA,NA,3.79199728887624
"962","3cd957deca8d893a6487062d1b824108","NCT03192176",0.046,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 3","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.29631447895437
"963","3cdaee9d391f9ab4ca51c9e4e2aa226e","NCT04591015",0.0471,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Summary of Diabetes Self-Care Activities - Exercise - Change From Baseline to 90 Days","SECONDARY",NA,"D000086382; D003920; D003924","Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19",FALSE,109,"t-test",NA,NA,NA,1.48119518741233
"964","3ce7e47750428cdbb20a914c9dc48911","NCT02128763",0.02,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Change in Tear Break up Time by Keratography","OTHER_PRE_SPECIFIED",NA,"D015352; D007638","Dry Eye Assessment and Management Study",FALSE,234,"linear_regression",NA,NA,NA,1.03383709895217
"965","3cecea6719209ec66197c0fb6b660a1f","NCT03705286",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Cognitive Function","PRIMARY",NA,"D011014; D053717","Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia",FALSE,149,"logistic_regression",NA,NA,NA,1.81146252531541
"966","3d25940f541f5ecec7852b938c44f437","NCT03596450",0.033,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Number of Participants With Glycosylated Haemoglobin (HbA1c) Less Than 7.0 Percentage (%) (53 Millimoles Per Mole [mmol/Mol]) at Year 1 (Yes/No)","PRIMARY","Estimate and p-value are based on logistic regression model with logit link function, treatment as categorical effect, and baseline HbA1c as covariate.","D003920; D003924","Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial",FALSE,892,"logistic_regression",NA,NA,NA,3.08450616790348
"967","3d3173b0efef7ec3ee1ca58acb08c00b","NCT05137041",0.024,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Time Course of Pain Relief","SECONDARY","VRS: Day 5 Morning","D001416; D017116","Efficacy and Safety of FIRTECH in Patients With Mild to Moderate Acute Low Back Pain",FALSE,181,"t-test",NA,NA,NA,1.06823299057427
"968","3d327668f9886a343621551d0377aecf","NCT03497975",0.0309,"Logistic regression","INTERVENTIONAL",0,0,1,1,0,"Percentage of Participants With ≥ 4- Point Decrease in 7-day Average Worst Itch - Numerical Rating Scale (WI-NRS) up to Week 14","PRIMARY",NA,"D011537; D011536","PRISM Study-Pruritus Relief Through Itch Scratch Modulation",FALSE,230,"logistic_regression",NA,NA,NA,1.49169340046978
"969","3d34f2b3e24f48849a8a6d6e7ceee373","NCT02444988",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"30-day In-hospital Mortality","SECONDARY",NA,"D058186; D016638","Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit",TRUE,5381,"logistic_regression",NA,NA,NA,10.750392773245
"970","3d43c6df3068f97977aaed0640b22bcf","NCT01589445",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Comparison of Changes in Fasting Serum Glucose (FSG)With Pioglitazone and Metformin","PRIMARY","Change from Baseline in FSG at 3rd month","D003920; D003924","Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects",TRUE,80,"anova",2,NA,NA,1.34217713699512
"971","3d48001779720a1e0faf54b3bc77dcf6","NCT01517373",0.0319,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Body Weight at Week 2, 4, 6, 8, 12 and 14","SECONDARY","Week 4: Treatment difference and 80% CI were based on LS mean. MMRM analysis was performed with treatment, duration of T2DM, time and treatment-by-time interaction as fixed effects, baseline as the covariate, time was repeated for participant.","D003920; D003924","Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin",FALSE,117,"t-test",NA,NA,NA,1.10387872973624
"972","3d54d2138f4595d517cfd6fabf16f1d3","NCT05457647",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Uncorrected Distance Visual Acuity","OTHER_PRE_SPECIFIED","Assessment of change of UDVA value at 12-months follow-up visit.","D007640","Theranostic Guided Riboflavin/UV-A Corneal Cross-linking",TRUE,47,"mann_whitney",NA,NA,NA,1.04624856756472
"973","3d5e82879e2878eb38ab7e97f194dd97","NCT00755326",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"‡Pain Normalized Score","PRIMARY",NA,"D010003; D020370","Dose Escalation Study Of Chinese Herbs In Osteoarthritis Of The Knee",FALSE,92,"t-test",NA,NA,NA,1.4348242556313
"974","3d5f7a4890a8f5fab4734e813f50bb2b","NCT00245219",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mental Health (as Measured With the SF-36) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the education condition and the control condition at Time 2. The full regression model included 2 dummy coded variables, 1 contrasting the education and control condition, and 1 contrasting the peer support and control condition. The baseline measure of the outcome variable was included, in order to examine changes in the outcomes over time. This model tested the main effects of the conditions among patients with early stage cancer, late stage patients were excluded.","D001943","Understanding Shared Psychobiological Pathways",FALSE,131,"linear_regression",NA,NA,NA,1.70153588988359
"975","3d6a39d09585067d211bb736fee566ed","NCT00402324",0.046,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Clinically Significant Laboratory Values - Bilirubin Total Change From Baseline","SECONDARY",NA,NA,"A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients",FALSE,166,"anova",2,NA,NA,1.78102566999428
"976","3da274180d3e5e93ea82b56883ee2898","NCT00707447",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Eating Behavior (TFEQ) - Cognitive Restraint","SECONDARY",NA,"D003920","Evaluation of a Primary Type 2 Diabetes Prevention Programme",TRUE,166,"t-test",NA,NA,NA,1.90948799930043
"977","3da33df5c0fe304e3fd0c7e08f0e8069","NCT05302414",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Learning Cognitive Load","SECONDARY","For posttest right after intervention at the 4 weeks.",NA,"The Learning Outcome of Resuscitation Teamwork Training in Postgraduate Year Doctors and Nurses",TRUE,64,"kruskal_wallis",2,NA,NA,1.20770700959599
"978","3dae649bbc24719462f9ff7bde67dad6","NCT02034006",0.0461,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Patients in Different Categories of Changes From Baseline in BCVA","PRIMARY","Change from baseline in BCVA: Worsened vs. No change","D009362; D014786; D015354; D009216; D020256; D009389","A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.",FALSE,200,"logistic_regression",NA,NA,NA,1.9545014879928
"979","3db747e7e5320ee9b7e9edfbaaef3f1f","NCT02528253",0.0162,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 2, \>=70%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,813,"logistic_regression",NA,NA,NA,1.58947450863353
"980","3dba372808944802f75d50a91b68e633","NCT03458702",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Root Mean Square of Successive Differences (RMSSD) Assessed at Baseline, Post-Condition and Post-Exposure","PRIMARY",NA,"D001008","The Effects of Emotional Exposure on State Anxiety",FALSE,80,"anova",2,NA,NA,1.34217713699512
"981","3dbdf3bafa4fa2586b68f2e56c6b1938","NCT05384041",0.048,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in the Beck Depression Inventory Second Edition (BDI-II) at Weeks One and Four Compared to Baseline.","SECONDARY","Difference (Active - Control) at Week 1","D003866; D003863; D003865","Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults",FALSE,255,"t-test",NA,NA,NA,2.27801730418648
"982","3dcc7927245b21d0db9ea89cd91f9f7e","NCT01573442",0.029,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change in BPI Average Pain From Baseline to Month 1-6","PRIMARY","From baseline to month 1","D001943; D018771; D019584","Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment",FALSE,208,"mann_whitney",NA,NA,NA,1.34503890735303
"983","3de7a0079fdbb9d9c0caeb67ec4bdb07","NCT01225822",0.0114,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Proximal DVT, PE (Pulmonary Embolism) and VTE Related Mortality","SECONDARY","BIBR 1048 225 mg bid vs. Enoxaparin 40 mg qd, same methodology as primary endpoint.","D013923; D054556","BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery",FALSE,763,"logistic_regression",NA,NA,NA,1.12962697190191
"984","3e1333bf7dbce7613d348790a19885ab","NCT03676465",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Division of Diabetes Responsibilities Score","SECONDARY",NA,"D003920; D003922; D002908","CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management",FALSE,43,"t-test",NA,NA,NA,1.00454908915455
"985","3e5675e6c7f069d80470cbdf84cd5b7e","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Health Warning Label","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1752,"linear_regression",NA,NA,NA,6.13876469477842
"986","3e5c7bea1cca9cddcb0e385bf59d9aaa","NCT01822548",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Absolute Change in the Endothelial Progenitor Cell (EPC) Number","PRIMARY",NA,"D003920; D003924","Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes",TRUE,64,"anova",2,NA,NA,1.20770700959599
"987","3e60e841d5f08f429c09042e3d036e18","NCT04218123",0.05,"ANOVA","INTERVENTIONAL",0,0,1,1,0,"Number of Vertigo Episodes","PRIMARY",NA,"D008575","Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes",FALSE,80,"anova",2,NA,NA,1.34217713699512
"988","3e6fb509634d4c3f62f25214eabbe3f0","NCT00699907",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Colony Stimulating Factor-1 Receptor (CSF-1R) Expression in Ovarian Epithelium","PRIMARY",NA,"D010051; D000077216","Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer",FALSE,77,"mann_whitney",NA,NA,NA,1.31800316623017
"989","3eb423dfcb681972357deb03cbd663e4","NCT00530257",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Wechsler Intelligence Scale for Children-IV, Digit Span Subtest","PRIMARY","We evaluated the data for cross over effects. No statistical significant sequence effect were seen for our endpoints and hence we combined the data from both periods of the crossover design There was evidence against the assumption of normality for performance on some of the measures of attention. Thus we used the non-parametric Wilcoxon Signed Ranks Test to compare performance on OROS-methylphenidate versus placebo.","D006948; D001289","Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory",TRUE,60,"mann_whitney",NA,NA,NA,1.17169922891753
"990","3ebaac824c1a1359f88a1e796fb8b07a","NCT02494401",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Change in Visual Analogue Scale Pain Intensity Scale on the PROMIS® 29 Profile v 2.0 Outcome Measure","SECONDARY",NA,"D012595; D045743; D012598","Taking Charge of Systemic Sclerosis",FALSE,247,"mann_whitney",NA,NA,NA,2.32040326199209
"991","3ec03cd89ee43a8290f5c8c4cb8a9377","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Price)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1754,"linear_regression",NA,NA,NA,6.14225987828851
"992","3ecda2b03b7999a13394233e023fd21b","NCT02746679",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Endometrial Thickness Were Measured by Ultrasound in the Middle of Menstruation in All Patients.","SECONDARY",NA,"D006175; D003863","Impact of Mindfulness Based Stress Reduction on Anxiety, Depression and QOL in Women With Intrauterine Adhesion.",FALSE,151,"anova",2,NA,NA,1.82326813686662
"993","3ee81baddf86897319fb1a8be36712e3","NCT02991118",0.039,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)","SECONDARY",NA,"D002318; D050197; D006937; D006949; D006951","Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk",TRUE,707,"mann_whitney",NA,NA,NA,3.16798239582437
"994","3ef28fa11efe6fb318a02fc6931b9f1b","NCT03050918",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Number of Participants With In-patient Re-admissions","PRIMARY",NA,NA,"Discharge Follow-up Phone Call Program",FALSE,3054,"mann_whitney",NA,NA,NA,8.10112754497152
"995","3ef8f6641ea15c62dad44ab702711d1a","NCT01046136",0.0293,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Mean Change From Baseline in a 6 Point Severity Scale (0 = None, 1 = Very Mild, 2 = Mild or Slight, 3 = Moderate, 4 = Severe or 5 = As Bad as it Can be) for Cough.","PRIMARY",NA,"D003139","Mucinex Exploratory Cold Study",FALSE,369,"mann_whitney",NA,NA,NA,1.79837699184328
"996","3eff20a7d991c172e736fbe6e4912e43","NCT01378299",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Percent Change in Bone Mineral Density (BMD) According to the rs1062033 Polymorphism in the CYP19A1 Gene","PRIMARY","Analysis by intention to treat with the last value carry forward","D007006","CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy",TRUE,52,"anova",2,NA,NA,1.09617796589869
"997","3f0c7be809fe9a936ed6bbb38fc26eee","NCT02709486",0.0124,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants Who Took Rescue Medication During Weeks 2, 4, 8, 12, 16 and 24","SECONDARY","Week 12: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,566,"logistic_regression",NA,NA,NA,1.04963348693515
"998","3f0ca1da788ce0df5ecd1091d4d3913c","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in Fasting Plasma Glucose","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,110,"anova",2,NA,NA,1.56357043896758
"999","3f2756d8141272c62e3bf15abb388e85","NCT01114373",0.0492,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Mean Nighttime Diastolic Blood Pressure (DBP)","PRIMARY","The null hypothesis was that there is no interaction between the order of randomization and the primary outcome measures.","D006973","Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study",FALSE,72,"anova",2,NA,NA,1.25978322057599
"1000","3f31fe6d7c76da12a82430a7c058d052","NCT06138145",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Participants' Decision to Enroll in the CHOP Pediatric Clinical Trials Registry","PRIMARY",NA,NA,"Inclusion Appeal Videos and Intent to Register for Pediatric Clinical Trials",TRUE,125,"mann_whitney",NA,NA,NA,1.66328288934253
"1001","3f3dc0d5323d4c3e497298258e4ffd55","NCT00310466",0.04,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Global Improvement of Rhinoconjunctivitis Symptoms Assessed by the Subjects","SECONDARY",NA,NA,"Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With Hayfever",FALSE,196,"anova",2,NA,NA,1.71750893137232
"1002","3f4cec2001974c0e6b02c6918b61a630","NCT05127304",0.022,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"COPD-related Health Care Resource Utilization","PRIMARY","Ambulatory visits","D029424","A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",FALSE,11316,"linear_regression",NA,NA,NA,7.72394886634108
"1003","3f4d86c9bd67307f9a49bcbc52dce237","NCT01303796",0.0416,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Blood Products Transfused","SECONDARY",NA,"D007938; D007951; D015470","A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia",FALSE,469,"mann_whitney",NA,NA,NA,2.72924452024149
"1004","3f61a6ab4035b7fb3b3ffcbfa07fa7e5","NCT00767806",0.024,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to 12 Week Endpoint in Creatinine","SECONDARY","Tested was the null hypothesis that there is no difference between placebo and duloxetine groups in change of creatinine during 12 weeks of treatment.","D001416; D017116","A Study for Patient With Chronic Low Back Pain",FALSE,384,"anova",2,NA,NA,1.54440496324657
"1005","3f7f8893ba8dce3f6b1a768f184dede1","NCT02719327",0.05,"Linear regression","INTERVENTIONAL",0,0,1,1,0,"Cerebrospinal Fluid (CSF) Biomarkers of Alzheimer's Disease","SECONDARY","Phosphorylated tau (pTau181) measured in CSF was log-transformed prior to analysis to approximate a normal distribution.","D000544","Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid",FALSE,86,"linear_regression",NA,NA,NA,1.38926982128357
"1006","3f8a22b9339eaedb503598b4df046d15","NCT00724126",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6)","SECONDARY",NA,"D043183; D013577","Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)",FALSE,635,"logistic_regression",NA,NA,NA,1.69067290464651
"1007","3f8c3b6e619df148160b2c2a28daa19c","NCT02539394",0.049,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Degree of Dysphagia Patients Experience (Eating Duration)","PRIMARY","The distribution of 4-6 weeks SWAL-QOL - Eating duration is the same across the 2 arms","D007405; D055959; D003680; D013118","Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion",FALSE,109,"mann_whitney",NA,NA,NA,1.53077510312965
"1008","3f9496d0253291b0d049736c9f086a91","NCT03982368",0.035,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Patient Global Impression of Change (PGIC) - Full Analysis Set","SECONDARY","At week 12 (FUP)","D015352; D007638","A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye",FALSE,165,"mann_whitney",NA,NA,NA,1.41037467349166
"1009","3f96b60f3b41b3b74857aece4406dd18","NCT01178073",0.0321,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With a Satisfactory Clinical Response at Week 24","SECONDARY",NA,"D000081029; D006976; D006973","A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)",FALSE,347,"logistic_regression",NA,NA,NA,1.88646859410223
"1010","3f989cd435ae4caa2d65dbb5a070875d","NCT03035916",0.042,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Hemodynamic Parameters: Heart Rate.","PRIMARY","The Heart rate was measured from baseline to 48hours after surgery. The row ""Baseline"" is the preoperative level as the blank control.This Statistical Analysis applied to ""Induction"" row.",NA,"Transversus Abdominis Plane Block on Stress Response",FALSE,59,"t-test",NA,NA,NA,1.00623005316419
"1011","3f9a672b0af1cda2a2eb6f70afe843d4","NCT05302414",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Knowledge of Teamwork Assessment","PRIMARY","For pretest at the 0 week",NA,"The Learning Outcome of Resuscitation Teamwork Training in Postgraduate Year Doctors and Nurses",TRUE,64,"kruskal_wallis",2,NA,NA,1.20770700959599
"1012","3fa82b940916f2492101e08854573772","NCT00707447",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Fasting Glucose","SECONDARY",NA,"D003920","Evaluation of a Primary Type 2 Diabetes Prevention Programme",TRUE,166,"t-test",NA,NA,NA,1.90948799930043
"1013","3fa88aaa500eafdd50d86a99d1156341","NCT00698035",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Matched E2 by Commercial and Research (RIA) Analyses","SECONDARY","Comparison of week 4 estradiol between LC/MS and RIA","D012735","Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients",FALSE,126,"t-test",NA,NA,NA,1.66971913113983
"1014","3fb52f68f6e317f530a975b04f7b4047","NCT01179568",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Responder Status Based on Complicated Grief Clinical Global Impression-Improvement (CGI-I) Scale","PRIMARY","Our prespecified primary analysis was cross-sectional, comparing treatment response rates for CIT with CGT vs CIT at week 20 (aim 3) based on the intention-to-treat principle including all randomized participants.",NA,"A Study of Medication With or Without Psychotherapy for Complicated Grief",TRUE,200,"logistic_regression",NA,NA,NA,2.09181669397075
"1015","3fbc21ae40bc3d5726eaf47ab97cc651","NCT00789815",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"The Recovery Time to Orientation","SECONDARY",NA,NA,"Bispectral Index-guided Sedation for Flexible Bronchoscopy",FALSE,492,"t-test",NA,NA,NA,3.26223932627676
"1016","3fc627a51158abfb274a7764f414ad4f","NCT00536471",0.044,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Chloride, Urea Nitrogen, Cholesterol, Sodium","SECONDARY",NA,"D003866; D003863; D003865","A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients",FALSE,250,"anova",2,NA,NA,2.09711519364176
"1017","3fec86625a5cee931a26675e8911f6b4","NCT00442546",0.0416,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Range of Motion (ROM) Assessment of the Active Flexion of the Surgical Knee","SECONDARY","Week 4","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,147,"anova",2,NA,NA,1.54285464658706
"1018","3ff011a8f64baf447ce0119e0dec4409","NCT02111746",0.036,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Postoperative Pain as Assessed by a Numeric Pain Scale (NPS)","PRIMARY",NA,"D010149","PAIN - Postoperative Analgesia INvestigation",FALSE,319,"mann_whitney",NA,NA,NA,1.99558101463859
"1019","3ffeb0b426729e98f39b2aa2eddc7293","NCT02672176",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Depression Severity Measured by PHQ-9","SECONDARY",NA,"D003920","Improving Health in Diabetes Project",FALSE,285,"mann_whitney",NA,NA,NA,2.48992995915375
"1020","40114880babbf884157581d39f744c7d","NCT03652181",0.033,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Percent Change in QSM Value (Lesional Iron Content)","SECONDARY",NA,"D020786; D006391; D006392; D000013; D006470","CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness",FALSE,149,"t-test",NA,NA,NA,1.27677563668065
"1021","401e6543f5b3d194e5eaa3d93d05dd0e","NCT01499368",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"The Proportion of Days Without 'Cardinal Symptom'","SECONDARY",NA,"D004941","A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients",FALSE,284,"mann_whitney",NA,NA,NA,2.48561680610172
"1022","402a44bb1cefab299e9b2c2557eab00c","NCT00101933",0.047,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change in Most Severe Seizures","OTHER_PRE_SPECIFIED","Numbers provided indicate the percentage change from baseline in seizure frequency of each participant's most severe seizures. Negative values indicate improvement from baseline.","D004827","SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy",FALSE,81,"mann_whitney",NA,NA,NA,1.28259398352605
"1023","4033cf87849a8260097cb0826d0d0372","NCT02528253",0.0149,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 8, \>=50%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1012,"logistic_regression",NA,NA,NA,1.64648718309693
"1024","403a6760f7b98340c866c0da7a03fde4","NCT03089281",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Left Ventricular Ejection Fraction (Relative Change)","SECONDARY",NA,"D006333","Strategic Management to Optimize Response To Cardiac Resynchronization Therapy",FALSE,311,"t-test",NA,NA,NA,2.59956214364198
"1025","4044cb9e0f977e35a9d8271f2960432b","NCT00762762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"C-Peptide","PRIMARY","The null hypothesis states that there is no difference between groups.","D010518","Effectiveness of a Triclosan Containing Toothpaste in Maintaining Periodontal Health in a Type 2 Diabetic Population",FALSE,46,"anova",2,NA,NA,1.03597838019194
"1026","404c3093a91184f0649036ee0b125cab","NCT02748096",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Assessment of Functional Outcome","SECONDARY",NA,"D001168","The Assessment of Patient Specific Instrumentation for Unicompartmental Knee Replacement",TRUE,45,"t-test",NA,NA,NA,1.02560707988412
"1027","404c4a87532ecbb57624ba025c2f4dfb","NCT06624449",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Basic Life Support Competence","PRIMARY",NA,NA,"The Effect of Immediate Versus Delayed Debriefing on Basic Life Support Competence In Undergraduate Nursing Students.",TRUE,44,"t-test",NA,NA,NA,1.01513168983373
"1028","40649ab7bb79b2dc02e4128fb21d9a3e","NCT00725101",0.021,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Odds Ratios From Stepwise Logistic Regression Model of Longitudinal Adherence to Duloxetine Treatment for Fibromyalgia (FM) Over 12 Months: Generalized Anxiety Disorder-7 (GAD-7) Score, Pregabalin Use, and Non-Steroidal Anti-Inflammatory Drug (NSAID) Use","PRIMARY",NA,"D005356; D009209","Fibromyalgia Health Outcome Study on Cost of Treatments",FALSE,212,"logistic_regression",NA,NA,NA,1.02784066359136
"1029","40675407290ec719f865d701f6ea6bb7","NCT00922194",0.05,"Wilcoxon","INTERVENTIONAL",0,0,0,0,0,"Change in Fasting Blood Glucose From Baseline at 12 Months or More","PRIMARY","Analysis of difference between 12 months and baseline values","D003920; D003924; D050177","Metformin in Overweight Type 2 Diabetes Mellitus",TRUE,102,"wilcoxon",NA,NA,NA,1.50770356720122
"1030","406c300371ba2cb6c1bb4aa643b0c945","NCT01683383",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Time to Target Temperature","SECONDARY",NA,"D001927; D002545; D020925; D007511; D000860","California Transport Cooling Trial",FALSE,100,"mann_whitney",NA,NA,NA,1.23952993364171
"1031","4073ff4be9054e3e245d00ff1fa84c85","NCT01236053",0.0062,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,30.8971533278091
"1032","40795a6c9528e6f72722bc150aaea87c","NCT01941719",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Foot Complications","SECONDARY",NA,"D003929; D017719; D003920","Enhancing Diabetic Foot Education by Viewing Personal Plantar Pressures",TRUE,99,"anova",2,NA,NA,1.48621381452241
"1033","4080180c268583698a3c931e6869c095","NCT02110758",0.03,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Change in Health Care Utilization From Baseline to Follow up","PRIMARY","To estimate exposure to the intervention on Per Member Per Month Specialist Visits, we used a difference-in-differences model with fixed effects for practices. The dependent variable was Per Member Per Month Specialist Visits. The intervention effects were represented by the coefficient estimates for utilization time period (baseline or follow-up) interacted with status (pilot or comparison).","D009369","Evaluating the Impact of Patient-Centered Oncology Care",FALSE,123727,"logistic_regression",NA,NA,NA,33.3910970754549
"1034","4085d3119a480e5d82a020dd3fd47b49","NCT00536471",0.029,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Hematocrit","SECONDARY",NA,"D003866; D003863; D003865","A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients",FALSE,263,"anova",2,NA,NA,1.50882953962872
"1035","40a38142d997b1f10fbafd4b4966e65a","NCT00926211",0.046,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Increase in Hair Follicles Present","PRIMARY","The hypothesis to be tested is one of non-inferiority. Tests of non-inferiority are one-sided tests and the significance level will be 0.025.","D000505","Computer-Assisted Versus Manual Hair Harvest Comparative Study",FALSE,72,"t-test",NA,NA,NA,1.19146755871289
"1036","40c2de1399d1be3125e7cb5874bfbcc8","NCT03365934",0.049247,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Microbial Community Richness - (Day 2)","PRIMARY",NA,NA,"Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds",FALSE,59,"t-test",NA,NA,NA,1.14807002738666
"1037","40de3fb3ea9b8d9a49d22af405ca4772","NCT02005627",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Total Nasal Symptom Score After Nasal Allergen Challenge (NAC)","PRIMARY",NA,"D012220; D065631","Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study",TRUE,46,"t-test",NA,NA,NA,1.03597838019194
"1038","40e1ee6808badbfb8bf1893b5a4499fa","NCT00684060",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Infarct Volume","SECONDARY","Comparison of change in the active group minus change in the control group.","D018754; D018487","Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)",TRUE,80,"t-test",NA,NA,NA,1.34217713699512
"1039","40ebce16f376459663f9087e374b51b6","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient-Reported Outcomes Measurement Information System (PROMIS Short Forms 8a - Pediatrics v. 2.0) is a Set of Person-centered Measures That Evaluates and Monitors Physical, Mental, and Social Health in Children and Adolescents.","SECONDARY","This is analysis for 6 month outcomes of Emotional-distress - anxiety. See details in 3 month outcomes.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,126,"t-test",NA,NA,NA,1.66971913113983
"1040","4101a12b90ac7866d45aac2b27edde88","NCT01280617",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Rates of Acute Cellular Rejection Between Study Group","PRIMARY",NA,"D058186","Low Dose Thymoglobin in Renal Transplant Patients",TRUE,43,"t-test",NA,NA,NA,1.00454908915455
"1041","41045ef8a8b8a2beb6fa8451499244bc","NCT02886728",0.014,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved ACR 50% Improvement (ACR50) at Weeks 2, 4, 12, 24, 36, and 52","SECONDARY","Filgotinib 200 mg Monotherapy vs MTX Monotherapy at Week 36","D001168; D001172","Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy",FALSE,626,"logistic_regression",NA,NA,NA,1.22804846965121
"1042","4105aea9cbc2c68de11ddbe537858b5e","NCT00785928",0.044,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Achieving The American College of Rheumatology (ACR)20 Response up to 24 Weeks","SECONDARY",NA,"D001168; D001172","A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy",FALSE,156,"linear_regression",NA,NA,NA,1.66470662171866
"1043","410ee3c47aae96ca65ab0ec71fb54551","NCT01907217",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Hamilton Depression Rating Scale (HDRS)","PRIMARY","Based on a large bitemporal ECT series, we estimated that 69 patients were required per group to have 80% power to demonstrate, using a one-sided equivalence t test at 5% level, that the mean reduction in the 24-item HAM-D score following high-dose unilateral ECT was no more than 4 points (i.e., equivalent to 3 points on the 17-item HAM-D, deemed to be clinically relevant \[30\]) less than that achieved using bitemporal ECT.","D003863; D003866","Enhancing the Effectiveness of Electroconvulsive Therapy in Severe Depression",TRUE,138,"linear_regression",NA,NA,NA,1.74510680710624
"1044","4134a49054901042bfb036f295d57905","NCT00449696",0.041,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Acetaminophen Consumption","SECONDARY",NA,"D010003; D020370","Gel-200 Versus Placebo in Osteoarthritis of the Knee",FALSE,375,"mann_whitney",NA,NA,NA,2.41336873588304
"1045","4144444e691fd7b2dd3f5eb576364467","NCT00267111",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Pain Scores Assessed by Neonatal Facial Action","PRIMARY","We hypothesized that topical amethocaine gel 4% would reduce the pain from IM injection. The sample size was based on the pain scores obtained from a previous study that compared pain response during IM injection. To achieve a clinically significant reduction in pain scores by 20% between groups with 80% power and an alpha value of \< 0.05, we estimated sample size of 49 neonates in each group. A total of 110 neonates were enrolled to account for possible dropouts and missing data.",NA,"Topical Amethocaine Gel for Intramuscular Injection in Term Neonates",TRUE,107,"t-test",NA,NA,NA,1.54285677868397
"1046","4146b86fd132110311e78af46b77b92a","NCT04134728",0.0293,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With 20% Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 Superiority Comparison With Placebo","PRIMARY","The null hypothesis is that there is no difference between 90 mg dose of GSK3196165 and 200 mg dose of sarilumab alternating with placebo every week in the proportion of participants achieving ACR20 response at Week 12 versus the alternative hypothesis that the 90 mg dose of GSK3196165 differs from 200 mg dose of sarilumab alternating with placebo every week in the proportion of participants with ACR20 response at Week 12","D001168; D001172","Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors",FALSE,312,"logistic_regression",NA,NA,NA,1.65560036137154
"1047","416901f737a67d37d97b9d260c77c139","NCT02392806",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Number of Participants With Extubation Failure","PRIMARY",NA,"D012128; D012127","Comparative Effectiveness Study of Bubble CPAP Devices in the NICU",FALSE,43,"t-test",NA,NA,NA,1.00454908915455
"1048","416fc64c8b204212a6bf5e07a1ff59ca","NCT00293241",0.03,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Atrial Pacing Percentage","SECONDARY",NA,"D002318","PreFER Managed Ventricular Pacing (MVP) For Elective Replacement",FALSE,562,"mann_whitney",NA,NA,NA,2.25984124058911
"1049","418ad6864101e2e94270f549b7bc1ad2","NCT01702259",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Bilateral Upper Thigh Circumference Measurement","SECONDARY",NA,"D000071697","Study of the Effect of Low Level Laser Light Therapy on Reducing the Appearance of Cellulite in the Thighs and Buttocks.",TRUE,68,"t-test",NA,NA,NA,1.24268015567051
"1050","41af05176feb60bfdd97ac3da11a0b62","NCT00608530",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Numeric Pain Rating Scale (Numerical Rating Scale, 0-10) Psychologist-Delivered Treatment Study","SECONDARY","Repeated measures analysis of variance comparing groups at baseline and end of treatment.","D001416","Telehealth Outreach for Chronic Back Pain",FALSE,66,"anova",2,NA,NA,1.2253174109698
"1051","41d31f026c7e60c7218c593f7ac0eb3f","NCT03228680",0.017,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportions of Participants With Early OHSS (Including OHSS of Moderate/Severe Grade) and/or Preventive Interventions for Early OHSS","SECONDARY","Proportions of participants with early OHSS (any grade).","D007246","Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese Women",FALSE,347,"logistic_regression",NA,NA,NA,1.08837256018223
"1052","41d640d396601be00f5a78ab39092cac","NCT00105989",0.016,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score - Acute and Continuation Phases","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,412,"t-test",NA,NA,NA,1.1231272076488
"1053","41d9965d8c1759ddd3b53ec18ede24bb","NCT00245219",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Depressive Symptoms (as Measured With the CES-D) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the peer support condition and the control condition at Time 3. The full regression model included 2 dummy coded variables, 1 contrasting the education and control condition, and 1 contrasting the peer support and control condition. The baseline measure of the outcome variable was included, in order to examine changes in the outcomes over time. This model tested the main effects of the conditions among patients with early stage cancer, late stage patients were excluded.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"logistic_regression",NA,NA,NA,1.79957957739554
"1054","41d9b69e02fd017090d46fa97805905f","NCT03634397",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Upper-Extremity Fugl-Meyer Assessment (FM) Score From Baseline 2 (Prior to Training) to Post Test 1","PRIMARY",NA,"D020521","Predicting Ipsilesional Motor Deficits in Stroke With Dynamic Dominance Model",TRUE,53,"linear_regression",NA,NA,NA,1.10589694869732
"1055","41dd6d4f779c9dcaf6ff767d6834f7a7","NCT02528188",0.0296,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 24: \>=90% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1989,"logistic_regression",NA,NA,NA,4.18998103067598
"1056","41eb0806634d6be01e9880a0d8aa6699","NCT01567865",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Number/Percentage of Subjects With Demonstrated Seroprotection","PRIMARY","Null hypothesis: reference lot vs. Lot 1, 2, and 3 combined do differ in seroprotection (SP) rates among each other by more than 10%.

Slower than anticipated enrollment resulted in a smaller number of subjects with antibody response data for analysis. Consequently, additional power estimates were made in anticipation of the occurrence of smaller sample sizes. The power of the study to test non-inferiority of the combined new lots compared to the reference lot dropped from 99% to 87%.","D004672; D004660","Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine",TRUE,727,"t-test",NA,NA,NA,3.96052194988198
"1057","41ecc6cde4584539dbe3f97fb61c9a2b","NCT04992390",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Generalised Anxiety Disorder 2-item Scale (GAD-2)","SECONDARY","ITT analysis for Generalised Anxiety Disorder 2-item scale (GAD-2) (treatment effects for between-arm comparisons) at week 4.",NA,"A Brief GAmeplay Intervention for NHS ICU Staff Affected by COVID-19 Trauma (GAINS Study)",TRUE,86,"linear_regression",NA,NA,NA,1.38926982128357
"1058","41fb0b31a5b755f90e439fd81236f32c","NCT02481596",0.045,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Adherence to Diet - Use of Dietary Information","PRIMARY","3 months. Multiply imputed data (m=20) using chained equations.","D003920; D003924","FAMS Mobile Health Intervention for Diabetes Self-care Support",FALSE,379,"linear_regression",NA,NA,NA,2.62413149498086
"1059","41fe6a4895f04d99886913c94946c925","NCT03840135",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Total Score on Symptom Assessment Scale by 3 and 5 Day of Treatment","SECONDARY",NA,"D007239; D012141","Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI",TRUE,155,"mann_whitney",NA,NA,NA,1.84665325745721
"1060","4201f609d7cbab6daf87c8c93c713bae","NCT01066819",0.0139,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response Over Time by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for average number of drinks per week (1 vs 0). The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including total cumulative dose of peginterferon and ribavirin), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,674,"logistic_regression",NA,NA,NA,1.2657994780486
"1061","42089f11d604bb6aac6a0d3043db7e40","NCT01381406",0.007,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Incidence Rate Per 100 Person Years of Hospitalization or Emergency Department (ED) Visit Related to Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)","PRIMARY",NA,"D008171; D008173; D029424","Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations",FALSE,3333,"logistic_regression",NA,NA,NA,1.5226018423453
"1062","42124f169ed7b8596eef3311c740b4f7","NCT03044886",0.048,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Probing Depth (PD)","SECONDARY",NA,"D010538; D010518","Effects of Vitamin D on Moderate to Severe Periodontitis",FALSE,323,"anova",3,NA,NA,1.02145725864484
"1063","421a30e365aa7ad7ddf750e3ecdf83c3","NCT01066819",0.0125,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response Over Time by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for HCV RNA at BL in log10(IU/mL). The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including total cumulative dose of peginterferon and ribavirin), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,674,"logistic_regression",NA,NA,NA,1.15254982674436
"1064","42254088f38a88798a3db802b6b06de0","NCT00762528",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Interleukin-6 (IL-6)","PRIMARY","The null hypothesis states that there is no difference between groups.","D005891","Compare Anti-inflammatory Dentifrices",TRUE,49,"anova",2,NA,NA,1.06649684228356
"1065","4227f4f270084a298d5079aa79612faf","NCT02700815",0.0202,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Patients With Decrease in POMwp of at Least 30% From Baseline","SECONDARY","A logistic regression was used to compare change in number of patients with a decrease in POMwp of at least 30% from baseline between placebo and combination therapy diclofenac + capsaicin. The likelihood-ratio test was used to test for differences between treatments.","D019547; D059787","Capsaicin + Diclofenac Gel in Acute Back Pain or Neck Pain",FALSE,300,"logistic_regression",NA,NA,NA,1.1777650620122
"1066","423a45b67edf9e0abd918f8a64c8f66f","NCT01823341",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Percentage of Nights With 1 or More Sensor Glucose Values <70 mg/dL (<3.9 mmol/L)","SECONDARY",NA,"D003922; D007003","Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children",FALSE,72,"t-test",NA,NA,NA,1.06043757626689
"1067","423afea442151f51301dd7855295a90b","NCT03480022",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Adrenal Dehydroepiandrosterone Sulfate (DHEAS)","SECONDARY","Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect","D011085; D011236; D013577; D001835","Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS",FALSE,67,"anova",2,NA,NA,1.23402909436682
"1068","42403c6b0de819bcd7337408988a5f05","NCT02814565",0.0489,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Physician Rated Assessment of Presence of Local Pain on Days 3, 7, and 15 of Treatment","SECONDARY","Day 15. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.","D013035; D001416; D019547; D017116","Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin",FALSE,180,"mann_whitney",NA,NA,NA,1.95006259242493
"1069","42581eb389f9a4a13b7926424761fb25","NCT03815292",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change in Barthel Index Score","OTHER_PRE_SPECIFIED","This analysis applies to ∆ between baseline and after 24 weeks total scores row.","D020521; D000083242; D002544; D007511; D060825","Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke",FALSE,275,"mann_whitney",NA,NA,NA,2.02812584173536
"1070","425ab2c649911af6b3a9795249e2c548","NCT00408876",0.024,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Severity (BPI-S) - Least Pain Score","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,221,"t-test",NA,NA,NA,1.17737979327663
"1071","42684463fbd1534def613c9faff4f639","NCT02528253",0.0105,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 2, \>=50%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,810,"logistic_regression",NA,NA,NA,1.08170783589163
"1072","4271230464d0357973340da30b6753de","NCT02741284",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Umbilical Artery pH","SECONDARY","pH","D005311; D000860","Oxygen for Intrauterine Resuscitation of Category II Fetal Heart Tracings",TRUE,99,"t-test",NA,NA,NA,1.48621381452241
"1073","427dd6c65648bec33dca1b95c72e6147","NCT04058067",0.035,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Best-corrected Visual Acuity (BCVA) - Average Change From Baseline Over the Period Week 40 Through Week 52 for the Study Eye","PRIMARY",NA,"D014786; D015354; D008269; D004487","To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema",FALSE,263,"anova",2,NA,NA,1.77170143879445
"1074","428f43c57cbe91e48b0a12e589831f87","NCT02123797",0.0366,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Thoroughness of Invasive Staging, MD vs SC (Conference) vs SC (no Conference)","PRIMARY",NA,NA,"Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology",FALSE,450,"logistic_regression",NA,NA,NA,2.39890868156537
"1075","429108e91b83ce6aa8fe91f8ec911799","NCT02732145",0.0429,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Distribution of Aceto-Whitening Reaction in Relation to the Structures of the Outer Vulvar Ring","SECONDARY","Parameter: The difference in the incidence of aceto-whitening of Mons Pubis versus Perineum in patients with impaired vulvar skin and positive AWR.","D056650; D008010; D018459; D012871; D009450","Diagnostic Accuracy of ""Three Rings Vulvoscopy"" for Detection of Vulvar Dermatosis",FALSE,82,"t-test",NA,NA,NA,1.1956457723947
"1076","42939d1ea28d210ee5aebc2dc2562270","NCT03855189",0.02,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Response To Therapy At Day 4 (Physician-Evaluated)","SECONDARY","Pairwise treatment comparison based on t-test from an analysis of variance (ANOVA).","D012220; D065631; D006255","Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)",FALSE,229,"anova",2,NA,NA,1.02299044795298
"1077","42a92a9548f0e9fbee844ba3360b6fa2","NCT00453999",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Scores of Symptoms of Influenza","SECONDARY","Nasal Congestion: change from Baseline at Days 2, 3, 4, 5, 10, 14","D007251","Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza",FALSE,122,"mann_whitney",NA,NA,NA,1.64382327798156
"1078","42b11b662761aef16eaefa7fa0047e2e","NCT01462370",0.043,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Total Pain Relief Score Over the First 6 Hours (TOPAR6) After the Initial Dose","PRIMARY","With at least 128 participants, the study had a 92% power to establish that etoricoxib is noninferior to ibuprofen (null hypothesis). The power and sample size were based on the following assumptions: 1) an approximately 15% protocol violation rate, 2) a noninferiority margin of -3.7 units (etoricoxib minus ibuprofen), and 3) an intrapatient standard deviation of 8 units.","D004412","Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)",FALSE,260,"anova",2,NA,NA,2.09701630047407
"1079","42b1cb80710e9d17f723d461684b659e","NCT00406848",0.019,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Laboratory Values - Hemoglobin, Mean Cell Hemoglobin Concentration (MCHC)","SECONDARY",NA,"D003866; D003865","A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients",FALSE,337,"anova",2,NA,NA,1.18228166236133
"1080","42c5316a8c04b169f1cf13fe063803e6","NCT02413996",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Pain: Visual Analogue Scale (VAS)","PRIMARY","Does VRRS rehabilitation is superior to the traditional one?","D010003","Effects of Virtual Reality Rehabilitation in Patients With Total Knee Arthroplasty",FALSE,74,"t-test",NA,NA,NA,1.2933799900503
"1081","42c9c21ed100719dd5d46ff5eaf9657c","NCT04018001",0.0227,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants Who Met All Effectiveness Criteria up to 12 Months From the Index Date","PRIMARY",NA,"D001168; D001172","Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR)",FALSE,1057,"logistic_regression",NA,NA,NA,2.43121683549745
"1082","42caa0e7e18b77700531e6849b6b0c50","NCT00190684",0.044,"One-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to 5 Year Endpoint in Weight, Height, and Body Mass Index (BMI) Percentile Stratified by Baseline Quartile","PRIMARY","Tested was the null hypothesis that there would be no statistically significant difference between baseline and endpoint.","D006948; D001289","Long-Term, Open Label Atomoxetine Study",FALSE,251,"t-test",NA,NA,NA,2.10123731835109
"1083","42cf84165f70b7a207b9c58857f45c48","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Healthfulness","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1771,"linear_regression",NA,NA,NA,6.17188902328434
"1084","42d8144616f20ffb0797081e935b22ca","NCT04295135",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Medications for Opioid Use Disorder Prescription Ordered","SECONDARY",NA,"D059350","Chronic Pain OneSheet Clinical Trial",FALSE,132,"linear_regression",NA,NA,NA,1.70782824525799
"1085","42dc12f3bea6c47e798e7b49811c3a84","NCT01124838",0.044,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change In Logarithm of the Minimum Angle of Resolution (LogMAR) Best Corrected Visual Acuity (BCVA) In Each Eye From Baseline to the Final/Early Termination Visit","SECONDARY","The statistical test for the ranked secondary variables was carried out in hierarchical order at the significance level of 5%.","D014605","Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis",FALSE,257,"anova",2,NA,NA,2.1258023051768
"1086","4317394dc84f638612ee8e3a878795ce","NCT01459653",0.0079,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Predictors of Absolute Neutrophil Count","PRIMARY","Study drug dose (higher vs lower) as predictor for ANC","D009101; D009503; D064147; D000084462; D005334","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",FALSE,1185,"logistic_regression",NA,NA,NA,1.01381861788458
"1087","431b8f23808da3ab3d798f34abc11f67","NCT02867709",0.044,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose","SECONDARY",NA,"D008881","Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine",FALSE,920,"logistic_regression",NA,NA,NA,3.999264977642
"1088","4323f15b441f33a82ce49bcd289add35","NCT00958360",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Comparison of Changes in Visual Reading Ability From Baseline to Four Months Later Measured With 48 Item VA Low Vision Visual Functioning Questionnaire","PRIMARY",NA,"D015354","Low Vision Intervention Trial II (LOVIT II)",FALSE,323,"t-test",NA,NA,NA,2.64863200438123
"1089","4331567a2d28d8ae1471aa122e2736ae","NCT02100631",0.0062,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Mean Fold Change in Vibriocidal Antibody Titer Between Day 1 and Day 11","OTHER_PRE_SPECIFIED",NA,"D002771","A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults",FALSE,2978,"t-test",NA,NA,NA,1.29064690541302
"1090","433b17a8d9302cfdb34c5438208ce9f6","NCT02504671",0.037,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Achieving Categorical DAS28(CRP) Response (Moderate/Good [European League Against Rheumatism] EULAR Response) at All Assessment Time Points","SECONDARY",NA,"D001168; D001172","Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis",FALSE,74,"logistic_regression",NA,NA,NA,1.00624074568493
"1091","433b9c094607a124fc9e515512b68348","NCT01449955",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Clinician Administered Posttraumatic Stress Disorder Scale (CAPS)","PRIMARY","ANOVA comparing the results of change over time (e.g., comparing baseline to 1 month posttreatment) as well as comparing differences between condition (e.g., placebo compared to rapamycin).","D040921; D013313","Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory",FALSE,51,"anova",2,NA,NA,1.08637315449684
"1092","433c98c327338907bb4e064df30894bd","NCT01378299",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Percent Change in Prostate-specific Antigen (PSA) According to the rs700518 Polymorphism of the CYP19A1 Gene","SECONDARY","Analysis by intention to treat with the last value carry forward.","D007006","CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy",TRUE,63,"anova",2,NA,NA,1.19880559218312
"1093","433dbd0b55b91226ac8fe788ff79478e","NCT03270436",0.0293,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Mean Systolic Blood Pressure (mmHg)","SECONDARY","Repeated measures regression model used all available participant data (no listwise deletion).","D003920; D003924","Diabetes Prevention Program Lifestyle Intervention in the Marshallese Population",FALSE,378,"linear_regression",NA,NA,NA,1.81989739003044
"1094","435b60252e45295cfbfb9da3716c625b","NCT04858802",0.034,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Polypoid Edema in the Frontal Recess/FSO by Clinical Investigators","SECONDARY","Day 180","D000096825","A Clinical Evaluation of PROPEL® Contour Sinus Implant",FALSE,160,"t-test",NA,NA,NA,1.35564976763055
"1095","43627d69a2a07ff211916376ab22d0fc","NCT03886220",0.035,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Participants Who Were Responders With Menstrual Blood Loss (MBL) Volume < 80 mL at Final Month and >= 50% Reduction in MBL Volume From Baseline to the Final Month","PRIMARY",NA,"D007889; D047708; D008595; D006470","A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women",FALSE,82,"logistic_regression",NA,NA,NA,1.00790788386435
"1096","436ff2ad2c43aa1df71d2badff81bfcb","NCT01559259",0.024,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Relief Rating Score (PRR)","SECONDARY","0.25 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,181,"anova",2,NA,NA,1.06823299057427
"1097","4382eeafe669f13350bcca9ef32ba556","NCT02823652",0.035,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change of Scores on Patient-Reported Outcomes Measurement Information System (PROMIS) - Depression From Baseline to Post-genetic Education","PRIMARY",NA,"D009369","Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer",FALSE,388,"t-test",NA,NA,NA,2.1460810654111
"1098","438ff91695c1bfee17813a36e0c27e1c","NCT00778622",0.0422,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Total Cholesterol (TC) - Full Analysis Set","SECONDARY",NA,"D003924; D001835","Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients",FALSE,214,"t-test",NA,NA,NA,1.87582505986385
"1099","43b5f5b0e875e302b419063aa4a54d47","NCT02373813",0.031,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"SDAI Score at All Measured Timepoints","SECONDARY","Week 36","D001168; D001172","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",FALSE,152,"t-test",NA,NA,NA,1.22233716168314
"1100","43d91e38b0b04e06f0cc492fff84b252","NCT02543840",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Team Development Measure (TDM)- Communication","SECONDARY",NA,"D001523","Hybrid Collaborative Care Randomized Program Evaluation",FALSE,60,"t-test",NA,NA,NA,1.17169922891753
"1101","43e20c2f145116ecbf3ad64c4b14aa36","NCT01070550",0.0317,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for ALT ratio at BL (\<=1 vs \> 3). The logistic regression analysis for relapse 24 Weeks after EOT was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,1751,"logistic_regression",NA,NA,NA,4.17020362617278
"1102","43e9d770b3b60f488dd2deacd7548b7e","NCT00620373",0.016,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Diagnostic Yield","PRIMARY","Significant difference p ≤ 0.05","D001943","Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts",FALSE,1872,"t-test",NA,NA,NA,2.38093719132045
"1103","440990dfa07b3386bda2bdf811c7a041","NCT04560998",0.0108,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change in Vascular Quality of Life Questionnaire-6 (VascuQoL-6) Score","SECONDARY",NA,"D058729; D016491; D003920; D003924","A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes",FALSE,724,"mann_whitney",NA,NA,NA,1.04908346671373
"1104","440a5ed9e085763fc481eaa45bc25522","NCT00467285",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Changes in BMD at Femoral Neck","PRIMARY","comparison of changes in BMD at 6months compared to baseline","D010024; D003920; D003924","Effect of Diabetic Medications on Bone Metabolism",TRUE,92,"t-test",NA,NA,NA,1.4348242556313
"1105","441785208045b288f2a045f0c93254d6","NCT01197755",0.023,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of Patients Achieving DAS28-CRP <2.6 at Week 24, Comparison Between Fostamatinib and Placebo","SECONDARY","Non-responder imputation has been applied following premature withdrawal, or increased dose of methotrexate or any DMARD initiation, or for 8 weeks following receipt of any parenteral steroids, or for patients with no post baseline data.","D001168; D001172","Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist",FALSE,214,"logistic_regression",NA,NA,NA,1.11718418379091
"1106","44390d368deaf2df124c4da27e63e0ce","NCT02527148",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Cost Effectiveness: Wound Length","SECONDARY","To compare wound length between both groups.",NA,"A Trial of Mechanical Axis vs Kinematic Alignment in Total Knee Replacement",FALSE,99,"t-test",NA,NA,NA,1.48621381452241
"1107","4441eea2b35f14324ccac491b064daad","NCT02400736",0.033,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Income Earned From Competitive Jobs","SECONDARY",NA,"D019966; D003866; D003865; D040921; D001008; D013313; D001523; D011618","Supported Employment in Patient Aligned Care Teams",FALSE,119,"t-test",NA,NA,NA,1.14542079898344
"1108","44742a7b50495e89e3581cee1741e51f","NCT03687762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in Pain Interference (Micro-level Change)","PRIMARY",NA,"D059350","Back on Track to Healthy Living Study",FALSE,302,"anova",3,NA,NA,1.03237942189705
"1109","447789c0463e9cc31a3b77c3057178a4","NCT02886728",0.013,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With no Radiographic Progression From Baseline at Weeks 24, and 52","SECONDARY","Filgotinib 200 mg Monotherapy vs MTX Monotherapy at Week 24 for Change in mTSS \<= 0","D001168; D001172","Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy",FALSE,626,"logistic_regression",NA,NA,NA,1.15032859757066
"1110","448dabe36426210538e53251f721069e","NCT01970943",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"PET Diprenorphine","SECONDARY",NA,"D008881","Molecular and Functional PET-fMRI Measures of Analgesia in Migraine",FALSE,46,"t-test",NA,NA,NA,1.03597838019194
"1111","44917ac72664ce68ed3a4af5f5d73c5a","NCT01891396",0.0367,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score Comparing Cingal® to Monovisc® (ITT)","SECONDARY",NA,"D010003; D020370","Cingal Study for Knee Osteoarthritis",FALSE,299,"anova",2,NA,NA,1.96477977365699
"1112","44956627c1fb13388272673ec8a2f1b6","NCT00510146",0.021,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in Erythrocyte Count (Open-Label Phase)","SECONDARY",NA,"D001714","Olanzapine Treatment of Patients With Bipolar I Disorder",FALSE,380,"mann_whitney",NA,NA,NA,1.36847693529122
"1113","44b01e52ed65d15e9feb0e273532bebc","NCT04823494",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Aided Abbreviated Profile of Hearing Aid Benefit (APHAB)","PRIMARY","For the wear-time crossover field trial, the APHAB was measured following both the audiology best-practices hearing aid fitting (PRO-FIT) and the self-fitting method (SELF-FIT).

* Null hypothesis: Mean (APHAB SELF-FIT - APHAB PRO-FIT ) ≥ 8.4
* Alternative hypothesis: Mean (APHAB SELF-FIT - APHAB PRO-FIT) \< 8.4

The mean difference between the aided scores for the two fitting methods, Self-Fit minus Pro-Fit, represent the primary outcome measure. The expected difference = 0.","D034381; D003638; D006319","Wear-Time Trial for Self-Fitting Hearing Aid",TRUE,74,"t-test",NA,NA,NA,1.2933799900503
"1114","44b41151b13ac9765d3819c514d5da73","NCT01270828",0.0161,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Benefit From Treatment, Satisfaction With Treatment and Willingness to Continue Treatement (BSW)","SECONDARY","This analysis is for 'Benefit from treatment'. Proportional odds logistic regression was used with a term for treatment in the model.","D009437; D051474","Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia",FALSE,394,"logistic_regression",NA,NA,NA,1.10469118587467
"1115","44b6ddf644c66ec2ec4b1825f05dd367","NCT03008460",0.0428,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Colon Cleansing Score (4-point Scale)","SECONDARY","Analysis of the treatment difference (Eziclen®/Izinova® minus Klean-Prep®) was performed using a 2-way ANOVA, including treatment and country as covariates.","D004066; D005767","Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy",FALSE,241,"anova",2,NA,NA,2.01228205667793
"1116","44bb76d8646331dc2f16427526d82b35","NCT01340027",0.034,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Improvement in PPBC","SECONDARY",NA,"D053201; D014570; D001745; D020924","A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder",FALSE,222,"logistic_regression",NA,NA,NA,1.59059778860788
"1117","44c15327c5eb45273127458f26fe052d","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Total Bilirubin Value at Baseline and After Treatment Completion","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"1118","44ce45e11bf537e8ef57c7d9c4668cc8","NCT03192176",0.0458,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 3 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 10","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.29162039645315
"1119","44dd0d8787cc25f3bf37e4fcd5249bc6","NCT00256750",0.0299,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire","SECONDARY","Role Emotional, Month 36","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,424,"anova",2,NA,NA,1.9599336983426
"1120","44f241208f3856af19c9d4350e15f167","NCT02057042",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Cognitive Behavioral Therapy Skills","SECONDARY",NA,"D003863; D003866","Veteran Peer-Assisted Computerized Cognitive Behavioral Therapy for Depression",TRUE,330,"t-test",NA,NA,NA,2.67684084235139
"1121","45432f0f5f0c52f950756282810b1a9f","NCT02861118",0.044,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Impact of the Comorbidities Profile in IBD Participants on Loss of Treatment Response to Biological Therapy","PRIMARY","IBD","D007410; D015212","A Retrospective Observational Study to Assess the Impact of Co-morbidities on Treatment Response in Inflammatory Bowel Disease",FALSE,310,"logistic_regression",NA,NA,NA,2.33158452669986
"1122","455b37ff6c301c00c61be24722de4f96","NCT05731999",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Correct Classifications of Subjects, Evaluated Using a Combination of Different Pupillometric Variables for Indicating Use of Each Medicinal Product D1-D4 and Ambient Light Condition.","SECONDARY","The null hypothesis is that the logistic regression classifier is unable to correctly classify subjects into sober or under the influence of D1-D4. The smallest odds ratio from the group false positives and false negative is reported.","D019966","A First Study in Healthy Volunteers of a New Mobile Phone Application Measuring the Eyes Before and After Medication",TRUE,48,"logistic_regression",NA,NA,NA,1.05642048349345
"1123","458f9b669e867e67efdc501ab42a28cc","NCT04428411",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Last Visit","PRIMARY",NA,"D011565","Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).",TRUE,372,"t-test",NA,NA,NA,2.84021788100067
"1124","45adfdcc8483137c66661ebb6a44690d","NCT05481216",0.033,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Time Since HIV Diagnosis","PRIMARY","Conditional logistic regression models accounting for case-control matching will be used to identify risk factors for advanced immunodeficiency associated with COVID-19. Odds ratio (OR), and the 95% confidence intervals of the OR will be calculated","D000086382; D060085","HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV",FALSE,1492,"logistic_regression",NA,NA,NA,3.98513104134061
"1125","45c3cae2ce962ed1f7821da5b112506a","NCT00442546",0.0284,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Cumulative Total Amount of Opioids Used During the Entire Hospital Stay","SECONDARY","48 hours","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,169,"anova",2,NA,NA,1.19405030032377
"1126","45c42627d6f1be52d476d90e3c3d90c1","NCT04332614",0.0127,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Link Clicked: Within Less-is-better (Provider Communication vs. Managing Appointments vs. Medical Information Access)","SECONDARY",NA,NA,"Email Campaign to Increase Uptake of myGeisinger",FALSE,1072,"logistic_regression",NA,NA,NA,1.47156120012168
"1127","45d344bb8afe9fc043a6cda4766d9397","NCT03779048",0.03,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Phase 1: Baseline Sensitivity to Reward as Measured by the Behavioral Inhibition/Activation Scale (BIS/BAS)","OTHER_PRE_SPECIFIED",NA,"D015431","Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment",FALSE,134,"linear_regression",NA,NA,NA,1.11834035735343
"1128","45db7b7bc8a315f87faf1bbefd430c58","NCT00699660",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient Satisfaction","SECONDARY",NA,"D040921; D013313","Enhancing Equitable and Effective (E-3) Post Traumatic Stress Disorder (PTSD) Disability Assessment",FALSE,384,"t-test",NA,NA,NA,2.88519868378802
"1129","45dc7d170db9eb9a338cd383d5870a19","NCT03726489",0.013,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Concomitant Topical Psoriasis Treatment","SECONDARY","Analysis for Phototypes III/IV","D011565","Light Treatment Effectiveness (LITE) Study",FALSE,594,"linear_regression",NA,NA,NA,1.12083905612937
"1130","45f2f78499465c1de033063b6c8fb758","NCT04196803",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Changes of Cytosine Modification in TMPRSS2 (5-mC at cg26337277) by Magnesium Treatment Versus Placebo","SECONDARY",NA,"D015179","Ancillary Study of Methylation Biomarkers in a Randomized Controlled Trial of a Personalized Prevention of Colorectal Cancer",FALSE,239,"linear_regression",NA,NA,NA,2.28311078024125
"1131","4605b39c3f46dae121702e7faf0096e7","NCT00996632",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Time of Discharge","SECONDARY","null hypothesis is that Stay in Hospital Days are not different","D001943","The Use of a High-frequency Ultrasonic Knife in Breast Cancer Surgery",FALSE,94,"mann_whitney",NA,NA,NA,1.44969222080406
"1132","4616d41f5fdeeecc777dc6bd3d7b421a","NCT01431014",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Effect of Perioperative Steroid for the Postoperative Swelling After Orthognathic Surgery","PRIMARY",NA,NA,"Effect of Steroid for the Postoperative Swelling After Orthognathic Surgery",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"1133","461efafc078d7ebf4eccd7e63583789b","NCT02886728",0.043,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 2, 4, 12, 24, 36, and 52","SECONDARY","Filgotinib 200 mg + MTX vs MTX Monotherapy at Week 36","D001168; D001172","Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy",FALSE,832,"logistic_regression",NA,NA,NA,3.73100015532037
"1134","462c561e57f6d278a58e6e59558b7b56","NCT02617888",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Number of Excess Double-strand DNA Break Foci Per Cell in Peripheral Blood Samples Post-imaging","PRIMARY",NA,"D003324; D002637","Effects of Heart Imaging Radiation on DNA Double-Stranded Breaks in Blood Lymphocytes and Hair Follicle Cells",TRUE,44,"linear_regression",NA,NA,NA,1.01513168983373
"1135","465441a85eeafbe83bcc617583281986","NCT02697773",0.0154,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Meeting Outcomes Measures in Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Responder Index","SECONDARY","Week 12: Odds ratio and 95% confidence interval (CI) estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,463,"logistic_regression",NA,NA,NA,1.15043787406259
"1136","46609d7939cfc8f560b9cfb6d53226fc","NCT01650844",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Average Number of Days Without Asthma Symptoms (Symptom Free Days)","PRIMARY",NA,"D001249","School-Based Telemedicine Enhanced Asthma Management",TRUE,395,"linear_regression",NA,NA,NA,2.92582378873432
"1137","466ca6ac67a4b48ead8da85c1f8f51c9","NCT02476032",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Verbal Rating Scale: Mean Reduction in Sensitivity Between Groups","SECONDARY","Within group comparisons: t-tests comparing the mean change to 0 were utilized. P-values less than 0.05 were considered statistically significant. SAS V9.3 (SAS Institute Inc., Cary, NC) was used for analysis. The sample size of 20 participants per group was based on having 90% power to detect a one standard deviation difference between the DO-strip groups and the placebo group means using ANOVA with a 0.05 level of significance.","D003807; D006967","An Evaluation of the Efficacy of Oral-B New Product Sensi-Stop on Dentinal Hypersensitivity",FALSE,60,"t-test",NA,NA,NA,1.17169922891753
"1138","467269d75bbaab925c438bf496fbef7a","NCT00536471",0.037,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Hematocrit","SECONDARY",NA,"D003866; D003863; D003865","A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients",FALSE,263,"anova",2,NA,NA,1.85733356729778
"1139","4681645015a1da44923ae38ffe3439a3","NCT02373813",0.035,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in CDAI at All Measured Timepoints","SECONDARY","Change at Week 24","D001168; D001172","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",FALSE,152,"t-test",NA,NA,NA,1.35523514414799
"1140","4686fdd9bb84f6700772f15ce7a67632","NCT02732145",0.0429,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Distribution of Aceto-Whitening Reaction in Relation to the Structures of the Outer Vulvar Ring","SECONDARY","Parameter: The difference in the incidence of aceto-whitening of Labia Majora versus Perineum in patients with impaired vulvar skin and positive AWR.","D056650; D008010; D018459; D012871; D009450","Diagnostic Accuracy of ""Three Rings Vulvoscopy"" for Detection of Vulvar Dermatosis",FALSE,82,"t-test",NA,NA,NA,1.1956457723947
"1141","46bf40b87395e072e71c4abebba09cf7","NCT02732600",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Number of Unique Veterans Seen (Adjusted for Employment Period and Hours Worked Per Week)","SECONDARY",NA,"D001523","Evaluation of Peer Specialists on VA PACTs",FALSE,899,"t-test",NA,NA,NA,2.00913494561587
"1142","46caa51ffb611f3e118672c78d55099b","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Saturated Fat","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1757,"linear_regression",NA,NA,NA,6.14749892759128
"1143","46cad3821213abfcd89f29b65fe58dae","NCT03962738",0.025,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Health-Related Quality of Life (HRQoL) Total Score as Measured by the 24-Hour Migraine Quality of Life Questionnaire (MQoLQ)","SECONDARY","Migraine Symptoms","D008881","A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine",FALSE,364,"anova",2,NA,NA,1.55820541290217
"1144","46d412ed199579b304dcff0dd51f908f","NCT02312154",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Melanin Index","PRIMARY","The change in each of the biophysical parameters was calculated as the pretreatment value minus the posttreatment value for each visit, and these pre- vs posttreatment changes were used in the statistical analysis to minimize the intraindividual variation between the two cheeks. The Wilcoxon rank-sum test was performed to compare the week-by-week changes in parameters of the right and left cheeks (i.e., treated vs untreated).",NA,"Changing in Skin Physiology After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces",TRUE,48,"mann_whitney",NA,NA,NA,1.05642048349345
"1145","4704028ccdf115367de6d8f6136b1f60","NCT00205777",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Bone Histomorphometric Indices at Month 36: BFRBV","SECONDARY",NA,"D010024","Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women",FALSE,51,"anova",2,NA,NA,1.08637315449684
"1146","4706016fb4db856423202ee00d871a17","NCT01939002",0.0365,"One-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Mean Change From 4-Week Run-In Period at Each Visit for TSQM, Side-Effects Scale Factor: Overall Population","SECONDARY","change at Week 24","D009103; D012598","Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)",FALSE,194,"t-test",NA,NA,NA,1.58155071861765
"1147","470c616c9761e9d560415825d4eef143","NCT01529385",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Ankle Brachial Index","PRIMARY",NA,"D004487","Mild Compression Sock for Control of Lower Extremity Edema in Individuals With Diabetes",FALSE,77,"anova",2,NA,NA,1.31800316623017
"1148","470c9c3f2c6c014c2ed39cc86fbd948d","NCT01539070",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Children´s Consumption of Foods From Baseline to 3 Months by Intervention Assignment","PRIMARY","In intent-to-treat analyses, we used unadjusted and adjusted multivariate regression models, to examine differences from baseline to 3 months between the intervention and usual care groups. For continuous outcomes, we used linear regression models, and for dichotomous outcomes, we used logistic regression models. To account for clustering by practices, we performed generalized linear mixed models. The Estimator (Est) and Confidence Interval 95% (95% CI)are reported.","D009765; D063766","Intervention for the Prevention of Obesity in Preschool",TRUE,306,"linear_regression",NA,NA,NA,2.5788408992482
"1149","47289b00d23d29bc082d3b9810991472","NCT05178979",0.04,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Enacted HIV Stigma Among Clients","SECONDARY",NA,NA,"A Gender Transformative Implementation Strategy With Providers to Improve HIV Outcomes in Uganda",FALSE,108,"linear_regression",NA,NA,NA,1.28614653164923
"1150","473af5703d4c817dfe9a8f392949ed86","NCT02528188",0.048,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 4: \>=90% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,6.32769773257292
"1151","474217b61e61e9b0563b6fadd9e8fb11","NCT01908829",0.014,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With a Mean of at Least 8 Micturitions Per 24 Hours at Baseline and Less Than 8 Micturitions Per 24 Hours Postbaseline","SECONDARY","Week 8 odds ratios, 95% Two sided CIs for Odds ratios and p-values were from a logistic regression model including treatment group, sex, age group (\<65, \>=65 years), 4-week incontinence episode reduction group, geographic region as factors and baseline value as covariate.","D014570; D001745; D053201","A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)",FALSE,1412,"logistic_regression",NA,NA,NA,1.83941516751431
"1152","474cb9b2cb174f159a9952a8bd9ec014","NCT03855189",0.03,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the TNSS At Day 22 (Physician-Evaluated)","SECONDARY","Pairwise treatment comparison based on t-test from an analysis of variance (ANOVA).","D012220; D065631; D006255","Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)",FALSE,229,"anova",2,NA,NA,1.45135438024678
"1153","475a38a6e6effe8f5c73196bfbcee2f9","NCT01945034",0.02,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","SECONDARY","At Rest Day 3(AM): The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms. Upper limit of 95% CI \< 0 for Ibuprofen treatment significantly better than combined Placebo.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,219,"anova",2,NA,NA,1.00094501898898
"1154","47696aa34a12489caab1694c963e2adc","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Sodium","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1778,"linear_regression",NA,NA,NA,6.18404799831431
"1155","477a337d9c4228f65aa8910f72e862f8","NCT03950167",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Gallbladder (GB) Wall Thickness","PRIMARY",NA,"D006939","Gallbladder Functions & Serum Cholecystokinin Levels in Women Diagnosed With Hyperemesis Gravidarum",FALSE,46,"t-test",NA,NA,NA,1.03597838019194
"1156","479992669235db221a5143e4fc802682","NCT02960763",0.017,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Psychological Well-Being","PRIMARY",NA,"D003863; D003866; D003865; D061218","Optimizing Outcomes of Treatment-Resistant Depression in Older Adults",FALSE,408,"anova",2,NA,NA,1.17871814771884
"1157","47beb2e6b985716012016dcd0cc5137f","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in AUC of Glucose","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,109,"anova",2,NA,NA,1.55669642807029
"1158","47cc421858a2f44aef896b8a18f6a436","NCT01945034",0.03,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Sum of Pain Intensity Difference at Rest and on Weight Bearing Over 6 Hours on Day 1 and Over 2 Hours on Day 3","SECONDARY","At Rest over 2 Hours on Day 3: The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms. Upper limit of 95% CI \< 0 for Ibuprofen treatment significantly better than combined Placebo.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,219,"anova",2,NA,NA,1.4199782438289
"1159","47d30a66fca19e06af4253cd5d820473","NCT05556148",0.0481,"One-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in WURSS-21 Total QoL Domains Score","PRIMARY","Change from Baseline at Day 1","D003139","Otrivine: Quality of Life (QoL) Impact in a Real-World Setting",FALSE,102,"t-test",NA,NA,NA,1.45993454334947
"1160","47e0af2737e0d34c9ba86635b0664b5d","NCT03192176",0.0391,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 3 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 11","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.11271527992017
"1161","4801ce85fb3bbde2070110dbe49ee794","NCT03373383",0.045,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"50 % Responder Rate Over the 12 Week Maintenance Period","SECONDARY","PSL dose/placebo calculated using logistic regression with categorical factors for treatment group (each PSL dose group referenced to the placebo group), region (Europe, Non-Europe), Baseline SV2A use (0, 1) and log-transformed Baseline seizure frequency as a continuous covariate.","D004827; D012640; D000069279","Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy",FALSE,161,"logistic_regression",NA,NA,NA,1.72264805519969
"1162","4855ee8037cddbf4f1d3f3a88d708d23","NCT01631214",0.008,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24","SECONDARY",NA,"D010024","Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis",FALSE,3659,"logistic_regression",NA,NA,NA,1.79803889692901
"1163","4861a62e4229a9d9f555611257d7ebe1","NCT00245219",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Physical Health (as Measured With the SF36) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the education condition and the control condition at Time 2. The full regression model included 2 dummy coded variables, 1 contrasting the education and control condition, and 1 contrasting the peer support and control condition. The baseline measure of the outcome variable was included, in order to examine changes in the outcomes over time. This model tested the main effects of the conditions among patients with early stage cancer, late stage patients were excluded.","D001943","Understanding Shared Psychobiological Pathways",FALSE,131,"linear_regression",NA,NA,NA,1.70153588988359
"1164","486526f300f019d306f33176eace4500","NCT01640197",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Number of Participants With Significant Modulation of Health","SECONDARY",NA,NA,"Chronic Resveratrol Supplementation in Healthy Humans",FALSE,53,"anova",2,NA,NA,1.10589694869732
"1165","48684174779e827c8014fbf722ee4f2c","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Heart Rate at Screening/Visit 1, Visit 2, and Visit 3","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"1166","487492e73c761051686f41f06bc56285","NCT00762528",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Prostaglandin E2 (PGE2)","PRIMARY","The null hypothesis states that there is no difference between groups.","D005891","Compare Anti-inflammatory Dentifrices",TRUE,49,"anova",2,NA,NA,1.06649684228356
"1167","4878990c5916b379fc0ea81903c6c5d1","NCT03718832",0.0335498,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Times Eating Dark Green Vegetables in the Past 7 Days","SECONDARY","Unadjusted mean difference, 12 months after trial enrollment.",NA,"Fresh Food Farmacy: A Randomized Controlled Trial",FALSE,333,"t-test",NA,NA,NA,1.91957486258964
"1168","48aaf4b4110cd0766a580d319b667e27","NCT01753856",0.042,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Wall Thickness (W.Th) in the CC, EC and IC of the Iliac Crest","SECONDARY",NA,"D010024","Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis",FALSE,66,"mann_whitney",NA,NA,NA,1.06030073148046
"1169","48acc117d8ebdb204039bba956ae0e3a","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Specific Perceived Healthfulness","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1734,"linear_regression",NA,NA,NA,6.10721803093741
"1170","48b8c0fe8d0a1e9432e1ade3eb0aee5d","NCT02626819",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Weight Change (kg)","PRIMARY",NA,"D009765","Improving Weight Management at the VA",TRUE,43,"mann_whitney",NA,NA,NA,1.00454908915455
"1171","48cc89453c98068effbf0a92b25e5eb0","NCT01197508",0.046,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Response in the Clinical Global Impression-Improvement (CGI-I) Defined as CGI-I Rating of ""Very Much Improved"" or ""Much Improved"" From Randomization (Week 8) to End of Treatment (Week 16)","SECONDARY","Logistic regression model including treatment and pooled center as fixed effects and the randomization Clinical Global Impression Severity (CGI-S) as a covariate.","D003866; D003863; D003865","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.",FALSE,347,"logistic_regression",NA,NA,NA,2.55896358435224
"1172","48fe777d351bc77046c7d7c3f2f65414","NCT01416194",0.01,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Renal Failure","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",TRUE,7777,"linear_regression",NA,NA,NA,3.19773018380892
"1173","4900d1615d20e68236bca2767ea2e365","NCT02539394",0.039,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Patient Reported Swallowing Difficulty Over 1 Year","SECONDARY","The distribution of 4-6 weeks modified Eat-10 is the same across the 2 arms","D007405; D055959; D003680; D013118","Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion",FALSE,109,"mann_whitney",NA,NA,NA,1.26463740624272
"1174","4900dda41c34153eb61bfc513a852c5d","NCT03982368",0.04,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Quality of Life (Impact of Dry Eye on Everyday Life (IDEEL) Questionnaire vs Different Timepoints - Per Protocol Set","SECONDARY","Daily Activity Limitations - change from baseline to week 4","D015352; D007638","A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye",FALSE,151,"anova",2,NA,NA,1.51234908843685
"1175","4903ff1b0f5ac219600c82d10acfd686","NCT00474175",0.031,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Pain Relief Combined With Pain Intensity Difference (PRID) Scores","SECONDARY","10 minutes: P-value was calculated using ANOVA which was adjusted for treatment, site and baseline DPS. Treatment difference (Benzocaine 10% - Placebo) and corresponding 95% C.I. were calculated based on least-squares means from the ANOVA model with treatment, site, and baseline DPS effects.","D014098","Benzocaine Gel Toothache Dose-Response Study",FALSE,348,"anova",2,NA,NA,1.83364392865351
"1176","4907f9e92e9a0e497febec469e82229e","NCT01482091",0.048,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change in Pain Score 20 Minutes After Administration of Study Drug","PRIMARY",NA,"D000755","Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis",FALSE,49,"mann_whitney",NA,NA,NA,1.03129471114006
"1177","4911474a7426895561fcfbc4af528c71","NCT01256944",0.05,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"Homeostasis Model Assessment Insulin Resistance Index (HOMA-IR)","PRIMARY",NA,"D011085; D002318; D024821; D013577","To Study Polycystic Ovary Syndrome in Taiwanese Women",TRUE,290,"anova",2,NA,NA,2.51138465397077
"1178","4923d6773a8fb38f933bf8e5311d6cf3","NCT01182103",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"BDNF Levels of MDD Patients Before and After Treatment and Healthy Controls","SECONDARY",NA,"D003863; D003866; D003865","Epigenetic Regulation of BDNF in Major Depression",TRUE,158,"t-test",NA,NA,NA,1.86399982321523
"1179","493016a7d520e2901602c8b48efe1e3c","NCT00455533",0.0283,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]) to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR/RCB1","SECONDARY","ERCC1 203719_at","D001943","Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer",FALSE,295,"logistic_regression",NA,NA,NA,1.56328687382212
"1180","4945de20d102dc80fcca5815c3e00df9","NCT05457647",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Manifest Refraction","OTHER_PRE_SPECIFIED","Assessment of change of MSER value at 12-months follow-up visit.","D007640","Theranostic Guided Riboflavin/UV-A Corneal Cross-linking",TRUE,47,"mann_whitney",NA,NA,NA,1.04624856756472
"1181","4952a3db906e071aa14f0a69d51f19f0","NCT04634409",0.048,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants Demonstrating Symptom Resolution","SECONDARY",NA,"D000086382","A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness",FALSE,260,"logistic_regression",NA,NA,NA,2.29990327747183
"1182","495535c107606034f874fea14dfa679a","NCT01529385",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Cutaneous Water Content","PRIMARY",NA,"D004487","Mild Compression Sock for Control of Lower Extremity Edema in Individuals With Diabetes",FALSE,77,"anova",2,NA,NA,1.31800316623017
"1183","4959832dbd6669521327ceee5140215d","NCT00105989",0.028,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Mean Cell Volume (MCV) - Continuation Phase","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,384,"t-test",NA,NA,NA,1.76398263234856
"1184","4973b69be5141cb49dbf6687ec763772","NCT01234649",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Waist-to-Hip Ratio (WHR)","SECONDARY","Factorial repeated measures ANOVA","D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",FALSE,72,"anova",2,NA,NA,1.27670232702116
"1185","49a2c8539e56b2ca56484376a25542cf","NCT00244374",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Viral Transmission Risk Behavior Association With Travel","SECONDARY","Adjusted odds with 95% confidence intervals for travel as a risk factor for each behavior.","D006506; D006526; D006509; D006505; D019966; D015819","A Randomized Trial of Vaccine Adherence in Young Injection Drug Users",FALSE,355,"logistic_regression",NA,NA,NA,1.80046610261148
"1186","49af12fd11ce243e04ecf48c0b5f43d1","NCT01010009",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Modulation of Levels of Total Haemoglobin","PRIMARY","Data was analysed by omnibus ANOVA with a priori planned comparisons utilizing the mean squares error term from this ANOVA.",NA,"The Cognitive and Cerebral Blood Flow Effects of Resveratrol",TRUE,44,"anova",2,NA,NA,1.01513168983373
"1187","49b19c2d420986aaddc80ea4936caac1","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Environmental Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1771,"linear_regression",NA,NA,NA,6.17188902328434
"1188","49da6d0c3c2a161c598a06144870b3fa","NCT01236053",0.0161,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,102836,"logistic_regression",NA,NA,NA,17.7168074650813
"1189","4a00e4f05d15111c99c00ec607479ed0","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Specific Perceived Healthfulness","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1755,"linear_regression",NA,NA,NA,6.14400672442735
"1190","4a00fe8e15c0c040bf2bb26517bf957d","NCT01519674",0.022,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Responder for HbA1c, Proportion of Subjects Achieving Pre-defined HbA1c Targets (HbA1c < 7.0%)","SECONDARY",NA,"D003920; D003924","Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin",FALSE,372,"logistic_regression",NA,NA,NA,1.41002185672405
"1191","4a1c0fe5bb6c8ffdd7738a0705a61c4e","NCT00256750",0.0151,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire","SECONDARY","Role-Physical, Month 12","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,411,"anova",2,NA,NA,1.06619760525569
"1192","4a26a97802ed12eb10b4ae5b4c564f13","NCT02900378",0.0445,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Peak Six Minutes of Daytime Physical Activity","SECONDARY","Change from BL at Week 4","D006333","randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure",FALSE,604,"mann_whitney",NA,NA,NA,3.27522029767098
"1193","4a3606daa636cceaf9e73d5b645a3611","NCT02301793",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Proportion of Non Administration of Prescribed VTE Prophylaxis Medication Doses Which Are Documented as Patient Refusal","SECONDARY","The hypothesis comparing the different educational arms was evaluated using an intention-to-treat approach (i.e. all nurses were included regardless of training completion) accounting for clustering in the data and comparing rates of VTE prophylaxis dose non-administration at baseline and during the Post-Education period. Two per-protocol sensitivity analyses were performed. They compared the Baseline vs. Post-Education periods for nurses who received training and nurses who completed training.","D013927; D013923; D054556; D020246","Educating Nurses About Venous Thromboembolism (VTE) Prevention",FALSE,9084,"logistic_regression",NA,NA,NA,13.9658767893081
"1194","4a40051dbf0e35bedf31a2b977294d66","NCT03745651",0.0472,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a - 24-Hour Recall) Score at Week 8","SECONDARY",NA,"D003876; D003872; D004485","TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis",FALSE,323,"logistic_regression",NA,NA,NA,2.52388683569195
"1195","4a41e3dafd6c5dcd43faf9e75093fa45","NCT00422695",0.05,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"Spontaneous Pain Intensity","PRIMARY",NA,"D015658","Pain and Sensory Changes Assessment in HIV+ Patients",TRUE,143,"anova",2,NA,NA,1.77557547026144
"1196","4a4480f1456998205426f484751f1a81","NCT02249143",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Changes in the Measurements of Functional Residual Capacity (FRC) in Randomized Premature Infants","PRIMARY","FRC values over time were modeled using linear mixed effects regression with treatment group vs. time interaction and repeated measures for the randomization, 2 week, and discharge time points. Compound symmetric covariance structures were used to account for the correlation of FRC values within each patient. We compared outcomes between the two treatment groups and included adjustments for gender, twin gestation, and weight at randomization.","D012128; D012127; D001997","Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants",TRUE,44,"linear_regression",NA,NA,NA,1.01513168983373
"1197","4a607d4f20b865e208f0ab219dff978c","NCT01811238",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Pain Intensity of Patient With Spinal Disorder as Measured by NRS.","PRIMARY",NA,"D013122","An Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Spinal Disorders",TRUE,209,"t-test",NA,NA,NA,2.13748052036521
"1198","4a6fe526f2164a4f5b8312fdd056eb99","NCT03726489",0.0393,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Patient-reported Time Spent on Phototherapy Per Treatment","SECONDARY","Analysis for Phototypes I/II","D011565","Light Treatment Effectiveness (LITE) Study",FALSE,432,"linear_regression",NA,NA,NA,2.4972824273677
"1199","4a9413b39f39f75265014115a6a8d9c3","NCT02912650",0.017,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Relief Rating (PRR) Score","OTHER_PRE_SPECIFIED","6 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,347,"anova",2,NA,NA,1.08837256018223
"1200","4aa74024445afd35af8466753cf9e324","NCT04018001",0.0123,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Adherence to Tofacitinib by Medication Possession Ratio (MPR) up to 12 Months From the Index Date","PRIMARY",NA,"D001168; D001172","Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR)",FALSE,1057,"t-test",NA,NA,NA,1.42049788449292
"1201","4ab970e59968bd8f584ac554805cf71b","NCT01319721",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Postoperative Conjunctival Inflammation","SECONDARY",NA,"D011625; D012008","Recurrent Pterygium Surgery Using Mitomycin C With Limbal Conjunctival or Amniotic Membrane",TRUE,87,"mann_whitney",NA,NA,NA,1.39696496123414
"1202","4abc4bf4a2657b22e1794ca17dc41d0d","NCT01639560",0.047,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Point Prevalence Smoking Outcome at 24 Weeks (End of Study)","SECONDARY",NA,NA,"Varenicline for Light Smokers",FALSE,93,"logistic_regression",NA,NA,NA,1.37000893572851
"1203","4ae21792c10ae68b89f112418bb8a63a","NCT04684836",0.01,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Unplanned Hospital Admissions From the ED","PRIMARY","Difference-in-differences model","D008173; D029424; D006333","Comparative Effectiveness of Telemedicine in Primary Care",TRUE,33100,"linear_regression",NA,NA,NA,6.59489724428277
"1204","4af8719d865ab1d1edf8cdcaba08276f","NCT00112151",0.05,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Fat Free Mass (kg)","SECONDARY","As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in fat free mass measured by dual x-ray absorptiometry (DXA) with any T to placebo in subjects assigned to no PRT.",NA,"TEAM: Testosterone Supplementation and Exercise in Elderly Men",TRUE,72,"linear_regression",NA,NA,NA,1.27670232702116
"1205","4b0cbcb5b7d88b6fd04b4b2634c71bff","NCT02044874",0.0219,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"The 7 Day Point Prevalence or Weekly Abstinence at Week 12","SECONDARY",NA,NA,"A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation",FALSE,391,"logistic_regression",NA,NA,NA,1.4393849535998
"1206","4b231131b6dbee01c300cbbd30ebe847","NCT01368042",0.03,"Wilcoxon","OBSERVATIONAL",0,0,0,0,0,"Change From Enrollment to 6 Months Post-enrollment in Creatinine Levels (mg/dL)","SECONDARY",NA,"D007674; D051436; D006961; D006962","Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous",FALSE,254,"wilcoxon",NA,NA,NA,1.52697899497486
"1207","4b3f66107d6cb162e3911fb7b821aa78","NCT03191903",0.0438,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in WOMAC Pain Score at 3 Weeks in the Per-Protocol Population","OTHER_PRE_SPECIFIED",NA,"D010003; D020370","Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide",FALSE,482,"anova",2,NA,NA,2.88943377118134
"1208","4b4a81871b24f98638363874838fe036","NCT00551135",0.0467,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Total Cumulative Dose of Opioids and Tramadol Used During and After Surgery","SECONDARY","Day 6 PS; LS Means from ANOVA model with terms of treatment, pooled center. Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,202,"anova",2,NA,NA,1.98544715732357
"1209","4b59ae349fba69cd9dccab91fad7314a","NCT00270998",0.0492,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"""Much Better"" or ""Very Much Better"" on PGI-I at 12 Months","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",TRUE,299,"logistic_regression",NA,NA,NA,2.51540237553809
"1210","4b618a3e174c816a3b154a994c5e1838","NCT01884545",0.0459,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Stages of Change","SECONDARY","Exercise behavior","D006331; D003327; D003324; D017202; D003924; D011236; D004198","Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease",FALSE,146,"logistic_regression",NA,NA,NA,1.66999588838772
"1211","4b858911081b59db3621d140bf95a7ad","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Ham Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1745,"linear_regression",NA,NA,NA,6.1265158498702
"1212","4b91b4e594dc8eb5c8609920c9563eb9","NCT03646305",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Self-Ratings of Mood (Depression)","SECONDARY","Paired sample t-tests was conducted to measure differences in depressive mood from post-intervention to follow-up. Null hypothesis: there would be no significant differences in depressive mood from post-intervention to follow-up.",NA,"Singing Your Negative Body-Related Thoughts",FALSE,122,"t-test",NA,NA,NA,1.64382327798156
"1213","4b95201142cbb6ec31f5dad1f4adc152","NCT05384041",0.046,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in PHQ-9 From Baseline at Weeks 1, 2, and 4, Stratified by Gender (Per Protocol Analysis)","POST_HOC","Difference (Active-Control) at Week 1","D003866; D003863; D003865","Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults",FALSE,138,"linear_regression",NA,NA,NA,1.62784276031002
"1214","4ba8dc7a92cbe6daeabb9c8ff0c83224","NCT04552041",0.0329,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change in Mean Neuropsychiatric Inventory-Clinician (NPI-С) Score","SECONDARY","This analysis applies to domain ""Anxiety"" ∆ between baseline and 24 weeks row.","D003704; D015140; D001523; D000066553","Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.",FALSE,399,"mann_whitney",NA,NA,NA,2.06410353247437
"1215","4bc64313842b53973d89745922ef1501","NCT00673387",0.0404,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"LS Mean Change in Waist Circumference From Baseline to Week 12 and Week 28 - Evaluable Population","SECONDARY","Change at Week 28 based on a general linear model with factors for treatment group, sex, baseline BMI category, and baseline value as a covariate","D050177; D001835","Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects",FALSE,92,"t-test",NA,NA,NA,1.20108188298373
"1216","4bcbf83f1e81153517896b8e412bbfb4","NCT03301623",0.019,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"CG-CAHPS","PRIMARY","Question: Which communication strategy used during the clinical encounter is more effective in improving how satisfied patients feel over time after communicating with their physician about chronic pain treatment risks and benefits?

Regression model includes a fixed effect for time and an interaction effect between pre/post intervention and intervention arm dummy variables. Analysis is clustered at the PCP level.","D059350","Comparative Effectiveness Trial of Communication Strategies in the Management of Chronic Pain",FALSE,357,"logistic_regression",NA,NA,NA,1.21630226666409
"1217","4bcfae6cc29f2c6b114a5a0c4b3f7915","NCT00501592",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Hepatocellular Function","SECONDARY",NA,"D005234; D003920; D003924","Study of INT-747 in Patients With Diabetes and Presumed NAFLD",FALSE,44,"t-test",NA,NA,NA,1.01513168983373
"1218","4bd7dff433948690c7c6c31faead83dd","NCT03114969",0.042,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants Making at Least One Critical Error at Visit 2 in Primary DPI (Relvar Ellipta With or Without a LAMA DPI) Versus Any Other ICS/LABA DPI With or Without a LAMA DPI","SECONDARY",NA,"D008171; D029424","Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs",FALSE,190,"logistic_regression",NA,NA,NA,1.7626036344792
"1219","4bde8db419c7451531a6ae7c446238cc","NCT01522755",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Sensing Amplitude During and Post Implant of the CapsureFix MRI Lead Model 5086","PRIMARY",NA,"D001919","Predictive Factors of a Successful Implant of the CapsureFix MRI Model 5086",TRUE,409,"t-test",NA,NA,NA,2.97672685958764
"1220","4be4e37ac0aeae3eb30920b261d8237c","NCT02886715",0.0354,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change in Non-inflammatory Lesion Counts","PRIMARY",NA,"D000152","A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris",FALSE,638,"anova",2,NA,NA,2.77249963971067
"1221","4be89e8f8ac92a59a8fd50a1403ef515","NCT01559259",0.024,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Intensity Difference on 11-Point Numerical Scale (PID11)","SECONDARY","0.25 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, baseline numerical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,182,"anova",2,NA,NA,1.07109701754967
"1222","4beead45878816c776f04aedca277fd8","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"White Blood Cell Count at Baseline and After Treatment Completion","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"1223","4bf74114b6116d549aa1da1ee6d4a40e","NCT00286429",0.023,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Glycosylated Hemoglobin ≤ 7.0%.","SECONDARY","The null hypothesis that there is no treatment effect between alogliptin and placebo arms in incidence of HbA1c ≤7.0%. The treatment effect was evaluated as a contrast of each active dose versus placebo was evaluated inferentially with a Wald test at the 0.05 significance level","D003920","Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.",FALSE,258,"logistic_regression",NA,NA,NA,1.22414631969813
"1224","4bf8bbeaa7fbc7704ddeeb5bdcc10677","NCT01236053",0.0218,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,17853,"logistic_regression",NA,NA,NA,9.62411712457498
"1225","4c00b5dbf7cc544a0730b1270dbe4c94","NCT01783041",0.05,"ANOVA","INTERVENTIONAL",0,0,1,1,0,"Time to Regain Birthweight in Infants Who Receive L-carnitine Supplementation Compared to Controls","PRIMARY",NA,"D047928; D065886","Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants",TRUE,136,"anova",2,NA,NA,1.73276958204871
"1226","4c18cb61c9c4184e9447cc19d725caf0","NCT00408876",0.046,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Laboratory Assessment - Bilirubin, Direct","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,217,"t-test",NA,NA,NA,2.0305884470207
"1227","4c25fc57d3e884b3cf5a0fcaace1f089","NCT00810199",0.0497,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in DAS28 Score","SECONDARY","Week 24","D001168; D001172","A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment",FALSE,553,"mann_whitney",NA,NA,NA,3.43970504046116
"1228","4c4554d9815b035f5d8511813f554454","NCT01087905",0.017,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"7-Day Point Prevalence Abstinence From Smoking by Intervention","PRIMARY","Null hypothesis: No difference in abstinence rates for participants receiving NRT Monotherapy (Nicotine Patch Only) versus NRT Combination Therapy (Nicotine Patch plus Nicotine Gum). We hypothesized that Combination NRT would result in statistically significantly higher abstinence rates compared to NRT Monotherapy.

The study was originally powered to detect at least a 6.4% increase in the abstinence rate due to an enhanced intervention (e.g., Combination NRT).",NA,"Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines",FALSE,987,"logistic_regression",NA,NA,NA,1.8258284254506
"1229","4c48db095cd1d55bd418c8a4e6b870b5","NCT03089281",0.029,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Left Ventricular End Systolic Volume (Relative Change)","SECONDARY",NA,"D006333","Strategic Management to Optimize Response To Cardiac Resynchronization Therapy",FALSE,310,"t-test",NA,NA,NA,1.63586078334987
"1230","4c492182e5f083054a6424f1dfd979c0","NCT02276807",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in Depressive Symptoms at 12 Weeks","PRIMARY",NA,"D003863; D003866","Improving Mood in Veterans in Primary Care",TRUE,120,"anova",2,NA,NA,1.63072147479452
"1231","4c4c1a3bebbba00fff3cecfd2e3a7b8c","NCT00588692",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in Peak Oxygen Uptake (VO2) During Maximal Effort Exercise Stress Test According to Ejection Fraction Subgroups","PRIMARY","For 25-49% Ejection Fraction Subgroup","D006333","Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure",TRUE,50,"anova",2,NA,NA,1.07648023860356
"1232","4c665ab54fdcd2e10940ff846c3626e8","NCT01236053",0.0469,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,181.597850877652
"1233","4c73396ef3a7e31781d2e016a4afec8d","NCT00261443",0.033,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Adjusted Mean Change in CGI-BP From Preceding Phase (Mania) Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 28 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,1.87298078626147
"1234","4c89501a96237fbc98a4dd03d46bdd0a","NCT03258645",0.04,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"CHA2DS2-VASc of Patients According to Dabigatran Initiation Time Period","SECONDARY","Multivariate linear regression with the continuous dependent variable of time-to-initiation for dabigatran in days and independent variable of age, Diastolic blood pressure (DBP), CHA2DS2-VASc, HAS-BLED, and History/Predisposition To Bleeding at index date was applied.","D001281","This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke",FALSE,1240,"linear_regression",NA,NA,NA,4.28102212465268
"1235","4c9e94292e922491005e974b07995236","NCT02814565",0.025,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Physician Rated Assessment of Presence of Muscle Spasm on Days 3, 7, and 15 of Treatment","SECONDARY","Day 15. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.","D013035; D001416; D019547; D017116","Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin",FALSE,180,"mann_whitney",NA,NA,NA,1.10350399962337
"1236","4c9fbb0e6ea1c267c1a7cc3234ecfc50","NCT02698371",0.034,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Marginal Discoloration, Graded on a 3-point Scale, Using USPHS Criteria at 24 Month Follow-up Recall","SECONDARY","H0 - Bonding to NCCLs with FBDC by SE and enamel etching mode (FBDC-SE-EE; G2) and MM adhesives by Etch-and-Rinse mode (MM-ER; G3G5) result in similar (no significant differences) Marginal Discoloration performance at 24 month follow-up recall.",NA,"NCCL Direct Composite Restoration Performance With Self-Etch and Multimode Adhesives",FALSE,96,"mann_whitney",NA,NA,NA,1.05996090717406
"1237","4ccabd239142286549dd361caefcaadc","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Health Warning Label","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1770,"linear_regression",NA,NA,NA,6.17015007090058
"1238","4cd7a1c9578166b037aac9dd95ee1469","NCT02688400",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in WOMAC OA Scores","SECONDARY",NA,"D010003; D020370","Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis",FALSE,370,"mann_whitney",NA,NA,NA,2.83265165361863
"1239","4ce0cbccc1b1eb3a2bcf891514a54abb","NCT00305253",0.019,"Logistic regression","INTERVENTIONAL",0,1,1,0,0,"Extreme Adverse Outcomes (EAO) - a Combined Outcome of Maternal Mortality or Severe Morbidity (Cardiac,Respiratory, Renal or Cerebral Dysfunction)","PRIMARY","Relative risks and confidence intervals were computed for the primary outcome, Extreme Adverse Outcomes (EAO) - a combined measure of maternal mortality or severe mobidity.

To estimate the independent effect of the intervention net of the effects of other baseline characteristics, a multiple logistic regression model was used.","D006470; D012769; D020896","Efficacy Study of the Non-Pneumatic Anti-Shock Garment (NASG) in Egypt",FALSE,990,"logistic_regression",NA,NA,NA,2.01551197952684
"1240","4d10679782f640697bda84f3d2df582f","NCT02242201",0.033,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Maximum Postoperative Pain Score","PRIMARY",NA,NA,"Total Hip Arthroplasty (THA) Lumbar Plexus Verses Periarticular",FALSE,105,"mann_whitney",NA,NA,NA,1.07867902017387
"1241","4d141dfe7bfe3c11ba0ea37a0c2b2b27","NCT02440854",0.04,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Patient-rated Total Lung Cancer Symptom Scale (LCSS) Score","SECONDARY","Baseline vs 36-month post-baseline.","D002289","Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings",FALSE,76,"t-test",NA,NA,NA,1.08781774095059
"1242","4d1ef5d6bc471c7b8e36398fa7328ead","NCT01639339",0.0311,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Double-blind Period: Percentage of Participants With Primary Efficacy Renal Response (PERR) at Week 104","PRIMARY",NA,"D009393; D008181","Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis",FALSE,446,"logistic_regression",NA,NA,NA,2.07851251688888
"1243","4d449005fff946fdb924e6db523d1712","NCT00256750",0.0361,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire","SECONDARY","Vitality, Month 36","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,424,"anova",2,NA,NA,2.30218597944823
"1244","4d48aa150cb565603dc3783514b45d96","NCT01066793",0.0184,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for Gamma-GT in log10 (IU/L) at BL. The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Wk 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2b.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,960,"logistic_regression",NA,NA,NA,1.93002241389426
"1245","4d6b1b597809c0ad7dbd0fef1911b291","NCT01070550",0.0258,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for HCV RNA at BL in log10 (IU/mL). The logistic regression analysis for relapse 24 weeks after EOT was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including total cumulative dose of peginterferon and ribavirin), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,227,"logistic_regression",NA,NA,NA,1.26964116624856
"1246","4d6c3691de4054a711aeeeea9f5c4021","NCT01709422",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Procedure Related Time","PRIMARY",NA,"D005705","Efficacy and Safety Profiles of Combination Sedation Propofol With Midazolam and Meperidine.",FALSE,140,"t-test",NA,NA,NA,1.7573575639879
"1247","4d728712a5a275e2df320fa77277b034","NCT00408876",0.034,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in the 11-point Likert Scale, Weekly Mean 24-Hour Night Pain Score","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,165,"t-test",NA,NA,NA,1.37608301338561
"1248","4d7b52fbde87181b4ebad7cbcde0c4fd","NCT02872909",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Pain on VAS Score","PRIMARY","Sample size requirement estimation - Preliminary data showed pain scores of 1.25 with ambulatory PDT (n=12) and 5.26 (SD 2.38) for conventional PDT (n=50). Estimated that for 85% power to detect as significant at 5% level a difference in mean pain score in one group of 2cm compared with 4 cm in the other group, assuming two-sided testing, a minimum of 45 subjects needed. We aimed for 50 subjects, with an allocation ratio of 2 (twice as many randomised to ambulatory PDT as conventional PDT)","D012878","Randomized Comparison of Low and Conventional Irradiance PDT for Skin Cancer",TRUE,50,"t-test",NA,NA,NA,1.07648023860356
"1249","4d876e5cf2ade4092cea6ca5b1ebf33a","NCT02110758",0.013,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Change in Patient Experience From Baseline to Follow up","PRIMARY","To estimate exposure to the intervention on the Exchanging Information composite score, we used a difference-in-differences model with fixed effects for practices. The dependent variable was the composite score. The intervention effects were represented by the coefficient estimates for survey time period (pre or post) interacted with status (pilot or comparison).","D009369","Evaluating the Impact of Patient-Centered Oncology Care",FALSE,866,"logistic_regression",NA,NA,NA,1.3511408977339
"1250","4d8ebc01be576d9542046b17a1acf594","NCT00144339",0.0365,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 48","SECONDARY",NA,"D008171; D029424","Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients",FALSE,4890,"anova",2,NA,NA,7.85480621512073
"1251","4dacc28591ec047941396324ba1e86ee","NCT01197508",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Response in the Clinical Global Impression-Improvement (CGI-I) Defined as CGI-I Rating of ""Very Much Improved"" or ""Much Improved"" From Randomization (Week 8) to End of Treatment (Week 16)","SECONDARY","Logistic regression model including treatment and pooled center as fixed effects and the randomization Clinical Global Impression Severity (CGI-S) as a covariate.","D003866; D003863; D003865","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.",FALSE,344,"logistic_regression",NA,NA,NA,2.26485147068745
"1252","4dbccf0182f5526a29c65083b14777f4","NCT01066793",0.0128,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for Platelets x 10\*\*9/L at BL (\< 140 vs \>=180). The logistic regression analysis for mSVR was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,960,"logistic_regression",NA,NA,NA,1.40273226233087
"1253","4dcd18c8d0f43f1646142b5dbcc10a57","NCT00785928",0.042,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 Response up to 24 Weeks","PRIMARY",NA,"D001168; D001172","A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy",FALSE,156,"linear_regression",NA,NA,NA,1.6009220820398
"1254","4dd5e21157aaf76d3ad58640d4063079","NCT00935584",0.05,"Wilcoxon","INTERVENTIONAL",0,0,0,0,0,"Change in Total Number of EMR Mouse Click Per Visit (Median/Range)","PRIMARY","The null hypothesis is that there is no significant change in outcome from pre to post visit.",NA,"Patient Centered Evaluation of Computerized Patient Records System",TRUE,126,"wilcoxon",NA,NA,NA,1.66971913113983
"1255","4df1ba106d83e8733f840bb367f5e429","NCT00701727",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Triglycerides (TG)","SECONDARY",NA,"D006937","Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study",FALSE,52,"t-test",NA,NA,NA,1.09617796589869
"1256","4dfc35589ec65266c0bbff481e78a828","NCT03789474",0.048,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Femoral Artery Velocity at T2","PRIMARY",NA,NA,"Does Fluid Requirement Decrease With the Use of Pneumatic Compression Device on Lower Limbs",FALSE,60,"t-test",NA,NA,NA,1.13287941501804
"1257","4e1f30c70c35a904f3f2e7e7349f1f33","NCT03975790",0.0307,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Total All Cause Monthly Health Care Cost","SECONDARY","4 month after index date","D001168; D001172","Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX",FALSE,431,"t-test",NA,NA,NA,2.02109845940552
"1258","4e217f37924c58f89b3b6b16470e226c","NCT01626118",0.049,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"TOTPAR-8. Total Pain Relief (TOTPAR) Over 0 to 8 Hours","SECONDARY",NA,"D010149","Study of Indomethacin Capsules to Treat Pain Following Bunionectomy",FALSE,188,"t-test",NA,NA,NA,1.99541328988995
"1259","4e2a66f6cb4772cd4c5d1007089a0c4b","NCT01070550",0.0074,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for age per 10 years. The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including total cumulative dose of peginterferon and ribavirin), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,2981,"logistic_regression",NA,NA,NA,1.51376848627711
"1260","4e2dea8f96f53e5f587275733d06ff55","NCT00261443",0.019,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Median Baseline, Change From Baseline, and Highest Value of Change in Creatine Kinase, Phase 3 Safety Sample","SECONDARY","Treatment Comparison Change from baseline in Creatine Kinase at Week 52 (LOCF)","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"mann_whitney",NA,NA,NA,1.16314649710354
"1261","4e3eb5a758c6f0e95f0418fe94a304ca","NCT03192176",0.0381,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 2","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.10727357095963
"1262","4e4f8627a4902e9d3134567182460564","NCT02163538",0.0281,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Time From Port Placement to Bilateral Uterine Artery Ligation and Hemostatsis.","SECONDARY",NA,NA,"Articulating Enseal Versus Ligasure Energy Devices",FALSE,140,"mann_whitney",NA,NA,NA,1.08013011069307
"1263","4e69af9ebde6fd69aad5d16aa5a7b060","NCT03958071",0.0048,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Baseline Patient Characteristics: Age","PRIMARY",NA,"D011658; D054990; D005355","A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking",FALSE,12917,"t-test",NA,NA,NA,2.13147003243213
"1264","4e6f72b311fa39e1b0cb50091f7ee3d0","NCT03428100",0.045,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Gram Quantity of Low and Moderate Potency Background Topical Corticosteroid (TCS) Used (Tube Weights)","SECONDARY",NA,"D003876; D003872; D004485","A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable",FALSE,185,"anova",2,NA,NA,1.84359845691733
"1265","4e7a5e8f8913018058069f0af7ed8512","NCT02576587",0.03,"Conditional logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants With Paroxymal Atrial Fibrillation (PAF)","PRIMARY",NA,"D001049; D012891; D001281","Influence of Sleep Apnea on Risk of Atrial Fibrillation",FALSE,150,"logistic_regression",NA,NA,NA,1.18100900777326
"1266","4eca1e96709707615733e176093d8d54","NCT00442546",0.0355,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the OR-SDS - Overall Composite Score","SECONDARY","Week 6/ET","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,168,"anova",2,NA,NA,1.44002174415579
"1267","4ed3756c8f51d2f9e3160737ff3de131","NCT02649634",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Self-efficacy Related to Eating Patterns After the Second Motivational Interviewing or Attention Control Interview, Week 12","SECONDARY","Self-efficacy was analyzed via an independent sample t-test comparing the groups on mean global self efficacy rating on the WEL.","D009765; D050177; D015431","Does Motivational Interviewing Improve Behavioral Weight Loss Outcomes for Obesity?",FALSE,129,"t-test",NA,NA,NA,1.68888097915129
"1268","4ef2b8ef10d6b7c41ab368443651c83f","NCT03762135",0.044,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Calories Purchased From Restaurants","PRIMARY",NA,"D050177","Location Initiated Individualized Texts for Adolescent Health (LIITAH)",FALSE,78,"linear_regression",NA,NA,NA,1.19253001716793
"1269","4ef3e97472123ced6707c0423ce5338b","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Urinary Daidzein","SECONDARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",FALSE,96,"anova",2,NA,NA,1.46440978390488
"1270","4ef5a7a0a1e8a0c1a77e806b4b67b5f8","NCT02912650",0.024,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Time-weighted Sum of Pain Intensity Difference Scores on 4-Point Categorical Scale (SPID4) From 0 to 2 Hours, 0 to 6 Hours, 0 to 8 Hours, 0 to 12 Hours and 6 to 8 Hours Post-dose","OTHER_PRE_SPECIFIED","0-12 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,347,"anova",2,NA,NA,1.46915461823916
"1271","4f0927ccbea083a161b9191584a6adca","NCT01070550",0.0316,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for age per 10 years. The logistic regression analysis for relapse 24 weeks after EOT was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including total cumulative dose of peginterferon and ribavirin), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,227,"logistic_regression",NA,NA,NA,1.51076744577113
"1272","4f119aa3ee57545433224952c6b4e3ab","NCT00651820",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Differences in Scar Viscoelasticity Between Wounds Treated With Collagenase Santyl and Its Vehicle","SECONDARY","Stiffness: Paired t-test and Wilcoxon signed rank test were used for testing any significant differences (Sig. diff.) between the two treatments","D002921","Effect of Collagenase on Healing and Scarring",TRUE,56,"t-test",NA,NA,NA,1.13456029943022
"1273","4f13ab80c913a3760d85138bdb3bc407","NCT03192176",0.0352,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 8","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.0358658039854
"1274","4f30f84b7f957367f8e453067cddb791","NCT00514683",0.0317,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Absolute Change From Baseline in SpO2 at Rest by Categories","SECONDARY",NA,"D011658; D054990; D005355","Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis",FALSE,165,"logistic_regression",NA,NA,NA,1.29645355331542
"1275","4f327259460fa1a36deb83b4b6e17ba4","NCT01190254",0.048,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Total PANSS 30% Responders","SECONDARY",NA,"D012559; D012562; D012563","Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)",FALSE,204,"logistic_regression",NA,NA,NA,2.04142959709699
"1276","4f51f03b047210121f008b6b9c7b81e9","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Cuff DBP","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"1277","4f7063a78d99ec09de5ef75a2549b413","NCT03646305",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Self-ratings of Body Image Distress (Body Image State Scale)","SECONDARY","A paired sample t-test was conducted to measure the difference in state body image satisfaction from baseline to post intervention. Null hypothesis: there would be no significant differences in state body image satisfaction from baseline to post intervention.",NA,"Singing Your Negative Body-Related Thoughts",TRUE,122,"t-test",NA,NA,NA,1.64382327798156
"1278","4f8e40aa2b44ee7b5420d57c746db375","NCT02182440",0.03,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Patients Who Meet at Least One of the MAKE 90 Criteria","OTHER_PRE_SPECIFIED",NA,"D058186","A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI",FALSE,227,"logistic_regression",NA,NA,NA,1.44513360241605
"1279","4fa0210e0a466d8d0a4c0e28549b8e28","NCT03192176",0.04,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 4 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 9","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.13415394860463
"1280","4fb876f7956aa21387424605673a6d38","NCT04714320",0.045,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit","SECONDARY","Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 64","D006973","A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure",FALSE,90,"logistic_regression",NA,NA,NA,1.30071076151831
"1281","4fb8d5207d9b52977a83fcb5881daa46","NCT01628718",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Clinical Status of Participants as Measured by the Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV)","PRIMARY","Null hypothesis: AD is inferior to CPT Alternative hypothesis: AD is non-inferior to CPT-C","D013313","Adaptive Disclosure: A Combat-Specific PTSD Treatment",FALSE,122,"linear_regression",NA,NA,NA,1.64382327798156
"1282","4fe6d816a6a50d92fdafdadfde5416b4","NCT02528253",0.0389,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 56, \>=70%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1010,"logistic_regression",NA,NA,NA,3.77480859681275
"1283","4fe8a91497ec2788e72f6413fa7b37f4","NCT03458702",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Heart Rate Assessed at Baseline, During Condition, Post-Condition and Post-Exposure","PRIMARY",NA,"D001008","The Effects of Emotional Exposure on State Anxiety",FALSE,80,"anova",2,NA,NA,1.34217713699512
"1284","4ff27375cf0b1a029b5e5e0fead1dde1","NCT03039621",0.026,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Time to Alleviation of All ARVI Symptoms.","PRIMARY",NA,"D007239; D003141; D014777","Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children",FALSE,282,"mann_whitney",NA,NA,NA,1.42152662478381
"1285","4ff54783e70e1b98e23479a33bf208be","NCT01479621",0.0434,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline In Weekly Average Of Daily Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period","SECONDARY","A linear in log-dose trend contrast evaluated the time-averaged dose-response trend, where the logarithm of dose was defined as log(dose+1) to accommodate the case of a zero dose (placebo).","D001249","A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids",FALSE,473,"linear_regression",NA,NA,NA,2.84051046849432
"1286","4ffabed91b3fe41ff5d8d3bf915fde1f","NCT01087541",0.01,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Glycosylated Haemoglobin A1c at 6 Months","PRIMARY",NA,"D003920","SEGUDIAB Study: Evaluation of Safety in the Diabetic Patients",TRUE,6830,"t-test",NA,NA,NA,2.99689691879371
"1287","4ffdd2a39c714ff7a1901fb0462686a1","NCT01805089",0.05,"Mann-Whitney","INTERVENTIONAL",1,0,0,0,0,"Absolute Plasma Estradiol Levels After 4 Month Course of Melatonin or Placebo","PRIMARY",NA,"D001943","Melatonin Versus Placebo in Breast Cancer",TRUE,86,"mann_whitney",NA,NA,NA,1.38926982128357
"1288","50046bf1387cf1a185a359ef264cb6ca","NCT03687762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in Non-Judgment (i.e., Cognitive Process Mechanism; Macro-level)","OTHER_PRE_SPECIFIED",NA,"D059350","Back on Track to Healthy Living Study",FALSE,302,"anova",3,NA,NA,1.03237942189705
"1289","5004b27cc4b73572a47dec917e9a0395","NCT00279201",0.009,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"INITIATION: Rate of Self-reported Hypoglycemic Episodes","SECONDARY",NA,"D003920; D003924","The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)",FALSE,2050,"anova",2,NA,NA,1.49637904803928
"1290","500bf0832216f70a3fc4d8403316975e","NCT00719862",0.025,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in 12-hour Reflective SSCS for the Entire 14-day Study Period Compared to Placebo (Am and PM Combined)","SECONDARY","Change in baseline","D012220; D065631; D006255","A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies",FALSE,480,"anova",2,NA,NA,1.78636561486085
"1291","5028d2e58367605c0dc9eadb88d1eef9","NCT05384041",0.044,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in QIDS From Baseline at Weeks 1, 2, and 4, Stratified by Gender (Per Protocol Analysis)","POST_HOC","Difference (Active-Control) at Week 1","D003866; D003863; D003865","Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults",FALSE,138,"linear_regression",NA,NA,NA,1.56838061358595
"1292","509bccaf46cd44db2b96a581b5f21dda","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Environmental Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1752,"linear_regression",NA,NA,NA,6.13876469477842
"1293","50b5582fb534c41df3631a5465e87d10","NCT03883828",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,1,0,"Median Change in Quality of Life Scoring Rated by the Skindex-16 Dermatological Survey","PRIMARY",NA,"D003872; D011855","Bacterial Decolonization to Prevent Radiation Dermatitis",FALSE,75,"mann_whitney",NA,NA,NA,1.301639172202
"1294","50de68c488dfd27b547958f7d4789b57","NCT04697264",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Expression of These Biomarkers and Their Receptors in Endometrial Cancer Tissue and Adipose Tissue","SECONDARY","Expression of leptin and their receptors were studied in endometrial cancer tissue and fat tissue using qRT-PCR.","D016889; D009765","Adipocytokines in Endometrial Cancer",TRUE,78,"t-test",NA,NA,NA,1.32610986002301
"1295","50e08a486277e6055b0c048385c033c4","NCT01005719",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"The Difference in the Onset of Action Based on Median pH Values Between the Two Active Treatments Compared to No Treatment on Day 1 and Day 7","SECONDARY",NA,NA,"Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)",TRUE,118,"mann_whitney",NA,NA,NA,1.61751378500378
"1296","50f7dbf22fe88e7921514e5abb1f30a7","NCT03855189",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the TNSS At Day 15 (Physician-Evaluated)","SECONDARY","Pairwise treatment comparison based on t-test from an analysis of variance (ANOVA).","D012220; D065631; D006255","Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)",FALSE,227,"anova",2,NA,NA,2.22600157730289
"1297","510d75938b2e549c8119a4bdedc5a18b","NCT02672176",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Perceived Stress Measured by PSS","SECONDARY",NA,"D003920","Improving Health in Diabetes Project",FALSE,280,"mann_whitney",NA,NA,NA,2.4682888545649
"1298","51318fef7dafbc35ea30e8de6c5ba3d7","NCT01705288",0.05,"Mann-Whitney","INTERVENTIONAL",1,0,0,0,0,"Pain Medications Used","SECONDARY","Intention to Treat Analysis","D016889","Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study",FALSE,99,"mann_whitney",NA,NA,NA,1.48621381452241
"1299","5138d2883b768e49396d5bf0d53c0577","NCT03514134",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Competitive Employment","SECONDARY",NA,"D000067877","Modifying (Phase I) and Evaluating (Phase II) Virtual Reality Job Interview Training for Youth in Transition",TRUE,71,"logistic_regression",NA,NA,NA,1.26828177971868
"1300","5146226bf4de8ef9407908e4757ed321","NCT05170841",0.027,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Total Pain Relief (TOTPAR) at 8h After the First Dose - Single Dose Phase - Dexketoprofen/Tramadol vs Placebo","SECONDARY",NA,"D001416; D017116","Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain",FALSE,204,"t-test",NA,NA,NA,1.25312667561346
"1301","514e6c8dcc17ba2c5ac6239f0168019c","NCT01529385",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Foot Edema","PRIMARY",NA,"D004487","Mild Compression Sock for Control of Lower Extremity Edema in Individuals With Diabetes",FALSE,77,"anova",2,NA,NA,1.31800316623017
"1302","5165bb67f6e6a70c16a6598c047d0e94","NCT02912650",0.04,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Relief Rating (PRR) Score","OTHER_PRE_SPECIFIED","0.25 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,340,"anova",2,NA,NA,2.25180763341304
"1303","51666855ee92b56cbcf0e2a85739d6cb","NCT01532986",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Health Utilities Index (HUI3)","SECONDARY",NA,"D010300","Randomized Trial to Test the ""Coordinated Care for Health Promotion and Activities in Parkinson's Disease"" Intervention in the VA",FALSE,328,"t-test",NA,NA,NA,2.66881159065383
"1304","5177d8928eafa8c721fdb63742bc45b5","NCT03192176",0.0419,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 2 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 2","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.19915777186387
"1305","517e164f809aa029b25531dc3708c9f2","NCT05182840",0.0419,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Multiple Imputation","SECONDARY","The odds ratio, 95% confidence interval, and p-value were calculated based on logistic regression of binary outcome adjusting for treatment, and stratification factors as covariates.

Randomisation stratification was used, which is based on estimated glomerular filtration rate (eGFR) and urine albumin creatinine ratio (UACR) levels at screening.","D007674; D051436","A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease",FALSE,134,"logistic_regression",NA,NA,NA,1.48400614252743
"1306","5182f2ae454880409c7e07c1b2b87bcf","NCT00665366",0.031,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Total Score on the Longitudinal Interval Follow-up Evaluation-Rating Impaired Functioning Tool (LIFE-RIFT)(OC Data Set and Week 12 LOCF Data Set)","SECONDARY",NA,"D000087122; D001714","Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder",FALSE,362,"anova",2,NA,NA,1.86968043091473
"1307","518f1ef58c121c6938c1c68bc4f6f576","NCT02007369",0.033,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Self Reported Relapse Rate at 2 Months","PRIMARY",NA,"D012008","Relapse Prevention Through Social Networking Groups",FALSE,96,"logistic_regression",NA,NA,NA,1.03350966249045
"1308","51a609305ed6a91a5a3bfd00ed1a2719","NCT00567398",0.029,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline of Nutritional Status Determined by Albumin and Total Protein (Labs) at Month 3 and 6","SECONDARY","Estimate of Least Square Means Comparing Treatment Groups for Albumin-Month 6",NA,"IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients",FALSE,251,"anova",2,NA,NA,1.47464458060979
"1309","51ffe15fd7007a05fc0762ea5bb67ad5","NCT02539394",0.03,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Patient Reported Swallowing Difficulty Over 1 Year","SECONDARY","The distribution of 4-6 weeks Eat-10 is the same across the 2 arms","D007405; D055959; D003680; D013118","Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion",FALSE,109,"mann_whitney",NA,NA,NA,1.01271017194322
"1310","5213cd1b9c1ce7165d5d14cd0fc0fdf5","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Ambulatory Brachial Double Product","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"1311","52380b6714c6e4448d1589e53224ba68","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Ham Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1740,"linear_regression",NA,NA,NA,6.11775166016043
"1312","5261ee126d12fd524f40881dc6445d88","NCT05970861",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Gut Microbiome","PRIMARY","Null hypothesis: there is no statistical significance between the mean percentages of microbiota units of the main and control groups after the mare's milk administration.

Alternate hypothesis: statistical significance exists between the mean percentages of microbiota units of the main and control groups after the mare's milk administration.","D000086382","Effect of Natural Food on Gut Microbiome and Phospholipid Spectrum of Immune Cells in COVID-19 Patients",TRUE,60,"t-test",NA,NA,NA,1.17169922891753
"1313","52623cb0bb9309122b1bf6fa479b82b8","NCT04560998",0.038,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Follow-up Change in Maximum Walking Distance on a Constant Load Treadmill Test","SECONDARY",NA,"D058729; D016491; D003920; D003924","A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes",FALSE,662,"mann_whitney",NA,NA,NA,2.99928288232653
"1314","5274ee5ee39bba412986753ea1c49336","NCT00911768",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Visual Analogue Scale of Subjective Dry Mouth","PRIMARY",NA,"D014987","Effect of Korean Red Ginseng (KRG) on Dry Mouth",TRUE,90,"t-test",NA,NA,NA,1.41980120127578
"1315","52872fb4b22fc7cc2d69d98905b28fbf","NCT04242498",0.028,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Skin Pain Response at Week 16","SECONDARY",NA,"D017497; D016575","A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa",FALSE,157,"logistic_regression",NA,NA,NA,1.13821950424382
"1316","52958bc0553b3110dab51b69a0b9feaa","NCT05512949",0.045,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Vaccinia Virus Specific Plaque Reduction Neutralization Test (PRNT) Geometric Mean Titer (GMT) at Day 43","PRIMARY","The selection of the noninferiority (NI) margin was based on the pivotal Phase 3 trial by Pittman et al., in 2019 comparing one dose of ACAM2000 and the now licensed 2-dose standard MVA-BN regimen, which provided an estimated relative (peak) immune response of approximately 2-times higher for MVA-BN. An NI margin of 0.5 corresponds to an immune response of the lower-dose MVA-BN at least as high as what would be expected for ACAM2000.","D045908","Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine",FALSE,150,"t-test",NA,NA,NA,1.66428126331146
"1317","529a93ab41a68c7613905f78e1679a60","NCT00286754",0.047,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Systolic Blood Pressure","PRIMARY",NA,"D006973","A Behavioral Intervention To Improve Hypertension Control In Veterans",FALSE,329,"mann_whitney",NA,NA,NA,2.53788398251113
"1318","52ac44b7b0b517f997645824f2adb22a","NCT00922194",0.05,"Wilcoxon","INTERVENTIONAL",0,0,0,0,0,"Change in Glycosylated Haemoglobin (A1C) From Baseline at 12 Months or More","PRIMARY","Analysis of difference between 12 months and baseline values","D003920; D003924; D050177","Metformin in Overweight Type 2 Diabetes Mellitus",TRUE,102,"wilcoxon",NA,NA,NA,1.50770356720122
"1319","52b1149be7eb7da65876fa8a74b14c6a","NCT00453999",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change in Amount of Influenza Virus in Nose and Throat (Influenza A and B Combined)","SECONDARY","Change from Baseline at 96 hours","D007251","Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza",FALSE,112,"mann_whitney",NA,NA,NA,1.57722881888439
"1320","52ca00da8d4f515c2c2ab65b4dcb42d7","NCT01236053",0.0241,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,188924,"logistic_regression",NA,NA,NA,34.1530807095115
"1321","52d607750481e8d0dad84b2918cf20a1","NCT01911689",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"The Difference of T2* Value Between the Edematous AP and Necrotizing AP","SECONDARY","The independent T test was used to determine the differences for the T2\* value between the edematous AP and necrotizing AP","D010195","Magnetic Resonance Imaging Study of Acute Pancreatitis",FALSE,117,"t-test",NA,NA,NA,1.61086942334102
"1322","52d9a8846526b6d524d188bb2a10b3d1","NCT02528188",0.006,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Meeting Outcome Measures in Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Responder Index at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 8","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,1.02602381662469
"1323","52fb3ad4e8a61d4970e7d66ba008660d","NCT00771264",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"The Global Response Assessment (GRA) for Overall Bladder Symptoms to Compare the Proportion of Subjects Reporting ""Moderately"" or ""Markedly Improved"" Responses on the GRA After 12 Interventions of Randomized Therapy, in an Intent to Treat Analysis.","PRIMARY","Mean values were analyzed for significant change using a 2-sided paired t test and proportions were analyzed using chi-square methodology. Median values were analyzed using a Wilcoxon signed rank test with p\<0.05 considered statistically significant. A sample size estimate of 214 subjects, 107 per arm, was calculated using a 2-sided Fisher's exact binomial test based on an estimated 60% responder rate in the PTNS group and a 40% in the sham group with a 5% significance level and 80% power.","D053201","Study of Urgent PC Versus Sham Effectiveness in Treatment of Overactive Bladder Symptoms",FALSE,220,"t-test",NA,NA,NA,2.19200127568343
"1324","52fd3ae4dc496e3a2654135f085b138e","NCT00942890",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Pain Severity","SECONDARY",NA,"D000673","Strength, Pain and Function in Operation Iraqi Freedom/Operation Enduring Freedom Amputees: A Nurse-Managed Program",TRUE,44,"linear_regression",NA,NA,NA,1.01513168983373
"1325","53005c32a6457824eefac7a8804c2e3b","NCT00510458",0.0394,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in SF-12 Health Survey Score (Physical and Mental) From Pre-operative to Post-operative Intervals.","SECONDARY",NA,NA,"LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert Study",FALSE,69,"t-test",NA,NA,NA,1.0263768336017
"1326","530b7222f56dfb00f2a51784f68e448c","NCT02967510",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline to Week 3 in the Severity of Friability","SECONDARY",NA,"D001284","Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy",FALSE,136,"mann_whitney",NA,NA,NA,1.43748071441378
"1327","53140293cfddaa9861b1bd41bb7d656b","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in Fasting Plasma Glucose","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,111,"anova",2,NA,NA,1.5704144397227
"1328","533537f455444d68db40ecbc35c20609","NCT02301793",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Non Administration of Prescribed VTE Prophylaxis Medication Doses","PRIMARY","The hypothesis comparing the different educational arms was evaluated using an intention-to-treat approach (i.e. all nurses were included regardless of training completion) accounting for clustering in the data and comparing rates of VTE prophylaxis dose non-administration at baseline and during the Post-Education period. Two per-protocol sensitivity analyses were performed. They compared the Baseline vs. Post-Education periods for nurses who received training and nurses who completed training.","D013927; D013923; D054556; D020246","Educating Nurses About Venous Thromboembolism (VTE) Prevention",FALSE,9084,"logistic_regression",NA,NA,NA,13.9658767893081
"1329","533ead8c3d40cf06ed4ba055f6775dd0","NCT01138124",0.0053,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D002292; D007680; D010386; D010195; D050500; D012148","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",FALSE,30026,"logistic_regression",NA,NA,NA,3.5536613586909
"1330","535592eb0ee108237d4cdb65dba2252c","NCT02697422",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Systolic Blood Pressure (SBP)","PRIMARY",NA,"D002318; D006949","Veteran Peer Coaches Optimizing and Advancing Cardiac Health",FALSE,264,"linear_regression",NA,NA,NA,2.39772562409599
"1331","535680b1d55a5c4e278832b14cf636ca","NCT01066793",0.0168,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for Gamma-GT in log10 (IU/L) at BL. The logistic regression analysis for mSVR was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,960,"logistic_regression",NA,NA,NA,1.78223899819391
"1332","536012494cec8c22e959070b77c8060d","NCT02509312",0.048,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change in Pain Score Post-Cesarean Delivery","SECONDARY",NA,"D006473; D020141; D001778; D006470; D019106","Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery",FALSE,58,"mann_whitney",NA,NA,NA,1.11509023500646
"1333","5368a0079af421f0442233166ff54e68","NCT01539070",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Children´s Consumption of Foods From Baseline to 3 Months by Intervention Assignment","PRIMARY","In intent-to-treat analyses, we used unadjusted and adjusted multivariate regression models, to examine differences from baseline to 3 months between the intervention and usual care groups. For continuous outcomes, we used linear regression models, and for dichotomous outcomes, we used logistic regression models. To account for clustering by practices, we performed generalized linear mixed models. The Estimator (Est) and Confidence Interval 95% (95% CI)are reported.","D009765; D063766","Intervention for the Prevention of Obesity in Preschool",TRUE,306,"linear_regression",NA,NA,NA,2.5788408992482
"1334","536ba957e0e273814143329378e6987b","NCT00899392",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Subject (Parental) Satisfaction as Measured by Modified Group Health Association of America-9 Survey (mGHAA-9)","SECONDARY","Mann Whitney Test-non parametric","D001008","Improving Informed Consent in Pediatric Endoscopy",FALSE,130,"mann_whitney",NA,NA,NA,1.69522022135929
"1335","5381235e3aca06a7cf29fbd6063fb6fb","NCT00355914",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Average Numeric Rating Scale","PRIMARY","compared baseline, 3, 6, 12, 18, and 24 months between groups","D017116","Effectiveness of Lumbar Facet Joint Nerve Blocks",FALSE,120,"t-test",NA,NA,NA,1.63072147479452
"1336","53994630c7bdd65f4ce5c1257a3bbd3c","NCT02444988",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Major Adverse Kidney Event Within 30 Days","PRIMARY",NA,"D058186; D016638","Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit",TRUE,5381,"logistic_regression",NA,NA,NA,10.750392773245
"1337","539fd02256fa785dc61112b6d1429e9d","NCT01236053",0.0323,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Breast Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,188924,"logistic_regression",NA,NA,NA,43.9613421139209
"1338","53b668c6a7705d82e1408bbf9db4f5f3","NCT01070550",0.0204,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for age per 10 years. The logistic regression analysis for mSVR was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,275,"logistic_regression",NA,NA,NA,1.13825260932121
"1339","53f9185a67a7105da3dadc3f170c4ea4","NCT05507567",0.0382,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Viral Shedding Over Time","SECONDARY",NA,"D007251; D014777","Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model",FALSE,99,"mann_whitney",NA,NA,NA,1.18674005982236
"1340","5409d3f2d441af67fa1fbf26e9aa3918","NCT00927368",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Opioid Consumption","PRIMARY","The primary analysis for opioid was a linear regression model comparing ultrasound alone to stimulating needle on the log of cumulative opioid consumption score for a patient in the first 48 hours.",NA,"Comparison of 3 Techniques for Ultrasound-guided Femoral Nerve Catheter Insertion",FALSE,299,"t-test",NA,NA,NA,1.16570326036477
"1341","54109afe277e9b5a90dca5830ef76a31","NCT03722446",0.0204,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Time to Thread Epidural Catheter","SECONDARY",NA,"D048949","Epidural Catheter Thread Between Two Different Vendors",FALSE,240,"t-test",NA,NA,NA,1.06487136665015
"1342","54176f97db2493b82f438cedf2837d06","NCT01070550",0.0189,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for Cumulative PEG-IFN alfa-2a dose per 1000 ug, first 12 weeks. The logistic regression analysis for relapse 24 Weeks after EOT was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,1751,"logistic_regression",NA,NA,NA,2.66491592576988
"1343","542e11b7b5c4e939cebcd2c48a9286b7","NCT01517373",0.0335,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Body Weight at Week 2, 4, 6, 8, 12 and 14","SECONDARY","Week 12: Treatment difference and 80% CI were based on LS mean. MMRM analysis was performed with treatment, duration of T2DM, time and treatment-by-time interaction as fixed effects, baseline as the covariate, time was repeated for participant.","D003920; D003924","Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin",FALSE,116,"t-test",NA,NA,NA,1.14597615081876
"1344","5432526b7cbc17a0d1e95d820a099218","NCT01535014",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Average Body Weight Change After 24 Weeks of Treatment","PRIMARY",NA,NA,"Clinical Trial of Safety and Efficacy of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients",FALSE,257,"t-test",NA,NA,NA,1.53580391362835
"1345","54597b48bf56620ddf4330858b65a69a","NCT01138124",0.0031,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin","PRIMARY",NA,"D010190; D002292; D007680; D010386; D010195; D050500; D012148","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",FALSE,19046,"logistic_regression",NA,NA,NA,1.73969022761229
"1346","5463ede4fbbd08a5191f7224d1b86600","NCT04843566",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Percentage of Patient Reporting Biopsy Pain and Discomfort","SECONDARY","Immediately following biopsy - Discomfort","D007239; D003141","PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy",FALSE,560,"t-test",NA,NA,NA,3.4787354644444
"1347","546d9038c5dcd57c5bdbfe3a4b8aed3a","NCT00755807",0.034,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Platelet Count at Week 6 (Acute Phase)","OTHER_PRE_SPECIFIED",NA,"D009103; D012598","Duloxetine for Multiple Sclerosis Pain",FALSE,219,"anova",2,NA,NA,1.58003304486931
"1348","547a8eb930dc4390ab3a9d49eec4d9a9","NCT00434759",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change on Baseline in Center for Epidemiologic Studies Depression Scale (CES-D)","SECONDARY",NA,"D010698; D000072861","Social Phobia Intervention Study of Mannheim",TRUE,89,"anova",2,NA,NA,1.41222998379373
"1349","5488c927d9812f131304f96bfa26872f","NCT01133821",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ)-Short Form","SECONDARY",NA,"D003863; D003866; D001714","Acute Psychotherapy for Bipolar II Depression",FALSE,47,"linear_regression",NA,NA,NA,1.04624856756472
"1350","54b1ba83b2fb3ee005486fae45adbe8e","NCT00453999",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Scores of Symptoms of Influenza","SECONDARY","Aches and Pains: change from Baseline at Days 2, 3, 4, 5, 10, 14","D007251","Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza",FALSE,122,"mann_whitney",NA,NA,NA,1.64382327798156
"1351","54b7079b8ca4eaee2134b82293cfe9f2","NCT04295135",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Prescription Drug Monitoring Program (PDMP) Reports Reviewed","PRIMARY",NA,"D059350","Chronic Pain OneSheet Clinical Trial",FALSE,132,"linear_regression",NA,NA,NA,1.70782824525799
"1352","54e97089267964c9e62ff15376c39b80","NCT01641380",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Appointment Adherence (Efficacy)","PRIMARY","We also evaluated the difference between the number of days after the scheduled appointment patients returned.",NA,"Meaningful Use of Technology to Improve Health Care Delivery",TRUE,100,"linear_regression",NA,NA,NA,1.49341131573029
"1353","54edf902d3e477f3d831e733fff064b2","NCT05302414",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Team Performance Observation Tool","PRIMARY","For the pretest at week 0.",NA,"The Learning Outcome of Resuscitation Teamwork Training in Postgraduate Year Doctors and Nurses",TRUE,64,"kruskal_wallis",2,NA,NA,1.20770700959599
"1354","550aa3ee44dfa3e2a8947747d31c8c67","NCT04304001",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Colorectal Cancer Screening Knowledge Measure","SECONDARY","Bivariate analyses was conducted for the knowledge scale to compare differences between the intervention and control arms. Since knowledge was a continuous variable,the values between study arms were compared using two-sample independent t-tests.","D015179","Test Up Now Education Program",TRUE,93,"t-test",NA,NA,NA,1.44227732582979
"1355","5510192cbf40a6518fe0285675fde424","NCT02732145",0.0423,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Distribution of Non-Specific and Specific Lesions of the Inner Vulvar Ring According to the ""Three Rings Vulvoscopy""","SECONDARY","Parameter: The difference in the incidence of non-specific lesions of Hymenal Remnants versus non-specific lesions of Bartholin's Gland Opening in patients with vulvodynia.

The diagnosis of vulvodynia was based on anamnestic data (ISSVD Questionnaire) and clinical examination (Inspection, Q-Tip) following Friedrich's criteria. Vulvoscopic lesions were not relevant to the diagnosis of vulvodynia.","D056650; D008010; D018459; D012871; D009450","Diagnostic Accuracy of ""Three Rings Vulvoscopy"" for Detection of Vulvar Dermatosis",FALSE,82,"t-test",NA,NA,NA,1.18166080168428
"1356","551042a1a4db605826ede7cb45f22de0","NCT01519791",0.023,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Subjects Meeting the American College of Rheumatology 50 % Response Criteria (ACR50) at Week 52","SECONDARY","In order to control the overall study-wise Type I error rate at 5 %, hypothesis testing was performed in the following hierarchical order (each at a 2-sided 95 % alpha level):

1. Primary: sustained DAS28(ESR) remission at Week 52
2. Key secondary: sustained DAS28(ESR) LDA at Week 52
3. ACR50 response at Week 52 in relation to Baseline
4. Change from Baseline in HAQ-DI at Week 52
5. Change from Baseline in mTSS at Week 52","D001168; D001172","A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis",FALSE,868,"logistic_regression",NA,NA,NA,2.2295963291438
"1357","551c0b08b3f68589e60e842344f711fb","NCT01539070",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Children´s Consumption of Foods From Baseline to 3 Months by Intervention Assignment","PRIMARY","In intent-to-treat analyses, we used unadjusted and adjusted multivariate regression models, to examine differences from baseline to 3 months between the intervention and usual care groups. For continuous outcomes, we used linear regression models, and for dichotomous outcomes, we used logistic regression models. To account for clustering by practices, we performed generalized linear mixed models. The Estimator (Est) and Confidence Interval 95% (95% CI)are reported.","D009765; D063766","Intervention for the Prevention of Obesity in Preschool",TRUE,306,"linear_regression",NA,NA,NA,2.5788408992482
"1358","552406d1dc910b057c4c5db351c45120","NCT03593850",0.049,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Anxiety Score After the Intervention","SECONDARY",NA,"D004412","Music for Pain in Primary Dysmenorrhea",FALSE,52,"t-test",NA,NA,NA,1.07810868724201
"1359","552ada322e50a11975e176777d35da4e","NCT01576718",0.0296,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)","OTHER_PRE_SPECIFIED",NA,"D001249","A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications",FALSE,197,"linear_regression",NA,NA,NA,1.33299180970445
"1360","55540206460d539bc33f3cee5bd7f23c","NCT00261443",0.024,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Baseline and Adjusted Mean Change From Baseline in the CGI-BP Severity of Illness (Overall) Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 32 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,1.42467872326084
"1361","555d77eff570da30ac70af189b6e4e30","NCT02528253",0.0347,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Low Back Pain From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/ Last Observation CF (LOCF)","SECONDARY","Week 16: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline PGA of low back pain, baseline average LBPI, and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,813,"logistic_regression",NA,NA,NA,3.07458521646854
"1362","55603295f267d309e0354e6eaf7f7b42","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Environmental Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1734,"linear_regression",NA,NA,NA,6.10721803093741
"1363","55656f80c91c91d3f592ea1ff8467da7","NCT01780298",0.0418,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Impulse Oscillometry (IOS) Measurements: Resonant Frequency (Fres)","PRIMARY",NA,"D007249","Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study",FALSE,120,"t-test",NA,NA,NA,1.40405925870051
"1364","557ab9f8310a41cf7cc00cb272e61e54","NCT01215695",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Ease of Intubation","SECONDARY",NA,NA,"Video-laryngoscope With a Novel Video-stylet for Difficult Intubation",FALSE,70,"mann_whitney",NA,NA,NA,1.2598053214673
"1365","5580f5a355fa6e3c87b3fe624c1d0470","NCT03747302",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Behavioral Intention to Vaccinate Their Child With HPV Vaccine","SECONDARY","Change in mean scores for behavioral intent to vaccine: negative values: smaller values indicate more likely to vaccinate.","D010212","HPV Message Testing and Social Media Campaign",FALSE,189,"t-test",NA,NA,NA,2.03461515228821
"1366","55dca025683f5367be1078d7a8226629","NCT01559259",0.043,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Relief Rating Score (PRR)","SECONDARY","1.5 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,181,"anova",2,NA,NA,1.7556878500366
"1367","55f9cb4068ddc94b2d147d329441a064","NCT00377572",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percent Prevalence: Asthma-Related Medical Care Resource Utilization - Hospitalizations","SECONDARY",NA,"D001249","Inner-City Anti-IgE Therapy for Asthma",FALSE,419,"logistic_regression",NA,NA,NA,1.37636553180474
"1368","55fa09da738ddbddd1c367ea75034ae0","NCT01329380",0.0465,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Number of Participants With Adverse Drug Reactions by Baseline Factors","PRIMARY","Body mass index","D013166; D025241; D013167","Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)",FALSE,396,"mann_whitney",NA,NA,NA,2.75665211890299
"1369","56094b5308584848f0b93c13033b1ba2","NCT00572195",0.05,"Wilcoxon","INTERVENTIONAL",0,0,0,0,1,"Percentage Change From Baseline in Seizure Frequency","PRIMARY",NA,"D004827","RNS® System LTT Study",TRUE,230,"wilcoxon",NA,NA,NA,2.24041528002211
"1370","561fe8ecd06a54d69ef0a1e9adc41e06","NCT01945034",0.039,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","SECONDARY","At Rest Day 3(AM + 2 hours): The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,152,"anova",2,NA,NA,1.48516000324995
"1371","5628b907652c7b096959d084e5470299","NCT00635492",0.0193,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Diet and Exercise Advice in Diabetes Management Associated With Treatment Choice at Baseline","SECONDARY","Receipt of diet/exercise advice - Yes vs. No","D003920; D003924","CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy",FALSE,2492,"logistic_regression",NA,NA,NA,3.23637981061451
"1372","562db5f3ea6b1a77048a2a933b96669b","NCT00467857",0.039,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Post-CABG Procedure Bacterial Count - Sternal Site","SECONDARY",NA,NA,"Study of the Combination of a Cyanoacrylate and Surgical Solutions in Reducing Skin Flora Contamination",FALSE,252,"mann_whitney",NA,NA,NA,1.90167463861949
"1373","563e2ba6020e88afec48a3912fe5b0f6","NCT04218864",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Emotional Support (PES)","SECONDARY","Statistical analysis strategy is identical to that for the primary outcome.",NA,"Strength for U in Relationship Empowerment",FALSE,121,"linear_regression",NA,NA,NA,1.63728545358366
"1374","5648dd02e6ece3a685a14df923fa8250","NCT00762619",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Capnocytophaga sp. (DNA Probe Analysis) - Natural Teeth","PRIMARY","The null hypothesis states that there is no difference between groups.","D005882","Clinical Study to Examine Brushing on Dental Implants",FALSE,105,"anova",2,NA,NA,1.52889220751958
"1375","5654027479c2c9d2c85a6a7533daeb7c","NCT01375660",0.026,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Oral Glucose Insulin Sensitivity (OGIS)","PRIMARY",NA,"D018149","D Vitamin Intervention in VA",FALSE,173,"anova",2,NA,NA,1.11958729434159
"1376","5658d8e7985d0534608c16ee512116d8","NCT00417859",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Gait Stride Length","PRIMARY","FB group was designated the control group. We determined a sample size based in clinical criteria. Using an α of 0.05 and β of 0.8, the required sample size was calculated to be 24 patients in each group to achieve a power of 80%. Descriptive analysis was completed on demographic information and clinical and radiological outcomes. Nonparametric tests (Wilcoxon's signed ranks or rank sum tests) were used for comparison of scores. The chi-squared test was used for dichotomous variables.","D010003; D020370","Total Knee Arthroplasty: Comparison of Fixed and Mobile Bearings",FALSE,55,"mann_whitney",NA,NA,NA,1.12508606526115
"1377","5659308744e7fc3d54f8f8ff7c894d9d","NCT02009046",0.0218,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Percent of Participants Who Ever Used Sexual and Reproductive Health Services","PRIMARY",NA,"D012749","Randomized Evaluation of a Multi-Component, Rights-Based Sexuality Education Initiative for High School Students",FALSE,1447,"logistic_regression",NA,NA,NA,2.74451222615869
"1378","5662da23544a8acb8239ae67e1526553","NCT00984022",0.043,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change in Patient Rating of Pain","SECONDARY","Repeated measures ANOVA using 2 X 2 factorial design, with one between-subjects factor (Group) and one within-subjects factor (Time). Null hypothesis is: The type of dressing does not affect patient pain ratings.","D000038; D002481","Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage",FALSE,92,"anova",2,NA,NA,1.26547917519717
"1379","567225b4e8bcd02b8c2119ec7ab33412","NCT06468982",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"High-Sensitivity Cardiac Troponin Levels From Days 0-7","PRIMARY","After testing for normality, the baseline characteristics of the two groups will be analyzed using the Student's t-test or the Mann-Whitney U-test for continuous variables and the chi-square test or Fisher's exact test for categorical variables. Differences between the intra-aortic balloon pump group and the control group in terms of repeated measurements will be analyzed using mixed ANOVA.","D003324; D009203; D007238","Use of Intra-aortic Balloon Pump Before Surgery for Acute Myocardial Infarction",FALSE,156,"anova",2,NA,NA,1.85245347153569
"1380","5672a5a7a413941e837aadf45fdca892","NCT02516332",0.036,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Urinary Catecholamines (Epinephrine and Norepinephrine, Unit-weighted Z-score)","SECONDARY",NA,"D002318; D001008","Exercise and Pharmacotherapy for Anxiety in Cardiac Patients",FALSE,105,"linear_regression",NA,NA,NA,1.1610983923142
"1381","56a064873da8bc0ecece1251aac96cca","NCT03192176",0.0396,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 7","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,85,"logistic_regression",NA,NA,NA,1.13742455852668
"1382","56bda88b3d1b561dfa100c9e800825b2","NCT02912650",0.024,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (PRID4)","OTHER_PRE_SPECIFIED","10 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,231,"anova",2,NA,NA,1.20312216847693
"1383","56c930d5989ccd7bf4f5edbaa4e561e4","NCT02688400",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Absolute Changes From Baseline in Pain Visual Analogue Scale","SECONDARY",NA,"D010003; D020370","Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis",FALSE,370,"mann_whitney",NA,NA,NA,2.83265165361863
"1384","56de19ac548f1291b6412f4e44cac894","NCT00245219",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mental Health (as Measured With the SF-36) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the peer support condition and the control condition at Time 3. The full regression model included 2 dummy coded variables, 1 contrasting the education and control condition, and 1 contrasting the peer support and control condition. The baseline measure of the outcome variable was included, in order to examine changes in the outcomes over time. This model tested the main effects of the conditions among patients with early stage cancer, late stage patients were excluded.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"linear_regression",NA,NA,NA,1.79957957739554
"1385","5706b2fb29f2b9329d46682ca00c5c08","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient-Reported Outcomes Measurement Information System (PROMIS Short Forms 8a - Pediatrics v. 2.0) is a Set of Person-centered Measures That Evaluates and Monitors Physical, Mental, and Social Health in Children and Adolescents.","SECONDARY","We hypothesized that intervention adolescents would report less Fatigue than controls at 12 months post baseline.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,126,"t-test",NA,NA,NA,1.66971913113983
"1386","570d25ba5aec40ef67e760f0cf29ae31","NCT00708097",0.044,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Enamel Fluoride Uptake (Sound Enamel Specimens)","SECONDARY","Null hypothesis considered population means of the treatments in comparison, to be equal with respect to EFU. Statistical tests were 2-sided with a significance level of 0.05.",NA,"In Situ Caries Efficacy of Fluoride Toothpastes",FALSE,103,"anova",2,NA,NA,1.36175681540349
"1387","5724de46e6b0f192e8f5e6eb341b946b","NCT03655951",0.03,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Perceived Parental Permissiveness Toward Teen Sex - Child Report From Pretest to Posttest","SECONDARY",NA,NA,"Birds and Bees Research Study",FALSE,259,"linear_regression",NA,NA,NA,1.54165914779914
"1388","5735584e6aa0c8426660fc5463146691","NCT01066793",0.014,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for HCV RNA at BL in log10 (IU/mL). The logistic regression analysis for relapse was performed for association between treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,518,"logistic_regression",NA,NA,NA,1.11822684921285
"1389","573589d6dd48237eca9148446f8dd308","NCT01263015",0.01,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Plasma Human Immunodeficiency Virus -1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 96 and Week 144","SECONDARY",NA,"D000163; D015658","A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)",FALSE,833,"mann_whitney",NA,NA,NA,1.05027396748098
"1390","5748456128c80ae1441f00d6c0cafeb3","NCT00134563",0.0317,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Cerebral Magnetic Resonance Imaging [MRI] Assessment: Change From Baseline in Total Lesion Volume (Burden of Disease)","SECONDARY","Mixed-effect model with repeated measures \[MMRM\] on cubic root transformed total lesion volume data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction, baseline value (cubic root transformed) and baseline-by-visit interaction).","D009103; D012598","Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis",FALSE,728,"t-test",NA,NA,NA,2.69391602674319
"1391","574b8db630dd524fcecd15e9dfc963df","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Hemoglobin A1C","PRIMARY","Difference in treatment effect between the 2 groups","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",FALSE,50,"t-test",NA,NA,NA,1.07648023860356
"1392","575cfa7c8163bbbe82ba0aa3f3e1ad67","NCT01126580",0.021,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) of Less Than 7% and Less Than or Equal to 6.5% at 26 and 52 Weeks","SECONDARY",NA,"D003920; D003924","A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)",FALSE,530,"logistic_regression",NA,NA,NA,1.61295453278948
"1393","5766ab89641ad451818ddf003ee037ca","NCT06378749",0.029,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Connor Davidson Resilience Scale (CDRISC)","PRIMARY",NA,NA,"Previvors Recharge: A Resilience Program for Cancer Previvors",FALSE,134,"t-test",NA,NA,NA,1.08643619452519
"1394","5769e18f892303bc3fcca440e3400941","NCT03926039",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Decisional Conflict Scale","PRIMARY","Both group of average difference (95% CI) in intervention group and control group","D008113; D006528","Sharing Decision-making Program for HCC Patients Treatment Decisions",FALSE,69,"anova",2,NA,NA,1.25127183253256
"1395","576a978f86c7cafaca6d51fad297db1c","NCT01066793",0.0213,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for HCV RNA at BL in log10 (IU/mL). The logistic regression analysis for relapse was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Wk 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,518,"logistic_regression",NA,NA,NA,1.61456650529809
"1396","5782ea202229e2f1d7fc99bbee6da77c","NCT04714320",0.043,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit","SECONDARY","Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 50","D006973","A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure",FALSE,57,"logistic_regression",NA,NA,NA,1.00979682805616
"1397","5785bc939aff386d77d66cb62c58ba2e","NCT00105989",0.015,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Gamma-Glutamyl Transferase - Continuation Phase","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,392,"t-test",NA,NA,NA,1.03556119041477
"1398","578ba134702c1c766771713c27ff5a51","NCT02649634",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Self-efficacy Related to Eating Patterns After the First Motivational Interviewing or Attention Control Interview, Week 1 - 2","SECONDARY","Self-efficacy was analyzed via an independent sample t-test comparing the groups on mean global self efficacy rating on the WEL.","D009765; D050177; D015431","Does Motivational Interviewing Improve Behavioral Weight Loss Outcomes for Obesity?",FALSE,135,"t-test",NA,NA,NA,1.7265679672307
"1399","5790b8accd411554270125b554316c0f","NCT01796236",0.041,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Abbreviated Profile of Hearing Aid Benefit (APHAB)","OTHER_PRE_SPECIFIED","Baseline: Global (Aided)","D034381; D003638; D006314; D046089","Clinical and Health Economic Evaluation With a New Baha® Abutment Combined With a Minimally Invasive Surgical Technique",FALSE,103,"mann_whitney",NA,NA,NA,1.28354908721569
"1400","57a03052f6eb3ca833059cc5320f3160","NCT01070550",0.0126,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for age per 10 years. The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,2981,"logistic_regression",NA,NA,NA,2.43230612732139
"1401","57ba2040e0404b04e65a3fbcbcefa338","NCT04716010",0.022,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Red Meat Containing Products","PRIMARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1765,"linear_regression",NA,NA,NA,3.05428809132925
"1402","57ca9ea8e2a179c4ece5cd46c788571a","NCT04697264",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"The Difference in Circulating Plasma Levels of IL6 and TNFα Between Study and Control Patients.","PRIMARY","To compare biomarker levels between study and control populations, a linear regression model was used, adjusting for BMI, diabetes, and parity, which are the unmatched factors between the study and control groups. This adjustment aimed to mitigate the confounding impact of these factors, considering their individual influence on the risk of endometrial cancer.","D016889; D009765","Adipocytokines in Endometrial Cancer",TRUE,100,"linear_regression",NA,NA,NA,1.49341131573029
"1403","57cb5c98061b56328dcf48e1c02cef3a","NCT01049373",0.0426,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change in FFbH-R Between Screening and Week 15","PRIMARY",NA,"D001416; D017116","Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain",FALSE,192,"mann_whitney",NA,NA,NA,1.79293053453332
"1404","58197b9fb62d8bbe7652e3d1a65c29bd","NCT01196078",0.0388,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Participants Achieving a Best Overall Response of Complete Response (CR) or Partial Response (PR)","PRIMARY",NA,"D008175; D002289","A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer",FALSE,113,"logistic_regression",NA,NA,NA,1.2811839061791
"1405","581bc14c7d8254139170821b421c6845","NCT05120193",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Procedure Time","SECONDARY","The null hypothesis (H0) is that the mean procedure time for the investigational device (PTI) is greater than or equal to the mean procedure time for the control device (PTC). The alternative hypothesis (HA) is that the mean procedure time for the investigational device is less.

H0: PTI ≥ PTC versus HA: PTI \< PTC","D001281","Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System",FALSE,420,"t-test",NA,NA,NA,3.01611961816457
"1406","58241e0096d6dfbd9da3dcf0491557e8","NCT03246724",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Number of Participants Requiring Additional Anesthesia Intervention","OTHER_PRE_SPECIFIED","Null hypothesis:The total additional anesthesia interventions for oral triazolam will be statistically significant in comparison to additional anesthesia interventions for IV midazolam during cataracts, retina, cornea, and glaucoma procedures.

Alternate hypothesis:The total additional anesthesia interventions for oral triazolam will not be statistically significant in comparison to additional anesthesia interventions for IV midazolam during cataracts, retina, cornea, and glaucoma procedures",NA,"Oral Versus Intravenous Sedation for Ocular Procedures",TRUE,283,"t-test",NA,NA,NA,2.4812961584773
"1407","582c8c4a5dac81f6b18193773635bb1b","NCT01236053",0.0012,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,6.89716543035013
"1408","5830d54d340b4a0deacf15c828008a60","NCT01166594",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Intraocular Pressure","PRIMARY",NA,"D009901; D005901","Use of Bevacizumab in Trabeculectomy Surgery",TRUE,47,"t-test",NA,NA,NA,1.04624856756472
"1409","5831ef67e27a28af845258b430b31fb7","NCT01690117",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in Social Support on the ENRICHED-Social-Support-Instrument (ESSI) (5-point Scale) at Month 6","SECONDARY",NA,"D003704","German Adaptation of REACH II",TRUE,81,"t-test",NA,NA,NA,1.3501394396673
"1410","5836ec8fdf109addb956576fc140f65e","NCT03975790",0.0162,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Total RA Related Monthly Health Care Cost","SECONDARY","1 month before index date","D001168; D001172","Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX",FALSE,385,"t-test",NA,NA,NA,1.0981336333111
"1411","5851dfce9d4ab3f5394544f17df20d7e","NCT01187498",0.05,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Change in Nocturia Frequency","SECONDARY","Standard regression methods adjusting for baseline values","D053201","Behavioral Treatment of Overactive Bladder in Men",FALSE,124,"linear_regression",NA,NA,NA,1.6568216953838
"1412","5855bbaa488e471549ec3a33839fd6c8","NCT03687762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in Non-Judgment (i.e., Cognitive Process Mechanism; Micro-level)","OTHER_PRE_SPECIFIED",NA,"D059350","Back on Track to Healthy Living Study",FALSE,302,"anova",3,NA,NA,1.03237942189705
"1413","5870f1d6c61cffde31bd03bfafc73fff","NCT01305577",0.028,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With a CR-SMFRS 2-grade Response","SECONDARY",NA,NA,"Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat",FALSE,242,"logistic_regression",NA,NA,NA,1.40552443783605
"1414","587321ea09ba08dc00f8075359097e3a","NCT03716869",0.006,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Subgroup Analyses Based on School District Demographic Data","OTHER_PRE_SPECIFIED",NA,"D003866; D003863; D003865","Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder",FALSE,12909,"logistic_regression",NA,NA,NA,2.60642925477263
"1415","5873229024469725463f84e1a5afb917","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Pizza Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1755,"linear_regression",NA,NA,NA,6.14400672442735
"1416","587ac622517ea2dd053b4be929ffd144","NCT01859793",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Circulating Inflammatory Marker ICAM-1","SECONDARY","Outcome variables were compared across measurement periods by repeated measures ANOVA and post hoc analyses using Tukey's test were applied if significant differences were detected","D050197; D003920","Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy",TRUE,58,"anova",2,NA,NA,1.15327776573523
"1417","5894a85dd84ae1f70edf59b2683a3294","NCT00474175",0.023,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Pain Relief Combined With Pain Intensity Difference (PRID) Scores","SECONDARY","25 minutes: P-value was calculated using ANOVA which was adjusted for treatment, site and baseline DPS. Treatment difference (Benzocaine 20% - Placebo) and corresponding 95% C.I. were calculated based on least-squares means from the ANOVA model with treatment, site, and baseline DPS effects.","D014098","Benzocaine Gel Toothache Dose-Response Study",FALSE,343,"anova",2,NA,NA,1.4079671571009
"1418","58abeabcd6de8b87c52da1e0f62c30fa","NCT01911260",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,1,0,"Change in Height-for-Age Z-score (HAZ) From End of Supplementation to End of Follow-up Period.","PRIMARY","Null Hypothesis: There isn't difference in the HAZ mean difference between children with Growth Deficit who received zinc amino acid or placebo.

We attributed α=0.05, β=0.20, and power=0.80.","D004392","Weekly Zinc Chelate Supplementation on Children's Growth",TRUE,45,"t-test",NA,NA,NA,1.02560707988412
"1419","58b3e68f4e7c76ae56bfe92f7a076e82","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Fasting Active Plasma Glucagon Like-Peptide 1 (GLP-1)","SECONDARY","Difference in treatment effect between the 2 groups","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",FALSE,50,"t-test",NA,NA,NA,1.07648023860356
"1420","58b773c8c1ba6a8a24ceb02adacf2049","NCT03836807",0.043,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Time Profile of Pain Intensity Using VAS Scale","SECONDARY","at 45'","D059787","A Study to Assess Efficacy and Tolerability of Ketoprofen 40 mg Granules vs Placebo",FALSE,70,"anova",2,NA,NA,1.11159890037482
"1421","58b9c53a466589060b66a8db7aad2dc7","NCT00256750",0.0339,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire","SECONDARY","Bodily Pain, Month 36","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,424,"anova",2,NA,NA,2.18213298964621
"1422","58bc200f1ba3d05b888edfd2c27e46b3","NCT00662792",0.0285,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Response in Trough Peak Expiratory Flow Rate (PEF)","SECONDARY",NA,"D029424","Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD",FALSE,252,"anova",2,NA,NA,1.45564822573217
"1423","58c0912d5415d7b2ff114fe3bc1250f2","NCT05081843",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Changes in Intention to Use Tobacco Products","SECONDARY",NA,NA,"Pittsburgh and Rural Area High School Tobacco Prevention",FALSE,163,"t-test",NA,NA,NA,1.89255791089634
"1424","58d0353d04d6272b013b1746d92bd562","NCT01186770",0.0339,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Responded (Responder) to Study Drug During Weeks 1 to 4","SECONDARY","Analysis was performed using logistic regression model with treatment as effect and analysis region as covariate.","D003248; D000079689","A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain",FALSE,402,"logistic_regression",NA,NA,NA,2.12538411311229
"1425","58e7b816cbfeca0723a61169842d4db3","NCT03687086",0.039,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Rates of Hypnotic Discontinuation","PRIMARY",NA,"D007319","Sleep Without Insomnia or The Use of Chronic Hypnotics",FALSE,176,"logistic_regression",NA,NA,NA,1.59506258791191
"1426","58f3e4689f8e0b3504e77e41eb4c56e9","NCT03646305",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Self-Ratings of Thought Appraisals (Avoidance)","PRIMARY","Paired sample t-tests was conducted to measure differences in avoidance of target thought from baseline to post-intervention. Null hypothesis: there would be no significant differences in avoidance from baseline to post-intervention",NA,"Singing Your Negative Body-Related Thoughts",FALSE,122,"t-test",NA,NA,NA,1.64382327798156
"1427","5953205c3bc2fc5742b4ca294bd0778d","NCT00301262",0.0427,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Percentage of Occasions of Successful Intercourse (Event Log)","SECONDARY",NA,"D007172","Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied",FALSE,147,"t-test",NA,NA,NA,1.57706677186766
"1428","597dd3e64b532962c55de86219686b20","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Burger Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1728,"linear_regression",NA,NA,NA,6.09666620224612
"1429","5981cad8aed9256057efd0ea9524de81","NCT01066793",0.0089,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for on-treatment response (pEVR \[Partial Early Virological Response\] vs No RVR/EVR). The logistic regression analysis for mSVR was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,960,"logistic_regression",NA,NA,NA,1.0157612089616
"1430","5986c44882c176c8e8df8e15fa4b5af0","NCT05367492",0.02,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Mood and Anxiety Symptoms Questionnaire (MASQ-D30) General Distress Subscore (Weeks 4, 8, and 12)","SECONDARY",NA,"D014029","Varenicline for Nicotine Vaping Cessation in Adolescents",FALSE,261,"linear_regression",NA,NA,NA,1.09054830512418
"1431","5988ddf9249d26b55788cda0e9650ff9","NCT03372369",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Perceived Pregnancy Risk Score","PRIMARY","The null hypothesis is that the change in the perceived pregnancy risk score for the patient-centered poster between baseline and followup is 0.",NA,"Testing the Impact of Two Posters on Contraceptive Knowledge, Contraceptive Preferences, and Perceived Pregnancy Risk",FALSE,470,"t-test",NA,NA,NA,1.45670417032428
"1432","598f5768bd8860293f30a9b997f1fd04","NCT02746874",0.047,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score at 1 Month in Patients With Hospital Anxiety and Depression Scale (HADS) Scores of Less Than 11.","POST_HOC",NA,NA,"Does Radiofrequency Ablation of the Articular Nerves of the Knee Prior to Total Knee Replacement Improve Pain Outcomes",FALSE,59,"mann_whitney",NA,NA,NA,1.10462948081554
"1433","5995c3ccc684032033a4cb8841ab0ab9","NCT01286311",0.038,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Medication Prescriptions for Dyslipidemia","SECONDARY",NA,"D003324; D006937; D050171","Tailored Communication to Reduce Cardiovascular Risk",FALSE,435,"logistic_regression",NA,NA,NA,2.43539809644315
"1434","59a9d5431b2ef285a8068275b9ca1e9e","NCT05224453",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Muscle Cross Sectional Area","SECONDARY",NA,"D055948","Integrated Physical Training With Protein Diet in Older Adults With Sarcopenia Symptoms.",TRUE,71,"t-test",NA,NA,NA,1.26828177971868
"1435","59aad98bcba7e175ce8327224a4c107f","NCT00088153",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,1,0,"Change in N-terminal Propeptide of Type 1 Procollagen (P1NP) Over the Study Duration (18 Months)","SECONDARY","The null hypothesis was that there would be no differences between the groups for changes in P1NP levels over time","D000855; D000856","Effects of Anorexia Nervosa on Bone Mass in Adolescents",FALSE,110,"t-test",NA,NA,NA,1.56357043896758
"1436","59ae6d1a9e77adb1f708bcafa4879da8","NCT00406640",0.025,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Discontinuation-Emergent Signs and Symptoms (DESS) Total Score","SECONDARY","DVS SR vs. ESC: after 2 weeks of taper","D003863; D003866; D003865","Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women",FALSE,531,"t-test",NA,NA,NA,1.87792699568585
"1437","59d4be3998bc297376cb1d348e759e65","NCT02963506",0.04,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Axial Spondyloarthritis International Society 40% Response Criteria (ASAS40) at Week 12","PRIMARY","For differences in relation to placebo: Odds Ratio, confidence interval and p-value were derived from a logistic regression model including fixed effects for treatment, geographic region and prior tumor necrosis factor (TNF) inhibitor exposure.","D013166; D025241; D013167","A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis",FALSE,121,"logistic_regression",NA,NA,NA,1.35850149993441
"1438","59d6fafa83496b244628019d44a2e72c","NCT02626819",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Weight Change (kg)","PRIMARY",NA,"D009765","Improving Weight Management at the VA",TRUE,43,"mann_whitney",NA,NA,NA,1.00454908915455
"1439","59e33af10091e397d4bd1a39e23b38ac","NCT01049334",0.0393,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline","SECONDARY",NA,"D010612","A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis",FALSE,200,"anova",2,NA,NA,1.70890384018691
"1440","5a2607940006713fe0f8587bdcbec83b","NCT04697264",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Correlation Between the Markers and Control Patients' Obesity Status","PRIMARY","The impact of BMI on biomarker levels was assessed by categorising the population into two groups-normal weight and overweight/obese-for straightforward comparison.

Here, we present the associations between IL6, TNFα, IGF1, and IGF2 and the BMI of the control population at baseline.","D016889; D009765","Adipocytokines in Endometrial Cancer",FALSE,50,"linear_regression",NA,NA,NA,1.07648023860356
"1441","5a39819dc898d326b8d470c0d6424437","NCT02422797",0.022,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase","SECONDARY",NA,"D015658","Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)",FALSE,516,"mann_whitney",NA,NA,NA,1.65738987392648
"1442","5a3df120e05f7e593740ce901c034bbb","NCT00463047",0.0275,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Pain Relief Score (PR) at 10 Minutes","SECONDARY",NA,"D059350; D059390","Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain",FALSE,356,"mann_whitney",NA,NA,NA,1.673167816656
"1443","5a62e5338e42de2b6f5f976c514beb19","NCT03044886",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Alveolar Crest Height (ACH)","SECONDARY","One-way analysis of variance (ANOVA) and Neuman-Keuel test were carried out to determine difference between groups.","D010538; D010518","Effects of Vitamin D on Moderate to Severe Periodontitis",TRUE,323,"anova",3,NA,NA,1.0616039136936
"1444","5a66e5c93ff38d0f792c2080a6e5a579","NCT01319721",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Recurrence","PRIMARY",NA,"D011625; D012008","Recurrent Pterygium Surgery Using Mitomycin C With Limbal Conjunctival or Amniotic Membrane",TRUE,87,"mann_whitney",NA,NA,NA,1.39696496123414
"1445","5a6f5f6e4103e1ff06d4b92930d96cea","NCT05553366",0.0205,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Total Rescue Medication Usage, SUZ Compared to Placebo","SECONDARY",NA,"D059787","Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy",FALSE,642,"mann_whitney",NA,NA,NA,1.73684842779968
"1446","5aa320c144d0856880b1195e44f1eb6c","NCT00551135",0.0334,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Modified Brief Pain Inventory-Short Form (mBPI-sf): Worst Pain 24 Hours Post Surgery","PRIMARY","LS (least squares) means from ANOVA model with terms of treatment, pooled center and baseline worst pain (for baseline visit ANOVA model with terms of treatment and pooled center). Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,202,"anova",2,NA,NA,1.49594176982409
"1447","5ac7616eba811aaf5cc052188ab1c5d7","NCT01256944",0.05,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"Total Testosterone","PRIMARY",NA,"D011085; D002318; D024821; D013577","To Study Polycystic Ovary Syndrome in Taiwanese Women",TRUE,290,"anova",2,NA,NA,2.51138465397077
"1448","5ad20d6d20219f624596f136cfc09e72","NCT02528188",0.0262,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 16: \>=50% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,3.77651958976035
"1449","5ada60e5315df31c52ebe206ad35780f","NCT00286494",0.029,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Glycosylated Hemoglobin ≤ 7.0%.","SECONDARY",NA,"D003920; D003924","Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus",FALSE,294,"logistic_regression",NA,NA,NA,1.59375259914808
"1450","5ae99c36a9ada2e32d882c9c174c34ed","NCT00602420",0.037,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Area Under Curve (AUC) of Average Pain From Diary vs. Day (1-5), Calculated by the Trapezoidal Rule.","PRIMARY","Tested at the two-sided 0.05 significance level.",NA,"Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)",FALSE,461,"t-test",NA,NA,NA,2.45030279027818
"1451","5b083502661c127bafcbba8b87f02a03","NCT03840135",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Fever Duration (With a Superiority Cut-off Level δ=-0,52 Days)","PRIMARY","The value of δ = -0.52 days was considered as the boundary of superiority. The end of the fever period is considered to have an axillary body temperature of ≤36.9 ° C in two consecutive measurements (morning-evening / evening-morning).","D007239; D012141","Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI",TRUE,155,"t-test",NA,NA,NA,1.84665325745721
"1452","5b1be5524900b9f072ef3986fbb8a8c0","NCT00567489",0.029,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline of Nutritional Status Determined by Albumin and Total Protein (Labs) at Month 3 and 6","SECONDARY","Estimate of Least Square Means Comparing Treatment Groups for Albumin-Month 6",NA,"IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients",FALSE,251,"anova",2,NA,NA,1.47464458060979
"1453","5b4243123e058cd844f87960e0eea352","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in Low Density Lipoprotein Cholesterol","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,111,"anova",2,NA,NA,1.5704144397227
"1454","5b54d8baa3da0d63e1372a3f8bab4e3e","NCT04490109",0.0205,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Proportion of Subjects With Any Improvement in Worst Itch Numeric Rating Scale (WI-NRS)","SECONDARY","The frequency and rate of WI-NRS and AI-NRS responders will be reported and compared between treatment groups using a logistic regression model. Generalized estimating equations to account for repeated measures and within-subject variability may also be applied.","D003876; D003872; D004485; D011537","B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis",FALSE,340,"logistic_regression",NA,NA,NA,1.2686646234666
"1455","5b8abdfe106665fd074dd4fb99d5938f","NCT03192176",0.0342,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 2","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,87,"logistic_regression",NA,NA,NA,1.01652439806911
"1456","5ba49039e0d59f3598b5e63755ec4f5c","NCT01115673",0.028,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Relief (PAR) Scores at 15 Minutes","SECONDARY","The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.","D014098","To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery",FALSE,299,"anova",2,NA,NA,1.55933861644891
"1457","5bc83d2c544d436c1a3ac6cd73b219b0","NCT00111800",0.032,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants Who Were HbA1c Responders at Week 12","SECONDARY","Placebo versus DEN 45 mg for HbA1c \<7%. A closed test procedure was used, in an hierarchical manner, that is, test was applied sequentially where testing does not proceed to the next step unless the previous test was found to be significant.","D003920; D003924","A New Oral Treatment For Type II Diabetes Mellitus",FALSE,117,"logistic_regression",NA,NA,NA,1.1068190804332
"1458","5bcb074c3d91e45c4a483d378ec716d8","NCT02528253",0.0085,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 40, \>=90%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1012,"logistic_regression",NA,NA,NA,1.00077425573849
"1459","5bd7243bc55449ca276df0268daf4c7b","NCT01066819",0.0289,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response Over Time by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for cumulative ribavirin dose per 10000 mg, 1st 12 weeks. The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Wk 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,267,"logistic_regression",NA,NA,NA,1.51555754750313
"1460","5be3724889664c6e890390f56dfe4045","NCT01401153",0.03,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Tonic Alertness (Omission Errors)","PRIMARY",NA,NA,"Cognition Intervention Study Dortmund",FALSE,210,"mann_whitney",NA,NA,NA,1.39113539201043
"1461","5be82445c4cec94a9ab9affe52f70aed","NCT03182374",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline to 12 Months Post-injection in Mean EQ-5D in Both Arms of the Study (nSTRIDE APS and Synvisc One) - VAS Score","SECONDARY",NA,"D010003; D020370","nSTRIDE APS Versus Hyaluronic Acid for Knee Osteoarthritis",TRUE,200,"t-test",NA,NA,NA,2.09181669397075
"1462","5bea35c34fd78357536e76e51799c2fa","NCT00550550",0.042,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Participant Average Weekly Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ) Total Score Over the Entire GPS","SECONDARY",NA,"D012220; D003231","Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)",FALSE,220,"anova",2,NA,NA,1.89384634802241
"1463","5c01c4e81c18fd5a012809f4b60eb0c0","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Ambulatory Mean Heart Rate","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"1464","5c0d49ecb7de19bed84a9e281ca76cf7","NCT00910689",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change in the Number of Migraine Days Per 30 Days at Month 16","SECONDARY","Post-test contrast. Mean difference in change.","D008881; D006261","Drug and Non-Drug Treatment Of Severe Migraine",FALSE,108,"t-test",NA,NA,NA,1.28614653164923
"1465","5c0e6d724d8271eb37a49e5682bd5c31","NCT02912650",0.022,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (PRID4)","OTHER_PRE_SPECIFIED","7 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,347,"anova",2,NA,NA,1.36251008593949
"1466","5c126a81b8c5b2916449db25d5866f25","NCT01216163",0.029,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Relief Rating (PRR)","SECONDARY","0.25 hours: Treatment difference (Acetaminophen - Placebo) and corresponding 95% CI were calculated based on LS means from the ANOVA model.","D014098","Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain",FALSE,130,"anova",2,NA,NA,1.07068377980718
"1467","5c1e106207515db65a6a0adf2d825cd1","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Fasting Plasma Glucose Clearance","PRIMARY","Difference in treatment effect between the 2 groups","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",FALSE,50,"t-test",NA,NA,NA,1.07648023860356
"1468","5c22a1d603979935ecbab5a11e006d62","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Price)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1753,"linear_regression",NA,NA,NA,6.14051253521365
"1469","5c23ea0335b69b9ad57e0d83baf81fad","NCT01234649",0.046,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Triglyceride (TRG) Levels","SECONDARY","Factorial repeated measures ANOVA","D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",TRUE,72,"anova",2,NA,NA,1.19146755871289
"1470","5c248042e295d65706d2c35ce5955fa4","NCT03296527",0.012,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of Subjects With Early OHSS (Including OHSS of Moderate/Severe Grade) and/or Preventive Interventions for Early OHSS","SECONDARY","Proportion of participants with any preventive intervention",NA,"Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women",FALSE,1009,"logistic_regression",NA,NA,NA,1.35805052916669
"1471","5c2debef7744e2859bbf7464c6ebc1b1","NCT04833777",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Post-operative Analgesia Requirements","PRIMARY",NA,"D002349","Does a Different Local Anesthetic Improve Pain After Carpal Tunnel Release?",TRUE,139,"mann_whitney",NA,NA,NA,1.75124288073831
"1472","5c530c054952febfddc6f9c681c9e275","NCT03781167",0.0354,"One-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I Score: Change From Baseline to End of Study","SECONDARY","Week 26 vs Baseline","D010300","A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)",FALSE,244,"t-test",NA,NA,NA,1.72420317921736
"1473","5c5926dc45bde8ba14c387e6e0385513","NCT02912650",0.023,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference Scores on 4-Point Categorical Scale (SPRID4) Over 2, 6, 8, 12 and 6 to 8 Hours Post-dose","OTHER_PRE_SPECIFIED","0-12 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,347,"anova",2,NA,NA,1.4160300936537
"1474","5c5a3223df301e2be78d9e0d6d5c95f4","NCT02373813",0.029,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in CDAI at All Measured Timepoints","SECONDARY","Change at Week 36","D001168; D001172","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",FALSE,202,"t-test",NA,NA,NA,1.3259486466795
"1475","5c6ec2ab1fcf4b782c53b2f41fbb8720","NCT04323137",0.0035,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Flu Vaccination Rate","PRIMARY","This analysis compared all groups that were informed they were high risk (High risk only, High risk based on medical records, High risk based on algorithm) to control patients who were not sent a message.

Null hypothesis: informing patients they are high risk for flu and flu-related complications does not increase flu vaccination rate; Alternative hypothesis: informing patients they are high risk for flu and flu-related complications increases flu vaccination rate",NA,"Encouraging Flu Vaccination Among High-Risk Patients Identified by ML",FALSE,38598,"logistic_regression",NA,NA,NA,2.76573583909715
"1476","5c7114feaf28c9ba9c93a719c768be75","NCT01532986",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"World Health Organization Well-Being Index (WHO-5)","SECONDARY",NA,"D010300","Randomized Trial to Test the ""Coordinated Care for Health Promotion and Activities in Parkinson's Disease"" Intervention in the VA",FALSE,328,"t-test",NA,NA,NA,2.66881159065383
"1477","5c956a4f274ea8a15ee52bbd1ca5ba23","NCT00822510",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Center for Epidemiological Studies-Depression Scale","PRIMARY",NA,"D011471","Telephone Counseling: Men With Prostate Cancer & Partners",TRUE,71,"anova",2,NA,NA,1.26828177971868
"1478","5ca490ef9eaeda67ce786b8d1c6813a8","NCT02408965",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Amount of Post-procedure Blood Loss Measured in mL","PRIMARY",NA,"D006470","Uterotonic Prophylaxis Trial",FALSE,284,"t-test",NA,NA,NA,1.13663016215642
"1479","5ca4bc3afc9c3010e1020580afe6e6ce","NCT03328208",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Anxiety at the End of the Waiting Room Time (Change as Compared to Beginning of the Waiting Room Time)","OTHER_PRE_SPECIFIED",NA,"D014098","Nonpharmacologic Reduction of Periprocedural Distress and Drug Use",TRUE,72,"mann_whitney",NA,NA,NA,1.27670232702116
"1480","5ca8745770518dd7bb5c1cb5cb24a032","NCT01459653",0.011,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Modeling FN Episode: Patient Level","SECONDARY","Under- vs. over-prophylacted as patient-level predictor for FN episode","D009101; D009503; D064147; D000084462; D005334","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",FALSE,1376,"logistic_regression",NA,NA,NA,1.46691078398835
"1481","5cb6423a3cb3384f5ea686d0b83b4f6b","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Health)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1751,"linear_regression",NA,NA,NA,6.13701635655789
"1482","5ceeb2c2b4299c096fefc4e3e2e66780","NCT04954326",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pharmacokinetics Measurement","PRIMARY","AUCinf was natural log-transformed and analyzed using an analysis of variance (ANOVA) with fixed effect for formulation. The two one-sided tests procedures were performed on the geometric mean ratio (GMR) between test (S95014 lyophilizate) and reference (S95014 liquid formulation) treatments. The 90% confidence interval for the ratio was obtained within the framework of the ANOVA.","D007938; D054198; D007945","A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL)",FALSE,80,"anova",2,NA,NA,1.34217713699512
"1483","5cf6f70b6438e3053412bedc43d7042d","NCT00264537",0.025,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 52","PRIMARY","Null hypothesis: No difference in vdH-S score comparing Groups 1 vs 4.","D001168; D001172","A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive",FALSE,319,"anova",2,NA,NA,1.4601320655648
"1484","5d08e90a87fb4431d17c1722c29ae10c","NCT01357564",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"The Neuropsychiatric Inventory (NPI). Measures the Frequency and Severity of Behavioral Symptoms in Dementia.","PRIMARY","Sample size calculation was based on the main study hypothesis tested at 80% power for a 2-sided alternative hypothesis using a t-test comparing the treatment groups on 4-month values. Based on previous trials, we sought a medium effect size of 0.50 using a type I error rate of .05.","D003704","Tailored Activity Program-Veterans Affairs",FALSE,322,"t-test",NA,NA,NA,1.20892570729049
"1485","5d102ed891849e7225549af461d817be","NCT04223687",0.03,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Mean Intention to Give Sugar-sweetened Beverages to Child","SECONDARY",NA,NA,"Impact of Warnings on Sugar-Sweetened Beverages",FALSE,320,"mann_whitney",NA,NA,NA,1.71064867996479
"1486","5d21b36cdfc2d51aeaba403720705ecd","NCT00336284",0.016,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Early Detection of Cardiac Events","SECONDARY",NA,NA,"TRUST: Lumos-T Safely RedUceS RouTine Office Device Follow-up",FALSE,1339,"t-test",NA,NA,NA,2.01489883464833
"1487","5d30ab9190c6f70b52ee76d6968bc1d4","NCT00853723",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Serum Phosphorous","SECONDARY",NA,"D010024","Comparison Study of PTHrP and PTH to Treat Osteoporosis",TRUE,62,"anova",2,NA,NA,1.18983814919554
"1488","5d3e53c5fc9f0bec338a9fd2c98c5672","NCT03458702",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"High-frequency Band (HFNU) Assessed at Baseline, Post-Condition and Post-Exposure","PRIMARY",NA,"D001008","The Effects of Emotional Exposure on State Anxiety",FALSE,80,"anova",2,NA,NA,1.34217713699512
"1489","5d7e56873bb7863e56f9aed73dc60f2e","NCT00105989",0.022,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in Sheehan Disability Scale (SDS) - Maintenance Phase","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,245,"t-test",NA,NA,NA,1.14848339037031
"1490","5daceaa88b3791a94eb0db5131517f23","NCT00120042",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Post-Delivery Blood Loss","SECONDARY",NA,"D006473; D018457; D006470","Optimisation of the Management of Placental Delivery in Second Trimester Pregnancy Interruption",TRUE,251,"t-test",NA,NA,NA,2.33882663980222
"1491","5dbbed5a0ec8f3f3b2a792dfbafdd024","NCT01910519",0.0465,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Measurement of Microneutralization (MN) Titers With Influenza A Vaccine With and Without AS03 Adjuvant","PRIMARY","Correlation of vaccine-induced blood transcription modules (BTMs) M74-transcriptional targets of glucocorticoid receptor at day 1 with MN titers at day 42","D007251; D005585","Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)",FALSE,50,"anova",2,NA,NA,1.01404871870478
"1492","5dc5bfe7d7122529c6f2db1441534db8","NCT02886728",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved ACR20 Response at Weeks 2, 4, 12, 36, and 52","SECONDARY","Filgotinib 200 mg Monotherapy vs MTX Monotherapy at Week 36","D001168; D001172","Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy",FALSE,626,"logistic_regression",NA,NA,NA,2.38402557673113
"1493","5dcfe21e08691e35e1bc7177f968d0ba","NCT00710554",0.023,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Subject Global Impression of Change","SECONDARY","The two treatment groups were compared using ordinal logistic regression and the proportional odds model. The initial model incorporated treatment and centre group as factors. The odds ratio together with its 95% CI and associated p-value are presented.","D009437; D010523; D006930","A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia",FALSE,228,"logistic_regression",NA,NA,NA,1.15229395553525
"1494","5dd188a5a609c830b95c5655ca6dceab","NCT02732145",0.0429,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Distribution of Aceto-Whitening Reaction in Relation to the Structures of the Outer Vulvar Ring","SECONDARY","Parameter: The difference in the incidence of aceto-whitening of Mons Pubis versus Labia Majora in patients with vulvodynia and positive AWR.","D056650; D008010; D018459; D012871; D009450","Diagnostic Accuracy of ""Three Rings Vulvoscopy"" for Detection of Vulvar Dermatosis",FALSE,82,"t-test",NA,NA,NA,1.1956457723947
"1495","5dd2e48943cbea71763b39eb7ea39a56","NCT03257813",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Intraocular Pressure (IOP)","PRIMARY",NA,"D005901; D005902; D009798; D006973","Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)",FALSE,60,"t-test",NA,NA,NA,1.17169922891753
"1496","5ddeef2d6db3aa58958642049ae83637","NCT02939131",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Adherence Outcomes: Adherence to Psychiatric Medications - Number of Days in Last 30 With Any Missed Doses","SECONDARY","Comparison of COMB-R and ESC groups, number of days in last 30 with any missed depression medication doses reported at week 24.","D003863; D003866","IMPAACT 2002: Cognitive Behavioral Therapy and Medication Management for Treatment of Depression in US Youth With HIV",FALSE,49,"t-test",NA,NA,NA,1.06649684228356
"1497","5de592a16cca77896e0fd1ab99821b4e","NCT01392300",0.034,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Thumb-in-palm","SECONDARY",NA,"D009128; D020521","Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke",FALSE,259,"logistic_regression",NA,NA,NA,1.71555918131181
"1498","5ded3f39b3fdeb4edbea2e449e55fae7","NCT02649634",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Confidence for Change Ratings After the Second Motivational Interviewing or Attention Control Interview, Week 12","SECONDARY","Confidence for Change ratings were analyzed via an independent sample t-test comparing the groups on mean Confidence for Change ratings on the 11-point visual analogue scales","D009765; D050177; D015431","Does Motivational Interviewing Improve Behavioral Weight Loss Outcomes for Obesity?",FALSE,129,"t-test",NA,NA,NA,1.68888097915129
"1499","5e21eae3fd0eded9a4abca969c4f33a5","NCT01131299",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Serum Glucose Levels After 12-14 Weeks Intervention, Compared to Baseline for Alpha-cyclodextrin (a-CD) and Placebo Groups After 12-14 Weeks, Compared to Baseline","SECONDARY",NA,"D002318","Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol",FALSE,150,"t-test",NA,NA,NA,1.8173749039831
"1500","5e223561ca8b8f2aba6488be6cf87129","NCT02528253",0.0459,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 4, \>=50%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1010,"logistic_regression",NA,NA,NA,4.34139361926835
"1501","5e27d22ac6ede97b00a7381d69cc323f","NCT02674529",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,1,0,"Neural Responses During the Sham Neurofeedback fMRI Task.","SECONDARY","At the group-level, a random-effects analysis determines the main effects of the regressors of interest (e.g., high vs. low expectancy) resulting in statistical parametric maps (t or F statistics). To control for potential confounders, sex and depression severity will be entered as covariates in statistical models.","D003866; D003865","Study of Neural Responses Induced by Antidepressant Effects",TRUE,54,"t-test",NA,NA,NA,1.11553228437488
"1502","5e2bc8bbe61f1f93d8f5abd339563603","NCT01559259",0.036,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (PRID4)","SECONDARY","12 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,182,"anova",2,NA,NA,1.5151750544204
"1503","5e3d19d990186a0d049c0a9c963ac0b2","NCT01392742",0.042,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Predictive Power Values of Host-, Virus- and Treatment-related Factors and Virological Response","SECONDARY","Binary logistic regression for treatment duration at Week 12.","D006506; D006526; D019698; D006505","An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin",FALSE,238,"logistic_regression",NA,NA,NA,1.96839923605046
"1504","5e3dcc878fc1c4a6a2161fcafaf959f6","NCT02022566",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Level of Physical Activity/Low Activity","PRIMARY",NA,"D010003","Effect of Structured Info and Adapted Exercise in OA",TRUE,193,"anova",2,NA,NA,2.05559974063708
"1505","5e3efe11d170c3ef385d3e984d6bdc90","NCT00922272",0.0461,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change From Open-label Baseline in Behavioral Rating Inventory of Executive Function - Adult Version (BRIEF-A) T-scores at Week 10 Open-label Phase","SECONDARY","Behavioral Recognition Index","D012559","Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms",FALSE,70,"t-test",NA,NA,NA,1.17785277331249
"1506","5e4127c976bd5e882ba625f696ee4d86","NCT03940963",0.049,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Total Reported Pain From Baseline to 12 Months","SECONDARY",NA,"D009463; D000070607; D009437","Study of AxoGuard® Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma Pain",FALSE,73,"t-test",NA,NA,NA,1.26376663614063
"1507","5e51e8af90d2eab520f2bef2805c9e00","NCT03372369",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Mean Accuracy of Perceived Pregnancy Risk Score","POST_HOC","The null hypothesis is that the patient-centered poster does not produce a larger increase in the accuracy of perceived pregnancy risk score between baseline and followup than the CDC poster.",NA,"Testing the Impact of Two Posters on Contraceptive Knowledge, Contraceptive Preferences, and Perceived Pregnancy Risk",FALSE,936,"t-test",NA,NA,NA,2.04981899054956
"1508","5e544cdf8a595129daf729fff364712b","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Daytime ACRPP (Ambulatory Central Rate-Pressure Product (Also Called TTI, CTTI)","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"1509","5e585187ade8a1af436491ea27c4c7e6","NCT02528188",0.008,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 4: \>=30% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1989,"logistic_regression",NA,NA,NA,1.32673972673106
"1510","5e6bdb3301b78b2de00b255bd5ae0ea3","NCT02709486",0.0286,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >=30%, >=50%, >=70% and >=90% Response","SECONDARY","Week 2, \>=30%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,565,"logistic_regression",NA,NA,NA,2.17469369023139
"1511","5e789b6f107da88dd63a6802f27393ed","NCT02678286",0.0434,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Summed Pain Intensity Difference (SPID) at Other Intervals","SECONDARY",NA,"D010149","Evaluation of N1539 Following Abdominoplasty Surgery",FALSE,219,"t-test",NA,NA,NA,1.94249614460132
"1512","5e92bee87bc24494e783cd1e1b2a234c","NCT01234649",0.049,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Triglyceride to High Density Lipoprotein Cholesterol Ratio TRG/HDL-C)","SECONDARY","Factorial repeated measures ANOVA","D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",TRUE,72,"anova",2,NA,NA,1.25554363518273
"1513","5ee33d2dad1c4619af4f4085647db4a2","NCT04485637",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Who Measured Blood Pressure as Instructed (Assessed on Questionnaire)","PRIMARY","Enhanced graph \> Basic table","D006973","Helping Hypertension Patients to Interpret Blood Pressure Readings and Motivate Blood Pressure Control",FALSE,542,"logistic_regression",NA,NA,NA,3.42276043954353
"1514","5ee5294a40d7ec40a06d784693bafe3d","NCT01559259",0.041,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (PRID4)","SECONDARY","10 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,120,"anova",2,NA,NA,1.38145665253014
"1515","5ee5a9ef828c862e979491a85f9361e0","NCT02373813",0.032,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Disease Activity Score (28 Joint) Calculated Using the Erythrocyte Sedimentation Rate Formula (DAS28-ESR) at All Measured Timepoints","SECONDARY","Week 12","D001168; D001172","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",FALSE,202,"t-test",NA,NA,NA,1.44234146621663
"1516","5ee8f6b58f64732858b942c84103305c","NCT00879658",0.034,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Patients Without Any New MRI Disease Activity - Period 1 +2","SECONDARY",NA,"D009103; D020529; D012598","Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",FALSE,112,"logistic_regression",NA,NA,NA,1.1410662057828
"1517","5eea88c201e34c00ef3a633be8927b92","NCT03655951",0.02,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Supportive Parenting - Child Report From Pretest to Follow-up","SECONDARY",NA,NA,"Birds and Bees Research Study",FALSE,267,"linear_regression",NA,NA,NA,1.10275516908223
"1518","5eee4a2746c7cc311e7f50b3b2da5553","NCT02046980",0.02839,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Conversion in Direction of Nystagmus From Apogeotropic to Geotropic or Disappearance of Nystagmus","PRIMARY",NA,"D014717; D065635; D004244","Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo",FALSE,142,"logistic_regression",NA,NA,NA,1.09715044091127
"1519","5f237ba484b1362d1e4d38b7f677062f","NCT03468868",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient Determined Disease Steps (PDDS)","SECONDARY",NA,"D009103; D012598","Comparative Effectiveness Study Telerehab Versus Conventional",FALSE,379,"t-test",NA,NA,NA,2.86654244301488
"1520","5f3d019f5c094fe18112684c59c6ecb7","NCT04445792",0.0104,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Fatigue as Measured by PROMIS (Patient-Reported Outcomes Measurement Information System)","SECONDARY",NA,"D059350; D059787; D003863; D003866","A Depression and Opioid Pragmatic Trial in Pharmacogenetics (DCRI Coordinating Center)",FALSE,1113,"mann_whitney",NA,NA,NA,1.25586485439252
"1521","5f3f89e8c2e9392febd91fdc4280de97","NCT05919082",0.0199,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Decrease in mPASI of at Least 90% (mPASI-90) From Baseline to Day 29","SECONDARY",NA,"D011565","A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis",FALSE,604,"logistic_regression",NA,NA,NA,1.64206003460113
"1522","5f40d355e4f90118765dca2c793db218","NCT01818700",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change of Pain Intensity* at Week 8 of Treatment With the Study Drug From Baseline","PRIMARY",NA,"D013122","An Interventional Study to Assess the Efficacy and Safety of Buprenorphine in Korean Patients With Spinal Disorders",TRUE,210,"t-test",NA,NA,NA,2.14249424535415
"1523","5f47f4016159f868aa0a8053709df5c7","NCT00930943",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Rapid Visual Information Processing (RVP) Sensitivity [A']","PRIMARY",NA,"D059350","Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning",FALSE,60,"anova",2,NA,NA,1.17169922891753
"1524","5f4b46a13ceda535f2fc17d4cc0d0f13","NCT03192176",0.0402,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 13","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,87,"logistic_regression",NA,NA,NA,1.16466612250116
"1525","5f5a70410d3c80fadf66f169ac33f343","NCT05224453",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Changes in Hand Grip Strength","PRIMARY",NA,"D055948","Integrated Physical Training With Protein Diet in Older Adults With Sarcopenia Symptoms.",TRUE,71,"t-test",NA,NA,NA,1.26828177971868
"1526","5f7c98a1944fd7358bbf5560822af3ae","NCT03733301",0.045,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving EASI90","SECONDARY",NA,"D003876; D003872; D004485","A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis",FALSE,220,"logistic_regression",NA,NA,NA,2.00697234260806
"1527","5fa0ea792ecc52c767b4989c895f47e0","NCT02724774",0.026,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Parent Sensitivity in Teaching","PRIMARY","All analyses were conducted as intention-to-treat, analyzing all 252 cases as randomly assigned to the PFR and control group (CG). Multiple linear regression was used to examine the treatment effect of PFR (0 = CG, 1 = PFR). Covariates included preferred language (0 = English, 1 = Spanish) and the baseline measure.",NA,"Collaborative Perinatal Mental Health and Parenting Support in Primary Care",FALSE,225,"linear_regression",NA,NA,NA,1.27258995103854
"1528","5fa771be8bf2ae24f94f31bcd4a2e4fc","NCT00408876",0.041,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Interference (BPI-I) Score - Normal Work","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,220,"t-test",NA,NA,NA,1.85576548340687
"1529","5fab8d15946f2ddf4c082f6b1eef2e15","NCT01690117",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in Psychological Quality of Life on the German Version of the Mental Component Summary of the General Health Questionaire Short Form 12 (SF-12) at Month 6","SECONDARY",NA,"D003704","German Adaptation of REACH II",TRUE,81,"t-test",NA,NA,NA,1.3501394396673
"1530","5fb825134fe363875dd4be0136dcb220","NCT02748096",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Post-operative Change in Haemoglobin Between Baseline Baseline and 48 Hours After Surgery","OTHER_PRE_SPECIFIED",NA,"D001168","The Assessment of Patient Specific Instrumentation for Unicompartmental Knee Replacement",TRUE,45,"t-test",NA,NA,NA,1.02560707988412
"1531","5fbeae9d64790431a4b7bb3a0c5a1a19","NCT02473471",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Pain Interference /Pain Interrupted Sleep","SECONDARY","Day 7","D008310","Micro-osteoperforations and Tooth Movement",FALSE,62,"t-test",NA,NA,NA,1.18983814919554
"1532","5fd1a69b9e225f8bdffcc4f0a7beaa77","NCT00293033",0.032,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Episodes With Complete Pain Relief","SECONDARY",NA,"D059390","Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects",FALSE,153,"mann_whitney",NA,NA,NA,1.25985706347229
"1533","5fea4517532c1b8ed772431c0a3cee5d","NCT01539070",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Score z of Body Mass Index From Baseline to 3 Months by Intervention Assignment","PRIMARY","In intent-to-treat analyses, we used unadjusted and adjusted multivariate regression models, to examine differences from baseline to 3 months between the intervention and usual care groups. For continuous outcomes, we used linear regression models, and for dichotomous outcomes, we used logistic regression models. To account for clustering by practices, we performed generalized linear mixed models. The Estimator (Est) and Confidence Interval 95% (95% CI)are reported.","D009765; D063766","Intervention for the Prevention of Obesity in Preschool",TRUE,306,"linear_regression",NA,NA,NA,2.5788408992482
"1534","60043cf7b280ffd260529f2a432f6561","NCT01784965",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change in Weight Reported at 14 Weeks","PRIMARY",NA,"D003920; D011236; D015431","Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.",TRUE,51,"t-test",NA,NA,NA,1.08637315449684
"1535","6004cc32d875ae4c18e0b4d4b4d660e6","NCT01378299",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Percent Change in Bone Mineral Density (BMD) According to rs700518 Polymorphism in the CYP19A1 Gene","PRIMARY","Analysis by intention to treat with last value carry forward.","D007006","CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy",TRUE,59,"anova",2,NA,NA,1.16252463235142
"1536","6030ef574acb1d38adb5c3175a6977c7","NCT03039621",0.022,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Time to Alleviation of Flu-like Nonspecific Symptoms.","SECONDARY",NA,"D007239; D003141; D014777","Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children",FALSE,282,"mann_whitney",NA,NA,NA,1.2304279857742
"1537","60378a378fe5ed5568deafdad2a9f36c","NCT01796236",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Health Utilies Index (HUI-III & HUI-II)","OTHER_PRE_SPECIFIED","Month 36: Pain (HUI3)","D034381; D003638; D006314; D046089","Clinical and Health Economic Evaluation With a New Baha® Abutment Combined With a Minimally Invasive Surgical Technique",FALSE,103,"mann_whitney",NA,NA,NA,1.25721300217468
"1538","603aeb680e703f2cada678e4d6e90734","NCT04267614",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Change From Baseline in DAS28 at Month 12","OTHER_PRE_SPECIFIED",NA,"D001168; D001172","This Study is to Investigate the Effect of Etanercept in Early Versus Delayed Referral for Management of Rheumatoid Arthritis Patients.",TRUE,979,"t-test",NA,NA,NA,4.59283895163754
"1539","603de6119e64294c59ac9ab4c0a190dc","NCT00243230",0.0387,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline CD4 Count at Week 48 of the Double-blind Period","SECONDARY",NA,"D015658","Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)",FALSE,74,"anova",2,NA,NA,1.04489540874377
"1540","6054f63ff4670e49f934cd08b316f9e6","NCT01532986",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Activities of Daily Living (ADL), (Speech and Swallowing Only)","SECONDARY",NA,"D010300","Randomized Trial to Test the ""Coordinated Care for Health Promotion and Activities in Parkinson's Disease"" Intervention in the VA",FALSE,328,"t-test",NA,NA,NA,2.66881159065383
"1541","60582f5c2b1e022cf7ec51c06d21fc34","NCT01066819",0.0437,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response Over Time by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for (OTHER vs WHITE/CAUCASIAN). The logistic regression analysis for mSVR was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,674,"logistic_regression",NA,NA,NA,3.40612458158122
"1542","6059c90298a9b41065bb49a025df0f94","NCT03965754",0.035,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Logging in (7 Days)","PRIMARY",NA,NA,"Assessing the Impact of myHealth Rewards Enrollment Emails",FALSE,2850,"logistic_regression",NA,NA,NA,5.78766785633093
"1543","606c48318666c13a2e48455425be215a","NCT00650806",0.031,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Percent Change in Body Weight From Baseline to Week 12","PRIMARY",NA,"D009765; D050177","A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes",FALSE,181,"anova",2,NA,NA,1.33058763757677
"1544","6082cd1f9593234a3d86091a9170a34c","NCT01236053",0.019,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,83.5565380495062
"1545","60c280682e21c1bf4e46c41edd5e0038","NCT02481596",0.034,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Diabetes Self-efficacy","SECONDARY","6 months. Multiply imputed data (m=20) using chained equations.","D003920; D003924","FAMS Mobile Health Intervention for Diabetes Self-care Support",FALSE,379,"linear_regression",NA,NA,NA,2.06958024460905
"1546","60ccf22b2cc28b07885f32d76ffea996","NCT01385371",0.027,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Average Rhinoconjunctivitis Quality of Life Questionnaire With Standardized Activities for Participants ≥12 Years of Age (RQLQ12+) Over the Peak GPS","SECONDARY",NA,"D012220; D065631; D003231","A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)",FALSE,996,"mann_whitney",NA,NA,NA,2.74264654080734
"1547","61054f5990445dfee54723e780a23c2b","NCT02309138",0.0322,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Neonatal Composite Morbidity","SECONDARY",NA,"D016640; D003920; D018149","Comparison of Two Screening Strategies for Gestational Diabetes (GDM2)",FALSE,867,"logistic_regression",NA,NA,NA,2.97801439995559
"1548","610fbe933a0fa79ad3b299046d67d7d8","NCT02449044",0.0325,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Mean Change From Baseline in SF-12 (Health Survey) Mental Component Summary (MCS)","SECONDARY","Statistical analysis at Week 42","D007010","International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia",FALSE,103,"t-test",NA,NA,NA,1.05505735869487
"1549","6117a1c6bd6b381c212c2aee2ea4d623","NCT02867709",0.0167,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose","SECONDARY",NA,"D008881","Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine",FALSE,920,"logistic_regression",NA,NA,NA,1.73582772163615
"1550","61238147b621b2475464c47ff1ca4b1e","NCT01532986",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Proportion of Measures Adhered To in the PD Guidelines","PRIMARY",NA,"D010300","Randomized Trial to Test the ""Coordinated Care for Health Promotion and Activities in Parkinson's Disease"" Intervention in the VA",FALSE,328,"t-test",NA,NA,NA,2.66881159065383
"1551","6135d5409b84ef491421425e05ac382a","NCT00144339",0.0145,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment","SECONDARY",NA,"D008171; D029424","Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients",FALSE,3418,"mann_whitney",NA,NA,NA,2.94811740075467
"1552","6143d40f983edd510c0356a98723dddd","NCT01640197",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Number of Participants With Significant Modulation of Sleep","SECONDARY",NA,NA,"Chronic Resveratrol Supplementation in Healthy Humans",FALSE,53,"anova",2,NA,NA,1.10589694869732
"1553","614a39bc8e332a7daff8cd4dd448cc14","NCT01312766",0.02,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Controlled Ovarian Stimulation Duration (Days)","SECONDARY",NA,"D007246","Safety and Efficacy Study in in Vitro Fertilisation (IVF) Patients",FALSE,270,"anova",2,NA,NA,1.10880825088059
"1554","614c234c98f658c00edc2f88666c4246","NCT01285999",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"9 Month In-stent Late Loss","PRIMARY","H0: μt - μc = 0 H1: μt - μc ≠ 0 where μt and μc are the mean 9-month in-stent late loss values for the subjects in the PROMUS Element test and TAXUS Liberté control treatment groups, respectively.","D003324; D050197","Prospective, Randomized, Multicenter Trial to Assess PROMUS™ Element™ Stent",FALSE,500,"t-test",NA,NA,NA,3.28844923886065
"1555","615109c1b8d1ec76e009e4d96da9e4b6","NCT01753518",0.034,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Cosmetic Outcome","SECONDARY","Comparison between arms for patient: scar color is different.","D000072836","A Clinical Trial of Subcuticular Staples Versus Subcuticular Suture for Cesarean Section Skin Closure",FALSE,96,"mann_whitney",NA,NA,NA,1.05996090717406
"1556","6155ed8e998b90fcfc8f66e32a690aaa","NCT02757352",0.031,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving ASDAS Inactive Disease","SECONDARY",NA,"D013166; D025241; D000089183; D000089202","A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis",FALSE,207,"logistic_regression",NA,NA,NA,1.42065368984996
"1557","617e2f755cbfe786070c17af6b493304","NCT03372369",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Mean Accuracy of Perceived Pregnancy Risk Score","POST_HOC","The null hypothesis is that the change in the accuracy of perceived pregnancy risk score for the patient-centered poster between baseline and followup is 0.",NA,"Testing the Impact of Two Posters on Contraceptive Knowledge, Contraceptive Preferences, and Perceived Pregnancy Risk",FALSE,470,"t-test",NA,NA,NA,1.45670417032428
"1558","61a97ac57256b38e533242828c121664","NCT03031795",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Pain Before, During and After IUD Placement","PRIMARY","A 2 point difference was used to power the study. This is consistent with previous definitions of a clinically meaningful reductions in pain and provides a visually meaningful change on the 0-10 numerical rating scale with anchors at every other point, for example moving from ""very severe"" (8) to ""severe pain"" (6) or from ""moderate pain"" (4) to ""mild pain"" (2).",NA,"Oral Ketorolac for Pain Relief During IUD Insertion",TRUE,71,"mann_whitney",NA,NA,NA,1.26828177971868
"1559","61b1dcb95ab02bd30a58edd963d6ee72","NCT04679818",0.039,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Number of Analgesic Rescue Boluses","OTHER_PRE_SPECIFIED",NA,NA,"Postoperative Consequences of Intraoperative NOL Titration",FALSE,71,"mann_whitney",NA,NA,NA,1.03139503477057
"1560","61c59265d09a29fc34d68f9d70cc074c","NCT00037830",0.0368,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Scores From Baseline to Week 120 Assessed Off Medication.","PRIMARY","The null hypothesis for Phase II is that long-term use of GM1 does not affect the progression of PD symptoms and that there is no benefit to early start of GM1 use.","D010300","GM1 Ganglioside Effects on Parkinson's Disease",FALSE,75,"t-test",NA,NA,NA,1.00801844469037
"1561","61c78a67901b444fcf1064ea75176926","NCT00144339",0.0165,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 24","SECONDARY",NA,"D008171; D029424","Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients",FALSE,4807,"anova",2,NA,NA,3.9161782701272
"1562","61c817849de38d655b436607d0f0551e","NCT00270998",0.0492,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Satisfaction With Treatment at 12 Months","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",TRUE,295,"logistic_regression",NA,NA,NA,2.49873946067788
"1563","61ffc1b99dda24c8671d8905ffd9bc39","NCT01020773",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Number of Participants With Successful Extubation, Reintubation and in Hospital Mortality","PRIMARY",NA,"D012131","Extubation With or Without Spontaneous Breathing Trial",FALSE,60,"anova",2,NA,NA,1.17169922891753
"1564","620e7ad621cef6a13b6d9c143113bd63","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cancer Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1753,"linear_regression",NA,NA,NA,6.14051253521365
"1565","6240e90bffac394b99b3de20ecad8739","NCT00394355",0.023,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Summary of Change From Baseline to Endpoint in FEV1 (Forced Expiratory Volume in One Second).","SECONDARY","Least square means and Pstd (pooled standard deviations) are obtained from the ANOVA model with treatment effects.","D001249","Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)",FALSE,287,"anova",2,NA,NA,1.28980741448669
"1566","624327ec3c82d304f86423928c75d5f7","NCT03123549",0.034,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Composite Clinical Success (CCS) Rate of the Simplify® Disc","PRIMARY",NA,NA,"Investigation of the Two Level Simplify® Cervical Artificial Disc",FALSE,318,"t-test",NA,NA,NA,1.89788640996991
"1567","6278d96b137020f494a6f8f1a7e3349d","NCT01073605",0.03273,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Annual Growth Rate SDS","SECONDARY","2 years","D005317; D006130","Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation",FALSE,91,"mann_whitney",NA,NA,NA,1.00056058653667
"1568","6291fe6b62bbd529702ccfdfb4793d02","NCT03242759",0.046,"One-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Annual Change in Six-Minute Walk Test (6MWT) at Week 100","SECONDARY","Intra-group difference comparing to baseline was analyzed.","D011658","Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan",FALSE,88,"t-test",NA,NA,NA,1.3106115651693
"1569","629d545581e53007f0555d65f01d7c2d","NCT03334396",0.019,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving EASI50","SECONDARY",NA,"D003876; D003872; D004485","A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis",FALSE,376,"logistic_regression",NA,NA,NA,1.24776337588564
"1570","62ab5c0a4e1e8accecfe6308e250c6e8","NCT03224624",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"In-clinic Blood Pressure Change","PRIMARY","Comparing baseline-\>12month SBP change within usual care group.","D006973","Self-management of Blood Pressure Medication for Hypertensive Veterans",TRUE,60,"t-test",NA,NA,NA,1.17169922891753
"1571","62ac94c38658a4096b42ff738f525428","NCT03114969",0.029,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants Making at Least One Overall Error at Visit 2-Dual Device Comparisons (Relvar Ellipta DPI Versus All ICS/LABA DPIs With a LAMA Second DPI)","SECONDARY",NA,"D008171; D029424","Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs",FALSE,194,"logistic_regression",NA,NA,NA,1.30005950173705
"1572","62bd02f996c487ab08f04fbe43b331bc","NCT01462435",0.043,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"VASSPID-4. The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale (VASSPID) From 0 to 4 Hours After Trial Entry.","SECONDARY",NA,"D010149","Study of Diclofenac Capsules to Treat Pain Following Bunionectomy",FALSE,213,"t-test",NA,NA,NA,1.90133950264376
"1573","62bda43613bddb4e8faa34e5d7b76d15","NCT00755807",0.042,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Sodium at Week 18 (Open-label Extension Phase)","OTHER_PRE_SPECIFIED",NA,"D009103; D012598","Duloxetine for Multiple Sclerosis Pain",FALSE,201,"mann_whitney",NA,NA,NA,1.81182918230503
"1574","62c3925dbb42421dcca33fd9d2267073","NCT00443872",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Beck Anxiety Inventory Scores for All Subjects","SECONDARY",NA,"D010300","Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists",FALSE,60,"mann_whitney",NA,NA,NA,1.17169922891753
"1575","62c7c7178f236c303c75bb6a0104c1d2","NCT00442546",0.0321,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Visual Analogue Scale for Anxiety (VAS-Anxiety) Score Prior to Surgery","SECONDARY","5 hours","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,161,"anova",2,NA,NA,1.29484690940951
"1576","62d2b30ee925251b35f714d535e7fd33","NCT01215695",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"The Number of Intubation Attempts","SECONDARY",NA,NA,"Video-laryngoscope With a Novel Video-stylet for Difficult Intubation",TRUE,140,"mann_whitney",NA,NA,NA,1.7573575639879
"1577","62d5ecc20a3fd8ab44c6f866d4b4c072","NCT01294644",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With a CR-SMFRS 2-grade Response","SECONDARY",NA,NA,"Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat",FALSE,236,"logistic_regression",NA,NA,NA,1.03814406392062
"1578","62e6cb36649061309d551d76e4d37601","NCT02045862",0.012,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Participants Who Were Triple Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, ≥ 10 Points Improvement on OAB-q HRQL Total Score and ≥ 1 Point Improvement on PPBC) at Months 1, 3, 6, 9, 12 and EoT","SECONDARY","Odds ratio was from a logistic regression model including treatment group, sex, age group (\< 65, ≥ 65 years), previous study history and geographic region as factors and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q HRQL total score and baseline PPBC as covariates.","D053201; D014570; D001745","A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",FALSE,1492,"logistic_regression",NA,NA,NA,1.64973840138337
"1579","62ed513516e015e30d9c6ca5f47f0932","NCT03296527",0.029,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of Subjects With Early OHSS (Including OHSS of Moderate/Severe Grade) and/or Preventive Interventions for Early OHSS","SECONDARY","Proportion of participants with early OHSS (moderate/severe) and/or preventive interventions",NA,"Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women",FALSE,1009,"logistic_regression",NA,NA,NA,2.93560435440696
"1580","62f8456f827d46b9bcb5fc7358db17c6","NCT02340663",0.045,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Number of Bruxing Events Per Hour Sleep Per Night.","SECONDARY",NA,"D002012; D020186; D057085","Nocturnal Mouth Guards, SOVA vs. Standard Acrylic Orthotic; Phase IV",FALSE,53,"anova",2,NA,NA,1.01383269322847
"1581","62f9759118233b1e379c8b71de4bfbfd","NCT02174848",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change in Score on the BAD Scale -- Comparison of Treatment Groups Over Each Study","SECONDARY","This comparison is for the initial study, during which patients in the placebo-DFP group received placebo and patients in the DFP-DFP group received deferiprone.","D006211; D009410","Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration",FALSE,62,"t-test",NA,NA,NA,1.18983814919554
"1582","63002811b5260b58d58ecbbee43785e7","NCT02528253",0.0363,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Low Back Pain From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/ Last Observation CF (LOCF)","SECONDARY","Week 8: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline PGA of low back pain, baseline average LBPI, and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,811,"logistic_regression",NA,NA,NA,3.19107677995283
"1583","630454a82bacc0f997969c0273063fa6","NCT02962908",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Severity of Symptoms in RT-PCR Influenza-confirmed Subjects.","OTHER_PRE_SPECIFIED",NA,"D007251","A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine",FALSE,90,"mann_whitney",NA,NA,NA,1.41980120127578
"1584","6329d380c09f9661078c1ea7b1a5b661","NCT02709486",0.0129,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants Who Took Rescue Medication During Weeks 2, 4, 8, 12, 16 and 24","SECONDARY","Week 12: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,565,"logistic_regression",NA,NA,NA,1.0859966801272
"1585","6332ecd8706220c19e116017f10f661d","NCT04289623",0.007,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Rate of Enrollment (14 Days)","PRIMARY","We conducted a logistic regression among the previously enrolled group with the standard email as the reference group.",NA,"Assessing the Impact of myHealth Rewards Program-related Communications on Enrollment: Replication",FALSE,13021,"logistic_regression",NA,NA,NA,3.00703382766504
"1586","6336f1b5abd5a08f5197345899951e40","NCT02440711",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Borg Rating of Perceived Exertion (CR100), Participants With Unilateral Amputation","PRIMARY",NA,NA,"Evaluation of a Modified Running-specific Prosthetic Foot",FALSE,54,"t-test",NA,NA,NA,1.11553228437488
"1587","633fc3373c9fe24a28a2a5bde2448014","NCT01066793",0.0453,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for HCV RNA at BL in log10 (IU/mL). The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Wk 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2b.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,960,"logistic_regression",NA,NA,NA,4.18637838379981
"1588","634d046ab9e5df408f46c46da059f74f","NCT00755807",0.036,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Total Protein at Week 18 (Open-label Extension Phase)","OTHER_PRE_SPECIFIED",NA,"D009103; D012598","Duloxetine for Multiple Sclerosis Pain",FALSE,202,"mann_whitney",NA,NA,NA,1.59434891556857
"1589","63566388ce0c4d7af2080be354c0a43d","NCT04910165",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Numeric Rating Scale (NRS) Pain Score Improvement","PRIMARY",NA,"D010149","Exparel Use in Adductor Canal Block After Total Knee Arthroplasty",TRUE,100,"mann_whitney",NA,NA,NA,1.49341131573029
"1590","635d3d4efeef2f019c4b981455c77c97","NCT02858193",0.0482,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Carbocysteine Plasma PK Parameters: Cmax","PRIMARY",NA,"D001991","Crossover, Single Dose, Two-stage Bioequivalence Study of SCMC-Lys Salt 1.35 g Powder vs SCMC-Lys Salt 90 mg/mL Syrup",FALSE,60,"anova",2,NA,NA,1.13677791658557
"1591","636d204fc433f8c256c28d7a0ba21fd0","NCT00070707",0.033,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in AM and PM Total Nasal Symptom Severity (TNSS)","SECONDARY","Change at Week 4 (AM)","D012220; D001249; D006255; D065631","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",FALSE,187,"anova",2,NA,NA,1.42592285077671
"1592","638147284b922a9f78ff80708605a73c","NCT00834652",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change of Beck Depression Inventory-II Scores Over 16 Weeks","PRIMARY",NA,"D003863; D003866","Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight",TRUE,206,"t-test",NA,NA,NA,2.12236833271826
"1593","63866a314ec49ac9d4f27d17dbcc10d5","NCT00377260",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"The Distribution of Children With Observed or Parent Reported Adverse Events or Complications According to Treatment Assignment","SECONDARY","Null hypothesis: There is no difference between the two treatment groups regarding the proportion of children with protocol-defined diarrhea.","D010031; D010033","Acute Otitis Media (AOM) Therapy Trial in Young Children",FALSE,291,"logistic_regression",NA,NA,NA,2.08541226350095
"1594","638fd9e73ee661209e852e3514f26d23","NCT02528253",0.0447,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 40, \>=90%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1011,"logistic_regression",NA,NA,NA,4.24770783758353
"1595","639f4ea6b03e5cd963c594d994ceb79a","NCT01236053",0.0312,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,188924,"logistic_regression",NA,NA,NA,42.6744423502929
"1596","63a3164f67ecfec5f676b3474473692a","NCT02224703",0.0279,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Caregiver Global Impression Of Change (CGIC) At The Last Visit","SECONDARY",NA,"D004831; D013577","GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome",FALSE,131,"logistic_regression",NA,NA,NA,1.0396997151286
"1597","63c3437d20504555e6f2ecce2dcf224d","NCT01459653",0.0116,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Patient-level Predictors for All-cause Mortality","SECONDARY","Patient level predictor: History of anemia at enrollment","D009101; D009503; D064147; D000084462; D005334","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",FALSE,1272,"logistic_regression",NA,NA,NA,1.47871814613068
"1598","63cf1beca92fc9eff0f08db7d94783a3","NCT00518882",0.0254,"One-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change in High-density Lipoprotein-cholesterol at Week 78","SECONDARY","The analysis was made with a paired t test within the treatment group and 95% CIs for the difference between Weeks 0 and 78 were constructed. H0 was µ78- µ0=0 against HA: µ78 - µ0 ≠ 0. A difference between the two means was concluded when H0 was rejected at the 5% level.","D003920; D003924","Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes",FALSE,183,"t-test",NA,NA,NA,1.12771237715855
"1599","63d4cc5029596fdc7eb0f15be46c4d78","NCT02431299",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Illness Management and Recovery Treatment Integrity Scale","PRIMARY","Hypothesized that higher levels of IMR competence would predict higher IMRS outcomes.","D001523","Illness Management and Recovery Treatment Integrity Scale Validation and Leadership Intervention Development",TRUE,63,"linear_regression",NA,NA,NA,1.19880559218312
"1600","63e90a824d05cc851ca446732273e14d","NCT00297882",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Cure Rate Day 14","SECONDARY","Sample Size will be determined by N = {\[(Zα/2)/E\]\*2}pq where Where: n=sample size; Zα/2= Z value of a two-tailed test with 95% confidence level=1.96; p represents cure rate, q=1-p, which represents treatment failure rate of; E=precision of 5%","D008288","Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon",FALSE,816,"t-test",NA,NA,NA,4.19474101824876
"1601","63f813e436f9abf731df5e4ee0c693fb","NCT02009046",0.0211,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Percent of Participants Who Ever Used Sexual and Reproductive Health Services","PRIMARY",NA,"D012749","Randomized Evaluation of a Multi-Component, Rights-Based Sexuality Education Initiative for High School Students",FALSE,741,"logistic_regression",NA,NA,NA,1.91234865281504
"1602","63fb73481c5ddfdc0b7f2d4be142736c","NCT00455533",0.0396,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]) to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR/RCB1","SECONDARY","KLK6 204733_at","D001943","Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer",FALSE,295,"logistic_regression",NA,NA,NA,2.0817211882135
"1603","641c6ef90b0e3a38a49f8e1598d37046","NCT01256944",0.05,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"Cholesterol","PRIMARY",NA,"D011085; D002318; D024821; D013577","To Study Polycystic Ovary Syndrome in Taiwanese Women",TRUE,290,"anova",2,NA,NA,2.51138465397077
"1604","641e0e773f47fcb26c188afc1fec5d0f","NCT00472199",0.0315,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in RLS-6 Score ""Severity Falling Asleep"" After 26 Weeks","SECONDARY",NA,"D011595; D012148; D013577","Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)",FALSE,321,"mann_whitney",NA,NA,NA,1.78634788162683
"1605","643321e03314183b66729ea8d7f4e1d6","NCT01462435",0.026,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"TOTPAR-8. Total Pain Relief (TOTPAR) Over 0 to 8 Hours","SECONDARY",NA,"D010149","Study of Diclofenac Capsules to Treat Pain Following Bunionectomy",FALSE,215,"t-test",NA,NA,NA,1.24462616824063
"1606","643fbeaf80409540ede0cf7d100f9bdb","NCT02697773",0.0312,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >= 30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 2, \>=50%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,463,"logistic_regression",NA,NA,NA,2.12317852884026
"1607","64443751125765b3a8b6417d3ce29367","NCT03082196",0.037,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Dental Caries for Primary Molars Sound at Baseline","PRIMARY",NA,"D003731","Efficacy Of A PVP-I Fluoride Varnish",FALSE,139,"t-test",NA,NA,NA,1.36026571865357
"1608","6457ecc8a674feac93414366202ba6d0","NCT03365622",0.0499,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Number of Participants With Nausea","SECONDARY","A logistic regression model was used to examine the association between treatment assignment and incidence of nausea, adjusting for patient age, gender, body mass index (BMI), type of surgery (laparoscopic donor nephrectomy or laparoscopic nephrectomy for renal cancer), and whether the patient received a TAP block during surgery.",NA,"Efficacy of IV Acetaminophen Versus Oral Acetaminophen",FALSE,214,"logistic_regression",NA,NA,NA,2.1588232475036
"1609","6460225a3297163ee67632dbe1448b73","NCT00696436",0.029,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg","SECONDARY",NA,"D006973; D000075222","An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.",FALSE,541,"logistic_regression",NA,NA,NA,2.15396262574275
"1610","646a79cdc36ff80d2bdcea4cdca3c012","NCT02528253",0.0179,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants Who Responded for Chronic Low Back Pain Responder Index at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56","SECONDARY","Week 16: OR and 95% CI estimated from logistic regression model. Logistic regression model included treatment as fixed effect and baseline average LBPI, baseline PGA, and baseline RMDQ as covariates.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,808,"logistic_regression",NA,NA,NA,1.72943580353771
"1611","647168008b671b59899020b1013b4ecb","NCT01221597",0.0451,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)","PRIMARY",NA,"D010411","Study of AA4500 in the Treatment of Peyronie's Disease",FALSE,303,"anova",2,NA,NA,2.35382944752438
"1612","6475271feb217a4ca95d573c6f9b4929","NCT05018689",0.03,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in University of Michigan Depression Center Peer-to-Peer Depression Awareness Assessment Help-seeking Intentions Scores From Baseline (1 of 3)","PRIMARY","Clergy, priest, rabbi, or other religious person",NA,"Evaluation of the Aevidum Curriculum and Club",FALSE,2557,"linear_regression",NA,NA,NA,4.80458046762125
"1613","648413a0842264dc3b613059f4a7c1e0","NCT00442546",0.0283,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Interference With Sleep as Measured by the m-BPI-sf","SECONDARY","Month 6","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,166,"anova",2,NA,NA,1.18013849842024
"1614","648e227ba94ed5c6254f1a3bc9274430","NCT00127062",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Spirometry, Percentage Change in FEV1 From Baseline","PRIMARY",NA,"D001249","Health Effects of Diesel Exhaust in Asthmatic Patients: A Real-world Study in a London Street",FALSE,62,"t-test",NA,NA,NA,1.18983814919554
"1615","6497405933ec9849ae6828441758049a","NCT00645099",0.0325,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to End Point in Homeostatic Model Assessment of Beta-cell Function (HOMA-%B)","SECONDARY",NA,"D012559","A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia",FALSE,357,"mann_whitney",NA,NA,NA,1.93345386633962
"1616","64a583fac110a7531ac2ed15949bdeea","NCT00336479",0.0418,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Subjects With Undetectable Plasma HCV RNA at Week 12 After the Completion of Study Drug Dosing","SECONDARY",NA,"D006506; D006526; D019698; D006505","Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C",FALSE,154,"logistic_regression",NA,NA,NA,1.58452785384979
"1617","64a6185bfccb140e0493046b84bca4a7","NCT03428100",0.031,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (Placebo, 2 mg or 4 mg Baricitinib)","PRIMARY",NA,"D003876; D003872; D004485","A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable",FALSE,185,"logistic_regression",NA,NA,NA,1.34483611906822
"1618","64a6e59cf8ff30716b1f88b984445e09","NCT01392742",0.05,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Predictive Power Values of Host-, Virus- and Treatment-related Factors and Virological Response","SECONDARY","Binary logistic regression for HCV genotype at Week 4.","D006506; D006526; D019698; D006505","An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin",FALSE,238,"logistic_regression",NA,NA,NA,2.278406324604
"1619","64af8a8119537f989295eb2270ae5595","NCT01371734",0.048,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With a CGI-I Response Defined as a Score of 'Very Much Improved' or 'Much Improved'","SECONDARY","Week 3","D003866; D003863; D003865","A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD",FALSE,240,"logistic_regression",NA,NA,NA,2.21106061179241
"1620","64c8ee04471bc9938756df68d6adb895","NCT00408876",0.031,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Laboratory Assessment - Creatinine","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,221,"t-test",NA,NA,NA,1.46686444111381
"1621","64dc4e01cf0a68ee08adbbfa17df4c9d","NCT02311478",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Evaluate Changes in Bleeding Duration Among Women Initiating the Copper T380 IUD During the 90 Days Prior to Initiation Compared to Two 90 Periods After IUD Insertion.","PRIMARY","The estimation parameter compares the 90 days following to the 90 days prior.","D008796; D006470","Tracking IUD Bleeding Experiences: An Evaluation of Bleeding Profiles in New Intrauterine Device Users",TRUE,72,"t-test",NA,NA,NA,1.27670232702116
"1622","64f879259f41847b34d9176f452ed65c","NCT03978871",0.033,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Mean Change From Baseline to 4 Months in Emotion Mindset Scores","SECONDARY","We are reporting the p-value for the group (Growth Mindset vs. Brain Education) by time effect (pre-manipulation and post-manipulation) on fixed emotion mindset scores from time 1 to time 3. This is a test of between by within-subjects interaction effect.",NA,"Effect of Emotion Mindsets on Emotion Processing",FALSE,163,"anova",2,NA,NA,1.33366344930341
"1623","64f981ac28ed76b1b228197572ce1103","NCT01571427",0.04,"Linear regression","INTERVENTIONAL",1,0,0,0,0,"Changes in Cogstate Computerized Test: Detection Test (Post-study Test Score - Baseline Test Score)","PRIMARY","Analysis 3: CDR 0.5 (n=34)","D000544; D060825","Conversations as a Means to Delay the Onset of Alzheimer's Disease",FALSE,83,"linear_regression",NA,NA,NA,1.13415394860463
"1624","651de6ba0b701478c436cc8008024129","NCT01236053",0.0186,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,188924,"logistic_regression",NA,NA,NA,27.2538861041054
"1625","65287f125c17596bdc352b869677cc8c","NCT02571777",0.017,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Patients Achieving the Minimal Clinically Important Difference (MCID) ACQ ≥ 0.5 at Week 26 and Week 52","SECONDARY","Week 52","D001249","Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma",FALSE,1227,"logistic_regression",NA,NA,NA,2.03459763733556
"1626","65399353368e7b639f814178d8993a18","NCT01221623",0.0496,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)","PRIMARY",NA,"D010411","Study of AA4500 in the Treatment of Peyronie's Disease",FALSE,309,"anova",2,NA,NA,2.5739545413548
"1627","655377a49843a3a68f0b1c46786b0e34","NCT01680640",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Liver Fat","PRIMARY","A total sample size of 100 participants, with a 14% drop out during the study and 43 participants in each group completing the study provided 85% power to detect a difference of 40% in liver fat (in the treatment arm compared with the placebo), using a power calculation test with a 0.05 two-sided significance level. For change in liver fat percentage (and other secondary outcomes), ANCOVA will also be undertaken to assess effect sizes in the intervention group and placebo.","D008107; D005234; D065626","Investigation of Synbiotic Treatment in NAFLD",FALSE,89,"linear_regression",NA,NA,NA,1.41222998379373
"1628","6559d7aed321297ce6191df146f0621a","NCT01236053",0.0122,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,188924,"logistic_regression",NA,NA,NA,18.7985904494944
"1629","6564492b3e555f9055c80a61cc46cf3d","NCT01410240",0.044,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline at Postoperative Day 3, Week 1, Week 2, and Week 6 in Western Ontario and McMaster Universities (WOMAC) Scores","SECONDARY","Change Week 6: Stiffness","D010003","Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty",FALSE,96,"mann_whitney",NA,NA,NA,1.31655848324178
"1630","6564e80c0118e1bd681d67d7e630915f","NCT00291499",0.031,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change in Morning Stiffness Duration","SECONDARY",NA,"D010003","Efficacy Study of Condrosulf in the Treatment of Symptomatic OA of the Hand",FALSE,139,"mann_whitney",NA,NA,NA,1.17057246572143
"1631","656a996417e62e4b33f8b9aa14d2b8bd","NCT01994954",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Duration of Home Oxygen Therapy","PRIMARY","The trial was designed to have 97% power at a type I error rate of 5% to detect a 25% intervention effect with respect to the primary outcome. this was done using an independent sample t-test. P-value was calculated, and a p-value of 0.05 or less was interpreted as statistically significant result.","D047928","A Randomized Trial of Outpatient Oxygen Weaning Strategies in Premature Infants",TRUE,166,"t-test",NA,NA,NA,1.24052215774524
"1632","65790a2f63f4d5e2e4bdab0e3dc1deb4","NCT02528253",0.0114,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Low Back Pain From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/ Last Observation CF (LOCF)","SECONDARY","Week 4: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline PGA of low back pain, baseline average LBPI, and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,813,"logistic_regression",NA,NA,NA,1.16575156207987
"1633","657c5b5bafab6fb84f4ac741b618c06f","NCT02004613",0.026,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Number of Patients With Delirium","PRIMARY","hypothesis: Dexmedetomidine may reduce the incidence of postoperative delirium.","D006331","Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery",FALSE,776,"logistic_regression",NA,NA,NA,2.34494078569791
"1634","657f0ca03e03dcdf5505c83dbb901a06","NCT02259400",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,1,0,"Duration of NIV Support","PRIMARY",NA,"D047928","NIV Strategies for RDS in Preterm Infants. NIV (Non Invasive Ventilation), RDS (Respiratory Distress Syndrome)",TRUE,122,"mann_whitney",NA,NA,NA,1.64382327798156
"1635","6593a0a4ac8fe442fb2e60656aa5f959","NCT03192176",0.0376,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 7","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,87,"logistic_regression",NA,NA,NA,1.10107391345892
"1636","6597cdbd72e237225e1f7a813ee2ea0f","NCT00354029",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"NRS Pain = Numeric Rating Scale (0-10)","PRIMARY",NA,"D006484","Effect of Perioperative i.v. Low-dose S(+) Ketamine",FALSE,83,"t-test",NA,NA,NA,1.36592548755136
"1637","6598aa9813f2fbc50a96ce77e0964741","NCT00105989",0.035,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Chloride - Acute Phase","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,435,"t-test",NA,NA,NA,2.27094227068595
"1638","65b754939f40793506397a53b0d091b6","NCT01332851",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Child Emotion Regulation","SECONDARY","Tested mean differences by condition at 3-month follow-up controlling for baseline score, months between baseline and the end of the intervention, and age of child and using an ANVOVA/regression model. Null hypothesis was that post-intervention means were equal.",NA,"Supporting Parents Program: Intervention for Families in CPS",FALSE,247,"linear_regression",NA,NA,NA,2.32040326199209
"1639","65b8f9e7405a85ecffd657f84a74f6f5","NCT04381481",0.01,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Number of Teaspoons of Added Sugar Participants Think the Fruit Drink Contains (Fruit Drink Experimental Task 1)","SECONDARY","Beverages with claim compared to control beverage","D063766","Studying the Impact of Product Packaging in a Virtual Store Environment",TRUE,1515,"linear_regression",NA,NA,NA,1.41386458182062
"1640","65c53eff3306f8e84cd7a8199afa2850","NCT01794923",0.029,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Muscle Soreness With Movement at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 30, 36, 48, 54, 60 and 72 Hours Post-Dose 1","SECONDARY","2 Hours: Analysis was performed using an ANOVA model with treatment, baseline categorical PSR, sex, and baseline MSM terms.",NA,"Topical Ibuprofen for Delayed Onset Mulscle Soreness",FALSE,143,"anova",2,NA,NA,1.12107223848326
"1641","65f9071e4b4ba455ea8e6dddb2377efe","NCT01559259",0.042,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (PRID4)","SECONDARY","1.5 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,181,"anova",2,NA,NA,1.72128246631383
"1642","6604c0986ff973826b9e6c2fda9467bc","NCT00430248",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Percent Change From Baseline in Serum Urate Levels at Final Visit.","SECONDARY",NA,"D006073","Efficacy and Safety of Oral Febuxostat in Participants With Gout",FALSE,1512,"anova",2,NA,NA,5.70381467203539
"1643","660bdaabc8937ffe17cdfaf4f7ea0357","NCT00090584",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Satisfaction","SECONDARY","Null hypothesis: No difference in satisfaction at 8 months post intervention","D014549; D004775","Behavior Enhances Drug Reduction of Incontinence (BE-DRI)",FALSE,238,"logistic_regression",NA,NA,NA,1.04243325371139
"1644","66230df7c3eb57edd253a27d9af4d7cc","NCT02349152",0.046,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Stress Hormone Levels-ACTH, GH, Glucagon (pg/ml)","SECONDARY","GH-Post-bypass","D006331; D006943","Remifentanil and Glycemic Response in Cardiac Surgery",FALSE,106,"t-test",NA,NA,NA,1.43290438344616
"1645","662802a3041f411051f70aaf613a9058","NCT01251757",0.041,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Systolic Blood Pressure (SBP)","SECONDARY","We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline SBP level groups.","D002318","Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies",FALSE,7960,"linear_regression",NA,NA,NA,11.0601328332185
"1646","6634769d17b068e26d22cf49cfa94da3","NCT01138124",0.0212,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","PRIMARY",NA,"D010190; D002292; D007680; D010386; D010195; D050500; D012148","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",FALSE,30026,"logistic_regression",NA,NA,NA,12.1807885993887
"1647","6637bba4efcd2c231fb2416775ad1f12","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Sodium","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1761,"linear_regression",NA,NA,NA,6.15447738929084
"1648","66389dcd9cf3a8bb91bae24301a0ff04","NCT00094302",0.01,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Sodium","SECONDARY","Since the p-value for the preceding test (Statistical Analysis 1) was not significant at the 0.05 level, another generalized linear model was fit, omitting the interaction between treatment group and month of visit. This tests whether the value of the post-baseline laboratory parameter differs by treatment group, taking into account that measurements in the same subject over time may be correlated.","D006333; D002318; D006331","Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function",TRUE,3445,"linear_regression",NA,NA,NA,2.12942984619502
"1649","6643c089d4ea8950bd98b93e1129549d","NCT02969707",0.046,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Change in Hypnotic Induction Profile Score","SECONDARY","Non-parametric analysis, comparison of change (post-treatment minus pre-treatment)","D005356; D009209","Use of Repetitive Transcranial Magnetic Stimulation to Augment Hypnotic Analgesia",FALSE,80,"mann_whitney",NA,NA,NA,1.25244927179379
"1650","6649d4018e8f4f8f1244410e46c1867b","NCT00510146",0.035,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in Hemoglobin (Open-Label Phase)","SECONDARY",NA,"D001714","Olanzapine Treatment of Patients With Bipolar I Disorder",FALSE,380,"mann_whitney",NA,NA,NA,2.12409742579009
"1651","664ac16fe9ea3aa630ad2ac5d90869a6","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Environmental Warning Label","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1746,"linear_regression",NA,NA,NA,6.1282671837603
"1652","665ba5ac63fd9cc95d7e04620536bc7d","NCT03192176",0.0461,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 2 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 2","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.27687466035215
"1653","66766123dd3484e2e847fadb7286b1be","NCT04876482",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Apnea Hypopnea Index (AHI)","PRIMARY","We hypothesized that the improvements in the AHI would be higher in patients who underwent TORS combined with OPR than in those who underwent only TORS and those who received conservative treatment (controls).

.","D001049; D012891; D020181","Myofunctional Training for Obstructive Sleep Apnea Patients After Transoral Robotic Surgery",TRUE,74,"linear_regression",NA,NA,NA,1.2933799900503
"1654","668a42137f723c6e8a5c15ca09536748","NCT01911260",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,1,0,"Change in Height-for-Age Z-score (HAZ) From End of Supplementation to End of Follow-up Period.","PRIMARY","Null Hypothesis: There isn't difference in the HAZ mean difference between children with Normal Height who received zinc amino acid or placebo.

We attributed α=0.05, β=0.20, and power=0.80.","D004392","Weekly Zinc Chelate Supplementation on Children's Growth",TRUE,54,"t-test",NA,NA,NA,1.11553228437488
"1655","669729267e74287a8c91957d7468da49","NCT00455533",0.0275,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]) to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR/RCB1","SECONDARY","TYMS 202589_at","D001943","Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer",FALSE,295,"logistic_regression",NA,NA,NA,1.52524070196342
"1656","66ae87154552d2117604fd7e22a1a996","NCT00958360",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Comparison of Changes in Visual Information Processing From Baseline to Four Months Later Measured With 48 Item VA Low Vision Visual Functioning Questionnaire","SECONDARY",NA,"D015354","Low Vision Intervention Trial II (LOVIT II)",FALSE,323,"t-test",NA,NA,NA,2.64863200438123
"1657","66af93a3eef96d8ebe2505473291b0a9","NCT03779048",0.04,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Phase 1: Baseline Implicit Wanting, Reaction Time on Leeds Food Preference Questionnaire","SECONDARY",NA,"D015431","Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment",FALSE,137,"linear_regression",NA,NA,NA,1.4425925954964
"1658","66b742990a481795d52b07a5fb951879","NCT01779362",0.05,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Insulin Sensitivity, M/I","PRIMARY",NA,"D011236","RISE Adult Medication Study",FALSE,232,"linear_regression",NA,NA,NA,2.24997314719514
"1659","66cbbd6253d26de6dd2719557d0cc46d","NCT03083990",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Cmax","SECONDARY",NA,NA,"Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male",FALSE,98,"anova",2,NA,NA,1.47898140162831
"1660","66ee3db438e3b22662d7d6169189b510","NCT00927862",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,1,0,"The Percent of Out of Range (OOR) International Normalized Prothrombin Time Ratio (INRs) in the Standard and Modified Pharmacogenetic Arms.","PRIMARY","Comparisons between groups for primary endpoints were made using the unpaired T-test. All consented, randomized patients who were successfully genotyped and received at least one dose of warfarin with at least one post-dose INR were included in efficacy analyses (modified intention to treat \[mITT\]).","D013923","Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin",TRUE,477,"t-test",NA,NA,NA,3.2125195040161
"1661","66f11b611fdc1c5f53a17a957f3567a0","NCT04491591",0.0302,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Knowledge as Measured by Decision Quality Instrument","SECONDARY",NA,"D001943","Implementing BREASTChoice Into Practice",FALSE,315,"kruskal_wallis",2,NA,NA,1.70711979788167
"1662","671b4517279bf373c21e0fd912e00c5d","NCT03365934",0.046422,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Microbial Community Richness - (Day 5)","PRIMARY",NA,NA,"Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds",FALSE,58,"t-test",NA,NA,NA,1.08470206091449
"1663","67421da05b89b0eb7b2c9d9ca5762344","NCT00810199",0.0308,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Patient Global Assessment of Pain (VAS)","SECONDARY","Week 52","D001168; D001172","A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment",FALSE,553,"mann_whitney",NA,NA,NA,2.29299377487751
"1664","6752eb4969160ff276b6fb5d5eb48b5d","NCT03980483",0.0362,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving 20 Percentage (%) Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 Superiority Comparison With Placebo","PRIMARY","The null hypothesis is defined as there is no difference between the 150mg dose of GSK3196165 and placebo in the proportion of participants achieving ACR20 response at Week 12, versus the alternative hypothesis that the 150mg dose of GSK3196165 differs from placebo in the proportion of participants achieving ACR20 response at Week 12.","D001168; D001172","Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate",FALSE,766,"logistic_regression",NA,NA,NA,3.09449873028814
"1665","67617c6eda73c2f485b9ad097d193802","NCT02863198",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Spiral Artery Pulsatility Indices in All Patients","PRIMARY",NA,"D007246","Endometrial Injury for Unexplained Infertility",TRUE,120,"t-test",NA,NA,NA,1.63072147479452
"1666","6785574b29de5cd4f08a13a22eed39a1","NCT01312766",0.04,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Number of Cleaved Embryos","SECONDARY",NA,"D007246","Safety and Efficacy Study in in Vitro Fertilisation (IVF) Patients",FALSE,270,"anova",2,NA,NA,2.00988917336908
"1667","678849d53e6cb9e0af3c60faa659c556","NCT00270998",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"""Much Better"" or ""Very Much Better"" on PGI-I at 3 Months","PRIMARY","A priori, the combination treatment was considered superior (75% success rate) to either single-modality therapy (60% success rate) at 80% power with 150 participants per group.","D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",FALSE,299,"logistic_regression",NA,NA,NA,1.16570326036477
"1668","67c428b07619e6b1baf1e6e920dabfde","NCT01027780",0.03,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Electroencephalography Measurement","PRIMARY",NA,"D013315","Mindfulness to Improve Elders' Immune and Health Status",FALSE,110,"anova",2,NA,NA,1.01714525448484
"1669","67c85988e6691ad8c282913e65774cf1","NCT01392742",0.037,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Predictive Power Values of Host-, Virus- and Treatment-related Factors and Virological Response","SECONDARY","Binary logistic regression for EVR at Week 12.","D006506; D006526; D019698; D006505","An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin",FALSE,238,"logistic_regression",NA,NA,NA,1.76838904780691
"1670","67d0dc90b474a13426968ed1b0836133","NCT01234649",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Total Cholesterol (CHOL) Levels","SECONDARY","Factorial repeated measures ANOVA","D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",FALSE,72,"anova",2,NA,NA,1.27670232702116
"1671","67f67b178a8bef1769d389215ef17258","NCT01783990",0.04,"Kruskal-Wallis","OBSERVATIONAL",0,0,0,0,0,"Change in Howell Jolly Body (HJB) Count From Randomized Control Trial Baseline Measurement - Compared Between Children on Hydroxyurea vs Off Hydroxyurea","PRIMARY","Kruskal-Wallis test was used to test if there were a statistically significant difference between the two treatment groups.","D000755","Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol",FALSE,127,"kruskal_wallis",2,NA,NA,1.39063029513526
"1672","67fec2b245ac6d2c876f504673614773","NCT00552786",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Temporary Threshold Shift Measurement by Pure Tone Audiometry (A Total of Four Hearing Assessments Were Completed for Each Formulation Period on the 1st Day Pre- and Post-shift, and the 14th Day Pre- and Post-shift)","PRIMARY",NA,"D034381; D003638; D006317","Antioxidation Medication for Noise-induced Hearing Loss",TRUE,106,"anova",2,NA,NA,1.53589031932405
"1673","68287bc0f39612eafd56009ac0af791f","NCT03704064",0.04,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Treatment Acceptability at Week 20","SECONDARY","Overall treatment acceptability","D015431","Behavioral Weight Loss and Stigma Reduction",FALSE,92,"anova",2,NA,NA,1.19109765408682
"1674","683cc196fd0894760896ccbc73f910b2","NCT01713868",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Adherence With Recommended Supine Sleep Position","PRIMARY","Sample size provided power of detecting the effect of an individual intervention in the presence of interaction.We assumed pre-study prevalence of a safe sleep practice ranging from 50% to 60% across hospitals. We powered the study to detect a 10 percentage point difference between two study groups, and determined that an analysis sample of n=1280 (320 per treatment group) was needed for 80% power (testing at two-sided p\<0.05). Allowing for 20% loss to follow-up, this led to a sample of n=1600.",NA,"Social Media And Risk-reduction Training for Infant Care Practices (SMART)",FALSE,1256,"logistic_regression",NA,NA,NA,3.37053763862179
"1675","6891dbc7dbed0e26aa66294acf063d82","NCT01521923",0.041,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Subjects With Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) <= 3.2 at Week 104 in RA0055 Period 2 Without Flaring","PRIMARY","In order to control the overall study-wise Type I error rate at 5 %, hypothesis testing was performed in a hierarchical order. A hierarchical test procedure was applied to protect the Overall significance level for the multiplicity of endpoints. Hypothesis testing was performed in the following predefined order, each at a 2-sided 95 % alpha level","D001168; D001172","A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis",FALSE,205,"logistic_regression",NA,NA,NA,1.79262844188331
"1676","68b312df4b7a3dacd07ac6401da0dfeb","NCT00227903",0.04,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Proportion of Participants (Without a Baseline Diagnosis of Drug Abuse or Dependence) Abstinent From Both Drugs and Alcohol According to Combined Self-report and Urine","SECONDARY",NA,"D002189; D000437; D019970","Therapeutic Substance Abuse Treatment in Pregnancy - 1",FALSE,114,"logistic_regression",NA,NA,NA,1.32003258782958
"1677","68b321db363d0c8e2b83a515629759de","NCT03962738",0.044,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Who Are Free of Most Bothersome Symptoms (MBS) Associated With Migraine","SECONDARY",NA,"D008881","A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine",FALSE,307,"logistic_regression",NA,NA,NA,2.32042359355324
"1678","68c100f16f84e7d08e5a4faed02f6f0f","NCT02177201",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Postoperative Vomiting","PRIMARY","Null hypothesis: The antiemetic effect was not significantly different for two groups in this study","D014839; D020250","Effect of Intraoperative Crystalloid Volume on Postoperative Vomiting",FALSE,154,"t-test",NA,NA,NA,1.84083479148392
"1679","68cdddaaace87af923fe4a6a58db7039","NCT04262882",0.04,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Family Planning Intentions","SECONDARY",NA,NA,"Multilevel Family Planning Intervention",FALSE,139,"linear_regression",NA,NA,NA,1.45276250438256
"1680","68cfb4cd125f61fa57a3bdc10b57f863","NCT00385671",0.047,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Mean Change From Baseline to 12 Weeks in Fasting Plasma Glucose","SECONDARY","Tested was the null-hypothesis that there would be no difference between pregabalin and gabapentin+duloxetine in mean change from baseline to 12 Weeks in fasting blood glucose.","D009437; D003929","An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain",FALSE,164,"t-test",NA,NA,NA,1.80266763443876
"1681","68e3bd30660fc0f58442436e1a5c67a7","NCT03599648",0.035,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in Parenting Behavior (Parent Report)","SECONDARY",NA,"D000066553","The Pro-Parenting Study: Helping Parents Reduce Behavior Problems in Preschool Children With Developmental Delay",FALSE,122,"t-test",NA,NA,NA,1.21852472301753
"1682","68ee977ae2574149484fc0355936c4af","NCT01070550",0.0271,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for liver fibrosis (not assessed/missed vs cirrhosis). The logistic regression analysis for mSVR was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,665,"logistic_regression",NA,NA,NA,2.25094836133472
"1683","68f42732f943134955b75a252cdef8b2","NCT00099359",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Risk Factors for Perinatal HIV-1 Transmission","SECONDARY",NA,"D015658; D000163","Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission",FALSE,1591,"logistic_regression",NA,NA,NA,1.44874236808248
"1684","69084bc72fca0f8147e2a5b475c8449d","NCT01919814",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Difference in Pizza Consumed During Two Meals","PRIMARY",NA,"D050177","A Short-Term Appetite Suppression Trial Using Appethyl™: The Pizza",FALSE,118,"t-test",NA,NA,NA,1.61751378500378
"1685","6925efab511a0033542d53e60794d8f2","NCT02697773",0.0436,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >= 30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 2, \>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,463,"logistic_regression",NA,NA,NA,2.82149878107177
"1686","693772cf7a20847d4362ad9a13bbe8e2","NCT00112151",0.05,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Upper Body Muscle Strength (1-RM, kg)","SECONDARY","As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in average upper body strength with any T to placebo in subjects assigned to PRT.",NA,"TEAM: Testosterone Supplementation and Exercise in Elderly Men",TRUE,71,"linear_regression",NA,NA,NA,1.26828177971868
"1687","6945f170d1eef276c86c5cb0bf57b9c5","NCT01761084",0.039,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Productivity","SECONDARY","Month 12","D050723; D058866; D016103","Build Better Bones With Exercise",FALSE,141,"t-test",NA,NA,NA,1.43197648200698
"1688","6948f3670ae4ee49024991c3f0dc9848","NCT05819190",0.0424,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Duration of Cold Symptoms Assessed by Means of the WURSS-21: Duration of Sneezing","SECONDARY",NA,"D003139","Testing the Efficacy in Adults With Cold of HEalsea Rescue*",FALSE,200,"mann_whitney",NA,NA,NA,1.82188937091384
"1689","694e769462b3edeea795161f95805f84","NCT01896050",0.032,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Effect of Medication on Change in Grip Strength","SECONDARY","Comparison of change in maximum grip strength between baseline and 12 months for aromatase inhibitor-treated versus tamoxifen-treated patients","D001943; D018771","Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer",FALSE,115,"mann_whitney",NA,NA,NA,1.09769340477643
"1690","695975e55b01c8ba4786c5d01e63f2fa","NCT01314911",0.0243,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Number Of Participants Shedding Virus -- Team Collected Samples","SECONDARY",NA,"D007251","Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults",FALSE,501,"mann_whitney",NA,NA,NA,1.78036775936582
"1691","6975b2e03b08d3af43a02fc1003ba3ec","NCT00256750",0.0392,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire","SECONDARY","Role-Physical, Month 12","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,424,"anova",2,NA,NA,2.46894645754005
"1692","6993711cf4e2f62581445c45f5f14126","NCT00791921",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"American College of Rheumatology 20% (ACR20) Response at Week 24","SECONDARY",NA,"D001168; D001172","Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)",TRUE,230,"logistic_regression",NA,NA,NA,2.24041528002211
"1693","699688c224f43f2d1761a989af78f277","NCT04018001",0.0364,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Adherence to Tofacitinib as Assessed by Greater Than or Equal to (>=) 0.8 Medication Possession Ratio (MPR) up to 6 Months From the Index Date","SECONDARY",NA,"D001168; D001172","Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR)",FALSE,1057,"logistic_regression",NA,NA,NA,3.6492907803995
"1694","69a2bb19e6927193335486813395a29e","NCT00385671",0.026,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Mean Change From Baseline to 12 Weeks in Sexual Functioning Questionnaire (CSFQ) Total Score and Subscale Scores","SECONDARY","Tested was the null-hypothesis that there would be no difference between pregabalin and gabapentin+duloxetine in female participants in mean change from baseline to 12 Weeks in Sexual Functioning Questionnaire (CSFQ) orgasm subscore.","D009437; D003929","An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain",FALSE,210,"t-test",NA,NA,NA,1.23040623756291
"1695","69a8b4322b0c400e65a6a43e106ceb3f","NCT00442546",0.0311,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Interference With Enjoyment of Life as Measured by the m-BPI-sf","SECONDARY","Month 6","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,166,"anova",2,NA,NA,1.27925143148193
"1696","69b0a077a1c4c1d53f3262f17553f175","NCT00539240",0.04,"Linear regression","INTERVENTIONAL",0,0,1,1,0,"Nighttime Heartburn, Number of Days in Week Symptom Activity Score <3 (Better) in Week 6 Compared to Baseline","PRIMARY",NA,"D005764","Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI",FALSE,101,"linear_regression",NA,NA,NA,1.24545208094669
"1697","69b2bddaa024b073c73f9d51b98aa945","NCT00303186",0.034,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"C-reactive Protein (CRP)","SECONDARY","Statistical analysis was carried out between categories, Month 12 and Month 60.","D001168; D015535; D011565","Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy",FALSE,107,"mann_whitney",NA,NA,NA,1.11635143688109
"1698","69bc92615921f59322c21123854d627f","NCT01329380",0.0328,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Number of Participants With Adverse Drug Reactions by Baseline Factors","PRIMARY","Age","D013166; D025241; D013167","Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)",FALSE,396,"mann_whitney",NA,NA,NA,2.05107866541721
"1699","69ce8c53778a1e2834889f219908702b","NCT00409773",0.042,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Percent Change From Baseline in Apolipoprotein-A1 (Apo-A1) at Week 6","SECONDARY",NA,"D024821; D006937; D013577","Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)",FALSE,430,"anova",2,NA,NA,2.63556843242432
"1700","69d04a6bebcddec468552ff86e5d492b","NCT03952546",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Functional Outcomes","SECONDARY",NA,"D006470; D016063","To Evaluate the Safety and Efficacy of the Saline-coupled Bipolar Sealer in Primary Unilateral Total Knee Arthroplasty",TRUE,152,"t-test",NA,NA,NA,1.82914240849702
"1701","69d6aa0bc0813a156b5caff84d14c37e","NCT03718832",0.0480884,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Weight (lb)","SECONDARY","Adjusted mean difference for full controls, 6 months after trial enrollment",NA,"Fresh Food Farmacy: A Randomized Controlled Trial",FALSE,400,"linear_regression",NA,NA,NA,2.84957249316732
"1702","69d899bbef7ae9513e2a409ce48e0c6a","NCT00406133",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"26-week A1c Level <7.0%, With no Severe Hypoglycemic Events for Cohort With Baseline HbA1c >=7.0%)","POST_HOC","A post-hoc defined binary outcome of 26-week glycated hemoglobin \<7.0% with no severe hypoglycemic events was analyzed in logistic regression models, adjusted for baseline glycated hemoglobin level and clinical center.","D003920; D003922","Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes",FALSE,322,"logistic_regression",NA,NA,NA,1.20892570729049
"1703","69da97e32c982ff75c59792996cd0ca6","NCT00790335",0.02,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Change in Leg Circumference","SECONDARY",NA,"D013927; D013923; D054556; D020246; D054070; D011186; D013577","Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis",FALSE,628,"linear_regression",NA,NA,NA,1.68140827441442
"1704","69ebccde6e52c8f1aa04ecadd2aebbd9","NCT00070707",0.047,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in AM and PM Total Nasal Symptom Severity (TNSS)","SECONDARY","Change at Final Week (AM)","D012220; D001249; D006255; D065631","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",FALSE,187,"anova",2,NA,NA,1.92208248349972
"1705","6a108ba88c299e44c1bd1ed1cc3830b3","NCT01638000",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period","SECONDARY","Difference vs Mirabegron. Differences of the percentages were calculated by subtracting the percentage of mirabegron 50 mg group from the percentage of solifenacin 5 mg group.","D053201; D014570; D001745","A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.",FALSE,1870,"logistic_regression",NA,NA,NA,4.11015154681086
"1706","6a2f131c824fb8d83b51d38dcfc2a779","NCT00303979",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Observe the Relative Change Between Baseline of Cohort A and 6 Months of Cohort B in Performance Measures and Composite Score for the Aggregate Practices.","SECONDARY","Performance Measure #4: the relative change of Cohort B (6 months) compared with Cohort A at baseline in anticoagulation for AF for the aggregate practices.","D006333; D009203; D018754; D018487; D007238","IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting",FALSE,25169,"t-test",NA,NA,NA,23.2436292028174
"1707","6a37d7d3e7160fd01f72903dcdd7a910","NCT02572427",0.039,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Skill in Intubating Neonatal Manikin","PRIMARY",NA,"D001238; D001237","Resident Training Enhanced by New Innovations: Teleintubation",FALSE,67,"t-test",NA,NA,NA,1.00371696006588
"1708","6a3c4b90be52a0beb9fdf867e44bf61b","NCT00787800",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Number of Appropriate Shocks by ICD","SECONDARY",NA,"D001281; D013610; D017180; D014693; D013617","The Use of Dual Chamber ICD With Special Programmed Features to Lower the Risk of Inappropriate Shock",FALSE,100,"t-test",NA,NA,NA,1.49341131573029
"1709","6a5bd2c52528b55ac8d6170a6b61e7eb","NCT02293655",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Math Computation - Number of Problems Completed Correctly","PRIMARY","Comparison at Randomization Phase 1 (week 9)","D001289","The Effects of ADHD Medication (TEAM) Study",FALSE,108,"t-test",NA,NA,NA,1.54979200994087
"1710","6a6b13b18683e25d5669b9f612fcc97c","NCT04376684",0.0456,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Part 1: Percentage of Participants Alive and Free of Respiratory Failure at Day 28","PRIMARY",NA,"D000086382; D045169","Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease",FALSE,782,"logistic_regression",NA,NA,NA,3.80124140839045
"1711","6aa16eff74b74aa954c39671b73fd1b4","NCT01559259",0.03,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Intensity Difference on 11-Point Numerical Scale (PID11)","SECONDARY","0.25 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, baseline numerical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,123,"anova",2,NA,NA,1.07314063124432
"1712","6aa2a739c5e55256d318e6040c71af8a","NCT00256750",0.0214,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire","SECONDARY","General Health, Month 24","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,424,"anova",2,NA,NA,1.46836520180466
"1713","6abd96c3fa23c130d3084f8f419824e5","NCT00591578",0.016,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg.","SECONDARY",NA,"D006973; D000075222","Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension",FALSE,645,"logistic_regression",NA,NA,NA,1.40170094095612
"1714","6b1863e041914a5042cfc391f2fbab34","NCT00458406",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Change in NOSE Scale Score From Month 1 to Month 3","SECONDARY","Mann-Whitney test. We hypothesized that Bi-Flex would result in improved adherence but similar efficacy to CPAP.

The study sample size of 45 in the Bi-Flex group and 15 in the CPAP group had 80% power to detect an effect size ≥ 0.85 with a 0.05 two-sided significance level. In addition, with this sample size, the 95% CI for the difference between the 2 means had a range of 1.282 SD.","D001049; D012891; D020181","Evaluation of Adherence and Therapeutic Effectiveness of Bi-Flex Versus CPAP in Children With OSA",FALSE,56,"mann_whitney",NA,NA,NA,1.13456029943022
"1715","6b1cfc38af0f10e9aefd4fce57bb82a7","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Environmental Warning Label","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1750,"linear_regression",NA,NA,NA,6.13526752012651
"1716","6b2b548b381058368a2f5bd1bbcc138e","NCT01066793",0.0264,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for age per 10 years. The logistic regression analysis for mSVR was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,427,"logistic_regression",NA,NA,NA,1.76711876043696
"1717","6b3551afddd605add27619054d8bcf1e","NCT01739803",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Health-related Quality of Life (HQoL)","SECONDARY",NA,NA,"Behavioral Contract Adherence Intervention",FALSE,135,"anova",2,NA,NA,1.7265679672307
"1718","6b430df75005c11c11c352736c9922e6","NCT00755131",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Peak Oxygen Consumption (VO2peak) at Baseline and 6 Months","SECONDARY",NA,"D009203; D007238","Effects of Cardiac Rehabilitation on High Mobility Group Box-1 Levels After Acute Myocardial Infarction",TRUE,75,"t-test",NA,NA,NA,1.301639172202
"1719","6b46eedb8fd5c504087401c014797aab","NCT03843541",0.037,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Day 3 in Mean Expectoration Difficulty Score of NAC and Placebo","SECONDARY","For the superiority comparisons of NAC vs. placebo, the Bonferroni correction was used.","D012140","A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions",FALSE,218,"mann_whitney",NA,NA,NA,1.69387647144539
"1720","6b7b8ee94bd47cfab511500548d44c23","NCT02140593",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"The Surgical Rating Score During Fascial Closure","SECONDARY",NA,"D005770","The Laparotomy Study",TRUE,128,"mann_whitney",NA,NA,NA,1.68251789784767
"1721","6b8e53d918fc06bb767090e4ba89e71a","NCT03655951",0.02,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Awareness of Family Having Rules About Media Use - Child Report From Pretest to Follow-up","SECONDARY",NA,NA,"Birds and Bees Research Study",FALSE,280,"linear_regression",NA,NA,NA,1.12875096791111
"1722","6badf9e144f40bf181dbee2947148175","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Sodium","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1740,"linear_regression",NA,NA,NA,6.11775166016043
"1723","6bd92fcaf7e79e91e91fecdf8fe27b0c","NCT01761084",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Physical Activity","SECONDARY","Only Month 6 and Month 12 strength and balance physical activity differences were significant.","D050723; D058866; D016103","Build Better Bones With Exercise",TRUE,141,"t-test",NA,NA,NA,1.76345107862741
"1724","6bdf26d9bce3a3d699e0248f95747c90","NCT03239496",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Seroconversion Non-inferiority of 2 Dose f-IPV ID vs 3 Dose IPV IM","SECONDARY","The group sizes are chosen to provide ≥ 80% power for each of the primary objectives, for the individual statistical tests of each serotype, as well as across both serotypes simultaneously. Power of ≥80% is also available for all secondary objectives, except for the comparison of the f-IPV regimen administered at weeks 14 and 36 to the 3-dose IPV regimen, which has power of 62% for individual serotypes, and 39% for the combined serotypes.","D011051","A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV",FALSE,373,"t-test",NA,NA,NA,2.84399344783164
"1725","6be5fb5f41b3d1f89f9d3375fb40f33b","NCT00126113",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Abbreviated Profile of Hearing Aid Benefit (APHAB)","SECONDARY",NA,"D034381; D003638","The Performance-Perceptual Test as a Counseling Tool",FALSE,69,"anova",2,NA,NA,1.25127183253256
"1726","6c07c13a32778ab44dea7d3ed307b20a","NCT04858802",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"FSO Cross-sectional Area Change From Baseline on CT by an Independent, Blinded Reviewer - Baseline Zinreich's Modified Lund-Mackay Score ≥ 1 on Both Sides by Independent Reviewer Subgroup","POST_HOC","Day 45","D000096825","A Clinical Evaluation of PROPEL® Contour Sinus Implant",FALSE,92,"t-test",NA,NA,NA,1.19109765408682
"1727","6c0a4189f7849e0bd8c15730912c0748","NCT03855228",0.03,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Total Symptom Score (Assessed by Participant)","PRIMARY","This analysis compares Change From Baseline values.","D012220; D065631; D006255","Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)",FALSE,341,"anova",2,NA,NA,1.76508744981598
"1728","6c367a70b025fb746fa0cb01bee27a8d","NCT03085797",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Requiring at Least One Course of Systemic Steroids for Nasal Polyps up to Week 52","SECONDARY",NA,"D009298; D011127","Effect of Mepolizumab in Severe Bilateral Nasal Polyps",FALSE,407,"logistic_regression",NA,NA,NA,1.35677138551958
"1729","6c586764c968adfa91c21430ca018143","NCT04047121",0.0277,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants Who Met Infusion Glucocorticoid Effectiveness Criteria During 12 Months Post-index Date","SECONDARY","To control and remove the possible influence of the independent variables (like treatment cohort, demographic and clinical characteristics of interest, etc. and clinical judgement) on the outcome measure, multivariable analysis was performed.","D001168; D001172","A Study to Evaluate Patient Characteristics and Treatment Patterns Among Rheumatoid Arthritis Patients",FALSE,366,"logistic_regression",NA,NA,NA,1.70679356991858
"1730","6c5ed181d48a87517266567f29176e83","NCT01915914",0.0394,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Cutaneous Atrophy Sign Score, Epidermal Thickening /Lichenification Sign Score and Abnormal Pigmentation Score Using Visual Analogue Scale (VAS) at the End of the Maintenance Phase and Follow-up Phase","SECONDARY",NA,"D003876; D003872; D012871","A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis",FALSE,107,"mann_whitney",NA,NA,NA,1.26424546289212
"1731","6c7170ac62fda209491e028d86ced6fd","NCT03882047",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis at Day 4 (Participant Evaluation)","SECONDARY",NA,"D012220; D065631; D006255","Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)",FALSE,207,"anova",2,NA,NA,2.12741764789973
"1732","6c77a609dff0429e508d07ca51e7308a","NCT03235050",0.048,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Achieving Weight Loss of ≥5% and ≥10%","SECONDARY","weight loss \>=10% at Week 26","D003920; D050177; D003924","A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes",FALSE,212,"logistic_regression",NA,NA,NA,2.08032025749574
"1733","6c952f5a830b010092dcd10bb2bd991d","NCT01193660",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Comparison of Changes in Brain Glucose Metabolism Using by Brain 18F-FDG PET: Increased and Decreased Areas of Brain Glucose Metabolism","SECONDARY","In our analysis, the null hypothesis is that the effects of three experimental groups are same each other, and the alternative hypothesis is that the therapeutic effect of combination intervention Group (Umbilical Cord Blood + Erythropoietin + Rehabilitation) has much higher than that of either Erythropoietin + Rehabilitation Group or Rehabilitation Group. This study is a pilot study and therefore, power calculation was not applicable in our study. The sample size of each group is more than 30.","D010243; D002547","Allogenic Umbilical Cord Blood and Erythropoietin Combination Therapy for Cerebral Palsy",FALSE,96,"t-test",NA,NA,NA,1.46440978390488
"1734","6c9d371e1750a7e5f95cf18b5f9ce3bf","NCT01416194",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Ischemic Stroke","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",TRUE,7777,"logistic_regression",NA,NA,NA,3.19773018380892
"1735","6ca1b53b76ac7df80f63374bf43aa305","NCT03192176",0.0488,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 4 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 4","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.33869778682453
"1736","6ca874f207ff3d3dc88bf036e3f4294c","NCT01559259",0.038,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Relief Rating Score (PRR)","SECONDARY","0.25 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,123,"anova",2,NA,NA,1.31138152845637
"1737","6ca97c7c80b47a736750c953f00579c7","NCT03781167",0.0493,"One-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I Score: Change From Baseline to End of Study","SECONDARY","Week 26 vs Baseline","D010300","A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)",FALSE,131,"t-test",NA,NA,NA,1.68168561305872
"1738","6cb2a5490e1a0bd73ef41d56c4000cef","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Ham Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1754,"linear_regression",NA,NA,NA,6.14225987828851
"1739","6cbd157f4511e320f699a0ee52e6178e","NCT02697773",0.0276,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >= 30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 2, \>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,465,"logistic_regression",NA,NA,NA,1.91515100843334
"1740","6cdcfc82e82a96c4f30790eeaedcf27d","NCT02754674",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Instability","SECONDARY",NA,"D012421","Comparison of Femoral Tunnel and Clinical Outcome Using Two Anterior Cruciate Ligament Reconstruction Techniques",FALSE,54,"t-test",NA,NA,NA,1.11553228437488
"1741","6cf2ef7f82848a402dee99668f4c2301","NCT01340027",0.023,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With a Micturition Response","SECONDARY",NA,"D053201; D014570; D001745; D020924","A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder",FALSE,228,"logistic_regression",NA,NA,NA,1.15229395553525
"1742","6d00fd1cfa0ce73608211449c6014d1c","NCT01641237",0.0389,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"%SMHR","SECONDARY","Null hypothesis considered treatments in comparison to be equal.",NA,"Effect of Fluoride in a Dentifrice on Remineralization of Erosive Lesions",FALSE,122,"anova",2,NA,NA,1.3322594616236
"1743","6d13dabbc7b4cf358db797652a8e3c3a","NCT04003142",0.017,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate, and Severe VMS From Baseline to Each Study Week Up to Week 12","SECONDARY","Week 10","D019584","A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2",FALSE,334,"logistic_regression",NA,NA,NA,1.06813175309371
"1744","6d2195057198029cc154f99ee1e35075","NCT00227877",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Any Risky Riding or Driving at 12 Months - Prague, CZR","SECONDARY",NA,"D019966","Screening and Brief Advice to Reduce Teen Substance Use",TRUE,529,"logistic_regression",NA,NA,NA,3.38175793713038
"1745","6d23693ff63562f9235191cecbf84775","NCT00879658",0.035,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of All New Gd-enhanced T1 Lesions - Period 1 +2 at Month 3","SECONDARY","Pairwise treatment comparison between different BAF312 dose group and placebo used a two-sided significance level of 5% without adjusting for multiplicity.","D009103; D020529; D012598","Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",FALSE,104,"logistic_regression",NA,NA,NA,1.12860111468277
"1746","6d2caae65d785efab91a21ab22c06c3b","NCT04542343",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Mean Change in COVID-19 Knowledge Among Parishioners After 6 Months Intervention With Support From a Health Ambassador","PRIMARY",NA,"D018352","COVID-19 Risk Reduction Among African American Parishioners",TRUE,110,"t-test",NA,NA,NA,1.56357043896758
"1747","6d3b17e34a02ecca3722d042ae345510","NCT01234649",0.047,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Body Mass Index (BMI)","SECONDARY","Factorial repeated measures ANOVA","D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",TRUE,72,"anova",2,NA,NA,1.21292808377467
"1748","6d4a19f96eeead67ac897a2863c0a294","NCT01575834",0.011,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 12","SECONDARY",NA,"D010024; D015663","Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis",FALSE,6643,"logistic_regression",NA,NA,NA,3.21712292008677
"1749","6d4cb52a553931190ea4ccbeaf202e97","NCT02596126",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Efficacy Endpoints","SECONDARY","Patient satisfaction is measured at visit 1 (6 months) and visit 3 (2 years) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument comprising of four domains: effectiveness (questions 1 to 3), side effects (questions 4 to 8), convenience (questions 9 to 11) and global satisfaction (questions 12 to 14).","D009362; D002318; D009203; D007238","Secondary Prevention of Cardiovascular Disease in the Elderly Trial",TRUE,2466,"t-test",NA,NA,NA,7.28069129722027
"1750","6d59621054574e3a73fee6983c6258df","NCT01780298",0.0418,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Stethographics Measurements: Non-Weighted Acoustic Chronic Obstructive Pulmonary Disease Scores (ACOPDS)","PRIMARY",NA,"D007249","Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study",FALSE,120,"t-test",NA,NA,NA,1.40405925870051
"1751","6d611ba14f662d82f9545842c5e661b1","NCT05081843",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Changes in Normative Beliefs About Tobacco Products","SECONDARY",NA,NA,"Pittsburgh and Rural Area High School Tobacco Prevention",FALSE,167,"t-test",NA,NA,NA,1.91509814041121
"1752","6d7a6a282b195c91fb2e858e5492181d","NCT00773175",0.0314,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Mean Total Volume of Fluid Administered at All Infusion Sites, From the Start to the Cessation of Fluid Administration, for All Randomized Participants","SECONDARY",NA,"D003681","Subcutaneous Rehydration Compared to Intravenous Rehydration",FALSE,148,"anova",2,NA,NA,1.21990325265897
"1753","6d80d4b783d6e54dfc1014b2c3e8fa38","NCT04612244",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Primary Effectiveness Treatment Success Tested for Superiority","SECONDARY","The secondary effectiveness endpoint for the ADVENT Trial is Treatment Superiority uses the same definition as the primary effectiveness endpoint for Treatment Success, but the test is for superiority between MITT subjects in the PFA and Thermal Groups.","D001281","The FARAPULSE ADVENT PIVOTAL Trial PFA System vs SOC Ablation for Paroxysmal Atrial Fibrillation",FALSE,607,"t-test",NA,NA,NA,3.62081552656458
"1754","6da08121b9e90dbebfa5c3689e057da4","NCT02697422",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Body Mass Index (BMI)","SECONDARY",NA,"D002318; D006949","Veteran Peer Coaches Optimizing and Advancing Cardiac Health",FALSE,264,"linear_regression",NA,NA,NA,2.39772562409599
"1755","6dac7c230cbfb2a368802e0021fc75f3","NCT00442546",0.0353,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Visual Analogue Scale for Anxiety (VAS-Anxiety) Score Prior to Surgery","SECONDARY","5 hours","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,157,"anova",2,NA,NA,1.38670547538925
"1756","6dc093dc4a621bf825d36f47234ef978","NCT02889796",0.012,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With no Radiographic Progression From Baseline at Week 24","SECONDARY","Filgotinib 100 mg vs Placebo at Week 24 for change in mTSS ≤ SDC (1.36).","D001168; D001172","Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate",FALSE,955,"logistic_regression",NA,NA,NA,1.32144419814741
"1757","6dce3639596b4fa46ecd646be90c654b","NCT02851511",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Improvement in Cognitive Ability.","PRIMARY","Null hypothesis: The combination of cognitive training (12 weeks) and active stimulation (over the dorsolateral prefrontal cortex) will not lead to beneficial changes on the NIH Toolbox Cognition Battery.

The study is designed to have at least 90% power to detect a difference of effect size 0.42 between cognitive training+tDCS and cognitive training+sham, using a normal inverse combination test at one-sided 0.025 level.",NA,"Augmenting Cognitive Training In Older Adults",TRUE,334,"linear_regression",NA,NA,NA,2.69282754356471
"1758","6dd32cd8696b700c73d4dfab31d8a86c","NCT00531661",0.028,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Days Alive Outside of the Hospital","SECONDARY",NA,"D006333","CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients",FALSE,550,"mann_whitney",NA,NA,NA,2.1071041853102
"1759","6ddc9cb6dbccf1f9d662fcc3ed8a77d3","NCT00270998",0.0492,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"75% Reduction in Weekly Urinary Incontinence Episodes at 3 Months","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",TRUE,296,"logistic_regression",NA,NA,NA,2.50291558562827
"1760","6df96e6ab6da2d3a003ab56b0cdffac8","NCT03521791",0.045,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Breakup Time (BUT)","PRIMARY",NA,"D011625; D007249","Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.",FALSE,83,"mann_whitney",NA,NA,NA,1.25145793557016
"1761","6e0a548c08a86a872106afbe3e542cfd","NCT02633358",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Soluble Interleukin-6 Receptor - the Plasma Level of Participants","OTHER_PRE_SPECIFIED",NA,"D006323; D012770; D007035","Anti-inflammatory Effect of Therapeutic Hypothermia in Out-hospital Cardiac Arrest Patients With Cardiogenic Shock",TRUE,141,"t-test",NA,NA,NA,1.76345107862741
"1762","6e1e992561dc67631adfb0b4708295c0","NCT04025710",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"SADE-free Rate Until the 3-month Follow-up","PRIMARY","The primary hypothesis evaluates the SADE free rate (pSADE_free) at 3 months. Ho: SADE-free rate through 3 months post-implant ≤ 90.0% Ha: SADE-free rate through 3 months post-implant \> 90.0%","D013575; D000083242; D001281; D013610","Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)",FALSE,159,"t-test",NA,NA,NA,1.86974629389364
"1763","6e555b509c2c2bc69bb6244742dc909e","NCT02141672",0.045,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Subjects Achieving Complete Renal Remission at 24 Weeks","PRIMARY","Voclosporin low dose vs. placebo","D009393; D008181","AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)",FALSE,89,"logistic_regression",NA,NA,NA,1.29378891369224
"1764","6e5fac69a02ef91b4c6405a075f7996b","NCT01183013",0.0363,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Occurrence of Cumulative Treat to Target Efficacy Response, of HbA1c Under Treatment of < 6.5% After 30 Weeks of Treatment","SECONDARY","Treatment comparisons are for fixed dose combination versus monotherapy.","D003924","30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks",FALSE,255,"logistic_regression",NA,NA,NA,1.79993039092277
"1765","6e62c4e2a3d0692baa5b5a500253548e","NCT01236053",0.0326,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Breast Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,188924,"logistic_regression",NA,NA,NA,44.3108868990739
"1766","6e6c03336d5eb9182440af1ed904c538","NCT02284178",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Clinical Outcome: Hospital Length of Stay","POST_HOC",NA,"D012131","Oral Suction Intervention to Reduce Aspiration and Ventilator Events: NO-ASPIRATE",FALSE,410,"t-test",NA,NA,NA,2.98032953131242
"1767","6e6c69ed6e6d8eb9b80cbfd5c31989f4","NCT00261443",0.029,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Adjusted Mean Change in CGI-BP From Preceding Phase (Mania) Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 44 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,1.67691244505512
"1768","6e88c6e33b9e7ac88cc8a82ce9773d3a","NCT03802396",0.047,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change in CSF IL-8 Cytokine Levels Between Drug vs Placebo Treated Patients","SECONDARY","Baseline to 6 weeks","D000069544; D003693; D000071257; D004660; D007249; D000079690; D060825","Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction",FALSE,135,"mann_whitney",NA,NA,NA,1.63976950915422
"1769","6e979b0a2ef578ed86a06166f6a439df","NCT02528188",0.0187,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants Who Withdrew Due to Lack of Efficacy","SECONDARY","OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline diary average pain, baseline WOMAC pain score, classification variables index joint, highest Kellgren-Lawrence grade, NSAID and treatment.","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,2.81695941729465
"1770","6e9e98d3cc9c3f780728cd1177221fa3","NCT04490109",0.0365,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Proportion of Subjects With ≥50% Improvement in Eczema Area Severity Index (EASI-50)","OTHER_PRE_SPECIFIED","Responder rates for IGA and EASI will be summarized using descriptive statistics and analyzed using a logistic regression model at each respective timepoints.","D003876; D003872; D004485; D011537","B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis",FALSE,335,"logistic_regression",NA,NA,NA,2.06844605196537
"1771","6ea1ccd9576aba9953c61754c2881501","NCT03365934",0.047937,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Microbial Community Evenness - Day 5","PRIMARY",NA,NA,"Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds",FALSE,52,"t-test",NA,NA,NA,1.05880668018282
"1772","6ea32ddb65d86a3f9b8b379531cc4676","NCT02845440",0.036,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Who Are Abstinent at the Intervention Year 2 Assessment in Cohort 1","PRIMARY","Missing data at year 2 of intervention was imputed using MICE based on baseline characteristics and outcome values at year 1 of intervention. The statistical model was a mixed effects logistic regression with terms for TAU, AD, and AD+CHW (cohort 1) and a clinic-varying random intercept. Regression coefficients were pooled using Rubin's rule over 10 imputation runs.","D012559; D003866; D001714; D001523; D003865","Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness",FALSE,523,"logistic_regression",NA,NA,NA,2.54833994029649
"1773","6eaef5b85d1333d0ce7760fcab827bd2","NCT00261443",0.019,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Mean Baseline and Adjusted Mean Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 52 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,1.16314649710354
"1774","6eb124bc9f540dc0415093b69a265c06","NCT01102491",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Incidence of Nausea and Vomiting","PRIMARY",NA,"D020370; D020250","Additional Anti-emetic Effect of Ramosetron Prophylaxis After Total Knee Arthroplasty",TRUE,142,"t-test",NA,NA,NA,1.7695236426303
"1775","6ebd3bcf8ea26d549ab34c761a3a0d24","NCT01589445",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Comparison of Changes in Glycosylated Hemoglobin (HbA1c)With Pioglitazone and Metformin","PRIMARY",NA,"D003920; D003924","Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects",FALSE,80,"anova",2,NA,NA,1.34217713699512
"1776","6ed2e3e234748ccb3c4076a99bb2a3d4","NCT01690117",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in Frequency of Problem Behavior on a German Version of the Frequency Subscale of the Revised Memory and Behavior Problem Checklist (RMBPC) - (5-point Scale) at Month 6","SECONDARY",NA,"D003704","German Adaptation of REACH II",FALSE,81,"t-test",NA,NA,NA,1.3501394396673
"1777","6ed7001e200584f5cd02646798c7fa95","NCT00043186",0.047,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Urine NTX/Creatinine Percent Change From Baseline at Month 48","SECONDARY",NA,"D001851","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",FALSE,62,"mann_whitney",NA,NA,NA,1.13053456955146
"1778","6ef292fe3973e36b47f23e972ee58e5b","NCT03334422",0.024,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)","SECONDARY",NA,"D003876; D003872; D004485","Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis",FALSE,369,"logistic_regression",NA,NA,NA,1.51434863836009
"1779","6ef96a7b0e3a6e9d70198cc34622c586","NCT01638000",0.016,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit","SECONDARY","Final visit (≥1 point improvement) Odds Rato vs. Mirabegron","D053201; D014570; D001745","A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.",FALSE,1786,"logistic_regression",NA,NA,NA,2.32577745433544
"1780","6f02f570fd07bd017baacd96c5846760","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in AUC of Glucose","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,111,"anova",2,NA,NA,1.5704144397227
"1781","6f0730515afd06b782fae2ac1f15d707","NCT01047501",0.014,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Non-High-Density Lipoprotein Cholesterol Levels","SECONDARY",NA,"D015228","Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)",FALSE,461,"mann_whitney",NA,NA,NA,1.05567069998301
"1782","6f17fb88192904e48cbb7924ec069ce8","NCT03552822",0.02,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Postoperative Temperature","SECONDARY",NA,NA,"Cesarean Section Via Enhanced Recovery",FALSE,532,"mann_whitney",NA,NA,NA,1.54876973449789
"1783","6f231639f494b1dc876fae3c97460fd5","NCT02078713",0.0496,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Patient Decisional Conflict in Contraceptive Choice","SECONDARY","Comparison of informed decision subscale",NA,"Patient-Centered Support for Contraceptive Decision-Making",FALSE,749,"logistic_regression",NA,NA,NA,3.99274089210198
"1784","6f2c3741e3d31d6d6eb1a464dd0041a6","NCT03083990",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"AUC0 - t","PRIMARY",NA,NA,"Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male",FALSE,98,"anova",2,NA,NA,1.47898140162831
"1785","6f59b14d4b2b6cddcb91928b16f9a4cf","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Calories","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1765,"linear_regression",NA,NA,NA,6.1614479472587
"1786","6f60a05667f6e0ac1792c9f464c97e1d","NCT02528253",0.0143,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 32, \>=70%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1010,"logistic_regression",NA,NA,NA,1.58638986098027
"1787","6f677d2f7e15c9ea576c32bc87e676ed","NCT01753518",0.041,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Cosmetic Outcome","SECONDARY","Comparison between arms for patient: scar stiffness is different.","D000072836","A Clinical Trial of Subcuticular Staples Versus Subcuticular Suture for Cesarean Section Skin Closure",FALSE,96,"mann_whitney",NA,NA,NA,1.24099903377859
"1788","6f6ce8d804ad2dd5ccc6478433f382c9","NCT03597464",0.035,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number (and Percent) of Subjects in Renal Response","SECONDARY","Month 24","D009393; D008181","Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin",FALSE,216,"logistic_regression",NA,NA,NA,1.60856325347735
"1789","6f7f08d1b0f5ac6d3df868c35725824d","NCT03718832",0.0454857,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Proportion of Participants Filing Outpatient Insurance Claims With Insurance","SECONDARY","Adjusted mean difference for full controls, 6 months after trial enrollment",NA,"Fresh Food Farmacy: A Randomized Controlled Trial",FALSE,465,"linear_regression",NA,NA,NA,2.93014106190435
"1790","6f82ceb8bc532e61304ab68cebb9bd27","NCT04172701",0.0212,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Adjusted Chronic Obstructive Pulmonary Disease (COPD)-Related Costs: Hospitalization Costs (Per Person Per Month)","SECONDARY",NA,"D029424","A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)",FALSE,4888,"t-test",NA,NA,NA,4.91688179094802
"1791","6f9294d1cee5fd95c21a4553099a6f15","NCT04803734",0.0328,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Cmax","PRIMARY",NA,"D053120","Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation in Healthy Volunteers Under Fasting Conditions",FALSE,106,"anova",2,NA,NA,1.07801023286583
"1792","6fa2bf3565a5b1946f0d90df4440a6b5","NCT02112370",0.035,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"NRS Pain Scores for the First 12 Hours","PRIMARY","Left chest pain","D013964","Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy",FALSE,148,"t-test",NA,NA,NA,1.33781281228607
"1793","6faaf8204f5220d62e21d562b5dc0a8f","NCT02912650",0.017,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Relief Rating (PRR) Score","OTHER_PRE_SPECIFIED","7 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,347,"anova",2,NA,NA,1.08837256018223
"1794","6fba5cb034d4c861ab1bf3300d81e5ea","NCT01416636",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Effect on Hemodynamic Parameter (mPAP - Mean Pulmonary Arterial Pressure)","SECONDARY",NA,"D006976; D006973","Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)",FALSE,94,"mann_whitney",NA,NA,NA,1.20338768890662
"1795","6ff09d5b04984ca33bd542a1fcb13808","NCT05457647",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Stratification Groups","OTHER_PRE_SPECIFIED",NA,"D007640","Theranostic Guided Riboflavin/UV-A Corneal Cross-linking",TRUE,47,"mann_whitney",NA,NA,NA,1.04624856756472
"1796","6ff269ba1c60a43381341ea38504c97a","NCT01988129",0.033,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Firefighters' Health, as Determined by Number of 'Sick' Days Over 12 Months","PRIMARY","Analysis for 'disability/injury' days","D020181; D012893; D011595; D012148; D020178; D005221","Fire Fighter Fatigue Management Program: Operation Healthy Sleep",FALSE,1189,"t-test",NA,NA,NA,3.55891586615265
"1797","700a8ae78b648425a8a9bbbd9b806c93","NCT04910165",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Hospital Length of Stay","PRIMARY",NA,"D010149","Exparel Use in Adductor Canal Block After Total Knee Arthroplasty",TRUE,100,"mann_whitney",NA,NA,NA,1.49341131573029
"1798","702f8f5cda6b1e2e5476a220cc4e0a79","NCT02214186",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Neutrophil Gelatinase-associated Lipocalin (NGAL) as New Marker of Renal Injury in Preeclampsia","SECONDARY",NA,"D004461; D011225","Restrictive Fluid Therapy in Severe Preeclampsia",TRUE,46,"mann_whitney",NA,NA,NA,1.03597838019194
"1799","703174f372a24167cefdefabf11a4d4f","NCT03055156",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Sleep Efficiency Assessed by Polysomnography (PSG)","PRIMARY",NA,"D012893; D020447","Effect of High Rebound Mattress Toppers on Sleep and Sleep-Related Symptoms",FALSE,416,"t-test",NA,NA,NA,1.37149323031259
"1800","70399d0f2f16d37bcc337e056f96ae9e","NCT02110485",0.03,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Decision Self-Efficacy Scale","PRIMARY",NA,"D001064","Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis (Antibiotics Alone vs. Appendectomy)",FALSE,200,"mann_whitney",NA,NA,NA,1.35837046038327
"1801","70595e6dfd546a1d90a42dd392443606","NCT03855189",0.04,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the TNSS At Day 4 (Physician-Evaluated)","SECONDARY","Pairwise treatment comparison based on t-test from an analysis of variance (ANOVA).","D012220; D065631; D006255","Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)",FALSE,227,"anova",2,NA,NA,1.84563466362737
"1802","7082617781a9667943e97ae553d7f561","NCT03646305",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Self-Ratings of Mood (Anxiety)","SECONDARY","Paired sample t-tests was conducted to measure differences in anxious mood from post-intervention to follow-up. Null hypothesis: there would be no significant difference in anxious mood from post-intervention to follow-up",NA,"Singing Your Negative Body-Related Thoughts",FALSE,122,"t-test",NA,NA,NA,1.64382327798156
"1803","70d8c20751cb449ff1e7ea25fc453e3e","NCT01957202",0.0478,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Weighted Mean of the Magnitude of Symptom Relief on Total Ocular Symptom Score (TOSS) (2-4) Hours (h) Post Start of Allergen Chamber Challenge on Day 1 of Each Treatment Period","SECONDARY",NA,"D012220; D065631; D012221","A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)",FALSE,107,"anova",2,NA,NA,1.48619071315628
"1804","711110dac9b1cfbe90db8b617ddcf604","NCT00270998",0.0492,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"No Bothersome Stress Incontinence Symptoms at 12 Months.","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",TRUE,296,"logistic_regression",NA,NA,NA,2.50291558562827
"1805","711d4d1b7daaef824a9291d060574325","NCT00689793",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Ferritin Change Before and After 4 Weeks of Treatment/Placebo","SECONDARY",NA,"D018798; D000090463; D005221","Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors",TRUE,145,"linear_regression",NA,NA,NA,1.7876177554477
"1806","7128c6e43679df574b14b5a0de93203c","NCT02115308",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Late Gadolinium Enhancement (LGE) and RADIAL Myocardial Strain","SECONDARY","Regadenoson STRESS","D003324","Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging",FALSE,46,"t-test",NA,NA,NA,1.03597838019194
"1807","713fcd737e8b86a38177081202431d7d","NCT03636490",0.037,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Systolic Blood Pressure Dipping (Aim 2)","PRIMARY",NA,"D013315","Stress, Salt Excretion, and Nighttime Blood Pressure",FALSE,175,"linear_regression",NA,NA,NA,1.5213785538583
"1808","713fdf5f1f08c351d81923619258f80b","NCT01240902",0.0126,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Quality of Life (QoL) Change","SECONDARY","Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score from baseline to 1 year: TAVR vs. SAVR from secondary objective #8. The one-sided two-sample t-test was used to test non-inferiority at a level 0.05 the hypotheses:

H0: µ MCS TAVR ≤ µ SAVR -5 HA: µ MCS TAVR \> µ SAVR -5 In the above expression µ MCS TAVR and µ SAVR denoted the mean improvements in the KCCQ score from baseline to 1 year.","D001024; D003251","Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement",FALSE,750,"t-test",NA,NA,NA,1.22381739572422
"1809","715bd328f5031522177425e291ac3f91","NCT01223703",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"LV Diastolic Function","SECONDARY",NA,"D006333; D009202; D002311","PUFAs and Left Ventricular Function in Heart Failure",TRUE,133,"t-test",NA,NA,NA,1.7140975432625
"1810","7165b9bb7757a62f48bcc93848b1279c","NCT01715896",0.035,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Day 169","SECONDARY",NA,"D001168; D001172; D009336","A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis",FALSE,138,"logistic_regression",NA,NA,NA,1.29323260594363
"1811","716b783b49ed1544567b209fea15b7af","NCT02714868",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Goal Attainment Scaling (GAS)","PRIMARY","For goal attainment, we calculated independent t-tests to compare GAS t-scores across groups at outcome. Lowest score is 0, highest score is 100. 100 is highest goal attainment.","D002547; D008607; D002658","Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)",FALSE,77,"t-test",NA,NA,NA,1.31800316623017
"1812","717bd60ebed9ab97a69f472251684343","NCT01462162",0.037,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Regression Coefficient Between Change in Fatigue Score as Measured by the FACIT-F at Week 12 and 24 With Change in Disease Activity Parameters at Week 12 and 24","SECONDARY","change in fatigue score at Week 12 versus change in degree of pain Week 12","D001168; D001172","A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis",FALSE,84,"linear_regression",NA,NA,NA,1.06833123731843
"1813","718bd292169de7fecc4139ef850a6e59","NCT01043432",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Iowa Gambling Test","PRIMARY","Linear regressions were utilized to model the outcomes of interest as a function of SA, TBI group, and the interaction between the two groups.","D001930; D000070642; D013405","Executive Dysfunction and Suicide in Psychiatric Outpatients and Inpatients",FALSE,132,"linear_regression",NA,NA,NA,1.70782824525799
"1814","718f29a72aa6eb00a90764033f68abf4","NCT01696396",0.047,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Response at Week 8","SECONDARY","Comparisons between treatment groups were made using response rates estimated from a logistic regression model adjusted for baseline CDAI score and stratification factors (prior vs no prior TNF antagonist use and enrollment pre- vs post-protocol amendment).","D003424","Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease",FALSE,182,"logistic_regression",NA,NA,NA,1.89676171671273
"1815","7198c963da67ac9cfbcf94b8f63604a8","NCT03040141",0.037,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Clinical Status of Participants on Day 7","PRIMARY","All p-values are presented for informational purposes only; there were no adjustments for multiple comparisons.","D007251","Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A",FALSE,85,"logistic_regression",NA,NA,NA,1.0743441881629
"1816","71a548714cc3b11375b0afb383a4a509","NCT03841331",0.02,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in WI-NRS at Weeks 2, 4, 6, 8, and 10","PRIMARY","At Week 8","D011537","Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin",FALSE,233,"anova",2,NA,NA,1.03167688140366
"1817","71bdd3d1ea1d6edd3809c57dacd62cfb","NCT00962754",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Duration of Admission at the Ward in Days","PRIMARY","We calculated that 85 patients in each group would give a power in excess of 85% to detect a difference of two days or more in the geometric mean length of hospital stay with a two-sided significance level of 0.05.","D001724","Fluid Balance Study in Sick Neonates",TRUE,170,"t-test",NA,NA,NA,1.93183092008029
"1818","71c4e31fff580dc123b25ebe90a31c98","NCT02670538",0.0417,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)","PRIMARY",NA,"D003863; D001714","Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder",FALSE,325,"t-test",NA,NA,NA,2.28102173941344
"1819","71c806b0233d091a3bb0e3dd453cfdd9","NCT01765920",0.02,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,1,0,"Dynamics of Acute URTI Symptoms Severity According to the Daily Wisconsin Upper Respiratory Symptom Survey - 21 (WURSS-21) Assessment of the Patient (Including the Total WURSS-21 Score, ""Symptoms"" Domain Score, and ""Ability"" Domain Score).","SECONDARY",NA,"D007239; D003141; D012141","Clinical Trial of Safety and Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adults",FALSE,333,"kruskal_wallis",2,NA,NA,1.22906042710581
"1820","71ca5dacf43804aa4a825388915a95fb","NCT02045862",0.019,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours at Months 1, 3, 6, 9, 12 and EoT","SECONDARY","Odds ratio wa from a logistic regression model including treatment group, sex, age group (\< 65, ≥ 65 years), previous study history and geographic region as factors and baseline mean number of incontinence episodes per 24 hours as a covariate.","D053201; D014570; D001745","A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",FALSE,1492,"logistic_regression",NA,NA,NA,2.4719870336665
"1821","71d7cfab26a58663cb3635485366d29f","NCT01066819",0.014,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response Over Time by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for Ethnic origin (OTHER vs WHITE/CAUCASIAN). The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,674,"logistic_regression",NA,NA,NA,1.27382311575952
"1822","71f36ee631747746caf122d9726933d1","NCT00600704",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Mean Number of Packed Red Cells Units Transfused During Hospital Stay","PRIMARY","Sample size calculation was based on a two-sided alpha error of .05 and 80% power. After applying the protocol in two equal groups of 10 patients, the analysis showed that the study requires 60 patients per group. However, we decided to enroll up to 100 patients per group to allow for patient attrition or missing data, and also in order to look for differences with regards to transfusion between patient subgroups.","D003324","Impact of Fluid Restriction Policy in Reducing the Use of Red Cells in Cardiac Surgery",TRUE,192,"t-test",NA,NA,NA,2.0503737111932
"1823","72013ea2e2151dbe836a13d5a2348d02","NCT00468845",0.044,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Percent Change From Baseline in Peak Expiratory Flow","SECONDARY","48 hours PS","D010149","Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy",FALSE,235,"anova",2,NA,NA,2.03428181490307
"1824","724636fab70e4956d840b4d8d8e2e058","NCT03104543",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Primary Care Provider Attitudes","SECONDARY",NA,"D050171","Communicating Health Information and Improving Coordination With Primary Care",FALSE,156,"t-test",NA,NA,NA,1.85245347153569
"1825","7280443a5fe8239cabf7d4484677161a","NCT05780047",0.05,"One-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Changes in Environmental Health Literacy Using the Environmental Literacy Survey","SECONDARY","Paired samples t-tests were run to compare whether EHL knowledge, attitudes and behavior changed after the intervention. EHL scores were expected to increase between pre and post testing.",NA,"Personalized Mobile Intervention to Reduce Exposure to Endocrine Disrupting Chemicals in Adults of Child-Bearing Age",TRUE,174,"t-test",NA,NA,NA,1.95391863793846
"1826","729f0fecd4c7e12e0a7e665df3a442cc","NCT03192176",0.0449,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 10","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.27044068920662
"1827","729fdf6c2b26edd282bd19a5d85abf6e","NCT01850446",0.026,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Severity of Influenza Symptoms (Fever, Flu Non-specific and Nasal/Throat/Chest Symptoms) in Scores According to the Symptoms Severity Scale.","SECONDARY","Severity of influenza symptoms (day2 morning)","D007251","Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza",FALSE,184,"t-test",NA,NA,NA,1.1536443139008
"1828","72a309252da15534bcaf53ff5a18c51b","NCT02373813",0.037,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"SDAI Score at All Measured Timepoints","SECONDARY","Week 12","D001168; D001172","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",FALSE,202,"t-test",NA,NA,NA,1.63182060479042
"1829","72d63266c198007f84b64e8edf4fff7d","NCT01175902",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Intraocular Pressure (IOP), Period 1","PRIMARY","Comparison between two arms were made for IOP, systolic BP, diastolic BP and OPP at each time period.","D005901; D057066","Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma",FALSE,44,"t-test",NA,NA,NA,1.01513168983373
"1830","72d9a106a8411abc857cbba554b2da8c","NCT00703963",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Mean Percentage of INR Tests Within the Therapeutic Range","SECONDARY","Statistical significance was defined as p \< 0.05.",NA,"Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care",FALSE,179,"mann_whitney",NA,NA,NA,1.98118237283235
"1831","72e12153a53f778cec8592642544760e","NCT03687762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in Pain Catastrophizing (i.e., Cognitive Content Mechanism; Macro-level)","OTHER_PRE_SPECIFIED",NA,"D059350","Back on Track to Healthy Living Study",FALSE,302,"anova",3,NA,NA,1.03237942189705
"1832","72e53d0ece88bb4751dd1f8e259367cd","NCT04490109",0.04,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Proportion of Subjects With ≥4 Point Improvement in Average Itch Numeric Rating Scale (AI-NRS)","SECONDARY","The frequency and rate of WI-NRS and AI-NRS responders will be reported and compared between treatment groups using a logistic regression model. Generalized estimating equations to account for repeated measures and within-subject variability may also be applied.","D003876; D003872; D004485; D011537","B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis",FALSE,337,"logistic_regression",NA,NA,NA,2.241974969484
"1833","730232810da2627e307e1f66a1f06488","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Alanine Aminotransferase (ALT) Value at Baseline and After Treatment Completion","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"1834","730f727470b94bb9c7f9b9106eb515b6","NCT03192176",0.0338,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week","SECONDARY","Week 4","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.00096859798305
"1835","732c96d8f79da6dd5860bdd98e89e038","NCT02732145",0.036,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Distribution of Aceto-Whitening Reaction in Relation to the Structures of the Inner Vulvar Ring","SECONDARY","Parameter: The difference in the incidence of aceto-whitening of Bartholin's Gland Opening versus Vestibule in patients with vulvar dermatosis and positive AWR.","D056650; D008010; D018459; D012871; D009450","Diagnostic Accuracy of ""Three Rings Vulvoscopy"" for Detection of Vulvar Dermatosis",FALSE,82,"t-test",NA,NA,NA,1.03212410407845
"1836","732dffc839c68eea7d1c71e80c3674d0","NCT01252966",0.033,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Performance (Attention)","SECONDARY","Multiple regression models were used to estimate effects of treatment on change in cognitive performance. Age, Shipley IQ score, number of cigarettes smoked per day at baseline, and EOT smoking status were included as covariates.","D014029","Cognitive Training for Nicotine Dependence",FALSE,174,"linear_regression",NA,NA,NA,1.3767155882454
"1837","733ca1b77057fa071198d866cce465bb","NCT00227877",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Past-12-month Substance Use at 12 Months Among Baseline Substance Users, New England, USA","PRIMARY",NA,"D019966","Screening and Brief Advice to Reduce Teen Substance Use",FALSE,466,"logistic_regression",NA,NA,NA,3.1755636484131
"1838","735a969cd9e3009f21cf9c67bd3e4047","NCT00672737",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Experimental Heat-induced Pain - IGFBP-1","PRIMARY","Beta for SaO2: for every 1-%-absolute decrease in the nadir SaO2, the heat pain threshold will additionally increase by 0.0172 'C for every 1-mcg/mL increase in the plasma level of remifentanil.","D001049; D012891; D020181","Study of Pain Processing in Subjects Suffering From Obstructive Sleep Apnea",TRUE,48,"linear_regression",NA,NA,NA,1.05642048349345
"1839","7383fdadbb95d51c187d36a892420146","NCT00707447",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Eating Behavior (TFEQ) - Disinhibition","SECONDARY",NA,"D003920","Evaluation of a Primary Type 2 Diabetes Prevention Programme",TRUE,166,"t-test",NA,NA,NA,1.90948799930043
"1840","738c388e53fafdd80759c9142d74cf3e","NCT00672737",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Experimental Heat-induced Pain - IGFBP-1","PRIMARY","Beta for IGFBP-1: for every 1-pg/mL increase in its serum level, the heat pain threshold will additionally decrease by 0.0001 'C for every 1-mcg/mL increase in the plasma level of remifentanil.","D001049; D012891; D020181","Study of Pain Processing in Subjects Suffering From Obstructive Sleep Apnea",TRUE,48,"linear_regression",NA,NA,NA,1.05642048349345
"1841","7394e4b9fabbfd46c36a062a81f877e4","NCT03372369",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Effective Contraception Preference Score","PRIMARY","The null hypothesis is that the change in the effective contraception preference score for the patient-centered poster between baseline and followup is 0.",NA,"Testing the Impact of Two Posters on Contraceptive Knowledge, Contraceptive Preferences, and Perceived Pregnancy Risk",TRUE,470,"t-test",NA,NA,NA,1.45670417032428
"1842","73ba4a6ac13a4a90e70a92e763889967","NCT03953508",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Puff Topography","PRIMARY",NA,NA,"Perceptions of Cigarette Smoking in Young Adults",FALSE,121,"anova",2,NA,NA,1.63728545358366
"1843","73c1f4e546d67a41c2943d84adc82195","NCT02528253",0.0335,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 2, \>=70%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1012,"logistic_regression",NA,NA,NA,3.32694317708287
"1844","73d2ca1304d950191b4d85c29b87dc49","NCT00768053",0.035,"One-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Sensitivity to Change of the EULAR-RAID Score: Change From Baseline to Week 4","PRIMARY","Comparison of change from baseline between EULAR-RAID score and Sleep NRS value","D001168; D001172","Evaluation of EULAR-RAID Score in Rheumatoid Arthritis Patients",FALSE,108,"t-test",NA,NA,NA,1.14919024367779
"1845","73d8c411a71293707da96e1281c63470","NCT01708902",0.0271,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"The Frequency of Patients With Use of Rescue Therapy During 24 Week Treatment Period in Main Group","SECONDARY","Comparison of 'Main: Linagliptin 2.5mg / Metformin 1000mg BID' / 'Main: Linagliptin 5mg QD'.

The logistic regression includes treatment and continuous baseline HbA1c. The validity of the model is questionable as there is possibly a quasi-complete separation of data points, the results shown are based on the last maximum likelihood iteration.","D003924","Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients",FALSE,282,"logistic_regression",NA,NA,NA,1.47314484853463
"1846","73e9a67694e2460618697c3b789c8750","NCT00212134",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Parenting Stress","SECONDARY","ITT analyses comparing parents of children randomized to receive an IOL to those left aphakic.","D002386; D001035","Infant Aphakia Treatment Study (IATS)",TRUE,108,"t-test",NA,NA,NA,1.54979200994087
"1847","73ef6994a2dfe834ac32d293f781b16f","NCT00051363",0.045,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Executive and Frontal-Lobe (E/F) Function: SWMT- Mid-day Activation Index (SWMT-ActMD)","SECONDARY","Comparison of means (regression estimates) between arms for covariate adjusted 2M E/F Function- SWMT-ActMD.

Covariates were designated in the a priori secondary analysis plan as being the most likely to explain variation in the outcomes. Covariates included: study arm, OSA severity, sex, race, % of total sleep time oxygen saturation \< 85% (PSG), age \< 60 years, WASI Verbal IQ, and WASI Performance IQ.","D001049; D012891; D008171","Apnea Positive Pressure Long-Term Efficacy Study",FALSE,1098,"linear_regression",NA,NA,NA,4.45101890355325
"1848","740631fed54aff9bf96a6c930132c366","NCT00551135",0.0221,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Baseline and Change From Baseline in Anxiety Visual Analog Scale (VAS) Score","SECONDARY","Day 4 PS; LS Means from ANOVA model with terms of treatment, pooled center, baseline VAS score and baseline PCS score (for baseline visit ANOVA model with terms of treatment and pooled center). Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,200,"anova",2,NA,NA,1.04425734941414
"1849","7409d5f8c0920cb38a6d9c9306e8e8c0","NCT03114969",0.03,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants Making at Least One Critical Error at Visit 1-Dual Device Comparisons (Relvar Ellipta With or Without a LAMA DPI) Versus Any Other ICS/LABA DPI With or Without a LAMA DPI)","PRIMARY",NA,"D008171; D029424","Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs",FALSE,200,"logistic_regression",NA,NA,NA,1.35837046038327
"1850","740f29fc6e78e483ff457c63889703f0","NCT00106964",0.0244,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Sero-Response to Hepatitis B Surface Antigen; Predictor: STUDY ARM","SECONDARY",NA,"D006506; D006509; D006505","Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth",FALSE,224,"logistic_regression",NA,NA,NA,1.20218934593893
"1851","7415061f94b299e01aeabcec4d7bcac1","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Price)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1751,"linear_regression",NA,NA,NA,6.13701635655789
"1852","7419a51aeecaa12245d5475618529c8d","NCT00410384",0.0167,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"SLE Responder Index (SRI) Response Rate at Week 52","PRIMARY",NA,"D008180","A Study of Belimumab in Subjects With Systemic Lupus Erythematosus",FALSE,548,"logistic_regression",NA,NA,NA,1.34251977690418
"1853","7423527359bf35087302ded0d5cabcd7","NCT00442546",0.0373,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Current Pain During the Hospital Stay Assessed by the Pain NRS","SECONDARY","64 hours","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,170,"anova",2,NA,NA,1.51032292731977
"1854","74329a4c8cbe90d2cebc5e3b7df18e81","NCT03252587",0.0371,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants Who Achieve Lupus Low Disease Activity State (LLDAS)","SECONDARY","BMS-986165 6 mg vs Placebo","D008180","An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus",FALSE,183,"logistic_regression",NA,NA,NA,1.5584772742716
"1855","744114271767e01e212bc946b1fba1ed","NCT01079962",0.042,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Brachial Blood Pressure (BP) at Week 4 and Week 12","SECONDARY","Change in DBP at Week 12: p-value was calculated by 2 sided t-test.","D006973","An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION])",FALSE,191,"t-test",NA,NA,NA,1.76713529351056
"1856","745fe7dcf75b2259956da463f58b3b21","NCT00740051",0.0374,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Patients With HbA1c<7.0 at Week 18 (Interim Analysis)","SECONDARY","Linagliptin versus Placebo","D003924","A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate",FALSE,204,"logistic_regression",NA,NA,NA,1.65471066038167
"1857","74686407d5be5d54e95f0b0cbe02412a","NCT00803114",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Time to First Request for Analgesia","SECONDARY",NA,NA,"Epidural Morphine Following Vaginal Delivery",FALSE,228,"t-test",NA,NA,NA,2.2308164865578
"1858","746c387b18b4356b32e9e9558a33d9c2","NCT02845440",0.013,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Who Are Abstinent at the Intervention Year 2 Assessment in Cohort 1","PRIMARY","Missing data at year 2 of intervention was imputed using MICE based on baseline characteristics and outcome values at year 1 of intervention. The statistical model was a mixed effects logistic regression with terms for TAU, AD, and AD+CHW (cohort 1) and a clinic-varying random intercept. Regression coefficients were pooled using Rubin's rule over 10 imputation runs.","D012559; D003866; D001714; D001523; D003865","Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness",FALSE,523,"logistic_regression",NA,NA,NA,1.05246348417206
"1859","746f7630cf0e2c4c51ad8bdf37e8bea4","NCT00150345",0.049,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association of Positive PCR Assessments With Achievement of Continuous Defervescence (Yes)","SECONDARY","Continuous defervescence achieved=Yes","D009181","Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients",FALSE,63,"linear_regression",NA,NA,NA,1.17897751993381
"1860","748c60e258cf548180d291fa1682e9f1","NCT03372369",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Perceived Pregnancy Risk Score","PRIMARY","The null hypothesis is that the patient-centered poster does not produce a larger increase in the perceived pregnancy risk score between baseline and followup than the CDC poster.",NA,"Testing the Impact of Two Posters on Contraceptive Knowledge, Contraceptive Preferences, and Perceived Pregnancy Risk",FALSE,936,"t-test",NA,NA,NA,2.04981899054956
"1861","7490688b0d9b42cb9c4b8a8385182368","NCT00725101",0.026,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Odds Ratios From Stepwise Logistic Regression Model of Longitudinal Adherence to Duloxetine Treatment for Fibromyalgia (FM) Over 12 Months: Generalized Anxiety Disorder-7 (GAD-7) Score, Pregabalin Use, and Non-Steroidal Anti-Inflammatory Drug (NSAID) Use","PRIMARY",NA,"D005356; D009209","Fibromyalgia Health Outcome Study on Cost of Treatments",FALSE,212,"logistic_regression",NA,NA,NA,1.23611381743147
"1862","7491013a192de1d7f5e54e44a981369d","NCT00402987",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Difficulty Swallowing Scale (DSS) Difference at Least 50% Gone at 12 Hours Post-First Dose","OTHER_PRE_SPECIFIED",NA,"D010612","Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat",FALSE,179,"logistic_regression",NA,NA,NA,1.28685496131803
"1863","7494787033c0761c6d2bf7cd2211ab57","NCT03069482",0.046,"Two-sample t-test","INTERVENTIONAL",0,1,0,0,0,"Usability of App Design as Measured by the System Usability Scale (SUS)","PRIMARY",NA,"D014029; D001523","Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness",FALSE,62,"t-test",NA,NA,NA,1.11057688235318
"1864","750353c4dbe6f96f3acd3659ac2f19ee","NCT03192176",0.049,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week","SECONDARY","Week 7","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.34324620430308
"1865","75084cea48119054837215cac971f3ad","NCT04047121",0.0303,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Mean of All Cause Emergency Department (ED) Visits During 12 Months Post-index Date","SECONDARY","To control and remove the possible influence of the independent variables (like treatment cohort, demographic and clinical characteristics of interest, etc. and clinical judgement) on the outcome measure, multivariable analysis was performed.","D001168; D001172","A Study to Evaluate Patient Characteristics and Treatment Patterns Among Rheumatoid Arthritis Patients",FALSE,609,"linear_regression",NA,NA,NA,2.37184077456102
"1866","7508fdc5a8d4d46c90426b491f6648d2","NCT00105989",0.021,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hematocrit - Continuation Phase","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,384,"t-test",NA,NA,NA,1.37556015762117
"1867","751be5dc94e518d167ccdff420140fdb","NCT05127304",0.036,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"COPD and/or Pneumonia-related Health Care Resource Utilization","PRIMARY","Outpatient visits","D029424","A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",FALSE,11316,"linear_regression",NA,NA,NA,11.8062426731356
"1868","753e7081592c3d70f429ff6a5bb4f4c9","NCT01822548",0.05,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Absolute Change in the Endothelial Progenitor Cell (EPC) Number","PRIMARY",NA,"D003920; D003924","Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes",TRUE,64,"linear_regression",NA,NA,NA,1.20770700959599
"1869","754dca478af7c9f456487aa8af7ad129","NCT02128763",0.02,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Change in Tear Osmolarity","OTHER_PRE_SPECIFIED",NA,"D015352; D007638","Dry Eye Assessment and Management Study",FALSE,350,"linear_regression",NA,NA,NA,1.25954511945179
"1870","75514e957a3998d4996fa2610b1376fb","NCT01782898",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Postoperative Opioid Consumption","SECONDARY",NA,NA,"The Effect of Intraoperative Esmolol to Improve Postoperative Quality of Recovery and Pain After Ambulatory Surgery",FALSE,58,"mann_whitney",NA,NA,NA,1.15327776573523
"1871","7558c55947a6274422e3ec21a12c50d1","NCT00105989",0.021,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Eosinophils - Acute Phase","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,423,"t-test",NA,NA,NA,1.44280100422149
"1872","7559d58b4c1632225fdeffb319cb467e","NCT03192176",0.0405,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 11","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.16551924914018
"1873","7562cd2cb442426bc7333fb35fbb6348","NCT04516759",0.0286,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Clinical Improvement at Day 7, 14 and 21","SECONDARY",NA,"D000086382","AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19",FALSE,153,"mann_whitney",NA,NA,NA,1.14466523377014
"1874","756e3c1b34075cd14f2d16b0808b1fa2","NCT00551135",0.0456,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Baseline and Change From Baseline in Anxiety Visual Analog Scale (VAS) Score","SECONDARY","Day 3 PS; LS Means from ANOVA model with terms of treatment, pooled center, baseline VAS score and baseline PCS score (for baseline visit ANOVA model with terms of treatment and pooled center). Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,200,"anova",2,NA,NA,1.93671763972089
"1875","7576c72820a257e3d469a8ae608a9db5","NCT03521115",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Frequency of Parental Approval for Teen Drinking (in Moderation)","PRIMARY","6 month follow-up. Among those assigned to intervention, dosage was assigned as 0 for no exposure, 1 for completing only the communication, and 2 for completing the alcohol component. A probit analysis predicting completion was conducted from baseline measures and an instrumental variable, inverse Mills' ratio (IMR) representing the underlying selection processes was included as a covariate accounting for factors related to program completion. All controls were assigned 0 dosage.","D019973; D000435; D000374; D000428; D064829","Family Based Prevention of Alcohol and Risky Sex for Older Teens",TRUE,405,"linear_regression",NA,NA,NA,2.96227236579898
"1876","75a5a55ce14ae5027b6170f63b77941f","NCT03036293",0.031,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in the Total EQ-5D-3L Score at 12 Weeks of Treatment in Patients From: 5.1. Group 1 (Tenoten®, 4 Tablets a Day); 5.2. Group 3 (Tenoten®, 8 Tablets a Day).","SECONDARY","Median changes (begin-end) within groups are compared","D009497","Tenoten® in the Treatment of Somatoform, Stress-related and Other Neurotic Disorders",FALSE,258,"mann_whitney",NA,NA,NA,1.58251576288915
"1877","75a727cbd012d54dce24d118b3d8aff5","NCT00689793",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Aerobic Capacity Using an Indirect Measurement of VO2Max : Chester Step Test","SECONDARY",NA,"D018798; D000090463; D005221","Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors",FALSE,145,"linear_regression",NA,NA,NA,1.7876177554477
"1878","75b416cbf58ceb8e830f31e2ed9b83ff","NCT04299425",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Average Number of Parathyroid Glands Identified With High Confidence Per Patient","PRIMARY",NA,"D000236; D010282; D006934; D006961; D049950; D006965","Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy",FALSE,160,"t-test",NA,NA,NA,1.55554427892999
"1879","75bbb9f2b31568c0e7de279c4c11639d","NCT02596126",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Efficacy Endpoints","SECONDARY","Patient satisfaction is measured at visit 1 (6 months) and visit 3 (2 years) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument comprising of four domains: effectiveness (questions 1 to 3), side effects (questions 4 to 8), convenience (questions 9 to 11) and global satisfaction (questions 12 to 14).","D009362; D002318; D009203; D007238","Secondary Prevention of Cardiovascular Disease in the Elderly Trial",TRUE,2466,"t-test",NA,NA,NA,7.28069129722027
"1880","75c9390d72a705410db8e3185e674a13","NCT00406133",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Relative Decrease in A1c Level by >=10% (for Cohort With Baseline HbA1c >=7.0%)","OTHER_PRE_SPECIFIED","Within each age group, in addition to the primary ANCOVA analysis, pre-specified 26-week binary glycated hemoglobin outcomes (relative decrease by \>=10%, 26-week level \<7.0%, absolute decrease by \>=0.5%, relative increase by \>=10%, absolute increase by \>=0.5%) were evaluated in logistic regression models, adjusted for baseline glycated hemoglobin level and clinical center.","D003920; D003922","Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes",FALSE,322,"logistic_regression",NA,NA,NA,2.19215042010315
"1881","75d55b31dfac0839748085b6070d55c9","NCT02501590",0.05,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Normilized Muscle Activity","PRIMARY",NA,NA,"Differences in Muscle Activity Patterns and Graphical Product Quality in Children With Graphomotor Impairment",FALSE,48,"mann_whitney",NA,NA,NA,1.05642048349345
"1882","75d8f9ab9e48947ca427f7bb15752eb4","NCT03982368",0.032,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Schirmer I Test (Without Anesthesia) vs Week 4 - Per Protocol Set","PRIMARY",NA,"D015352; D007638","A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye",FALSE,152,"anova",2,NA,NA,1.25585729060319
"1883","75dd49f0b6d09af80902f23cc84e7245","NCT02764385",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Patients Contacted for Quitline Enrollment","PRIMARY",NA,"D014029","Using a Teachable Moment Communication Process to Improve Outcomes of Quitline Referrals",FALSE,1819,"logistic_regression",NA,NA,NA,6.25479021708618
"1884","75ee3af6a3896692e3308b68b96a9894","NCT01211145",0.021,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Headache Response at 2 Hours Post-treatment","SECONDARY",NA,"D008881; D006261","Zomig - Treatment of Acute Migraine Headache in Adolescents",FALSE,334,"logistic_regression",NA,NA,NA,1.28421619622654
"1885","761de18acf622a63966292bbb159c4bf","NCT02203357",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Immunogenicity of Hepatitis B Vaccine With Different Doses and Schedules in Healthy Young Adults","PRIMARY",NA,"D006506; D006509; D006505","A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults",TRUE,353,"anova",3,NA,NA,1.10180362417963
"1886","761f2a12c8f109ba17a978507911c00f","NCT03114969",0.035,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants Making at Least One Overall Error at Visit 2-Dual Device Comparisons (Relvar Ellipta With or Without a LAMA DPI) Versus Any Other ICS/LABA DPI With or Without a LAMA DPI)","SECONDARY",NA,"D008171; D029424","Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs",FALSE,190,"logistic_regression",NA,NA,NA,1.51077429224149
"1887","763196e0217f1d981201194b4e061a3c","NCT03192176",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week","SECONDARY","Week 5","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.38926982128357
"1888","7661346c7002f937faa40fe49f251234","NCT03857230",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Maximum Serum Concentration of Follicle Stimulating Hormone (FSH) (Cmax)","PRIMARY",NA,NA,"The Safety and Pharmacokinetics of Primapur and Gonal-f",FALSE,48,"anova",2,NA,NA,1.05642048349345
"1889","766240dda50dfd93e0947c7c157094df","NCT00425698",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,1,0,"Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR)","PRIMARY","Null hypothesis: Erythopoietin significantly improves kidney graft function. Power calculation: with a difference of at least 4 mL/min in mean eGFR between groups the number of patients enrolled per group (at least 41) would allowed the detection of a significant difference between groups at a 5% level (p\<0.05)",NA,"Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation",TRUE,44,"t-test",NA,NA,NA,1.01513168983373
"1890","7668009062cb5dc26d9ec3635a5bdb44","NCT00665366",0.044,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Mania) Scale (LOCF Data Set)","SECONDARY",NA,"D000087122; D001714","Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder",FALSE,362,"anova",2,NA,NA,2.51719249781023
"1891","767a8aee43724fb3c61f4739c23802f3","NCT00179621",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Functional Assessment of Cancer Therapy-Anemia (FACT-An) Endpoints at Week 12","SECONDARY",NA,"D011289; D009190; D000013; D013577","Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality",TRUE,100,"anova",2,NA,NA,1.49341131573029
"1892","7682b7ecf8291a0508ecacb9e266c98b","NCT02528253",0.024,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 56, \>=70%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1012,"logistic_regression",NA,NA,NA,2.49688217272391
"1893","768a3b153bc546ee1930489ea86889c2","NCT04507776",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Absolute Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Baseline and Last Visit: Participants Adherent and Not Adherent to Treatment","OTHER_PRE_SPECIFIED","Year 7 Adherence: Baseline","D025242","Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel",TRUE,763,"t-test",NA,NA,NA,4.05689111055728
"1894","76a261c299b235e37512ced8a2fcebb5","NCT03192176",0.04,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 3 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 6","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,85,"logistic_regression",NA,NA,NA,1.14705113663484
"1895","76b893591ef7f2969bdc881ec89d4ea6","NCT02539394",0.032,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Patient Reported Swallowing Difficulty Over 1 Year","SECONDARY","The distribution of POD2 Eat-10 is the same across the 2 arms","D007405; D055959; D003680; D013118","Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion",FALSE,109,"mann_whitney",NA,NA,NA,1.06985113016006
"1896","76d9addb022b1e9c97e2de41daa94fdc","NCT01010009",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Number of Participants With Significant Modulation of Cognitive Performance","SECONDARY","Performance on each cognitive task was assessed via omnibus ANOVA with a priori planned comparisons.",NA,"The Cognitive and Cerebral Blood Flow Effects of Resveratrol",FALSE,44,"anova",2,NA,NA,1.01513168983373
"1897","76da0fb5b273464cb04408b9575b5b0c","NCT00927368",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Time Weighted Average Verbal Response Scale Pain Score","PRIMARY","The primary analysis for pain was a linear regression model comparing ultrasound alone to stimulating catheter on the mean time-weighted average pain score for a patient in the first 48 hours.",NA,"Comparison of 3 Techniques for Ultrasound-guided Femoral Nerve Catheter Insertion",FALSE,285,"t-test",NA,NA,NA,1.13859144767247
"1898","76ffb0219bb0928d147cf51c90149431","NCT01236053",0.0131,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,60.2500823645776
"1899","77003f6f3b844abd59d0d84aad18aea9","NCT01086475",0.048,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Social Responsiveness Scale (SRS) at Follow-Up","PRIMARY",NA,"D000067877; D001321; D002658; D002659; D020817","D-Cycloserine and Social Skills Training in Autism Spectrum Disorders",FALSE,67,"t-test",NA,NA,NA,1.19307303227173
"1900","770254a791b6d645c0d6312503aa1665","NCT01869491",0.0433,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"OTE as a Measure of Patient Responsiveness/Satisfaction: Question 2 - Patient's Evaluation of the Importance of the Change in Symptoms","SECONDARY",NA,"D005764; D004415","Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study",FALSE,1073,"mann_whitney",NA,NA,NA,4.25963824456521
"1901","770882e7492f90e1f83c90eb696a6761","NCT02590939",0.037,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Pain Score 24 Hours","SECONDARY",NA,"D008881","Acute Treatment of Migraine With e-TNS",FALSE,106,"mann_whitney",NA,NA,NA,1.19367226159169
"1902","772d41569b64a7caf00c46fc37e0a5be","NCT02528188",0.0434,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 2: \>=70% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,5.8129921095981
"1903","774bb45f4ba7c5249e7b2c365cbdb8d8","NCT04455633",0.031,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Patient Global Impression of Change (PGIC) Scale Score at Week 6","SECONDARY","Analysis of variance (ANOVA) model was used for the analysis with treatment and the randomization stratum of baseline pain severity (moderate, severe) as fixed covariates.","D009437; D010523","Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain",FALSE,202,"anova",2,NA,NA,1.40378162644234
"1904","777520185afa60c8638328b68bfe71a2","NCT04231318",0.0423,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score","PRIMARY",NA,"D010003; D020370","Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain",FALSE,132,"anova",2,NA,NA,1.48503606290615
"1905","778af8b3baeb1c4c3c8ba8345cf43a80","NCT00741936",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Complete Spontaneous Bowel Movement (CSBM)","SECONDARY",NA,"D005767; D004066; D003248","An Effectiveness and Safety Study of Chinese Herbal Medicine for Functional Constipation",TRUE,120,"t-test",NA,NA,NA,1.63072147479452
"1906","77a151856c98657e309d8a2740d2ce07","NCT00393705",0.0471,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Patients Achieving Hemoglobin A1c (HbA1c) <7% and HbA1c ≤6.5% at 16 Week Endpoint","SECONDARY",NA,"D003924","Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)",FALSE,266,"logistic_regression",NA,NA,NA,2.28931179697297
"1907","77e517f87546b3f1e97ceaad664ecccf","NCT01378299",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Percent Change in Bone Turnover Markers According to the rs1062033 Polymorphism of the CYP19A1 Gene","SECONDARY","Analysis by intention to treat with the last value carry forward.","D007006","CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy",TRUE,52,"anova",2,NA,NA,1.09617796589869
"1908","77f1122d19a09b46b8f9fcc5427177d0","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Calories","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1757,"linear_regression",NA,NA,NA,6.14749892759128
"1909","781531b09264bfc43d56f696aff03f65","NCT01787461",0.027,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Trans-Epidermal Water Loss (TEWL) at Week 6, 12, 18 and 24","SECONDARY","Change at Week 12, Left Cheek: Analysis was performed using ANOVA model with treatment, Glogau classification of photoaging, site, baseline and treatment-by-baseline interaction (if applicable) terms.",NA,"A Study to Assess the Effects of an Oral Dietary Supplement on Overall Facial Appearance Among Healthy Adult Women With Existing Skin Damage From Sun Exposure",FALSE,190,"anova",2,NA,NA,1.21043171014778
"1910","782b1304897c4cd5cc191765e699e082","NCT02635646",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"2h OGTT Glucose","SECONDARY",NA,"D011236; D018149","Interdisciplinary and Family Intervention to Prevent Type 2 Diabetes",TRUE,71,"t-test",NA,NA,NA,1.26828177971868
"1911","7848eab8f027868ac9a48fef6a89b1b2","NCT01314911",0.022,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Area Under The Curve (AUC) Of Viral Shedding For Self Collected Samples","SECONDARY",NA,"D007251","Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults",FALSE,499,"mann_whitney",NA,NA,NA,1.63014152716534
"1912","7871869075b514cbda9b14c50ca9a592","NCT02697422",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Number of Emergency Room (ER) Visits","SECONDARY",NA,"D002318; D006949","Veteran Peer Coaches Optimizing and Advancing Cardiac Health",FALSE,264,"linear_regression",NA,NA,NA,2.39772562409599
"1913","7873d782f71ee5e978da1b1235472e40","NCT01272921",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Duration of Motor and Sensory Block of the Sciatic With 0.5% Bupivacaine and Ropivacaine After Ultrasound-guided Nerve-stimulator-Assisted Needle Positioning Beneath the CIEL","PRIMARY","The sample selected for this study,70 per drug group (or 10 in each of the 7 groups), achieves 88% power to detect a minimal difference of 4 hours in duration at a significance level (α) of 0.05 and a standard deviation of 3 hours using Williams test. We chose a difference of 4 hours as this was the interval used for assessment in the postoperative period at night. We sought to detect a difference that was equal to 1 observation period difference.",NA,"The Use of Bupivacaine and Ropivacaine for Sciatic Nerve Block",FALSE,69,"mann_whitney",NA,NA,NA,1.25127183253256
"1914","78827adcb7919a724118bdec0885cef1","NCT03331978",0.0257,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Dichotomous Adherence","PRIMARY","Tested with repeated measures logistic regression where all 6 past-month post-intervention measurements of adherence were stacked together such that each participant could contribute up to 6 records. Standard errors were adjusted for clustering on participant, and weights for presence of data were used. Fixed effects were an intervention indicator and baseline dichotomous adherence. Model included all participants with adherence data (a) at baseline and (b) at least one follow-up month.","D000163; D015658","A Randomized Controlled Trial of an Antiretroviral Treatment Adherence Intervention for HIV+ African Americans",FALSE,164,"logistic_regression",NA,NA,NA,1.08010587040557
"1915","7884dc682da7411e5c5f2475f0391a22","NCT01939002",0.0315,"One-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline Visit (Day 1) to Week 48 in Walking Disability Status as Measured by Patient Determined Disease Steps (PDDS): Overall Population","SECONDARY","change at Week 48","D009103; D012598","Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)",FALSE,194,"t-test",NA,NA,NA,1.39528449211045
"1916","78d12266995361eff27d55196558af3e","NCT00762762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"TNF-α (Tumor Necrosis Factor - Alpha)","PRIMARY","Means and standard deviations. 1 factor ANOVA to balance treatment groups to show no difference between groups. The null hypothesis states that there is no difference between groups.","D010518","Effectiveness of a Triclosan Containing Toothpaste in Maintaining Periodontal Health in a Type 2 Diabetic Population",FALSE,60,"anova",2,NA,NA,1.17169922891753
"1917","78f808bf4f2b4bc08299f8e963d687c6","NCT02649634",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Confidence for Change Ratings After the First Motivational Interview or Attention Control Interview, Week 1- 2","SECONDARY","Confidence for Change ratings were analyzed via an independent sample t-test comparing the groups on mean Confidence for Change ratings on the 11-point visual analogue scales","D009765; D050177; D015431","Does Motivational Interviewing Improve Behavioral Weight Loss Outcomes for Obesity?",FALSE,135,"t-test",NA,NA,NA,1.7265679672307
"1918","790fd99012c6df65d1f26a5c1fbf05e7","NCT00420927",0.028,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than or Equal to 0.5), and ACR70 Response at Week 78","SECONDARY",NA,"D001168; D001172","Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis",FALSE,217,"logistic_regression",NA,NA,NA,1.33247690602592
"1919","791126f5b2c11181efaa285b7d7c89c5","NCT01606189",0.037,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Mean McGill Pain Questionnaire Part 2 Score for 'Intensity of Pain' at the End of Each Treatment Period (Each Lasting 14-20 Days)","SECONDARY","Intensity of Pain scores were compared between treatment groups using ANOVA. The model included factors for patient, treatment and period. The significance of the overall treatment effect was assessed using the F-test from the ANOVA. The model used was as follows: Intensity of Pain Score = Patient + Treatment + Period",NA,"A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain",FALSE,95,"anova",2,NA,NA,1.1327286790019
"1920","79114ad2a07c5393f51f16ffbd66c30b","NCT03192176",0.0446,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week","SECONDARY","Week 5","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.26336011630253
"1921","7922babc7f3de4dcc02fd7db025a5467","NCT01559259",0.047,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Intensity Difference on 4-Point Categorical Scale (PID4)","SECONDARY","10 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,123,"anova",2,NA,NA,1.56742805079436
"1922","7929dfb147452431c1069f0af81d8e2d","NCT02439320",0.037,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Phonophobia Free","SECONDARY",NA,"D008881","Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:",FALSE,555,"logistic_regression",NA,NA,NA,2.68638783538604
"1923","792a3f5335c8b9cef0e754ed1f996161","NCT02373813",0.046,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Disease Activity Score (28 Joint) Using the C-Reactive Protein Formula (DAS28-CRP) at All Measured Timepoints","SECONDARY","Week 36","D001168; D001172","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",FALSE,152,"t-test",NA,NA,NA,1.70615172205507
"1924","7935fc6796be00a8dc5521a0d76b04d4","NCT02214186",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"International Normalized Ratio (INR) of Prothrombin Time (PT) in Restrictive Fluid Management of Severe Preeclampsia During Cesarean Section","SECONDARY",NA,"D004461; D011225","Restrictive Fluid Therapy in Severe Preeclampsia",TRUE,46,"mann_whitney",NA,NA,NA,1.03597838019194
"1925","795bc51f7ea5d740392ac384bda48909","NCT02044874",0.0477,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Abstinence for the Last 4 Weeks of Treatment From Weeks 9-12","PRIMARY",NA,NA,"A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation",FALSE,391,"logistic_regression",NA,NA,NA,2.79856016211379
"1926","7964cf343311eb80483bb48386eb1727","NCT01859793",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Circulating Inflammatory Markers VCAM-1","SECONDARY","Outcome variables were compared across measurement periods by repeated measures ANOVA and post hoc analyses using Tukey's test were applied if significant differences were detected","D050197; D003920","Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy",TRUE,58,"anova",2,NA,NA,1.15327776573523
"1927","79670607aeda43425df35a17991cf227","NCT02473471",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Pain Interference /Swelling of the Surgical Side","SECONDARY","Day 1","D008310","Micro-osteoperforations and Tooth Movement",FALSE,62,"t-test",NA,NA,NA,1.18983814919554
"1928","796ba78111d9dc7ef5dc0773b2e8d86a","NCT04381481",0.01,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Appeal of Fruit Drink (Fruit Drink Experimental Task 1)","SECONDARY","beverages with claim compared to control beverage","D063766","Studying the Impact of Product Packaging in a Virtual Store Environment",TRUE,2192,"linear_regression",NA,NA,NA,1.69952696756211
"1929","7981e3ac2e1e5d52861bdb4711ae3fa9","NCT03943953",0.036,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"FACE-Q Psychological Function","PRIMARY","This is a comparison between Time 1 and Time 2","D020330; D005158; D019066","Self-guided Psychosocial Intervention for Facial Palsy",FALSE,88,"t-test",NA,NA,NA,1.06726535581155
"1930","79839a4e7477289fb3cd26ac324f4222","NCT00190749",0.045,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline to 12 Week Endpoint in Eating Behavior Assessment Scale Scores","SECONDARY","Item 3","D012559; D011618","Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder",FALSE,59,"t-test",NA,NA,NA,1.06556506237742
"1931","7991e102e691c08dd1525c1e2a6c82e2","NCT03228680",0.041,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of Participants With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved","SECONDARY","Proportion of participants with 4-7 oocytes retrieved (moderate response).","D007246","Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese Women",FALSE,342,"logistic_regression",NA,NA,NA,2.30597414056801
"1932","799303ae94f35e089db91b0db29402d4","NCT04015440",0.027,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Driving Aggression","PRIMARY",NA,"D000374","Hostile Bias Modification Training Online Study II",FALSE,217,"linear_regression",NA,NA,NA,1.29151030990228
"1933","79996c9d5531341bbaffec86dbfce553","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Calories","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1761,"linear_regression",NA,NA,NA,6.15447738929084
"1934","79b86dfbd64c37edbad259876da189fe","NCT00696436",0.032,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg","SECONDARY",NA,"D006973; D000075222","An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.",FALSE,553,"logistic_regression",NA,NA,NA,2.36928522823479
"1935","79dbe3b2d0471dfa0231a93fb11ecdd7","NCT01482091",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change in Pain Score at 30 Minutes","SECONDARY",NA,"D000755","Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis",FALSE,49,"mann_whitney",NA,NA,NA,1.06649684228356
"1936","79e369454bf75ba2255fabc743797034","NCT00905840",0.025,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Crestal Bone Level Between Surgery and 12 Months, to Compare Between the Titan Zircon Implant and the Titan Grade IV Implant.","PRIMARY","Null hypothesis: Change of functional bone level at the test implant 12 month after surgery is more than 0.1 lower (inferior) than change of functional crestal bone level at the control implant 12 month after surgery.

H-1: Change of functional bone level at the tst implant 12 month after surgery is up to 0.1 lower, equal, or higher (not inferior) than change of functional crestal bone level at the control implant 12 month after surgery.","D007575; D009066","A Study to Treat Patients With Edentulous Mandibles With Two Straumann 3.3mm Diameter Bone Level Implants",FALSE,178,"t-test",NA,NA,NA,1.09752837663917
"1937","79e58fb37b73b5343d423be2f4879a91","NCT04593940",0.0213,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Clinical Status for Day 14 Using an 8 Point Ordinal Scale","SECONDARY",NA,"D000086382","Immune Modulators for Treating COVID-19",FALSE,1012,"logistic_regression",NA,NA,NA,2.25110807902985
"1938","7a111e3b5067badc16695cc2cd3c29ae","NCT00762528",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Gingival Index (GI)","PRIMARY","The null hypothesis states that there is no difference between groups.","D005891","Compare Anti-inflammatory Dentifrices",TRUE,49,"anova",2,NA,NA,1.06649684228356
"1939","7a1458f7e388e4dce73911cb9eafa51e","NCT00070707",0.022,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in AM and PM Total Nasal Symptom Severity (TNSS)","SECONDARY","Change at Week 1 (AM)","D012220; D001249; D006255; D065631","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",FALSE,187,"anova",2,NA,NA,1.00671037798545
"1940","7a2f4200c2ccaa91d47ede4d4bc2aca6","NCT00550147",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Modified Overt Aggression Scale (MOAS)","SECONDARY","This was a repeated-measures analysis, using a single group of subjects who were administered quetiapine in addition to OROS mph. Results reported here are for the augmentation period (Visit 5-10). See Kronenberger et al. (2007, Journal of Child and Adolescent Psychopharmacology) for additional information.","D001289; D000374","Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.",TRUE,48,"t-test",NA,NA,NA,1.05642048349345
"1941","7a406f1299a1eefcfba2ad4cdf6f4411","NCT02266576",0.04,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in Body Mass Index (BMI) Through Month 12","PRIMARY","Baseline vs month 6","D003920; D024821; D003924; D007333","A Patient-Centered Strategy for Improving Diabetes Prevention in Urban American Indians",FALSE,205,"linear_regression",NA,NA,NA,1.75566941808034
"1942","7a4863dd1c10c3a017b5d9b2ae6dabf4","NCT00256750",0.0257,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of Physical and Mental Components Using SF-36 Questionnaire","SECONDARY","Physical Component Score; Month 6","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,404,"anova",2,NA,NA,1.68004538867188
"1943","7a4b439b32a41c4ec55e771c31792856","NCT04994691",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Who Scheduled an Appointment for a Well Child Check Visit.","SECONDARY",NA,NA,"Effect of Varied Outreach Methods on Appointment Scheduling and Appointment Completion Using MyChart",FALSE,630,"logistic_regression",NA,NA,NA,3.05648371713924
"1944","7a5d1ed20f375bd18816182f8acf3455","NCT00673231",0.0166,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of Participants With Calculated Mean Daily Insulin Dose Reduction","SECONDARY","H0: proportion(treat) minus proportion(placebo) = 0 versus the alternative HA: proportion(treat) minus proportion(placebo) =/= 0","D003920; D003924","Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin",FALSE,385,"logistic_regression",NA,NA,NA,1.12185622034442
"1945","7a62ac8ff7cdfc771e10dbc25c6c9ad4","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Postprandial Insulin (AUC)","SECONDARY","Difference in treatment effect between the 2 groups","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",TRUE,50,"t-test",NA,NA,NA,1.07648023860356
"1946","7a6be525336b519d8ee4195282de3907","NCT01115673",0.02,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Intensity Difference (PID) at 90 Minutes","SECONDARY","The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.","D014098","To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery",FALSE,480,"anova",2,NA,NA,1.47194289655965
"1947","7a849514d57b8c0ec62a601af4c130ad","NCT00323492",0.034,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline to Week 12 in Fasting Triglycerides","PRIMARY","Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).","D015658","TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada",FALSE,89,"mann_whitney",NA,NA,NA,1.02246598915334
"1948","7aa441ef96d13e5ecef743be8ed6a105","NCT06111742",0.046,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient Induction Compliance Assessed by Induction Compliance Checklist","SECONDARY",NA,"D001008","Audiovisual Interactive Games to Alleviate Pediatric Perioperative Anxiety",FALSE,74,"t-test",NA,NA,NA,1.20700004663968
"1949","7ab46c3cd2067491449d88d4e1615461","NCT03655951",0.04,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Parent Skepticism of Media Messages From Pretest to Posttest","SECONDARY",NA,NA,"Birds and Bees Research Study",FALSE,266,"linear_regression",NA,NA,NA,1.99517988644048
"1950","7ab7b452f927b4325c3ef2ac7c48481d","NCT04547192",0.006,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Appropriate Use of Key Performance Indicators in Initial Assessment and Management of the Injured at Non-tertiary Hospitals in Ghana","PRIMARY","Tetanus Considered for bites, burns, lacerations, and abrasions","D000066553","Improving Initial Management of the Injured at Ghanaian District and Regional Hospitals With a Trauma Intake Form",FALSE,4077,"linear_regression",NA,NA,NA,1.46570014552785
"1951","7accc71aa305d178a4eeb15388de6778","NCT00270998",0.0492,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"75% Reduction in Weekly Urinary Incontinence Episodes at 12 Months","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",TRUE,299,"logistic_regression",NA,NA,NA,2.51540237553809
"1952","7ad8d77795eadac61231f9dc245cfc98","NCT00798707",0.0154,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With a Response on the HAM-D17 at FOT Evaluation (Week 8 or ET)","SECONDARY","Analysis was conducted using a logistic regression model with treatment as a factor and baseline HAM-D17 score as a covariate.","D003866; D003863; D003865","Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder",FALSE,467,"logistic_regression",NA,NA,NA,1.15533394764041
"1953","7ae76c628872316ef835114e51a36e4a","NCT00662792",0.0418,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Response in Means Number of Awakenings Due to Shortness of Breath (SOB)","SECONDARY",NA,"D029424","Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD",FALSE,252,"anova",2,NA,NA,2.01635878312392
"1954","7ae902fc90a42a0b1da596bbe832853e","NCT01010009",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Modulation of Levels of Total Haemoglobin","PRIMARY","Data was analysed by omnibus ANOVA with a priori planned comparisons utilizing the mean squares error term from this ANOVA.",NA,"The Cognitive and Cerebral Blood Flow Effects of Resveratrol",FALSE,44,"anova",2,NA,NA,1.01513168983373
"1955","7afe8bc8d08d4227169fd910b61d6f88","NCT02649634",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Importance of Change Ratings After the First Motivational Interview or Attention Control Interview, Week 1 - 2","SECONDARY","Importance of Change ratings were analyzed via an independent sample t-test comparing the groups on mean Importance of Change ratings on the 11-point visual analogue scales","D009765; D050177; D015431","Does Motivational Interviewing Improve Behavioral Weight Loss Outcomes for Obesity?",FALSE,135,"t-test",NA,NA,NA,1.7265679672307
"1956","7b0979a5ac87be99b0ce40cb0accc169","NCT02475655",0.043,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change in Alanine Aminotransferase (ALT) (SGPT) Values From Entry","SECONDARY","Null hypothesis: There is no difference between the two arms in the change in Alanine Aminotransferase (ALT) (SGPT) values from Entry to Week 10/12.","D015658","Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults",FALSE,60,"t-test",NA,NA,NA,1.03417040936323
"1957","7b11ff6a2a08de0a87c2ab1953ac240b","NCT02045862",0.014,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With ≥ 10 Points Improvement From Baseline in HRQoL Total Score at Months 1, 3, 6, 9, 12 and EoT","SECONDARY","Odds ratio was from a logistic regression model including treatment group, sex, age group (\< 65, ≥ 65 years), previous study history and geographic region as factors and baseline OAB-q subscale as a covariate.","D053201; D014570; D001745","A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",FALSE,1492,"logistic_regression",NA,NA,NA,1.89058860622311
"1958","7b280bdb88570bf60befcf4b6dc600eb","NCT01592435",0.04,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Radlex Scale for Diagnostic Capability Ratings - Cedara Accustitch Software (Predicate)","PRIMARY",NA,"D013124","Carestream Digital Radiography Long Length Imaging Software Data Collection Protocol",FALSE,76,"t-test",NA,NA,NA,1.08781774095059
"1959","7b835561662c3f2302ae1ead597b7a18","NCT00583011",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Intensity of Perceived Maternal Pain as Measured by the 101 Point Numerical Rating Scale (NRS-101)","SECONDARY",NA,NA,"Local Anesthesia and Pain Perception During an Amniocentesis",TRUE,76,"mann_whitney",NA,NA,NA,1.30984657914153
"1960","7b8a3ba2a22860ed8942edcf43c80713","NCT04718129",0.048,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Momentary Negative Affect Assessed With Ecological Momentary Assessment","PRIMARY",NA,NA,"Testing the Effect of the Youth Mindful Awareness Program on Negative Affect",FALSE,110,"linear_regression",NA,NA,NA,1.51137509549455
"1961","7b8e5b641a59f788207f7efe56858e1a","NCT02609828",0.0359,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Reduction of >=30, 50, 70 and 90% From Baseline in Daily Worst Pain Intensity NRS Score in the Index Bone Metastasis Cancer Pain Site at Weeks 1, 2, 4, 6, 8, 12, 16 and 24","SECONDARY","Week 4 Reduction \>=50%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","D009362; D001859; D001855; D000072716","Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy",FALSE,144,"logistic_regression",NA,NA,NA,1.34886923063288
"1962","7bbf5de079e8fced5f1bbeee61827534","NCT01368185",0.01,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Diastolic Blood Pressure (DBP)","SECONDARY","Comparison between Month 3 and Baseline","D006973","Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)",TRUE,1705,"t-test",NA,NA,NA,1.49953882648572
"1963","7bc16564e8b4d241c75484d55e1bf96a","NCT01070550",0.0295,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for age per 10 years. The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,275,"logistic_regression",NA,NA,NA,1.56502649217984
"1964","7bde35caede216d8f1007bb6d4db4824","NCT01183689",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Mean Change in Fasting Glucose From Baseline to 2 Years","SECONDARY","Mean changes from baseline to year 2 among the 3 arms were compared using analysis of variance.","D015430","Study of Novel Approaches for Prevention",FALSE,312,"anova",2,NA,NA,2.60368660980166
"1965","7c065ef0b2e3646da79b07be7535a65a","NCT00117572",0.034,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Quality of Life (Normalcy of Diet)","SECONDARY",NA,"D006258; D007822; D010255; D010610","Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)",FALSE,161,"t-test",NA,NA,NA,1.35976094103919
"1966","7c1a572f19db5b9296575c7117a3a403","NCT00981292",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Number of Participants With Significant Modulation of Mood.","SECONDARY","Mood data was analysed via student t-test.",NA,"Effects of Epigallocatechin Gallate (EGCG) in Healthy, Young Adults",FALSE,81,"t-test",NA,NA,NA,1.3501394396673
"1967","7c1a8dc62822a62bbd8d1af1bc681c33","NCT00440700",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,1,0,0,"Length of Mechanical Ventilatory Support","SECONDARY","Length of mechanical ventilatory support was assessed among all 3 groups. Usual usual care was the reference group as compared to the experimental patient-directed music group.","D001008","Anxiety Self-Management for ICU Patients Receiving Mechanical Ventilation",TRUE,246,"kruskal_wallis",2,NA,NA,2.31577452762438
"1968","7c2561be37813466afb3cf5d69a040cf","NCT02418234",0.05,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"Differences of T790M Mutation by ddPCR Among the Different Clinical Modes of TKI Failure","SECONDARY",NA,"D008175; D002289","T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure",TRUE,314,"anova",3,NA,NA,1.0491949670499
"1969","7c49b0ef91f08867c6e96cea2dc04593","NCT01559259",0.031,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Relief Rating Score (PRR)","SECONDARY","10 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,123,"anova",2,NA,NA,1.10354236097153
"1970","7c53b8cd5aea49cf2da4893d2a63a719","NCT04992390",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Intention to Leave Job","SECONDARY","ITT analysis for Intention to leave job (treatment effects for between-arm comparisons) at week 4.",NA,"A Brief GAmeplay Intervention for NHS ICU Staff Affected by COVID-19 Trauma (GAINS Study)",FALSE,86,"linear_regression",NA,NA,NA,1.38926982128357
"1971","7c69e8e360024d8145226f51535c3598","NCT05457647",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Central Corneal Thickness","OTHER_PRE_SPECIFIED","Assessment of change of CCT value at 12-months follow-up visit.","D007640","Theranostic Guided Riboflavin/UV-A Corneal Cross-linking",TRUE,47,"mann_whitney",NA,NA,NA,1.04624856756472
"1972","7c743a12d257868297819840dda33473","NCT01796236",0.047,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Abbreviated Profile of Hearing Aid Benefit (APHAB)","OTHER_PRE_SPECIFIED","Baseline: Ease of Communication (Aided)","D034381; D003638; D006314; D046089","Clinical and Health Economic Evaluation With a New Baha® Abutment Combined With a Minimally Invasive Surgical Technique",FALSE,103,"mann_whitney",NA,NA,NA,1.43881896664113
"1973","7c7cd4a732f0ead3ea32c9081288f94c","NCT00126113",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"International Outcome Inventory for Hearing Aids (IOI-HA)","SECONDARY",NA,"D034381; D003638","The Performance-Perceptual Test as a Counseling Tool",FALSE,69,"anova",2,NA,NA,1.25127183253256
"1974","7c87b6af72f338f707ad6a9f9675101c","NCT00882050",0.05,"Logistic regression","INTERVENTIONAL",0,1,1,0,0,"The Primary Objective is to Determine the Ability of Intravenous Exenatide to: Maintain Intraoperative Euglycemia in Subjects With Initial Blood Glucose < 126 mg/dL in Surgical Subjects as Compared to Placebo,","PRIMARY","logistic regression","D007003; D006943","Intravenous Exenatide (Byetta) During Surgery",FALSE,104,"logistic_regression",NA,NA,NA,1.52186200926557
"1975","7c8c674db69d6b85064d2d9674c90f0e","NCT00442546",0.0286,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the OR-SDS - Severity Composite Score","SECONDARY","Week 6/ET","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,168,"anova",2,NA,NA,1.19778876606184
"1976","7c9b3d4136912128a62c2a0299267142","NCT06138145",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Participants' Decision to Enroll in the CHOP Pediatric Clinical Trials Registry","PRIMARY",NA,NA,"Inclusion Appeal Videos and Intent to Register for Pediatric Clinical Trials",TRUE,125,"mann_whitney",NA,NA,NA,1.66328288934253
"1977","7c9e4b387ad9729508cce696b4d2e0f8","NCT04427501",0.022,"Logistic regression","INTERVENTIONAL",0,0,1,1,0,"Phase 2: Percentage of Participants Demonstrating Symptom Improvement","SECONDARY",NA,"D000086382","A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness",FALSE,253,"logistic_regression",NA,NA,NA,1.16668850762238
"1978","7cb8aff5c4b7859e500f0c6523f630d6","NCT00474175",0.035,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Sum of Pain Relief Combined With Pain Intensity Differences (SPRID) Scores","SECONDARY","SPRID 60: P-value was calculated using Analysis of Variance (ANOVA) which was adjusted for treatment, site and baseline DPS. Treatment difference (Benzocaine 20% - Placebo) and corresponding 95% C.I. were calculated based on least-squares means from the ANOVA model with treatment, site, and baseline DPS effects.","D014098","Benzocaine Gel Toothache Dose-Response Study",FALSE,343,"anova",2,NA,NA,2.01931329581925
"1979","7cbaa9296f63ee1d7ed550b52d282daf","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Total Protein Value at Baseline and After Treatment Completion","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"1980","7cbdcc7ff3a42224eb1ecf97f2d2c161","NCT00468845",0.0398,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Total Cumulative Dose of Opioids Following Surgery","SECONDARY","Till Discharge","D010149","Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy",FALSE,303,"anova",2,NA,NA,2.11836696073045
"1981","7cbeb7d69b22df0f255f395859918efa","NCT04507776",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Absolute Bath Ankylosing Spondylitis Functional Index (BASFI) Score at Baseline and Last Visit: Participants Adherent and Not Adherent to Treatment","OTHER_PRE_SPECIFIED","Year 1 Adherence: Year 1 (Month 12)","D025242","Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel",TRUE,763,"t-test",NA,NA,NA,4.05689111055728
"1982","7ccd25b06323a7ae0c6b07bec7632c30","NCT00741936",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Changes on Individual Symptom Scores","SECONDARY",NA,"D005767; D004066; D003248","An Effectiveness and Safety Study of Chinese Herbal Medicine for Functional Constipation",TRUE,120,"t-test",NA,NA,NA,1.63072147479452
"1983","7ce0fe170ebc1c367a67c1fea0ba9bbc","NCT04716010",0.024,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Count of Products That Contain Red Meat","PRIMARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1765,"linear_regression",NA,NA,NA,3.2939254853532
"1984","7ce60d8ccc0069b64f68967557578bdf","NCT03982368",0.025,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Schirmer II Test (With Anesthesia) vs Week 4 - Full Analysis Set","SECONDARY","The secondary endpoint was analyzed using analysis of variance (ANOVA) including only treatment as the main factor, followed by preplanned comparisons from vehicle and rhNGF dosages according to Williams' procedure.","D015352; D007638","A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye",FALSE,165,"anova",2,NA,NA,1.05786586192695
"1985","7d187ee9268c47d2f4d14f8015884e2d","NCT00352027",0.042,"Wilcoxon","INTERVENTIONAL",0,0,1,0,0,"Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: Social Functioning","SECONDARY",NA,"D008223; D006689","Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma",FALSE,61,"wilcoxon",NA,NA,NA,1.02196776455204
"1986","7d4ade5f39da9bc097ca26a4613435ab","NCT00535405",0.039,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12","SECONDARY",NA,"D006331; D003327; D003324; D017202; D006937","A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)",FALSE,151,"logistic_regression",NA,NA,NA,1.48040395336888
"1987","7d55ccf98e33e7a0553a6268b920e809","NCT02845440",0.032,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Who Are Abstinent at the Intervention Year 2 Assessment in Cohorts 1 and 2","SECONDARY","Missing data at year 2 of intervention was imputed using MICE based on baseline characteristics and outcome values at year 1 of intervention. The statistical model was a mixed effects logistic regression with terms for the factorial design (TAU, AD, CHW, and cohort) and a clinic-varying random intercept. Regression coefficients were pooled using Rubin's rule over 10 imputation runs.","D012559; D003866; D001714; D001523; D003865","Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness",FALSE,637,"logistic_regression",NA,NA,NA,2.54147816749595
"1988","7d5666e49e07c5bcdf940f71ed5f2e36","NCT01891396",0.044,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Evaluator Global Assessment Comparing Cingal® to Monovisc® (ITT)","SECONDARY",NA,"D010003; D020370","Cingal Study for Knee Osteoarthritis",FALSE,299,"anova",2,NA,NA,2.29039532879029
"1989","7d776fc5f7402d9df41cc2c6be873cd4","NCT03711786",0.017,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Achieving Depression Remission at 3 Months","SECONDARY",NA,"D003863","The Sub-Saharan Africa Regional Partnership for Mental Health Capacity Building",FALSE,539,"logistic_regression",NA,NA,NA,1.35250047950731
"1990","7d78f8284386ff5093cd2a639c966cc1","NCT03655951",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Child Reported Parent-child Communication Quality From Pretest to Posttest","SECONDARY",NA,NA,"Birds and Bees Research Study",FALSE,273,"linear_regression",NA,NA,NA,2.43766868625107
"1991","7d83e1022854e81caeabe81a5c710cdc","NCT00976521",0.034,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Primary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Abciximab Infusion vs. No Infusion","PRIMARY","The primary endpoint of infarct size at 30 days measured by cardiac MRI, was summarized using the median, IQR, minimum and maximum values, in each infusion group, comparing the pooled active infusion arm to the pooled control non-infusion arm with the Wilcoxon rank sum test in the ITT analysis set. Data was only analyzed in subjects completing the cardiac MRI study and for whom the imaging data was received and deemed analyzable by the core laboratory.","D009203; D056988; D007238","The INFUSE - Anterior Myocardial Infarction (AMI) Study",FALSE,353,"mann_whitney",NA,NA,NA,1.99820340602358
"1992","7db01338244887eeb45fff0807ead491","NCT00630812",0.041,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Change in Absolute FEV1 From Baseline Over 26 Weeks","PRIMARY",NA,"D003550; D005355","Long Term Administration of Inhaled Mannitol in Cystic Fibrosis",FALSE,305,"logistic_regression",NA,NA,NA,2.1792796113967
"1993","7db2cf2637d952b64087e3955fd31aee","NCT02539394",0.043,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Degree of Dysphagia Patients Experience (Eating Desire)","PRIMARY","The distribution of Pre-operative SWAL-QOL - Eating desire is the same across the 2 arms","D007405; D055959; D003680; D013118","Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion",FALSE,109,"mann_whitney",NA,NA,NA,1.37267189072055
"1994","7dc6f24cafda38d54bc38c524d836787","NCT02697422",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Number of Hospitalizations","SECONDARY",NA,"D002318; D006949","Veteran Peer Coaches Optimizing and Advancing Cardiac Health",FALSE,264,"linear_regression",NA,NA,NA,2.39772562409599
"1995","7dc6fd7c99757ed5f43e3d3e59503430","NCT03192176",0.0431,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 4 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 2","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.20723179559676
"1996","7dd808ee4bab8b2d58a1ea3eff74f462","NCT02709486",0.018,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 12, \>=70%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,565,"logistic_regression",NA,NA,NA,1.45541436766881
"1997","7df47808cbc0f1e8d2a5d73daebadc8b","NCT03740919",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Documented Post-dose Hypoglycemic Events Within 1 and 2 Hours After the Prandial Dose","SECONDARY","\< 54 mg/dL 2 hour post-dose","D003920; D003922","A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes",FALSE,578,"logistic_regression",NA,NA,NA,1.61368646017929
"1998","7dfaf2ec17016e1a3e673c630ddd8bdc","NCT01156142",0.0297,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Total Drowsiness Increase","SECONDARY",NA,"D006258; D052016; D013280","Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy",FALSE,140,"mann_whitney",NA,NA,NA,1.13248594037001
"1999","7e02ad9686999a040f46a7f28f443d60","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Hematocrit Values at Baseline and After Treatment Completion","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"2000","7e231352f10203fbf3b3ecb8e43f7460","NCT04876482",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Computer Tomography (CT)_AP Distance","PRIMARY","We hypothesized that the improvements in the anteror to posterior distance on the tip of epiglottis would be more in patients who underwent TORS combined with OPR than in those who underwent only TORS and those who received conservative treatment (controls).","D001049; D012891; D020181","Myofunctional Training for Obstructive Sleep Apnea Patients After Transoral Robotic Surgery",TRUE,74,"linear_regression",NA,NA,NA,1.2933799900503
"2001","7e28bba6f0100591df5a6eada9baba95","NCT01796236",0.038,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Abbreviated Profile of Hearing Aid Benefit (APHAB)","OTHER_PRE_SPECIFIED","Week 24: Aversiveness (Unaided)","D034381; D003638; D006314; D046089","Clinical and Health Economic Evaluation With a New Baha® Abutment Combined With a Minimally Invasive Surgical Technique",FALSE,103,"mann_whitney",NA,NA,NA,1.20412308962124
"2002","7e40c30c22f73f6971c938593d4d9f46","NCT01378299",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Percent Change in Hematocrit According to the Genotype of the 700518 Polymorphism of the CYP19A1gene","SECONDARY","Analysis by intention to treat with the last value carry forward.","D007006","CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy",TRUE,59,"anova",2,NA,NA,1.16252463235142
"2003","7e49533ac206b85422cc1de0ecdf3a5b","NCT01649375",0.0325,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving ASAS Partial Remission at Week 16","SECONDARY",NA,"D013166; D025241; D013167","16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis",FALSE,147,"logistic_regression",NA,NA,NA,1.25207714202227
"2004","7e60d9a955b6da318da9a03106e3d60f","NCT02820051",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Residual Sedation Assessed Using the Aldrete Scale","SECONDARY",NA,NA,"Non-anesthesiologist-administered Propofol During the Flexible Bronchoscopy",TRUE,91,"mann_whitney",NA,NA,NA,1.42733241699876
"2005","7e7fa05edbb6d668051a19f29ad75b71","NCT04172701",0.0494,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"All-cause Healthcare Costs: Hospitalization Costs (Per Person Per Month)","SECONDARY",NA,"D029424","A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)",FALSE,4888,"t-test",NA,NA,NA,10.1432657589733
"2006","7e821a014d858c57b56fbba948958db1","NCT01187095",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"The Effect of Expressive Writing Intervention on Fertility Related Stress","PRIMARY",NA,"D007246","Involuntary Childlessness and Stress Management",TRUE,295,"logistic_regression",NA,NA,NA,2.53265767287746
"2007","7ea0e19e781340696105210339dc28a6","NCT01881373",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Prevalence of Acanthosis Nigricans","PRIMARY","Intervention vs control comparing 24 months to baseline.","D000052; D009765; D056128","Children's Healthy Living Community Randomized Trial",TRUE,5645,"logistic_regression",NA,NA,NA,2.72481930777285
"2008","7ea96bfdc12dfbe70d38a0a3b20de493","NCT01970943",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Pain Anticipation fMRI BOLD Signal","SECONDARY",NA,"D008881","Molecular and Functional PET-fMRI Measures of Analgesia in Migraine",FALSE,46,"t-test",NA,NA,NA,1.03597838019194
"2009","7eae018512ff05870ca02713c23cc2ed","NCT03192176",0.0347,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 9","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,85,"logistic_regression",NA,NA,NA,1.01777797432448
"2010","7ecbb8a56a9b9e40669f6a20149ec852","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient-Reported Outcomes Measurement Information System (PROMIS Short Forms 8a - Pediatrics v. 2.0) is a Set of Person-centered Measures That Evaluates and Monitors Physical, Mental, and Social Health in Children and Adolescents.","SECONDARY","We hypothesized that adolescents randomized to the intervention compared to controls would report less Pain Interference at 6 months post baseline.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,126,"t-test",NA,NA,NA,1.66971913113983
"2011","7ecfdc226574a8df2ed0c21c3807df92","NCT01852955",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Postoperative Opioid Consumption","SECONDARY",NA,NA,"Perioperative Systemic Acetaminophen to Improve Postoperative Quality of Recovery After Ambulatory Breast Surgery",FALSE,65,"mann_whitney",NA,NA,NA,1.01075402027553
"2012","7ed2714259473ba125daa771e2a2d693","NCT00551135",0.0347,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Total Cumulative Dose of Opioids and Tramadol Used During and After Surgery","SECONDARY","24 h PS; LS Means from ANOVA model with terms of treatment, pooled center. Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,200,"anova",2,NA,NA,1.53782637110124
"2013","7edbec52b3a94f2c627b30d537d9bfb5","NCT01005719",0.0465,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Achievement of Sustained Difference in Inhibition of Intragastric Acidity Based on Median pH Values Between the Two Active Study Treatments at Steady-state on Day 1","SECONDARY",NA,NA,"Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)",FALSE,116,"mann_whitney",NA,NA,NA,1.51011261400279
"2014","7ee3b4d86fa0f2b2cb82dd10a9bf3ccc","NCT01543685",0.022,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Total Pain Relief (TOTPAR) Over 0 to 4 Hours (TOTPAR-4).","SECONDARY",NA,"D010149","Study of Indomethacin Capsules to Treat Pain Following Bunionectomy",FALSE,185,"t-test",NA,NA,NA,1.00146427292608
"2015","7ee3f1306744b4683a05211140b5a645","NCT00608530",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Roland and Morris Disability Questionnaire Psychologist-Delivered Treatment Study","PRIMARY","Repeated measures analysis of variance compared differences between and within groups (CBT and Supportive Care) from baseline to end of treatment. Statistical testing was performed using 2-tailed tests and alpha level of .05 for declaring statistical significance. The trial was powered at the \>.80 level to detect differences between condition based on projected sample N = 130; given the N = 66 actually achieved our a priori power for detecting differences between groups was .63.","D001416","Telehealth Outreach for Chronic Back Pain",FALSE,66,"anova",2,NA,NA,1.2253174109698
"2016","7f043cc94d24e1b94815f78694f9ed10","NCT01822548",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Absolute Change in HbA1C Compared to Baseline","SECONDARY",NA,"D003920; D003924","Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes",TRUE,64,"anova",2,NA,NA,1.20770700959599
"2017","7f1b2fee23cc4643971f951a66ae333e","NCT05170841",0.022,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Percentage of Maximum TOTPAR (%Max TOTPAR) at 8 Hours After the First Dose- Single Dose Phase - Dexketoprofen/Tramadol vs Placebo","SECONDARY",NA,"D001416; D017116","Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain",FALSE,204,"t-test",NA,NA,NA,1.05024640197002
"2018","7f2f5f34bd528fc0f41d6fd43e42d0f7","NCT00535626",0.048,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in SF-36 From Pre-operative to Post-operative Visits","SECONDARY",NA,NA,"Trident® Tritanium™ Acetabular Shell Revision Study",FALSE,181,"t-test",NA,NA,NA,1.92525154373258
"2019","7f4a5c3087828951974db71c3709e136","NCT01891396",0.0323,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Patient Global Assessment (PGA) Comparing Cingal® to Monovisc® (ITT)","SECONDARY",NA,"D010003; D020370","Cingal Study for Knee Osteoarthritis",FALSE,299,"anova",2,NA,NA,1.76232386925792
"2020","7f769cc51751a9cc727620d35970d48f","NCT00303979",0.033,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Observe the Relative Change Between Baseline of Cohort A and 18 Months of Cohort C in Performance Measures and Composite Score for the Aggregate Practices.","SECONDARY","Performance Measure #4: the relative change of Cohort C (18 months) compared with Cohort A at baseline in anticoagulation for AF for the aggregate practices.","D006333; D009203; D018754; D018487; D007238","IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting",FALSE,24818,"t-test",NA,NA,NA,16.2300464012304
"2021","7f8075d959917a141cffb41918ccbeff","NCT02115308",0.048,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"RADIAL STRAIN","PRIMARY","REST-TO-STRESS Change","D003324","Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging",FALSE,46,"t-test",NA,NA,NA,1.00182926567556
"2022","7f9992181d029cd489e33abcf543105d","NCT03114969",0.038,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants Making at Least One Critical Error at Visit 2-Primary Device Comparisons","SECONDARY",NA,"D008171; D029424","Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs",FALSE,97,"logistic_regression",NA,NA,NA,1.1700368461578
"2023","7fc004aa00c75fed23fe01ab3c412c34","NCT03202134",0.048,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Skin Temperature","SECONDARY",NA,NA,"Impact of Opioid Free Anesthesia on Outcome After DIEPflap Surgery",FALSE,204,"mann_whitney",NA,NA,NA,2.04142959709699
"2024","7fc80e1f251b01c87e9baf07171900d8","NCT02912650",0.024,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (PRID4)","OTHER_PRE_SPECIFIED","8 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,347,"anova",2,NA,NA,1.46915461823916
"2025","7fd03d77eed432b980d2dd7d2f787ffc","NCT02535026",0.025,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With PR Status (Positive or Negative) Based on Lymphovascular Invasion","PRIMARY","PR status association with lymphovascular invasion.","D002277","An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants",FALSE,579,"anova",2,NA,NA,1.96020010324914
"2026","7fd6ea9ee7a18c806d126f1959a211cd","NCT04837807",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Ocular Surface Disease Index (OSDI) Questionnaire","SECONDARY",NA,"D015352","Digital Device Users Who Are Treated With Systane Hydration PF",TRUE,59,"anova",2,NA,NA,1.16252463235142
"2027","7fec4eaa1844d9b19c40da527fbf6dbb","NCT01881373",0.009,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Waist Circumference","PRIMARY","The children from each community recruited each time were NOT the same children. The number of communities is consistent across time.","D000052; D009765; D056128","Children's Healthy Living Community Randomized Trial",FALSE,3987,"linear_regression",NA,NA,NA,2.08514706909587
"2028","7fed85fc7886923ad1d389ea3729d3c9","NCT01908829",0.036,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With a Mean of at Least 8 Micturitions Per 24 Hours at Baseline and Less Than 8 Micturitions Per 24 Hours Postbaseline","SECONDARY","EoT odds ratios, 95% Two sided CIs for Odds ratios and p-values were from a logistic regression model including treatment group, sex, age group (\<65, \>=65 years), 4-week incontinence episode reduction group, geographic region as factors and baseline value as covariate.","D014570; D001745; D053201","A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)",FALSE,1412,"logistic_regression",NA,NA,NA,4.17613399011916
"2029","7ff01c34cb2c1407989cf628b9636bf7","NCT01985581",0.0392,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Effect of Adjunctive INTUNIV Extended Release Treatment on Executive Function as Assessed by Change From Baseline on the BRIEF-parent Questionnaires","PRIMARY",NA,"D006948; D001289","Efficacy of GXR as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD",FALSE,95,"anova",2,NA,NA,1.18913811357582
"2030","80253496e1c2f27b937badbf326c12a6","NCT04281784",0.027,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Proportion of Patients With EHR Documentation of Goals of Care Discussions","PRIMARY","Usual care = reference group; intervention arm = comparison group","D009369; D009362; D008175; D008103; D008171; D029424; D017563; D051437; D007676; D006333; D014652; D016491; D058729; D002908","Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)",FALSE,2512,"linear_regression",NA,NA,NA,4.34917096019431
"2031","8036ec076a8cde55c7d2b27ab1b8f55a","NCT03203512",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Ex Vivo Agonist-stimulated Platelet Activation Detected by Plate-based Platelet Aggregation Assay","SECONDARY","Null hypothesis is that there was no difference in change of platelet function in affecting LogEC50 values in response to epinephrine between fish oil and placebo capsules. Comparisons of this parameter after each intervention were drawn using 2-way ANOVA with the Turkey multiple comparisons test.","D001768","Fish Oil-derived N-3 Polyunsaturated Fatty Acids and Extracellular Vesicles",FALSE,80,"anova",2,NA,NA,1.34217713699512
"2032","80444912f05061a89dc17ef99d8355ac","NCT01717872",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"The View of the Larynx (Glottis Opening) as Determined by POGO Score (Percentage of Glottic Opening).","PRIMARY","MAC blade lifting the tongue versus Miller blade lifting the epiglottis",NA,"Comparing the Laryngoscopy View Using Miller and Macintosh Laryngoscopy Blades in Infants Under Two Years of Age",FALSE,50,"mann_whitney",NA,NA,NA,1.07648023860356
"2033","804b36b2ecf7432a387114ad987d9170","NCT01690000",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Changes in Bone Mineral Density (BMD)","PRIMARY","The p-value was calculated","D010024; D001851","Treatment of Osteopenia With Melatonin",TRUE,76,"t-test",NA,NA,NA,1.30984657914153
"2034","80559cda6d73a483a0a4966adcea13bf","NCT01185522",0.05,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Participants With Clinically Significant Improvement in Fatigue at Month 4 With Respect to Predictive Factors","PRIMARY","Comparison between time since initial diagnosis: \>= 10 years and \< 10 years","D001168; D001172","An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS)",FALSE,264,"logistic_regression",NA,NA,NA,2.39772562409599
"2035","807f969b1379230de55dcb4d4be99259","NCT05226884",0.05,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Non-inferiority of Target-corrected Binocular Intermediate (66 cm) Visual Acuity With Offset","PRIMARY",NA,"D019591","Intermediate Vision in Patients With Clareon IOLs Compared to Eyhance IOLs",TRUE,310,"mann_whitney",NA,NA,NA,2.59543112524924
"2036","8088537b0aac8d728545aa78b9649d5f","NCT01894230",0.0371,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Reporting New Statin Prescriptions","SECONDARY",NA,"D006937","Genetically Guided Statin Therapy",FALSE,145,"logistic_regression",NA,NA,NA,1.39158695593023
"2037","80adf948a8be129435502d769484d0bb","NCT00337675",0.045,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Daily Average of the Mean Symptom Scores (Wheeze, Difficulty Breathing, Interference With Activity, and Daytime Cough) Assessed Over the 12-day Treatment Period of Asthma Episodes","SECONDARY","The secondary hypothesis stated that montelukast (daily regimen, or \[intermittent and daily regimens\]), compared with placebo, results in improvement of respiratory symptoms assessed over 3 days prior to asthma attacks, or assessed over the 12-day treatment period of asthma episodes in pediatric patients aged 6 months to 5 years with episodic asthma and treated over 1 year.","D001249","Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)",FALSE,733,"anova",2,NA,NA,3.640038734373
"2038","80e273908439447567a5a7a68de516fd","NCT02528253",0.0285,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 56, \>=50%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1012,"logistic_regression",NA,NA,NA,2.89628841301419
"2039","80ee6d366fb5416097ab1df48f1b04c7","NCT00315302",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Visual Acuity Distribution in the Amblyopic Eye","PRIMARY","Null hypothesis: proportion 20/25 or better at 18wks in atropine group = proportion 20/25 or better at 18wks in atropine plus plano group

Alternative hypothesis: proportion 20/25 or better at 18wks in atropine group NOT equal to proportion 20/25 or better at 18wks in atropine plus plano group","D000550","Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye for Amblyopia in Children 3 to <7 Years Old",FALSE,172,"logistic_regression",NA,NA,NA,1.26211756568296
"2040","80f2a9f21b5b54aef2a21bb91c0064d9","NCT03239496",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Seroconversion Non-inferiority of 2 Doses IPV IM vs 3 Doses IPV IM","PRIMARY","The group sizes are chosen to provide ≥ 80% power for each of the primary objectives, for the individual statistical tests of each serotype, as well as across both serotypes simultaneously. Power of ≥80% is also available for all secondary objectives, except for the comparison of the f-IPV regimen administered at weeks 14 and 36 to the 3-dose IPV regimen, which has power of 62% for individual serotypes, and 39% for the combined serotypes.","D011051","A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV",FALSE,337,"t-test",NA,NA,NA,2.70475557731607
"2041","80f4469f3cae733b1deb1a655a4769e8","NCT03634397",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Jebsen-Taylor Hand Function Test (JTHFT) Times From Baseline 2 to Post Test 1","PRIMARY",NA,"D020521","Predicting Ipsilesional Motor Deficits in Stroke With Dynamic Dominance Model",TRUE,53,"linear_regression",NA,NA,NA,1.10589694869732
"2042","80fac1f65efcacef23c54ee839f6a2ab","NCT01056718",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Metabolic Equivalent (METS) Level","PRIMARY","Nebivolol treatment group refers to 50 patients that completed 10 weeks of open label nebivolol treatment. Results were compared using paired T-tests in a pre - post study design before and after 10 weeks of his/her treatment. Each subject served as own control.","D006973; D054160","Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function",TRUE,50,"t-test",NA,NA,NA,1.07648023860356
"2043","81262cf5dc59cc6c866d04bb4533cb8f","NCT04736628",0.0497,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Patients Achieving UACR Decreases in First Morning Void Urine of at Least 20% From Baseline After 20 Weeks of Trial Treatment","SECONDARY","Treatment and sodium-glucose co-transporter-2 inhibitor (SGLT2i) use at randomization were used as covariates in the logistic regression model.","D007674; D051436","A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease",FALSE,126,"logistic_regression",NA,NA,NA,1.66138101804674
"2044","81321146b7b1bb77ab8e1ad25d0c33e0","NCT01472432",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"VEGF","SECONDARY",NA,"D016523; D003924; D014456","DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes",TRUE,106,"t-test",NA,NA,NA,1.53589031932405
"2045","813dad452d60d8234418ed8b1579f01e","NCT02886728",0.023,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Weeks 2, 4, 12, 36, and 52","SECONDARY","Filgotinib 200 mg Monotherapy vs MTX Monotherapy at Week 36","D001168; D001172","Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy",FALSE,626,"logistic_regression",NA,NA,NA,1.89562922536615
"2046","8140d0f6cd6b439298b8fb760cec7ae9","NCT03625115",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Measure of Adversity Experienced in Childhood","OTHER_PRE_SPECIFIED","A logistic regression was run to determine if the intervention arm, adjusted for child sex, income, maternal education, and primary care site, was associated with the completion of early intervention referrals for families with an adverse childhood experience survey score of greater than 2.",NA,"The Opening Doors to Early Intervention Study",FALSE,312,"logistic_regression",NA,NA,NA,1.19032607967294
"2047","814600bafff7d04be407ec9429faab08","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Environment)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1751,"linear_regression",NA,NA,NA,6.13701635655789
"2048","814b12f265b0459c6d39bc8be100c3f9","NCT00105989",0.029,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in 36-item Short-Form Health Survey (SF-36) - Maintenance Phase","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,247,"t-test",NA,NA,NA,1.4630722397355
"2049","81529ba86e57a1696b43085e7eb386e5","NCT01860521",0.047,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Total Levobupivacaine Consumption","SECONDARY",NA,NA,"Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Termination of Pregnancy Analgesia",FALSE,104,"mann_whitney",NA,NA,NA,1.44552042589897
"2050","8159c69833f49924e643ca9cfd108134","NCT01539070",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Children´s Time of Physical Activity From Baseline to 3 Months by Intervention Assignment","PRIMARY","In intent-to-treat analyses, we used unadjusted and adjusted multivariate regression models, to examine differences from baseline to 3 months between the intervention and usual care groups. For continuous outcomes, we used linear regression models, and for dichotomous outcomes, we used logistic regression models. To account for clustering by practices, we performed generalized linear mixed models. The Estimator (Est) and Confidence Interval 95% (95% CI) are reported.","D009765; D063766","Intervention for the Prevention of Obesity in Preschool",TRUE,306,"linear_regression",NA,NA,NA,2.5788408992482
"2051","81609f13fdc8f7489612460c1faf8a46","NCT03953508",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Average Daily Subjective Response From Smoking","PRIMARY",NA,NA,"Perceptions of Cigarette Smoking in Young Adults",FALSE,124,"t-test",NA,NA,NA,1.6568216953838
"2052","8180a499ceb9ad3e3f35f614182a5b7d","NCT01638000",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Improvement in Symptom Bother Score as Assessed by the OAB-q: ≥ 10 Points Improvement in OAB-q at Week 12 and Final Visit","SECONDARY","Week 12 Odds Ratio vs. Mirabegron","D053201; D014570; D001745","A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.",FALSE,1833,"logistic_regression",NA,NA,NA,1.55459672277149
"2053","8181e15b78ef73998dcd4c367665d509","NCT04700137",0.04,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Anxiety as Measured by the Generalized Anxiety Disorder 7 Item Scale (GAD-7)","SECONDARY","Difference in anxiety (GAD-7) among healthcare providers/staff by intervention arm at follow-up (6 months).","D000086382","Mental Health Among Patients, Providers, and Staff During the COVID-19 Era",FALSE,335,"linear_regression",NA,NA,NA,2.2353958401786
"2054","819aff3dd2a80af01ced2ffb6096a8df","NCT01368042",0.03,"Wilcoxon","OBSERVATIONAL",0,0,0,0,0,"Change From Baseline to 6 Months Post-enrollment in RAND 36-Item Health Survey 'Physical Functioning' Scale Scores","PRIMARY",NA,"D007674; D051436; D006961; D006962","Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous",FALSE,254,"wilcoxon",NA,NA,NA,1.52697899497486
"2055","81acd2baecf9d9a6f7d50e70013c6356","NCT01690117",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in Burden on the German Version of Zarit Caregiver Burden Interview (ZBI) (5-point Scale) at Month 9","PRIMARY",NA,"D003704","German Adaptation of REACH II",TRUE,62,"t-test",NA,NA,NA,1.18983814919554
"2056","81b2b6a273537d23f5e8b26bc6331349","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Ambulatory Mean Central Diastolic BP","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"2057","81dd2c66a072b283fd522e9c13c23040","NCT00027378",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Alcohol Use Behaviors","PRIMARY","Repeated measures ANOVA","D000437; D003863","Pharmacological Intervention Project (Fluoxetine)",FALSE,50,"anova",2,NA,NA,1.07648023860356
"2058","81e2ecacf101d40078deb2103197b841","NCT00535626",0.0254,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in SF-36 From Pre-operative to Post-operative Visits","SECONDARY",NA,NA,"Trident® Tritanium™ Acetabular Shell Revision Study",FALSE,181,"t-test",NA,NA,NA,1.12170227407144
"2059","81fd17e9e3af3d8f0bdc2fd723ee8cb6","NCT00023595",0.03,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"H02: SF-12 Mental Component Summary (MCS) Scale","SECONDARY",NA,"D006333; D002318; D006331; D003327","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",FALSE,859,"mann_whitney",NA,NA,NA,2.78982671766205
"2060","81ffd8c85cc8f64cc5b4acb951fd56dc","NCT00227877",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Past-90-day Substance Use at 3 Months Among Baseline Substance Users - New England, USA","PRIMARY",NA,"D019966","Screening and Brief Advice to Reduce Teen Substance Use",TRUE,482,"logistic_regression",NA,NA,NA,3.22917782815841
"2061","820b373378cdaf2ca132d013580839f8","NCT02270671",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Fear of Negative Evaluation at 4-week Post-Intervention and 12-week Follow-Up","SECONDARY",NA,"D003863","Attention Bias Modification Training for Young People",FALSE,120,"anova",2,NA,NA,1.63072147479452
"2062","82135334a961f8dec1b84fc5b9fcad58","NCT05127304",0.043,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"COPD-related Health Care Resource Utilization","PRIMARY","Outpatient visits","D029424","A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",FALSE,11316,"linear_regression",NA,NA,NA,13.7283955920549
"2063","82170a23afdab28a0206fc88f7bee0f9","NCT03962738",0.037,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Very Much or Much Better as Measured by the Patient Global Impression of Change (PGI-C)","SECONDARY",NA,"D008881","A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine",FALSE,299,"logistic_regression",NA,NA,NA,1.97840478351401
"2064","8225bee6b9c2a46ae92b23f9178c9fcb","NCT03847896",0.044,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With a Clinically Meaningful Difference on the Asthma Control Questionnaire 7-item Version (ACQ-7) at Week 12.","SECONDARY","Comparison is not type-I error controlled.","D001249","A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma",FALSE,324,"logistic_regression",NA,NA,NA,2.38297804429426
"2065","822ba3b17c6e0f5a069332902f7de123","NCT00483548",0.0392,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"CGI-Improvement Score","SECONDARY","Week 1; LOCF; Analysis of variance model with treatment, country, type of mood stabilizer as fixed effects.","D003863; D003866; D001714","Adjunctive Ziprasidone in the Treatment of Bipolar I Depression",FALSE,290,"anova",2,NA,NA,2.04660482914106
"2066","824bdb0aaa31842d6d0661fd3fa0bb4a","NCT00699907",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Colony Stimulating Factor-1 Receptor (CSF-1R) Expression in Ovarian Stroma","PRIMARY",NA,"D010051; D000077216","Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer",FALSE,84,"mann_whitney",NA,NA,NA,1.37375080866169
"2067","826f90b5c61854eae2d3016dc3be58ea","NCT02625402",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Hip and Knee Decision Quality Instruments Knowledge Subscale Scores","PRIMARY",NA,"D010003; D020370; D015207","Pilot RCT Comparing Effectiveness of Two Decision Aids for Hip and Knee Osteoarthritis",TRUE,58,"t-test",NA,NA,NA,1.15327776573523
"2068","82929dd2c58b47dc121d43ec862824d2","NCT02178995",0.048,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"CPT Outcomes (Secondary Variables) (Open-label Portion)","SECONDARY","Epilepsy v healthy ANOVA Omissions","D004827; D001289; D003072; D060825","Methylphenidate Treatment of Attention Deficits in Epilepsy",FALSE,82,"t-test",NA,NA,NA,1.31286011435274
"2069","829bc8b6292d3fb86006845205feeec1","NCT01567865",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Number/Percentage of Subjects With Demonstrated Seroprotection","PRIMARY","Null hypotheses: each new lot does not differ in seroprotection (SP) rates among each other by more than 10%.

Slower than anticipated enrollment resulted in a smaller number of subjects with antibody response data for analysis. Consequently, additional power estimates were made in anticipation of the occurrence of smaller sample sizes. With a total study population of only 772 subjects, the power of the study to test lot-to-lot consistency declined from 90% to 85%.","D004672; D004660","Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine",TRUE,389,"t-test",NA,NA,NA,2.90373508666391
"2070","82aceba8e0a9c5dfba9763fcf1ebcb6c","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Intention to Reduce","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1735,"linear_regression",NA,NA,NA,6.10897489711546
"2071","82cb6a085d37fe1b6ce01bd764d22dba","NCT00762762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"C-Peptide","PRIMARY","Means and standard deviations. 1 factor ANOVA to balance treatment groups to show no difference between groups. The null hypothesis states that there is no difference between groups.","D010518","Effectiveness of a Triclosan Containing Toothpaste in Maintaining Periodontal Health in a Type 2 Diabetic Population",FALSE,60,"anova",2,NA,NA,1.17169922891753
"2072","82d2c8d7801b2ea1e1a660c8fc86e107","NCT02528253",0.0092,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 8, \>=30%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1012,"logistic_regression",NA,NA,NA,1.07401255203274
"2073","82d7bffa2be853153bf4a1b2ce8a9cb0","NCT00070707",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in AM and PM Total Nasal Symptom Severity (TNSS)","SECONDARY","Change at Week 2 (PM)","D012220; D001249; D006255; D065631","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",FALSE,187,"anova",2,NA,NA,2.02404134451695
"2074","82e649ce4974e89896ad301c7ff7532b","NCT01010009",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Number of Participants With Significant Modulation of Cognitive Performance","SECONDARY","Performance on each cognitive task was assessed via omnibus ANOVA with a priori planned comparisons.",NA,"The Cognitive and Cerebral Blood Flow Effects of Resveratrol",FALSE,44,"anova",2,NA,NA,1.01513168983373
"2075","82f2528a19f8ab0a2237dd6e582acece","NCT04218864",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Self-efficacy (GSE)","OTHER_PRE_SPECIFIED","Statistical Analysis strategy is identical to that for primary outcome measure.",NA,"Strength for U in Relationship Empowerment",FALSE,121,"linear_regression",NA,NA,NA,1.63728545358366
"2076","8306431e7d578ac9c69e138c6bd8a742","NCT03358030",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Percent Change From Baseline in Factor XI (FXI) Activity","OTHER_PRE_SPECIFIED","Day 12 through Day 176","D007674; D007676","A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis",TRUE,78,"mann_whitney",NA,NA,NA,1.32610986002301
"2077","8308498d92640806a5f0c4a68f94d040","NCT03209440",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Treatment Preference","SECONDARY",NA,NA,"Palliative Care for Elderly Outpatients",FALSE,450,"linear_regression",NA,NA,NA,3.12102872995164
"2078","8326d8bc2ecbf84e92dbf8390c6a0372","NCT04547192",0.006,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Appropriate Use of Key Performance Indicators in Initial Assessment and Management of the Injured at Non-tertiary Hospitals in Ghana","PRIMARY","Airway assessed","D000066553","Improving Initial Management of the Injured at Ghanaian District and Regional Hospitals With a Trauma Intake Form",FALSE,4077,"linear_regression",NA,NA,NA,1.46570014552785
"2079","832f495a5d9abd78f7210c3432ca4ec9","NCT02369536",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Hematic Levels of Hepatic Enzymes AST","PRIMARY","Intention-to-treat-analysis. Differences between basal values in active and control groups and between T1 vsT0 changes in the two groups assessed by ANOVA and Fisher's exact test.","D008107; D005234; D065626","Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)",TRUE,113,"anova",2,NA,NA,1.58401395671428
"2080","833f78a1f33f45f304652d523ab06eda","NCT02889796",0.011,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 2, 4, 12, and 24","SECONDARY","Filgotinib 100 mg vs Placebo at Week 4.","D001168; D001172","Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate",FALSE,955,"logistic_regression",NA,NA,NA,1.22333655881212
"2081","833f7b3f699af71067eae6026d76ccba","NCT00459706",0.02,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Participant Satisfaction by the Hospital Anxiety Depression (HAD) Anxiety Subscale Score for 2 Different Delivery Mechanisms for Etanercept","SECONDARY","All categories","D001168; D001172","Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept",FALSE,637,"linear_regression",NA,NA,NA,1.69331063291126
"2082","8354b6a8eaca5367e190788776f0e068","NCT03687762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in Depression Severity","SECONDARY",NA,"D059350","Back on Track to Healthy Living Study",FALSE,302,"anova",3,NA,NA,1.03237942189705
"2083","83645bc8e69b2dd2d5c1ca9cd16701a7","NCT03192176",0.0402,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week","SECONDARY","Week 10","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,85,"logistic_regression",NA,NA,NA,1.1518568015563
"2084","8366b33fad5e93ca54d2fbf29e75f1e7","NCT01559259",0.045,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (PRID4)","SECONDARY","12 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,119,"anova",2,NA,NA,1.4875448823352
"2085","8391305b0cc212562ab9423c6e3438d5","NCT01270828",0.0378,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Benefit From Treatment, Satisfaction With Treatment and Willingness to Continue Treatement (BSW)","SECONDARY","This analysis is for 'Satisfaction with treatment'. Proportional odds logistic regression was used with a term for treatment in the model.","D009437; D051474","Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia",FALSE,394,"logistic_regression",NA,NA,NA,2.30862124771545
"2086","83a60313f8f85686ee24f2f9e56213a5","NCT01836445",0.025,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mean Score of Health Protective Communication Skills at Baseline and 3 Months","SECONDARY","Analysis for HIV Testing items","D006069","Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men",FALSE,528,"linear_regression",NA,NA,NA,1.87266493662713
"2087","83c62f241aa697db5aa91560a4f84be3","NCT03192176",0.0431,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 3 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 5","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.22779946727555
"2088","83dbce1bf985a4ec94ccd7659a547f4f","NCT03950167",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Gallbladder (GB) Volume","PRIMARY",NA,"D006939","Gallbladder Functions & Serum Cholecystokinin Levels in Women Diagnosed With Hyperemesis Gravidarum",FALSE,46,"t-test",NA,NA,NA,1.03597838019194
"2089","83f2183860ca9120191d4b48cf5fa574","NCT03170271",0.0233,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Patient Global Impression of Severity (PGI-S): Responder Status at the EOT (Week 24)","SECONDARY","Estimate of the log odds of being a responder classified as type 'Improvement' at Week 24 in the benralizumab group compared to the placebo group using a logistic regression.","D001249","A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.",FALSE,532,"logistic_regression",NA,NA,NA,1.76854769275036
"2090","83f5a4b6e79640f6ce31521dcd4e303d","NCT00245219",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Depressive Symptoms (as Measured With the CES-D) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The interaction between the peer support condition and breast cancer stage at Time 3. The full regression model consisted of 3 steps: The 1st step contained the baseline measure of the dependent variable. The 2nd step contained two dummy coded variables contrasting each condition with control. The 3rd step contained the interaction between the peer support condition and cancer stage. Patients in the education condition were excluded from this analysis.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"logistic_regression",NA,NA,NA,1.79957957739554
"2091","8427cce19cd6029465718eedc62bd859","NCT00327717",0.028,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Median Percent Change From Baseline in All Partial Seizure Frequency (Complex Partial Seizures (CP)+ Simple Partial Seizures (SP) + Secondary Generalization Seizures (SGS)) During the Fixed-dose Phase","PRIMARY",NA,"D012640","Evaluating the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures",FALSE,217,"anova",2,NA,NA,1.33247690602592
"2092","8429b59d379c19f2f4b40f5ad3262775","NCT00256750",0.0289,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire","SECONDARY","Vitality, Month 6","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,411,"anova",2,NA,NA,1.87446571512376
"2093","8431e0fed019f68ba98266343e2dcb4c","NCT03471767",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change in Smoking Intensity","PRIMARY",NA,"D014029","AXS-05 Phase II Trial on Smoking Behavior",FALSE,58,"t-test",NA,NA,NA,1.15327776573523
"2094","844b3b9883f0694e9748e3ee6fb5eba3","NCT00932737",0.03,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Response Based on the 4-point Verbal Rating Scale (VRS) of ""Very Satisfied"" in Episode 1","PRIMARY",NA,"D015746","(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis",FALSE,145,"logistic_regression",NA,NA,NA,1.16178740612582
"2095","8477012bc3bebac5074354695293b300","NCT02371759",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Width of Anesthetic Field After Maxillary Infiltration Anesthesia","SECONDARY",NA,"D003920; D003924","Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2",TRUE,110,"mann_whitney",NA,NA,NA,1.56357043896758
"2096","8490e34ad306554a2f4c35a8b963562f","NCT01251393",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Compulsion","PRIMARY","We evaluated the normality (Kolmogorov's test) and homogeneity (Levene's test) of the sample.","D019970","Cocaine/Crack and Reduction of Compulsion With Biperiden",TRUE,111,"anova",2,NA,NA,1.5704144397227
"2097","849e97d27c3effc82fae286cfff86cf2","NCT03141307",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Quality of Informed Consent","SECONDARY",NA,NA,"The Effect of Electronic Informed Consent Information (EICI) on Residual Newborn Specimen Research",TRUE,664,"t-test",NA,NA,NA,3.78597833043156
"2098","850726d588a3ba1fd28e588368ba9ddf","NCT03868254",0.0472,"One-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Change From Baseline in the Number of Topical IOP-lowering Medications 48 Months After Implantation","SECONDARY",NA,"D005901","Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)",FALSE,73,"t-test",NA,NA,NA,1.22517242927605
"2099","850fab6e674283e6da4a94e997121b5a","NCT01559259",0.03,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Relief Rating Score (PRR)","SECONDARY","12 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,182,"anova",2,NA,NA,1.29731252492619
"2100","851595668227db997bae34a59ed051e1","NCT00572832",0.025,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Geometric Mean Antibody Titers Following the Third Dose of Human Papilloma Virus (HPV) Vaccine by Virus Type and by Administration Schedule","PRIMARY","Non-inferiority tested against 1-sided null hypothesis (alpha=.025) that the post Dose 3 GMT ratio of the Alternate to Standard schedule was ≤ 0.5 for each HPV type","D030361; D010212","Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting",FALSE,188,"anova",2,NA,NA,1.12709022236649
"2101","85186b54f19ea8c1121b0eee95fa54f0","NCT02517099",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Number of Unscheduled Healthcare Visits (UHCV)","PRIMARY",NA,NA,"Preschool Wheeze: Inflammation/Infection Guided Management",FALSE,52,"mann_whitney",NA,NA,NA,1.09617796589869
"2102","85333c32e37d08cebefe2cbea7efb03e","NCT00899392",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Subject (Parental) State Anxiety as Measured by the Spielberger-State Trait Anxiety Inventory (s-STAI) (State Section)","SECONDARY",NA,"D001008","Improving Informed Consent in Pediatric Endoscopy",FALSE,123,"t-test",NA,NA,NA,1.65033525744316
"2103","853b5dabbd9571c3e1fcef41d7626bd7","NCT01070550",0.0128,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for Platelets x 10\^9/L at BL (\< 140 vs \>=180). The logistic regression analysis for relapse 24 Weeks after EOT was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,1751,"logistic_regression",NA,NA,NA,1.89168608132356
"2104","855010d51d59531eac05532bac2cca35","NCT00324857",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Change in Willingness.","PRIMARY","Comparisons of the baseline demographic and clinical characteristics (TKR) across the 4 intervention groups were performed using chi-square tests for categorical data and analysis of variance for continuous variables. Willingness were compared across the groups over time using mixed-effect logistic regressions for dichotomous outcomes.","D010003","Educational Intervention for Knee Pain",TRUE,639,"logistic_regression",NA,NA,NA,3.71444269891167
"2105","855a3ed579dd996fca2545cf91153935","NCT01317277",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Text-reported METH Use","SECONDARY","Text-reported METH use days",NA,"Personalized Text Messages to Improve Antiretroviral Treatment (ART) Adherence in HIV+ Methamphetamine Users",FALSE,43,"mann_whitney",NA,NA,NA,1.00454908915455
"2106","8586c56f98521c5f43de43569fbdfb48","NCT02709486",0.0152,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >=30%, >=50%, >=70% and >=90% Response","SECONDARY","Week 24, \>=50%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,563,"logistic_regression",NA,NA,NA,1.25270472224328
"2107","858d25068f76a4eaee4c3d6e3c6a24fe","NCT00337662",0.026,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Body Weight","SECONDARY",NA,"D012559; D011618","Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia",FALSE,327,"anova",2,NA,NA,1.52890023300832
"2108","85901739d414ba81adba9a6d2bf553f7","NCT01126580",0.023,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) of Less Than 7% and Less Than or Equal to 6.5% at 26 and 52 Weeks","SECONDARY",NA,"D003920; D003924","A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)",FALSE,530,"logistic_regression",NA,NA,NA,1.74553639034593
"2109","85c13f4bb5feb0e8d03a2adb8001e13d","NCT00657241",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Cardiac Output","SECONDARY","Statistical analysis performed on treatment groups (valsartan or carvedilol CR) at end of treatment period (4 weeks), not on the randomization arms in the crossover design (which controlled for carryover effects of the prior treatment arm).","D006973","Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril",FALSE,60,"t-test",NA,NA,NA,1.17169922891753
"2110","85da6b68a96cbb68e60ebccce064d623","NCT02697773",0.036,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >= 30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 8, \>=30%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,463,"logistic_regression",NA,NA,NA,2.39901850770833
"2111","85e83360ad9e037e01bd8d0b1093b6f9","NCT01378299",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Percent Change in Bone Mineral Density According the Presence of Diabetes Mellitus","SECONDARY","Analysis by intention to treat with the last value carry forward.","D007006","CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy",TRUE,84,"anova",2,NA,NA,1.37375080866169
"2112","860a114090872bb346e4a93af2dcda10","NCT01066793",0.0182,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for age per 10 years. The logistic regression analysis for relapse was performed for association between treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,960,"logistic_regression",NA,NA,NA,1.91166333383767
"2113","8611f4bf7151a44459a78234b17a8a69","NCT02967510",0.032,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline to Week 12 in the Severity of Dry Mucosa","SECONDARY",NA,"D001284","Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy",FALSE,137,"mann_whitney",NA,NA,NA,1.19425772625913
"2114","864f3b660e61a0437d160e76d1d79329","NCT01789970",0.0293,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With a 30% or Greater Increase in Weekly Average Pain Intensity (API) From Baseline to Week 12 Visit, and an Average API Score of 5 or Higher at Week 12","SECONDARY","API increase \>=30% and API \>=5","D001416; D017116","Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain",FALSE,285,"logistic_regression",NA,NA,NA,1.58348455625596
"2115","865c6906354637f3f2cce25e63e88ad3","NCT01259011",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change Over Time: Hospital Anxiety and Depression Scale Scores","SECONDARY",NA,"D007674; D007676; D003643","A Representational Intervention to Promote Preparation for End-of-life Decision Making",TRUE,45,"linear_regression",NA,NA,NA,1.02560707988412
"2116","8663dc2340625dffdbc4f922f7d3604e","NCT00620828",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Numeric Pain Score","PRIMARY","Patient cohort was inclusive of patient undergoing single TKA from June 2007 to July 2008. Effect size was calculated for the numeric pain rating scale at the immediate post-operative period, 4-hour, 8-hour , 12-hour, and 24-hour time periods as a means to assess post-operative pain control.","D010149","The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty",TRUE,67,"t-test",NA,NA,NA,1.23402909436682
"2117","866d1390fad5574f88eb96fb6d8fcc33","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient-Reported Outcomes Measurement Information System (PROMIS Short Forms 8a - Pediatrics v. 2.0) is a Set of Person-centered Measures That Evaluates and Monitors Physical, Mental, and Social Health in Children and Adolescents.","SECONDARY","The results here are for the outcome variable Emotional Distress - Depressive symptoms at 3 month outcomes. We hypothesized that adolescents randomized to the intervention would have lower depressive symptoms than controls.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,126,"t-test",NA,NA,NA,1.66971913113983
"2118","86a3174c9e5ea75ea3aa45da557fb69e","NCT02539394",0.031,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Degree of Dysphagia Patients Experience (Communication)","PRIMARY","The distribution of 4-6 weeks SWAL-QOL - Communication is the same across the 2 arms","D007405; D055959; D003680; D013118","Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion",FALSE,109,"mann_whitney",NA,NA,NA,1.04136929846193
"2119","86dddd89023baa5af61457bb4796469a","NCT00113087",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Ventricular Mass Z-score","SECONDARY",NA,"D006333; D000080039; D006330; D000013","Trial of Angiotensin Converting Enzyme Inhibition in Infants With Single Ventricle--Pediatric Heart Network",FALSE,184,"t-test",NA,NA,NA,2.00807633240483
"2120","86e070737c0aad8b98b0c39de5e157d1","NCT03192176",0.0389,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 2 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 13","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,87,"logistic_regression",NA,NA,NA,1.13298103726377
"2121","86e5129b4fd931c46a6715b525807f6a","NCT05407064",0.0492,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores","SECONDARY","Change from baseline in total CGI-S scores determined by the difference in means and difference between treatment and placebo (p-value determined from two-sample t-test).","D001008","A Dose-Finding Study of MM-120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms",FALSE,62,"t-test",NA,NA,NA,1.17410576579481
"2122","872b0d10fe7314ed7f4e00bdbe8b7ecd","NCT04547192",0.013,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Appropriate Use of Key Performance Indicators in Initial Assessment and Management of the Injured at Non-tertiary Hospitals in Ghana","PRIMARY","Important Clinical Data Document","D000066553","Improving Initial Management of the Injured at Ghanaian District and Regional Hospitals With a Trauma Intake Form",FALSE,4077,"linear_regression",NA,NA,NA,2.92343698874167
"2123","8733533d00e48c4755029cc898704b04","NCT04673214",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS.","PRIMARY","Assuming a difference of 2 days in the modification of the clinical course (symptoms of fever, cough, headache, myalgia, odynophagia, anosmia, rhinorrhea, arthralgia, chest pain, dyspnea, conjunctivitis) of patients diagnosed with COVID-19 in early intervention treatment vs. therapeutic failure, for 14 days followed by video call, with a power of 90%, a type I error rate of 1% and a loss to follow-up of the twenty%","D000086382","Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment",FALSE,111,"t-test",NA,NA,NA,1.5704144397227
"2124","873398fc469028e45d829f265e130286","NCT00734604",0.046,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in the Overall Satisfaction (OS) Domain of the IIEF","SECONDARY",NA,"D007172","A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.",FALSE,705,"t-test",NA,NA,NA,3.63687754474358
"2125","874c0d2597fd8c860a67f669d1de62d9","NCT02528253",0.0229,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 12, \>=30%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,810,"logistic_regression",NA,NA,NA,2.1461484535348
"2126","8750b4055aeb8aee39501c929590f0d7","NCT04992390",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Patient Health Questionnaire 2-item Version (PHQ-2)","SECONDARY","ITT analysis for Patient Health Questionnaire 2-item version (PHQ-2) (treatment effects for between-arm comparisons) at week 4.",NA,"A Brief GAmeplay Intervention for NHS ICU Staff Affected by COVID-19 Trauma (GAINS Study)",FALSE,86,"linear_regression",NA,NA,NA,1.38926982128357
"2127","875ac8ac68ab0e771432b5288e6cd561","NCT05556148",0.0364,"One-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Each of the WURSS-21 Symptom Domains Score: Feeling Tired","PRIMARY","Change from Baseline at Day 2","D003139","Otrivine: Quality of Life (QoL) Impact in a Real-World Setting",FALSE,102,"t-test",NA,NA,NA,1.15582602857712
"2128","878b1469241bea13c0f8e0998cad614e","NCT00335452",0.012,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Occurrence of Major Bleeding - Clopidogrel Dose Regimen Comparison","SECONDARY",NA,"D003327; D003324","Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS",FALSE,25086,"logistic_regression",NA,NA,NA,6.75122400688639
"2129","8795ac1d0d0c9d4726251705b3fd37ca","NCT03773978",0.032,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving PedACR90 Responder Index","SECONDARY","at week 32","D001168; D001171","A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis",FALSE,163,"logistic_regression",NA,NA,NA,1.29917891829169
"2130","87a39f70f227537ebd63153ad234746b","NCT00261443",0.047,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Adjusted Mean Change in CGI-BP From Preceding Phase (Overall) Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 48 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,2.52642598430683
"2131","87baf14bcd148b24730b089af992af72","NCT00755807",0.032,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Pulse Rate at Week 18 (Open-label Extension Phase)","SECONDARY",NA,"D009103; D012598","Duloxetine for Multiple Sclerosis Pain",FALSE,207,"t-test",NA,NA,NA,1.45968173401249
"2132","87c1d4b8edb74ff513ac8f1b7d977432","NCT00910689",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change in Number of Migraine Episodes Per 30 Days at Month 16.","SECONDARY","Post-test contrast. Mean difference in change.","D008881; D006261","Drug and Non-Drug Treatment Of Severe Migraine",FALSE,110,"t-test",NA,NA,NA,1.56357043896758
"2133","87c9e49f7342ea09ff502e3320b19079","NCT01070550",0.018,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for Alanine transaminase (ALT) ratio at BL (\<=1 vs \> 3). The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,2981,"logistic_regression",NA,NA,NA,3.32966308094747
"2134","87d1206c5f56d747cad8021f82d31550","NCT00110812",0.03,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change in HIV-RNA Copies/ml (log10) From Baseline to Month 12","SECONDARY",NA,"D007239","Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People",FALSE,151,"anova",2,NA,NA,1.18481598771633
"2135","87ec4172d7033c37d785413bd463e2bb","NCT00489411",0.03,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change in the Total Score of the FACT/COG-NTX From Week 1 to Week 5","SECONDARY",NA,"D010523; D020258","Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer",FALSE,181,"mann_whitney",NA,NA,NA,1.29383604857421
"2136","8809afa70197b6bd957fdac9226a96ad","NCT01234649",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Alanine Aminotransferase /Aspartate Aminotransferase (ALT/AST) Ratio","SECONDARY","Factorial repeated measures ANOVA","D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",FALSE,72,"anova",2,NA,NA,1.27670232702116
"2137","884038a646cf41fc22f5886f3bff49aa","NCT03184519",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Number of Participants With Early Detection of Pregnancy","PRIMARY",NA,NA,"Comparison of hhCG With hCG+ß in the Early Prediction of Ongoing Pregnancy.",FALSE,142,"t-test",NA,NA,NA,1.7695236426303
"2138","8861e6544e9dc047eae836098cb282e8","NCT01081301",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"SF12: Physical Health","SECONDARY","Generalized estimating equations were used to determine change in patterns of SF-12v2 Physical health scores over time (Day 7, 14 and 3, 6, and 12 months) compared to baseline. The advantage of utilizing general estimating equations was that it effectively increases the sample size (increasing power) and estimated more robust standard errors by taking into account the repeated measures and adjusting for covariates.","D009369","Living With Hope Program for Rural Women Caregivers",TRUE,58,"anova",2,NA,NA,1.15327776573523
"2139","88a41d21ca22aa193b47c512ee34a116","NCT00779324",0.0353,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Change in Neuropsychiatric Inventory - Irritability Domain Assessed by Participants Day 60","SECONDARY",NA,"D001930; D000070642; D014947; D000374","Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study",FALSE,157,"mann_whitney",NA,NA,NA,1.38670547538925
"2140","88cabc01cc5832f1fcf9fc987eeae01e","NCT01081301",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"SF12 Mental Health","SECONDARY","Generalized estimating equations were used to determine change in patterns of SF-12v2 Mental health scores over time (Day 7, 14 and 3, 6, and 12 months) compared to baseline. The advantage of utilizing general estimating equations was that it effectively increases the sample size (increasing power) and estimated more robust standard errors by taking into account the repeated measures and adjusting for covariates.","D009369","Living With Hope Program for Rural Women Caregivers",TRUE,58,"anova",2,NA,NA,1.15327776573523
"2141","88d9b3991ca415a0deee93768f16c98b","NCT04593940",0.0313,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Mean Change in the 8-point Ordinal Scale From Day 0 to Day 28","SECONDARY",NA,"D000086382","Immune Modulators for Treating COVID-19",FALSE,996,"t-test",NA,NA,NA,3.11423893186259
"2142","88ed0242f20f7e7275059b0a795456a6","NCT02963935",0.0469,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of Subjects Losing More Than 10% of Baseline Body Weight at Week 56","SECONDARY","Treatment policy estimand. Week 56 responses were analysed using a logistic regression model with treatment, BMI groups, and sex as factors and baseline body weight as covariate. Analysis of in-trial data with missing observations imputed from the placebo arm based on a jump to reference multiple (x10000) imputation approach.","D009765; D009748","Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting",FALSE,282,"logistic_regression",NA,NA,NA,2.3477773506089
"2143","88ee04224491bb22ebcc02c5cd17e821","NCT03911843",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,1,0,"Daily Insulin Need (IU/Kg/Day) and Daily Insulin Pre-meal Demand (Pre-meal IU/Kg/Day) at 12 Months","PRIMARY",NA,"D003922","Omega-3 and Vitamin D Supplements in Childhood T1D",TRUE,59,"mann_whitney",NA,NA,NA,1.16252463235142
"2144","88ff40ff9d089485ddc9cfb74088b6bf","NCT03543176",0.013,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Count of Unique Medications-Baseline All Cause Utilization","SECONDARY",NA,"D008171; D029424","Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness",FALSE,789,"t-test",NA,NA,NA,1.29012312297142
"2145","89387be2bf4666e3d0b40fec9933493a","NCT02429791",0.024,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase","SECONDARY",NA,"D015658","Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)",FALSE,508,"mann_whitney",NA,NA,NA,1.77347147772873
"2146","893b2cda8e9009b1c4007afd8eea9fde","NCT03897049",0.022,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mini-Medical Outcomes Study--Social Support Survey (mMOS-SS)","SECONDARY",NA,"D000163; D015658","Evaluation of the Trans Women Connected Mobile App for Changes in Sexual Health-related Behavior Among Transgender Women",FALSE,353,"linear_regression",NA,NA,NA,1.37406267932732
"2147","8950d7b96b7f3f4c82ae0722dbc4959e","NCT03199053",0.042,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Low-dose/High-dose Versus Placebo (Weighted): Percentage of Participants With Baseline HbA1c ≥ 7% Who Achieved HbA1c < 7% at Week 26","SECONDARY",NA,"D003920; D003924","Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old",FALSE,94,"logistic_regression",NA,NA,NA,1.25362713744152
"2148","8957bc3798897cfde7d47b2670ae35e1","NCT02867709",0.0129,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose","SECONDARY",NA,"D008881","Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine",FALSE,892,"logistic_regression",NA,NA,NA,1.36180709607605
"2149","895c270df0443e374970b7876435918e","NCT01705977",0.0284,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Participants Whose Average Prednisone (or Equivalent) Dose to Treat SLE Has Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52","SECONDARY",NA,"D008180","Belimumab Assessment of Safety in SLE",FALSE,1976,"logistic_regression",NA,NA,NA,4.03021740097292
"2150","89a0bcd4f745a763f221f99b08bab15d","NCT03007485",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Composite of COPD Hospital Readmission/Death Within 6 Month of Discharge","PRIMARY","Sample size and power calculation was a composite of COPD-related hospital readmissions or death within 6 months of discharge. First level of analysis was the ITT, which included all the patients randomly assigned to an arm at the beginning of the study (excluding those who were found to not meet inclusion criteria for referral). The second included all the patients medically cleared and third included all the patients who were medically cleared and who had participated in at least 1 PR session.",NA,"Telehealth Pulmonary Rehabilitation for Hispanic and African-American Patients Admitted With Exacerbation of COPD",TRUE,432,"t-test",NA,NA,NA,3.05851503858615
"2151","89a58fe77f584fb8d71fa59326f89d3c","NCT00885079",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change in Fluorescein Corneal Staining (FCS) Score From Baseline","PRIMARY",NA,"D015352; D007638","Confirmatory Study of OPC-12759 Ophthalmic Suspension",TRUE,188,"t-test",NA,NA,NA,2.02933512924615
"2152","89b53141ea3e9c7afda85c6b9debaf97","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Specific Perceived Environmental Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1753,"linear_regression",NA,NA,NA,6.14051253521365
"2153","89b61ae700905d3154b1b72d0e5b62de","NCT02209181",0.041,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Intensity Difference From Baseline (PID) Scores at 3 Hours Post Dose","SECONDARY","The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.","D014098","A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine",FALSE,136,"anova",2,NA,NA,1.46766542653711
"2154","89bc5139db9010214ff4d849bf2d40d0","NCT04856163",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Breastfeeding Satisfaction","SECONDARY",NA,NA,"The Impact of Telelactation Services on Breastfeeding Outcomes",FALSE,1908,"linear_regression",NA,NA,NA,6.40566456543916
"2155","89c8752b04d31f4275625f98027ec6bd","NCT00383110",0.03,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"Systolic Blood Pressure","SECONDARY",NA,"D003920","Racial/Ethnic Differences in Trust/Mistrust and Its Effect on Diabetes Outcomes",FALSE,287,"anova",2,NA,NA,1.62141516463487
"2156","89cd45d1f003dce7ede3d2583463994f","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient-Reported Outcomes Measurement Information System (PROMIS Short Forms 8a - Pediatrics v. 2.0) is a Set of Person-centered Measures That Evaluates and Monitors Physical, Mental, and Social Health in Children and Adolescents.","SECONDARY","We hypothesized that adolescents randomized to the intervention would have no differences in fatigue at baseline if randomization was successful. In this analysis we examine the baseline results.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,126,"t-test",NA,NA,NA,1.66971913113983
"2157","89d61e0e5df85cdf07a967fd8465ff79","NCT05807828",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Time Needed to Perform Each Task","SECONDARY","Median difference between the time needed for cup implantation for Control cup group and the time needed for cup implantation for VR cup group","D015207","VR Simulation and Basic Skills in THA",TRUE,101,"mann_whitney",NA,NA,NA,1.50057440421219
"2158","89e3b28089102f4822a753f3b75a0472","NCT02057042",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Anxiety","SECONDARY",NA,"D003863; D003866","Veteran Peer-Assisted Computerized Cognitive Behavioral Therapy for Depression",TRUE,330,"t-test",NA,NA,NA,2.67684084235139
"2159","89ec43e019cdd0c33e19bb8489f2dd72","NCT03192176",0.0364,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 7","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.06555464089628
"2160","89ede20901ebe1046dc469c6bec3bad2","NCT02709486",0.0126,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >=30%, >=50%, >=70% and >=90% Response","SECONDARY","Week 4, \>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,565,"logistic_regression",NA,NA,NA,1.06365381087395
"2161","89fcbafbb0e04b995db6757c6fa07dd0","NCT03192176",0.0484,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 8","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.35229607354779
"2162","8a0a328d62554871281ee8e522da0cf8","NCT04567342",0.018,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Receipt of MMR Vaccination","PRIMARY",NA,"D000079263","Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of MMR Vaccination",FALSE,655,"logistic_regression",NA,NA,NA,1.56598485486982
"2163","8a0df033b7ccdbce91e3c5325868ce92","NCT03235050",0.024,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Rescued or Discontinued for Lack of Glycaemic Control","SECONDARY","received rescue medication at 14 wks","D003920; D050177; D003924","A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes",FALSE,212,"logistic_regression",NA,NA,NA,1.15372122567056
"2164","8a113455f8f50c820ca04be76f9a8dba","NCT00472199",0.0489,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Restless Legs Syndrome-6 (RLS-6) Score ""Satisfaction With Sleep"" After 26 Weeks","SECONDARY",NA,"D011595; D012148; D013577","Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)",FALSE,321,"mann_whitney",NA,NA,NA,2.59184746419851
"2165","8a19d9957e8d52c800583c249cbed8ea","NCT01183689",0.03,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Mean Change in Fasting Insulin From Baseline to 2 Years","SECONDARY","Mean changes between baseline and year 2 were compared among the 3 arms using analysis of variance.","D015430","Study of Novel Approaches for Prevention",FALSE,312,"anova",2,NA,NA,1.68944895420687
"2166","8a69377e8484c9aea47e6040d57a46e6","NCT03552822",0.037,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Overall Average Pain Scores","SECONDARY",NA,NA,"Cesarean Section Via Enhanced Recovery",FALSE,541,"mann_whitney",NA,NA,NA,2.65255807327915
"2167","8a70a240f18350f6a926f489ab4d4134","NCT04003142",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Percent Reduction of >=50% in the Mean Frequency of Moderate and Severe VMS From Baseline to Each Study Week Up to Week 12","SECONDARY","Week 1","D019584","A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2",FALSE,333,"logistic_regression",NA,NA,NA,1.22906042710581
"2168","8a9f9082743791bb165e8dcd42399374","NCT02137512",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"LBGI - Main Phase, Day Only","SECONDARY",NA,"D003922","Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use",FALSE,58,"t-test",NA,NA,NA,1.15327776573523
"2169","8aa195c7b36f0642aa30c7b4aafa3933","NCT01236053",0.0046,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,20382,"logistic_regression",NA,NA,NA,2.57597139139188
"2170","8aa82bcd7794ed92251dd62f57767ccf","NCT00813488",0.0443,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Pain Relief Score at 15 Minutes Post-treatment","SECONDARY",NA,"D059350; D059390","Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain",FALSE,274,"mann_whitney",NA,NA,NA,2.20648398395957
"2171","8ab33f366ec3ed1cd799610b4a197e27","NCT02746107",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the CHA2D2s-VASC Risk Score","OTHER_PRE_SPECIFIED",NA,"D020521; D001281","Intention to Prescribe/Take OAC Depending on the Number of Risk Diagrams , and Period for the Estimation of the Risk.",FALSE,390,"logistic_regression",NA,NA,NA,1.88601247795062
"2172","8ab7ab444fb921fab25180f64d37a224","NCT04156620",0.0234,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Pittsburgh Sleep Quality Index (PSQI)","SECONDARY",NA,"D013166; D025241; D013167; D000089183","Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA",FALSE,495,"logistic_regression",NA,NA,NA,1.71289941185145
"2173","8ae163c1af13cd705d1d28cbde52c8a0","NCT01347931",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Arterial Oxygen Saturation","SECONDARY","Two-tailed t test","D008171; D029424; D012131; D008173","In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory Insufficiency",TRUE,58,"t-test",NA,NA,NA,1.15327776573523
"2174","8af68d5b5ba212b8528ef0599e2b51ea","NCT02481375",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Hemoglobin Levels at 12-weeks. Marginal Means (95% CI).","PRIMARY","Marginal means (95% CI) of ferritin concentrations at 12-weeks using a generalized mixed-effects model with adjustments for baseline values and village clusters","D000740; D018798; D006453; D000090463; D007249","Is Iron Deficiency the Cause of Anemia Among Women in Cambodia?",TRUE,809,"linear_regression",NA,NA,NA,4.1767951843968
"2175","8b03e3026a28617bf968410734dbddb7","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Health)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1754,"linear_regression",NA,NA,NA,6.14225987828851
"2176","8b24a24ba43da379512b32a867ac128c","NCT00424593",0.028,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 and Week 54 Endpoints in Vital Signs: Pulse Rate","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,224,"anova",2,NA,NA,1.35332733361848
"2177","8b2c9577394edb2583737bc65f8b2e42","NCT00789815",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"The Global Tolerance for Flexible Bronchoscopy by Verbal Analogus Scale","PRIMARY","The null hypothesis: the global tolerance of patients in study is worse than that in the control group.",NA,"Bispectral Index-guided Sedation for Flexible Bronchoscopy",FALSE,492,"mann_whitney",NA,NA,NA,3.26223932627676
"2178","8b3216b7589aca25cc05832972985b01","NCT00696436",0.036,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response","SECONDARY",NA,"D006973; D000075222","An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.",FALSE,541,"logistic_regression",NA,NA,NA,2.59145938294138
"2179","8b3591a0ad107f07e5b8a231569d5e0a","NCT01234649",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"High Density Lipoprotein Cholesterol (HDL-C) Levels","SECONDARY","Factorial repeated measures ANOVA","D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",FALSE,72,"anova",2,NA,NA,1.27670232702116
"2180","8b424019d6c14f778656bfc6b2a2fe4a","NCT05182840",0.0285,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Multiple Imputation","SECONDARY","The odds ratio, 95% confidence interval, and p-value were calculated based on logistic regression of binary outcome adjusting for treatment, and stratification factors as covariates.

Randomisation stratification was used, which is based on estimated glomerular filtration rate (eGFR) and urine albumin creatinine ratio (UACR) levels at screening.","D007674; D051436","A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease",FALSE,134,"logistic_regression",NA,NA,NA,1.07040711383234
"2181","8b5d2ddce487b7bd06c5f1c0b119dbb0","NCT00759954",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Area Under the Curve to Infinity for Plasma Morphine","SECONDARY",NA,NA,"Comparison of One Morphine Sulfate Sustained-Release 200 mg Capsule With Two 100 mg KADIAN Capsules on Applesauce",TRUE,56,"anova",2,NA,NA,1.13456029943022
"2182","8b6712cdaff3a573cd94280d81cad896","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Burger Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1746,"linear_regression",NA,NA,NA,6.1282671837603
"2183","8b7119f8a703855611e41c3f9499479e","NCT02321462",0.0256,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean BBPS Score by Segment and Globally (ITT Population)","SECONDARY","Treatment difference for Global BBPS Score.",NA,"Efficacy, Safety and Tolerability of Eziclen in Adult Subjects Undergoing Colonoscopy",FALSE,282,"anova",2,NA,NA,1.4026606301272
"2184","8b7224ca60e244679531c4993c19e2e3","NCT05493787",0.035,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Number of Patients Who Self-scheduled a Flu Shot","PRIMARY","Null hypothesis: Flu shot self-scheduling does not differ between those sent a Protect Yourself - Frequent message and those not sent a message (i.e., those in the Passive Control group); Alternative hypothesis: Sending a Protect Yourself - Frequent message increases self-scheduling compared with sending no message. Analysis combines across November and December send dates.",NA,"Nudging Flu Vaccination by Making it Easy for Patients to Schedule a Flu Shot",FALSE,46495,"linear_regression",NA,NA,NA,23.3596520447599
"2185","8b7c9ddaf4dbc3031eef58ec6fe2f252","NCT00110461",0.0468,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change in General Behavior Inventory Scale (GBI) Total Subject Version Mania Score at Week 4","SECONDARY","Analyses were performed by fitting an ANCOVA model with treatment as factor, and baseline score as covariate. Two pair-wise comparisons, aripiprazole 10 mg target dose versus placebo and aripiprazole 30 mg target dose versus placebo, were performed within the ANCOVA or ANOVA model.","D001714","Aripiprazole in Children and Adolescents With Bipolar I Disorder",FALSE,187,"t-test",NA,NA,NA,1.91523533430707
"2186","8b81a1eb05825aceb2bea005044d1f33","NCT04866303",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"SARS-CoV-2 Home-testing Kit Completion Active vs. Passive Arms","PRIMARY","Minimum testing kit completion rate of 70% in the passive study arm, and calculated that 400 total subjects would provide us with 90% power to detect an effect size associated with a rate ratio of 1.20, or an absolute difference of 14% (70% in passive, 84% in active). A futility boundary of 60% was identified by Community Advisory Board members as justification to prematurely halt trial enrollment if, after completing 25% of expected enrollment, successful test completion fell below that rate.","D000086382","Protecting Our Community: COVID-19 Testing",FALSE,268,"logistic_regression",NA,NA,NA,2.00254802853272
"2187","8b95ce7282851c8b3834ecf9eb35e55a","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Specific Perceived Environmental Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1771,"linear_regression",NA,NA,NA,6.17188902328434
"2188","8ba902e3aae8793ac13d2501f4bdef1d","NCT01761084",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Physical Activity","SECONDARY","Only Month 6 and Month 12 strength and balance physical activity differences were significant.","D050723; D058866; D016103","Build Better Bones With Exercise",TRUE,141,"t-test",NA,NA,NA,1.76345107862741
"2189","8bc2a743d040b4fb8fa600f37560b921","NCT00408876",0.024,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Interference (BPI-I) Score - Sleep","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,163,"t-test",NA,NA,NA,1.01530249637199
"2190","8bec27b44b140a4ca746403a94333171","NCT01318538",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Group Attendance","OTHER_PRE_SPECIFIED",NA,"D019966; D019973","Women's Recovery Group (WRG) Study - A Randomized Controlled Stage II Trial",FALSE,100,"t-test",NA,NA,NA,1.49341131573029
"2191","8bfe1431b73d33a020434941a23076a8","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Burger Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1764,"linear_regression",NA,NA,NA,6.15970604727369
"2192","8bfec1429f016fc93c57d0ed36926c9e","NCT05170841",0.037,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Total Pain Relief (TOTPAR) at 72h After the First Dose - Multiple Dose Phase - Dexketoprofen/Tramadol vs Tramadol","SECONDARY",NA,"D001416; D017116","Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain",FALSE,499,"t-test",NA,NA,NA,2.54837604259274
"2193","8c07a7755e4f61f569bf2497ce5a002e","NCT00112047",0.049,"Wilcoxon","INTERVENTIONAL",0,0,0,1,0,"Change in Trunk Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)","SECONDARY","Null Hypothesis: Change from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) trunk fat value is equal to zero. Alternative hypothesis: Change from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) trunk fat value is not equal to zero.","D015658","Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects",FALSE,213,"wilcoxon",NA,NA,NA,2.12137948173931
"2194","8c08f5665b6c3882e86a46f904893fd6","NCT01691560",0.0467,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 4","PRIMARY","Null hypothesis considered change from baseline to be same for treatments in comparison.","D003807; D006967","Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity",FALSE,67,"mann_whitney",NA,NA,NA,1.16624332128302
"2195","8c11487f5e46950bf4e4d77f6d66b77f","NCT01379924",0.037,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Rapid Repeat Pregnancy","PRIMARY","Multiple logistic regression modeling used to compute adjusted odds ratios for 12-month follow-up data.",NA,"Young Parents Program, Project Connect",FALSE,117,"logistic_regression",NA,NA,NA,1.25166241898985
"2196","8c22bb615d407c8a11ed80a13f68c839","NCT02732145",0.0414,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Distribution of Non-Specific and Specific Lesions of the Outer Vulvar Ring According to the ""Three Rings Vulvoscopy""","SECONDARY","Parameter: The difference in the incidence of non-specific lesion of Labia Majora versus non-specific lesions of the Perineum in patients with vulvar dermatosis.","D056650; D008010; D018459; D012871; D009450","Diagnostic Accuracy of ""Three Rings Vulvoscopy"" for Detection of Vulvar Dermatosis",FALSE,82,"t-test",NA,NA,NA,1.16060290427193
"2197","8c2623d1e521d3a3d8de6b6882e57bd7","NCT02675907",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Summed Pain Intensity Difference (SPID) at Other Intervals","SECONDARY",NA,"D010149","Evaluation of N1539 Following Bunionectomy Surgery",TRUE,201,"t-test",NA,NA,NA,2.09693952229299
"2198","8c2bce63f578e4561dc8696fdb5f340a","NCT00812214",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Quality of Sleep","SECONDARY","Null hypothesis is that there is no difference between Eszopiclone and placebo groups in daytime fatigue averaged over 6 weeks of treatment.","D007319","Treatment of Insomnia in Migraineurs",FALSE,75,"t-test",NA,NA,NA,1.301639172202
"2199","8c34e016d84269edb043020dbe392bdf","NCT02697773",0.0262,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants Who Took Rescue Medication During Weeks 2, 4, 8, 12 and 16","SECONDARY","Week 4: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,463,"logistic_regression",NA,NA,NA,1.82725665885874
"2200","8c3e22945c9ff8da0cbc40200956da53","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Nighttime Central Systolic Pressure","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"2201","8c49144246cd89b8e65938c77042bd9b","NCT03726489",0.0158,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Concomitant Topical Psoriasis Treatment","SECONDARY","Analysis for Phototypes I/II","D011565","Light Treatment Effectiveness (LITE) Study",FALSE,594,"linear_regression",NA,NA,NA,1.33088563491721
"2202","8c64d7e8aee8e1f18b5fe7b2b1dd54cd","NCT04673214",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Average Days of COVID-19 Symptoms Under Treatment of Early Intervention Due to Outcome in UMF 13 and 20 of the IMSS","OTHER_PRE_SPECIFIED","Assuming a difference in days of effectiveness in clinical modification and therapeutic failure of patients diagnosed with COVID-19 in treatment with Azithromycin / Ivermectin / Ribaroxaban / Paracetamol vs. Azithromycin / Ribaroxaban / Paracetamol followed for 14 days followed by video call, with a potency 90%, a Type I error rate of 1%, and a loss to follow-up of 20%","D000086382","Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment",FALSE,111,"t-test",NA,NA,NA,1.5704144397227
"2203","8c67bcce5d44ecbef42dbde7b00d2b2c","NCT03978871",0.048,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Mean Difference in Parameter Estimates of BOLD Signal for Frontal Parietal Network-Amygdala Connectivity- Go/No-go Task","PRIMARY",NA,NA,"Effect of Emotion Mindsets on Emotion Processing",FALSE,148,"t-test",NA,NA,NA,1.74511873849739
"2204","8c6fdbc96d17b9322113c6ffcb3cf68b","NCT00292188",0.032,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Number of Subjects With 30% and 50% Response in Weekly Mean Daily Pain Rating Score (DPRS) From Baseline Until Endpoint (Week 8)","SECONDARY","30% responder","D009437","P4 (Pregabalin for Peripheral Posttraumatic Pain)",FALSE,251,"logistic_regression",NA,NA,NA,1.60422113786125
"2205","8c71feab69224429df5f2a1a7811316a","NCT03082729",0.046,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Changes in Cardiometabolic Markers Between Baseline and Week 16: Leucine","PRIMARY",NA,"D002318; D011565; D007249","Vascular Inflammation in Psoriasis - Apremilast",FALSE,58,"t-test",NA,NA,NA,1.07653587658755
"2206","8c861efbb196fa646b4eb4fc1103c6ef","NCT02371759",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Onset of Intraoral Local Anesthesia","SECONDARY",NA,"D003920; D003924","Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2",TRUE,221,"mann_whitney",NA,NA,NA,2.19689065872099
"2207","8c882ae620e463655def9bbf2a2d716f","NCT02451137",0.0308,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe Hypoglycemia","PRIMARY","A logistic regression model was used with treatment arm as a fixed effect and adjusted for: randomization strata of HbA1c target (\<8%,\<7%), sulfonylurea (SU) use (yes/no), glucagon like peptide1-receptor agonists (GLP-1 RA) use (yes/no) and baseline HbA1c (as continuous).","D003920; D003924","A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)",FALSE,3304,"logistic_regression",NA,NA,NA,5.58515738270313
"2208","8c9dfe89cb5bec5b4004e97eb615d82a","NCT04742907",0.037,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of GIR Responders","SECONDARY","For Day 2",NA,"Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel Resection",FALSE,258,"logistic_regression",NA,NA,NA,1.83988846942376
"2209","8ca2b751b864f95766c1f162e0a95871","NCT02528253",0.0109,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Low Back Pain From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/ Last Observation CF (LOCF)","SECONDARY","Week 4: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline PGA of low back pain, baseline average LBPI, and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1012,"logistic_regression",NA,NA,NA,1.24890873473731
"2210","8cc4c2fab048180f9db5c51ae310ecb5","NCT00510146",0.023,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in ECG (Open-Label Phase)","SECONDARY",NA,"D001714","Olanzapine Treatment of Patients With Bipolar I Disorder",FALSE,366,"t-test",NA,NA,NA,1.45371872309388
"2211","8cd1b452cf5c1efdd0d91880afe1d0c8","NCT03950167",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Gallbladder (GB) Wall Thickness","PRIMARY",NA,"D006939","Gallbladder Functions & Serum Cholecystokinin Levels in Women Diagnosed With Hyperemesis Gravidarum",FALSE,46,"t-test",NA,NA,NA,1.03597838019194
"2212","8ce87de6ed36fa7f72e1286abf01a53b","NCT02618772",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Per-Protocol: Faces Pain Scale-Revised/ FLACC Scale","SECONDARY",NA,"D022125; D001008","Intranasal Midazolam for Treatment of Anxiety in Children Undergoing Suturing in the Pediatric Emergency Department",TRUE,71,"t-test",NA,NA,NA,1.26828177971868
"2213","8d01a7042c045b7cbb33fbf6be312f3a","NCT04172701",0.0062,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"All-cause Healthcare Resource Utilization (HCRU): Number of Inpatient Visits (Per Person Per Month)","SECONDARY",NA,"D029424","A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)",FALSE,4888,"mann_whitney",NA,NA,NA,1.65271227124242
"2214","8d18714a647f9a59797107de9d846904","NCT02979613",0.0186,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in FibroTest® Score at Week 48","SECONDARY","P-value, difference in least squares mean (LSM), and its 95% CI were derived from analysis of variance (ANOVA) model with baseline age groups (\< 50, ≥ 50 years), baseline HBeAg status, and treatment group as fixed effects in the model.","D006506; D006509; D019694; D006505; D006521","Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed",FALSE,470,"anova",2,NA,NA,1.36737115867524
"2215","8d237e32805fb9ac9445efc3c3ec8ffc","NCT04876482",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Tongue Lateralization Muscle Strength","PRIMARY","We hypothesized that the improvements in the tongue lateralization muscle strength would be more in patients who underwent TORS combined with OPR than in those who underwent only TORS and those who received conservative treatment (controls).","D001049; D012891; D020181","Myofunctional Training for Obstructive Sleep Apnea Patients After Transoral Robotic Surgery",TRUE,74,"linear_regression",NA,NA,NA,1.2933799900503
"2216","8d27e7fdb9b7bb5df328dc28b4814400","NCT00261443",0.023,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Adjusted Mean Change in CGI-BP From Preceding Phase (Mania) Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 52 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,1.37317185944936
"2217","8d2eaba75a68276644fd6cf6b9075ffe","NCT01773733",0.002,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Adverse Events","SECONDARY",NA,"D009765","The PRIMAVERA Study: Reduxine Safety Monitoring in Patients With Alimentary Obesity",TRUE,69810,"t-test",NA,NA,NA,2.23014546895094
"2218","8d32294b21260e729b8f5cd206cf396b","NCT01190254",0.028,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Total PANSS 30% Responders","SECONDARY",NA,"D012559; D012562; D012563","Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)",FALSE,196,"logistic_regression",NA,NA,NA,1.26787227018938
"2219","8d55409df56d4853b0b60cbf75338268","NCT02912650",0.02,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Intensity Difference on 4-Point Categorical Scale (PID4)","OTHER_PRE_SPECIFIED","8 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,340,"anova",2,NA,NA,1.24170354272197
"2220","8d58f5da516ac1658e3bf8cbb8428fd7","NCT00662792",0.0317,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Response in Trough Forced Expiratory Volume in 1 Second (FEV1)","PRIMARY","The Tiotropium free combination (T18GEL+S_DPI) was included in order to characterise this treatment in comparison with the FDC Tiotropium/Salmeterol (T+S_PE). No formal hypotheses were defined.","D029424","Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD",FALSE,254,"anova",2,NA,NA,1.60067764569625
"2221","8d5c41586e01c9e13de8b32c35a7c467","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in AUC of Glucose","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,110,"anova",2,NA,NA,1.56357043896758
"2222","8d7b21a1196c2bbd1d4796968714c095","NCT00377858",0.014,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"7-point Self-monitored Blood Glucose Profiles","SECONDARY",NA,"D003920; D003924","Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)",FALSE,479,"anova",2,NA,NA,1.07581818877783
"2223","8d88ce2c06d9add0c7ab74a9c240c08a","NCT01355419",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Change in Total Sleep Time Before and After CPAP Therapy in Obstructive Sleep Apnea Patients","PRIMARY","A power analysis conducted prior to the study predicted that a sample of 144 patients would provide an 80% power to detect a mean difference in sleep time of 40 minutes, assuming a standard deviation of 85 minutes and using a two-sided significance level of 5%.","D001049; D012891; D020181","Sleep Schedules Modifications in Sleep Apnea Patients Treated by nCPAP",TRUE,142,"t-test",NA,NA,NA,1.7695236426303
"2224","8d8b24d60ff27ff97bd92259213b8e5f","NCT00408876",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in 36-Item Short-Form Health Survey (SF36) - Vitality","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,203,"t-test",NA,NA,NA,2.10714784407435
"2225","8d971576cd02816c151487ea1aebd869","NCT00620828",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Total Fentanyl Patient-Controlled Anesthesia (PCA) Narcotic Consumption","SECONDARY","Significant differences in Fentanyl PCA pump usage across study arms were assessed for the 4-8h,8-12h,and 12h-24h time frames.","D010149","The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty",FALSE,67,"anova",2,NA,NA,1.23402909436682
"2226","8da9997a8da4213b2cc2eaa190e5e674","NCT02439320",0.029,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Headache Recurrence","SECONDARY",NA,"D008881","Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:",FALSE,1116,"logistic_regression",NA,NA,NA,3.08663774474969
"2227","8dab7294342b05c5746c986f17f7b61d","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Nighttime Brachial Systolic Pressure","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"2228","8db9973899b035d76d33a1b25a642378","NCT01070550",0.0363,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for sex (male vs female). The logistic regression analysis for mSVR was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,2981,"logistic_regression",NA,NA,NA,6.1059541459796
"2229","8dbe15cc7cd61c42c342489f4eb6f3f2","NCT00482170",0.025,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Assessment of Fear of Device Based on Response to Question Concerning Emotional Distress or Anxiety About Injection","SECONDARY","Last observation: Logistic regression was used to analyze individual concepts and questions measuring participant perception.","D011565","Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept",FALSE,417,"logistic_regression",NA,NA,NA,1.66633043029647
"2230","8dbf33858f8e34505ba573a4e81e1c63","NCT02216214",0.012,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Participants With Zero Incontinence Episodes Per 24 Hours","SECONDARY","Odds Ratio: Logistic regression was performed with treatment group, sex, age group (\<75, \>=75 years), and country as fixed factors and baseline value as a covariate.","D053201","Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)",FALSE,863,"logistic_regression",NA,NA,NA,1.25662447579918
"2231","8dd3a4427575c14f7778d6b59b2acb83","NCT04044664",0.0382,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"CAPS-5 [Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)] Total Score and Subscores","PRIMARY","Arousal and Reactivity sub-score","D040921; D013313","Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder",FALSE,129,"t-test",NA,NA,NA,1.34784963780749
"2232","8de767f9ea1b1d797ae90237b724e4ed","NCT00658138",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Percentage of Restorations Scoring Alpha","PRIMARY","Null hypothesis is adhesives are not different in clinical performance at one year","D003731","Clinical Evaluation of 3M™ ESPE™ Adper™ Scotchbond™ SE Self-Etch Adhesive in Class I and Class II Restorations in Adults",FALSE,80,"mann_whitney",NA,NA,NA,1.34217713699512
"2233","8e3385a03d330f7203238c4f623b83a8","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Saturated Fat","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1761,"linear_regression",NA,NA,NA,6.15447738929084
"2234","8e386489189b4cc4b75846cb18dbd139","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Postprandial Rate of Total Glucose Disposal Area Under the Curve (AUC)","PRIMARY","Difference in treatment effect between the 2 groups","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",FALSE,51,"t-test",NA,NA,NA,1.08637315449684
"2235","8e393c0572a1d4d20a89ed9313444ee5","NCT00083889",0.0128,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Overall Survival (OS)","SECONDARY","Unstratified analysis: Hazard Ratio (SU011248 vs IFN-α).","D002277; D002292","SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma",FALSE,750,"mann_whitney",NA,NA,NA,1.24097278285899
"2236","8e44406585cee539875e68336e46f34d","NCT03084796",0.042,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Transition Dyspnea Index (TDI) Response (Focal Score ≥1) at Week 3 and Week 6","SECONDARY","Week 3

Comparison treatment groups for this analysis were:

Treatment D (CHF 5259 pMDI 100 μg TDD) versus Treatment E (Placebo).

Statistical analysis was performed as described for the statistical analysis 1 of this outcome measure.","D008171; D008173; D029424","A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease",FALSE,244,"logistic_regression",NA,NA,NA,1.99263083453196
"2237","8e4ab2aaa7fcf0a63ec813e3b9b7592f","NCT02900378",0.0297,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Mean Daily Non-sedentary Daytime Activity in Weekly Intervals","SECONDARY","Change from BL at Week 3","D006333","randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure",FALSE,604,"mann_whitney",NA,NA,NA,2.32196348735262
"2238","8e4d16528081a20fa1ba92570bf14586","NCT00789815",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"The Recovery Time to Ambulation","SECONDARY",NA,NA,"Bispectral Index-guided Sedation for Flexible Bronchoscopy",FALSE,492,"t-test",NA,NA,NA,3.26223932627676
"2239","8e6003139eeb87610974cf5eccbd7dad","NCT00244374",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Viral Transmission Risk Behavior Association With Travel","SECONDARY","Adjusted odds with 95% confidence intervals for travel as a risk factor for each behavior.","D006506; D006526; D006509; D006505; D019966; D015819","A Randomized Trial of Vaccine Adherence in Young Injection Drug Users",FALSE,355,"logistic_regression",NA,NA,NA,2.77524765919219
"2240","8e6060380686215c3458a64bfe8d1bc4","NCT00510146",0.024,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in Platelet Count (Open-Label Phase)","SECONDARY",NA,"D001714","Olanzapine Treatment of Patients With Bipolar I Disorder",FALSE,380,"mann_whitney",NA,NA,NA,1.53644741316283
"2241","8e66cdf4afbf85cec2b2166eae62d71f","NCT00536471",0.045,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Chloride, Urea Nitrogen, Cholesterol, Sodium","SECONDARY",NA,"D003866; D003863; D003865","A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients",FALSE,250,"anova",2,NA,NA,2.13709618015495
"2242","8e850c8b69965eefffff603c5ac7e0f9","NCT03035916",0.046,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Side Effects: Number of Participants With Sedation","SECONDARY",NA,NA,"Transversus Abdominis Plane Block on Stress Response",FALSE,61,"t-test",NA,NA,NA,1.10216422170376
"2243","8ea7bcb47ece11bd58078eb2c695fbd9","NCT00105989",0.029,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in Sheehan Disability Scale (SDS) - Maintenance Phase","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,245,"t-test",NA,NA,NA,1.45725163450757
"2244","8eb5acdc234b5617be0f5001edbad04c","NCT02905149",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Total Opioid Usage","PRIMARY",NA,NA,"Impact of the Serratus Plane Block in Pain and the Use of Opioids in Breast Surgery",TRUE,58,"mann_whitney",NA,NA,NA,1.15327776573523
"2245","8eb8feff6548a77b7409bf9cc6a43465","NCT01055639",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Brief Pain Inventory-severity Subscale","SECONDARY",NA,"D059350","Telehealth Therapy for Chronic Pain: Comparison of In-person vs. Video-administered ACT for Pain",FALSE,126,"t-test",NA,NA,NA,1.38532711624811
"2246","8ec3c9e826a869b1db4e1545e095f408","NCT01234649",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Low Density Lipoprotein Cholesterol (LDL-C) Levels","SECONDARY","Factorial repeated measures ANOVA","D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",FALSE,72,"anova",2,NA,NA,1.27670232702116
"2247","8ec9421f85c6b9b065f00442de35dddf","NCT03192176",0.0466,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 11","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.31036970478904
"2248","8eca80933fb962931854cc061efb9644","NCT05807828",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Medical Students Surgical Skills Differences Between VR and Control Group.","PRIMARY","The median difference between the stem angle of the Control Group for Stem Training and the stem angle of VR Group for Stem Training.","D015207","VR Simulation and Basic Skills in THA",TRUE,101,"mann_whitney",NA,NA,NA,1.50057440421219
"2249","8ecccb2e078654c95d85273b05d6eb3f","NCT00736996",0.05,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Change in Peak Oxygen Uptake (VO2 Peak)","SECONDARY","The mean change with PIO was compared with the mean change with Placebo in a linear regression conditioned on the stratification categories (MCI subtype and number of APOE ε4 alleles) and the baseline level of the outcome variable.","D060825","Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)",TRUE,49,"linear_regression",NA,NA,NA,1.06649684228356
"2250","8ece76f50b241c0651b11c0a0a129959","NCT00790335",0.05,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Change in Leg Circumference","SECONDARY",NA,"D013927; D013923; D054556; D020246; D054070; D011186; D013577","Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis",FALSE,619,"linear_regression",NA,NA,NA,3.6562066715951
"2251","8eda1a88927de53adfd01bc31179c6fb","NCT00270998",0.0492,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"75% Reduction in Weekly Urinary Incontinence Episodes at 12 Months","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",TRUE,295,"logistic_regression",NA,NA,NA,2.49873946067788
"2252","8ee02c83b816319b930e382ae5a3ace2","NCT05127304",0.003,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"COPD or Pneumonia-attributable Health Care Costs (Insurer + Patient Paid Amounts)","PRIMARY","Outpatient visits costs","D029424","A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",FALSE,11316,"linear_regression",NA,NA,NA,1.30166137514094
"2253","8ee894ab65f4e3564ed026b5bbc1c9d3","NCT01543685",0.028,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"VASSPID-8. The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale (VASSPID) From 0 to 8 Hours After Trial Entry.","SECONDARY",NA,"D010149","Study of Indomethacin Capsules to Treat Pain Following Bunionectomy",FALSE,187,"t-test",NA,NA,NA,1.23915521488167
"2254","8ee8eeb082dcc2c202e3bb98ba2995e3","NCT05538065",0.039,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Change in Inappropriate Prescribing","PRIMARY","Outcomes were evaluated using generalized estimating equations with a log link and binary errors, adjusting for provider-level clustering and Holm-Bonferroni multiple comparisons.","D064420","NUDGE-EHR Replication Trial at Mass General Brigham",FALSE,752,"logistic_regression",NA,NA,NA,3.26665794249646
"2255","8ef3fae669055a8019ca0c276d2f5bf5","NCT01081301",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Herth Hope Index","PRIMARY","Generalized estimating equations were used to determine change in patterns of the Herth Hope Index over time (Day 7, 14 and 3, 6, and 12 months) compared to baseline. The advantage of utilizing general estimating equations was that it effectively increases the sample size (increasing power) and estimated more robust standard errors by taking into account the repeated measures and adjusting for covariates.","D009369","Living With Hope Program for Rural Women Caregivers",TRUE,58,"anova",2,NA,NA,1.15327776573523
"2256","8ef4f66f3265ba9288e1d9dc1fc79e7f","NCT01783041",0.05,"ANOVA","INTERVENTIONAL",0,0,1,1,0,"Rate of Head Growth in Infants Who Receive L-carnitine Supplementation Compared to Controls","SECONDARY",NA,"D047928; D065886","Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants",TRUE,136,"anova",2,NA,NA,1.73276958204871
"2257","8f008b9c44e3c8f790b620722ac1379a","NCT00762762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"High Sensitivity CRP (C-Reactive Protein)","PRIMARY","The null hypothesis states that there is no difference between groups.","D010518","Effectiveness of a Triclosan Containing Toothpaste in Maintaining Periodontal Health in a Type 2 Diabetic Population",FALSE,46,"anova",2,NA,NA,1.03597838019194
"2258","8f27b6203faaad1b68df985c1c01d0cd","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Satisfaction Questionnaire","OTHER_PRE_SPECIFIED","Family member positively worded score comparing intervention with treatment as usual.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,234,"t-test",NA,NA,NA,2.25949060683958
"2259","8f4633d7f86d5efe40eaf591ae9f783f","NCT03192176",0.0385,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 2 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 7","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.11703331366467
"2260","8f5ed6bd09853343b3cde01ce034fa25","NCT03224403",0.026,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Confirmed Perceptible Relief From 30 Minutes to Successively Earlier Minutes in One-minute Increments - 12 Minutes","SECONDARY",NA,"D014098","Randomized, Double-Blind, Single-Dose, Efficacy and Safety Study of Test Acetaminophen Tablet in Postoperative Dental Pain",FALSE,308,"logistic_regression",NA,NA,NA,1.48451178768168
"2261","8f6e156e678f304f12cea6c752df2efe","NCT05034328",0.05,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Respiratory Complication Requiring Antibiotic Prescription After the10-day Treatment Period","SECONDARY","The impact of the treatment chosen on the risk to develop respiratory complication requiring antibiotic prescription during a 20-day follow-up was analyzed by a multivariate logistic model","D003139","Symbiofilm Trial in Allergic Kids (SYMBIOFILM-TAK)",FALSE,186,"logistic_regression",NA,NA,NA,2.01873369003327
"2262","8f88a63c1df6fc0a1baa3545ae33ec92","NCT01361568",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Summed Pain Intensity Difference From 0-24 Hours (SPID 0-24) Following Postoperative Study Drug Treatment Using Last Observation Carried Forward (LOCF)","SECONDARY",NA,"D010149","Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery",TRUE,142,"t-test",NA,NA,NA,1.7695236426303
"2263","8f8986bcd11cb67dacfe83c7fcd65bc8","NCT00453999",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change in Amount of Influenza Virus in Nose and Throat (Influenza A and B Combined)","SECONDARY","Change from Baseline at 12 hours","D007251","Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza",FALSE,112,"mann_whitney",NA,NA,NA,1.57722881888439
"2264","8f8a556ed7e114e65bf3f562d8d52188","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Environment)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1769,"linear_regression",NA,NA,NA,6.16841062828897
"2265","8f8d8a008466738b145367960866658a","NCT01234649",0.042,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Waist to Height Ratio (WHtR)","SECONDARY","Factorial repeated measures ANOVA","D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",FALSE,72,"anova",2,NA,NA,1.10456065278256
"2266","8f92f6dabb45f09c8ede5df4c22f2c81","NCT00657241",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Difference in Resting CTTI Between Carvedilol CR (Beta-blocker) and Valsartan (ARB) in Combination With Lisinopril.","PRIMARY","Statistical analysis performed on treatment groups (valsartan or carvedilol CR) at end of treatment period (4 weeks), not on the randomization arms in the crossover design (which controlled for carryover effects of the prior treatment arm).","D006973","Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril",TRUE,60,"t-test",NA,NA,NA,1.17169922891753
"2267","8f9b4bd657fd958d76a2a6200c8b847f","NCT01065428",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Neuroventilatory Efficiency (NVE)","PRIMARY",NA,"D012131","Extubation Readiness and Neuroventilatory Efficiency After Acute Respiratory Failure",TRUE,52,"t-test",NA,NA,NA,1.09617796589869
"2268","8faee5abc33826e81daa41d5fa9302a4","NCT02043379",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Interferon-gamma Plasma Cytokine Levels","SECONDARY","24 hours post-operative","D006331; D006330; D000361","Post-bypass Prophylactic IVIG in Infants and Neonates",FALSE,50,"mann_whitney",NA,NA,NA,1.07648023860356
"2269","8fb16185fc0b988a67868262a7be107f","NCT05182840",0.0348,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Week - All Patients - Last Observation on Treatment Carried Forward (LOCF)","SECONDARY","The odds ratio, 95% confidence interval, and p-value were calculated based on logistic regression of binary outcome adjusting for treatment, and stratification factors as covariates.

Randomisation stratification was used, which is based on estimated glomerular filtration rate (eGFR) and urine albumin creatinine ratio (UACR) levels at screening.","D007674; D051436","A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease",FALSE,261,"logistic_regression",NA,NA,NA,1.75648358381846
"2270","8fb9499e2f1d5fb699434ffca28949cf","NCT03855189",0.03,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 15 (Physician-Evaluated)","SECONDARY","Pairwise treatment comparison based on t-test from an analysis of variance (ANOVA).","D012220; D065631; D006255","Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)",FALSE,227,"anova",2,NA,NA,1.44513360241605
"2271","8fc24ef334316ac852a0b43494e61343","NCT00455533",0.0235,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]), to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR","SECONDARY","ERCC1 203719_at","D001943","Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer",FALSE,295,"logistic_regression",NA,NA,NA,1.33189658692329
"2272","8fc4a8dd5cab6d427587955052cab11b","NCT00762762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"HbA1c Levels in Blood","PRIMARY","Means and standard deviations. 1 factor ANOVA to balance treatment groups to show no difference between groups. The null hypothesis states that there is no difference between groups.","D010518","Effectiveness of a Triclosan Containing Toothpaste in Maintaining Periodontal Health in a Type 2 Diabetic Population",FALSE,60,"anova",2,NA,NA,1.17169922891753
"2273","8fc67816e1692021a88b271f4c8eb0d0","NCT02528253",0.0202,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 2, \>=70%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1010,"logistic_regression",NA,NA,NA,2.14740443761808
"2274","8fe7404999c278b8a28be784fec13999","NCT02609828",0.0352,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Cumulative Reduction of >=30, 50, 70 and 90 Percent (%) From Baseline in Daily Average Pain Intensity NRS Score in the Index Bone Metastasis Cancer Pain Site at Weeks 1, 2, 4, 6, 8, 12, 16 and 24","SECONDARY","Week 6 Reduction \>=70%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","D009362; D001859; D001855; D000072716","Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy",FALSE,144,"logistic_regression",NA,NA,NA,1.32655317332461
"2275","8fe7d540a5580bec249628b3091db38f","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Calories","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1778,"linear_regression",NA,NA,NA,6.18404799831431
"2276","90029b760d64a7b28078952bf0928059","NCT00482170",0.045,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Influence of Age on Participant Satisfaction With Injection Device","SECONDARY","Statistical analysis was carried out between all categories, by 10 unit increment. Univariate model in which all continuous variables were considered continuous and mean centered was used.","D011565","Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept",FALSE,417,"linear_regression",NA,NA,NA,2.75121289718629
"2277","9002d330d2942911e853b15e3ce06541","NCT02609828",0.0457,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Reduction of >=30, 50, 70 and 90% From Baseline in Daily Worst Pain Intensity NRS Score in the Index Bone Metastasis Cancer Pain Site at Weeks 1, 2, 4, 6, 8, 12, 16 and 24","SECONDARY","Week 8 Reduction \>=50%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","D009362; D001859; D001855; D000072716","Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy",FALSE,144,"logistic_regression",NA,NA,NA,1.65278346412611
"2278","90143208f19c737d5603bf42e0cc564a","NCT04593940",0.0399,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Mean Change in the 8-point Ordinal Scale From Day 0 to Day 10","SECONDARY",NA,"D000086382","Immune Modulators for Treating COVID-19",FALSE,1016,"t-test",NA,NA,NA,3.86834283478706
"2279","901752f6eeecfee4e65618221eeab56e","NCT00792610",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Hepatitis B Surface Antibody Seroprotective Rate(Seroprotective: for Those Who Had Anti-HBs(Surface Antibody Against Hepatitis B) Titer Higher Than 10 mIU/mL)","PRIMARY","Chi-square analysis and Fischer's exact test were used for comparing group proportions between seropositive and seronegative participants. GMT and their 95% confidence intervals were also calculated using the software developed by Kirkman, T.W. (18) An ANOVA test was performed to compare the difference of the three groups at one, six and seven months categorized by the anti-HBs titers at 7-10 days after the booster.","D006506; D006509; D006505","The Hepatitis B Vaccine Booster Response Among the Youth Who Had Completed Neonatal Hepatitis B Vaccines",TRUE,127,"t-test",NA,NA,NA,1.67613070702987
"2280","9043fbd9e06a36057c535494339f815e","NCT02553629",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Mean Arterial Blood Pressure","SECONDARY",NA,"D004194","Effect of Deep Neuromuscular Block on Surgical Conditions in Morbidly Obese Patients",FALSE,100,"t-test",NA,NA,NA,1.49341131573029
"2281","9044484ddbac327e491e3db98eb8fdb7","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient-Reported Outcomes Measurement Information System (PROMIS Short Forms 8a - Pediatrics v. 2.0) is a Set of Person-centered Measures That Evaluates and Monitors Physical, Mental, and Social Health in Children and Adolescents.","SECONDARY","We hypothesized that adolescents randomized to the intervention would report less Fatigue at 6 months post baseline compared to control adolescents.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,126,"t-test",NA,NA,NA,1.66971913113983
"2282","9050c644818cacc198b1b6fe5a64e90f","NCT02449434",0.05,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Basic Erosive Wear Examination","PRIMARY","A minimum sample size of 490 participants (245 in each group) was needed. This calculation assumed the proportion of adults with high dietary acid intake (3+ times/day) was 55% among cases and 40% among controls (expected odds ratio of 2.25), case- control ratio of 1-to-1, 90% statistical power and 95% significance level.","D057085","Timing of Dietary Acid Intake, Brushing Teeth and Acid Erosion.",TRUE,600,"logistic_regression",NA,NA,NA,3.60001003495228
"2283","90681c1562cf972cfe0dacbe709df2d2","NCT00536471",0.046,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Bilirubin, Creatinine, Uric Acid","SECONDARY",NA,"D003866; D003863; D003865","A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients",FALSE,330,"anova",2,NA,NA,2.49623055237448
"2284","9096f1477ab1dbe6a28b3dfa83b539d2","NCT00261443",0.045,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Median Baseline, Change From Baseline, and Highest and Lowest Values in Supine Diastolic BP During Phase 3","SECONDARY","Week 52 LOCF Treatment Comparison; Aripiprazole/Placebo","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,323,"mann_whitney",NA,NA,NA,2.42474705145528
"2285","90a79c26f381eae2e609b6f8e1ac1f04","NCT01236053",0.0193,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,22537,"mann_whitney",NA,NA,NA,9.72320086400133
"2286","90ad15ce6814ed357e35f095e00b9ab9","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Nighttime ACRPP","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"2287","9112be4c37642b5e0c5b27aa4804af13","NCT04148989",0.02,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Antibiotic Spectrum (Sepsis Patients)","OTHER_PRE_SPECIFIED","Differences-in-differences analysis using multivariable ??? regression to estimate the change in outcome after versus before intervention implementation at the intervention site adjusted for the change observed at control sites and for subjects' age, sex, Elixhauser Comorbidity Score, ED arrival via ambulance, English language preference, temperature, systolic blood pressure, Acute Physiology Score, Sequential Organ Failure Assessment score, and ED-diagnosed source of infection.","D018805; D014115; D004630","Effects of Code Sepsis Implementation on Emergency Department (ED) Sepsis Care",FALSE,10027,"linear_regression",NA,NA,NA,6.69151976045445
"2288","9124824aa42bf51ce287d222f0ba5e46","NCT00536198",0.02,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"DRSP","PRIMARY","Group by time: comparison rates of change","D065446","Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder",FALSE,228,"anova",2,NA,NA,1.02080730373115
"2289","912b1e090396c05bd59583e4a672dc64","NCT00707577",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Weight Loss","PRIMARY",NA,"D050177","A Maintenance Program for the Be Fit Employee Wellness Program",TRUE,302,"linear_regression",NA,NA,NA,2.56214328648509
"2290","915ab02eeaa089374f67b5279b57e77a","NCT03958071",0.0112,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Baseline Patient Characteristics: BMI","PRIMARY",NA,"D011658; D054990; D005355","A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking",FALSE,12841,"t-test",NA,NA,NA,4.54395309324975
"2291","9163316077ea3dcd2d739f7832813e7f","NCT01234649",0.04,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Insulin Secretion-Sensitivity Index (IS-SI)","PRIMARY","Factorial repeated measures design","D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",TRUE,72,"anova",2,NA,NA,1.06043757626689
"2292","918da229594e71a51814ca0e9b383784","NCT00587158",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Degree of Interstitial Fibrosis on Graft Biopsy at One Year","SECONDARY","The number of subjects with moderate to mild interstitial fibrosis (Banff ci score greater than or equal to 2) at one year was compared between treatment groups.","D051437; D007676; D006961; D006962","Oral Paricalcitol in Kidney Transplant Recipients",FALSE,76,"t-test",NA,NA,NA,1.08781774095059
"2293","91e6fc98ed79942f48d74f6c9dcea4dc","NCT02672176",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Diabetes Self-Efficacy Measured Using the Diabetes Empowerment Scale Short Form (DES-SF)- Scores at 9-months","PRIMARY",NA,"D003920","Improving Health in Diabetes Project",FALSE,280,"mann_whitney",NA,NA,NA,2.4682888545649
"2294","91ecd13bec6ebeb55a404f1ccc12dc97","NCT00279201",0.006,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"INITIATION: Rate of Self-reported Hypoglycemic Episodes","SECONDARY",NA,"D003920; D003924","The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)",FALSE,2050,"anova",2,NA,NA,1.04027780967844
"2295","91fb3b5e40ce485117c6bb54bb8e7ae4","NCT00245219",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Depressive Symptoms (as Measured With the CES-D) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The interaction between the peer support condition and breast cancer stage at Time 2. The full regression model consisted of 3 steps: The 1st step contained the baseline measure of the dependent variable. The 2nd step contained two dummy coded variables contrasting each condition with control. The 3rd step contained the interaction between the peer support condition and cancer stage. Patients in the education condition were excluded from this analysis.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"logistic_regression",NA,NA,NA,1.79957957739554
"2296","9215032fed63e15900468a59002d77a9","NCT00495469",0.042,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants Who Were Fasting Plasma Glucose (FPG) Responders at Week 12","SECONDARY","Placebo vs GSK189075 1000 mg QD: Responders (\<7.8 mmol/L)","D003920; D003924","Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive",FALSE,68,"logistic_regression",NA,NA,NA,1.07525481112397
"2297","9229f31f8106e14f6a4eea5a17be5bf0","NCT01177410",0.0432,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Proportion of Subjects Who Are Monthly Responders in Both Abdominal Pain and Stool Consistency for at Least 2 Months During the 3-month Treatment Period","SECONDARY",NA,"D043183; D013577; D003967","Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea",FALSE,98,"logistic_regression",NA,NA,NA,1.30938733889423
"2298","92390a4aefa0c909f0721d8b89b42ed7","NCT02886728",0.015,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With no Radiographic Progression From Baseline at Weeks 24, and 52","SECONDARY","Filgotinib 200 mg + MTX vs MTX Monotherapy at Week 24 for Change in mTSS \<= 0","D001168; D001172","Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy",FALSE,832,"logistic_regression",NA,NA,NA,1.50266146778456
"2299","923c4bd7236e170a7a52d3483c4253d4","NCT00658138",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Percentage of Restorations Scoring Alpha","PRIMARY","Hypothesis was no difference between adhesives tested at one year. Restorations were scored using USPHS subjective clinical criteria.","D003731","Clinical Evaluation of 3M™ ESPE™ Adper™ Scotchbond™ SE Self-Etch Adhesive in Class I and Class II Restorations in Adults",FALSE,80,"mann_whitney",NA,NA,NA,1.34217713699512
"2300","924eb4fafa0e6da446eb17131779ac5a","NCT03428100",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving IGA of 0 or 1 With a ≥ 2 Point Improvement","SECONDARY",NA,"D003876; D003872; D004485","A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable",FALSE,185,"logistic_regression",NA,NA,NA,1.30768657920885
"2301","92748aa70920cf337fdea407109e6981","NCT00518882",0.0344,"One-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change in Apolipoprotein B, Weeks 26-78","SECONDARY","A paired t test was made within the treatment group and 95% confidence intervals for the difference between Weeks 26 and 78 were constructed. H0 was µ78 - µ26 = 0 against HA: µ78 - µ26 ≠ 0. A difference between the two means (Week 26 and Week 78) was concluded when H0 was rejected at the 5% level.","D003920; D003924","Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes",FALSE,184,"t-test",NA,NA,NA,1.46560984725535
"2302","927573cacf88c8decb1008693a65589c","NCT00935584",0.05,"Wilcoxon","INTERVENTIONAL",0,0,0,0,0,"Change in Total Number of EMR Mouse Click Per Visit (Mean/SD)","PRIMARY","The null hypothesis states that there is no significant change in outcome from pre-intervention clinical visit (baseline) to post-intervention clinic visit.",NA,"Patient Centered Evaluation of Computerized Patient Records System",TRUE,126,"wilcoxon",NA,NA,NA,1.66971913113983
"2303","92897ccf9819ba2a19d22a733c3fd73b","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Environmental Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1750,"linear_regression",NA,NA,NA,6.13526752012651
"2304","929181e11a4f1b0d0f0167f61230cc7b","NCT00931528",0.0422,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Patients Maintaining Spontaneous (Off-drug) EF at Years 1 and 2 After Initiation of RT","SECONDARY","Year 2: Logistic regression using generalized estimating equations was performed modeling the probability of non-responders. Only treatment arm (Placebo vs. Tadalafil), age (\> 65 vs. other), RT method (External RT vs. brachytherapy), and significant pretreatment characteristics \[N stage (NX)\] were retained in the model. (Dropped pretreatment characteristics: ethnicity, Zubrod, T stage, PSA.) The results for each explanatory variable are reported separately. RT method is reported here.","D011471; D007172","Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy",FALSE,217,"logistic_regression",NA,NA,NA,1.88867580592873
"2305","92ad611a7114401ca06cb8670eab76d9","NCT02553629",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Pain","SECONDARY",NA,"D004194","Effect of Deep Neuromuscular Block on Surgical Conditions in Morbidly Obese Patients",FALSE,100,"t-test",NA,NA,NA,1.23952993364171
"2306","92c715a773290732620d8b63fa0ec0ec","NCT00935818",0.03,"Logistic regression","INTERVENTIONAL",0,0,1,1,0,"Prolonged Smoking Abstinence Rates at 26 Weeks in Cigarettes Smokers.","SECONDARY","Logistic Regression - adjusting for study site",NA,"Varenicline and Bupropion for Smoking Cessation",FALSE,506,"logistic_regression",NA,NA,NA,2.14529197508637
"2307","92df96afba0e78b3aa45c3e396465f6a","NCT02873936",0.039,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved ACR 70% Improvement (ACR70) at Weeks 4, 12, and 24","SECONDARY","Filgotinib 100 mg vs Placebo at Week 4","D001168; D001172","Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment",FALSE,301,"logistic_regression",NA,NA,NA,2.07549405916746
"2308","92fb4604242727a384bd5a85aff82cbe","NCT04714320",0.044,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit","SECONDARY","Seated Automated Office SBP ≤ 140 mmHg at Day 64","D006973","A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure",FALSE,58,"logistic_regression",NA,NA,NA,1.03760063507558
"2309","930c4f15517899d3da231c2ee084ebfc","NCT02887183",0.0181,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) and Change in Left Ventricular End Systolic Volume Index (LVESVi) by Selected Groups of Interest at Month 6","SECONDARY","Subjects not receiving target dose","D006333","Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.",FALSE,794,"t-test",NA,NA,NA,1.73123912778453
"2310","931e2beb1f6187beeb882a6f77c80ac1","NCT03100747",0.039,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Eyes With Presence of Post-Operative Trichiasis Within 12 Months","PRIMARY",NA,"D058457","Maximizing Trichiasis Surgery Success",FALSE,3210,"logistic_regression",NA,NA,NA,6.73449641242652
"2311","932710adc4a358137a92e93b4d89961c","NCT02896400",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Tobacco Abstinence","PRIMARY","8 arms including BNI (BNI only, BNI+NRT, BNI+QL, BNI+Text, BNI+NRT+QL, BNI+NRT+Text, BNI+QL+Text, BNI+NRT+QL+Text) compared to the 8 arms that do not include BNI (Control, NRT only, QL only, Text only, NRT+QL, NRT+Text, QL+Text, NRT+QL+Text)","D014029","Optimizing Tobacco Dependence Treatment in the Emergency Department",FALSE,1053,"logistic_regression",NA,NA,NA,1.17986665608715
"2312","9330cad4f6db997af4fa6235b02b2c0c","NCT02703467",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Hydrogen Sulphide in Exhaled Breath","PRIMARY",NA,"D001249","Exhaled Hydrogen Sulphide as a Biomarker of Airways Disease in Asthma",FALSE,65,"t-test",NA,NA,NA,1.21654382470971
"2313","93440400d008b3acfeefdbcbae52792d","NCT00762762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"High Sensitivity CRP (C-Reactive Protein)","PRIMARY","Means and standard deviations. 1 factor ANOVA to balance treatment groups to show no difference between groups. The null hypothesis states that there is no difference between groups.","D010518","Effectiveness of a Triclosan Containing Toothpaste in Maintaining Periodontal Health in a Type 2 Diabetic Population",FALSE,60,"anova",2,NA,NA,1.17169922891753
"2314","9347e259560861efcc43c2460e417b42","NCT01115673",0.024,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Sum of Pain Intensity Difference and Pain Relief Scores (PRID) at 90 Minutes","SECONDARY","The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.","D014098","To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery",FALSE,480,"anova",2,NA,NA,1.72440790411601
"2315","9361371adea3600937183f5ebc2a06bd","NCT01416194",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Cardiac Disorders","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",FALSE,7777,"logistic_regression",NA,NA,NA,3.19773018380892
"2316","9364317ef8f51833b62393bc994e9d5e","NCT02528188",0.0116,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 8: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline PGA of OA scale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade, NSAID and treatment.","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1989,"logistic_regression",NA,NA,NA,1.84742651318759
"2317","9366748f17b7834f6649163df43e08c8","NCT03932799",0.02,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"On Time Loss (Not Working)","SECONDARY","* Primary predictor is binary (1 for Washington, 0 for Ohio)
* Models survey weighted
* Robust variance estimates","D009293","Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing",FALSE,2295,"logistic_regression",NA,NA,NA,3.20424312387883
"2318","936f1684f0413f8e324fa8f323db7132","NCT00091507",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Cardiac Arrest or Acute Mortality","SECONDARY",NA,"D006333; D002318; D006331; D009203; D003327; D000789; D007238","IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.",FALSE,871,"logistic_regression",NA,NA,NA,1.07377606522841
"2319","938a1f808d74e9dc4e22ce9d1c4ab8d3","NCT02270671",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Threat Bias Measurement at 4-week Post-intervention and 12-week Follow-up","PRIMARY",NA,"D003863","Attention Bias Modification Training for Young People",FALSE,120,"anova",2,NA,NA,1.63072147479452
"2320","939da6db78b3cd1b9dcc17db69388b28","NCT00922194",0.05,"One-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Weight From Baseline at 12 Months or More","PRIMARY","Analysis of difference between 12 months or more and baseline values","D003920; D003924; D050177","Metformin in Overweight Type 2 Diabetes Mellitus",TRUE,102,"t-test",NA,NA,NA,1.50770356720122
"2321","93b761077c053a8fdf4a61f0927af11d","NCT00674986",0.047,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in Confidence in Diabetes Self-Care (CIDS-2)","SECONDARY",NA,"D003920; D003924","A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes",FALSE,291,"t-test",NA,NA,NA,2.38869311162615
"2322","93c414ed90424845c8695d34e716f074","NCT03982368",0.03,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Quality of Life (Impact of Dry Eye on Everyday Life (IDEEL) Questionnaire vs Different Timepoints - Per Protocol Set","SECONDARY","Treatment Satisfaction - change from baseline to week 16","D015352; D007638","A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye",FALSE,152,"anova",2,NA,NA,1.18861079960632
"2323","93d826604a8264917c6509fa82ee48b1","NCT00930943",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Spatial Working Memory (SWM) Test Total Errors","SECONDARY",NA,"D059350","Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning",FALSE,60,"anova",2,NA,NA,1.17169922891753
"2324","93dbcb865f12bd8d8d6b65b09278966c","NCT00146848",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change in Self Assessed Physical Activity","SECONDARY","Compare the difference in the changes in physical activity scores between groups using a t-test.

To adjust for multiple comparisons, an alpha level of 0.025 should be used to deem significance.","D006333","PEGASUS CRT Study: Atrial Support Study in Cardiac Resynchronization Therapy",FALSE,687,"t-test",NA,NA,NA,3.19087328743637
"2325","93dffe98cdb3c431257bfd02f9834a36","NCT00824564",0.045,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Post-operative Blood Loss","SECONDARY","For 4 hour post-surgery, the mean difference with associated SE, and corresponding 95% CI for the comparisons of tranexamic acid plus standard of care against Standard of care was presented along with the p-value for the test. Two-sample t-test was performed at 5% level of significance.","D006470; D050723; D005264","Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Surgery For Long Bone Fracture",FALSE,81,"t-test",NA,NA,NA,1.23702739382114
"2326","93f249a913fd6adab7f958f648944e58","NCT01179568",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Responder Status Based on Complicated Grief Clinical Global Impression-Improvement (CGI-I) Scale","PRIMARY","Our prespecified primary analysis was cross-sectional, comparing treatment response rates for CIT with CGT vs PLA with CGT at week 20 (aim 2) based on the intention-to-treat principle including all randomized participants.",NA,"A Study of Medication With or Without Psychotherapy for Complicated Grief",TRUE,195,"logistic_regression",NA,NA,NA,2.06601217424953
"2327","940b87e5d88ac02367a6aff9bd48c767","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Healthfulness","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1753,"linear_regression",NA,NA,NA,6.14051253521365
"2328","94194ab90b0687a41606ff0b73c81348","NCT01236053",0.0103,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,102836,"logistic_regression",NA,NA,NA,11.9334701723116
"2329","941f30efa285759c17634610347cf9ef","NCT04143945",0.0395,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Intensity of Injection Site Pain","PRIMARY","The intensity of pain was analysed by a fixed analysis of variance model with VAS pain score as the dependent variable, and product, injection side (right side, left side), injection number (first injection, second injection), and participant as fixed effects.","D009765; D050177; D003924","A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity",FALSE,208,"anova",2,NA,NA,1.74952238957009
"2330","94347591a1a561ba4fc384e627f36dcf","NCT02820038",0.0466,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mean Illness Intrusiveness at 6-Month Follow-up Adjusted for Baseline","SECONDARY","The investigators hypothesized that participants would exhibit a greater decrease in illness intrusiveness between baseline and the 6-month follow-up if they were assigned to receive written medication information via the DrugFactsBox® format compared to the Other CMI format.","D001168; D001172","Enhancing Patient Ability to Understand and Utilize Complex Information Concerning Medication Self-management",FALSE,116,"linear_regression",NA,NA,NA,1.51282205010098
"2331","944ce46b914317da8e7080bfaae045d8","NCT01221623",0.034,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Severity of Peyronie's Disease Symptoms Domain of the PDQ","SECONDARY",NA,"D010411","Study of AA4500 in the Treatment of Peyronie's Disease",FALSE,309,"anova",2,NA,NA,1.87122189524069
"2332","94702b4a16ed2a42708f8a1ea78de1d4","NCT00390949",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Scoring 60% or Above on an Index of HIV/AIDS Knowledge","SECONDARY",NA,"D015658","Scientific Evaluation of Peer Education and STD Treatment to Reduce the Spread of HIV in Zimbabwe",TRUE,5273,"logistic_regression",NA,NA,NA,10.6420402339723
"2333","9475860567691f0f64fecbcffa1a0dc2","NCT00261443",0.029,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Baseline and Adjusted Mean Change From Baseline in the CGI-BP Severity of Illness (Overall) Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 28 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,1.67691244505512
"2334","9480f79ccb3bf2d54341afa93731c55a","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"24-hour Brachial Systolic BP","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"2335","9485fa1c77648096cd094ba74d6764fc","NCT05746494",0.041,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"The Ambiguous Intentions Hostility Questionnaire (AIHQ)","SECONDARY",NA,"D012559; D019964; D011618","The Efficacy of Neural Stimulation in Individuals With Schizophrenia",FALSE,100,"t-test",NA,NA,NA,1.26548787757283
"2336","9496a226c6ef5614da0617c4d4bf119d","NCT05037513",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Initiating PrEP","PRIMARY",NA,NA,"Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky",TRUE,77,"logistic_regression",NA,NA,NA,1.31800316623017
"2337","94a877438a006540037de1887bfa5823","NCT03714425",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Hospital Anxiety and Depression Scale","SECONDARY",NA,"D005356; D009209","Efficacy of the Quell Wearable Device for Fibromyalgia",TRUE,119,"t-test",NA,NA,NA,1.62413102595047
"2338","94ae29fdf012b3e130c9d666f3183779","NCT01816477",0.0484,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Use of Analgesic Narcotic","PRIMARY","Comparison between groups for day 6.","D005660; D010149","Post Operative Pain Control Using Ropivacaine and the ON-Q System in the Adult Pectus Excavatum Patient",FALSE,68,"t-test",NA,NA,NA,1.20970933100105
"2339","94d8e8862d2a8242ce41470f77982643","NCT02886715",0.0185,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change in Inflammatory Lesion Counts","PRIMARY",NA,"D000152","A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris",FALSE,638,"anova",2,NA,NA,1.58317342699381
"2340","94df6b47dd784ce0fc5ea833fbb70098","NCT01832961",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Spirometry - Forced Expiratory Volume at 1 Second (FEV1) and Forced Vital Capacity (FVC)","SECONDARY",NA,"D008171; D008173; D029424","Acute Effects of a Flutter Device in COPD",TRUE,45,"t-test",NA,NA,NA,1.02560707988412
"2341","9501ee225f853734ffc8f274f5577718","NCT00762762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"TNF-α (Tumor Necrosis Factor - Alpha)","PRIMARY","The null hypothesis states that there is no difference between groups.","D010518","Effectiveness of a Triclosan Containing Toothpaste in Maintaining Periodontal Health in a Type 2 Diabetic Population",FALSE,46,"anova",2,NA,NA,1.03597838019194
"2342","9542c20a2bb6dd1d4164544dd8a7d396","NCT00261443",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Baseline and Adjusted Mean Change From Baseline in Clinical Global Impression Scale for Bipolar Disorder (CGI-BP) Severity of Illness Score (Mania) Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 28 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,2.66075811637609
"2343","9549392e7fd977bafd9056a5a00fbe49","NCT03911843",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,1,0,"HbA1c Percentage","PRIMARY",NA,"D003922","Omega-3 and Vitamin D Supplements in Childhood T1D",TRUE,59,"mann_whitney",NA,NA,NA,1.16252463235142
"2344","955a9868ae67849c0758c98435a9bb2a","NCT04490109",0.0486,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Proportion of Subjects With ≥4 Point Improvement in Average Itch Numeric Rating Scale (AI-NRS)","SECONDARY","The frequency and rate of WI-NRS and AI-NRS responders will be reported and compared between treatment groups using a logistic regression model. Generalized estimating equations to account for repeated measures and within-subject variability may also be applied.","D003876; D003872; D004485; D011537","B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis",FALSE,336,"logistic_regression",NA,NA,NA,2.63737733517662
"2345","956efe292be5c31cbff8b58a493a1a08","NCT02528253",0.0093,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Low Back Pain From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/ Last Observation CF (LOCF)","SECONDARY","Week 16: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline PGA of low back pain, baseline average LBPI, and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1012,"logistic_regression",NA,NA,NA,1.08441401128004
"2346","958a4b0846198e1ec82a5223c1d74b94","NCT01116544",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Strength Test Extension","SECONDARY","Both treatment groups combined","D020521; D010291","Treatment of Chronic Stroke With AMES + EMG Biofeedback",FALSE,43,"mann_whitney",NA,NA,NA,1.00454908915455
"2347","9593d99bdf49381463d2298998b95ab3","NCT01519674",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Responder for HbA1c, Proportion of Subjects Achieving Pre-defined HbA1c Targets (HbA1c ≤ 6.5%)","SECONDARY",NA,"D003920; D003924","Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin",FALSE,372,"logistic_regression",NA,NA,NA,1.29793399186526
"2348","959f448431617bafff22b4112de15fdb","NCT01462162",0.05,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Change From Baseline in Sleepiness Score as Assessed on Epworth Sleepiness Scale at Week 12, 24","SECONDARY","Baseline for Week 24 versus Week 24","D001168; D001172","A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis",TRUE,83,"logistic_regression",NA,NA,NA,1.36592548755136
"2349","95a04641ce6d1dc9b5e274873ca7ebe5","NCT01874431",0.0428,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline to Day 90 in Serum Potassium","SECONDARY",NA,"D007674; D003928; D003920; D003924","Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy",FALSE,180,"t-test",NA,NA,NA,1.74409249847984
"2350","95a8e53970c34f730a6e7adcc805a441","NCT03995316",0.041,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Self-Efficacy","SECONDARY",NA,"D001238; D003863; D003866","Responsive e-Health Intervention for Perinatal Depression in Healthcare Settings",FALSE,191,"t-test",NA,NA,NA,1.73162668059326
"2351","95a9201ee3df6def9987941bace0e80c","NCT02214186",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Postoperative Renal Dysfunction Evaluated by the Acute Kidney Injury Network (AKIN) Index","PRIMARY",NA,"D004461; D011225","Restrictive Fluid Therapy in Severe Preeclampsia",TRUE,46,"mann_whitney",NA,NA,NA,1.03597838019194
"2352","95bce29429223cc41bdfb81b1f542fc3","NCT03035916",0.047,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Questionnaire: Pain Scores at Rest","SECONDARY","The pain score were measured from 1 hour to 48hours after surgery. This Statistical Analysis applied to ""6 hours after surgery"" row.",NA,"Transversus Abdominis Plane Block on Stress Response",FALSE,61,"t-test",NA,NA,NA,1.12196535825906
"2353","95c30d3c1aafdc85cc260d8d7bdad01c","NCT00551135",0.043,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Pain Catastrophizing Scale (PCS) Total Score and Subscales","SECONDARY","Helplessness change at 3 h PS; LS Means from ANOVA model with terms of treatment, pooled center and baseline PCS score (for baseline visit ANOVA model with terms of treatment and pooled center). Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,203,"anova",2,NA,NA,1.85704984404098
"2354","95c668ac18f28281e73e6c4cbd305456","NCT00377260",0.04,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"The Mean Score Representing Parental Satisfaction With the Study Medication As Recorded at the End-of-therapy Visit According to Treatment Assignment","SECONDARY","Null hypothesis: There is no difference between the groups regarding the mean parental satisfaction score at the end-of-therapy visit.","D010031; D010033","Acute Otitis Media (AOM) Therapy Trial in Young Children",FALSE,278,"linear_regression",NA,NA,NA,2.03898959022174
"2355","95d1f0f8bf448322029c86628c76d3a6","NCT00406133",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Relative Increase in A1c Level by >=0.5% (for Cohort With Baseline HbA1c >=7.0%)","OTHER_PRE_SPECIFIED",NA,"D003920; D003922","Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes",FALSE,322,"logistic_regression",NA,NA,NA,1.20892570729049
"2356","9607919ba5082ca8bfff8e5851e2b899","NCT00552513",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Composite of Death, MI, Stroke, Refractory Ischemia or Repeat Revascularization at 180 Days","SECONDARY",NA,"D009203; D054058; D000789; D007238","Early Versus Delayed Timing of Intervention in Patients With Acute Coronary Syndromes",FALSE,3031,"logistic_regression",NA,NA,NA,6.68641218785922
"2357","96144b74a9cfa2980bf09e75201c7bb8","NCT03252587",0.0439,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants Who Meet Response Criteria for Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] at Week 48","SECONDARY","BMS-986165 12 mg vs Placebo","D008180","An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus",FALSE,179,"logistic_regression",NA,NA,NA,1.77683359629763
"2358","962d83003cb7d4767c7bdcaa0a0f571d","NCT03670810",0.018,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Migraine Quality of Life Questionnaire (MQoLQ) Score at 24 Hours Post First Dose of Study During First Attack","SECONDARY","Feelings/Concerns 200 mg","D008881","A Study of Lasmiditan (LY573144) Over Four Migraine Attacks",FALSE,596,"anova",2,NA,NA,1.49442352195255
"2359","963c72f2d5af3a1a063fb4a49e42918d","NCT02912650",0.026,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Relief Rating (PRR) Score","OTHER_PRE_SPECIFIED","6 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,221,"anova",2,NA,NA,1.26147874774985
"2360","963cf3bdcc012b55ed5c02ad599b37fa","NCT02754674",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Clinical Knee Scoring","SECONDARY","We used the Kolmogorov-Smirnov test to assess the normality of the data distribution. Student's t-test or the Mann-Whitney U-test was used to analyze intergroup differences. The paired t-test or Wilcoxon signed rank test was used to analyze differences between pre- and postoperative values. Pearson's Chi-square test or Fisher's exact test was used to analyze categorical variables between groups. The statistical significance level was set at .05.","D012421","Comparison of Femoral Tunnel and Clinical Outcome Using Two Anterior Cruciate Ligament Reconstruction Techniques",FALSE,54,"t-test",NA,NA,NA,1.11553228437488
"2361","964f6b1bf972d90c7895d62984947a90","NCT02845440",0.012,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Effect of Varenicline Use on Number of Participants Who Are Abstinence at the Intervention Year 2 Assessment in Cohort 1","SECONDARY","Missing abstinence rates at year 2 of intervention were imputed using MICE based on baseline characteristics and abstinence rates at year 1 of intervention. The statistical model was a mixed effects logistic regression with terms for TAU, AD, and AD+CHW (cohort 1) as well as varenicline use and a clinic-varying random intercept. Regression coefficients were pooled using Rubin's rule over 10 imputation runs.","D012559; D003866; D001714; D001523; D003865","Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness",FALSE,787,"logistic_regression",NA,NA,NA,1.20044102336241
"2362","967c3d7a15ea7c56e7932addffa86b91","NCT02475655",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change in (CD3+CD8+) CD38+HLADR+","SECONDARY","Null hypothesis: There is no difference between the two arms in the change in the expression of CD38+HLADR+ among CD8+ T-cells from Entry to Week 5.","D015658","Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults",FALSE,51,"t-test",NA,NA,NA,1.08637315449684
"2363","96a7706ffa3626bad7a78289c5774ab5","NCT03201419",0.046,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Responder Rate in Nocturnal Voids at Week 12","SECONDARY",NA,"D011141; D053158","A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults",FALSE,109,"logistic_regression",NA,NA,NA,1.45228895985011
"2364","96b0eac083eef2e719455c0632455950","NCT00149643",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Days Per Week of Cannabis Use.","PRIMARY","Groups' categorical baseline measures were compared by chi-square analysis, corrected for continuity. Statistical analyses were completed on an intent to-treat study group basis. Outcome measures for depression and for cannabis use and alcohol use across treatment groups were compared by repeated measures analysis of variance. The last observation carried forward (LOCF)method was used for handling missing data in the data analyses.","D002189; D003866; D003863; D003865","Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence",TRUE,70,"anova",2,NA,NA,1.2598053214673
"2365","96bec87c8142ea588d142cf20e4e991e","NCT01340027",0.042,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With 50% Reduction in Incontinence Episodes","SECONDARY",NA,"D053201; D014570; D001745; D020924","A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder",FALSE,59,"logistic_regression",NA,NA,NA,1.00623005316419
"2366","96cf91e355847e6ace489bb675aa96f8","NCT03530098",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Paired Difference of Skeletal Age Estimate","PRIMARY",NA,NA,"Validation of an Artificial Intelligence-based Algorithm for Skeletal Age Assessment",FALSE,1531,"t-test",NA,NA,NA,4.75536472821492
"2367","96d4286f2ddd0cbcc0650f8615b9785c","NCT00297427",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Mental Health Related Quality of Life","PRIMARY",NA,"D014549; D004775","Acupuncture for Urinary Incontinence",FALSE,127,"mann_whitney",NA,NA,NA,1.39063029513526
"2368","96d6c9a30d357ad16c8664ad8602fd26","NCT04196777",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Cases Who Received a Late Antimicrobial Prescription","SECONDARY","To model this secondary outcome, we used a logistic regression model and a set of four explanatory variables: time, a binary indicator for an observation occurring within the intervention phase, an interaction term between these two main effects (time and intervention), and a binary indicator for the primary outcome. This last variable was included to assess the risk of these secondary outcomes in patients who were not exposed to post-procedural antimicrobials compared to those who were exposed.","D014570; D064420","Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists",FALSE,1797,"logistic_regression",NA,NA,NA,5.15088343130295
"2369","96efe80671ecc63966fe9a34560ce87c","NCT00293033",0.031,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Percentage of Pain Free Episodes","SECONDARY",NA,"D059390","Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects",FALSE,154,"mann_whitney",NA,NA,NA,1.23010803222095
"2370","96faf0730327d402d6948c371493aa1c","NCT02553629",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Extubation","SECONDARY",NA,"D004194","Effect of Deep Neuromuscular Block on Surgical Conditions in Morbidly Obese Patients",FALSE,100,"t-test",NA,NA,NA,1.49341131573029
"2371","96fb619ed656bed3ed8787ef63d3df25","NCT03687762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in Activity Level (Actigraph, Vector Magnitude Average Counts)","OTHER_PRE_SPECIFIED",NA,"D059350","Back on Track to Healthy Living Study",FALSE,302,"anova",3,NA,NA,1.03237942189705
"2372","973054598802afdcb7d37a6e9796f44d","NCT02440854",0.045,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Patient-rated Lung Cancer Symptom Scale (LCSS) Individual Item Scores: Overall Symptomatic Distress","SECONDARY","Baseline vs 18-month post-baseline.","D002289","Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings",FALSE,76,"t-test",NA,NA,NA,1.20019654687181
"2373","9746d019ff4be49f80e7a2858fdfd651","NCT02815982",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Satisfaction and Exit Survey Composite Scale Score -- ONLY CAREGIVERS COMPLETED THIS MEASURE","PRIMARY",NA,NA,"Targeting Caregivers to Enhance Health Behaviors in Pediatric Cancer Survivors",TRUE,53,"t-test",NA,NA,NA,1.10589694869732
"2374","974c5e607583d6e20e18e7eb7d7583c7","NCT00333801",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"PTSD, Depression, Disability Outcomes","SECONDARY",NA,"D040921; D013313","The Impact of Vocational Rehabilitation on Mentally III Veterans",FALSE,85,"mann_whitney",NA,NA,NA,1.381532008495
"2375","97698c6fdc69503b3ecd7a0553ed82dc","NCT01416194",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Venous Thromboembolism (VTE)","PRIMARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",TRUE,7777,"logistic_regression",NA,NA,NA,3.19773018380892
"2376","976ad644eca6b41c7313e957213655a3","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Intention to Reduce","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1771,"linear_regression",NA,NA,NA,6.17188902328434
"2377","9775ab2e838969f064c8121cc89bddb5","NCT03442322",0.043,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Rejection of Care","PRIMARY",NA,"D000544; D003704","Optimizing Care for Patients With Dementia",FALSE,2301,"linear_regression",NA,NA,NA,6.19497450218244
"2378","977dccf49f9ee2c054192fc915c06dea","NCT03192176",0.0386,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 4 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 2","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.1194699445616
"2379","9788585edfe081c8ed1d355392d6ea10","NCT04876482",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Computer Tomography (CT)_minimal Area","PRIMARY","We hypothesized that the improvements in the minimal area on the tip of epiglottis would be more in patients who underwent TORS combined with OPR than in those who underwent only TORS and those who received conservative treatment (controls)","D001049; D012891; D020181","Myofunctional Training for Obstructive Sleep Apnea Patients After Transoral Robotic Surgery",TRUE,78,"linear_regression",NA,NA,NA,1.32610986002301
"2380","97a0aed6bfeb9eab68bce4e1ddbc33f5","NCT00530257",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"ADHD Rating Scale-IV, Parent and Teacher Version","SECONDARY","A paired t-test was used to compare the medication versus placebo.","D006948; D001289","Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory",TRUE,60,"t-test",NA,NA,NA,1.17169922891753
"2381","97a5ce9cee0e326605fa9f4793a6c06e","NCT01187004",0.05,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Acute Lung Injury After Cardiac Surgery","PRIMARY","Our hypothesis was that mechanical ventilation with large tidal volume might represent a risk factor for acute lung injury in patients undergoing cardiopulmonary bypass.","D055370; D055371; D058186; D014947","Extracardiac Complications After Cardiac Surgery",TRUE,164,"logistic_regression",NA,NA,NA,1.8982180321277
"2382","97bbf9f512106ec36bf02b1e1ed37156","NCT01234649",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Systolic Blood Pressure","SECONDARY","Factorial repeated measures ANOVA","D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",FALSE,72,"anova",2,NA,NA,1.27670232702116
"2383","97cc515a60e81408ae872e096d75fa6b","NCT01329029",0.0262,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Rate of COPD Exacerbations Per Patient Per Year All Categories","SECONDARY","COPD Exacerbations treated with Glucocorticosteroids and/or Antibiotics","D008171; D008173; D029424","Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)",FALSE,1935,"linear_regression",NA,NA,NA,3.72036938476321
"2384","97de61708a1eb64e3df921767d5c150f","NCT00111800",0.034,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants of FPG Responders at Week 12","SECONDARY","Placebo versus DEN 45 mg for FPG reduction \>=1.7 mmol/L. A closed test procedure was used, in an hierarchical manner, that is, test was applied sequentially where testing does not proceed to the next step unless the previous test was found to be significant.","D003920; D003924","A New Oral Treatment For Type II Diabetes Mellitus",FALSE,122,"logistic_regression",NA,NA,NA,1.18896057073057
"2385","97f102d8f725985de687d3e29be0ca04","NCT01355224",0.015,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Intentions to Lose Weight - Effect of Study Arm on Outcomes","PRIMARY",NA,"D009765","Communicating Risk Information for Obesity",FALSE,696,"linear_regression",NA,NA,NA,1.37532659145238
"2386","980d9fb5e6a7ec6062d9e74943c42e81","NCT03292458",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,1,0,"Minimum Treatment Efficacy","PRIMARY","The minimum and average efficacy of sodium oxybate vs. placebo in improving symptoms compared to the baseline were determined using binomial logistic regression.","D055154; D006685; D014202","Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor",FALSE,50,"logistic_regression",NA,NA,NA,1.07648023860356
"2387","980ef2624f88a0ad9da61b2bb75e145a","NCT04796909",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Level of Therapeutic Alliance During Coaching Session","OTHER_PRE_SPECIFIED",NA,"D002658","Occupational Performance Coaching With Parents of Young Children With Developmental Disability",FALSE,50,"t-test",NA,NA,NA,1.07648023860356
"2388","980f5a9e7cb4f960608b6e37f16a7d51","NCT00453999",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Scores of Symptoms of Influenza","SECONDARY","Cough: change from Baseline at Days 2, 3, 4, 5, 10, 14","D007251","Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza",FALSE,122,"mann_whitney",NA,NA,NA,1.64382327798156
"2389","981b8092dddb95853e01ada917b943af","NCT02988622",0.0281,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Observer Total Score","PRIMARY",NA,NA,"Comparison of Lasers in the Treatment of Scars",FALSE,166,"t-test",NA,NA,NA,1.17299100494939
"2390","9820de5d72c75d46ec8a211a8b7fe471","NCT02373813",0.023,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Clinical Disease Activity Index (CDAI) at All Measured Timepoints","SECONDARY","Week 36","D001168; D001172","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",FALSE,202,"t-test",NA,NA,NA,1.08618832940174
"2391","98257def75896c36413fa9423943704c","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Urinary Genistein","SECONDARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",FALSE,96,"anova",2,NA,NA,1.46440978390488
"2392","983d0c931ff2f3576f4f07e98ddfbd00","NCT00453999",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Scores of Symptoms of Influenza","SECONDARY","Sore Throat: change from Baseline at Days 2, 3, 4, 5, 10, 14","D007251","Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza",FALSE,122,"mann_whitney",NA,NA,NA,1.64382327798156
"2393","98416bd8b4833c43c05f37049412f955","NCT00762528",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Nuclear Factor Kappa B Ligand (RANK-L)","PRIMARY","The null hypothesis states that there is no difference between groups.","D005891","Compare Anti-inflammatory Dentifrices",TRUE,49,"anova",2,NA,NA,1.06649684228356
"2394","984e2f2a994adb4df600d92f82131851","NCT02886728",0.045,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With no Radiographic Progression From Baseline at Weeks 24, and 52","SECONDARY","Filgotinib 100 mg + MTX vs MTX Monotherapy at Week 52 for Change in mTSS \<= 0.5","D001168; D001172","Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy",FALSE,623,"logistic_regression",NA,NA,NA,3.35743985694787
"2395","9863868c6e688ad865eb435de998a828","NCT01049334",0.0476,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05","SECONDARY","Minutes post dose: 40","D010612","A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis",FALSE,204,"anova",2,NA,NA,2.02719164392572
"2396","986388eb61c085d7719905c33370c182","NCT02081391",0.0404,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"For the US FDA: The Total Amount of Supplemental Opioid Analgesic Medication Used Within the First 12 Hours After First Intake of Investigational Medicinal Product (IMP) [Tapentadol Oral Solution or Placebo]","PRIMARY","The endpoint was analyzed using an analysis of variance model. This included treatment, baseline age group, and the used SOAM as factors. For participants discontinuing treatment before 12 hours for any other reason than no further need of opioid analgesics or switch to exclusively oral opioid analgesics, cumulative SOAM use over the respective time period was based on the observed SOAM use up to the time of the participant's discontinuation.","D059787","A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain",FALSE,160,"anova",2,NA,NA,1.56864458950198
"2397","987d0393d5abf028f095b0a47aad6681","NCT01956240",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Scapular Kinematics After Pectoralis Minor Stretching Protocol","SECONDARY",NA,"D020069","Effects of a Pectoralis Minor Muscle Stretching Protocol",FALSE,50,"anova",2,NA,NA,1.07648023860356
"2398","98981c122b61c35da4ae08841c8e49d1","NCT02688400",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Quality of Life SF-36","SECONDARY",NA,"D010003; D020370","Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis",FALSE,370,"mann_whitney",NA,NA,NA,2.83265165361863
"2399","9899c50b389659f7e72279176247e29e","NCT00523614",0.05,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Risk of Venous Thromboembolism (VTE) Between Women Who Use Dienogest/Ethinylestradiol (DNG/EE) and Women Who Use Other Low-dose Combined Oral Contraceptives (COC)","PRIMARY","Null hypothesis: OR ≥ 2 (VTE of DNG/EE vs. other low-dose COC)","D013923; D054556","Use of Oral Contraceptives (OCs) Containing Dienogest and Risk of Venous Thromboembolism",TRUE,3400,"logistic_regression",NA,NA,NA,8.54717539637633
"2400","98ac88fd5526151a153516b1f791e231","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Calories","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1753,"linear_regression",NA,NA,NA,6.14051253521365
"2401","98b1b1598c7c46b9c226f32634ad5335","NCT02709486",0.0373,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 4, \>=70%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,563,"logistic_regression",NA,NA,NA,2.7241612517318
"2402","98e8c9203a9e9afd7cd87b6366a13372","NCT02057068",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"BEF-SHI Total Number of Negative Sleep Hygiene Behaviors","SECONDARY",NA,NA,"Improving Sleep in Veterans and Their CGs",TRUE,96,"anova",2,NA,NA,1.46440978390488
"2403","9904332498da374f8cfd1ea4e72d1a7b","NCT00256750",0.0423,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire","SECONDARY","General Health, Month 12","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,424,"anova",2,NA,NA,2.63306616700049
"2404","990a597ba1d197627fe2dcb56194522c","NCT01065428",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Neuromechanical Efficiency (NME)","SECONDARY",NA,"D012131","Extubation Readiness and Neuroventilatory Efficiency After Acute Respiratory Failure",TRUE,52,"t-test",NA,NA,NA,1.09617796589869
"2405","990a79a9a26195fff3ae22ac484d81ed","NCT00056316",0.05,"Two-sample t-test","INTERVENTIONAL",0,1,1,0,0,"Primary Outcome: Beck Depression Inventory II (Beck, Steer & Brown, 1996)","PRIMARY",NA,"D003704; D003863; D003866","Reducing Depression in Dementia Caregivers",FALSE,74,"t-test",NA,NA,NA,1.2933799900503
"2406","99128083e5741ddeefd9f1cb95c002b0","NCT00724126",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).","PRIMARY",NA,"D043183; D013577","Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)",FALSE,635,"logistic_regression",NA,NA,NA,2.40097398025449
"2407","99174c42a710f51c0df333cc40fbd097","NCT01070550",0.0129,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for ALT ratio at BL (\> 1 - 3 vs \> 3). The logistic regression analysis for relapse 24 Weeks after EOT was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,1751,"logistic_regression",NA,NA,NA,1.90474945962195
"2408","991e94828858a64cc1a2397584a4e899","NCT02340663",0.049,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Functional Efficacy -- Alteration of Bruxism Habit, Self-Report of Muscle Relaxation","SECONDARY",NA,"D002012; D020186; D057085","Nocturnal Mouth Guards, SOVA vs. Standard Acrylic Orthotic; Phase IV",FALSE,61,"mann_whitney",NA,NA,NA,1.16128313184243
"2409","9923dc57129895921f1afecc19432caa","NCT00088153",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,1,0,"Change in Spine Bone Mineral Density Z-scores Over the Study Duration (18 Months)","PRIMARY","The null hypothesis was that the groups would not differ for changes in spine bone density z-scores over the study duration","D000855; D000856","Effects of Anorexia Nervosa on Bone Mass in Adolescents",TRUE,110,"t-test",NA,NA,NA,1.56357043896758
"2410","99269f6c59f7d3476ec74f41eed677af","NCT03962738",0.037,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Headache Pain Relief","SECONDARY",NA,"D008881","A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine",FALSE,296,"logistic_regression",NA,NA,NA,1.9685997988198
"2411","992ecdc06a5b48d55a6d99c3e38dc74f","NCT00270998",0.0492,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"75% Reduction in Weekly Urinary Incontinence Episodes at 3 Months","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",TRUE,299,"logistic_regression",NA,NA,NA,2.51540237553809
"2412","992f423793016a5ea2864e74f9f72db4","NCT00307164",0.034,"Mann-Whitney","INTERVENTIONAL",0,0,1,1,0,"Change in Fasting High-density Lipoprotein (HDL) Cholesterol From Baseline (Week 48 - Baseline)","SECONDARY",NA,"D008060","Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy",FALSE,150,"mann_whitney",NA,NA,NA,1.31383193533767
"2413","99545aef68ca92e91976983495e80454","NCT04878055",0.047,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Mean Changes From Baseline in Clinical Severity Score Based on the 7-point WHO-OS at Fixed Timepoints","SECONDARY","At Day 3 - Please note that the number of subjects in this analysis is not 270 but 255","D000086382; D011014; D011024","Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.",FALSE,270,"mann_whitney",NA,NA,NA,2.30210288728616
"2414","99731111d062fd91c633d5b3b91c247f","NCT02709486",0.021,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >=30%, >=50%, >=70% and >=90% Response","SECONDARY","Week 4, \>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,565,"logistic_regression",NA,NA,NA,1.66484274711772
"2415","9989ae6add706e3b53d1a607f33ab909","NCT03646305",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Self-Ratings of Body Image Cognitions (Appearance Dissatisfaction)","SECONDARY","Paired sample t-tests was conducted to measure differences in appearance dissatisfaction from baseline to post-intervention. Null hypothesis: the control conditions would have no significant difference in appearance dissatisfaction from baseline to post-intervention",NA,"Singing Your Negative Body-Related Thoughts",FALSE,122,"t-test",NA,NA,NA,1.64382327798156
"2416","99a2f9e507eb42d76c67153283794037","NCT03670810",0.016,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Satisfied With Their Treatment Measured by a 4-Item Questionnaire","SECONDARY","Extremely/Very Satisfied","D008881","A Study of Lasmiditan (LY573144) Over Four Migraine Attacks",FALSE,904,"logistic_regression",NA,NA,NA,1.65729570573522
"2417","99a68d93cac6e8bc8bf98f090ebe6a7c","NCT01559259",0.023,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Intensity Difference on 4-Point Categorical Scale (PID4)","SECONDARY","0.25 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,181,"anova",2,NA,NA,1.02970628152889
"2418","99b74509f76ca4bbf68b2a6e2b67a244","NCT02465515",0.003,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change in Estimated Glomerular Filtration Rate (eGFR) Calculated Using Modification of Diet in Renal Disease (MDRD) Formula","SECONDARY",NA,"D003920; D003924","Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",FALSE,9432,"t-test",NA,NA,NA,1.18846720911115
"2419","99be64e8bdb6bf2a1d3551b323b1a3cb","NCT00424476",0.0129,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"SLE Responder Index (SRI) Response Rate at Week 52","PRIMARY",NA,"D008180","A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)",FALSE,575,"logistic_regression",NA,NA,NA,1.09546087287062
"2420","99de7b491805b0c94a82ad6c232c26c0","NCT05302414",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Team Performance Observation Tool","PRIMARY","For posttest right after intervention at the 4 weeks.",NA,"The Learning Outcome of Resuscitation Teamwork Training in Postgraduate Year Doctors and Nurses",FALSE,64,"kruskal_wallis",2,NA,NA,1.20770700959599
"2421","99f05609dad6fbe5712fdb218db0dbda","NCT02373813",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in DAS28-CRP at All Measured Timepoints","SECONDARY","Change at Week 12","D001168; D001172","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",FALSE,152,"t-test",NA,NA,NA,1.18861079960632
"2422","99f7798f4a941b7af19518454546205b","NCT01183689",0.03,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Mean Change in Fasting Insulin From Baseline to 2 Years","SECONDARY","Analysis of variance was used to compare mean differences from baseline to 2 years among the 3 groups.","D015430","Study of Novel Approaches for Prevention",FALSE,317,"anova",2,NA,NA,1.70272970012108
"2423","9a1143f0ec71bf4b9acdeb4e087ba5b0","NCT01901419",0.046,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Post-op Dopamine Infusion","SECONDARY",NA,"D000138; D000140","Nitroglycerin Infusion During Cardiac Surgery",FALSE,63,"t-test",NA,NA,NA,1.11892688556849
"2424","9a14aaf86d84b82cafacdc2cfcb7184d","NCT02528253",0.0125,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 2, \>=50%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,811,"logistic_regression",NA,NA,NA,1.26328302316739
"2425","9a16b3bd6d98e32f33d15fdb95bca8c1","NCT01459653",0.024,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Modeling CIN/FN-related Chemotherapy Disturbance: Cycle Level","SECONDARY","Center type: academic vs non-academic as center-level predictor for CIN/FN-related chemotherapy disturbance","D009101; D009503; D064147; D000084462; D005334","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",FALSE,1045,"logistic_regression",NA,NA,NA,2.53706396262362
"2426","9a271fb64d8aa0657497ffb65f600d09","NCT01781481",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Number of Visits to the Hospital Emergency Department","PRIMARY","A hierarchical multiple (linear) regression analysis was conducted to determine the predictive relation between the Pediatric INTERMED indicator of case complexity and the number of ER Visits. Gender, and time since diagnosis were entered as covariates (Step 1), followed by current disease severity (Step 2) and the Pediatric INTERMED Complexity Index (Step 3). Diagnostic tests for collinearity were conducted and all assumptions for the analysis were met.","D007410; D015212","The Pediatric Intermed: A New Clinical Decision Making Tool",TRUE,148,"linear_regression",NA,NA,NA,1.80553081332474
"2427","9a2eacd9b58a9dd9d068d28a7d6c92a8","NCT00112151",0.05,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Power (Power Rig, Watts)","SECONDARY","As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in leg extensor power with any T to placebo in subjects assigned to no PRT.",NA,"TEAM: Testosterone Supplementation and Exercise in Elderly Men",TRUE,72,"linear_regression",NA,NA,NA,1.27670232702116
"2428","9a355c4d612477d822400f9e186f6c3b","NCT01796236",0.045,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"The Aesthetic Outcome of Surgery, the 'Patient and Observer Scar Assessment Scale' Consisted of Two Parts - a Patient and an Observer Scale, Week 12, Month 12 and 36.","SECONDARY","Month 36: Surface Area (observer)","D034381; D003638; D006314; D046089","Clinical and Health Economic Evaluation With a New Baha® Abutment Combined With a Minimally Invasive Surgical Technique",FALSE,103,"mann_whitney",NA,NA,NA,1.38756817056338
"2429","9a37a4175ae24e6dcf0397e0b084f6b9","NCT00408876",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Laboratory Assessment - Potassium","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,217,"t-test",NA,NA,NA,1.41361952915884
"2430","9a496cc280e7fa4ba899ad5ac6333e5a","NCT03655951",0.04,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Parent Skepticism of Media Messages From Pretest to Follow-up","SECONDARY",NA,NA,"Birds and Bees Research Study",FALSE,255,"linear_regression",NA,NA,NA,1.9541588411268
"2431","9a4995b44eadf515a439f75f63591b3d","NCT01972841",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q Symptom Bother Scale) at Weeks 4, 8, 12 and EoT","SECONDARY","Odds ratio from a logistic regression model including treatment group, sex, age group (\<65, \>=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours and baseline OAB-q symptom bother scale as covariates.","D053201; D014570; D001745","This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",FALSE,1242,"logistic_regression",NA,NA,NA,4.28446143680138
"2432","9a4eb638bfbe8bd37df981868d23b23e","NCT03334422",0.026,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib)","PRIMARY",NA,"D003876; D003872; D004485","Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis",FALSE,367,"logistic_regression",NA,NA,NA,1.61837663937308
"2433","9a4f77bc85cd9a3d280bda1add477e8c","NCT01081301",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"General Self-Efficacy Score (GSES)","SECONDARY","Generalized estimating equations were used to determine change in patterns of General Self Efficacy Scale scores over time (Day 7, 14 and 3, 6, and 12 months) compared to baseline. The advantage of utilizing general estimating equations was that it effectively increases the sample size (increasing power) and estimated more robust standard errors by taking into account the repeated measures and adjusting for covariates.","D009369","Living With Hope Program for Rural Women Caregivers",TRUE,58,"anova",2,NA,NA,1.15327776573523
"2434","9a83e9c26c67520bdc48eef8834df54b","NCT02912650",0.024,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Time-weighted Sum of Pain Relief Rating (TOTPAR) From 0 to 2 Hours, 0 to 6 Hours and 0 to 12 Hours Post Dose","OTHER_PRE_SPECIFIED","0 to 12 hours: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,347,"anova",2,NA,NA,1.46915461823916
"2435","9aaab9a777803b914f066c0217608400","NCT00549198",0.0266,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Exploratory Analysis of Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) at Week 96","OTHER_PRE_SPECIFIED",NA,"D007239; D003141; D015658; D000163","KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects",FALSE,207,"anova",2,NA,NA,1.24600347844714
"2436","9ac3792d6ffa0df13505afee481638d9","NCT02900378",0.0316,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Total Weekly Time Spent in Non-sedentary Daytime Physical Activity","SECONDARY","Change from BL at Week 2","D006333","randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure",FALSE,604,"mann_whitney",NA,NA,NA,2.44875088976665
"2437","9ac7101ea2840f1d2800a5c9414eceb2","NCT01182103",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Histone Modification of MDD Patients Before and After Treatment and With Healthy Controls","PRIMARY",NA,"D003863; D003866; D003865","Epigenetic Regulation of BDNF in Major Depression",TRUE,113,"t-test",NA,NA,NA,1.58401395671428
"2438","9ad5d21478414f990bfcd156286201be","NCT03761147",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Time to the Resumption of Bowel Functioning as Assessed by Flatus Passage","PRIMARY",NA,"D007410","Gastrointestinal Activation Post-elective CS (Cesarean Section) :A Comparison of Paula Method to Standard Care",TRUE,53,"t-test",NA,NA,NA,1.10589694869732
"2439","9ad9d262ae2d32a898c8919f2fa449cd","NCT00622284",0.024,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Patients With HbA1c <6.5% at Week 104","SECONDARY","Linagliptin versus Glimepiride","D003924","Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes",FALSE,1470,"logistic_regression",NA,NA,NA,3.00694765127614
"2440","9b064d9f871120779afed729e6e5778d","NCT01515072",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Change in Troponins","SECONDARY",NA,"D007511; D003643","Remote Ischemic Preconditioning in Neurological Death Organ Donors",FALSE,241,"mann_whitney",NA,NA,NA,1.9006709790229
"2441","9b08328fdc1db663b9b2ab56401909d3","NCT00105989",0.03,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Glucose - Maintenance Phase","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,232,"anova",2,NA,NA,1.46063591502644
"2442","9b0b11d710a3d5f36dc788f53ca325b9","NCT00550147",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Swanson, Nolan and Pelham IV (SNAP-IV) Oppositional-Defiant Disorder Subscale","SECONDARY","This was a repeated-measures analysis, using a single group of subjects who were administered quetiapine in addition to OROS mph. Results reported here are for the augmentation period (Visit 5-10). See Kronenberger et al. (2007, Journal of Child and Adolescent Psychopharmacology) for additional information.","D001289; D000374","Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.",TRUE,48,"t-test",NA,NA,NA,1.05642048349345
"2443","9b4e6bc244ef3a88d0149da56374e58d","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient-Reported Outcomes Measurement Information System (PROMIS Short Forms 8a - Pediatrics v. 2.0) is a Set of Person-centered Measures That Evaluates and Monitors Physical, Mental, and Social Health in Children and Adolescents.","SECONDARY","We hypothesized that at 12 month outcome adolescents randomized to the intervention would report less Pain Interference compared to control adolescents.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,126,"t-test",NA,NA,NA,1.66971913113983
"2444","9b4e880847063e79557df0ba289774ea","NCT02528188",0.0235,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 4: \>=90% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,3.43719246933538
"2445","9b6ac2b140a1313518643292b89504ec","NCT01422876",0.0224,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Occurrence of Treat to Target Efficacy Response for Treatment Naive Patients","SECONDARY","Logistic regression includes treatment, baseline eGFR (MDRD), geographical region and baseline HbA1c.","D003920; D003924","Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients",FALSE,239,"logistic_regression",NA,NA,NA,1.15248251646425
"2446","9b6ff1669a6b098a834b4c13a429168f","NCT03192176",0.0343,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 2 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 6","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.01346462935777
"2447","9b709e92a9656e7b95b65d8336727c7c","NCT00088153",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,1,0,"Percent Change in Spine Bone Density Over the Study Duration (18 Months)","PRIMARY","Power analysis: We have previously demonstrated that normal female adolescents gain bone density at the rate of 0.039 +/- 0.0507 per year. The pooled SD in that study was 0.046. Based on these data, with a sample size of 110 girls with anorexia nervosa (AN), half of whom are randomized to receive estrogen and half placebo (with a 10% drop-out rate), there will be an 80% chance that we will detect an increase in bone density to 75% of normal in the girls who receive estrogen.","D000855; D000856","Effects of Anorexia Nervosa on Bone Mass in Adolescents",TRUE,110,"t-test",NA,NA,NA,1.56357043896758
"2448","9b8fad9ddeff21637655d223ee85b06f","NCT03718832",0.045506,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Times Eating Fruit in the Past 7 Days","SECONDARY","Unadjusted mean difference, 12 months after trial enrollment",NA,"Fresh Food Farmacy: A Randomized Controlled Trial",FALSE,333,"t-test",NA,NA,NA,2.48477762055261
"2449","9bbe47c9bc9c394d702a07a3053ce175","NCT03358030",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Percent Change From Baseline in Factor XI (FXI) Activity","OTHER_PRE_SPECIFIED","Day 15 through Day 176","D007674; D007676","A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis",TRUE,45,"mann_whitney",NA,NA,NA,1.02560707988412
"2450","9bbe5e3e4bc0097bb183eeb678c3462f","NCT01728636",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Total Red Blood Cells Transfused in the Intraoperative Period","PRIMARY",NA,"D013121","The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery",FALSE,61,"mann_whitney",NA,NA,NA,1.1808032050005
"2451","9bd063d501410004ad580b945557c821","NCT02528253",0.0256,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 56, \>=30%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1011,"logistic_regression",NA,NA,NA,2.6389852111054
"2452","9bdd08b4ab83c65bb72dac0f44a25f47","NCT04172701",0.0091,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"All-cause Healthcare Costs: Outpatient Medical Costs (Per Person Per Month)","SECONDARY",NA,"D029424","A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)",FALSE,4888,"t-test",NA,NA,NA,2.33128060000249
"2453","9c2128fd6059076f5c146f27233ed699","NCT02543840",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Team Development Measure (TDM)- Cohesion","SECONDARY",NA,"D001523","Hybrid Collaborative Care Randomized Program Evaluation",FALSE,59,"t-test",NA,NA,NA,1.16252463235142
"2454","9c27f7c31ba8ef2d2ac9781b56edc25c","NCT03623386",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in Motor Impairment","PRIMARY","Testing for main effects (group), time effect and the interaction of group and time.","D010300","Effect of Mental Imagery Training on Brain Plasticity and Motor Function in Individuals With Parkinson's Disease",FALSE,44,"anova",2,NA,NA,1.01513168983373
"2455","9c2d4764f91a558b95f5037f7dc8fcf4","NCT02389816",0.0186,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"MADRS Remission at Week 8 (LOCF)","SECONDARY",NA,"D003866; D003863; D003865","A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder",FALSE,329,"logistic_regression",NA,NA,NA,1.1469174008257
"2456","9c2f31ce6bf14c7c256ff767e4b1fddd","NCT00755807",0.025,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Multiple Sclerosis Quality of Life-54 Instrument (MS-QOL-54) at Week 18 (Open-label Extension Phase)","SECONDARY",NA,"D009103; D012598","Duloxetine for Multiple Sclerosis Pain",FALSE,201,"t-test",NA,NA,NA,1.16440076478334
"2457","9c33f84fd7ccbec994428067c7ea4368","NCT03334396",0.025,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)","SECONDARY",NA,"D003876; D003872; D004485","A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis",FALSE,376,"logistic_regression",NA,NA,NA,1.5833330932624
"2458","9c37af29e39e58d965bae0fee25607e4","NCT02672176",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Diabetes Self-efficacy Measured Using the Diabetes Empowerment Scale Short Form (DES-SF)- Scores at Baseline","PRIMARY",NA,"D003920","Improving Health in Diabetes Project",FALSE,287,"mann_whitney",NA,NA,NA,2.49853393660761
"2459","9c3996c0ff1e89305e5be81579c25a00","NCT01347931",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Activity Endurance Time","PRIMARY","A sample size of 26 patient pairs was determined based on the assumption of a true treatment difference in mean ADL endurance time of 4 ± 7 minutes using a two-tailed, paired t test (α=0.05, power=0.80).","D008171; D029424; D012131; D008173","In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory Insufficiency",TRUE,58,"t-test",NA,NA,NA,1.15327776573523
"2460","9c3a9aa76fd22c2203370bbb1b7bcb55","NCT01058356",0.05,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Presence of AAD","PRIMARY","Null hypothesis: The efficay of the probiotic Lactobacilli (Lacidofil cap®) for the prevention of AAD in adults is not different form the placebo group in multi-center, randomized, placebo-controlled, double-blind trial.

Power calculation:

The assumption of sample size calculation:

difference 18% (8% : 26%) α: 0.05, statistical power: 90%, two sided difference: 18% Compliance: 80%

- Unadjusted sample size (N=200) 180 + 10(%) drop out = 180 + 180/ (1-0.1)2 = 222.2 Total 220 subjects","D004761; D003092; D003967","Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea",TRUE,214,"logistic_regression",NA,NA,NA,2.16243298173887
"2461","9c3ea60c0687dc536094d16361300c71","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in Total Cholesterol","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,111,"anova",2,NA,NA,1.5704144397227
"2462","9c48f1cba5729aec9e3367f8d3d4f29c","NCT03547531",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Baseline Gingival Condition","PRIMARY","null hypotesis: there is no difference of mean of gingival index between groups","D003773; D009066","Comparison of Modified Circular and Natural Tooth Brushing Methods in Effectiveness of Dental Plaque Removal",FALSE,124,"t-test",NA,NA,NA,1.6568216953838
"2463","9c55ac20ac9eba4b650ace8ecdea13dd","NCT00453999",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change in Amount of Influenza Virus in Nose and Throat (Influenza A and B Combined)","SECONDARY","Change from Baseline at 36 hours","D007251","Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza",FALSE,112,"mann_whitney",NA,NA,NA,1.57722881888439
"2464","9c5c61d8547e4f39fa3dc1088aa89aa2","NCT00286442",0.034,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.5%.","SECONDARY",NA,"D003920","Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus",FALSE,311,"logistic_regression",NA,NA,NA,1.87718006142285
"2465","9c893110579f893e2397716c7ed4445b","NCT01752634",0.0245,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants Achieving American College of Rheumatology 50 (ACR50) Response Criteria","SECONDARY",NA,"D001168; D015535","Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis",FALSE,197,"logistic_regression",NA,NA,NA,1.13314769322239
"2466","9c8c5af02331494bb071a7c7956c7fd3","NCT01529385",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Microcirculation for Medial Calf","PRIMARY",NA,"D004487","Mild Compression Sock for Control of Lower Extremity Edema in Individuals With Diabetes",FALSE,77,"anova",2,NA,NA,1.31800316623017
"2467","9c8d128421764370feacf196296bd6fa","NCT02861118",0.024,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Impact of the Comorbidities Profile in Inflammatory Bowel Disease (IBD) Participants on Lack of Treatment Response to Biological Therapy","PRIMARY","IBD","D007410; D015212","A Retrospective Observational Study to Assess the Impact of Co-morbidities on Treatment Response in Inflammatory Bowel Disease",FALSE,310,"logistic_regression",NA,NA,NA,1.38983784860344
"2468","9c9333fd50a3afe82fa3b8ccc3dd3c4d","NCT01258738",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in SF-36 Mental Component Summary (MCS) at Time Points","SECONDARY","Within group comparisons to baseline were \<0.05, from paired t-test.","D013166; D025241; D013167","Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes",TRUE,186,"t-test",NA,NA,NA,2.01873369003327
"2469","9c9ac605922d2aa5fb6d81f5bb7649fc","NCT00781079",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Patient Activation Measure","SECONDARY","comparisons between the PS and Usual Care groups were completed with a regression testing the interaction of group (PS vs Usual Care) and time (baseline vs follow-up) for the outcome measure. The measure was analyzed with mixed effect hierarchical regressions which accounted for the nesting of site under treatment, subjects within sites, and subjects over time.","D001523","Do Consumer Providers Enhance Recovery?",FALSE,238,"linear_regression",NA,NA,NA,2.278406324604
"2470","9cada6f8491f283b48690eabd3dbbd60","NCT03634397",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change of Score on Barthel Index From Baseline 2 (Prior to Training) to Post Test 1","PRIMARY",NA,"D020521","Predicting Ipsilesional Motor Deficits in Stroke With Dynamic Dominance Model",TRUE,53,"linear_regression",NA,NA,NA,1.10589694869732
"2471","9cae9c07f7e55b2a1241c58a748274a7","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Tax","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1746,"linear_regression",NA,NA,NA,6.1282671837603
"2472","9cb509ffe65b5524daf7b9ac03453b13","NCT00791999",0.025,"Logistic regression","INTERVENTIONAL",0,0,1,1,0,"American College of Rheumatology 20% (ACR20) Response at Week 12","PRIMARY","For ACR20 responder rate at Week 12, treatment comparisons versus placebo for the two CDP870 dose groups, the CDP870 200 mg group the CDP870 400 mg, were performed. The ACR20 responder rate in the CDP870 100 mg group was used for the secondary analysis.","D001168; D001172","Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)",TRUE,239,"logistic_regression",NA,NA,NA,1.2671862666417
"2473","9cc37dc63bee0fc4546301e2c1c46a16","NCT01056640",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,1,0,"Mean # Participants Who Had Hospitalizations or ED Visits Compared to Usual Care in a High Risk Group of Adults ≥ 60 Years of Age With Mixed Chronic Disease.","PRIMARY","All analyses were performed using an intent-to-treat method. Wilcoxon rank sum test, 2-sample t test, or Chi-Square analysis was used to compare baseline characteristics. The primary end points of combined and individual percentages of hospitalizations and ED visits were compared using Chi-Square test. Statistical adjustment was planned only if there were statistical differences in clinical variables between the groups. All tests for significance used a 2-sided P value of .05.",NA,"Telemonitoring Versus Usual Care",FALSE,205,"mann_whitney",NA,NA,NA,2.11730698477287
"2474","9cc8c296a765ab7c62211808ee86b8c6","NCT02480764",0.015,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved Target Clinic SBP <130 mm Hg, Target Clinic DBP <80 mm Hg or Both at Week 8","SECONDARY",NA,"D006973; D000075222","Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension",FALSE,413,"logistic_regression",NA,NA,NA,1.06252977846007
"2475","9cd485e561e1b4f560e374c3b893aa07","NCT04697264",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"The Difference in Circulating Plasma Levels of Leptin, IGF1 and IGF2 Between Study and Control Patients.","PRIMARY","To compare biomarker levels between study and control populations, a linear regression model was used, adjusting for BMI, diabetes, and parity, which are the unmatched factors between the study and control groups. This adjustment aimed to mitigate the confounding impact of these factors, considering their individual influence on the risk of endometrial cancer.","D016889; D009765","Adipocytokines in Endometrial Cancer",FALSE,100,"linear_regression",NA,NA,NA,1.49341131573029
"2476","9cd5be50015a37f2e3d2f9b8df325b14","NCT02214186",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Cystatin C as New Marker of Renal Injury in Preeclampsia","SECONDARY",NA,"D004461; D011225","Restrictive Fluid Therapy in Severe Preeclampsia",TRUE,46,"anova",2,NA,NA,1.03597838019194
"2477","9cd69f2e986d7f1c23a7d839e3a0f635","NCT03239665",0.0243,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Mean Change in Knowledge and Awareness About Vaccine-Preventable Diseases","PRIMARY","Testing zoster knowledge score change between groups from baseline to post intervention","D003141; D007239; D018410","Vaccination Education Through Pharmacists and Senior Centers (VEPSC)",FALSE,287,"mann_whitney",NA,NA,NA,1.35260610555965
"2478","9cd7cb8c7ba793403cb984776189bbaa","NCT03733301",0.025,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving SCORAD90","SECONDARY",NA,"D003876; D003872; D004485","A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis",FALSE,220,"logistic_regression",NA,NA,NA,1.21687804891747
"2479","9ce06f65dfc9b47503e7819a12d71375","NCT01567865",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Number/Percentage of Subjects With Demonstrated Seroprotection","PRIMARY","Null hypotheses: each new lot does not differ in seroprotection (SP) rates among each other by more than 10%.

Slower than anticipated enrollment resulted in a smaller number of subjects with antibody response data for analysis. Consequently, additional power estimates were made in anticipation of the occurrence of smaller sample sizes. With a total study population of only 772 subjects, the power of the study to test lot-to-lot consistency declined from 90% to 85%.","D004672; D004660","Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine",TRUE,386,"t-test",NA,NA,NA,2.89262749619186
"2480","9ce933e81ecdf72a1e02be846dcf66b4","NCT02932904",0.046,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Participants Meeting Criteria for Sexual Dysfunction at Weeks 1, 2, 3, 4 and 5","SECONDARY","Week 5",NA,"Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers",FALSE,180,"logistic_regression",NA,NA,NA,1.85287998809326
"2481","9cf7ae1bae8dcdf1169d655914b55f77","NCT04473222",0.045,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Child Sleep Patterns: Nighttime Sleep Duration","SECONDARY",NA,"D012892","Behavioral Sleep Intervention in Urban Primary Care: Aim 3",FALSE,97,"t-test",NA,NA,NA,1.34817303752635
"2482","9cff97c2a572e3fc6ab47440ee881de5","NCT02027311",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Number of Intervention","PRIMARY","If the true difference in the experimental and control means is 4, total 26 experimental subjects and 26 control subjects was required to reject the null hypothesis that the means of the primary outcome values of experimental and control groups are equal with probability (power) 0.8. The Type I error probability associated with this test of this null hypothesis is 0.05.","D018281; D010195; D042883","Etomidate vs. Midazolam for Sedation During ERCP",FALSE,63,"logistic_regression",NA,NA,NA,1.19880559218312
"2483","9d2476a2d2797132435a16637a5019a8","NCT02658240",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Postoperative Pain Score at Resting","PRIMARY","The study was powered to detect a mean difference of 1.5 in pain scores in favor of patients undergoing SFICB procedure assuming a standard deviation of 2.5. With a two sided alpha level of 0.05, a total of 52 patients would be needed to have 80% power using a repeated measures ANOVA F test with 6 observations on each subject. Correlation on the repeat observations was assumed to be 0.5. Assuming a 14% loss to follow-up, 60 patients were enrolled at 1:1 ratio.","D010149","Ultrasound-guided Fascia Iliaca Compartment Block Versus Periarticular Infiltration",FALSE,60,"anova",2,NA,NA,1.17169922891753
"2484","9d367e9b10951cb6a1b0bdf5bab56e85","NCT01368185",0.01,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Systolic Blood Pressure (SBP)","SECONDARY","Comparison between Month 3 and Baseline","D006973","Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)",TRUE,1705,"t-test",NA,NA,NA,1.49953882648572
"2485","9d674e50cca323d862ea8ec1fe1e4f11","NCT02696031",0.0149,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 20 Response","SECONDARY","week 16","D013166; D025241; D000089183","Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis",FALSE,370,"logistic_regression",NA,NA,NA,1.0006359930996
"2486","9d727619b87fc0785bf4725d67216722","NCT00195351",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Number of Microbiologically Evaluable Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit.","SECONDARY",NA,"D007239; D003141; D001064; D010538; D059413; D003428; D002764; D042101; D004238","Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection",FALSE,275,"t-test",NA,NA,NA,1.11882400860572
"2487","9dbe8ce4af5d34df4725e60968cd4a2d","NCT00331773",0.047,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Comparison of Disease-specific HRQOL Change in Expanded Prostate Cancer Index Composite (EPIC); the Utilization of Sexual Medications/Devices Supplements the EPIC","SECONDARY","EPIC Urinary Domain at 60 months","D011471","Radiation Therapy in Treating Patients With Stage II Prostate Cancer",FALSE,1092,"mann_whitney",NA,NA,NA,4.60432152418551
"2488","9dc48973b291b9b62c8e19002cb15554","NCT02528188",0.0108,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 16: \>=90% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1989,"logistic_regression",NA,NA,NA,1.73387845726896
"2489","9dc62320abad33ecf4f47d7ea3bc4925","NCT01522755",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Pacing Threshold During and Post Implant of the CapsureFix MRI Lead Model 5086","PRIMARY",NA,"D001919","Predictive Factors of a Successful Implant of the CapsureFix MRI Model 5086",TRUE,409,"t-test",NA,NA,NA,2.97672685958764
"2490","9dce26f7ecf7f876d0cd437b94e14a6f","NCT03597464",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number (and Percent) of Subjects in Partial Renal Response","SECONDARY","Month 30","D009393; D008181","Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin",FALSE,216,"logistic_regression",NA,NA,NA,1.80121336885754
"2491","9ddd05ee177dd63de400b7c3048be0e6","NCT03965754",0.02,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Logging in (7 Days)","PRIMARY",NA,NA,"Assessing the Impact of myHealth Rewards Enrollment Emails",FALSE,2850,"logistic_regression",NA,NA,NA,3.56990639752634
"2492","9ddf990548b0976dc825d5611105793d","NCT00455533",0.0192,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]) to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR/RCB1","SECONDARY","GTSE1 204318_s_at","D001943","Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer",FALSE,295,"logistic_regression",NA,NA,NA,1.1175934183513
"2493","9de3ffdfd5a7514ce263a09c1072dbd0","NCT00475540",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Number of Participants With Anatomic Cure at 3 Years","PRIMARY","Sample size primary outcome 1 year: 45 participants per arm, 20% difference success (70% no mesh and 90% mesh), alpha of .05 and 80% power, 15% loss to follow-up.","D020047; D052858; D014596; D011391; D056887","Efficacy Study of Vaginal Mesh for Prolapse",TRUE,51,"t-test",NA,NA,NA,1.08637315449684
"2494","9e015b97c7270d00e57ddfb3543e27d9","NCT00070707",0.03,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in AM and PM Rhinorrhea Symptom Score","SECONDARY","Change at Week 4 (AM)","D012220; D001249; D006255; D065631","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",FALSE,187,"anova",2,NA,NA,1.31455719552922
"2495","9e09ca7c199acd7b28d5ba043340ea27","NCT02708095",0.041,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Who Achieve Remission of Arthritis and/or Rash Defined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)","PRIMARY",NA,"D008180","A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)",FALSE,209,"logistic_regression",NA,NA,NA,1.80968020360447
"2496","9e0c4bca23cae4a61441fa6c37ca8353","NCT00565812",0.047,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Joint Space Narrowing Progression","SECONDARY","Odds ratio, 95 percent CI and P-values were obtained from a logistic regression model, with treatment group, (collapsed) KLG, geographic region, and gender as factors, age and body mass index as covariates.","D010003; D020370","A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee",FALSE,848,"logistic_regression",NA,NA,NA,4.05955092472927
"2497","9e1afd9030800f1de98f3a4caa250876","NCT02270671",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Social Phobia and Anxiety at 4-week Post-intervention and 12-week Follow-up","PRIMARY",NA,"D003863","Attention Bias Modification Training for Young People",FALSE,120,"anova",2,NA,NA,1.63072147479452
"2498","9e1b2e72107940f3f62d6a0c178c4519","NCT02528253",0.0126,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 4, \>=70%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,810,"logistic_regression",NA,NA,NA,1.27143747204344
"2499","9e5cd791f60c4120220d98022c81066c","NCT00362115",0.0429,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.","SECONDARY",NA,"D006973","Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension",FALSE,95,"anova",2,NA,NA,1.28254291101734
"2500","9e9e0c88aab4d861bafcbeb0d11e9f60","NCT01850446",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Duration of Clinical Symptoms of Influenza (Fever, Non-specific Symptoms and Nasal/ Throat/ Chest Symptoms) in Days.","SECONDARY","Fever duration","D007251","Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza",FALSE,184,"t-test",NA,NA,NA,1.66526992555918
"2501","9ea09cd26ad64de87264aa41ca96a498","NCT02078713",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Patient Contraceptive Counseling Satisfaction","SECONDARY",NA,NA,"Patient-Centered Support for Contraceptive Decision-Making",FALSE,749,"logistic_regression",NA,NA,NA,2.60613189144527
"2502","9eb4f11f4b172de7f26280a754a92ae3","NCT00762762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"IL-6 (Interleukin - 6)","PRIMARY","The null hypothesis states that there is no difference between groups.","D010518","Effectiveness of a Triclosan Containing Toothpaste in Maintaining Periodontal Health in a Type 2 Diabetic Population",FALSE,46,"anova",2,NA,NA,1.03597838019194
"2503","9ec7e97b352dc3c953de2c9fe7ea52e7","NCT00377260",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"The Distribution of Children With Nasopharyngeal (NP) Colonization With Penicillin-susceptible Streptococcus Pneumoniae (S. pn) at the Follow-up Visit","SECONDARY","Null hypothesis: There is no difference between the two groups regarding the proportion of children colonized with penicillin-susceptible Streptococcus pneumoniae.","D010031; D010033","Acute Otitis Media (AOM) Therapy Trial in Young Children",FALSE,257,"logistic_regression",NA,NA,NA,1.96168098215128
"2504","9ed4c88af0c1ba1760862784f6203f58","NCT00286468",0.025,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Glycosylated Hemoglobin ≤ 7.5%.","SECONDARY",NA,"D003920","Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.",FALSE,302,"logistic_regression",NA,NA,NA,1.42132297071072
"2505","9ee4a841c47a58537d7bb85cee0f0f1b","NCT03192176",0.0377,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 2 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 3","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.07915920046559
"2506","9eedd689334cf41dd7e4899a53e1d203","NCT03713619",0.0248,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving NRS30","SECONDARY","Logistic regression analysis of skin pain/NRS30 response at Week 16 (pooled data, multiple imputation)","D017497; D016575","This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).",FALSE,250,"logistic_regression",NA,NA,NA,1.28647669286758
"2507","9ef731239b442cc3d660c12e3ea65bb3","NCT03239496",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Seroconversion Non Inferiority of 3 Doses f-IPV ID vs 3 Doses IPV IM","SECONDARY","The group sizes are chosen to provide ≥ 80% power for each of the primary objectives, for the individual statistical tests of each serotype, as well as across both serotypes simultaneously. Power of ≥80% is also available for all secondary objectives, except for the comparison of the f-IPV regimen administered at weeks 14 and 36 to the 3-dose IPV regimen, which has power of 62% for individual serotypes, and 39% for the combined serotypes.","D011051","A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV",FALSE,338,"t-test",NA,NA,NA,2.70871991927501
"2508","9f090d6d78c9fe9025285b411397f60f","NCT01908907",0.048,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Feasibility and Tolerability of Daily Enteral DHA Oil - Weight Change","PRIMARY","Linear mixed models were used to explore growth over time (weight, length and head circumference). These models included a random effect for intercepts and slopes to account for subject specific growth over time as well as a random effect for possible correlation between twins and triplets present in the data set. Fixed effects included both a linear and quadratic time effect, GA at birth, treatment group, full feeds (yes/no), and interactions. Non-significant interactions were eliminated.","D047928","Bridging the Docosahexaenoic Acid (DHA) Gap: The Effects of Omega-3 Fatty Acid Supplementation in Premature Infants",FALSE,60,"linear_regression",NA,NA,NA,1.13287941501804
"2509","9f0d57dacb1fcda8e447d7b3e56420cb","NCT02900378",0.0465,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Total Weekly Time Spent in Moderate-to-Vigorous Non-sedentary Daytime Physical Activity","SECONDARY","Change from BL at Week 4","D006333","randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure",FALSE,604,"mann_whitney",NA,NA,NA,3.3986340760396
"2510","9f101e69d61c2e56e98a267b0efd4e1b","NCT01234649",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Insulinogenic Index (IGI) /HOMA-IR","SECONDARY","Factorial repeated measures ANOVA","D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",FALSE,72,"anova",2,NA,NA,1.27670232702116
"2511","9f10cdc6e75329d1864830a7ba6aaef8","NCT01459653",0.024,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Modeling CIN/FN-related Hospitalization: Cycle Level","SECONDARY","Over- vs. correctly prophylacted as patient-level predictor for CIN/FN-related hospitalization","D009101; D009503; D064147; D000084462; D005334","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",FALSE,1383,"logistic_regression",NA,NA,NA,2.91692748142937
"2512","9f12ef5a162137470ca78eeb39f1c668","NCT01416194",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Biliary Events","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",TRUE,7777,"logistic_regression",NA,NA,NA,3.19773018380892
"2513","9f141b7db28931253917ff4f74b46351","NCT02028676",0.03,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"LCM vs CDM, Induction ART: Change From Baseline in Absolute CD4 to Week 144","SECONDARY",NA,"D000163; D015658","Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa",FALSE,646,"linear_regression",NA,NA,NA,2.42152762614784
"2514","9f23be0910830b16929262f4fe459e94","NCT01616771",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"The Differences in the Glottis View (C&L Grade) of Macintosh Laryngoscope and GVL Selected by Weight.","PRIMARY","An improvement of C\&L grade ordinal scale by 2 was considered a clinically significant change. The mean difference of C\&L grade ordinal scale between DL and GVLw was 1.3, and its standard deviation was 2.0 in our pilot study. The required sample size for the Wilcoxon signed rank test was 21 with an α error of 0.05 and 80% power.",NA,"GlideScope®Video Laryngoscope for Difficult Intubation: Implication of the Size of Blade",TRUE,46,"mann_whitney",NA,NA,NA,1.03597838019194
"2515","9f26fe939d46b14cecd7310f4c196644","NCT00301262",0.0257,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 3 or 4","SECONDARY",NA,"D007172","Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied",FALSE,162,"t-test",NA,NA,NA,1.07370073775507
"2516","9f2dc6f681f7757f63b93ba61869b07d","NCT01434680",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup C 28 Days After Vaccination","PRIMARY","The study would be considered a success if the two-sided 95% confidence intervals (CIs) for the hSBA GMT ratios comparing MenC-CRM ROS to MenC-CRM EMV at 28 days after a single vaccination were both within the equivalence interval (0.5, 2.0).","D008589; D008585; D008581","Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers",TRUE,540,"anova",2,NA,NA,3.41648438836919
"2517","9f4ea253019aa4585292579dd5e051fb","NCT02891226",0.029,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Achieving Patient Reported Outcome Remission at Week 12","SECONDARY",NA,"D003424","A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease",FALSE,128,"logistic_regression",NA,NA,NA,1.062720269585
"2518","9f4fcc3d152fda42e4167f95c21ff6b6","NCT00884221",0.025,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Number of Follicles of >= 12mm, 12-14 mm, 15-16 mm and >= 17 mm in Each Participant, Intention-to-treat (ITT) Analysis Set","SECONDARY","Comparison between treatment groups of the average number of follicles \>= 12 mm on the last stimulation day","D007246","MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer",FALSE,749,"mann_whitney",NA,NA,NA,2.22727781090795
"2519","9f56404cc5ccd550d72fe64dba9b8173","NCT01044706",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"AUC0-144 (Area Under the Concentration-time Curve From Time Zero to 144 Hour Post-dose)","PRIMARY","Using GLM procedures in SAS, ANOVA was performed on ln-transformed AUC0-144 at the alpha level of 0.05. Factors incorporated in the model will include: Group, Treatment and Treatment\*Group. Intra-subject coefficient of variation (CV%) will be estimated. The ratio of means (T/R) and 90% geometric confidence interval for the ratio of means, based on least-squares means from the ANOVA of the ln-transformed data, will be calculated for AUC0-144 hour.","D044342","Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex® 50 mg Tablet in Healthy Subjects Under Fed Conditions",TRUE,60,"anova",2,NA,NA,1.17169922891753
"2520","9f6f486a4ddf31311fd1fe101c0ccffc","NCT00537940",0.0252,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) Score.","SECONDARY","Baseline: Logistic regression model was used to estimate odds ratio and corresponding 95% CI of treatment difference, with treatment as fixed effect and for post-baseline assessments baseline was included as a covariate.","D004827; D012640; D004828; D017029","Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures",FALSE,478,"logistic_regression",NA,NA,NA,1.79499303911206
"2521","9f7c666e62ce0650137f53ba288eb4fe","NCT01089582",0.0382,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Participants for Change From Baseline for the Caregiver's Assessment of Improvement at Week 12","PRIMARY","The effect of possible prognostic factors on response: significant medical history. Participants were classified as responders if they were much improved or improved from baseline.","D000544","Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets",FALSE,603,"logistic_regression",NA,NA,NA,2.8762104048177
"2522","9f80acaf300e2e117888b3361629434f","NCT03573830",0.033,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Interest in the Communication Material","SECONDARY",NA,"D014947","Randomized Control Trial of Booster Seat Education Material to Increase Perceived Benefit Among Parents",FALSE,720,"t-test",NA,NA,NA,2.77289754227668
"2523","9f9b522a5ad7b99ecc83eeac6bbd1bcb","NCT03199053",0.042,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Low-dose Versus Placebo (Weighted): Percentage of Participants With Baseline HbA1c ≥ 7% Who Achieved HbA1c < 7% at Week 26","SECONDARY",NA,"D003920; D003924","Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old",FALSE,88,"logistic_regression",NA,NA,NA,1.21477853799606
"2524","9f9eed56a6df19b71174d54ef08311e4","NCT01517373",0.0454,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Body Weight at Week 2, 4, 6, 8, 12 and 14","SECONDARY","Week 2: Treatment difference and 80% CI were based on LS mean. MMRM analysis was performed with treatment, duration of T2DM, time and treatment-by-time interaction as fixed effects, baseline as the covariate, time was repeated for participant.","D003920; D003924","Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin",FALSE,119,"t-test",NA,NA,NA,1.49859032778185
"2525","9fc3418667fdb489145d26e464f63c79","NCT02303704",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Post-op CK-MB Levels","PRIMARY","Null hypothesis was there is no significant difference between the means of two groups",NA,"Myocardial Protection With Multiport Antegrade Cold Blood Cardioplegia",TRUE,434,"t-test",NA,NA,NA,3.06552394865376
"2526","9fcbb6c3ace416de4d1315b90fe32004","NCT02123797",0.0474,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Stage-Appropriateness Treatment Selection, MD vs SC (Conference) vs SC (no Conference)","PRIMARY","We examined treatment selection practices with or without MD care in a single healthcare system.",NA,"Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology",FALSE,438,"logistic_regression",NA,NA,NA,2.94476953950871
"2527","9fcd1a6a59aaa753cc0b7d614afc8144","NCT03962738",0.018,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With 48-Hour Sustained Pain Freedom","SECONDARY",NA,"D008881","A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine",FALSE,392,"logistic_regression",NA,NA,NA,1.21493952771955
"2528","9fd0f74e59fd08ce54e320c2e88e3a72","NCT00783198",0.032,"ANOVA","INTERVENTIONAL",0,0,1,1,0,"Average Combined Rhinoconjunctivitis DSS and DMS Over the Entire RS","SECONDARY",NA,"D012220; D001249; D065631; D003231","Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)",FALSE,318,"anova",2,NA,NA,1.80219898371573
"2529","9fd38a1507b5edba3363a0c04866ab52","NCT03170271",0.0401,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Patient Global Impression of Severity (PGI-S): Responder Status at the EOT (Week 24)","SECONDARY","Estimate of the log odds of being a responder classified as type 'Important Improvement' at Week 24 in the benralizumab group compared to the placebo group using a logistic regression.","D001249","A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.",FALSE,532,"logistic_regression",NA,NA,NA,2.81639504926603
"2530","9fd9eae4beff136a923115806b35467a","NCT00438464",0.03,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Comparison of Biomarkers Between Treatment Arms: Percentage Change of Tumor Cells Exhibiting Detectable Staining Within Gleason Grade 3 (GG3) Biomarker Subgroups at Prostatectomy","PRIMARY","Cleaved Caspase 3 (Caspase), Within GG3","D011471","Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery",FALSE,130,"mann_whitney",NA,NA,NA,1.10211797931882
"2531","9fe0948ac6a575a28f8d26568bc620bb","NCT02209181",0.028,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Intensity Difference From Baseline (PID) Scores at 1.5 Hours Post Dose","SECONDARY","The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.","D014098","A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine",FALSE,136,"anova",2,NA,NA,1.06188324741234
"2532","9fec5932f2f50f7858015a61d6dab802","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cancer Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1750,"linear_regression",NA,NA,NA,6.13526752012651
"2533","9ff2dcba38d0b6df5e165216f199b268","NCT01559259",0.038,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Relief Rating Score (PRR)","SECONDARY","10 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,120,"anova",2,NA,NA,1.29585716458414
"2534","9ff9e074e77a1b4b48493f12821ca2c2","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Daytime Heart Rate","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"2535","a00d2310c07f4c63d331130bde257ce6","NCT03192176",0.0392,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 2 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 2","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,85,"logistic_regression",NA,NA,NA,1.12777749916249
"2536","a02282550b96c26947526ebeac5f0a12","NCT03705286",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Airway Related Complications","SECONDARY","We evaluated whether there are differences in the risk of laryngeal injury between the PU-EVAC and PVC treatment groups, comparing their respective risk difference (i.e., probability\[PU-EVAC\] - probability \[PVC\]). We fit a logistic regression model and incorporated robust (i.e., Huber-White heteroskedastic consistent) standard error estimates for our hypothesis test and 95% confidence interval estimates.","D011014; D053717","Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia",FALSE,156,"logistic_regression",NA,NA,NA,1.85245347153569
"2537","a028759dd263ae5ac386790af23557d4","NCT01236053",0.0033,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,17.4515838842603
"2538","a03b452a310c07ee5e86586f30679f96","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Saturated Fat","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1753,"linear_regression",NA,NA,NA,6.14051253521365
"2539","a03c832acac0b0ab265cfafe9258a677","NCT00539539",0.016,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"CPR Fraction","SECONDARY","Cluster adjusted difference in average CPR fraction.","D006323","Automated Real-time Feedback on CPR Study",FALSE,1586,"linear_regression",NA,NA,NA,2.19213850377385
"2540","a042d21947feb099e2b74a33e4e83f47","NCT02237950",0.015,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Recurrence of BV Where a Diagnosis of BV is Defined as the Presence of at Least 3 Clinical Findings","PRIMARY",NA,"D016585; D014623; D012008","Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)",FALSE,585,"logistic_regression",NA,NA,NA,1.26191295949806
"2541","a0490ffe3c0019ba6aad7cec23765d0a","NCT00967330",0.0485,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ - C30) at Baseline, Post-Baseline (up to Month 30)","SECONDARY","Nausea/Vomiting. ANOVA included all post-baseline data (Months 3 through 21).","D005909","A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma",FALSE,170,"anova",2,NA,NA,1.88336545941277
"2542","a0622c4b6bbf58477ed06599e611875c","NCT03965754",0.038,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Enrollment (7 Days)","PRIMARY","We conducted a logistic regression with the three email conditions as dummy variables with no email as the reference group (among employees who never enrolled in the program).",NA,"Assessing the Impact of myHealth Rewards Enrollment Emails",FALSE,2847,"logistic_regression",NA,NA,NA,6.20438017297959
"2543","a06969994a57ae058f1263f1ede07b45","NCT01044706",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Cmax (Maximum Observed Concentration of Drug Substance in Plasma)","PRIMARY","Using GLM procedures in SAS, ANOVA was performed on ln-transformed Cmax at the alpha level of 0.05. Factors incorporated in the model will include: Group, Treatment and Treatment\*Group. Intra-subject coefficient of variation (CV%) will be estimated. The ratio of means (T/R) and 90% geometric confidence interval for the ratio of means, based on least-squares means from the ANOVA of the ln-transformed data, will be calculated for Cmax.","D044342","Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex® 50 mg Tablet in Healthy Subjects Under Fed Conditions",TRUE,60,"anova",2,NA,NA,1.17169922891753
"2544","a071b2dddae3c08df048a4dfecc28bdc","NCT01056718",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Mitral Valve E/A Ratio","SECONDARY","Nebivolol treatment group refers to 50 patients that completed 10 weeks of open label nebivolol treatment. Results were compared using paired T-tests in a pre - post study design before and after 10 weeks of his/her treatment. Each subject served as own control.","D006973; D054160","Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function",TRUE,50,"t-test",NA,NA,NA,1.07648023860356
"2545","a07920e40be0d494352d7354fe88a4eb","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Fasting Endogenous Glucose Production","PRIMARY","Treament difference in fasting EGP between the 2 groups were compared.","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",FALSE,50,"t-test",NA,NA,NA,1.07648023860356
"2546","a07a735e154f43452961ebc62694b382","NCT03203512",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Ex Vivo Agonist-stimulated Platelet Activation Detected by Plate-based Platelet Aggregation Assay","SECONDARY","Null hypothesis is that there was no difference in change of platelet function in affecting LogEC50 values in response to TRAP-6 between fish oil and placebo capsules. Comparisons of this parameter after each intervention were drawn using 2-way ANOVA with the Turkey multiple comparisons test.","D001768","Fish Oil-derived N-3 Polyunsaturated Fatty Acids and Extracellular Vesicles",FALSE,80,"anova",2,NA,NA,1.34217713699512
"2547","a086089357ffc267469570ca038f2434","NCT01631214",0.008,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With New Vertebral Fractures Through Month 12","SECONDARY",NA,"D010024","Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis",FALSE,3399,"logistic_regression",NA,NA,NA,1.73310705050442
"2548","a08664b5876a71927336179b82f77085","NCT02067728",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Perception of Patient Centeredness of Encounter","OTHER_PRE_SPECIFIED",NA,"D009765","Family Nutrition Physical Activity Tool Use During Well Child Visits",TRUE,372,"t-test",NA,NA,NA,2.84021788100067
"2549","a0980eeeaacfe1436193e471a084419a","NCT04047121",0.0421,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"All Cause Total Health Care Cost During 12 Months Post-index Date","SECONDARY",NA,"D001168; D001172","A Study to Evaluate Patient Characteristics and Treatment Patterns Among Rheumatoid Arthritis Patients",FALSE,609,"t-test",NA,NA,NA,3.13839400486868
"2550","a0a9f1d4a2d60686efa3553fb3f34b5c","NCT01445730",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"B48 Plasma AUC","PRIMARY",NA,"D015228; D056128","Fructose Consumption and Metabolic Dysregulation",FALSE,71,"mann_whitney",NA,NA,NA,1.05348219904379
"2551","a0c83fbdf32be9c4cb2e92291c600c63","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Fasting Gluconeogenesis","PRIMARY","Difference in treatment effect between groups was evaluated","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",FALSE,50,"t-test",NA,NA,NA,1.07648023860356
"2552","a0d1809c08f1f667f364fe5101480efc","NCT03192176",0.0433,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 7","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.21190689456284
"2553","a0df77c29a8e11f942f643901666054b","NCT00949884",0.0096,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Participants Achieving Blood Pressure Goals at Week 8","OTHER_PRE_SPECIFIED","Percentage of participants achieving diastolic blood pressure goal of \<80 mmHg","D006973","Olmesartan Comparison to Losartan in Hypertensive Subjects",FALSE,850,"logistic_regression",NA,NA,NA,1.02299787627187
"2554","a0ea48d09d99578dafbf31fc8f2093a6","NCT02900352",0.04,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Level of Alcohol-related Problems","SECONDARY",NA,"D000437; D000428","Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action",FALSE,108,"anova",2,NA,NA,1.28614653164923
"2555","a0ee1846347dbc1e63b4535ba6cdad43","NCT03353415",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Percentage of Time Sensor Glucose Level >180 mg/dL During Period of CGM Wear, Masked Versus Unmasked Phase","SECONDARY",NA,"D007003","Continuous Glucose Monitoring to Reduce Hypoglycemia and Improve Safety After Gastric Surgery",FALSE,44,"mann_whitney",NA,NA,NA,1.01513168983373
"2556","a0f75a9a1e87e059970e0bdd0ed0edcb","NCT00023595",0.01,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"H02: Seattle Angina Questionnaire (SAQ) Anginal Frequency Subscale","SECONDARY",NA,"D006333; D002318; D006331; D003327","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",FALSE,970,"mann_whitney",NA,NA,NA,1.13271769496004
"2557","a10a50e556d77fe67d0d1b51bbda9d01","NCT00918736",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in the Ankle Osteoarthritis Scale (AOS) Score at 6 Months","PRIMARY","Previous report using 5 weekly injections, mean AOS score reduction is 2.6 with the SD of 1.8 in 75 patients. To test whether AOS reduction would be \> 1 using pair t-test after 3 weekly injections, investigators need \> 42 patients to give \> 90% power to reject the null hypothesis-mean AOS score reduction \<1 at 6 months, given that both the mean and standard deviation of AOS score reduction equal to 2. Considering possible dropout of participants, investigators decide to include 50 patients","D010003","Efficacy of 3 Weekly Injections of Hyaluronate in Patients With Ankle Osteoarthritis",TRUE,46,"t-test",NA,NA,NA,1.03597838019194
"2558","a10bb2c5f54dce3dbdf1cde76e33ae33","NCT04761302",0.041,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"24hrs VAS Pain Score","PRIMARY",NA,"D050723; D005264; D013978","Postoperative Pain Management in Patients Undergoing Intramedullary Nail Fixation After Tibia and Femoral Fractures",FALSE,96,"t-test",NA,NA,NA,1.24099903377859
"2559","a10d1bea00b4c16fb0861faa2b943d77","NCT04473222",0.032,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Child Sleep Problems: Bedtime Difficulties","SECONDARY",NA,"D012892","Behavioral Sleep Intervention in Urban Primary Care: Aim 3",FALSE,97,"t-test",NA,NA,NA,1.01188064687256
"2560","a1269dec61d0b2a33f65b636b37a342b","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Environmental Warning Label","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1752,"linear_regression",NA,NA,NA,6.13876469477842
"2561","a15134a64b18b2c148ff3438f1a1c7bb","NCT03625986",0.043,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Cigarettes Per Day","SECONDARY",NA,"D014029","Does Switching to Nicotine Containing Electronic Cigarettes Reduce Health Risk Markers",FALSE,67,"mann_whitney",NA,NA,NA,1.0889434872484
"2562","a15e56f8af282884f8a8471b8cde5314","NCT00261443",0.022,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Adjusted Mean Change in CGI-BP From Preceding Phase (Mania) Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 48 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,1.32128119120301
"2563","a177471c4b8cdb84cc8fd6b13cc8025a","NCT02596126",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Efficacy Endpoints","SECONDARY","Patient satisfaction is measured at visit 1 (6 months) and visit 3 (2 years) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument comprising of four domains: effectiveness (questions 1 to 3), side effects (questions 4 to 8), convenience (questions 9 to 11) and global satisfaction (questions 12 to 14).","D009362; D002318; D009203; D007238","Secondary Prevention of Cardiovascular Disease in the Elderly Trial",TRUE,2466,"t-test",NA,NA,NA,7.28069129722027
"2564","a1818c4adf05d84a65f365658beea48c","NCT00931528",0.0467,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Patients Maintaining Spontaneous (Off-drug) Erectile Function (EF) at Weeks 28-30 After Initiation of Radiation Therapy (RT)","PRIMARY","Logistic regression using generalized estimating equations was performed modeling the probability of non-responders. Only treatment arm (Placebo vs. Tadalafil), age (\> 65 vs. other), RT method (External RT vs. brachytherapy), and significant pretreatment characteristics \[N stage (NX vs. N0)\] were retained in the model. (Dropped pretreatment characteristics: ethnicity, Zubrod, T stage, PSA.) The results for each explanatory variable are reported separately. Age is reported here.","D011471; D007172","Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy",FALSE,141,"logistic_regression",NA,NA,NA,1.66583536614134
"2565","a18661b60bf78d42e56df5e5cd0ef91a","NCT04289623",0.035,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Rate of Enrollment (14 Days)","PRIMARY","We conducted a logistic regression among the never enrolled group with the rank-and-file email as the reference group.",NA,"Assessing the Impact of myHealth Rewards Program-related Communications on Enrollment: Replication",FALSE,12216,"logistic_regression",NA,NA,NA,11.9752892138374
"2566","a186f887be9b6be6cf6a3bd3fade50eb","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Total Urinary Isoflavones","SECONDARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,102,"anova",2,NA,NA,1.50770356720122
"2567","a1b07daa02844f3c80e93dd5a7f67721","NCT03055156",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Sleep Latency Assessed by PSG","PRIMARY",NA,"D012893; D020447","Effect of High Rebound Mattress Toppers on Sleep and Sleep-Related Symptoms",FALSE,413,"t-test",NA,NA,NA,1.36660356395087
"2568","a1b52172f422ae1ce5b8e5b4a85e4bf8","NCT03192176",0.04,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week","SECONDARY","Week 8","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,85,"logistic_regression",NA,NA,NA,1.14705113663484
"2569","a1bf4ad45328e156e79a926c85af63f1","NCT02887183",0.0495,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) and Change in Left Ventricular End Diastolic Volume Index (LVEDVi) by Selected Groups of Interest at Month 6","SECONDARY","Subjects with HFrEF and ""low"" NT-proBNP","D006333","Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.",FALSE,794,"t-test",NA,NA,NA,4.10339060953462
"2570","a1e9695bf9d1228f830c9ab1bb04663a","NCT03748420",0.0103,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Blood Pressure Medication Adherence","PRIMARY",NA,"D006949","Medication Adherence Clinical Decision Support",FALSE,1730,"logistic_regression",NA,NA,NA,1.55070616349361
"2571","a20123fb97f1bda4f8823c3a8419a9bc","NCT02186808",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Success Rate of Bridge Procera Bridge Zirconia","PRIMARY",NA,NA,"T-116_Procera-Bridge Zirconia - A Clinical Study",TRUE,78,"mann_whitney",NA,NA,NA,1.32610986002301
"2572","a209181500a07c4efd29ee9b26ca91e7","NCT02494401",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Change in Quality of Life on the European Quality of Life-5 Dimensions (EQ-5D) Index Scale","SECONDARY",NA,"D012595; D045743; D012598","Taking Charge of Systemic Sclerosis",FALSE,247,"mann_whitney",NA,NA,NA,2.32040326199209
"2573","a21b1d533a14531ca85ddb6d8273ef50","NCT02421315",0.0464,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Brain Gray Matter Thickness","SECONDARY",NA,"D009771","Overlapping Neural Circuits in Pediatric OCD",FALSE,55,"t-test",NA,NA,NA,1.05783422199837
"2574","a21f9a6e6d6347ad2ee12da0330b1fa3","NCT00312195",0.0217,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"The Number of Subjects With Ineffective Treatment During the Double-blind Evaluation Phase.","PRIMARY","H0: the odds of ineffective treatment is the same for subjects receiving placebo as for those receiving BTDS versus the alternative H1: the odds of ineffective treatment is different for subjects receiving placebo from those receiving BTDS.",NA,"Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain",FALSE,266,"logistic_regression",NA,NA,NA,1.18153390539015
"2575","a234c3e2c16a42aca684d46680c5a27c","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Cuff SBP","SECONDARY",NA,"D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"2576","a2357da393959327a04ae1a8215d9e68","NCT00434759",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in Social Phobia Scale (SPS)","PRIMARY",NA,"D010698; D000072861","Social Phobia Intervention Study of Mannheim",TRUE,89,"anova",2,NA,NA,1.41222998379373
"2577","a236c861888b021b04e586d764cf55bc","NCT02939131",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"COMB-R and ESC Acceptability Among Participants","SECONDARY","The average score for all participants at each site was computed. These site-level averages were compared across treatment groups.","D003863; D003866","IMPAACT 2002: Cognitive Behavioral Therapy and Medication Management for Treatment of Depression in US Youth With HIV",FALSE,138,"t-test",NA,NA,NA,1.13433136566805
"2578","a2371b757d3d1b1bb79b20d38a4de83f","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in Fasting Plasma Glucose","PRIMARY","Null hypothesis: There are no difference in the difference of changes in plasma glucose.

Power calculation: The sample size of 55 subjects per group provided about 90% power to detect a significant change in the FG concentration of 8 mg/dL (7%) by using a general assumption of a 2-tailed a level of 0.05 and allowing for a 20% withdrawal rate.","D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,109,"anova",2,NA,NA,1.55669642807029
"2579","a25e8179e493302405da487551a7a388","NCT04591015",0.0493,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient-Reported Outcomes Measurement Information System (PROMIS) Global-10 Health Scale - Mental - Change Between Baseline and 90 Days","SECONDARY",NA,"D000086382; D003920; D003924","Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19",FALSE,109,"t-test",NA,NA,NA,1.5385638927549
"2580","a260634ef2740f9f16dc9334d2385ed9","NCT01138124",0.0095,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin","PRIMARY",NA,"D010190; D002292; D007680; D010386; D010195; D050500; D012148","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",FALSE,19046,"logistic_regression",NA,NA,NA,4.77941922316343
"2581","a2708292ef53a3a98d10c0e132230b4f","NCT00406848",0.036,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Laboratory Values - Chloride and Fasting Glucose","SECONDARY",NA,"D003866; D003865","A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients",FALSE,342,"anova",2,NA,NA,2.06531253266909
"2582","a28ce39942d9cf9561955d3c3b75b06b","NCT05241470",0.0394,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Fluorescein Staining in the Total Eye Sum - Both Eyes Together","POST_HOC",NA,"D015352; D007638; D005128","Study of ST-100 as Treatment for Dry Eye Disease",FALSE,96,"t-test",NA,NA,NA,1.20022290513246
"2583","a2abe7d24710f1397d9c89e9c1232e25","NCT01626118",0.036,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"TOTPAR-48. Total Pain Relief (TOTPAR) Over 0 to 48 Hours","SECONDARY",NA,"D010149","Study of Indomethacin Capsules to Treat Pain Following Bunionectomy",FALSE,188,"t-test",NA,NA,NA,1.53935436816288
"2584","a2ef49cd50bf356a094dc5a301a8a3ca","NCT00040443",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"15-Item Word List Delayed Recall","PRIMARY",NA,"D060825","Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.",TRUE,175,"t-test",NA,NA,NA,1.95940170334017
"2585","a2fa500b97036f8b63d7ad24f86d99a6","NCT05081843",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Tobacco-related Media Literacy","SECONDARY",NA,NA,"Pittsburgh and Rural Area High School Tobacco Prevention",FALSE,174,"t-test",NA,NA,NA,1.95391863793846
"2586","a31871062df1201c4dda907f0e4e149f","NCT02886728",0.015,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 2, 4, 12, 24, 36, and 52","SECONDARY","Filgotinib 100 mg + MTX vs MTX Monotherapy at Week 36","D001168; D001172","Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy",FALSE,623,"logistic_regression",NA,NA,NA,1.30185176581259
"2587","a32e77c485c1b6c5ece2bb17f81c0474","NCT03950167",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Blood Cholecystokinin (CCK) Levels","PRIMARY","Since this is the first study comparing both CCK levels and GB functions in patients diagnosed with hyperemesis gravidarum (HG) and healthy pregnant women, a power analysis was not feasible.","D006939","Gallbladder Functions & Serum Cholecystokinin Levels in Women Diagnosed With Hyperemesis Gravidarum",FALSE,46,"t-test",NA,NA,NA,1.03597838019194
"2588","a32f3f8c85972933536d7e735add1f01","NCT00252538",0.05,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"Phenotype and Genotype Based on Presence of Interferon Induced MDD.","PRIMARY","All statistics employed Statistical Package for Social Science (SPSS) 17.0. Analysis of variances were used to compare viral responses in genotypes of interest, employing Scheffe's post-hoc analyses. Repeated-measure mixed-effect analyses were used to compare changes in subjective symptoms over time, including age, gender, and self identified race as covariates. Kaplan-Meier survival analyses examining time until MDD development were compared using theMantel-Cox log rank test.","D003863; D003866","Genetic and Biochemical Markers of Interferon-Induced Depression.",FALSE,133,"anova",2,NA,NA,1.7140975432625
"2589","a333a95198477070fe52e1e3dcc7470a","NCT01340027",0.04,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Improvement in PPBC","SECONDARY","All statistical comparisons are for End of Treatment using 2-sided tests at the 0.05 significance level. No adjustment for multiple testing was performed.

The logistic regression model includes the 2 main factors mirabegron dose and solifenacin dose and their interaction, sex, age group and geographic region as fixed factors and baseline measurement as a covariate.","D053201; D014570; D001745; D020924","A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder",FALSE,220,"logistic_regression",NA,NA,NA,1.81749209412144
"2590","a33c2f4abee15064318ab1acc6691806","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient-Reported Outcomes Measurement Information System (PROMIS Short Forms 8a - Pediatrics v. 2.0) is a Set of Person-centered Measures That Evaluates and Monitors Physical, Mental, and Social Health in Children and Adolescents.","SECONDARY","We hypothesized that adolescents randomized to the intervention compared to controls would report less Pain Interference at 3 months post baseline.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,126,"t-test",NA,NA,NA,1.66971913113983
"2591","a340bcfc5da5becb47255dab2dc28d4a","NCT00407745",0.0256,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With >=50% Reduction in Weekly Mean Pain Score From Baseline","SECONDARY","Null hypothesis - The rate of responder for the pregabain group was equal to the rate of responder for the placebo group; Alternative hypothesis - The rate of responder for the pregabain group was not equal to the rate of responder for the placebo group.","D013119; D009437; D014947","A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury",FALSE,210,"logistic_regression",NA,NA,NA,1.21409651608367
"2592","a35b517d47a9bba26d8a3e08ce2c9578","NCT01362244",0.037,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Endoscopic Nasal Polyp (ENP) Score Dynamics at Weeks 1, 2, 5, 9, 13, 17, 21, and 25","SECONDARY",NA,"D009298","Mepolizumab in Nasal Polyposis",FALSE,100,"logistic_regression",NA,NA,NA,1.16082537706836
"2593","a35ce1401ae4d3471755b593f194e41d","NCT02504671",0.044,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Achieving Categorical DAS28(CRP) Response (Moderate/Good [European League Against Rheumatism] EULAR Response) at All Assessment Time Points","SECONDARY",NA,"D001168; D001172","Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis",FALSE,74,"logistic_regression",NA,NA,NA,1.16318373930117
"2594","a35ec6cd2019039eb06c6a8354c3d44d","NCT02670538",0.0417,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score","SECONDARY",NA,"D003863; D001714","Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder",FALSE,325,"t-test",NA,NA,NA,2.28102173941344
"2595","a3895f444576416f4c1bfd89ec8e5686","NCT01219959",0.03,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline of Metabolic Control Determined by Lipoproteins at Month 3 and 6","SECONDARY","Estimate of Least Square Means Comparing Treatment Groups for Apo B-Month 6","D007676","Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients",FALSE,239,"anova",2,NA,NA,1.4820669901068
"2596","a39d38d7bfdd1a4badb0105ee2549469","NCT02022462",0.049,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Changed Score on Self Management Motivation","SECONDARY","Baseline to 6 months between-group comparisons of the mean change.","D012559; D001523","Project Bridge: Peer Health Navigator Intervention",FALSE,123,"t-test",NA,NA,NA,1.62282598686827
"2597","a39f09a5a3ddee60e1989fbb70586606","NCT00741286",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study","PRIMARY","To determine between-group differences of changes in the PIs at 14 and 90 days from the baseline study.","D002544; D059409; D007238","Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler",TRUE,164,"t-test",NA,NA,NA,1.8982180321277
"2598","a3af267688f813b41315e477d4ef6f41","NCT00190684",0.032,"One-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to 5 Year Endpoint in Weight, Height, and Body Mass Index (BMI) Percentile Stratified by Baseline Quartile","PRIMARY","Tested was the null hypothesis that there would be no statistically significant difference between baseline and endpoint.","D006948; D001289","Long-Term, Open Label Atomoxetine Study",FALSE,251,"t-test",NA,NA,NA,1.60422113786125
"2599","a3b0986c1153f058282bc7f96e214633","NCT00320489",0.02,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Number of Hospitalization Days","SECONDARY",NA,"D012559","Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia",FALSE,524,"anova",2,NA,NA,1.53720010503454
"2600","a3b62551e3ac1972eb0531cfae8198e8","NCT03050918",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Patient Satisfaction: Likelihood to Recommend the Facility","SECONDARY",NA,NA,"Discharge Follow-up Phone Call Program",FALSE,474,"mann_whitney",NA,NA,NA,3.20248292259743
"2601","a3ce2095f44dceda42510d75db16a136","NCT01316419",0.0152,"One-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Environment Domain","SECONDARY",NA,"D006973","Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension",FALSE,1490,"t-test",NA,NA,NA,2.0312974926495
"2602","a3fc6f9a4eba960f8ba416c1a798de96","NCT02460562",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Saliva Fluoride Concentration (Part Per Million,Ppm)","PRIMARY","Mean saliva fluoride concentration (part per million) collected at different time points was compared in order to assess the change in capacity for fluoride release and recharge from the resin denture base and to assess differences between the control and the intervention group.","D003731","Caries Prevention Effect of S-PRG Filler Incorporated in Denture Base Resins on Edentulous Elderly People",TRUE,150,"anova",2,NA,NA,1.8173749039831
"2603","a4150b4474772f866c8d8e002352f83e","NCT03141307",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Residual Decisional Regret","SECONDARY",NA,NA,"The Effect of Electronic Informed Consent Information (EICI) on Residual Newborn Specimen Research",TRUE,532,"t-test",NA,NA,NA,3.39126404984637
"2604","a4293078003cbed627003af3255a4de3","NCT00777608",0.041,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Evaluate the Efficacy of Donepezil by Determining the Change in Mean CogState Composite Score at Week 2, Week 8 and Week 12","SECONDARY",NA,"D000544","A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)",FALSE,81,"anova",2,NA,NA,1.14453106326353
"2605","a4486aa9735dad5959bbf65c9f7a4b82","NCT01272921",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Duration of Motor and Sensory Block of the Sciatic With 0.5% Bupivacaine and Ropivacaine After Ultrasound-guided Nerve-stimulator-Assisted Needle Positioning Beneath the CIEL","PRIMARY","The sample selected for this study,70 per drug group (or 10 in each of the 7 groups), achieves 88% power to detect a minimal difference of 4 hours in duration at a significance level (α) of 0.05 and a standard deviation of 3 hours using Williams test. We chose a difference of 4 hours as this was the interval used for assessment in the postoperative period at night. We sought to detect a difference that was equal to 1 observation period difference.",NA,"The Use of Bupivacaine and Ropivacaine for Sciatic Nerve Block",FALSE,70,"mann_whitney",NA,NA,NA,1.2598053214673
"2606","a4548d1e8aa310a98cbf2bd639a3387a","NCT02323204",0.0201,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Conduct Problems (SDQ Subscale) Through the First and Last Survey Administered Post-Baseline","PRIMARY","A Generalized Linear Mixed Model (GLMM) with log link and gamma distribution was fit to five imputed data sets. Obtained estimates and standard errors were adjusted accordingly.

A comparison of intervention efficacy was made through the intervention-time interaction effect included in the model. Statistical significance of the interaction effect is indicative of a difference in effect between interventions over time.","D014947; D000067073","PCORI-1306-02918 Evaluation of Parent-based Programs to Support Children After Traumatic Injury",FALSE,253,"t-test",NA,NA,NA,1.07872393474561
"2607","a457b0b74488ff4b428397b38a38fbcc","NCT04332614",0.0133,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Email Opened: Control vs. Less-is-better vs. Social Proof vs. Endowment","PRIMARY",NA,NA,"Email Campaign to Increase Uptake of myGeisinger",FALSE,4232,"logistic_regression",NA,NA,NA,3.0390904722902
"2608","a464fc9e11c4af80aa1ed1b3a2176cab","NCT01335932",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"CMV AUC in Throat","SECONDARY",NA,"D012128; D012127; D012131; D055371; D055370; D014947","Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure",FALSE,156,"t-test",NA,NA,NA,1.20367065317116
"2609","a4699c7830c06a42246176aa29ad5dbb","NCT00105989",0.022,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Acute and Continuation Phases (Females)","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,286,"t-test",NA,NA,NA,1.23896251788341
"2610","a4752041dc6488b13b258df0ade24d0e","NCT04381481",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Percent of Participants Who Selected Apple-flavored Fruit Drink (Fruit Drink Experimental Task 1)","SECONDARY","beverages with claim compared to control beverage","D063766","Studying the Impact of Product Packaging in a Virtual Store Environment",TRUE,2219,"logistic_regression",NA,NA,NA,1.70993042143803
"2611","a47c2fb99ac456eb4b39ea95d8103ae9","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Ambulatory Daytime Brachial Rate-pressure Product","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"2612","a4939936fd2d3a62fafcbd637730c35a","NCT02044874",0.0379,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"The 7 Day Point Prevalence or Weekly Abstinence at Week 8","SECONDARY",NA,NA,"A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation",FALSE,391,"logistic_regression",NA,NA,NA,2.30507317293435
"2613","a4984d8051e0a4161d9b74ffd33733c4","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Pizza Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1741,"linear_regression",NA,NA,NA,6.11950550223942
"2614","a49cc846522019fff79fa4d6bd9791a1","NCT02528253",0.0178,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Low Back Pain From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/ Last Observation CF (LOCF)","SECONDARY","Week 40: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline PGA of low back pain, baseline average LBPI, and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1010,"logistic_regression",NA,NA,NA,1.92277527077459
"2615","a49d2bf252a6f84f8c948f899862f12f","NCT01955382",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Parasite Clearance Half-life","PRIMARY",NA,"D008288","Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria",FALSE,70,"mann_whitney",NA,NA,NA,1.2598053214673
"2616","a4c70cf5e7a5cb2618fa469b10f26fd7","NCT00474175",0.044,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Pain Relief Combined With Pain Intensity Difference (PRID) Scores","SECONDARY","20 minutes: P-value was calculated using ANOVA which was adjusted for treatment, site and baseline DPS. Treatment difference (Benzocaine 20% - Placebo) and corresponding 95% C.I. were calculated based on least-squares means from the ANOVA model with treatment, site, and baseline DPS effects.","D014098","Benzocaine Gel Toothache Dose-Response Study",FALSE,343,"anova",2,NA,NA,2.45100386008604
"2617","a4cc0b4446dd69877d5e122093116fdc","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient-Reported Outcomes Measurement Information System (PROMIS Short Forms 8a - Pediatrics v. 2.0) is a Set of Person-centered Measures That Evaluates and Monitors Physical, Mental, and Social Health in Children and Adolescents.","SECONDARY","We hypothesized that adolescents randomized to the intervention arm would report less Fatigue at 3 months outcome compared to controls.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,126,"t-test",NA,NA,NA,1.66971913113983
"2618","a4d0b2e4e3f0cb4eb4a9e30da688aa2a","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in HbA1C","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,110,"anova",2,NA,NA,1.56357043896758
"2619","a4d36a45b60167496f8bf559e42f554c","NCT00482170",0.028,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Assessment of Fear of Device Based on Response to Question Concerning Nervousness About Injections","SECONDARY","Last observation: Logistic regression was used to analyze individual concepts and questions measuring participant perception.","D011565","Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept",FALSE,417,"logistic_regression",NA,NA,NA,1.83730247564418
"2620","a4e3e414ceda89b27293758cb3a9dbdd","NCT05074251",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Partner HIV Testing","PRIMARY",NA,"D006679","Evaluation of Secondary Distribution of HIV Self-screening Tests by Women With HIV",TRUE,91,"logistic_regression",NA,NA,NA,1.42733241699876
"2621","a51d73a16ae510c778686b41f062392c","NCT02373813",0.032,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in DAS28-ESR at All Measured Timepoints","SECONDARY","Change at Week 12","D001168; D001172","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",FALSE,152,"t-test",NA,NA,NA,1.25585729060319
"2622","a521d7c3ff9908bf702786a93a5a53e2","NCT00245219",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Depressive Symptoms (as Measured With the CES-D) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the peer support condition and the control condition at Time 2. The full regression model included 2 dummy coded variables, 1 contrasting the education and control condition, and 1 contrasting the peer support and control condition. The baseline measure of the outcome variable was included, in order to examine changes in the outcomes over time. This model tested the main effects of the conditions among patients with early stage cancer, late stage patients were excluded.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"logistic_regression",NA,NA,NA,1.79957957739554
"2623","a52611a6cd0ce0121e2fad3ae3961481","NCT02389816",0.0341,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"MADRS Response at Week 8 (Last Observation Carried Forward (LOCF))","SECONDARY",NA,"D003866; D003863; D003865","A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder",FALSE,329,"logistic_regression",NA,NA,NA,1.93481283353214
"2624","a5283d9f773b5f2a15484d270d282a24","NCT02276807",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in Sleep Disturbances at 12 Weeks","SECONDARY",NA,"D003863; D003866","Improving Mood in Veterans in Primary Care",TRUE,116,"anova",2,NA,NA,1.60419760559468
"2625","a532ceed5d50363c272ceffca2ed5852","NCT00581009",0.05,"ANOVA","INTERVENTIONAL",0,1,1,0,0,"Total Score on the Hamilton Rating Score for Depression (HRSD) - 21 Item Version","PRIMARY",NA,"D012892; D003866; D003865; D001714","The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients",TRUE,49,"anova",2,NA,NA,1.06649684228356
"2626","a53453cb05b52310d145398345e7b980","NCT00650845",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Percent Change of Serum Creatinine Level Variation From Baseline to 72±24 Hours After Examination, in the Per Protocol Population","SECONDARY","Serum creatinine level fluctuation in terms of difference between baseline and 72 ±24hours after imaging procedure values was computed for both MRI procedures and compared between the 2 groups. A linear regression model was used to model the serum creatinine changes from baseline as a function of the MRI procedure with adjustment on centers.","D051437","Renal Safety Evaluation After Dotarem®-Enhanced MRI",FALSE,67,"t-test",NA,NA,NA,1.02519287579014
"2627","a534d6db355adabf5c9442afc63c730d","NCT01028014",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG","PRIMARY","Using difference in EMG amplitude as primary outcome, assuming standard deviation of 6, we had greater than 80% power to detect a 10-microvolt change in urethral muscle activity with sample size of 9 participants per group. Due to non-normality and small sample sizes, non-parametric tests were used and data presented as median (IQR). Kruskal-Wallis p-values are reported to compare median scores across groups. Wilcoxon sign-test p-values are reported to evaluate 2-week change within groups.",NA,"Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters",FALSE,48,"mann_whitney",NA,NA,NA,1.05642048349345
"2628","a537079305d53be0f2c1ff9a381fe170","NCT01236053",0.0464,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,179.967108601531
"2629","a55a782e5015f4ad5abfd9bfd3a76ee7","NCT00847587",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Crematocrit of Human Milk","SECONDARY",NA,NA,"Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant",TRUE,43,"t-test",NA,NA,NA,1.00454908915455
"2630","a5665d5c7e5861f2bff39e1542f39f88","NCT00048061",0.045,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Relative Change From Baseline at One Year (12 Months) in Mean Lumbar Spine (L2 - L4) Bone Mineral Density","PRIMARY",NA,"D010024; D015663","MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis",FALSE,636,"anova",2,NA,NA,3.39206484207404
"2631","a56da81a7d8229bd502ee951432627ac","NCT03523273",0.033,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change in Weight at 16 Weeks","SECONDARY",NA,"D009765; D015431","Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity",FALSE,136,"mann_whitney",NA,NA,NA,1.2215863326398
"2632","a5745a1e2e891e3445065c990314bc20","NCT02516202",0.05,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Vaginal Symptoms Index","SECONDARY",NA,"D004414","The Vaginal Health Trial",FALSE,198,"linear_regression",NA,NA,NA,2.08153324376651
"2633","a5750a7d14f102466cc51d77700b3600","NCT02886728",0.018,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved ACR 70% Improvement (ACR70) at Weeks 2, 4, 12, 24, 36, and 52","SECONDARY","Filgotinib 200 mg + MTX vs MTX Monotherapy at Week 2","D001168; D001172","Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy",FALSE,832,"logistic_regression",NA,NA,NA,1.76333116887818
"2634","a59b0091e10be7ea171e2be4f4431b78","NCT01256944",0.05,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"Fasting Insulin","PRIMARY",NA,"D011085; D002318; D024821; D013577","To Study Polycystic Ovary Syndrome in Taiwanese Women",TRUE,290,"anova",2,NA,NA,2.51138465397077
"2635","a59b5befa635d959746f473456373ede","NCT01766076",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Percentage Change in Immune Activation Levels After 12 Weeks of Atorvastatin 80mg Daily","PRIMARY",NA,"D000163; D015658; D007153","Atorvastatin for HAART Suboptimal Responders",TRUE,60,"mann_whitney",NA,NA,NA,1.17169922891753
"2636","a5bd623cd70e933f8859d3d0e77b92be","NCT00105989",0.031,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Platelet Count - Acute Phase","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,422,"t-test",NA,NA,NA,2.01684481953562
"2637","a5bee94a7f24e99bcbf6de6c52b206db","NCT00885079",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change in Lissamine Green Conjunctival Staining (LGCS) Score From Baseline","PRIMARY",NA,"D015352; D007638","Confirmatory Study of OPC-12759 Ophthalmic Suspension",TRUE,188,"t-test",NA,NA,NA,2.02933512924615
"2638","a5c42addcad57153900091c040f93405","NCT00651625",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Physician Satisfaction","SECONDARY","group comparisons using t-test and confidence intervals.","D016606","Reciprocating Medical Devices - a Study of a New Safety Device",FALSE,437,"t-test",NA,NA,NA,3.07600737430638
"2639","a5c895dfe39d3ec555a47bc7b6998e62","NCT04642820",0.05,"Two-sample t-test","INTERVENTIONAL",1,0,0,0,0,"Change in SUbjective Effects as Assessed by Score on ""Feel Drug"", ""Feel High"", ""Like Drug"", and ""Want More"" Sub-scales of Drug Effects Questionnaire (DEQ).","PRIMARY",NA,NA,"Drugs Brain and Behavior (DDP)",FALSE,226,"t-test",NA,NA,NA,2.22117623685084
"2640","a5d158598748cf650d0a7824c644cfb4","NCT00662363",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Patient Assessment of Constipation (PAC) - Symptoms (Sym)","PRIMARY","Primary outcome measures chosen were between group comparisons for change on Constipation Symptom Questionnaire ratings at exit from the study. The PAC-SYM is a symptom scale where higher numbers indicate more symptoms. Change from baseline to Day 7 was calculated and larger negative differences indicated greater improvement in constipation symptoms. The PAC-QOL is a quality of life scale where higher numbers indicate better quality of life. Change from baseline to 7 days was calculated.","D003248; D000079689","Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation",TRUE,56,"t-test",NA,NA,NA,1.13456029943022
"2641","a5e56c8d7908f6df9abc45eb34b3bc20","NCT03114969",0.024,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants Making at Least One Overall Error at Visit 2-Dual Device Comparisons (Relvar Ellipta With or Without a LAMA DPI) Versus Any Other ICS/LABA DPI With or Without a LAMA DPI)","SECONDARY",NA,"D008171; D029424","Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs",FALSE,196,"logistic_regression",NA,NA,NA,1.11041922893997
"2642","a5e9af62980d2c4db360a3d4f506711a","NCT00261443",0.034,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Baseline and Adjusted Mean Change From Baseline in CGI-BP Severity of Illness (Depression) Score Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 32 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,1.92127768105927
"2643","a5fc7e5547496093872357fa10504ba8","NCT00539240",0.04,"Linear regression","INTERVENTIONAL",0,0,1,1,0,"Daytime Heartburn, Number of Days in Week Symptoms Intensity Score < 3 (Better)","PRIMARY",NA,"D005764","Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI",FALSE,101,"linear_regression",NA,NA,NA,1.24545208094669
"2644","a641c7bfddb14729578f0680b26f7a23","NCT03676465",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Child Self Management Score","SECONDARY",NA,"D003920; D003922; D002908","CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management",FALSE,43,"mann_whitney",NA,NA,NA,1.00454908915455
"2645","a6448e8d15758da4313062341e7610ee","NCT01621009",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"7-day Point Prevalence Abstinence From Smoking at 6 Months","PRIMARY",NA,"D014029","Bupropion SR Plus Counseling for Smoking Cessation",FALSE,229,"logistic_regression",NA,NA,NA,2.23562103193216
"2646","a648e792289c135dbe5899d0acc28153","NCT03192176",0.0473,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 11","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.30444903780792
"2647","a66376435f9910e3f2eaa4ddcfdbecad","NCT02912650",0.041,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Intensity Difference on 4-Point Categorical Scale (PID4)","OTHER_PRE_SPECIFIED","7 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,347,"anova",2,NA,NA,2.32256518219652
"2648","a66db061df67236247eea19b341124a1","NCT00591578",0.018,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response.","SECONDARY",NA,"D006973; D000075222","Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension",FALSE,645,"logistic_regression",NA,NA,NA,1.55408771874016
"2649","a675344d33dc1cf39bd85420d995f9ed","NCT02091284",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Craving","PRIMARY","Additional comparisons between initial and final OCDS scores were done by paired t tests for each group, and differences between final and initial scores were compared between sham-tDCS and tDCS groups with unpaired t tests.","D000437; D019966","Bilateral Prefrontal Modulation in Alcoholism",TRUE,45,"t-test",NA,NA,NA,1.02560707988412
"2650","a686ade7e65ef5162dec7dd69120e91a","NCT02306122",0.01,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Duration of Nonadherence Event","PRIMARY",NA,"D006937","Pharmacy Home Adherence Reporting and Monitoring Outcomes Study",TRUE,956,"linear_regression",NA,NA,NA,1.12457005606209
"2651","a68789715bc8c47da6fd9fd8011d0933","NCT02617446",0.042,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change in E/A Ratio","SECONDARY","Null hypothesis: No difference in E to A ratio between istaroxime and placebo participants.","D006333","The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure",FALSE,60,"anova",2,NA,NA,1.01412910280044
"2652","a69b0ce2a8c093198d86c58d3e93ce69","NCT03192176",0.0443,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 12","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.23521248192884
"2653","a6a213056f0fcb82b6626475e62dc1c8","NCT02249143",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Measurements of Passive Respiratory Compliance in Randomized Premature Infants","SECONDARY",NA,"D012128; D012127; D001997","Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants",FALSE,44,"t-test",NA,NA,NA,1.01513168983373
"2654","a6a8927b50cdfb87a3a2b0ccaef2fd10","NCT04697264",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Correlation Between the Markers and Study Patients' Obesity Status","PRIMARY","The impact of BMI on biomarker levels was assessed by categorising the population into two groups-normal weight and overweight/obese-for straightforward comparison.

Here, we present the associations between adiponectin and the BMI of the study population at baseline.","D016889; D009765","Adipocytokines in Endometrial Cancer",FALSE,50,"linear_regression",NA,NA,NA,1.07648023860356
"2655","a6c305023cb822f0b7db0f55e37fd081","NCT01070550",0.0262,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for ALT ratio at BL (\> 1 - 3 vs \> 3). The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,2981,"logistic_regression",NA,NA,NA,4.61564005470466
"2656","a6ea507796cf4143857f5a0e4796eb74","NCT01881373",0.02,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Waist Circumference","PRIMARY","The children from each community recruited each time were NOT the same children. The number of communities is consistent across time.","D000052; D009765; D056128","Children's Healthy Living Community Randomized Trial",FALSE,5645,"linear_regression",NA,NA,NA,5.02183234305821
"2657","a6eae21723a36ea1631644b9665dd330","NCT00600704",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mean Number of Packed Red Cells Units Transfused During Hospital Stay","PRIMARY","Null hypothesis :restrictive fluid protocol does not have any effect concerning the mean number of PRC units transfused.","D003324","Impact of Fluid Restriction Policy in Reducing the Use of Red Cells in Cardiac Surgery",TRUE,192,"linear_regression",NA,NA,NA,2.0503737111932
"2658","a6f4e8f1850d18aa603b8e20989ff5ed","NCT01874431",0.048,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline to Day 90 in eGFR","SECONDARY",NA,"D007674; D003928; D003920; D003924","Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy",FALSE,202,"t-test",NA,NA,NA,2.03159069792011
"2659","a6f71edde50b0a09f6afc27c4942a77b","NCT03710486",0.0215,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Infections, Serious Infections and Malignancies","SECONDARY",NA,"D003092; D003424; D003093; D014456","A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants",FALSE,199,"logistic_regression",NA,NA,NA,1.01717870626388
"2660","a6fd8bd64149eb6fe5cbeac7192e1132","NCT00536471",0.043,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Chloride, Urea Nitrogen, Cholesterol, Sodium","SECONDARY",NA,"D003866; D003863; D003865","A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients",FALSE,250,"anova",2,NA,NA,2.05694155901261
"2661","a71498410927158a25d42a2692dff114","NCT00666978",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Number of Participants for Each CYP2B6 Allele","SECONDARY",NA,"D008175; D010190; D013274; D002583; D001749; D004938; D008113; D014029","Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking",TRUE,268,"linear_regression",NA,NA,NA,2.41555960484265
"2662","a72241c1204c7b386db2d5b719b79d0f","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Pizza Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1747,"linear_regression",NA,NA,NA,6.1300180173027
"2663","a72d2f531da11eb873277784d0b854c2","NCT00783198",0.0472,"ANOVA","INTERVENTIONAL",0,0,1,1,0,"Average Rhinoconjunctivitis DSS for the Peak RS","SECONDARY",NA,"D012220; D001249; D065631; D003231","Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)",FALSE,314,"anova",2,NA,NA,2.48891077740526
"2664","a733a3db0fa23faa35e72fe2afe3a144","NCT00571064",0.0431,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in NPI-8 Total Score by Visit","SECONDARY","Week 12 LOCF (Study Endpoint)","D000544","The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility",FALSE,93,"t-test",NA,NA,NA,1.27450662941382
"2665","a750031b063ac17f4dc7c511e69c00bc","NCT04229992",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Comparisons of the Changes of Genera Prevotella by Mg Treatment vs. Placebo in Rectal Mucosa, Swab and Stool Samples","PRIMARY","1. GG genotype and magnesium treatment vs GG genotype and placebo;
2. GA/AA genotype and magnesium treatment vs GA/AA genotype and Placebo.","D007249","Calcium: Magnesium Balance, Microbiota, and Necroptosis and Inflammation",TRUE,229,"linear_regression",NA,NA,NA,2.23562103193216
"2666","a76544afb46f62762814cc7100949b24","NCT03573830",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Projected Intent to Learn","SECONDARY",NA,"D014947","Randomized Control Trial of Booster Seat Education Material to Increase Perceived Benefit Among Parents",FALSE,720,"t-test",NA,NA,NA,2.55550491978796
"2667","a766c591820c4cadccf92aae90eb9907","NCT01197508",0.042,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 12, Week 14, and End of Treatment (Week 16)","SECONDARY","Logistic regression model including treatment and pooled center as fixed effects and the randomization MADRS total score as a covariate.","D003866; D003863; D003865","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.",FALSE,336,"logistic_regression",NA,NA,NA,2.33288817244348
"2668","a7792cb85dedfd5352e4a2e5f64732ef","NCT00510146",0.044,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in ECG (Open-Label Phase)","SECONDARY",NA,"D001714","Olanzapine Treatment of Patients With Bipolar I Disorder",FALSE,366,"t-test",NA,NA,NA,2.53090644762016
"2669","a796e0b5937c1e6b0d7f6bf78858c5b9","NCT01891396",0.0289,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score Comparing Cingal® to Monovisc® (ITT)","SECONDARY",NA,"D010003; D020370","Cingal Study for Knee Osteoarthritis",FALSE,299,"anova",2,NA,NA,1.60227442856898
"2670","a7ae5bf50efa366dff0d71f24077a176","NCT02527148",0.0342,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Knee Pain","SECONDARY","To compare VAS mobilisation at 6 months between both groups.",NA,"A Trial of Mechanical Axis vs Kinematic Alignment in Total Knee Replacement",FALSE,99,"t-test",NA,NA,NA,1.08098331025961
"2671","a7c3e25524addb3180082a97550e924b","NCT02045862",0.019,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Were Double Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 1 Point Improvement on PPBC) at Months 1, 3, 6, 9, 12 and EoT","SECONDARY","Odds ratio was from a logistic regression model including treatment group, sex, age group (\< 65, ≥ 65 years), previous study history and geographic region as factors and baseline mean number of incontinence episodes per 24 hours and baseline PPBC as covariates.","D053201; D014570; D001745","A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",FALSE,1492,"logistic_regression",NA,NA,NA,2.4719870336665
"2672","a813701b9015529aad27b40a9a190aa4","NCT00689793",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Hemoglobin Variation Before and After Treatment vs Placebo","SECONDARY",NA,"D018798; D000090463; D005221","Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors",TRUE,145,"linear_regression",NA,NA,NA,1.7876177554477
"2673","a817dd6259088dc2825174b277dcdd72","NCT01218243",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change of Bladder Residual Urine at the 6th Week","SECONDARY",NA,"D011470; D006965","An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia",FALSE,100,"mann_whitney",NA,NA,NA,1.49341131573029
"2674","a82d4b76a98099ac7b90aeb2a5a01f5b","NCT00051363",0.0236,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Subjective Sleepiness/Alertness: Epworth Sleepiness Scale- Total Score (ESS-TS)","SECONDARY","Comparison of means (regression estimates) between arms for 2M Subjective Sleepiness/Alertness- ESS-TS.","D001049; D012891; D008171","Apnea Positive Pressure Long-Term Efficacy Study",FALSE,1098,"linear_regression",NA,NA,NA,2.56269732177405
"2675","a8838edc00a0ab859832620975563e2b","NCT01575197",0.038,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"IgA Geometric Mean Titers (GMTs): 6 & 10 Week vs. 6, 10, & 14 Week Vaccination Schedules","SECONDARY",NA,"D005759","Evaluation of the Human Rotavirus Vaccine at Varying Schedules and Doses in Rural Ghana",FALSE,285,"t-test",NA,NA,NA,1.97641812011225
"2676","a89b422ecb4e45d837aad536029731fb","NCT00408876",0.024,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Interference (BPI-I) Score - Enjoyment of Life","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,220,"t-test",NA,NA,NA,1.1747745655454
"2677","a8aa54af11d5663abfac941ca522a295","NCT02609828",0.0254,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Cumulative Reduction of >=30, 50, 70 and 90 Percent (%) From Baseline in Daily Average Pain Intensity NRS Score in the Index Bone Metastasis Cancer Pain Site at Weeks 1, 2, 4, 6, 8, 12, 16 and 24","SECONDARY","Week 4 Reduction \>=50%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","D009362; D001859; D001855; D000072716","Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy",FALSE,144,"logistic_regression",NA,NA,NA,1.00406017933725
"2678","a8aefa5bbef72955232f6f291e292671","NCT02455388",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in d13C: delta13C Added Sugar Biomarker","SECONDARY",NA,NA,"d13C Added Sugar Intake Biomarker: Determining Validity in Children",TRUE,64,"anova",2,NA,NA,1.20770700959599
"2679","a8da9b35dbb2657bcd12c3f31ab4878d","NCT01236053",0.0494,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,20382,"logistic_regression",NA,NA,NA,20.7064282504471
"2680","a8dfc7fc7b2fa66f30a11f840daa1685","NCT05081843",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Changes in Attitudes Toward Tobacco Products","SECONDARY",NA,NA,"Pittsburgh and Rural Area High School Tobacco Prevention",FALSE,171,"t-test",NA,NA,NA,1.93737643288737
"2681","a8ebc1ae33ca72b900d4d87c702b5206","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Environmental Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1755,"linear_regression",NA,NA,NA,6.14400672442735
"2682","a8ef49c23e5694931d40f778f67bc0db","NCT03975790",0.0435,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Total All Cause Monthly Health Care Cost","SECONDARY","2 months before index date","D001168; D001172","Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX",FALSE,385,"t-test",NA,NA,NA,2.57019744741926
"2683","a8fb1c6660f0a2ff5a360c4922042bcc","NCT00927368",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Time Weighted Average Verbal Response Scale Pain Score","PRIMARY","The primary analysis for pain was a linear regression model comparing stimulating catheter to stimulating needle on the mean time-weighted average pain score for a patient in the first 48 hours.",NA,"Comparison of 3 Techniques for Ultrasound-guided Femoral Nerve Catheter Insertion",FALSE,290,"t-test",NA,NA,NA,1.629729104484
"2684","a910fa3e241110be349c37af51b20acd","NCT02528253",0.0304,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Low Back Pain From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/ Last Observation CF (LOCF)","SECONDARY","Week 32: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline PGA of low back pain, baseline average LBPI, and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1010,"logistic_regression",NA,NA,NA,3.05845057772152
"2685","a927f67d0102d0ac6ab1952ce5da8639","NCT02900378",0.0143,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Total Weekly Time Spent in Light Non-sedentary Daytime Physical Activity","SECONDARY","Change from BL at Week 2","D006333","randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure",FALSE,604,"mann_whitney",NA,NA,NA,1.22923500988956
"2686","a9364d8ebb1f87a6a796ecad1a6e0785","NCT03975790",0.0336,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Total RA Related Monthly Health Care Cost","SECONDARY","1 month after index date","D001168; D001172","Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX",FALSE,431,"t-test",NA,NA,NA,2.18326214259391
"2687","a9554d597c96a8226d3d2ba21724b488","NCT00630812",0.042,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Sputum Weight at Baseline in Response to First Dose of Treatment","SECONDARY",NA,"D003550; D005355","Long Term Administration of Inhaled Mannitol in Cystic Fibrosis",FALSE,294,"mann_whitney",NA,NA,NA,2.18413625806396
"2688","a957915db4961f6d912e6aba612624e2","NCT03781167",0.0304,"One-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score: Change From Baseline to End of Study","SECONDARY","Week 4 vs Baseline","D010300","A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)",FALSE,131,"t-test",NA,NA,NA,1.11876091634786
"2689","a95ee5214851e3515fd1400895fac1cc","NCT02078713",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Patient Decisional Conflict in Contraceptive Choice","SECONDARY","Comparison of uncertainty subscale of DCS",NA,"Patient-Centered Support for Contraceptive Decision-Making",FALSE,749,"logistic_regression",NA,NA,NA,2.60613189144527
"2690","a96723350197ff4f55e1c922cd88e093","NCT03713619",0.0418,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)","PRIMARY","Logistic regression analysis of HiSCR50 response at Week 16 (multiple imputation)","D017497; D016575","This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).",FALSE,360,"logistic_regression",NA,NA,NA,2.40407336389793
"2691","a96a3cbbc61617156effcbea8a8cbdfc","NCT02672176",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Diabetes Self-Efficacy Measured Using the Diabetes Empowerment Scale Short Form (DES-SF)","PRIMARY",NA,"D003920","Improving Health in Diabetes Project",FALSE,285,"mann_whitney",NA,NA,NA,2.48992995915375
"2692","a98289336a251804d5355fa92548a963","NCT01543685",0.029,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"TOTPAR-48. Total Pain Relief (TOTPAR) Over 0 to 48 Hours","SECONDARY",NA,"D010149","Study of Indomethacin Capsules to Treat Pain Following Bunionectomy",FALSE,187,"t-test",NA,NA,NA,1.27697656961933
"2693","a996a858da587691141cddeb0e73805b","NCT01217892",0.0455,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of Participants With HbA1c<7.0% at Week 16, in Participants Who Had HbA1c ≥7.0% at Baseline.","SECONDARY","H0: proportion(treat) minus proportion(placebo) = 0 versus the alternative HA: proportion(treat) minus proportion(placebo) =/= 0","D003924","Evaluation of Dapagliflozin Taken Twice-daily",FALSE,176,"logistic_regression",NA,NA,NA,1.81593552165491
"2694","a9b3c981fa80b6dfb28aac8a3106efc1","NCT03721952",0.029,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Healthcare Utilization: Hospital Readmission - Patient","SECONDARY","Superior outcome for Group2 (Patient-Intervention)","D009369; D009362; D008175; D008103; D008171; D029424; D001930; D002561; D051437; D007676; D006333; D002908; D009102","Facilitating Communication Study",FALSE,157,"linear_regression",NA,NA,NA,1.17292388208069
"2695","a9b4c3951fc9c4dd13887e6cd61be131","NCT00913458",0.0286,"One-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52 and Final on Therapy","SECONDARY","Significance tests were based on paired t-tests using a 2-sided α=0.05.

Final on therapy","D001168; D001172","Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis",FALSE,306,"t-test",NA,NA,NA,1.60617650633126
"2696","a9cc696bcfdeaa48fbdad9aa3430f5c1","NCT01236053",0.0019,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,20382,"logistic_regression",NA,NA,NA,1.14979083623068
"2697","a9f97c6c25ab3f90638e4d81f698ed69","NCT00395746",0.0433,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 24 Weeks of Treatment","SECONDARY","ANOVA model included treatment group and pre-trial SU as fixed effects and corresponding baseline value as a covariate. Two null hypotheses were statistically tested, when the hypothesis μ0.9 = μ0.6 = μSU was rejected at a significance level of 5%:

H10: μ0.9 = μSU, H11: μ0.9 ≠ μSU H20: μ0.6 = μSU, H21: μ0.6 ≠ μSU where μ0.6, μ0.9 and μSU are population mean after 24-week treatment for 0.6 mg+SU, 0.9 mg+SU and SU mono, respectively.","D003920; D003924","Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes",FALSE,164,"anova",2,NA,NA,1.68296618519249
"2698","aa1763db01b56043278d7531497e1fa2","NCT01236053",0.0103,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,48.6743050484992
"2699","aa1a39ee62fa5b27703d65e2ee991f05","NCT02697422",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Health-Related Quality of Life (HRQoL), Physical Component Summary Score (PCS)","SECONDARY",NA,"D002318; D006949","Veteran Peer Coaches Optimizing and Advancing Cardiac Health",FALSE,264,"linear_regression",NA,NA,NA,2.39772562409599
"2700","aa25c1e7e19fbf49e8a9fd2ddc126d41","NCT00635492",0.0107,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Frequent Blood Glucose Self Monitoring Associated With Treatment Choice at Baseline","SECONDARY","Blood glucose self-monitoring - 1 test/week more","D003920; D003924","CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy",FALSE,1978,"logistic_regression",NA,NA,NA,1.71485884690189
"2701","aa5274567a32a71850d0580e3fa39a3b","NCT03975790",0.0316,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Total RA Related Monthly Health Care Cost","SECONDARY","10 months before index date","D001168; D001172","Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX",FALSE,431,"t-test",NA,NA,NA,2.07172200413508
"2702","aa61fd6b31c52593cc9b3d1b65d5d8f2","NCT01260584",0.0447,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Responder Rate by Treatment and Smoking Status Based on Platelet Reactivity Index (PRI) <= 50%","SECONDARY",NA,"D003324; D017202; D003327","The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease",FALSE,102,"logistic_regression",NA,NA,NA,1.37338677190425
"2703","aa820a9a8988069c53fe4608735d65b5","NCT00442546",0.0388,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain-Related Sleep Interference Post Surgery","SECONDARY","24 hours","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,167,"anova",2,NA,NA,1.54802320937486
"2704","aa8e8d815faeed2f76b3b75cf67fec9e","NCT04105244",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Number of Technology-Dependent Children With ER Visits","SECONDARY",NA,"D002908; D000071069","Self-Management in Parents of Technology-Dependent Children",TRUE,197,"t-test",NA,NA,NA,2.07637243500742
"2705","aaca1159c12fd4926be22ad448301d4d","NCT05302414",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Team Performance Observation Tool","PRIMARY","For follow-up test at the 16 weeks.",NA,"The Learning Outcome of Resuscitation Teamwork Training in Postgraduate Year Doctors and Nurses",FALSE,64,"kruskal_wallis",2,NA,NA,1.20770700959599
"2706","aaded9a196efa7cad24262c294d21d88","NCT00472199",0.0206,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in SF-36 Dimension Vitality After 26 Weeks","SECONDARY",NA,"D011595; D012148; D013577","Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)",FALSE,307,"mann_whitney",NA,NA,NA,1.2116636311979
"2707","aae4bd2839887159498a29a88512490c","NCT01712009",0.0443,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Mean Patient-reported Bone Pain by Cycle and Across Cycles","SECONDARY","Difference across all treatment cycles","D001943","NOLAN: Naproxen or Loratadine and Neulasta",FALSE,391,"anova",2,NA,NA,2.62999308221482
"2708","ab07f773e2de49edccf75c67f14daf17","NCT00402987",0.024,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Subjects Who Achieved Their Own Level of 'Meaningful Relief' and 'Much Improvement' at 2 and 6 Hours Post-First Dose","OTHER_PRE_SPECIFIED",NA,"D010612","Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat",FALSE,179,"logistic_regression",NA,NA,NA,1.0624818152341
"2709","ab0bdc2e5a63d52571090381fb008feb","NCT01301027",0.047,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in High Molecular Weight Adiponectin (HMW-A) Concentration in Plasma From Baseline to 6 Months","PRIMARY",NA,"D007674; D007676","Effect of Adipokines in Hemodialysis Patients",FALSE,80,"t-test",NA,NA,NA,1.2750402477889
"2710","ab218f6f74638e2e17619f8895349d12","NCT01677507",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Variation in Episcleral Venous Pressure.","SECONDARY","Right Eye, treated vs. untreated","D005901","Glaucoma Biomarkers",FALSE,110,"t-test",NA,NA,NA,1.29753990593975
"2711","ab2c1ee7bfe52a0bad0768c43ae8d15b","NCT01355224",0.0365,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Intention to Lose Weight - Impact of Risk Status","PRIMARY",NA,"D009765","Communicating Risk Information for Obesity",FALSE,524,"linear_regression",NA,NA,NA,2.5808627139483
"2712","ab2fdd7efdead2c6e7a6a261fcf6ac20","NCT00144339",0.0248,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 30","SECONDARY",NA,"D008171; D029424","Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients",FALSE,4807,"anova",2,NA,NA,5.58754169459016
"2713","ab3b1acb66d3a5a62ea86753241d2f4c","NCT04295135",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Pain and Function Goal-setting","PRIMARY",NA,"D059350","Chronic Pain OneSheet Clinical Trial",TRUE,135,"linear_regression",NA,NA,NA,1.7265679672307
"2714","ab3f378cb29dfa27e2ead7e777d8af53","NCT01657500",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Endothelial Cell Loss Post EK for Donor Corneas Preserved in Life 4°C and Optisol GS Corneal Storage Media","PRIMARY","Main outcome measure was endothelial cell loss at 6 months after EK. Sample size and statistical power calculations for testing equivalence of means within 10% range were performed at 80% power/0.025 level of significance. 20% variability was assumed. 6-month endothelial cell loss) should not differ significantly for surgeon-prepared versus eye bank-prepared tissue. Assuming pairs of corneas matched by pt. diagnosis and other characteristics, the required sample size was 34 donor pairs.",NA,"Life 4°C Versus Optisol in Corneal Storage Media",TRUE,64,"t-test",NA,NA,NA,1.20770700959599
"2715","ab56ac307b7886bfc0dbd93edc94a4a2","NCT01423812",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Absolute Value Change in CD4+ From Baseline to Week 48","SECONDARY",NA,NA,"DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects",TRUE,60,"t-test",NA,NA,NA,1.17169922891753
"2716","ab62bed889402edcaf9f14ebfd2d5f0c","NCT03982368",0.046,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Quality of Life (Impact of Dry Eye on Everyday Life (IDEEL) Questionnaire vs Different Timepoints - Per Protocol Set","SECONDARY","Treatment Satisfaction - change from baseline to week 16","D015352; D007638","A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye",FALSE,151,"anova",2,NA,NA,1.70067762553962
"2717","ab63fd9b9820e631409b597f4a89dea2","NCT05193500",0.049,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Object Preference for Verbs","PRIMARY",NA,"D000067877","Study 3 Learning Verbs and Pronouns",FALSE,60,"t-test",NA,NA,NA,1.15233499097851
"2718","ab732c56ec02faf30c50fe3b6cad0154","NCT00112151",0.05,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Power (Power Rig, Watts)","SECONDARY","As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in leg extensor power with any T to placebo in subjects assigned to PRT.",NA,"TEAM: Testosterone Supplementation and Exercise in Elderly Men",TRUE,71,"linear_regression",NA,NA,NA,1.26828177971868
"2719","ab79e2a109fb6cb725684c57a76480f8","NCT00261443",0.034,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Median Baseline, Change From Baseline, and Highest Value of Change in Lactate Dehydrogenase, Phase 3 Safety Sample","SECONDARY","Treatment Comparison Baseline Lactate Dehydrogenase","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,325,"mann_whitney",NA,NA,NA,1.91836936384699
"2720","ab87e1188d9e4c05fd3a62e1446cec9f","NCT02922153",0.0446,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Primary Outcome 1: Forced Expiratory Volume (FEV1) at 48-Hours Post-Surgery","PRIMARY",NA,NA,"The cryoICE™ CryoAnalgesia Study For Pain Management in Post thoRacic Procedures Via intercOSTal Cryoanalgesia (FROST)",FALSE,62,"t-test",NA,NA,NA,1.08247119567449
"2721","abc4b718325f1709b41301ad9ed7f8fd","NCT00245219",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Physical Health (as Measured With the SF36) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the peer support condition and control condition at Time 2, among both late and early stage patients. The full regression model consisted of 3 steps: The 1st step contained the baseline measure of the dependent variable. The 2nd step contained two dummy coded variables contrasting each condition with control. The 3rd step contained the interaction between the peer support condition and cancer stage. Patients in the education condition were excluded from this analysis.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"linear_regression",NA,NA,NA,1.79957957739554
"2722","abc678747b192f1f83b2e05c15f85990","NCT01879826",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Parent Perception of Patient Pain Report","SECONDARY",NA,"D001008","Pediatric Laser Acupuncture and Renal Biopsy",FALSE,69,"t-test",NA,NA,NA,1.0394329659436
"2723","abe35c1f5790754f51e3a01146f5f7e1","NCT00308308",0.0124,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Incidence of Total Hypoglycemia","SECONDARY",NA,"D003920","Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes",FALSE,565,"logistic_regression",NA,NA,NA,1.04871609152048
"2724","abf76acd6a03fdf25ca0b9443e29a469","NCT00355914",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Oswestry Disability Index","PRIMARY","baseline, 3, 6, 12, 18, and 24 months between groups","D017116","Effectiveness of Lumbar Facet Joint Nerve Blocks",FALSE,120,"t-test",NA,NA,NA,1.63072147479452
"2725","ac22ec522024b342fafe4f0d2710dc9b","NCT02422797",0.037,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase","SECONDARY",NA,"D015658","Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)",FALSE,516,"mann_whitney",NA,NA,NA,2.59104956317628
"2726","ac3834eefcfc917c407407742305c1fd","NCT00408876",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in the 11-point Likert Scale, Weekly Mean 24-Hour Night Pain Score","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,222,"t-test",NA,NA,NA,1.82557706497181
"2727","ac5a4594876a6376b1d94da9eb8f715f","NCT01199601",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Utilization of Postpartum Contraception","PRIMARY","Outcomes were assessed by crude and adjusted risk ratios with log-binomial generalized linear models.","D006509","Blood-borne Infection Screening in an Afghan Antenatal Population",TRUE,697,"linear_regression",NA,NA,NA,3.87838567678856
"2728","ac5e4233c7d6acb5b06c9a2a12a46d6f","NCT02445196",0.035,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in PTSD Symptoms Measured by the Post Traumatic Stress Disorder Checklist (PCL)","PRIMARY","Repeated measures ANOVAs assessed the condition by time (baseline to posttreatment) interaction effects covarying PTSD treatment. Following the ITT principle, data from all randomized participants were analyzed and multiple imputation replaced missing values. A power analysis indicated that to achieve 80% power to detect an effect size in the magnitude (i.e., d = 0.25 to .33) with alpha of .05 and a correlation between repeated measures of .5, 60 participants per condition would be needed.",NA,"PTSD Coach App Evaluation",FALSE,120,"anova",2,NA,NA,1.20886253625254
"2729","ac6125d3d334b54abf236f893ab341f6","NCT01794923",0.04,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Muscle Soreness Relief at Each Time Point","SECONDARY","72 Hours: Analysis was performed using an ANOVA model with treatment, baseline categorical PSR and sex terms.",NA,"Topical Ibuprofen for Delayed Onset Mulscle Soreness",FALSE,122,"anova",2,NA,NA,1.36390872585206
"2730","ac64bb88502504f16f398d0a00ea0ac0","NCT01300351",0.023,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Clinical Benefit Rate","SECONDARY",NA,"D001943","Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women",FALSE,221,"logistic_regression",NA,NA,NA,1.13487469639298
"2731","ac6e6790cff3027f599462ef038c7f1e","NCT01070550",0.0071,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for AST ratio at BL (\> 1.5 vs \<=1.5). The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including total cumulative dose of peginterferon and ribavirin), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,2981,"logistic_regression",NA,NA,NA,1.4585973850124
"2732","ac821feee44a944d140bf1cfe7146d9f","NCT02697773",0.0173,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >= 30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 4, \>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,465,"logistic_regression",NA,NA,NA,1.27668947077497
"2733","ac8b468082a0113b99455a247fd90ffb","NCT06468982",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"In-hospital Mortality","SECONDARY","The prognostic value of risk factors for in-hospital mortality was evaluated by multivariate logistic regression analysis","D003324; D009203; D007238","Use of Intra-aortic Balloon Pump Before Surgery for Acute Myocardial Infarction",TRUE,156,"mann_whitney",NA,NA,NA,1.85245347153569
"2734","ac9484fa3acf87aed9f0e3687e8db893","NCT00023595",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"H02: Cardiac Self-Efficacy (CSE) Maintain Functioning Subscale","SECONDARY",NA,"D006333; D002318; D006331; D003327","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",FALSE,968,"mann_whitney",NA,NA,NA,3.78426775730041
"2735","acb1886874b9e061e1473f64422a8ae5","NCT03023930",0.011,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Effectiveness","PRIMARY",NA,"D009293; D019966","Opioid Use Disorder in the Emergency Department: CTN 0069",FALSE,756,"logistic_regression",NA,NA,NA,1.08941194264763
"2736","acd7393b95946d911c6f59c1be692a60","NCT01931670",0.013,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Responders for Each Month, Except Month 3, in NMPP","SECONDARY","Month 5","D004715","A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain",FALSE,579,"logistic_regression",NA,NA,NA,1.10674543847774
"2737","acf53dffe98b549e88ae098c5744d699","NCT00922194",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Change in Waist Circumference (Cms)/Hip Circumference (Cms)From Baseline at 12 Months or More","PRIMARY","Analysis of difference between 12 months or more and baseline values","D003920; D003924; D050177","Metformin in Overweight Type 2 Diabetes Mellitus",TRUE,102,"mann_whitney",NA,NA,NA,1.50770356720122
"2738","acf981462dc96672678d1a951f081e2e","NCT03789474",0.043,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"FLUID REQUIREMENT (Cumulative)","PRIMARY",NA,NA,"Does Fluid Requirement Decrease With the Use of Pneumatic Compression Device on Lower Limbs",FALSE,60,"t-test",NA,NA,NA,1.03417040936323
"2739","ad10ba7dd25384a28ea8fbfe8ed048c7","NCT02873936",0.036,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved ACR 70% Improvement (ACR70) at Weeks 4, 12, and 24","SECONDARY","Filgotinib 100 mg vs Placebo at Week 12","D001168; D001172","Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment",FALSE,301,"logistic_regression",NA,NA,NA,1.9392609973852
"2740","ad178448cd8191a30404eaf705c3ec09","NCT03431012",0.025,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Perceived Severity of the Pandemic","SECONDARY","Based on the literature, it was predicted that the Virus Agency would lead to higher perceptions of severity of the pandemic than the human agency assignment.",NA,"Improving Communication During a Pandemic Flu Outbreak",FALSE,216,"anova",2,NA,NA,1.20601975209486
"2741","ad182684a21b610ad9c9278131eb2ba0","NCT03442322",0.02,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Wandering","PRIMARY",NA,"D000544; D003704","Optimizing Care for Patients With Dementia",FALSE,2677,"linear_regression",NA,NA,NA,3.46007276618319
"2742","ad32c5bd1030a61cfd685d78968aaeef","NCT01236053",0.0141,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,2067,"logistic_regression",NA,NA,NA,2.2380266088699
"2743","ad41e965be62daeeb50eff7f385d6711","NCT03687827",0.0321,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Percentage of Time Spent in Glycaemic Target Range 70-180 mg/dL (3.9-10.0 mmol/L) Both Inclusive, Using Flash Glucose Monitoring (FGM)","PRIMARY",NA,"D003920; D003924","A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study",FALSE,896,"t-test",NA,NA,NA,3.01910128871637
"2744","ad53538adb80f2c000e4ad8b7c7f704d","NCT01138124",0.0042,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D002292; D007680; D010386; D010195; D050500; D012148","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",FALSE,30026,"logistic_regression",NA,NA,NA,2.87892363995787
"2745","ad597ace2eb43aa2ca746d4dbe3a9c73","NCT00126113",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Hearing Handicap Inventory (HHI)","SECONDARY",NA,"D034381; D003638","The Performance-Perceptual Test as a Counseling Tool",FALSE,69,"anova",2,NA,NA,1.25127183253256
"2746","ad599b41a115d72d0c10729e7dc5b90d","NCT02558296",0.0272,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of Participants With Incidence of Hospitalization for Heart Failure","OTHER_PRE_SPECIFIED",NA,"D003924","Bexagliflozin Efficacy and Safety Trial",FALSE,453,"logistic_regression",NA,NA,NA,1.8669288088993
"2747","ad6ee44af4c2c647018e68a7f0c9b413","NCT02022566",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Level of Physical Activity/Sedentary Time","PRIMARY",NA,"D010003","Effect of Structured Info and Adapted Exercise in OA",TRUE,193,"anova",2,NA,NA,2.05559974063708
"2748","ad7eb92cec60ec28e3d277f857886af0","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Total Energy Intake at Follow-up","SECONDARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,104,"anova",2,NA,NA,1.52186200926557
"2749","adab854fffdb16fb229222965c64462b","NCT02528253",0.0445,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Low Back Pain From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/ Last Observation CF (LOCF)","SECONDARY","Week 2: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline PGA of low back pain, baseline average LBPI, and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,813,"logistic_regression",NA,NA,NA,3.79659410833446
"2750","adb7a5461cac28f323d533a9bef3e771","NCT04148989",0.02,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Antibiotic Spectrum (All ED Patients)","OTHER_PRE_SPECIFIED","Differences-in-differences analysis using multivariable linear regression to estimate the change in outcome after versus before intervention implementation at the intervention site adjusted for the change observed at control sites and for prespecified covariates.","D018805; D014115; D004630","Effects of Code Sepsis Implementation on Emergency Department (ED) Sepsis Care",FALSE,24511,"linear_regression",NA,NA,NA,10.4604535635587
"2751","adc45a2b0b8ca8502759c78ec5e75b67","NCT03203512",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Pro-thrombotic Activities of Platelet-derived Extracellular Vesicles (PDEVs) Prepared From the Supernatants of Stimulated Platelets (Endpoint and Maximum of Thrombus Formation)","SECONDARY","Null hypothesis is that there was no difference in change of pro-thrombotic activity of PDEVs in affectingamximum for ex vivo thrombus formation between fish oil and placebo capsules. A general linear model with fixed factors of treatment and period was conducted to determine the differences in the effect of two treatments and two periods on the pro-thrombotic activity of PDEVs.","D001768","Fish Oil-derived N-3 Polyunsaturated Fatty Acids and Extracellular Vesicles",FALSE,80,"anova",2,NA,NA,1.34217713699512
"2752","adc5d70cc4dc0304fdca32c72b5eebfe","NCT03209440",0.02,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Dignity Impact Scale","PRIMARY",NA,NA,"Palliative Care for Elderly Outpatients",FALSE,450,"linear_regression",NA,NA,NA,1.42573831008843
"2753","adcc44124b43c4fea43a983b48eebab3","NCT01216163",0.028,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Sum of Pain Relief Rating and Pain Intensity Difference (PRID)","SECONDARY","1.5 hours: Treatment difference (Ibuprofen sodium - Acetaminophen) and corresponding 95% CI were calculated based on LS means from the ANOVA model.","D014098","Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain",FALSE,173,"anova",2,NA,NA,1.19311321597845
"2754","add8302884f551a9f851ad5dce22a90a","NCT03039621",0.024,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Time to Alleviation of Respiratory Symptoms.","SECONDARY",NA,"D007239; D003141; D014777","Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children",FALSE,282,"mann_whitney",NA,NA,NA,1.32666776501473
"2755","adee591143f931b450db94cb2b2985aa","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cancer Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1771,"linear_regression",NA,NA,NA,6.17188902328434
"2756","adf338353404c3b42c282226190e74dc","NCT01262456",0.0386,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Adjusted Probability of Participants Achieving a >33% Reduction From Baseline in Number of Nocturnal Voids at Month 3","SECONDARY","The active treatment groups were compared to placebo using a step-down approach from highest dose (75 µg) to lowest dose (50 µg).","D053158","Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients",FALSE,228,"logistic_regression",NA,NA,NA,1.79474431061303
"2757","adf54d1386eef8ef8e197d642f55ba2e","NCT02279043",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Mean Change in Attitude About Hormonal IUC as Method for Women in General Between Pre-survey and Post-survey","SECONDARY",NA,NA,"Online Peer Influence on IUD Behaviors and Attitudes",FALSE,330,"t-test",NA,NA,NA,1.7367846389211
"2758","ae0ee70debad22130f15584b47529953","NCT01070550",0.0459,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for sex (male vs female). The logistic regression analysis for mSVR was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,665,"logistic_regression",NA,NA,NA,3.52633700892224
"2759","ae15d3d1ec72220a292dd29b63d7c28f","NCT00301873",0.0418,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Mean Change in Bone Mass Density (BMD)","SECONDARY","59 patients were accrued to the study. The 19 patients with follow-up at 12 months are included in an analysis to assess the association between baseline steroid use and bone mass density at 12 months using linear regression","D001932; D010024","Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma",FALSE,59,"linear_regression",NA,NA,NA,1.00224176464283
"2760","ae1848644ad2616cfcf157774264b5ff","NCT00941603",0.04,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Direct Non-HDL-C at Week 8","SECONDARY",NA,"D006950; D006954; D008064; D006937; D006949; D006951","Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)",FALSE,202,"anova",2,NA,NA,1.74304200085886
"2761","ae2a0a4772729ca647e407b813aa5262","NCT02352948",0.037,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Objective Response Rate (ORR)","SECONDARY","For sub-study B: durvalumab plus tremelimumab treatment arm was compared with SoC.","D008175; D055752","A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",FALSE,292,"logistic_regression",NA,NA,NA,1.95545004439573
"2762","ae459fcbca5fa00e85b71dee87b77403","NCT03828019",0.028,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Corticosteroid Discontinuation Success by 12 Months","SECONDARY","Generalized estimating equations were used to fit logistic regression models to compare the cumulative proportion of corticosteroid discontinuation between the two treatment groups over time while accounting for correlation between replicate measurements on the same individual with an unstructured covariance matrix. 2 stratification variables (initial prednisone dose and immunosuppression use at baseline) were included","D014605","Adalimumab vs. Conventional Immunosuppression for Uveitis Trial",FALSE,207,"logistic_regression",NA,NA,NA,1.30211216036261
"2763","ae47693cda2c97f660aaa30a5370a347","NCT02656420",0.05,"Linear regression","INTERVENTIONAL",0,1,1,0,0,"Modulation of Air Pollutant Excretion in Sequential Overnight 12-Hour Urine Samples","SECONDARY","All broccoli sprout arms were compared with the placebo arm.","D063646","Broccoli Sprout Dose Response: Bioavailability and Effects of Air Pollutants",TRUE,132,"linear_regression",NA,NA,NA,1.70782824525799
"2764","ae485cc8962157765c717fc940bbf20a","NCT00488683",0.0436,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Linear Regression Coefficients (1) Between Serogroup A, C, W-135 and Y Memory B Cells at 5 Months and Rise in hSBA Titers, (2) Between Serogroup A, C, W-135 and Y Memory B Cells at 5 Months and Rise in IgG, After Third Dose of MenACWY-CRM at 12 Months","SECONDARY","Linear regression coefficient between demographic factors, memory B cells one month after primary vaccination and rise in serogroup specific IgG concentration after booster vaccination age for the serogroup W-135","D008589","B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants",FALSE,85,"linear_regression",NA,NA,NA,1.23279726981677
"2765","ae533be727b9dbeb4662e3f6a427f4c5","NCT04700137",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Suicidal Ideation & Behavior as Measured by the Columbia Suicide Severity Rating Scale","SECONDARY","Difference in suicidal ideation and behavior (C-SSRS) among patients by intervention arm at follow-up (6 months).","D000086382","Mental Health Among Patients, Providers, and Staff During the COVID-19 Era",FALSE,331,"linear_regression",NA,NA,NA,2.68084645273318
"2766","ae629e9ad5a3e253597d12764d49b7f6","NCT00962585",0.0381,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Menopause Rating Scale (MRS) - Dryness of Vagina- S-equol Groups Combined","POST_HOC",NA,NA,"Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients",FALSE,167,"mann_whitney",NA,NA,NA,1.52439361854265
"2767","ae6a9b929b3e58ae0da8aa04c4768829","NCT00536471",0.031,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Bilirubin, Creatinine, Uric Acid","SECONDARY",NA,"D003866; D003863; D003865","A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients",FALSE,330,"anova",2,NA,NA,1.78624373773441
"2768","ae994c82be0e5abe71394239ca3ee789","NCT03584373",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Average Pain Intensity Level","PRIMARY",NA,"D053040; D007669","Pain Outcomes of Non-opioid vs. Opioid Analgesia for Kidney Stone Surgery.",FALSE,90,"t-test",NA,NA,NA,1.17868007673095
"2769","aeab9ba4dd328fe8e10752303ec2965e","NCT04730271",0.0282,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Accuracy of the Proximal Tibial Varus-valgus Angle Measured on Long-leg X-rays at 12 Weeks","SECONDARY",NA,"D010003; D020370","Comparison of Alignment Achieved Using the VELYS Robotic-Assisted Solution Versus Manual Instrumentation in Total Knee Arthroplasty",FALSE,171,"t-test",NA,NA,NA,1.19364745306766
"2770","aeb654c51edd932745717a71f637c814","NCT02300233",0.0474,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Treatment Response Rate Defined as Participants With Fasting TG < 150 mg/dL Reduction From Baseline at Month 3","SECONDARY",NA,"D015228","The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia",FALSE,113,"logistic_regression",NA,NA,NA,1.51516116428445
"2771","aeb8512893a40b84cfcf9f9ebf0b0f76","NCT01001234",0.025,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Pain Freedom at 2 Hours Post Dose in Participants Between 12 and 17 Years of Age","PRIMARY","The comparison of rizatriptan versus placebo with respect to the primary outcome was conducted using a logistic regression model with factors for treatment, Stage 2 baseline pain severity (moderate or severe) and region (United States \[US\] or ex-US). Model-derived odds ratio and a two-sided p-value were provided. An odds ratio \>1 is in favor of the rizatriptan group.","D008881","A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)",FALSE,570,"logistic_regression",NA,NA,NA,1.9450389536726
"2772","aee17e56d3109b189b1a310a1f7cce6f","NCT01437995",0.022,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,1,"Pulmonary Function- Change in Peak Expiratory Flow","SECONDARY",NA,"D001249","Long-acting Beta Agonist Step Down Study",FALSE,301,"kruskal_wallis",2,NA,NA,1.27045684088071
"2773","aef182fa948fd6318410c0cc74963ebf","NCT02276807",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in the Level of Reward/Positive Mood When Engaging in Various Experiences at 12 Weeks","SECONDARY",NA,"D003863; D003866","Improving Mood in Veterans in Primary Care",TRUE,112,"anova",2,NA,NA,1.57722881888439
"2774","aefa12bc3546b9c7e38ae9f6a710a5ff","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Specific Perceived Environmental Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1755,"linear_regression",NA,NA,NA,6.14400672442735
"2775","af0bd7af43447c562b11ebab6dee251b","NCT03773978",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving PedACR90 Responder Index","SECONDARY","at week 40","D001168; D001171","A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis",FALSE,163,"logistic_regression",NA,NA,NA,1.89255791089634
"2776","af0bfdd35eeb0f2f0133f92ea12e690f","NCT00551135",0.0473,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Daily Sleep Interference Rating Scale (DSIRS) Score","SECONDARY","Day 9 PS; LS Means from ANOVA model with terms of treatment, pooled center. Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,202,"anova",2,NA,NA,2.00677850208042
"2777","af0ce1c52df130e22dda58d0a834c156","NCT01982942",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF).","PRIMARY","The null hypothesis states that the BPF rates of change in the treatment and placebo groups are equal, which can be evaluated based on as assessment of parameter estimates from a linear mixed model (LMM).","D009103; D020528; D012598","Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis",FALSE,214,"t-test",NA,NA,NA,1.79301862839811
"2778","af0eaf8918497f98864f02a2e958d05a","NCT01138124",0.0015,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D002292; D007680; D010386; D010195; D050500; D012148","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",FALSE,30026,"logistic_regression",NA,NA,NA,1.12273711620794
"2779","af0fc773a40219ae1976a62a0d41d0af","NCT04398732",0.036,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Percent Body Surface Area (BSA) at Baseline, Month 4, and Month 12 in Participants Adherent and Not Adherent to Treatment","SECONDARY","Baseline","D011565","Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients",FALSE,486,"t-test",NA,NA,NA,2.45733089917123
"2780","af2259652d18e6e120796321fac21a18","NCT03266016",0.045,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Median Duration of Weaning","PRIMARY","This analysis is comparing length of weaning between REDvent acute group and control acute group.","D012140; D012120","Real-time Effort Driven VENTilator Management",FALSE,215,"logistic_regression",NA,NA,NA,1.98445621956927
"2781","af2be6f013d8bed8ecee370ba58a6bf3","NCT01236053",0.0134,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,61.4682967981261
"2782","af2c540aa5ff2dfbc4fa70c0a10849b5","NCT04667338",0.0394,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Treatment Satisfaction of Participants Assessed by Treatment Satisfaction Questionnaire for Medication (TSQM-9)","SECONDARY","Effectiveness","D009290","A Study to Collect Information of People With Narcolepsy in Spain",FALSE,187,"t-test",NA,NA,NA,1.65720443369062
"2783","af4318b98ec8e8c1f1cc8e7b46ba1ed6","NCT00767806",0.031,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to 12 Week Endpoint in Albumin","SECONDARY","Tested was the null hypothesis that there is no difference between placebo and duloxetine groups in change of Albumin during 12 weeks of treatment.","D001416; D017116","A Study for Patient With Chronic Low Back Pain",FALSE,384,"anova",2,NA,NA,1.92494711610665
"2784","af60633485883040804b54baf9193207","NCT02709486",0.0132,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Osteoarthritis","SECONDARY","Week 2: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline patient global assessment of osteoarthritis scale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,563,"logistic_regression",NA,NA,NA,1.10632259650483
"2785","af730f7e2cbfa7f12cbc7929ac8a386d","NCT00838916",0.0172,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52","PRIMARY",NA,"D003920; D003924","A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes",FALSE,731,"t-test",NA,NA,NA,1.5890935434801
"2786","af85d442b17636888fc7c5f334e58117","NCT01735279",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Concentration of Serum Cotinine at Baseline and After 90 Days of Treatment","POST_HOC",NA,"D014029","Studying the Effects of Administration of Polyunsaturated Fatty Acids (PUFAS) of Omega-3 Series in Nicotine Dependence",TRUE,58,"anova",2,NA,NA,1.15327776573523
"2787","af88fb9e4bda20da42d2e62721b85789","NCT03815292",0.0445,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change in MoCA (The Montreal Cognitive Assessment Test) Score","OTHER_PRE_SPECIFIED","This analysis applies to ∆ between baseline and after 24 weeks total scores row.","D020521; D000083242; D002544; D007511; D060825","Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke",FALSE,275,"mann_whitney",NA,NA,NA,2.21883476964126
"2788","afa6a0c6728f80cdf9926b5a3f98b305","NCT03328208",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Pain the End of the Waiting Room Time (Change as Compared to Beginning of the Waiting Room Time)","OTHER_PRE_SPECIFIED",NA,"D014098","Nonpharmacologic Reduction of Periprocedural Distress and Drug Use",TRUE,72,"mann_whitney",NA,NA,NA,1.27670232702116
"2789","afa9fcb48b763227f9d585787fff96df","NCT02373098",0.035,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Baseline Serum Cytokine and Chemokine Levels of Healthy Controls and RRMS Patients - ELISA","PRIMARY","IL17A","D009103; D020529; D012598","Fingolimod Effect on Cytokine and Chemokine Levels",FALSE,126,"mann_whitney",NA,NA,NA,1.23762344953907
"2790","afd7a1b5c366e9724076f4c546019283","NCT00105989",0.029,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in 36-item Short-Form Health Survey (SF-36) - Acute and Continuation Phase","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,377,"t-test",NA,NA,NA,1.8015348201676
"2791","aff1ea57283f78969e769f8e8d78516a","NCT00587158",0.035,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Serum Bone Alkaline Phosphatase (BAP) Level Over Time","SECONDARY","The median BAP level at 90 days was compared between the two treatment groups.","D051437; D007676; D006961; D006962","Oral Paricalcitol in Kidney Transplant Recipients",FALSE,87,"mann_whitney",NA,NA,NA,1.03656615187216
"2792","aff4effd1200ab3bfad1b267ca8f56dc","NCT01437995",0.032,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,1,"Change in Pulmonary Function: FEV1 and FVC","SECONDARY","Comparison of change in pre-bronchodilator FVC","D001249","Long-acting Beta Agonist Step Down Study",FALSE,301,"kruskal_wallis",2,NA,NA,1.75408153145009
"2793","b0219e46611a79e76c332655ee2dadda","NCT02868281",0.027,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Participants Who Had an ACT Total Score >=20 or an Improvement of More Than 3 Points in ACT During the 24-week Treatment Period","PRIMARY",NA,"D001249","Asthma Control Test Guided Treatment in Chinese Subjects",FALSE,502,"logistic_regression",NA,NA,NA,1.95182703586346
"2794","b02d012c596173b0497bc3fe6a52b39f","NCT03193047",0.046,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Month 1 and Month 2","SECONDARY","hs-CRP at Month 1","D006937","Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy",FALSE,53,"mann_whitney",NA,NA,NA,1.03242555086437
"2795","b037240fea8f80eca1d1623f681e834b","NCT02477332",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Complete Hives Response (HSS7=0)","PRIMARY",NA,"D014581; D000080223","Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU",TRUE,297,"logistic_regression",NA,NA,NA,2.54111703380653
"2796","b03b28e2fce2c478b6596b79a1192887","NCT02262507",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Undergoing Acoustic Reflectance","PRIMARY",NA,"D001930; D000070642","Concussion Device Audiological Measures",TRUE,410,"mann_whitney",NA,NA,NA,2.98032953131242
"2797","b066bbfccc75520074950bd8a79243d6","NCT00482170",0.049,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Assessment of Fear of Device Based on Response to Question Concerning Nervousness About Inserting Needle Into Skin","SECONDARY","Last observation: Logistic regression was used to analyze individual concepts and questions measuring participant perception.","D011565","Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept",FALSE,417,"logistic_regression",NA,NA,NA,2.95504310334136
"2798","b0675e1a38cdaec3e936fa065f379267","NCT02900378",0.0252,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Total Weekly Time Spent in Non-sedentary Daytime Physical Activity","SECONDARY","Change from BL at Week 4","D006333","randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure",FALSE,604,"mann_whitney",NA,NA,NA,2.01554498398389
"2799","b083b584c648615eff94fc6cd2ba6278","NCT01255670",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Recovering From Peritonsillar Abscess","SECONDARY","Mann-Whitney U-test and Fisher's exact test","D000038; D000039","Penicillin and Metronidazole in Treatment of Peritonsillar Abscess",FALSE,174,"mann_whitney",NA,NA,NA,1.95391863793846
"2800","b0922e497c916c0c83078672a94c604a","NCT00393705",0.0287,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Patients Achieving Hemoglobin A1c (HbA1c) <7% and HbA1c ≤6.5% at 16 Week Endpoint","SECONDARY",NA,"D003924","Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)",FALSE,266,"logistic_regression",NA,NA,NA,1.50378319311606
"2801","b0b0fff6cc33b53cb2abc4e83480f23f","NCT04925934",0.037,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 48","SECONDARY","Adjusted response rate, rate difference and p-value are from logistic regression analysis with treatment and randomization stratification factors in the model.","D008180","Study of VIB7734 for the Treatment of Moderate to Severely Active SLE",FALSE,133,"logistic_regression",NA,NA,NA,1.33152330352999
"2802","b0b9996d73ff486c5a4e5ad3c57228fb","NCT02899988",0.039,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)","SECONDARY",NA,"D011565","A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis",FALSE,103,"logistic_regression",NA,NA,NA,1.23073869944513
"2803","b0bd21e0c29a583b709e9865bfa4444f","NCT01262456",0.0233,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Adjusted Probability of Participants Achieving a >33% Reduction From Baseline in Number of Nocturnal Voids at Month 3","SECONDARY","The active treatment groups were compared to placebo using a step-down approach from highest dose (75 µg) to lowest dose (50 µg).","D053158","Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients",FALSE,231,"logistic_regression",NA,NA,NA,1.17274583715989
"2804","b0c29ecbb327ddc668a6bf2d25962112","NCT03718832",0.0398937,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Times Eating Dark Green Vegetables in the Past 7 Days","SECONDARY","Adjusted mean difference for full controls, 12 months after trial enrollment",NA,"Fresh Food Farmacy: A Randomized Controlled Trial",FALSE,333,"linear_regression",NA,NA,NA,2.22378629447076
"2805","b0fcd2d25cbc9a8c5cdf504901042a9c","NCT01638000",0.037,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Improvement in HRQoL Scales as Assessed by the OAB-q: ≥10 Points Improvement in OAB-q at Week 12 and Final Visit","SECONDARY","Week 12 Odds Ratio vs. Mirabegron","D053201; D014570; D001745","A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.",FALSE,1833,"logistic_regression",NA,NA,NA,4.86874132076735
"2806","b1074112909317742613bec1b4d6198f","NCT01754909",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Radiation Pneumonitis","PRIMARY",NA,"D011014; D017564","Mitigation of Radiation Pneumonitis and Fibrosis",FALSE,43,"t-test",NA,NA,NA,1.00454908915455
"2807","b124a0771623b7b02b11f1b1814c1733","NCT00601172",0.0443,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Maximum Nausea Score, Assessed by a Visual Analogue Scale (VAS)","SECONDARY","Placebo vs Casopitant 90 mg (0-24 hours)","D009325; D014839","A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.",FALSE,707,"mann_whitney",NA,NA,NA,3.52835148926913
"2808","b168f8cefce4fedc9ccfe1ad4f7cede7","NCT03387189",0.031,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Composite Variable of Maternal Morbidity of Second Stage Cesarean Section","PRIMARY",NA,"D007744","Evaluation of a Quality Improvement Project on Impacted Fetal Head at Cesarean Section",FALSE,409,"logistic_regression",NA,NA,NA,1.98588462587845
"2809","b186a77a71386824a6fa824f532b7d03","NCT00310310",0.046,"Two-sample t-test","INTERVENTIONAL",0,0,1,1,0,"CPAP Adherence","PRIMARY",NA,"D001049; D012891","Effect of Self-Management on Improving Sleep Apnea Outcomes",FALSE,190,"t-test",NA,NA,NA,1.90254542151046
"2810","b1a5ed0ef1c0a4e6cb3ec5bac19222ce","NCT01066793",0.0429,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for on-treatment response (cEVR vs No RVR/EVR). The logistic regression analysis for relapse was performed for association between treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,960,"logistic_regression",NA,NA,NA,3.99855305757389
"2811","b1dba337d197cdec650eccc38da46d95","NCT03992872",0.0475,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Geometric Mean Titer of Anti-CHIKV Total Antibody Response","SECONDARY","Day 29: Geometric mean ratio (prior alpha group over naïve alpha group) and 95% confidence interval","D065632","Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)",FALSE,60,"anova",2,NA,NA,1.12311685514327
"2812","b1ebdf84ba778cd1c689da2e16d6f23a","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Creatinine Value at Baseline and After Treatment Completion","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"2813","b1f48ac9e370f3447fc103e6d600a03d","NCT05502081",0.04,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,1,"Platelets at Day 3","SECONDARY",NA,"D000086382","Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients",FALSE,212,"kruskal_wallis",2,NA,NA,1.78478629323192
"2814","b209f8544b50438211f14051fb26c2eb","NCT03879772",0.03,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Total Nasal Symptom Score (TNSS) on Day 29 as Assessed by Investigator","SECONDARY","Pairwise comparisons were performed using least square means from two-way ANOVA.","D012220; D065631; D006255","Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)",FALSE,272,"anova",2,NA,NA,1.5791894308081
"2815","b210adcb2edfc784543858b82b14932c","NCT05502081",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,1,"D-dimer at Day 7","SECONDARY",NA,"D000086382","Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients",FALSE,123,"kruskal_wallis",2,NA,NA,1.65033525744316
"2816","b22becceb62d3c4c64aa92134730002e","NCT00754546",0.038,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Exercise Endurance Time","PRIMARY","Arformoterol versus normal saline with cycle exercise","D008173; D029424","Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD",FALSE,80,"t-test",NA,NA,NA,1.0675951775835
"2817","b254fc95b629da256d997321aeb75b78","NCT03569202",0.047,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline Ocular Protection Index (OPI)","SECONDARY","Between-group comparison, change from baseline","D015352; D007638","Piiloset Trehalose Emulsion Eye Drop Study in Moderate or Severe Dry Eye",FALSE,52,"anova",2,NA,NA,1.04171046154734
"2818","b260399bf1320588d67dbc9a8946ec91","NCT02954848",0.02,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Severity of Symptoms of Heartburn in Subgroup Stratified by Both the Response at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N or M)","SECONDARY","Statistical analysis for Criteria 1, Grade M and improved response","D005764; D004942","Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)",FALSE,483,"mann_whitney",NA,NA,NA,1.47648385350465
"2819","b2673def5852a87f8b7447d263a61317","NCT03048422",0.048,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Infant Creatinine Clearance","SECONDARY","Null hypothesis of no difference between arms at week 26 (DTG+FTC/TDF - EFV/FTC/TDF).","D015658","Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants",FALSE,374,"t-test",NA,NA,NA,2.75209434603573
"2820","b26f7af92354451c09c6ad2dbb0ec709","NCT00360529",0.0454,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Satisfying Sexual Event Monthly Change From Baseline at Final Visit","PRIMARY","Flibanserin 50 mg qhs versus placebo","D020018","24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder",FALSE,576,"mann_whitney",NA,NA,NA,3.25330067172503
"2821","b295944bbb3afb0a4762b36c41299a2e","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Burger Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1754,"linear_regression",NA,NA,NA,6.14225987828851
"2822","b29a934ff880d36a87585f8237dc32ce","NCT00261443",0.035,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Baseline and Adjusted Mean Change From Baseline in the CGI-BP Severity of Illness (Overall) Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 36 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,1.96930142702439
"2823","b2a931e3fc4a6d78b8213128a68910f6","NCT03828370",0.04,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Measure of Primary Outcome Variable: IID Lockout Events.","PRIMARY",NA,NA,"DWI Offenders and Their Families App for Smartphones",FALSE,71,"anova",2,NA,NA,1.05348219904379
"2824","b2b14da33bf83072a6410d6803d8b333","NCT02577354",0.032,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Mean Change in Low Back Pain VAS","PRIMARY",NA,"D001416; D017116","ReActiv8 Implantable Neurostimulation System for Chronic Low Back Pain",FALSE,201,"t-test",NA,NA,NA,1.4388483627554
"2825","b2b2e24937be9ce3967184bb1ad288f3","NCT01728246",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Visual Analogue Scale for Pain (VAS-pain) Score at Week 2","PRIMARY",NA,"D010003","An Efficacy, Safety and Effects on Quality of Life of Tramadol/Paracetamol as Add-on Therapy in Chronic Osteoarthritis",TRUE,473,"t-test",NA,NA,NA,3.19913039915235
"2826","b2b5faa2a12873484536d88bf12cad8e","NCT01256944",0.05,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"LDL","PRIMARY",NA,"D011085; D002318; D024821; D013577","To Study Polycystic Ovary Syndrome in Taiwanese Women",TRUE,290,"anova",2,NA,NA,2.51138465397077
"2827","b2c07404bf08b7bf4b87095624672185","NCT03687762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in Anxiety Severity","SECONDARY",NA,"D059350","Back on Track to Healthy Living Study",FALSE,302,"anova",3,NA,NA,1.03237942189705
"2828","b2ca51e19f20bb64757cb3ec9193eda2","NCT03247543",0.0276,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Effect of SPN-812 Assessed by 50% Responder Rate Per the Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5)","SECONDARY",NA,NA,"Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD",FALSE,194,"logistic_regression",NA,NA,NA,1.24607190220129
"2829","b2d2f6fdbe6223f92561a53d16613c66","NCT00770146",0.032,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Percent Change From Baseline in Apolipoprotein A1 at the Primary Efficacy Time Point","OTHER_PRE_SPECIFIED",NA,"D006331; D003327; D003324; D017202; D006937","Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients",FALSE,151,"t-test",NA,NA,NA,1.25184476306916
"2830","b2e0793024255c240ef90ceaf166a70c","NCT02528253",0.0164,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 8, \>=50%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1011,"logistic_regression",NA,NA,NA,1.79043757393117
"2831","b2e294146788dbe1593d4c44e22c491e","NCT01400243",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Heart Rate","SECONDARY",NA,"D002189","Nicotine Patch for Marijuana Withdrawal",TRUE,108,"anova",2,NA,NA,1.54979200994087
"2832","b2e342109186be2195cb3b20fb38a933","NCT02259127",0.038,"Logistic regression","INTERVENTIONAL",0,0,1,1,0,"HIV-1 RNA <400c/mL at 96 Weeks","SECONDARY",NA,"D007239; D015658; D000163","ODYSSEY (PENTA 20)",FALSE,72,"logistic_regression",NA,NA,NA,1.01584213929469
"2833","b2eeb8e8d3d07d05df8c95b6304ca0e3","NCT02709486",0.0296,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >=30%, >=50%, >=70% and >=90% Response","SECONDARY","Week 24, \>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,565,"logistic_regression",NA,NA,NA,2.23986083782277
"2834","b3052e265e11be6296b1bd058a792d79","NCT02451917",0.047,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Number of Hypoglycemic Events","PRIMARY","A sample size of 34 participants (16randomized to sequence IGlar/INPH and 18 randomized to sequence INPH/IGlar) provided 90% power and assuming an SD of 0.85%, and a type I error of 5%.","D007674; D051436; D003924","Glargine Versus NPH in Patients With Chronic Kidney Disease",FALSE,68,"anova",2,NA,NA,1.18065552240523
"2835","b3067cc4d72860fe3d51e812b02d4072","NCT01256944",0.05,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"Triglycerides","PRIMARY",NA,"D011085; D002318; D024821; D013577","To Study Polycystic Ovary Syndrome in Taiwanese Women",TRUE,290,"anova",2,NA,NA,2.51138465397077
"2836","b30d4156b0a40de132ea3b9ceec6af24","NCT03334396",0.029,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving EASI90","SECONDARY",NA,"D003876; D003872; D004485","A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis",FALSE,372,"logistic_regression",NA,NA,NA,1.78970052376175
"2837","b31464fa0d876852d5bbe72c40559dd3","NCT02806895",0.0432,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"SDLP at 6 Hours Post-dose","SECONDARY",NA,"D012891; D020181; D006970; D000077260","Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA",FALSE,64,"anova",2,NA,NA,1.06993330053087
"2838","b32e64f8d49a62b2fdc85208a692af42","NCT00252512",0.0497,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Psychiatric Status","SECONDARY","12 month analysis","D019966","The Effect of a Contingency Management Intervention on Substance Use",FALSE,267,"t-test",NA,NA,NA,2.39902230102614
"2839","b338670a08530daea2563b54c961a882","NCT01236053",8e-04,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,4.73824365385732
"2840","b37168802c119ec9fa310b03228d3a73","NCT00070707",0.022,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in AM and PM Rhinorrhea Symptom Score","SECONDARY","Change at Week 4 (PM)","D012220; D001249; D006255; D065631","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",FALSE,187,"anova",2,NA,NA,1.00671037798545
"2841","b3767268d7503ab3e3e5bb8ac0633ea0","NCT02528188",0.0114,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 4: \>=30% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1998,"logistic_regression",NA,NA,NA,1.82324211902484
"2842","b3857bdcb2ea9fac7670b70ae4c17076","NCT01005810",0.029,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Negative Urine Cannabinoid Tests During Treatment","PRIMARY",NA,"D002189","A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana",FALSE,116,"logistic_regression",NA,NA,NA,1.01363050411392
"2843","b389a557239cbf722b5e633d3664af38","NCT01945034",0.022,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","SECONDARY","At Rest 1 hour Day 1: The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms. Upper limit of 95% CI \< 0 for Ibuprofen treatment significantly better than combined Placebo.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,237,"anova",2,NA,NA,1.12998529527379
"2844","b3995b4a6db5fb87f74f9295c069171b","NCT03879772",0.02,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Total Nasal Symptom Score (TNSS) at Day 8 as Assessed by Investigator","PRIMARY","Pairwise comparisons were performed using least square means from two-way ANOVA.","D012220; D065631; D006255","Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)",FALSE,266,"anova",2,NA,NA,1.1007300844237
"2845","b3a190bd9da04ef6f306fddd33b665c0","NCT03192176",0.0442,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week","SECONDARY","Week 2","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.23288712794089
"2846","b3b096471fbc6cb3cabeaede3e011249","NCT01410240",0.036,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in SF-36 Scores at Postoperative Weeks 1, 2, and 6","SECONDARY","Change Week 6: Role-Emotional","D010003","Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty",FALSE,97,"mann_whitney",NA,NA,NA,1.11791870286728
"2847","b3b5ab4579719d0802c9053daef6bc9b","NCT02416934",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Quality of Life","SECONDARY","Comparing the changes in VNDI between Dexamethasone and Saline from baseline to last visit","D003680","Dysphagia Following Anterior Cervical Spine Surgery; Steroid vs Saline",TRUE,64,"t-test",NA,NA,NA,1.20770700959599
"2848","b3c0aa83688de9767bc87c62b6ba02eb","NCT01360996",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Post Therapy BMI.","SECONDARY",NA,"D011085; D017588; D013577","Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism",FALSE,53,"anova",2,NA,NA,1.10589694869732
"2849","b3f3370ad56846d6c4a253309ffd9ead","NCT01437995",0.031,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,1,"Pulmonary Function: Change in FEV1/FVC Ratio","SECONDARY","Comparison of change in FEV1/FVC ratio","D001249","Long-acting Beta Agonist Step Down Study",FALSE,297,"kruskal_wallis",2,NA,NA,1.69590753030205
"2850","b3f3ff8aaa97174b2085b852c8c96d1d","NCT03163264",0.028,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Mean Percent Weight Change From Baseline to 12 Months","PRIMARY",NA,"D050177","The Peer Assisted Lifestyle Intervention",FALSE,281,"mann_whitney",NA,NA,NA,1.51245550374387
"2851","b3fbdb301f07e68ae20f199e36e7c3da","NCT03085797",0.02,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Composite VAS Score (Combining VAS Scores for Nasal Obstruction, Nasal Discharge, Mucus in the Throat and Loss of Smell) During the 4 Weeks Prior to Week 52","SECONDARY",NA,"D009298; D011127","Effect of Mepolizumab in Severe Bilateral Nasal Polyps",FALSE,407,"mann_whitney",NA,NA,NA,1.35677138551958
"2852","b3fcff981bd480b16ce3ad83dfc9f7ed","NCT00279201",0.036,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes","SECONDARY",NA,"D003920; D003924","The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)",FALSE,419,"anova",2,NA,NA,2.28331944235908
"2853","b402172672f21a3d9290b33fa740b8c7","NCT00459706",0.012,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Participant Satisfaction by Health Assessment Questionnaire - Disability Index (HAQ-DI) for 2 Different Delivery Mechanisms for Etanercept","SECONDARY","All categories, by 1-unit increments.","D001168; D001172","Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept",FALSE,637,"linear_regression",NA,NA,NA,1.08101871593904
"2854","b40b44c67221f1cf9aeb4f37213e09b8","NCT01879826",0.044,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient Pain/Anxiety","PRIMARY",NA,"D001008","Pediatric Laser Acupuncture and Renal Biopsy",FALSE,69,"t-test",NA,NA,NA,1.1254328622826
"2855","b4251dda3ce8d28bee4a43fbb298afab","NCT00741936",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Bowel Movement","SECONDARY",NA,"D005767; D004066; D003248","An Effectiveness and Safety Study of Chinese Herbal Medicine for Functional Constipation",TRUE,120,"t-test",NA,NA,NA,1.63072147479452
"2856","b438a8a5b44c0f63a6028ce1076bd1f2","NCT05169424",0.045,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Incidence Rate of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation After Cohort Entry","PRIMARY",NA,"D008171; D008173; D029424","A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)",FALSE,5902,"mann_whitney",NA,NA,NA,10.3041215891195
"2857","b45f467f5352aacc5169a904d20617b8","NCT04196803",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Changes of Cytosine Modification in TMPRSS2 (5-hmC at cg16371860) by Magnesium Treatment Versus Placebo","SECONDARY",NA,"D015179","Ancillary Study of Methylation Biomarkers in a Randomized Controlled Trial of a Personalized Prevention of Colorectal Cancer",FALSE,239,"linear_regression",NA,NA,NA,2.28311078024125
"2858","b4654b12466e75191a8ad93d3b44183f","NCT00468845",0.0214,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Brief Pain Inventory-Short Form (m-BPI-sf): Pain Severity Index Scores","SECONDARY","Day 14","D010149","Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy",FALSE,304,"anova",2,NA,NA,1.24640208927073
"2859","b47a0c893651617decbb744d348a559c","NCT00455533",0.0281,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]) to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR/RCB1","SECONDARY","ERCC1 203719_at","D001943","Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer",FALSE,295,"logistic_regression",NA,NA,NA,1.55379383108004
"2860","b47b00993c258d32bc1e194476f7e0fc","NCT01529385",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Microcirculation for Lateral Calf","PRIMARY",NA,"D004487","Mild Compression Sock for Control of Lower Extremity Edema in Individuals With Diabetes",FALSE,77,"anova",2,NA,NA,1.31800316623017
"2861","b4893f37cb8e20fbccfef480c6dcc5b5","NCT01860521",0.047,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Total Sufentanil Consumption.","SECONDARY",NA,NA,"Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Termination of Pregnancy Analgesia",FALSE,104,"mann_whitney",NA,NA,NA,1.44552042589897
"2862","b48a59eb3b2dfa6325dc14c3ac617780","NCT00935584",0.05,"Wilcoxon","INTERVENTIONAL",0,0,0,0,0,"Change in EMR Mouse Click Per Minute Per Visit (Mean/SD)","PRIMARY","The null hypothesis states that there is no significant change in outcome from pre-intervention clinical visit (baseline) to post-intervention clinic visit.",NA,"Patient Centered Evaluation of Computerized Patient Records System",TRUE,126,"wilcoxon",NA,NA,NA,1.66971913113983
"2863","b4bc07a27150df3857231536904a0d53","NCT01685047",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Among Patients With an Appropriate ICD Therapy (Shock or ATP) for Ventricular Tachycardia or Fibrillation, the Number of Patients Who Have Characterized ST Segment Changes From Baseline Prior to the Therapy Was Calculated.","PRIMARY","There were no formal pre-specified statistical hypotheses for the endpoints of the study due to the exploratory nature of this study. Some data was excluded from the primary analysis. All device detections resulting in therapy have been reviewed for appropriateness of the therapy. VT/VF therapy delivered from the device as a result of a non-ventricular arrhythmia or as a result of oversensing by the device has not been included in the primary data analysis.","D003324; D017202; D003327; D001145","A Clinical Evaluation of ST Changes in a Group of Patients Having Ventricular Arrhythmias",TRUE,117,"t-test",NA,NA,NA,1.61086942334102
"2864","b4c413cf9757eb2abd2a920569264053","NCT04593940",0.0281,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Mortality Through 28 Days","SECONDARY",NA,"D000086382","Immune Modulators for Treating COVID-19",FALSE,1049,"logistic_regression",NA,NA,NA,2.91285527060027
"2865","b500ef6b98ddf3a8fe5ddc81692e484d","NCT04242446",0.021,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16","SECONDARY",NA,"D017497; D016575","A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa",FALSE,361,"logistic_regression",NA,NA,NA,1.33431845326371
"2866","b501c7afedbbd2c0846f9af1ddaf6fb1","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Urinary Genistein","SECONDARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,102,"anova",2,NA,NA,1.50770356720122
"2867","b526f7fd9ed0ed5e9fc7b3fe06e33506","NCT04044664",0.0364,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Responders (30% and 50% Improvement From Baseline) in CAPS-5 Total Score","POST_HOC","greater than or equal to 30% decrease from baseline","D040921; D013313","Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder",FALSE,129,"t-test",NA,NA,NA,1.29400620942616
"2868","b55cb0d31e3654f0782954dd612fedb0","NCT03019796",0.04,"ANOVA","INTERVENTIONAL",1,0,0,0,0,"Mean Arterial Pressure","PRIMARY",NA,"D024821; D013577","Exercise Training Effects on Metabolic Syndrome: Interactions With Medication",FALSE,76,"anova",2,NA,NA,1.08781774095059
"2869","b55d901a542c4ed79b686d5769c6e18d","NCT00858208",0.0433,"One-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Change From Baseline VA at Each Visit","SECONDARY","Change from baseline at Week 6","D008268; D057135","Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.",FALSE,67,"t-test",NA,NA,NA,1.09526437358804
"2870","b56460129d9ba3bb7d784eb4691c63d3","NCT02724774",0.029,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Infant Behavioral Regulation: Externalizing T Score","SECONDARY",NA,NA,"Collaborative Perinatal Mental Health and Parenting Support in Primary Care",FALSE,243,"linear_regression",NA,NA,NA,1.45140770545594
"2871","b56a608d44d0067f7637a5e882b3fbe2","NCT00185211",0.0141,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Relapse-based Efficacy Domain (Supportive): Annualized Relapse Rate","SECONDARY","Relapse rate was analyzed by a generalized linear Poisson regression model with individual relapse counts as dependent variable, covariates: treatment arm, steroid use during first event, onset of disease and categorized number of T2 lesions at screening and offset variable natural log of time (in years) as difference between last clinical visit and baseline visit. The treatment effect on the relapse rate was of primary interest.","D009103; D012598","BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study",FALSE,468,"linear_regression",NA,NA,NA,1.07023889103927
"2872","b5a0ce95f6af0c8d85c89b42d145da1f","NCT00070707",0.041,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in AM and PM Nasal Sneezing Symptom Score","SECONDARY","Change at Week 4 (AM)","D012220; D001249; D006255; D065631","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",FALSE,187,"anova",2,NA,NA,1.71379923005537
"2873","b5ba7f39e93540977eb64dad1ba76462","NCT03645954",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Ability of Early Ambulation After Surgery","SECONDARY",NA,NA,"Femoral Triangle and Adductor Canal Blocks Versus Femoral Nerve Block for Total Knee Arthroplasty",FALSE,77,"t-test",NA,NA,NA,1.31800316623017
"2874","b5dc417bd674adddd4e2c6d2937536ce","NCT00882050",0.05,"Logistic regression","INTERVENTIONAL",0,1,1,0,0,"The Primary Objective is to Determine the Ability of Intravenous Exenatide to: Maintain Intraoperative Euglycemia in Subjects With Initial Blood Glucose < 126 mg/dL in Surgical Subjects as Compared to Placebo,","PRIMARY","Primary t tests of glucose between the 3 groups at 90 minutes post. Secondary MANOVA to determine the effect over time. Change in mean glucose of 20 mg/dl between all groups detectable by 18 subjects per group assuming a SD of 20mg/dl., an 82% power with an alpha of 0.05. Because we tested interventions against the placebo arm, we increased our subjects to overcome loss of power. 23 per group will provide 80% power assuming a reduced alpha of 0.01 to accommodate the multiple testing issues.","D007003; D006943","Intravenous Exenatide (Byetta) During Surgery",FALSE,104,"logistic_regression",NA,NA,NA,1.52186200926557
"2875","b5f38852f801efab03810571ab73078c","NCT04954326",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pharmacokinetics Measurements","SECONDARY","Cday14 was natural log-transformed and analyzed using an analysis of variance (ANOVA) with fixed effect for formulation. The two one-sided tests procedures were performed on the geometric mean ratio (GMR) between test (S95014 lyophilizate) and reference (S95014 liquid formulation) treatments. The 90% confidence interval for the ratio was obtained within the framework of the ANOVA.","D007938; D054198; D007945","A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL)",FALSE,80,"anova",2,NA,NA,1.34217713699512
"2876","b608b2d6d94eb751c48482f989473c19","NCT01178073",0.0264,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With a Satisfactory Clinical Response at Week 24","SECONDARY",NA,"D000081029; D006976; D006973","A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)",FALSE,460,"logistic_regression",NA,NA,NA,1.8333731703046
"2877","b6225ba94b3a05a9d246e7cecc61b239","NCT03011775",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Lipid Metabolism 3","SECONDARY",NA,"D006331; D050197; D003327; D003324; D017202; D007333; D024821; D018450","Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease",TRUE,43,"mann_whitney",NA,NA,NA,1.00454908915455
"2878","b63646115a278848c0fad0777511ed0f","NCT01191268",0.014,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at Weeks 26 and 52","SECONDARY",NA,"D003920; D003924","A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)",FALSE,555,"logistic_regression",NA,NA,NA,1.15702509912007
"2879","b639c8b4ef9b19ef8b851a2f0f9f24ff","NCT01898208",0.037,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Duration of Antimicrobial Therapy (Hours)","PRIMARY","For vancomycin-susceptible enterococci","D016470; D018805; D016469; D004198","Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures",FALSE,617,"kruskal_wallis",3,NA,NA,1.04950940363233
"2880","b63ee9d96062b4b23d4ad33c9aec3753","NCT04452318",0.0273,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Cohort B: Number of Weeks of Symptomatic SARS-CoV-2 Infection (Broad-term) Within 14 Days of a Positive RT-qPCR at Baseline or During the EAP","SECONDARY",NA,"D000086382","COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay",FALSE,204,"mann_whitney",NA,NA,NA,1.26507545971271
"2881","b6407c2256f0e32f9e5ebbd59d872cc1","NCT01223703",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change in Left Ventricular (LV) Systolic Function Expressed as Left Ventricular Ejection Fraction (LVEF) Between Baseline and 12-month Follow-up","PRIMARY","null hypothesis is no difference n3 PUFA administration and placebo. To demonstrate an effect size of 0.5 in LVEF, a sample of 65 patients in each group was calculated to have 80% power to detect such 0.5 effect size with alpha=0.05 (2-tailed) at the Student t test.

for unpaired data.","D006333; D009202; D002311","PUFAs and Left Ventricular Function in Heart Failure",TRUE,133,"t-test",NA,NA,NA,1.7140975432625
"2882","b641d3e7379df254f271122495a9c17b","NCT01416194",0.01,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of All Malignancies","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",TRUE,7777,"linear_regression",NA,NA,NA,3.19773018380892
"2883","b6433ced290f793a36a82fcffc4da584","NCT01138124",0.042,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D002292; D007680; D010386; D010195; D050500; D012148","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",FALSE,19046,"logistic_regression",NA,NA,NA,17.4582558609529
"2884","b65bf16b2ced55bf6365d3731803e0d2","NCT03192176",0.0389,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week","SECONDARY","Week 5","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.12677195388214
"2885","b6739b75181765ad538bbca1a9ddd60f","NCT04242446",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16","PRIMARY",NA,"D017497; D016575","A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa",FALSE,216,"logistic_regression",NA,NA,NA,1.41042943219353
"2886","b678b877b5c19df2a3bb613eba62d64b","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient-Reported Outcomes Measurement Information System (PROMIS Short Forms 8a - Pediatrics v. 2.0) is a Set of Person-centered Measures That Evaluates and Monitors Physical, Mental, and Social Health in Children and Adolescents.","SECONDARY","We hypothesized that there would be no differences at baseline between intervention and control adolescents with respect to Pain Interference.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,126,"t-test",NA,NA,NA,1.66971913113983
"2887","b6920f5b8545cfba889cb94a5f0d58d8","NCT01708902",0.048,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 24 Weeks of Treatment in Main Group","SECONDARY","Comparison of 'Main: Linagliptin 2.5mg / Metformin 1000mg BID' / 'Main: Metformin 1000mg BID'.

The logistic regression includes treatment and continuous baseline HbA1c.","D003924","Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients",FALSE,274,"logistic_regression",NA,NA,NA,2.36010500944814
"2888","b693f9c29df04f5706eac5f0ff582d64","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Daytime Central Systolic Pressure","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"2889","b6c00ba87d5e5e6b9a5b23cb40314418","NCT00657241",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Stroke Volume (SV)","SECONDARY","Statistical analysis performed on treatment groups (valsartan or carvedilol CR) at end of treatment period (4 weeks), not on the randomization arms in the crossover design (which controlled for carryover effects of the prior treatment arm).","D006973","Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril",FALSE,60,"t-test",NA,NA,NA,1.17169922891753
"2890","b6eb137e019593d16e1ac88e26e35486","NCT02886728",0.014,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 2, 4, 12, 24, 36, and 52","SECONDARY","Filgotinib 200 mg Monotherapy vs MTX Monotherapy at Week 52","D001168; D001172","Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy",FALSE,626,"logistic_regression",NA,NA,NA,1.22804846965121
"2891","b708df1625966d9ec8a5e6a135af5353","NCT01234649",0.048,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Absolute Body Weight","SECONDARY","Factorial repeated measures ANOVA","D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",TRUE,72,"anova",2,NA,NA,1.23428615273922
"2892","b715151135eab9b24801186a4b85563a","NCT00797277",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"The Change of the Positive and Negative Symptom Scale Excited Component (PANSS-EC) Score From Baseline to 120 Minutes After First Injection","PRIMARY","we hypothesized that there would be no statistical significant difference between the 2 groups in the primary outcome.","D011595; D012559; D011618","Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia",TRUE,67,"t-test",NA,NA,NA,1.23402909436682
"2893","b718a883aece9aea10cefcb62cbc1afa","NCT05401149",0.007,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Distribution of Modified Rankin Scale (mRS) Score at 1 Year","SECONDARY",NA,"D020521","Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients",FALSE,1560,"logistic_regression",NA,NA,NA,1.04296450750662
"2894","b71ba32def62ff68a8e2746c86fc4ccf","NCT02683954",0.05,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Serum Nesfatin 1","PRIMARY","Normality of numerical data distribution was examined by the Shapiro-Wilk. Normally distributed numerical variables were presented as mean±SD and inter-group differences were compared using unpaired t test. Skewed numerical variables were presented as median and interquartile range and between-group differences were compared using Mann-Whitney U test. Ordinal data were compared using the chi-squared test for trend. Correlations among numerical variables were tested by Spearman rank correlation.","D004715","The Association Between Endometriosis, Obesity and nesfatin1",FALSE,60,"mann_whitney",NA,NA,NA,1.17169922891753
"2895","b7306c524ddd6703cb2e0d9f9a976e5d","NCT01482091",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change in Pain Score at 10 Minutes","SECONDARY",NA,"D000755","Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis",FALSE,49,"mann_whitney",NA,NA,NA,1.06649684228356
"2896","b7454d4ceb941f070bbf746b39f471c5","NCT02596126",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Efficacy Endpoints","SECONDARY","Patient satisfaction is measured at visit 1 (6 months) and visit 3 (2 years) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument comprising of four domains: effectiveness (questions 1 to 3), side effects (questions 4 to 8), convenience (questions 9 to 11) and global satisfaction (questions 12 to 14).","D009362; D002318; D009203; D007238","Secondary Prevention of Cardiovascular Disease in the Elderly Trial",TRUE,2466,"t-test",NA,NA,NA,7.28069129722027
"2897","b74ae63a498852a955b6c7e960cf7c8c","NCT01066793",0.0279,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for Gamma-GT in log10 (IU/L) at BL. The logistic regression analysis for mSVR was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2b.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,960,"logistic_regression",NA,NA,NA,2.77005303269199
"2898","b74bb358bc7e43e4edbdc046921a4120","NCT01070550",0.0279,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for AST ratio at BL (\> 1.5 vs \<=1.5). The logistic regression analysis for mSVR was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,2981,"logistic_regression",NA,NA,NA,4.87295183653699
"2899","b75c7d991d93c48e03d98981e9b38489","NCT05226884",0.05,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Non-inferiority of Target-corrected Binocular Distance (4 m) Visual Acuity With Offset","PRIMARY",NA,"D019591","Intermediate Vision in Patients With Clareon IOLs Compared to Eyhance IOLs",TRUE,310,"mann_whitney",NA,NA,NA,2.59543112524924
"2900","b764736bd4e9f6e328d29d734339c262","NCT03203512",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Pro-thrombotic Activities of Platelet-derived Extracellular Vesicles (PDEVs) Prepared From the Supernatants of Stimulated Platelets (Area Under Curve)","SECONDARY","Null hypothesis is that there was no difference in change of pro-thrombotic activity of PDEVs in affecting area under curve for ex vivo thrombus formation between fish oil and placebo capsules. A general linear model with fixed factors of treatment and period was conducted to determine the differences in the effect of two treatments and two periods on the pro-thrombotic activity of PDEVs.","D001768","Fish Oil-derived N-3 Polyunsaturated Fatty Acids and Extracellular Vesicles",FALSE,80,"anova",2,NA,NA,1.34217713699512
"2901","b76d37fb11531669129ebd5c54bc2e9a","NCT01926028",0.03,"Mann-Whitney","INTERVENTIONAL",0,1,1,0,0,"Number of Patients <40 Years Old Who Were Recurrence-free Over the 12-month Post-vaccination Period","SECONDARY",NA,"D002177; D002181","Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis",FALSE,107,"mann_whitney",NA,NA,NA,1.00378146408722
"2902","b7736c2e81d954fed65b663dd5f22757","NCT00205777",0.012,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in European Foundation for Osteoporosis Quality of Life Questionnaire (QUALEFFO) at Month 12, 24 and 36","SECONDARY","Change at Month 36 in QUALEFFO: P value was calculated using ANOVA.","D010024","Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women",FALSE,2985,"anova",2,NA,NA,2.33100626501122
"2903","b77bb780ed64801487e23decce64bcb2","NCT01070550",0.0251,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for BMI in kg/m\^2. The logistic regression analysis for relapse 24 Weeks after EOT was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,1751,"logistic_regression",NA,NA,NA,3.41069780235416
"2904","b7840c17eddc768262dd87327c62fe9b","NCT00833638",0.022,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Earliest Onset Day Measured by Cumulative Percentage of Participants With Yes Response to Sexual Encounter Profile Diary Question 3","PRIMARY","The null-hypothesis was tested that there is no statistically significant difference in the onset of efficacy between tadalafil 5 mg and placebo as determined by the earliest day on which the cumulative percentage of participants achieving at least 1 successful intercourse (within 4 days of starting treatment) is statistically significantly different between active drug and placebo.","D007172","A Study in Erectile Dysfunction",FALSE,234,"logistic_regression",NA,NA,NA,1.12297003461437
"2905","b799bc421b25950f8536b45fb44b8671","NCT00462839",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Difference in Actual Blood Volume and Estimated Blood Volume in Milliliters.","PRIMARY","Repeated measures ANOVA comparing all levels of blood estimation (P=0.0002). Post-hoc comparisons using Bonferroni corrects t-tests.","D006473; D006470","Accuracy of Blood Loss Estimation After Vaginal Delivery",TRUE,106,"anova",2,NA,NA,1.53589031932405
"2906","b79ef7d31ce5878b2457f80bb3c90249","NCT03228680",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of Participants With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved","SECONDARY","Proportion of participants with \>= (more than equal to) 20 oocytes retrieved (severe hyperresponse).","D007246","Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese Women",FALSE,342,"logistic_regression",NA,NA,NA,1.76763797022308
"2907","b7b7dbc77d7814a09aac7b5301a1196b","NCT04497987",0.021,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With SARS-CoV-2","SECONDARY",NA,"D000086382","A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff",FALSE,972,"logistic_regression",NA,NA,NA,2.17933950917009
"2908","b7c2ef86264be6a8dbc7b14e08ca6c1c","NCT02165826",0.017,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason","PRIMARY","Analyses were performed using a hierarchical testing procedure.","D008173; D029424","Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD",FALSE,884,"logistic_regression",NA,NA,NA,1.7285165537244
"2909","b7e7dd0eca4690da67073fdda7c69169","NCT03911843",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,1,0,"Daily Insulin Need (IU/Kg/Day) and Daily Insulin Pre-meal Demand (Pre-meal IU/Kg/Day) at 12 Months","PRIMARY",NA,"D003922","Omega-3 and Vitamin D Supplements in Childhood T1D",TRUE,59,"mann_whitney",NA,NA,NA,1.16252463235142
"2910","b7ea172d634df23a61783f5e5898729d","NCT02697773",0.0422,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Osteoarthritis","SECONDARY","Week 4: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline PGA of osteoarthritis, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,463,"logistic_regression",NA,NA,NA,2.74488227591872
"2911","b84fe164658af0b341d41c64c926dead","NCT01459653",0.028,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Modeling Composite Outcome (Any of CIN Grade 4, FN, CIN/FN-related Hospitalization, CIN/FN-related Chemotherapy Disturbance): Patient Level","SECONDARY","GIS at enrollment (1 vs. 0) as patient-level predictor for composite outcome (any of CIN Grade 4, FN, CIN/FN-related hospitalization, CIN/FN-related chemotherapy disturbance)","D009101; D009503; D064147; D000084462; D005334","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",FALSE,1291,"logistic_regression",NA,NA,NA,3.22013208650329
"2912","b86e4cd5b6195214183cc68462d32382","NCT00550173",0.031,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With a Tumor Response of Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]","SECONDARY",NA,"D008175; D002289","A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer",FALSE,158,"logistic_regression",NA,NA,NA,1.24550460828991
"2913","b881b352128781f0e6dd9124d13c84e4","NCT03880461",0.014,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Total Gestational Weight Gain (GWG)","PRIMARY",NA,"D050177; D001835; D015430; D000078064","A Mobile Health Intervention to Achieve Appropriate Gestational Weight Gain in Overweight/Obese Women",FALSE,1111,"t-test",NA,NA,NA,1.63256703915477
"2914","b8830e27105418756a4d1b69aeed5231","NCT01814878",0.0485,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID)","SECONDARY",NA,"D010149","A Study Comparing the Effectiveness and Safety of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen With Immediate Release (IR) Tramadol HCl/Acetaminophen in Participants With Moderate to Severe Postoperative Pain",FALSE,312,"t-test",NA,NA,NA,2.53819206045248
"2915","b88b724a0d6b65e61645622b4de9ddba","NCT00394901",0.0393,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Patients Not Reporting Hyperalgesia","SECONDARY","Hypothesis testing was conducted using two-sided tests with significance level of 0.05.","D009437; D051474","A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia",FALSE,188,"logistic_regression",NA,NA,NA,1.65796721510718
"2916","b8900ee72b3688334056d7981028bc89","NCT03192176",0.0396,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week","SECONDARY","Week 12","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.1246383285618
"2917","b899fb29b82156d12646b3a221642fde","NCT04304001",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Colorectal Cancer Screening Self-Efficacy Scale","SECONDARY","Bivariate analyses was conducted for the self-efficacy scale to compare differences between the intervention and control arms. Since self-efficacy was a continuous variable, the values between study arms were compared using two-sample independent t-tests.","D015179","Test Up Now Education Program",TRUE,93,"t-test",NA,NA,NA,1.44227732582979
"2918","b89a9bfcdd81dcffc746f5c2e6b57c25","NCT00656201",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Percentage of Pregnant Patients After IVF Treatments","PRIMARY",NA,"D007246","Comparison of Crinone 8% Intravaginal Gel and IM Progesterone Supplementation for In Vitro Fertilization (IVF)",TRUE,407,"mann_whitney",NA,NA,NA,2.96950840601583
"2919","b89fffdcdc7cebef2b056657fe891734","NCT03468309",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Number of Psychiatric Medications","SECONDARY",NA,NA,"Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population",TRUE,50,"t-test",NA,NA,NA,1.07648023860356
"2920","b8ad8288825af848c7e4ba9cc8b1923a","NCT01588470",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change in Hemoglobin A1c","SECONDARY",NA,"D006331; D003327; D003324; D017202; D003920; D003924","Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)",TRUE,142,"anova",2,NA,NA,1.7695236426303
"2921","b8b3119e812a64a43a8f7d4c709c9a07","NCT02732145",0.0389,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Distribution of Aceto-Whitening Reaction in Relation to the Structures of the Middle Vulvar Ring","SECONDARY","Parameter: The difference in the incidence of aceto-whitening of the Interlabial Sulci versus Posterior Commissure in patients with vulvar dermatosis and positive AWR.","D056650; D008010; D018459; D012871; D009450","Diagnostic Accuracy of ""Three Rings Vulvoscopy"" for Detection of Vulvar Dermatosis",FALSE,82,"t-test",NA,NA,NA,1.10158768933139
"2922","b8b4a8d48d5dea1fddfcd3a5d098de66","NCT01066793",0.0452,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for BMI in kg/m\^2. The logistic regression analysis for relapse was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,427,"logistic_regression",NA,NA,NA,2.79409462445843
"2923","b8d2002d69ca27578a3a28e1c3575fb3","NCT04858802",0.028,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Inflammation Score in the Frontal Recess/FSO by Clinical Investigators","SECONDARY","Day 90","D000096825","A Clinical Evaluation of PROPEL® Contour Sinus Implant",FALSE,160,"t-test",NA,NA,NA,1.1487115326062
"2924","b906ee014c974ff8b63b2e503a6c961d","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in 120-minutes Postload Plasma Glucose","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,111,"anova",2,NA,NA,1.5704144397227
"2925","b913ea5e3a155d76b152dbdb0372ccde","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Health Warning Label","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1732,"linear_regression",NA,NA,NA,6.10370278152778
"2926","b9263ea6df9f4efe3366680e681f5caf","NCT03906136",0.029,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Patients Achieving an ASAS40 Response at Week 12","SECONDARY","Week 12","D013166; D025241; D000089183","AScalate: Treat-to-target in Axial Spondyloarthritis",FALSE,290,"logistic_regression",NA,NA,NA,1.58305064847222
"2927","b94b513df1eb468f00657c3b4261f338","NCT00919893",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Symptomatic Improvement in the Pain Domain of National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI)","PRIMARY","Null hypothesis: Cernilton compared to placebo induces a better or the same outcome of symptomatic improvement in the pain domain of symptomatic Pelvic Pain Syndrome verified by the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI).

Power calculation: A power of 1-beta=0.8 was calculated.","D011472; D013577; D017699; D002908; D013001","Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS)",TRUE,139,"t-test",NA,NA,NA,1.75124288073831
"2928","b95469a74a84dc046c51d604a0086fa1","NCT03332979",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Pre-death Grief in Dementia Caregiving","PRIMARY",NA,NA,"Experiencing Loss and Planning Ahead Study",TRUE,150,"linear_regression",NA,NA,NA,1.8173749039831
"2929","b95e1c4a46e442ba1efcdfafcb702301","NCT04697264",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Correlation Between Circulating Levels of These Markers (Day 0) and Cancer Characteristics in the Study Population, Using Linear Regresion.","PRIMARY","Effects of tumour grade (Grade 1/2), stage (Stage 1/ \>/=1), histology (type 1 and type 2), and MSI (presence or absence) on the biomarker levels (adiponectin, leptin, IGF 1 and 2, IL6 and TNF) were assessed using multivariate linear regression, with binary categorisations to facilitate comparisons.","D016889; D009765","Adipocytokines in Endometrial Cancer",FALSE,50,"linear_regression",NA,NA,NA,1.07648023860356
"2930","b96c0b41dd479cb0b4bfd0a9a65727e8","NCT00935584",0.05,"Wilcoxon","INTERVENTIONAL",0,0,0,0,0,"Change in Patient's Satisfaction, Change in Provider's Satisfaction (Mean/SD)","PRIMARY","The null hypothesis states that there is no significant change in outcome from pre-intervention clinical visit (baseline) to post-intervention clinic visit.",NA,"Patient Centered Evaluation of Computerized Patient Records System",FALSE,126,"wilcoxon",NA,NA,NA,1.66971913113983
"2931","b96cadc66c3a04545761495dd00671e0","NCT03854578",0.048,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Mean BOLD Signal % Change in an Emotional Paradigm in the Corticolimbic System Using the Affective Pictures of the Open Affective Standardised Image Set (OASIS).","SECONDARY","Mean BOLD signal % change/ Amygdala Right","D003866; D003863; D003865","A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions",FALSE,46,"anova",2,NA,NA,1.00182926567556
"2932","b97813b8c13c387920f3527bf3ef014f","NCT04003155",0.026,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate, and Severe VMS From Baseline to Each Study Week Up to Week 12","SECONDARY","Week 9","D019584","A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause",FALSE,348,"logistic_regression",NA,NA,NA,1.57650841173441
"2933","b97b14ca34759b6ec4203294f09411d6","NCT03646305",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Self-Ratings of Body Image Cognitions (Weight Dissatisfaction)","SECONDARY","A paired sample t-test was conducted to measure differences in weight dissatisfaction from post-intervention to follow-up. Null: there would be no differences in weight dissatisfaction from post-intervention to follow-up",NA,"Singing Your Negative Body-Related Thoughts",TRUE,122,"t-test",NA,NA,NA,1.64382327798156
"2934","b9823c9bf8583f1b468b4b2163a6d5e6","NCT01596582",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Provider Satisfaction","SECONDARY",NA,"D015179","Risk Stratification to Promote Effective Shared Decision-Making for Colorectal Cancer Screening",FALSE,74,"mann_whitney",NA,NA,NA,1.2933799900503
"2935","b9879ba0a8ed82f0e5749eb9eb1159e1","NCT00245219",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Physical Health (as Measured With the SF36) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the peer support condition and the control condition at Time 3. The full regression model included 2 dummy coded variables, 1 contrasting the education and control condition, and 1 contrasting the peer support and control condition. The baseline measure of the outcome variable was included, in order to examine changes in the outcomes over time. This model tested the main effects of the conditions among patients with early stage cancer, late stage patients were excluded.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"linear_regression",NA,NA,NA,1.79957957739554
"2936","b988b31718da3e2b30eaa1511be84383","NCT00261443",0.039,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Baseline and Adjusted Mean Change From Baseline in Clinical Global Impression Scale for Bipolar Disorder (CGI-BP) Severity of Illness Score (Mania) Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 24 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,2.15879458692739
"2937","b98c61f66b7aa6f94f3b00445816a3ef","NCT03504852",0.0498,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Subjects Who Achieve Investigator Global Assessment (IGA Modified 2011) Score of 0 or 1 - Week 16 (Full Analysis Set)","SECONDARY",NA,"D011565","Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis",FALSE,331,"logistic_regression",NA,NA,NA,2.6718793935732
"2938","b98d461613836edadd2137c64b0c451a","NCT00787254",0.0355,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 12)","SECONDARY",NA,"D004381; D013276; D014456","Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs",FALSE,119,"mann_whitney",NA,NA,NA,1.21854291989652
"2939","b99459d1a643d1464ae4e6d6f4224f74","NCT01138124",0.0034,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D002292; D007680; D010386; D010195; D050500; D012148","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",FALSE,19046,"logistic_regression",NA,NA,NA,1.8924365962416
"2940","b9b75a70b63c8272dc61693f1a904246","NCT01236053",0.013,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,188924,"logistic_regression",NA,NA,NA,19.8859096728524
"2941","b9d9734bb82fae6e00d1787dae520c8c","NCT02369536",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Plasma Levels of Hepatic Enzymes","SECONDARY","Intention-to-treat-analysis. Differences between basal values in active and control groups and between T1 vsT0 changes in the two groups assessed by ANOVA and Fisher's exact test.","D008107; D005234; D065626","Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)",TRUE,113,"anova",2,NA,NA,1.58401395671428
"2942","ba08a49cf06ff7553bb6c88bd93fc0d9","NCT03050918",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Patient Satisfaction: Experience","SECONDARY",NA,NA,"Discharge Follow-up Phone Call Program",FALSE,476,"mann_whitney",NA,NA,NA,3.20917746408618
"2943","ba163dce532d91bc68c3f4fe86a11f24","NCT01732536",0.049,"ANOVA","INTERVENTIONAL",0,0,1,1,0,"Bilateral Polyp Grade","PRIMARY","Bilateral polyp grade change in a subset of 67 patients with higher polyp burden at baseline (grade 2 or higher on each side confirmed by the independent panel)","D012852; D009298; D011127","Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps",FALSE,100,"anova",2,NA,NA,1.46856433219717
"2944","ba1c5e883d142d2803794d2541b99ebb","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Postprandial Endogenous Glucose Production","PRIMARY","differerences in treatment effect between the 2 groups","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",FALSE,51,"t-test",NA,NA,NA,1.08637315449684
"2945","ba1cbbcbd04484b8cf523b568b01f380","NCT00442936",0.026,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Total Migraine Freedom (TMF) at 2 Hours Post-Dose","SECONDARY",NA,"D008881","Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)",FALSE,645,"logistic_regression",NA,NA,NA,2.13925494644354
"2946","ba1ccb491c36677f49118f76e822cc69","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Pizza Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1728,"linear_regression",NA,NA,NA,6.09666620224612
"2947","ba410feb6ac8786cf46e8a0d450ebc22","NCT01639443",0.024,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Length of Workday","SECONDARY","We counted days containing at least one Fast-tracked participant as a ""Fast-tracked"" day for the sake of analysis at the clinic level. Our null hypothesis is that these days will not differ in terms of length of workday. We are powered to detect approximately 0.5 SD difference in workday length in hours (Type I error rate = 5%; Power = 81%), with a equal ratio of Experimental and Control days.","D003110","Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy",FALSE,1672,"t-test",NA,NA,NA,3.20622809564639
"2948","ba45bc93b493ea1a5b90577bec48530d","NCT01056718",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Resting EF","SECONDARY","Nebivolol treatment group refers to 50 patients that completed 10 weeks of open label nebivolol treatment. Results were compared using paired T-tests in a pre - post study design before and after 10 weeks of his/her treatment. Each subject served as own control.","D006973; D054160","Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function",TRUE,50,"t-test",NA,NA,NA,1.07648023860356
"2949","ba52f3541ec05a5c7b2b5b52efc7ffce","NCT00070707",0.023,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in AM and PM Cough Symptom Score","SECONDARY","Baseline (AM)","D012220; D001249; D006255; D065631","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",FALSE,187,"anova",2,NA,NA,1.04615473483941
"2950","ba5b14d012b5da3048ae13ae8fae8725","NCT02939131",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Adherence Outcomes: Adherence to Anti-HIV Medications - Number of Days in Last 30 With Any Missed Doses","SECONDARY","Comparison of COMB-R and ESC groups, number of days in last 30 with any missed HIV medication doses reported at week 24.","D003863; D003866","IMPAACT 2002: Cognitive Behavioral Therapy and Medication Management for Treatment of Depression in US Youth With HIV",FALSE,125,"t-test",NA,NA,NA,1.38000360714949
"2951","ba63c504e675e95074f94222392b3fda","NCT05302414",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Medical Task Performance","SECONDARY","For follow-up test at the 16 weeks.",NA,"The Learning Outcome of Resuscitation Teamwork Training in Postgraduate Year Doctors and Nurses",FALSE,64,"kruskal_wallis",2,NA,NA,1.20770700959599
"2952","ba78e19fbe0b8223ad575d41c60bbdca","NCT01783041",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,1,0,"Brain Volumes in Infants Who Received L-carnitine Supplementation Compared to Controls","SECONDARY",NA,"D047928; D065886","Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants",TRUE,126,"t-test",NA,NA,NA,1.66971913113983
"2953","ba796826de44f9c2353eb3b6a4b58da5","NCT01694485",0.041,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Mucosal Healing at Week 8","SECONDARY","Comparisons between treatment groups were made using healing rates from a logistic regression model adjusted for baseline rectosigmoidoscopy score and stratification factors (prior vs no prior TNF antagonist use and enrollment pre- vs post-protocol amendment).","D003092; D003093; D014456","Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis",FALSE,195,"logistic_regression",NA,NA,NA,1.74927263452303
"2954","ba9e8ce8b231b089f3cc1aa064f8d198","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Environmental Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1753,"linear_regression",NA,NA,NA,6.14051253521365
"2955","bab395e29d963e37da92a855de243f08","NCT03980483",0.023,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving 20 Percentage (%) Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 Superiority Comparison With Placebo","PRIMARY","The null hypothesis is defined as there is no difference between the 90mg dose of GSK3196165 and 05mg dose of Tofacitinib in the proportion of participants achieving ACR20 response at Week 12, versus the alternative hypothesis that the 90mg dose of GSK3196165 differs from 05mg dose of Tofacitinib in the proportion of participants achieving ACR20 response at Week 12.","D001168; D001172","Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate",FALSE,771,"logistic_regression",NA,NA,NA,2.10211388400519
"2956","bac76000584ee1bb5e633d98234a06c9","NCT01115673",0.032,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Relief (PAR) Scores at 90 Minutes","SECONDARY","The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.","D014098","To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery",FALSE,480,"anova",2,NA,NA,2.20876756561472
"2957","bae37c49945ad8bd2453ecb67389b09e","NCT00562159",0.015,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Participant Average Rhinoconjunctivitis Daily Symptom Score (DSS) Over the Entire GPS","SECONDARY",NA,"D012220; D003231","Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)",FALSE,391,"anova",2,NA,NA,1.03425943966608
"2958","bae860c9cc0922cc82adec6207036d5b","NCT03693989",0.047,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Central Thickness of the Retina","SECONDARY",NA,"D002386; D007249","Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification",FALSE,171,"t-test",NA,NA,NA,1.83983105868952
"2959","bb01eb86774e27d2ccd522d3b1b962d1","NCT01972841",0.037,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With ≥ 10 Points Improvement From Baseline in the OAB-q Symptom Bother Score at Weeks 4, 8, 12 and EoT","SECONDARY","Odds ratio from a logistic regression model including treatment group, sex, age group (\<65, \>=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline OAB-q subscale as a covariate.","D053201; D014570; D001745","This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",FALSE,1242,"logistic_regression",NA,NA,NA,4.00997351723478
"2960","bb20a3ac2c65a4700d19ba03f3c2c3e0","NCT01378299",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Percent Change in Prostate-specific Antigen (PSA) According to the rs1062033 Polymorphism of the CYP19A1 Gene","SECONDARY","Analysis by intention to treat with the last value carry forward.","D007006","CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy",TRUE,63,"anova",2,NA,NA,1.19880559218312
"2961","bb2527e2d17de57a631a48dad0646db9","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Intention to Reduce","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1756,"linear_regression",NA,NA,NA,6.1457530740539
"2962","bb29bf66a5ceece5696cea1c27000ed3","NCT02110758",0.025,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Change in Patient Experience From Baseline to Follow up","PRIMARY","To estimate exposure to the intervention on the Access composite score, we used a difference-in-differences model with fixed effects for practices. The dependent variable was the composite score. The intervention effects were represented by the coefficient estimates for survey time period (pre or post) interacted with status (pilot or comparison).","D009369","Evaluating the Impact of Patient-Centered Oncology Care",FALSE,866,"logistic_regression",NA,NA,NA,2.39384291235098
"2963","bb2bc1ff89d2654649461aca4f8e5dd6","NCT02448381",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score When Compared to Patients Receiving Placebo","PRIMARY",NA,"D008223; D016399; D016411; D009182; D016410","FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)",FALSE,166,"logistic_regression",NA,NA,NA,1.58368763190938
"2964","bb3b62d73fd7040eea2a4c656d4226a6","NCT01559259",0.031,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Intensity Difference on 4-Point Categorical Scale (PID4)","SECONDARY","11 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,119,"anova",2,NA,NA,1.08614060492588
"2965","bb44729f27b4a85ccfe2580877b464d6","NCT00105989",0.047,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Acute and Continuation Phases (Males)","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,109,"t-test",NA,NA,NA,1.47857354645762
"2966","bb602db9720bb53d7de27a0c8e428746","NCT01505491",0.0303,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Area Under the Concentration-time Curve of the BI 695501 in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC0-tz)","PRIMARY","ANOVA (analysis of variance) model on the logarithm scale was used with 'treatment' and 'age' as fixed effect.",NA,"Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects",FALSE,129,"anova",2,NA,NA,1.10738107012245
"2967","bb627ac6da9d544ef5e00ceb8929b98b","NCT01972841",0.009,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 3 Diary Days at Weeks 4, 8, 12 and EoT","SECONDARY","Odds ratio from a logistic regression model including treatment group, sex, age group (\<65, \>=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.","D053201; D014570; D001745","This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",FALSE,1242,"logistic_regression",NA,NA,NA,1.16599222821441
"2968","bb6a54b9837ac56322d9753e3b70bc94","NCT00279201",0.035,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Mean of Post Meals Blood Glucose and Average of All Blood Glucose","SECONDARY",NA,"D003920; D003924","The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)",FALSE,405,"anova",2,NA,NA,2.19206458896904
"2969","bbb294a256f4112f0659e7fd6a890d70","NCT05556148",0.0313,"One-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Each of the WURSS-21 Symptom Domains Score: Cough","PRIMARY","Change from Baseline at Day 2","D003139","Otrivine: Quality of Life (QoL) Impact in a Real-World Setting",FALSE,102,"t-test",NA,NA,NA,1.01714294370693
"2970","bbb2a289436c13ea020fc2bd4195ab2e","NCT04552041",0.0174,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change in Mean Neuropsychiatric Inventory-Clinician (NPI-С) Score","SECONDARY","This analysis applies to domain ""Agitation"" ∆ between baseline and 24 weeks row.","D003704; D015140; D001523; D000066553","Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.",FALSE,399,"mann_whitney",NA,NA,NA,1.18979612223665
"2971","bbb7e88837d637c8e34b356e155da780","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Nighttime Heart Rate","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"2972","bbbc4b0a9988548dd794ae099f08de7a","NCT02949271",0.03,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Ratio of Patient Controlled Epidural Analgesia (PCEA) Successful Attempts to Unsuccessful Attempts","SECONDARY",NA,"D048949","Comparison of PIEB vs CEI for Labor Analgesia",FALSE,120,"mann_whitney",NA,NA,NA,1.06048017302915
"2973","bbbf1e29c0d6d79c2b08124435be585d","NCT03676465",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"HbA1c, Final","SECONDARY",NA,"D003920; D003922; D002908","CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management",FALSE,43,"t-test",NA,NA,NA,1.00454908915455
"2974","bbc5f5e8abf433cbd1285342e03311bb","NCT01236053",0.0369,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,148.230773303583
"2975","bbc79b75ae19c714a47521bfe96dd90e","NCT02930018",0.028,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Subjects With mRS Score of 0 to 2 in the No-alteplase Sub-group","POST_HOC",NA,"D020521","Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke",FALSE,446,"logistic_regression",NA,NA,NA,1.89940066542641
"2976","bbd35b444b97a2b2e7aa0f91bfcad658","NCT04547192",0.047,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Appropriate Use of Key Performance Indicators in Initial Assessment and Management of the Injured at Non-tertiary Hospitals in Ghana","PRIMARY","Date of Injury Recorded","D000066553","Improving Initial Management of the Injured at Ghanaian District and Regional Hospitals With a Trauma Intake Form",FALSE,4077,"linear_regression",NA,NA,NA,8.88485338638038
"2977","bbde77e2c956ee92b562240f9a9c5999","NCT01459653",0.0235,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Predictors of Absolute Neutrophil Count","PRIMARY","ECOG (per 1 point) as predictor for ANC","D009101; D009503; D064147; D000084462; D005334","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",FALSE,1185,"linear_regression",NA,NA,NA,2.65205137346095
"2978","bbedef50b508e62220914a97d0a42063","NCT03114969",0.045,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants Making at Least One Overall Error at Visit 1-Primary Device Comparisons","SECONDARY",NA,"D008171; D029424","Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs",FALSE,100,"logistic_regression",NA,NA,NA,1.36801192328237
"2979","bbf66067553b38fb0be4743f458d7642","NCT01910116",0.031,"Mann-Whitney","INTERVENTIONAL",0,0,1,1,0,"Patient Global Assessment, Change From Baseline","SECONDARY",NA,"D010003","Efficacy of Shinabro in Hand Osteoarthritis",FALSE,215,"mann_whitney",NA,NA,NA,1.44724034290976
"2980","bc1828401f0f71853a4c87544183e528","NCT00911768",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Unstimulated Salivary Flow Rates","SECONDARY",NA,"D014987","Effect of Korean Red Ginseng (KRG) on Dry Mouth",TRUE,90,"t-test",NA,NA,NA,1.41980120127578
"2981","bc26e50618a65d6319676cceac547a89","NCT00707447",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Weight Change","PRIMARY","independent t-tests for between group comparisons, dependent t-tests for within group comparisons","D003920","Evaluation of a Primary Type 2 Diabetes Prevention Programme",TRUE,166,"t-test",NA,NA,NA,1.90948799930043
"2982","bc3549631c2252d26f9cc2f0c7410f7b","NCT03773978",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving PedACR90 Responder Index","SECONDARY","at week 28","D001168; D001171","A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis",FALSE,163,"logistic_regression",NA,NA,NA,1.56967894171416
"2983","bc3a3505de3026f1c6312d31a514a9cc","NCT00608985",0.0376,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Day 1&2 in Wake After Sleep Onset (WASO)","PRIMARY","Change from baseline to day 1\&2 compared with placebo","D007319","Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia",FALSE,345,"mann_whitney",NA,NA,NA,2.15227283288574
"2984","bc3ac8c18a6676b29d8f0b7d1d6d62c0","NCT01951885",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Length of Time on Continuous Infusion Narcotics","SECONDARY",NA,"D007938; D009101; D054198; D015451; D007951; D015464; D006689; D015456; D009190; D009196","Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention",TRUE,96,"mann_whitney",NA,NA,NA,1.46440978390488
"2985","bc4cd2c8b98e2621d4c242ea00b92901","NCT02807480",0.049,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Depressive Symptoms as Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Depression Scale.","SECONDARY","Relationships between baseline average approach behavior during conflict trials on the AAC and trajectory of PROMIS Depression symptoms: time x treatment x approach behavior interaction","D001008","Approach-Avoidance Conflict-a Multi-level Predictor for Therapy Response",FALSE,56,"linear_regression",NA,NA,NA,1.11583235469993
"2986","bc4d7b58495454adb1c173998395ad45","NCT03192176",0.0475,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 3 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 9","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.30902949075322
"2987","bc531c21b323609a0de1bd13689c7d5f","NCT01319721",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Healing Time of Corneal Epithelial Defect","SECONDARY",NA,"D011625; D012008","Recurrent Pterygium Surgery Using Mitomycin C With Limbal Conjunctival or Amniotic Membrane",FALSE,87,"mann_whitney",NA,NA,NA,1.39696496123414
"2988","bc5728cf76cfc12d8b3fe488281e779f","NCT02528253",0.0416,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 2, \>=90%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,811,"logistic_regression",NA,NA,NA,3.58225006347442
"2989","bc66f389bebbd13162e3430d3a489cce","NCT00043186",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Serum CTX Percent Change From Baseline at Month 48","SECONDARY",NA,"D001851","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",FALSE,51,"mann_whitney",NA,NA,NA,1.08637315449684
"2990","bc817713fc4c0920b38f1277ebb02f88","NCT01874431",0.0386,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline to Day 90 in KDQOL-36 Domain Score (Effects of Kidney Disease)","SECONDARY",NA,"D007674; D003928; D003920; D003924","Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy",FALSE,177,"t-test",NA,NA,NA,1.58560815630652
"2991","bcc5fc9e791937d5b6a5e24da52371f5","NCT02493660",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Composite Endpoint Component Level Success for ASES at Month 12 Compared to Baseline in the Per Protocol Population (PP)","SECONDARY","Results from logistic regression model.","D000070636","A Pivotal Study to Assess the InSpace™ Device for Treatment of Full Thickness Massive Rotator Cuff Tears",TRUE,176,"logistic_regression",NA,NA,NA,1.96486948340861
"2992","bcce17655f2333f706542b619f723894","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in Total Cholesterol","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,110,"anova",2,NA,NA,1.56357043896758
"2993","bce25f1ffda9112ee6c7c2255e8469d1","NCT01848054",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Retention in Treatment in the Per Protocol Population","PRIMARY",NA,"D009293","Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence",TRUE,256,"t-test",NA,NA,NA,2.36165385862108
"2994","bcf24f535aaea15fe94aa34a1384ba16","NCT04773028",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Concentration of Matrix Metalloproteinase 2 and 9 Enzymes","PRIMARY",NA,"D006976; D006973","The Role of Matrix Metalloproteinase 2 and 9 Enzymes in Developing Chronic Thromboembolic Pulmonary Hypertension",TRUE,48,"t-test",NA,NA,NA,1.05642048349345
"2995","bcf96dfc4bc7da9696d7c43c13fc1e60","NCT02746679",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Menstruation Was Evaluated With Visual Analogue Scale (VAS) in Which the Menstruation Was Assessed by the Patients Themselves With 0 as Amenorrhea and 100 as Normal Menstruation","SECONDARY",NA,"D006175; D003863","Impact of Mindfulness Based Stress Reduction on Anxiety, Depression and QOL in Women With Intrauterine Adhesion.",FALSE,151,"anova",2,NA,NA,1.82326813686662
"2996","bd01253ffa01e6b736d9d051d75951fc","NCT00245219",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Physical Health (as Measured With the SF36) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The interaction between the peer support condition and breast cancer stage at Time 2. The full regression model consisted of 3 steps: The 1st step contained the baseline measure of the dependent variable. The 2nd step contained two dummy coded variables contrasting each condition with control. The 3rd step contained the interaction between the peer support condition and cancer stage. Patients in the education condition were excluded from this analysis.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"linear_regression",NA,NA,NA,1.79957957739554
"2997","bd1143a43e6430c97d0a9da2e161dde7","NCT00105989",0.046,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in Hamilton Depression Rating Scale Subscales, Including the Core, Maier, Anxiety/Somatization, Retardation/Somatization, and Sleep Subscales, and the Depressed Mood Item - Acute and Continuation Phases","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,412,"t-test",NA,NA,NA,2.78583173151835
"2998","bd1d721ac556f17502d98c893cf207fd","NCT00698035",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Matched E2 by Commercial and Research (RIA) Analyses","SECONDARY","Comparison of baseline estradiol between LC/MS and RIA","D012735","Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients",FALSE,126,"t-test",NA,NA,NA,1.66971913113983
"2999","bd4340a8e5adc9b94329d62baa76b67a","NCT01070550",0.0062,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for cumulative ribavirin dose per 10000 mg, first 12 weeks. The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,2981,"logistic_regression",NA,NA,NA,1.29129519806126
"3000","bd44883391a9cb88c1a9bb244ab28f53","NCT01236053",0.0024,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,20382,"logistic_regression",NA,NA,NA,1.42443668212094
"3001","bd695422b909b5d900b97b79bb08a207","NCT03192176",0.0384,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 7","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,87,"logistic_regression",NA,NA,NA,1.12073570140138
"3002","bd74039c0fe1c7c86acbf15cfd33691f","NCT01236053",0.0144,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,2067,"logistic_regression",NA,NA,NA,2.27996374323798
"3003","bd7a188e45fd540d8870cca4978463a0","NCT01836445",0.036,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mean Score of Health Protective Communication Skills at Baseline and 12 Months","SECONDARY","Analysis for Relationship Maintenance items","D006069","Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men",FALSE,529,"linear_regression",NA,NA,NA,2.56279368807103
"3004","bd801fc9c4b4cdcd464520ace371aa58","NCT04118348",0.021,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Lipid Panel Screening","PRIMARY","HMT was set as the reference group.","D006938; D006937; D006949","Evaluating the Efficacy of Pediatric Lipid Screening Alerts",FALSE,6706,"logistic_regression",NA,NA,NA,5.71091902818603
"3005","bd88920047b23cebbcfb95293b183626","NCT01529385",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Toe Brachial Index","PRIMARY",NA,"D004487","Mild Compression Sock for Control of Lower Extremity Edema in Individuals With Diabetes",FALSE,77,"anova",2,NA,NA,1.31800316623017
"3006","bd95fe825a420d1a5c22127f4a1c2d29","NCT04876482",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Computer Tomography (CT)_Lateral Distance","PRIMARY","We hypothesized that the improvements in the lateral distance on the tip of epiglottis would be more in patients who underwent TORS combined with OPR than in those who underwent only TORS and those who received conservative treatment (controls).","D001049; D012891; D020181","Myofunctional Training for Obstructive Sleep Apnea Patients After Transoral Robotic Surgery",TRUE,74,"linear_regression",NA,NA,NA,1.2933799900503
"3007","bdad30817faddd4fcee22b33c1e961cb","NCT01340027",0.021,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Improvement in PPBC","SECONDARY",NA,"D053201; D014570; D001745; D020924","A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder",FALSE,291,"logistic_regression",NA,NA,NA,1.20011577276224
"3008","bdb1b054084573ea54f466db4427be45","NCT05226884",0.05,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Non-inferiority of Best Corrected Distance Visual Acuity","PRIMARY",NA,"D019591","Intermediate Vision in Patients With Clareon IOLs Compared to Eyhance IOLs",TRUE,310,"mann_whitney",NA,NA,NA,2.59543112524924
"3009","bdbb92dfae86964fe44ba8fe3a9c9fa4","NCT00279201",0.021,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"INITIATION: 7-point Self-monitored Plasma Glucose (SMPG) Profiles and Postprandial Excursions","SECONDARY",NA,"D003920; D003924","The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)",FALSE,1984,"anova",2,NA,NA,3.10924960717657
"3010","bdcaecee010df689ba476267f76af902","NCT03239496",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Seroconversion Non-inferiority of 2 Doses f-IPV ID vs 3 Doses f-IPV ID","PRIMARY","The group sizes are chosen to provide ≥ 80% power for each of the primary objectives, for the individual statistical tests of each serotype, as well as across both serotypes simultaneously. Power of ≥80% is also available for all secondary objectives, except for the comparison of the f-IPV regimen administered at weeks 14 and 36 to the 3-dose IPV regimen, which has power of 62% for individual serotypes, and 39% for the combined serotypes.","D011051","A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV",FALSE,355,"t-test",NA,NA,NA,2.77524765919219
"3011","bdeeaa02efb1f182c773bfd31fd48e2a","NCT03192176",0.0404,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 5","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,87,"logistic_regression",NA,NA,NA,1.16952145106278
"3012","bdf50362a7b96d2cb16c6ef582f4aabc","NCT01796236",0.041,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Abbreviated Profile of Hearing Aid Benefit (APHAB)","OTHER_PRE_SPECIFIED","Month 36: Aversiveness (Unaided)","D034381; D003638; D006314; D046089","Clinical and Health Economic Evaluation With a New Baha® Abutment Combined With a Minimally Invasive Surgical Technique",FALSE,103,"mann_whitney",NA,NA,NA,1.28354908721569
"3013","bdfc5c134c8c0d965ab2b5f959a2dffa","NCT00112151",0.05,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Fat Mass (kg)","SECONDARY","As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in fat mass measured by dual x-ray absorptiometry (DXA) with any T to placebo in subjects assigned to no PRT.",NA,"TEAM: Testosterone Supplementation and Exercise in Elderly Men",TRUE,72,"linear_regression",NA,NA,NA,1.27670232702116
"3014","bdfc73aae8b57833d2762348d3419cb3","NCT04697264",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Correlation Between Circulating Levels of These Markers and Demographic Characteristics.","PRIMARY","The influence of menopausal status on levels of adiponectin, leptin, IGF1 and 2 were analysed by dividing the population into binary groups (pre-menopausal and menopausal) to facilitate comparison.","D016889; D009765","Adipocytokines in Endometrial Cancer",FALSE,50,"linear_regression",NA,NA,NA,1.07648023860356
"3015","be184f507132e37381d47d69ae791972","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Price)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1772,"linear_regression",NA,NA,NA,6.1736274858545
"3016","be1dbd754aae92e9b918554dc7494848","NCT00144339",0.0069,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 12","SECONDARY",NA,"D008171; D029424","Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients",FALSE,4807,"anova",2,NA,NA,1.80446577668772
"3017","be30de0fe41e1997c63082749d99b378","NCT01098747",0.027,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Sum of Pain Relief Rating and Pain Intensity Difference (PRID)","SECONDARY","8 hours: Treatment difference \[Ibuprofen sodium - Ibuprofen (Advil + Motrin IB)\] and corresponding 95% CI were calculated based on LS means from the ANOVA model.","D014098","Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain",FALSE,268,"anova",2,NA,NA,1.43220129458883
"3018","be3ed207eefeef604ce1d511993c4990","NCT04267614",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Disease Activity Score 28 (DAS28) at Month 12","PRIMARY",NA,"D001168; D001172","This Study is to Investigate the Effect of Etanercept in Early Versus Delayed Referral for Management of Rheumatoid Arthritis Patients.",TRUE,979,"t-test",NA,NA,NA,4.59283895163754
"3019","be4683ebb8ccb279082a018c96a0f3ec","NCT01706926",0.03,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Who Achieved American College of Rheumatology 50 (ACR50) Responses at Day 169","SECONDARY",NA,"D001168; D001172","A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis",FALSE,166,"logistic_regression",NA,NA,NA,1.24052215774524
"3020","be49965eb4e44edd463275ce68790145","NCT00128713",0.02,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Platelet Utilization","SECONDARY",NA,"D013921","Optimal Platelet Dose Strategy for Management of Thrombocytopenia",FALSE,744,"mann_whitney",NA,NA,NA,1.82889201593309
"3021","be58c8c7e78a9a9a7f88dd9c1662d985","NCT00528879",0.0275,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])","SECONDARY",NA,"D003920; D003924","A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone",FALSE,267,"logistic_regression",NA,NA,NA,1.45230589985076
"3022","be6c8d9728b37d2c43d07be8e000a6b1","NCT01836445",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Participants Self-Reporting Condomless Anal Sex at Baseline and 12 Months","PRIMARY",NA,"D006069","Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men",FALSE,899,"logistic_regression",NA,NA,NA,3.64751129852964
"3023","be76efb1e41cb01761e1236c460559f0","NCT04229992",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Comparisons of the Changes of Genera Bacteroides by Mg Treatment vs. Placebo in Rectal Mucosa, Swab and Stool Samples","PRIMARY","1. GG genotype and magnesium treatment vs GG genotype and placebo;
2. GA/AA genotype and magnesium treatment vs GA/AA genotype and Placebo","D007249","Calcium: Magnesium Balance, Microbiota, and Necroptosis and Inflammation",TRUE,229,"linear_regression",NA,NA,NA,2.23562103193216
"3024","be7a2f970b9fa68051a683b95f238378","NCT01809002",0.037,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Analysis of Time to Recovery of Sensibility Measured By Static Two-Point Discrimination by Nerve Gap Length (Gap Length 11-25mm) (Data As-reported)","POST_HOC",NA,NA,"Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair",FALSE,110,"mann_whitney",NA,NA,NA,1.21507877985508
"3025","be854f2bf3f0a00cf5925a79ef1a2f33","NCT05807828",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Time Needed to Perform Each Task","SECONDARY","Median difference between the time needed for stem implantation for Control stem group and the time needed for stem implantation for VR stem group","D015207","VR Simulation and Basic Skills in THA",TRUE,101,"mann_whitney",NA,NA,NA,1.50057440421219
"3026","beb9d2456e7ed4e577662ce1b10054fb","NCT03427528",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Social Support Effectiveness","SECONDARY","We used a single group longitudinal pre-post design to evaluate study outcomes","D019052; D003863; D003866","Development, Feasibility and Acceptability of Fathers and Babies (FAB): A Pilot Study",FALSE,60,"t-test",NA,NA,NA,1.17169922891753
"3027","bebe40858d39c27d5ba711060578391a","NCT03828019",0.028,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Macular Edema Over 12 Months of Follow up","SECONDARY","Mixed effects models with a log link were used to assess treatment differences . The outcome measure was the odds ratio of having macular edema (OCT central subfield thickness \> 300 um) at 12 months compared to baseline (BL). The treatment effect was the ratio of Odds ratios (ADA/CID) at 12 months. Values less than one indicate improvement in macular edema for the ADA treatment group relative to the CID group. Decrease in subfield thickness is good","D014605","Adalimumab vs. Conventional Immunosuppression for Uveitis Trial",FALSE,223,"logistic_regression",NA,NA,NA,1.35036839244843
"3028","bec74ae9aeef95f1483527235cf39b16","NCT03962738",0.023,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Who Are Free of Most Bothersome Symptoms (MBS) Associated With Migraine","SECONDARY",NA,"D008881","A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine",FALSE,278,"logistic_regression",NA,NA,NA,1.26979297236372
"3029","bedba584635867555b707e212cdddce7","NCT04047121",0.0231,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"All Cause Total Health Care Cost During 12 Months Post-index Date","SECONDARY","To control and remove the possible influence of the independent variables (like treatment cohort, demographic and clinical characteristics of interest, etc. and clinical judgement) on the outcome measure, multivariable analysis was performed.","D001168; D001172","A Study to Evaluate Patient Characteristics and Treatment Patterns Among Rheumatoid Arthritis Patients",FALSE,374,"linear_regression",NA,NA,NA,1.47483021033877
"3030","beea69f783f94b2d4778a52ecd104f9f","NCT04742907",0.039,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"GIR Outcome Related to Length of Hospitalization (Mean)","SECONDARY",NA,NA,"Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel Resection",FALSE,258,"t-test",NA,NA,NA,1.92380217709813
"3031","bef993f47f16c6ec243f4384b6a9ad34","NCT02403674",0.033,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs)","PRIMARY","Altered sensorium difference","D000163; D015658; D007153","Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)",FALSE,728,"t-test",NA,NA,NA,2.78816324999305
"3032","bf26e3c2822f385239d71ed466d7d3c1","NCT02119325",0.0487,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Cmax for Glucose in IFG Status Participants","PRIMARY","H0: There was no difference in the post prandial glucose peak for participants with IFG between the test and placebo.

The primary parameter was analysed using a mixed effects model with glucose as dependent variable, treatment and period as fixed effects and subject as random effect.",NA,"The Effect of a Nutritional Supplement on Post Prandial Glucose and Lipids in an Adult Population",FALSE,52,"anova",2,NA,NA,1.07267119926245
"3033","bf440c76e20e7e423ab20140417d6f80","NCT01555671",0.029,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"The Duration of Active Phase of Labour","PRIMARY",NA,"D048949","Study of the Effectiveness of Administration of Meperidine on the Length of Active Phase of Labor in Women",FALSE,205,"mann_whitney",NA,NA,NA,1.33552784869456
"3034","bf518c787af460a96245fb13feaa6982","NCT03521115",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Quantity of Alcohol Consumed by Teens on Drinking Days for the Most Recent 30 Days Within the Past Six Months","PRIMARY","12 month follow-up. Among those assigned to intervention, dosage was assigned as 0 for no exposure, 1 for completing only the communication, and 2 for completing the alcohol component. A probit analysis predicting completion was conducted from baseline measures and an instrumental variable, inverse Mills' ratio (IMR) representing the underlying selection processes was included as a covariate accounting for factors related to program completion. All controls were assigned 0 dosage.","D019973; D000435; D000374; D000428; D064829","Family Based Prevention of Alcohol and Risky Sex for Older Teens",TRUE,398,"linear_regression",NA,NA,NA,2.93680585124797
"3035","bf5446c3536db3ac4f448976b5cb9879","NCT03117569",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Undetectable HCV RNA (ITT Population)","PRIMARY",NA,"D006506; D006526; D019698; D006505","Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients",TRUE,380,"t-test",NA,NA,NA,2.87028339010302
"3036","bf5ab11faeb9e24f8c81653030497cfc","NCT03975790",0.0497,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Total All Cause Monthly Health Care Cost","SECONDARY","9 month after index date","D001168; D001172","Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX",FALSE,385,"t-test",NA,NA,NA,2.87441159147592
"3037","bf6ddbe818dbb84aa6184305b72a508e","NCT01971463",0.05,"Wilcoxon","INTERVENTIONAL",0,0,1,0,0,"The Percentage of Change in Optical Cerebral Blood Flow (oCBF) During Bolus Normal Saline Compared to Baseline, as Measured by Diffuse Correlation Spectroscopy (DCS).","PRIMARY","Change in oCBF from baseline to post-bolus, ipsilesional hemisphere","D020521; D000083242","Bolus of Saline in Stroke",TRUE,57,"wilcoxon",NA,NA,NA,1.1439569152679
"3038","bf7238c80d6baeb1029cfa41bec21db4","NCT02528253",0.0144,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 16, \>=30%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1011,"logistic_regression",NA,NA,NA,1.59694659486102
"3039","bf75f15e4b56eb6489c785f75bba5334","NCT00268996",0.021,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Fibrous Tissue and Fibro-fatty as a Percent of IVUS-VH Plaque as IVUS-VH Assessments at Week 52","SECONDARY","Placebo vs Darapladib 160 mg EC tablet: Fibrous tissue as % of VH plaque","D050197","Integrated Biomarker And Imaging Study - 2",FALSE,239,"anova",2,NA,NA,1.08978401441348
"3040","bf767621cbcfc263bec6b81148e9ae46","NCT02214186",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Urine Output During Cesarean Section in Severe Pre-eclampsia","OTHER_PRE_SPECIFIED",NA,"D004461; D011225","Restrictive Fluid Therapy in Severe Preeclampsia",TRUE,46,"mann_whitney",NA,NA,NA,1.03597838019194
"3041","bf7bb43a90408c7c1bdc75523a915a7f","NCT01817530",0.032,"Kruskal-Wallis","INTERVENTIONAL",0,0,1,0,0,"Mean Percentage Change From Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit","SECONDARY","Month 6","D007889; D047708; D014592; D008595; D006470","Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)",FALSE,130,"kruskal_wallis",2,NA,NA,1.16439925871966
"3042","bf90bc9ffe959f2b8e54ba4e0bc34056","NCT02709486",0.0236,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >=30%, >=50%, >=70% and >=90% Response","SECONDARY","Week 24, \>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,563,"logistic_regression",NA,NA,NA,1.83913351735979
"3043","bf9ae150d50c639fe4f2f06c3bf593ab","NCT01005719",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"The Difference in the Onset of Action Based on Median pH Values Between the Two Active Treatments Compared to No Treatment on Day 1 and Day 7","SECONDARY",NA,NA,"Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)",TRUE,118,"mann_whitney",NA,NA,NA,1.61751378500378
"3044","bfa162df84d330cde22fd2f6c64c3d80","NCT02266277",0.0206,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Reliant Medical Group (RMG) Patients With Electronic Health Record (EHR) Documentation of Influenza Vaccine Completion for 2014/2015 Season","PRIMARY",NA,"D007251; D011008","System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts",FALSE,10000,"logistic_regression",NA,NA,NA,6.8570579763669
"3045","bfb25147c32384303ae0141694a78e2a","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Satisfaction Questionnaire","OTHER_PRE_SPECIFIED","Adolescent negative worded score comparing intervention to TAU.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,234,"t-test",NA,NA,NA,2.25949060683958
"3046","bfb4f6e8b8c7cad652dd43a244bc0f97","NCT00949884",0.028,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Participants Achieving Blood Pressure Goals at Week 8","OTHER_PRE_SPECIFIED","Percentage of participants achieving systolic blood pressure goal of \<130 mmHg","D006973","Olmesartan Comparison to Losartan in Hypertensive Subjects",FALSE,850,"logistic_regression",NA,NA,NA,2.61541949637615
"3047","bfb63d2063224a7456d7240d297f6112","NCT03192176",0.0383,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 10","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,87,"logistic_regression",NA,NA,NA,1.11828266038854
"3048","bfba9a235494fb67c088ff7bb527080c","NCT01779362",0.05,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"ACPRg","SECONDARY",NA,"D011236","RISE Adult Medication Study",FALSE,232,"linear_regression",NA,NA,NA,2.24997314719514
"3049","bfd02b5dfc6ad6e4bfa302c30e94124e","NCT01638000",0.011,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Improvement in Symptom Bother Score as Assessed by the OAB-q: ≥ 10 Points Improvement in OAB-q at Week 12 and Final Visit","SECONDARY","Final visit Odds Ratio vs. Mirabegron","D053201; D014570; D001745","A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.",FALSE,1833,"logistic_regression",NA,NA,NA,1.69208174021437
"3050","bfdbabc6b8a4fbf2dfc96d0bdb32ae51","NCT00424762",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Intra-myocardial Triglyceride Content Using in Vivo Magnetic Resonance Spectroscopy at 6 Months","SECONDARY","powered to detect at least 33% difference between groups","D003920; D003924","Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride",FALSE,49,"t-test",NA,NA,NA,1.06649684228356
"3051","bfe5488f485931284b95bfb97e8b78d0","NCT03192176",0.0486,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 3","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,87,"logistic_regression",NA,NA,NA,1.36444443049449
"3052","c01ae80a6311c664381ffe3ea49eb9db","NCT01070550",0.0316,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for age per 10 years. The logistic regression analysis for relapse 24 weeks after EOT was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,227,"logistic_regression",NA,NA,NA,1.51076744577113
"3053","c02a364d37e849d17dde944c7fe004aa","NCT05178979",0.04,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Total HIV Stigma Score Among Clients","SECONDARY",NA,NA,"A Gender Transformative Implementation Strategy With Providers to Improve HIV Outcomes in Uganda",FALSE,108,"linear_regression",NA,NA,NA,1.28614653164923
"3054","c03675f4afeea6512e81af5e3c808c82","NCT00551135",0.0388,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Total Cumulative Dose of Opioids and Tramadol Used During and After Surgery","SECONDARY","Day 4 PS; LS Means from ANOVA model with terms of treatment, pooled center. Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,202,"anova",2,NA,NA,1.698763770238
"3055","c058eed888e98af075636529c2d14e03","NCT02732145",0.0389,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Distribution of Aceto-Whitening Reaction in Relation to the Structures of the Middle Vulvar Ring","SECONDARY","Parameter: The difference in the incidence of aceto-whitening of the Labia Minora versus Posterior Commissure in patients with vulvar dermatosis and positive AWR.","D056650; D008010; D018459; D012871; D009450","Diagnostic Accuracy of ""Three Rings Vulvoscopy"" for Detection of Vulvar Dermatosis",FALSE,82,"t-test",NA,NA,NA,1.10158768933139
"3056","c0654296bded59d0f94920714d7b4f1f","NCT01787383",0.033,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Side Effects TSQM","SECONDARY",NA,"D055623; D007642","A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities",FALSE,163,"mann_whitney",NA,NA,NA,1.33366344930341
"3057","c07914921e545129dbf77c7fbd65f564","NCT00256750",0.0144,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of Physical and Mental Components Using SF-36 Questionnaire","SECONDARY","Physical Component Score; Month 12","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,421,"anova",2,NA,NA,1.03480473685755
"3058","c08411a66eba876f96e2c05e66e149fe","NCT02528253",0.0365,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 32, \>=50%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1011,"logistic_regression",NA,NA,NA,3.57768242821994
"3059","c0bb6b767e8aeb55d268d4c8ea7c2d58","NCT00407745",0.039,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With >=30% Reduction in Weekly Mean Pain Score From Baseline","SECONDARY","Null hypothesis - The rate of responder for the pregabain group was equal to the rate of responder for the placebo group; Alternative hypothesis - The rate of responder for the pregabain group was not equal to the rate of responder for the placebo group","D013119; D009437; D014947","A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury",FALSE,210,"logistic_regression",NA,NA,NA,1.73892121360607
"3060","c0d4cb6d5bfdbcc492987e072400d91b","NCT04321343",0.0424,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline to Week 36 in NAFLD Fibrosis Score","SECONDARY",NA,"D005234; D065626","Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)",FALSE,60,"linear_regression",NA,NA,NA,1.02215806172515
"3061","c0dccdd5d7e660bd56adaf03aa3f76ee","NCT01234649",0.04,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change in Body Weight From Baseline to End of Study (Expressed as % Compared to Baseline)","SECONDARY",NA,"D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",TRUE,72,"anova",2,NA,NA,1.06043757626689
"3062","c0f38fb347134735a9ad81f49275fbe2","NCT01337336",0.009,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Number of the Indicated COPD-related Exacerbations","SECONDARY",NA,"D008171; D008173; D029424","Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population",FALSE,4001,"t-test",NA,NA,NA,2.08879851249057
"3063","c0f766fc12c5b7c782fdf68220d80614","NCT02312154",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Elasticity","PRIMARY","The change in each of the biophysical parameters was calculated as the pretreatment value minus the posttreatment value for each visit, and these pre- vs posttreatment changes were used in the statistical analysis to minimize the intraindividual variation between the two cheeks. The Wilcoxon rank-sum test was performed to compare the week-by-week changes in parameters of the right and left cheeks (i.e., treated vs untreated).",NA,"Changing in Skin Physiology After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces",TRUE,48,"mann_whitney",NA,NA,NA,1.05642048349345
"3064","c114c4f9704379fc12347f055796fcd0","NCT02528188",0.0132,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 40: \>=90% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1989,"logistic_regression",NA,NA,NA,2.07131688626642
"3065","c1402c6a95a817d0ce54eda1e3a56044","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Health Warning Label","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1746,"linear_regression",NA,NA,NA,6.1282671837603
"3066","c1799d720138cbca91c6f63c7dd6619a","NCT01474876",0.02,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Predictors of Maintained Treatment Response and Remission in Participants With Ankylosing Spondylitis","SECONDARY","Treatment response and presence of enthesitis at Visit 0","D013166; D001168; D015535; D025241; D013167","Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis",FALSE,361,"logistic_regression",NA,NA,NA,1.27888353917954
"3067","c193965b4614cb74b63128ebfd5e9fc5","NCT02954848",0.0376,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Percentage of Days Without Symptoms of Heartburn Stratified by Subgroup of Both the Response at Week 2 and the Endoscopic Findings (the Modified LA Classification Grade N or M)","SECONDARY","Statistical analysis for Criteria 2, Grade N and improved response","D005764; D004942","Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)",FALSE,483,"mann_whitney",NA,NA,NA,2.54204903049171
"3068","c19447d0ead78ebfd8721502d18bc724","NCT00070707",0.026,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in AM and PM Rhinorrhea Symptom Score","SECONDARY","Change at Week 3 (PM)","D012220; D001249; D006255; D065631","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",FALSE,187,"anova",2,NA,NA,1.16275975046674
"3069","c19d6206f0f754e5bf1a3ab634bb68a5","NCT01098747",0.043,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Sum of Pain Relief Rating and Pain Intensity Difference (PRID)","SECONDARY","6 hours: Treatment difference \[Ibuprofen sodium - Ibuprofen (Advil + Motrin IB)\] and corresponding 95% CI were calculated based on LS means from the ANOVA model.","D014098","Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain",FALSE,268,"anova",2,NA,NA,2.12853319607921
"3070","c1a5e372a576cb0a178a5f1e68f8f506","NCT00408876",0.027,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in 36-Item Short-Form Health Survey (SF36) - Bodily Pain","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,210,"t-test",NA,NA,NA,1.27098608404993
"3071","c1ac45ff224180164e74d8dca596e5e0","NCT01552954",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Systolic and Diastolic Blood Pressure Change Between Weeks 8 and 16","SECONDARY",NA,"D007674; D051436; D006973","Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan",FALSE,245,"t-test",NA,NA,NA,2.31113652754097
"3072","c1b733554ce32f8f06883474d8b19060","NCT03975790",0.0467,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Total Dose of Oral Corticosteroids During Pre-Index Period","PRIMARY",NA,"D001168; D001172","Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX",FALSE,286,"t-test",NA,NA,NA,2.35568156827067
"3073","c1b757de369756882f7b04ebd653358c","NCT01898208",0.04,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Time to First Appropriate De-escalation or First Appropriate Escalation of Antibiotics","SECONDARY","For time to first appropriate escalation comparing the 3 groups.","D016470; D018805; D016469; D004198","Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures",FALSE,703,"kruskal_wallis",3,NA,NA,1.19746260478714
"3074","c1cbc951e8158bc30b1b3edd83ae97d3","NCT00443560",0.01,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Duration of Labor Analgesia","SECONDARY",NA,"D048949","The Association Between Decreasing Labor Analgesia Epidural Infusion and Forceps Delivery",TRUE,2072,"mann_whitney",NA,NA,NA,1.65249718004833
"3075","c1dae8cf7901a1fd7f24b4f3f993fab3","NCT02237950",0.014,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Recurrence of Individual Amsel Criteria","SECONDARY",NA,"D016585; D014623; D012008","Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)",FALSE,547,"logistic_regression",NA,NA,NA,1.14874729902063
"3076","c206ed0e71fc70fa177c7e0d363dee2f","NCT01183013",0.0345,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Occurrence of Cumulative Treat to Target Efficacy Response, of HbA1c Under Treatment of < 6.5% After 30 Weeks of Treatment","SECONDARY","Treatment comparisons are for fixed dose combination versus monotherapy.","D003924","30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks",FALSE,249,"logistic_regression",NA,NA,NA,1.70374008227294
"3077","c21369e2aa49c9c92c21e872b49c3b97","NCT02417233",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Retention in Care - ART Eligible (Participants Eligible for ART Who Initiated ART and Who Remain on Treatment)","PRIMARY",NA,NA,"Engagement to Care South Africa",FALSE,394,"logistic_regression",NA,NA,NA,1.89554347270814
"3078","c21cbf70f7eca5c805fa30b552450969","NCT02157519",0.025,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Quality of Life","PRIMARY","Analysis comparing the change in social QOL (FACT-Social Well-Being) from baseline to post-assessment between groups adjusting for change in perceived social support (MSPSS) from baseline to post-assessment.",NA,"Mobile Application for Improving Symptoms and Adherence to Oral Chemotherapy in Patients With Cancer",FALSE,164,"linear_regression",NA,NA,NA,1.05475324274229
"3079","c22fde14a4f7da16cd0b60e7e796e030","NCT05321810",0.013,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 24 Months: Secondary Prevention (Balanced) Cohorts","PRIMARY","Statistical analysis has been presented for all time points from 0 to 24 months.","D001281","Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation",FALSE,19397,"t-test",NA,NA,NA,6.37281264833648
"3080","c242b8f4edf3d9d2fc0570effe625537","NCT04003155",0.032,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate, and Severe VMS From Baseline to Each Study Week Up to Week 12","SECONDARY","Week 8","D019584","A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause",FALSE,348,"logistic_regression",NA,NA,NA,1.88411802496466
"3081","c2764576e50e4f2401ec02b2a31cd62a","NCT04567342",0.039,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Appointment Completed","SECONDARY",NA,"D000079263","Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of MMR Vaccination",FALSE,655,"logistic_regression",NA,NA,NA,3.04998425768728
"3082","c27e6ab3d3765c4f2c1f96ee890e23d7","NCT00023595",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"H02: SF-36 Mental Health Subscale","SECONDARY",NA,"D006333; D002318; D006331; D003327","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",FALSE,970,"mann_whitney",NA,NA,NA,3.78815809084818
"3083","c2816084348fcb88d5cc7f178c6b8acd","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Environment)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1753,"linear_regression",NA,NA,NA,6.14051253521365
"3084","c28581b59f365d4c2728de769dbc213c","NCT00455533",0.0434,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]) to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR/RCB1","SECONDARY","ERCC1 203719_at","D001943","Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer",FALSE,295,"logistic_regression",NA,NA,NA,2.249090613468
"3085","c297c921e33c0b4a7161c26200bb4c35","NCT02998203",0.017,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Overall Difference in Median 6-chloronicotininc Acid (6-CN) Levels in Urine Between the Conventional and Organic Periods*","PRIMARY","The overall differences in the medians of biomarkers between the conventional and the organic periods were assessed with the non-parametric Wilcoxon rank sum test","D007249","Organic Diet Intervention in Primary School Children",FALSE,298,"mann_whitney",NA,NA,NA,1.00996685399488
"3086","c2a309d86b0bf336a9c954ad682cdcfb","NCT05127304",0.037,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"COPD-related Health Care Resource Utilization: Pharmacy Fills","PRIMARY",NA,"D029424","A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",FALSE,11316,"linear_regression",NA,NA,NA,12.0850943643871
"3087","c2a9cab6dd26db0c18e15b2d82a88edd","NCT00759954",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Area Under the Curve to the Last Measurable Time Point for Plasma Morphine","SECONDARY",NA,NA,"Comparison of One Morphine Sulfate Sustained-Release 200 mg Capsule With Two 100 mg KADIAN Capsules on Applesauce",TRUE,56,"anova",2,NA,NA,1.13456029943022
"3088","c2b15c058a24bc8173965f82435b2abb","NCT01472432",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Capillary Density","PRIMARY","* Vildagliptin vs Placebo at 3 months.
* Placebo baseline versus placebo 3 months.
* Vildagliptin baseline versus Vildagliptin 3 months.","D016523; D003924; D014456","DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes",TRUE,106,"t-test",NA,NA,NA,1.53589031932405
"3089","c2b908154f7a347193c5cd3f0497d2ae","NCT00806819",0.0387,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Disease Control","SECONDARY","Analysis based on the central independent review","D002289","Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC",FALSE,713,"logistic_regression",NA,NA,NA,3.16054299058465
"3090","c2bb93ccda1be30c2b809afb194ca91e","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Ham Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1749,"linear_regression",NA,NA,NA,6.13351818505813
"3091","c2bc9531a0eff75579d8b876c745968c","NCT01779375",0.05,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"ß-cell Response Measured by Hyperglycemic Clamp","PRIMARY","Seemingly unrelated regression was used to compare treatment arms on the combination of insulin sensitivity (M/I as calculated from the hyperglycemic clamp) and insulin secretion (steady-state C-peptide and ACPRmax as co-primary; ACPRg as major secondary,). See statistical analysis plan for further details and R code.","D011236","RISE Pediatric Medication Study",FALSE,84,"linear_regression",NA,NA,NA,1.37375080866169
"3092","c2c18b150d8008a7eb4fd2ef39eb8087","NCT05268055",0.045,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Healthcare Provider Cultural Competency","PRIMARY","Group comparison of participants less than age 33.",NA,"Sign Here: How to Conduct Informed Consent With Deaf Individuals",FALSE,52,"t-test",NA,NA,NA,1.00495510440857
"3093","c2d035a0803661b64b66ce1856810079","NCT03036800",0.032,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Weight Loss of ≥15% From Baseline (Responder Population)","SECONDARY","A logistic regression with a binary outcome of weight loss of ≥15% from baseline at 16 weeks was fitted. The main covariate was randomised arm, with the model also being adjusted for the stratification variables: site and baseline body mass index (≥45kg/m2; \<45kg/m2).","D009765; D015431","Saxenda in Obesity Services (STRIVE Study)",FALSE,140,"logistic_regression",NA,NA,NA,1.20682863856786
"3094","c2d073dcb9e055e34d0b1ad40b31adb6","NCT00043186",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Serum CTX Percent Change From Baseline at Month 48","SECONDARY",NA,"D001851","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",FALSE,57,"mann_whitney",NA,NA,NA,1.1439569152679
"3095","c2d71dc7797c687a3c2cb85a9f1cb49a","NCT02561806",0.021,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With a sPGA (0) Remission","SECONDARY",NA,"D011565","A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis",FALSE,302,"logistic_regression",NA,NA,NA,1.22218046881734
"3096","c2f5bde9a61dab25931258b10bdd58e6","NCT00591578",0.041,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg.","SECONDARY",NA,"D006973; D000075222","Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension",FALSE,645,"logistic_regression",NA,NA,NA,3.15773479521251
"3097","c2f7a708875e27f2360e68f8ea3f5f31","NCT02175641",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Clinically Significant Weight Loss","PRIMARY",NA,NA,"Peer-Led Healthy Lifestyle Program in Supportive Housing",FALSE,252,"logistic_regression",NA,NA,NA,2.34340986400365
"3098","c305668c7f6ac81f96e6c23ea24a5b09","NCT01063855",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"The Percentage of Patients Who Reported At Least a 1-category Decrease (Improvement) in Interpersonal Difficulty Related to Ejaculation","SECONDARY","Null Hypothesis: No difference at Week 12 last postbaseline observation carried forward (LPOCF) Alternative Hypothesis:- PDE5I + Dapoxetine is superior to PDE5I + Placebo with respect to the outcome measure at Week 12 LPOCF.","D007172; D061686","Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction",FALSE,475,"logistic_regression",NA,NA,NA,3.20583194058481
"3099","c3165f0c73c17c5ba4b8343d711b31ca","NCT00619957",0.0346,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Percent Change From Baseline in Total Proximal Femur BMD, Month 12, ITT Population.","SECONDARY","A total of 210 patients will be randomized to 35 mg once a week risedronate and placebo groups in 2:1 ratio. Sample size will allow detection of a difference of at least 3% in lumbar spine BMD percent change from Baseline at 24 months between risedronate and placebo with at least 90% power. This calculation is based on the assumptions that the common within-group standard deviation (SD) would be below 5%, and the dropout rate within 2 years is about 35%.","D010024","Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis",FALSE,266,"anova",2,NA,NA,1.76427032541231
"3100","c3275cf8dcf94ee07f2be3b355492a9e","NCT02046980",0.0366,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Conversion in Direction of Nystagmus From Apogeotropic to Geotropic or Disappearance of Nystagmus","PRIMARY",NA,"D014717; D065635; D004244","Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo",FALSE,139,"logistic_regression",NA,NA,NA,1.34781976517953
"3101","c329cd14593323a533b3930e797bd07c","NCT01217801",0.05,"Linear regression","INTERVENTIONAL",0,1,0,0,0,"Area Under Plasma Concentration","PRIMARY","Linear mixed effect model, log transformed AUC, LSMeans for treatment Film and Tablet, the difference between the LSMeans and 90%CI calculated and transformed to geometric means, ratio estimates and 90%CI","D044342","Two Way Bioequivalence Study Under Fed Conditions",FALSE,90,"linear_regression",NA,NA,NA,1.41980120127578
"3102","c330ef7f2e10a614c5cbf635c69e6ca0","NCT01557322",0.016,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Blood Pressure (BP)","PRIMARY","Systolic Blood Pressure: p-value was calculated using 2-sided t-test.","D001168; D001172","Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)",FALSE,1682,"t-test",NA,NA,NA,2.25727280043526
"3103","c3477303273fba0afc1d015b2dc05d0b","NCT01065350",0.042,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Average Change in Diastolic Blood Pressure (DBP)","SECONDARY","Average change in Diastolic Blood Pressure from baseline to 10 minutes post induction was compared between treatment groups.",NA,"A Comparison of Ketofol (Ketamine and Propofol Admixture) Versus Propofol as Induction Agents on Hemodynamic Parameters",FALSE,84,"t-test",NA,NA,NA,1.18817748913687
"3104","c347c6ab9d2265f312c11d893365c852","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Saturated Fat","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1778,"linear_regression",NA,NA,NA,6.18404799831431
"3105","c34cd8b516cbbd1d01e2c256ecbd6911","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Total Energy Intake at Follow-up","SECONDARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",FALSE,101,"anova",2,NA,NA,1.50057440421219
"3106","c36935cbef7f85de1e1aa9d2e93a5b44","NCT00762762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"HbA1c Levels in Blood","PRIMARY","The null hypothesis states that there is no difference between groups.","D010518","Effectiveness of a Triclosan Containing Toothpaste in Maintaining Periodontal Health in a Type 2 Diabetic Population",FALSE,46,"anova",2,NA,NA,1.03597838019194
"3107","c36f07c553f52cab7d8308e899e42650","NCT01817530",0.04,"Kruskal-Wallis","INTERVENTIONAL",0,0,1,0,0,"Mean Percentage Change From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit","SECONDARY",NA,"D007889; D047708; D014592; D008595; D006470","Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)",FALSE,155,"kruskal_wallis",2,NA,NA,1.53169711141017
"3108","c3777e79ed9128bf122d36f52e657e46","NCT03928717",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"HIV-1 Viral Load (log10 Transformed)","PRIMARY",NA,"D000163; D015658","A Text-Based Adherence Game for Young People Living With HIV in Ghana",TRUE,48,"anova",2,NA,NA,1.05642048349345
"3109","c399b0f52b4568767eeef73ddc81ef0c","NCT00126113",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Psychosocial Impact of Assistive Devices Scale (PIADS)","PRIMARY",NA,"D034381; D003638","The Performance-Perceptual Test as a Counseling Tool",FALSE,69,"anova",2,NA,NA,1.25127183253256
"3110","c3b6852111d26a72c5eea149b255086f","NCT01539070",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Children´s Consumption of Foods From Baseline to 3 Months by Intervention Assignment","PRIMARY","In intent-to-treat analyses, we used unadjusted and adjusted multivariate regression models, to examine differences from baseline to 3 months between the intervention and usual care groups. For continuous outcomes, we used linear regression models, and for dichotomous outcomes, we used logistic regression models. To account for clustering by practices, we performed generalized linear mixed models. The Estimator (Est) and Confidence Interval 95% (95% CI)are reported.","D009765; D063766","Intervention for the Prevention of Obesity in Preschool",TRUE,306,"linear_regression",NA,NA,NA,2.5788408992482
"3111","c3cc646e0f384f68caad2873d3deca30","NCT02863198",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Measurement of Uterine Artery Resistance Index","PRIMARY",NA,"D007246","Endometrial Injury for Unexplained Infertility",TRUE,120,"t-test",NA,NA,NA,1.63072147479452
"3112","c3dfa217a8b2d4b87b20f3c942375f89","NCT01972841",0.009,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, at Least 10 Points Improvement on OAB-q Symptom Bother Scale and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT","SECONDARY","Odds ratio from a logistic regression model including treatment group, sex, age group (\<65, \>=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q symptom bother scale and baseline PPBC as covariates.","D053201; D014570; D001745","This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",FALSE,1242,"logistic_regression",NA,NA,NA,1.16599222821441
"3113","c3f45d8a3d3ba38b4bfe233c3a51d34f","NCT05302414",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Medical Task Performance","SECONDARY","For the pretest at week 0.",NA,"The Learning Outcome of Resuscitation Teamwork Training in Postgraduate Year Doctors and Nurses",TRUE,64,"kruskal_wallis",2,NA,NA,1.20770700959599
"3114","c417c1fefd9ebdecf62a6ce6214e846a","NCT01459653",0.016,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Modeling Composite Outcome (Any of CIN Grade 4, FN, CIN/FN-related Hospitalization, CIN/FN-related Chemotherapy Disturbance): Patient Level","SECONDARY","History of repeated infections at enrollment as patient-level predictor for composite outcome (any of CIN Grade 4, FN, CIN/FN-related hospitalization, CIN/FN-related chemotherapy disturbance)","D009101; D009503; D064147; D000084462; D005334","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",FALSE,1291,"logistic_regression",NA,NA,NA,1.97861395292725
"3115","c41ae4e13b5aac3224a1efea55c829f9","NCT01225822",0.0373,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Proximal DVT, PE (Pulmonary Embolism) and VTE Related Mortality","SECONDARY","BIBR 1048 225 mg bid vs. BIBR 1048 50 mg bid, same methodology as primary endpoint.","D013923; D054556","BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery",FALSE,753,"logistic_regression",NA,NA,NA,3.14741532930182
"3116","c41d020c4e157f873c4e4d913dc7e99f","NCT00397033",0.029,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Clinical Global Impression (CGI-C) - Change for Schizoaffective Disorder","SECONDARY",NA,"D011618","Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.",FALSE,211,"anova",2,NA,NA,1.35448325486683
"3117","c43d433035c0fccdc70f3d926b368b63","NCT03237481",0.024,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) for HTX 011 Compared With Bupivacaine HCl.","SECONDARY",NA,"D010149","Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)",FALSE,336,"mann_whitney",NA,NA,NA,1.44602825705517
"3118","c44262a735d83bf1b1f8e56f8ac72003","NCT00860470",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Extremely Pre-term","SECONDARY",NA,"D047928; D066087; D001724; D066088","Antenatal Micronutrient Supplementation and Infant Survival",FALSE,26808,"logistic_regression",NA,NA,NA,15.5439193719554
"3119","c44e104862e982ee4f9d821170312705","NCT00458406",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Minutes of Use Per Night at Month 3","PRIMARY","Two-sided t-test. We hypothesized that Bi-Flex would result in improved adherence but similar effi cacy to CPAP.

The study sample size of 45 in the Bi-Flex group and 15 in the CPAP group had 80% power to detect an effect size ≥ 0.85 with a 0.05 two-sided significance level. In addition, with this sample size, the 95% CI for the difference between the 2 means had a range of 1.282 SD.","D001049; D012891; D020181","Evaluation of Adherence and Therapeutic Effectiveness of Bi-Flex Versus CPAP in Children With OSA",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"3120","c47f083e9dbb4a55e111520b08653b7e","NCT03019796",0.04,"ANOVA","INTERVENTIONAL",1,0,0,0,0,"Systolic Blood Pressure","PRIMARY",NA,"D024821; D013577","Exercise Training Effects on Metabolic Syndrome: Interactions With Medication",FALSE,76,"anova",2,NA,NA,1.08781774095059
"3121","c4821e9ddbf6f8efe0f34be2be04cdce","NCT02528253",0.011,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 8, \>=30%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1011,"logistic_regression",NA,NA,NA,1.25845710743176
"3122","c494107bad82afe77fafba200b358e8e","NCT01342523",0.028,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"7-Day Point-Prevalence Abstinence From Smoking","PRIMARY","Null hypothesis: No difference in 3-month abstinence rates for participants receiving NRT vs No NRT. We hypothesized that NRT would result in significantly higher abstinence rates compared to No NRT.","D014029","Evaluation of National Cancer Institute (NCI) Smoking Intervention Resources",FALSE,1034,"logistic_regression",NA,NA,NA,2.88318611466369
"3123","c4b138a9a832eb2750c0e2b398ea9d4f","NCT04662060",0.05,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Time to First Resolution","SECONDARY",NA,"D000086382","COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol",FALSE,120,"linear_regression",NA,NA,NA,1.63072147479452
"3124","c4c305ef379666150586e24a379da6c4","NCT02696031",0.026,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 20 Response","SECONDARY","week 16","D013166; D025241; D000089183","Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis",FALSE,371,"logistic_regression",NA,NA,NA,1.6270537778269
"3125","c4c9a8f17548e979ac13f3a6161222f8","NCT04076020",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Proportion of Days Covered","PRIMARY","Proportion of days covered (PDC) analyzed as a binary variable with optimal adherence determined as ≥0.80) variables using logistic regression and adjustment for trial stratification factors. Our power calculations assume use of 2-sided tests with 0.05 significance level.","D001281; D006331; D001145; D010335","Atrial Fibrillation Health Literacy and Information Technology Trial in Rural Pennsylvania Counties",TRUE,250,"logistic_regression",NA,NA,NA,2.3342344209023
"3126","c4d6090ccbfc2a595039e08b537a1eb1","NCT00330733",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,1,0,"Change in Systemic Glucose Disposal- Glucose Infusion Rates","PRIMARY","Paired comparisons (follow-up vs baseline) and unpaired group comparisons were performed by Student's t tests or Wilcoxon signed rank tests.","D002318; D050197; D007333; D003924; D007249","Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk",TRUE,58,"t-test",NA,NA,NA,1.15327776573523
"3127","c4e23ba6f7311d495c6bb58fa35606b5","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Health Warning Label","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1756,"linear_regression",NA,NA,NA,6.1457530740539
"3128","c505102caf4361c945347f9d278c4336","NCT02528188",0.0349,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 2: \>=90% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1989,"logistic_regression",NA,NA,NA,4.82486041569943
"3129","c5061ec4eaf7654da9d71571781a5869","NCT01215695",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Intubation Time","PRIMARY",NA,NA,"Video-laryngoscope With a Novel Video-stylet for Difficult Intubation",TRUE,140,"mann_whitney",NA,NA,NA,1.7573575639879
"3130","c506f6c4ba36f183238e29de6c4256ea","NCT01951885",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Length of Hospitalization","SECONDARY",NA,"D007938; D009101; D054198; D015451; D007951; D015464; D006689; D015456; D009190; D009196","Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention",FALSE,96,"mann_whitney",NA,NA,NA,1.46440978390488
"3131","c51502be79d53e187e728a3891a7a8ce","NCT03750695",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percent Change in Endothelial Function","PRIMARY","Repeated measures linear regression","D016640; D004461; D011225; D011248","Acute Exercise Effects in Obese Pregnancy",TRUE,45,"linear_regression",NA,NA,NA,1.02560707988412
"3132","c51ad7c42d125ac145258aeba4b21230","NCT03930732",0.0089,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With SGRQ Improvement >=4 Points at Week 52","SECONDARY","Derived from logistic regression model which includes treatment group, region (pooled country), ICS dose, smoking status at screening, and baseline SGRQ total score as covariates. Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).","D008171; D008173; D029424; D007249","Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation",FALSE,939,"logistic_regression",NA,NA,NA,1.00466996376581
"3133","c52e2a117720383bb4cb50ba97290a87","NCT01539070",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Children´s Consumption of Foods From Baseline to 3 Months by Intervention Assignment","PRIMARY","In intent-to-treat analyses, we used unadjusted and adjusted multivariate regression models, to examine differences from baseline to 3 months between the intervention and usual care groups. For continuous outcomes, we used linear regression models, and for dichotomous outcomes, we used logistic regression models. To account for clustering by practices, we performed generalized linear mixed models. The Estimator (Est) and Confidence Interval 95% (95% CI)are reported.","D009765; D063766","Intervention for the Prevention of Obesity in Preschool",TRUE,306,"linear_regression",NA,NA,NA,2.5788408992482
"3134","c536d915120da54311eb24d40f752bff","NCT00762528",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Bleeding on Probing (BOP)","SECONDARY","The null hypothesis states that there is no difference between groups.","D005891","Compare Anti-inflammatory Dentifrices",TRUE,49,"anova",2,NA,NA,1.06649684228356
"3135","c547178fe3d8d904d611b73df7231732","NCT00070707",0.035,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in AM and PM Chest Tightness Symptom Score","SECONDARY","Change at Week 4 (AM)","D012220; D001249; D006255; D065631","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",FALSE,187,"anova",2,NA,NA,1.49908097015965
"3136","c5496962a10bfc3f57e5e4062b15e535","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Fasting Insulin","SECONDARY","Difference in treatment effect between the 2 groups","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",FALSE,50,"t-test",NA,NA,NA,1.07648023860356
"3137","c555342947bbe3411b287d1a2cfe4922","NCT03589768",0.0261,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"GMC of Serum IgG Antibodies to Tetanus in Infants Born to Women Receiving BOOSTRIX or Td","SECONDARY","Statistical analysis for one month after receipt of first dose of DTwP (approximately 10 weeks of age) time point","D013742; D004165; D013746","Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants",FALSE,188,"t-test",NA,NA,NA,1.16963687900689
"3138","c569b1da559aa5329d8fc09e5b686979","NCT01945034",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Physician Global Assessment of Ankle Injury at Day 3 and 10","SECONDARY","Day 10: The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline physician global assessment terms. Upper limit of 95% CI \< 0 for Ibuprofen treatment significantly better than combined Placebo.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,219,"anova",2,NA,NA,2.18710096911154
"3139","c5828dae55682c2851572829251fc8b0","NCT04876482",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Jaw Opening Muscle Strength","PRIMARY","We hypothesized that the improvements in the jaw opening muscle strength would be more in patients who underwent TORS combined with OPR than in those who underwent only TORS and those who received conservative treatment (controls).","D001049; D012891; D020181","Myofunctional Training for Obstructive Sleep Apnea Patients After Transoral Robotic Surgery",TRUE,74,"linear_regression",NA,NA,NA,1.2933799900503
"3140","c596224ccebf3dfd4e79776cd457c3f3","NCT01690117",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in Physical Quality of Life on the German Version of the Physical Component Summary of the General Health Questionaire Short Form 12 (SF-12) at Month 6","SECONDARY",NA,"D003704","German Adaptation of REACH II",FALSE,81,"t-test",NA,NA,NA,1.3501394396673
"3141","c5aba38edc6399097a007177bcfac5a1","NCT01459653",0.032,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Modeling CIN/FN-related Hospitalization: Cycle Level","SECONDARY","Under- vs. correctly prophylacted as patient-level predictor for CIN/FN-related hospitalization","D009101; D009503; D064147; D000084462; D005334","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",FALSE,1383,"logistic_regression",NA,NA,NA,3.73750851963124
"3142","c5ad8dfac5e9dbfc0b9cb64f2ca06d75","NCT01894230",0.0486,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Beliefs About Medications (BMQ) Score at Baseline, Month 3 and Month 8","SECONDARY",NA,"D006937","Genetically Guided Statin Therapy",FALSE,157,"linear_regression",NA,NA,NA,1.81475533513229
"3143","c5b649a1abe1e2f0009b9ca4994baefc","NCT02347124",0.02,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Motivation for Seeing a Dentist, From Baseline to 2-month Follow-up","OTHER_PRE_SPECIFIED",NA,"D009059","Promoting Oral Health Among Smokers Randomized Trial",FALSE,566,"linear_regression",NA,NA,NA,1.59700603636906
"3144","c5c0064dd1fec223a5781375eacadc6a","NCT01234649",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)","SECONDARY","Nested repeated measures design","D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",FALSE,72,"anova",2,NA,NA,1.27670232702116
"3145","c5c53a19007599cd0e971727f11996a9","NCT00683020",0.03,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Changes in the Physical Component Summary of the SF-12 Health Survey","PRIMARY",NA,NA,"Harnessing Health IT for Self-Management Support and Medication Activation in a Medicaid Health Plan",FALSE,238,"linear_regression",NA,NA,NA,1.47902440484229
"3146","c5e5eafb1fd5be0c541190134e4bf17d","NCT03085797",0.02,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Individual VAS Symptom Score: Loss of Smell During the 4 Weeks Prior to Week 52","SECONDARY",NA,"D009298; D011127","Effect of Mepolizumab in Severe Bilateral Nasal Polyps",FALSE,407,"mann_whitney",NA,NA,NA,1.35677138551958
"3147","c5ec334157aa747f83eb3d78e7d57b42","NCT04552041",0.0432,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change in Mean Neuropsychiatric Inventory-Clinician (NPI-С) Score","SECONDARY","This analysis applies to domain ""Aberrant vocalizations"" ∆ between baseline and 24 weeks row.","D003704; D015140; D001523; D000066553","Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.",FALSE,399,"mann_whitney",NA,NA,NA,2.60081193741117
"3148","c5eed28dc4d848575aefbc4887248a9f","NCT00455533",0.0266,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]), to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR","SECONDARY","TUBB2B 214023_x_at","D001943","Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer",FALSE,295,"logistic_regression",NA,NA,NA,1.48219912050431
"3149","c5f78b052851e159d15dba551ddd8c9c","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Tax","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1732,"linear_regression",NA,NA,NA,6.10370278152778
"3150","c633f9e6c155a141e59fe7ad81fd2406","NCT04490109",0.0195,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Proportion of Subjects With Any Improvement in Investigator's Global Assessment (IGA) From Baseline to Week 4","OTHER_PRE_SPECIFIED","Responder rates for IGA and EASI will be summarized using descriptive statistics and analyzed using a logistic regression model at each respective timepoints.","D003876; D003872; D004485; D011537","B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis",FALSE,335,"logistic_regression",NA,NA,NA,1.20581198717423
"3151","c64d3bb77e3f4be368915c821c9ae1d5","NCT04883541",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Comparison of Average Self-sufficiency Scores of Pregnant Women in the Study and Control Groups","SECONDARY",NA,"D048949","Effects of Yoga and Meditation on The Birth Process",TRUE,90,"t-test",NA,NA,NA,1.41980120127578
"3152","c6525194ef2e83b3ce66ea435ecf0cf2","NCT03773978",0.043,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving PedACR100 Responder Index","SECONDARY","at week 44","D001168; D001171","A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis",FALSE,163,"logistic_regression",NA,NA,NA,1.66818568538055
"3153","c658b66edbad29ed4848ed150f264a09","NCT02697773",0.0307,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Osteoarthritis","SECONDARY","Week 16: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline PGA of osteoarthritis, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,463,"logistic_regression",NA,NA,NA,2.09400024146671
"3154","c66d30b138eef798fc05aa6f9c943d62","NCT02528188",0.0358,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Progression of Osteoarthritis in the Index Knee (Kellgren-Lawrence Grade 2 or 3) According to Bland and Altman Method at Weeks 56 and 80","SECONDARY","Decrease in medial JSW at Week 56: Logistic regression model included treatment, and baseline JSW as covariate.","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1346,"logistic_regression",NA,NA,NA,4.05836489276818
"3155","c6799eb1e1a5637049201eb8e0794e0f","NCT02303704",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Pharmacological Inotropic Support (Nor-adrenaline)","SECONDARY","Null Hypothesis: The dose of nor-adrenaline on weaning from CPB is same for Group I and II.",NA,"Myocardial Protection With Multiport Antegrade Cold Blood Cardioplegia",TRUE,434,"t-test",NA,NA,NA,3.06552394865376
"3156","c67bab45ee50d9319f4902ffb5316c29","NCT01874262",0.025,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Non-adherence Score","PRIMARY",NA,"D009203; D007238","A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients Diagnosed With Myocardial Infarction",FALSE,162,"mann_whitney",NA,NA,NA,1.04850033988674
"3157","c68ed0dcc4f5ca7e060a9065abc07f86","NCT01945034",0.027,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","SECONDARY","Upon Weight Bearing 6 hour Day 1: The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity on weight bearing terms. Upper limit of 95% CI \< 0 for Ibuprofen treatment significantly better than combined Placebo.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,219,"anova",2,NA,NA,1.29731480013009
"3158","c6a34f80698e8949f371868f85f457ad","NCT00922194",0.05,"Wilcoxon","INTERVENTIONAL",0,0,0,0,0,"Change in Body Mass Index (BMI) From Baseline at 12 Months or More","PRIMARY","Analysis of difference between 12 months or more and baseline values","D003920; D003924; D050177","Metformin in Overweight Type 2 Diabetes Mellitus",TRUE,102,"wilcoxon",NA,NA,NA,1.50770356720122
"3159","c6ac3c39679a4b9dd2307c9578f999cf","NCT05819190",0.0296,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"AUC (Area Under Curve) of Wisconsin Upper Respiratory Symptom Survey (WURSS-21) During First 8 Days of Symptoms as Compared Between Both Groups - Per Protocol Set (PP)","PRIMARY","Comparison of the mean AUC of WURSS-21 scores assessed during the first 8 days of the study between both groups - PP set","D003139","Testing the Efficacy in Adults With Cold of HEalsea Rescue*",FALSE,126,"mann_whitney",NA,NA,NA,1.07329477529735
"3160","c6b12769988adbe90d04985b92ca5c87","NCT03855189",0.03,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Response To Therapy At Day 4 (Participant-Evaluated)","SECONDARY","Pairwise treatment comparison based on t-test from an analysis of variance (ANOVA).","D012220; D065631; D006255","Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)",FALSE,226,"anova",2,NA,NA,1.44201315901325
"3161","c6f2836dd2db388b29fa8000480d28d2","NCT02016781",0.0344,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Quality of Life (QOL) - Functional Assessment of Cancer Therapy-General (FACT-G)","SECONDARY","The null hypothesis is that the changes in FACT-G scores from enrollment are the same at 36 Months for both treatments.","D009190","Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)",FALSE,384,"anova",2,NA,NA,2.1038978341859
"3162","c6fe8998ef066fa905776340943fe66d","NCT02266277",0.0026,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Reliant Medical Group (RMG) Patients With Electronic Health Record (EHR) Documentation of Influenza Vaccine Completion for 2014/2015 Season","PRIMARY",NA,"D007251; D011008","System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts",FALSE,10000,"logistic_regression",NA,NA,NA,1.07379248329479
"3163","c7132a1d0db9d52fe3c1cc60c18d3169","NCT00755807",0.035,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Monocytes at Week 18 (Open-label Extension Phase)","OTHER_PRE_SPECIFIED",NA,"D009103; D012598","Duloxetine for Multiple Sclerosis Pain",FALSE,198,"mann_whitney",NA,NA,NA,1.54152338022429
"3164","c71de2ed86ce1a9dca37eadcdfd98091","NCT00468845",0.0271,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Brief Pain Inventory-Short Form (m-BPI-sf): Pain Interference Index Scores","SECONDARY","Day 7","D010149","Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy",FALSE,303,"anova",2,NA,NA,1.52609489204328
"3165","c730d6252e5fa53121e96416c53cc43a","NCT04057573",0.0436,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving a ≥ 25%, ≥ 75%, and ≥ 90% Improvement in the Total Body Vitiligo Area Scoring Index (T-VASI25/75/90) Score at Week 24","SECONDARY","T-VASI75","D014820","Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)",FALSE,331,"logistic_regression",NA,NA,NA,2.38981875886955
"3166","c744abcda459cb7d6d8bf198998021f4","NCT01272232",0.0142,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of Subjects Reaching Target HbA1c Below or Equal to 6.5%","SECONDARY","Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.","D050177; D009748; D001835","Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes",FALSE,616,"logistic_regression",NA,NA,NA,1.23361707491062
"3167","c754ee43b60faafa85ea51d2b9a5144d","NCT01350804",0.0458,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20).","PRIMARY",NA,"D001168; D001172","Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)",FALSE,276,"logistic_regression",NA,NA,NA,2.27722861627943
"3168","c75b826c8ace3cf22a7303b4d944b35f","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in HbA1C","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,111,"anova",2,NA,NA,1.5704144397227
"3169","c75c9dfb32ce8970359a558e099b1d70","NCT02528253",0.0124,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 16, \>=50%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1010,"logistic_regression",NA,NA,NA,1.39873547376895
"3170","c7715d8bfd01f5e793487343b19aa6ef","NCT01910116",0.042,"Mann-Whitney","INTERVENTIONAL",0,0,1,1,0,"Tender Joint Count, Change From Baseline","SECONDARY",NA,"D010003","Efficacy of Shinabro in Hand Osteoarthritis",FALSE,215,"mann_whitney",NA,NA,NA,1.87261091687708
"3171","c78554a10ebe43175973ca3e942bd4d5","NCT04833777",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Post-operative Pain","PRIMARY",NA,"D002349","Does a Different Local Anesthetic Improve Pain After Carpal Tunnel Release?",TRUE,139,"mann_whitney",NA,NA,NA,1.75124288073831
"3172","c7954636360d3c6114011ec0ecd2615d","NCT00608530",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Roland and Morris Disability Questionnaire Nurse-Delivered Treatment Study","PRIMARY","Primary analyses consisted of modified intent-to-treat analysis of all randomized participants who attended at least 1 treatment session, with multiple imputation to address missing data. The study was powered at 80% to detect large effect sizes (\>.50SD) and alpha of .05 with a recruitment goal N = 140; with the N = 61 actually obtained, our a priori power was .55 to detect between group differences.","D001416","Telehealth Outreach for Chronic Back Pain",FALSE,61,"anova",2,NA,NA,1.1808032050005
"3173","c79bfa699cf1822393bccade55da5f28","NCT01438489",0.029,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Type I Interferon (IFN) Test High Participants Achieving an Systemic Lupus Erythematosus Responder Index (SRI) (4) Response With Oral Corticosteroids (OCS) Tapering at Day 169","PRIMARY","High","D008180","A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus",FALSE,154,"logistic_regression",NA,NA,NA,1.16200720224721
"3174","c7a15e9fe26f3f8d7255b55d12410ac3","NCT05001165",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Change in the Number of Patients Receiving Beta-blockers","SECONDARY",NA,"D006333","Dashboard Activated Services and Tele-Health for Heart Failure",TRUE,300,"logistic_regression",NA,NA,NA,2.55375355277734
"3175","c7ae8faba008ccb8ab781798fa976aec","NCT04262882",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Change in Fertility Discordance Between Partners","SECONDARY",NA,NA,"Multilevel Family Planning Intervention",FALSE,139,"logistic_regression",NA,NA,NA,1.75124288073831
"3176","c7af1bf92bb8503cc60c4fdc3876f67a","NCT00297778",0.0337,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Week 12","SECONDARY",NA,"D010300; D003863","Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms",FALSE,280,"mann_whitney",NA,NA,NA,1.76918351425817
"3177","c7d2db677c2e36de32bf268d19422a3d","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Specific Perceived Environmental Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1752,"linear_regression",NA,NA,NA,6.13876469477842
"3178","c7d720bc6d630e6e13ddc6231f8aff73","NCT01416194",0.01,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Thyroid Disorders- Goitre","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",TRUE,3831,"linear_regression",NA,NA,NA,2.24534283552016
"3179","c7e93982755508ddad213cf433632353","NCT03978871",0.048,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Mean Change From Baseline to 2 Months in Self-Reported Emotion Regulation Strategies Scores","SECONDARY","We are reporting the p-value for the group (Growth Mindset vs. Brain Education) by time effect (pre-manipulation and post-manipulation) on ERD involuntary dysregulation scores from time 1 to time 2. This is a test of between by within-subjects interaction effect.",NA,"Effect of Emotion Mindsets on Emotion Processing",FALSE,144,"anova",2,NA,NA,1.72200625660618
"3180","c7e9d46482029039082b3a5d1ff8bfd1","NCT01957865",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Antiretroviral Therapy (ART) Adherence Levels","PRIMARY","In an intention-to-treat analysis, percentage doses taken each month were compared by linear generalized estimating equations (GEEs); more than 48-h and more than 96-h lapses in dosingwere compared by Poisson GEE regression.","D000163; D015658","Real-Time Antiretroviral Therapy Adherence Intervention in Uganda",TRUE,62,"linear_regression",NA,NA,NA,1.18983814919554
"3181","c7ed0918109956f7318ac8df5a93ef0e","NCT00408876",0.039,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to 13 Week Endpoint in Laboratory Assessments - Alanine Transaminase","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,160,"t-test",NA,NA,NA,1.52267454751667
"3182","c7fa01e5bdb3809e29507a1b3651336b","NCT03192176",0.0399,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 4","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,87,"logistic_regression",NA,NA,NA,1.15737355044745
"3183","c7fca1f3660a7a555953dedade2fca01","NCT01517373",0.0436,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12","PRIMARY","Treatment difference and 80% CI were based on LS mean. MMRM analysis was performed with treatment, duration of T2DM time and treatment-by-time interaction as fixed effects, baseline as the covariate, time was repeated for participant. Null hypothesis stated there was no difference between PF 04937319 and placebo, alternative hypothesis stated PF 04937319 was superior to placebo.","D003920; D003924","Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin",FALSE,114,"t-test",NA,NA,NA,1.41901946596152
"3184","c804e346c1adc5cbed0bb09f06711c94","NCT05302414",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Medical Task Performance","SECONDARY","For posttest right after intervention at the 4 weeks.",NA,"The Learning Outcome of Resuscitation Teamwork Training in Postgraduate Year Doctors and Nurses",FALSE,64,"kruskal_wallis",2,NA,NA,1.20770700959599
"3185","c83e483b89430382b3b6613234b3de16","NCT01236053",0.0101,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,188924,"logistic_regression",NA,NA,NA,15.8946220896043
"3186","c846690fef5adbcf40c1d66ced4d0110","NCT01474876",0.0438,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Predictors of Maintained Treatment Response and Remission in Participants With Ankylosing Spondylitis","SECONDARY","Remission and male gender","D013166; D001168; D015535; D025241; D013167","Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis",FALSE,361,"logistic_regression",NA,NA,NA,2.50412809494528
"3187","c86851ebce4aacb3c901ef6e9b3291c8","NCT02596126",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Efficacy Endpoints","SECONDARY","Patient satisfaction is measured at visit 1 (6 months) and visit 3 (2 years) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument comprising of four domains: effectiveness (questions 1 to 3), side effects (questions 4 to 8), convenience (questions 9 to 11) and global satisfaction (questions 12 to 14).","D009362; D002318; D009203; D007238","Secondary Prevention of Cardiovascular Disease in the Elderly Trial",TRUE,2466,"t-test",NA,NA,NA,7.28069129722027
"3188","c86e75b26b8cf99e6bf4099956b0f58d","NCT00658606",0.037,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Percentage of Subjects Reaching PASI 75 Over the Entire Course of the Study","SECONDARY",NA,"D011565","Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects",FALSE,98,"mann_whitney",NA,NA,NA,1.14966874144251
"3189","c870e670e82f3cc565f94df0779e30b8","NCT02863523",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Diabetes Self-care Activities","OTHER_PRE_SPECIFIED",NA,"D003920; D003924; D003863; D003866","COMRADE: Collaborative Care Management for Distress and Depression in Rural Diabetes",TRUE,139,"t-test",NA,NA,NA,1.13829410583231
"3190","c87b33557e318802277ba141a7ffea26","NCT02191046",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"the Effect of Squeezable Bottle and Syringe on Clinical Effectiveness in Sinusitis Children","PRIMARY","compare the mean 5S-score between 2 groups at 2 weeks after treatment","D012852","Effect of Squeezable Bottle Nasal Irrigation Device in Children With Sinusitis",TRUE,74,"t-test",NA,NA,NA,1.2933799900503
"3191","c88d86c6f3fb4377c7f1e7a5923e6d2e","NCT01191268",0.027,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at Weeks 26 and 52","SECONDARY",NA,"D003920; D003924","A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)",FALSE,555,"logistic_regression",NA,NA,NA,2.05132245005611
"3192","c893758ea64ca53db05b117400faadf5","NCT00535405",0.023,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Patients Without Atherosclerosis Vascular Disease (AVD) Who Achieved LDL-C <100 mg/dL or Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12","SECONDARY",NA,"D006331; D003327; D003324; D017202; D006937","A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)",FALSE,475,"logistic_regression",NA,NA,NA,1.65341918587423
"3193","c8993021edef9fefe44c3fc47293e994","NCT02757950",0.0127,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Subjects Reporting Pregnancy Hemorrhage","PRIMARY","The analysis contained only the subjects with vaccination date in the Exposed cohort and subjects from the Unexposed cohort.","D004165","A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.",FALSE,2458,"logistic_regression",NA,NA,NA,2.22465424270426
"3194","c8a7a934b2e92701d3051fc13bfaade0","NCT03713632",0.0206,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving NRS30","SECONDARY",NA,"D017497; D016575","Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)",FALSE,261,"logistic_regression",NA,NA,NA,1.11892599948968
"3195","c8ab0b2fe37dd836fb10b0ded0afdc8e","NCT04231318",0.0275,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Evaluator Global Assessment (EGA) Score","SECONDARY",NA,"D010003; D020370","Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain",FALSE,198,"anova",2,NA,NA,1.25462007705246
"3196","c8bb0947dd6a5ba99d97fd2f73b9e259","NCT03480022",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Systolic Blood Pressure","SECONDARY","Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect","D011085; D011236; D013577; D001835","Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS",FALSE,67,"anova",2,NA,NA,1.23402909436682
"3197","c8cf441d4ea6126ca1e00d4a6b5fddac","NCT02248662",0.05,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Association Between Patient Characteristics and Three-Level Cluster of Treatment Intensity for Primary DCIS","PRIMARY","Unadjusted associations between patient characteristics and the three-level cluster of treatment intensity for primary DCIS were evaluated using Chi-squared tests. We used multivariable modeling to adjust for potential confounders. We also conducted a sensitivity analysis using propensity score matching to balance regional treatment intensity for primary DCIS with respect to the covariates included in the multivariable models.",NA,"Impact of Radiation Therapy on Breast Conservation in DCIS",TRUE,1188,"logistic_regression",NA,NA,NA,5.05764325648716
"3198","c8d00efa5d65a762a82206382fe2b10c","NCT01639339",0.0167,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Double-blind Period: Percentage of Participants With Complete Renal Response (CRR) at Week 104","SECONDARY",NA,"D009393; D008181","Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis",FALSE,446,"logistic_regression",NA,NA,NA,1.21259814082425
"3199","c8d9e762b96340742f64884b1d8a0958","NCT00900627",0.026,"Logistic regression","INTERVENTIONAL",0,1,1,0,0,"Phase II: Objective Tumour Response Rate (ORR) Was Compared in Patients Treated With AZD8931 in Combination With Weekly Paclitaxel Versus Weekly Paclitaxel Alone","SECONDARY","Originally, 166 patients were to be randomised to observe at least 133 progression events, based on HR=0.67, 80% power, 2-sided 5% significant level and a median of 6 months for the placebo arm. After 190 patients were randomised, the analysis was agreed to be performed at an similar level of maturity (70%) as originally planned (72%), after approximately 133 events.","D001943; D009369","Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)",FALSE,173,"logistic_regression",NA,NA,NA,1.11958729434159
"3200","c8dcf615822ab0009e22c9d6015dda7c","NCT00406848",0.048,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Laboratory Values - Hemoglobin, Mean Cell Hemoglobin Concentration (MCHC)","SECONDARY",NA,"D003866; D003865","A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients",FALSE,337,"anova",2,NA,NA,2.61391652484698
"3201","c8e05261a3a00bebb1bd16b75f8ff42f","NCT01445730",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"TG Plasma iAUC","PRIMARY",NA,"D015228; D056128","Fructose Consumption and Metabolic Dysregulation",FALSE,71,"mann_whitney",NA,NA,NA,1.05348219904379
"3202","c8ee453812068d895036ad6c4ded20a3","NCT01368042",0.05,"Wilcoxon","OBSERVATIONAL",0,0,0,0,0,"Change From Baseline to 6 Months Post-enrollment in RAND 36-Item Health Survey 'Role Limitations Due to Physical Health' Scale Scores","PRIMARY",NA,"D007674; D051436; D006961; D006962","Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous",FALSE,254,"wilcoxon",NA,NA,NA,2.35254953828373
"3203","c90eea0e59edc93b8e7079a2eff8c82c","NCT00535405",0.017,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Patients Who Achieved LDL-C <100 mg/dL at Week 12","SECONDARY",NA,"D006331; D003327; D003324; D017202; D006937","A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)",FALSE,475,"logistic_regression",NA,NA,NA,1.27057134852459
"3204","c918dff1ac5ad2e091292748b79443a7","NCT01056718",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Mitral Valve Tissue Doppler Velocity (e')","SECONDARY","Nebivolol treatment group refers to 50 patients that completed 10 weeks of open label nebivolol treatment. Results were compared using paired T-tests in a pre - post study design before and after 10 weeks of his/her treatment. Each subject served as own control.","D006973; D054160","Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function",TRUE,50,"t-test",NA,NA,NA,1.07648023860356
"3205","c93980a0dd7b0828cfc63ea44501ab9f","NCT02022462",0.036,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Changed Number of Health Diagnoses From Baseline to 6 and 12 Months","SECONDARY",NA,"D012559; D001523","Project Bridge: Peer Health Navigator Intervention",FALSE,123,"t-test",NA,NA,NA,1.25284161740376
"3206","c93c524ae872203d52bb9e5ddcb49305","NCT00484419",0.0483,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Mean Change in FPG From Week 0(Baseline) to Week 8","SECONDARY","P-value presents results from 1-sample t-test for within-treatment difference from baseline.","D003920; D003924; D006949","Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin",FALSE,48,"t-test",NA,NA,NA,1.02681534550975
"3207","c96d590a827cc99d7b577646c368879c","NCT00840996",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"12-item Short Form Survey (SF-12) Physical Health Composite Score","SECONDARY",NA,NA,"Perioperative Intravenous Lidocaine or Epidural Anesthesia on Outcomes in Complex Spine Surgery",FALSE,105,"logistic_regression",NA,NA,NA,1.26886531179569
"3208","c98aa9e6276fb3946b1081b8e4f18f48","NCT02863198",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Spiral Artery Doppler Resistance Indices in All Patients","PRIMARY",NA,"D007246","Endometrial Injury for Unexplained Infertility",TRUE,120,"t-test",NA,NA,NA,1.63072147479452
"3209","c9ae636b4d387b0e3993ab10e117893a","NCT00434759",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in Brief Symptom Inventory (BSI)","SECONDARY",NA,"D010698; D000072861","Social Phobia Intervention Study of Mannheim",TRUE,89,"anova",2,NA,NA,1.41222998379373
"3210","c9bd79271cea0e0e7f4c584f8b50f726","NCT03192176",0.0465,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 3 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 4","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,87,"logistic_regression",NA,NA,NA,1.31526440635174
"3211","c9bdd24b04349f5e11e35220295f2545","NCT01056718",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Stress EF","SECONDARY","Nebivolol treatment group refers to 50 patients that completed 10 weeks of open label nebivolol treatment. Results were compared using paired T-tests in a pre - post study design before and after 10 weeks of his/her treatment. Each subject served as own control.","D006973; D054160","Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function",TRUE,50,"t-test",NA,NA,NA,1.07648023860356
"3212","c9c3d66f33c6660d445199a968f10f9d","NCT00420784",0.024,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing","PRIMARY",NA,"D006506; D006526; D006505","A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)",FALSE,225,"logistic_regression",NA,NA,NA,1.18774362447401
"3213","c9da199f54828279836f30d5b156445a","NCT01355419",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Change in Physical Activity (Number of Steps/Day)Before and After CPAP Therapy in OSA Patients","SECONDARY","Multiple regression modelling was used to determine whether actigraphic or polysomnographic data were predictors for physical activity, independently from age and BMI, stepwise forward selection of variables was performed.","D001049; D012891; D020181","Sleep Schedules Modifications in Sleep Apnea Patients Treated by nCPAP",TRUE,142,"linear_regression",NA,NA,NA,1.7695236426303
"3214","c9f974ea2530a608e61cd4bef6ac6c81","NCT00535405",0.039,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Patients Without Atherosclerosis Vascular Disease (AVD) Who Achieved LDL-C <100 mg/dL or Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12","SECONDARY",NA,"D006331; D003327; D003324; D017202; D006937","A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)",FALSE,470,"logistic_regression",NA,NA,NA,2.58691339563149
"3215","ca0c3215302325bfc50c25e357d4cfed","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Healthfulness","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1734,"linear_regression",NA,NA,NA,6.10721803093741
"3216","ca2b16e5170fc598eff91f42c983ee52","NCT00416572",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mental Health (Measured With the SF-36) at Baseline, Post-intervention (4-months Post-intervention) and Final Follow-up (13-months Post-intervention)","PRIMARY","Comparison between education intervention and the control condition at 4 months post-intervention. The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome","D001943","Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer",FALSE,146,"linear_regression",NA,NA,NA,1.79360862376457
"3217","ca40c2178c1dfd0b28d4924d88c52615","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Environmental Warning Label","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1756,"linear_regression",NA,NA,NA,6.1457530740539
"3218","ca5357445c43bb616504116893c3e972","NCT02216214",0.012,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Participants With ≥ 10-Point Improvement From Baseline in OAB-q HRQL Subscales","SECONDARY","HRQL Subscale - Sleep. Odds Ratio: Logistic regression was performed with treatment group, sex, age group (\<75, \>=75 years), and country as fixed factors and baseline value as a covariate.","D053201","Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)",FALSE,867,"logistic_regression",NA,NA,NA,1.25951208575905
"3219","ca5fd1fe137697c97a4d029c73bdd310","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Total Urinary Isoflavones","SECONDARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,96,"anova",2,NA,NA,1.46440978390488
"3220","ca6aaae45e73ee0fbba5768e6908b452","NCT01983228",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Overall Improvement Assessed by Patient Global Impression of Change Scale at 6 Months","SECONDARY",NA,"D059352","A Proactive Walking Trial to Reduce Pain in Black Veterans",FALSE,380,"linear_regression",NA,NA,NA,2.87028339010302
"3221","ca81e135d83a75670e507873f83a49b6","NCT00051363",0.0106,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Subjective Sleepiness/Alertness: Epworth Sleepiness Scale- Total Score (ESS-TS)","SECONDARY","Comparison of means (regression estimates) between arms for 6M Subjective Sleepiness/Alertness- ESS-TS.","D001049; D012891; D008171","Apnea Positive Pressure Long-Term Efficacy Study",FALSE,1098,"linear_regression",NA,NA,NA,1.26872209099061
"3222","ca8ada1f55ad3268842d5958b7ec154a","NCT02814565",0.0393,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Physician's Clinical Global Assessment on Day 3 of Treatment","SECONDARY","The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.","D013035; D001416; D019547; D017116","Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin",FALSE,180,"mann_whitney",NA,NA,NA,1.62312261978836
"3223","cab2958284084e1cb67f565dd80dfed5","NCT04249336",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Percent Change in Mean Score of Pain Response From Baseline on Schiff Cold Air Sensitivity Scale Using Air Blast Stimulus","PRIMARY",NA,"D003807; D006967","Clinical Efficacy Of BioMin F, Colgate Sensitive Pro-Relief And Sensodyne Rapid Action Dentifrices In DH",TRUE,64,"anova",2,NA,NA,1.20770700959599
"3224","cab71ecb29a88dc9babc433cb84aed6b","NCT01052545",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Urine Cultures Ordered","PRIMARY",NA,"D001437","Asymptomatic Bacteriuria Guideline Implementation Study",TRUE,1598,"logistic_regression",NA,NA,NA,5.8633822399763
"3225","cac175ca8c21e28ed5f90cf90ef89695","NCT00127712",0.03,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Length of Intensive Care Unit Stay","SECONDARY",NA,"D001281","Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery",FALSE,130,"mann_whitney",NA,NA,NA,1.10211797931882
"3226","cac2ad9b713033b73975f894b180b4ec","NCT01323010",0.046,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Changes in Respiratory Rate at at Discharge or Hospital Admission.","SECONDARY",NA,"D012135","Efficacy and Safety of Increasing Doses of Inhaled Albuterol in Children With Acute Wheezing Episodes",FALSE,119,"anova",2,NA,NA,1.51511887907838
"3227","caeac787383c9b36f3140ec34ba97ced","NCT03282955",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change of Liver Function Parameters From Baseline to Visit 2","PRIMARY",NA,NA,"The HOME Study (HPN With OMEGA-3)",FALSE,67,"t-test",NA,NA,NA,1.23402909436682
"3228","caf080de5881465b3cdf68ae90c6a553","NCT01983228",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Pain Self-efficacy Questionnaire (PSEQ) at 6 Months","OTHER_PRE_SPECIFIED",NA,"D059352","A Proactive Walking Trial to Reduce Pain in Black Veterans",FALSE,380,"linear_regression",NA,NA,NA,2.87028339010302
"3229","caf689fb6d4d3183c66aa09bc0eb9e1a","NCT01430403",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Asthma Control Test Score: Child Asthma Control Test (C-ACT), Treatment Steps 2-5: Omalizumab vs. Placebo","SECONDARY",NA,"D001249","Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations",FALSE,257,"linear_regression",NA,NA,NA,2.36619288852981
"3230","cb0901e309e9c01f1ca0cfaf208419ce","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Red Blood Cell Count at Baseline and After Treatment Completion","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"3231","cb17ad50c6cfc43ebd08102e0a604c1b","NCT00270998",0.0492,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Satisfaction With Treatment at 3 Months","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",TRUE,296,"logistic_regression",NA,NA,NA,2.50291558562827
"3232","cb295855569a5f1ddd17c537ec317368","NCT00637273",0.0165,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change in HbA1c From Baseline to Week 26","PRIMARY","Null hypothesis: no difference across treatments. Alternative hypothesis: a difference exists between exenatide once weekly and at least one comparator group (sitagliptin or pioglitazone). Power: Assuming 10% dropout, delta=0.5%, and common SD=1.2%, 450 subjects would provide \>90% power to detect a treatment difference (alpha=0.05, two-sided) in the change in HbA1c between exenatide once weekly and sitagliptin or pioglitazone, with Hochberg's multiplicity adjustment method.","D003920; D003924","A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",FALSE,319,"anova",2,NA,NA,1.01735919935058
"3233","cb2f76d406663286edb6b86ab5186d9c","NCT02709486",0.0214,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 4, \>=90%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,565,"logistic_regression",NA,NA,NA,1.69238346068466
"3234","cb44c486ed9defa5c9de78858852dcf0","NCT02209181",0.037,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Relief (PAR) Scores at 45 Minutes Post Dose","SECONDARY","The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.","D014098","A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine",FALSE,136,"anova",2,NA,NA,1.34597106780068
"3235","cb4be0a89abed0f71470eb2f9e8b7a8f","NCT00245219",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Physical Health (as Measured With the SF36) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the peer support condition and the control condition at Time 2. The full regression model included 2 dummy coded variables, 1 contrasting the education and control condition, and 1 contrasting the peer support and control condition. The baseline measure of the outcome variable was included, in order to examine changes in the outcomes over time. This model tested the main effects of the conditions among patients with early stage cancer, late stage patients were excluded.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"linear_regression",NA,NA,NA,1.79957957739554
"3236","cb50bf28bcf90abe89641b0fa6cfcb55","NCT01532986",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"General Self-Efficacy Scale (GSES)","SECONDARY",NA,"D010300","Randomized Trial to Test the ""Coordinated Care for Health Promotion and Activities in Parkinson's Disease"" Intervention in the VA",FALSE,328,"t-test",NA,NA,NA,2.66881159065383
"3237","cb5c7df68362a6a8edc30d84c672b522","NCT00707447",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Eating Behavior (TFEQ) - Hunger","SECONDARY",NA,"D003920","Evaluation of a Primary Type 2 Diabetes Prevention Programme",TRUE,166,"t-test",NA,NA,NA,1.90948799930043
"3238","cb605be1499a23b89c8d1f7ba992b52f","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in High Density Lipoprotein Cholesterol","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,110,"anova",2,NA,NA,1.56357043896758
"3239","cb6ea43d028742a55ec952e30aa8df30","NCT04364165",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"HIV Testing Uptake","PRIMARY",NA,"D000163; D015658","Effect of U=U Messaging on HIV in South Africa",FALSE,1048,"logistic_regression",NA,NA,NA,1.1770798124339
"3240","cb6f7effb1cf399899fc2a9d3d47dfc2","NCT03951766",0.0349,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Within-person Changes in Theorized Mechanism of Behavior Change - Brief Coping Orientation to Problems Experienced (Carver, 1997)","SECONDARY",NA,NA,"Version 2 of the Smoking Cessation Smartphone App ""Smiling Instead of Smoking"" (SiS)",FALSE,100,"t-test",NA,NA,NA,1.10495531545493
"3241","cb76c9d1b94ef60b3e24ea79029e59f7","NCT00147446",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"No.of Gd+ Lesions From Week 8 to Week 24","PRIMARY","It was hypothesized that treatment with stress management produced a significant reduction in cumulative Gd+ lesions compared to the control condition during the treatment period","D009103; D012598","Stress Management for Patients With Multiple Sclerosis",FALSE,121,"mann_whitney",NA,NA,NA,1.35850149993441
"3242","cb854b724fa0ffc1be5360a3872bfaca","NCT00904670",0.0491,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"SKAMP Attention Subscale Score Over 12 Hours","SECONDARY","Hour 12: Treatment comparisons for observed scores were assessed using linear models with sequence (Placebo/NWP06 and NWP06/Placebo), period, and treatment (NWP06 and Placebo) as fixed effects, and participant within sequence as a repeated effect with a compound symmetry correlation structure. A negative point difference indicated a positive effect of NWP06 over Placebo.","D006948; D001289","Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)",FALSE,78,"anova",2,NA,NA,1.30631341606493
"3243","cb8c7766c0fe8975f8127b26744bb6ba","NCT03449147",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With a ≥1.3 Point Change From Baseline in the Leicester Questionnaire (LCQ) Total Score at Week 24","SECONDARY",NA,"D003371; D000096822","A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)",FALSE,805,"logistic_regression",NA,NA,NA,3.45250014686642
"3244","cb8df7e6df3328cc2e5f307c325f8148","NCT01138124",0.0026,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","PRIMARY",NA,"D010190; D002292; D007680; D010386; D010195; D050500; D012148","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",FALSE,19046,"logistic_regression",NA,NA,NA,1.48159231840286
"3245","cba9a9ecf17e2adb570bebe9b34e62f7","NCT00469144",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Treatment-related Mortality (TRM)","PRIMARY","1 Year, Between Arms: Participants not in CR","D007938; D015470; D011289; D007951; D009190; D013577","IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome",FALSE,86,"mann_whitney",NA,NA,NA,1.38926982128357
"3246","cbe29491280075bf374bf3506c99c217","NCT00525174",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Impact of Treatment on Patient and Family at 6 Weeks","SECONDARY","A t-test was used to evaluate treatment group difference of impact of treatment at 6 weeks.","D000550","Full-time Bangerter Filters Versus Part-time Daily Patching for Moderate Amblyopia in Children",FALSE,160,"t-test",NA,NA,NA,1.21854475433189
"3247","cbed8e989015f67abc648cdca543b972","NCT02491671",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Duration of Air Leaks","SECONDARY",NA,NA,"Effectiveness Novel Tissue Sealant, Prevention Prolonged Air Leak (PAL) After Lung Resection",FALSE,236,"mann_whitney",NA,NA,NA,2.26896816685712
"3248","cbfca7c5525b6d43c52e85fdcdf8276d","NCT00657241",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Systemic Vascular Resistance","SECONDARY","Statistical analysis performed on treatment groups (valsartan or carvedilol CR) at end of treatment period (4 weeks), not on the randomization arms in the crossover design (which controlled for carryover effects of the prior treatment arm).","D006973","Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril",FALSE,60,"t-test",NA,NA,NA,1.17169922891753
"3249","cc0753b9f4472682f39b2535d3cb4a78","NCT02260934",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Hypocomplementemic for Complement Component C3 at Week 24, Week 48, and Week 96","SECONDARY","Treatment group was the independent variable in the logistic regression.","D009393; D008181","Rituximab and Belimumab for Lupus Nephritis",FALSE,43,"logistic_regression",NA,NA,NA,1.00454908915455
"3250","cc165b24156e565fb9922cffcedc46a7","NCT05525104",0.041,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"The Influence of DSA Monitoring on the Speed of Emergence.","PRIMARY",NA,NA,"The Effect of DSA on Recovery of Anaesthesia in Children",FALSE,96,"mann_whitney",NA,NA,NA,1.24099903377859
"3251","cc2397061210454d1dbe1f733f284bf5","NCT02709486",0.0155,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >=30%, >=50%, >=70% and >=90% Response","SECONDARY","Week 16, \>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,563,"logistic_regression",NA,NA,NA,1.27440502102337
"3252","cc278454b0b47ada3d25facd32ad4724","NCT02440854",0.042,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Patient-rated Lung Cancer Symptom Scale (LCSS) Individual Item Scores: Overall Symptomatic Distress","SECONDARY","Baseline vs 12-month post-baseline.","D002289","Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings",FALSE,76,"t-test",NA,NA,NA,1.13311430298744
"3253","cc4ae7762d525240338aa82e22ba703e","NCT01098747",0.036,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Intensity Difference (PID)","SECONDARY","6 hours: Treatment difference \[Ibuprofen sodium - Ibuprofen (Advil + Motrin IB)\] and corresponding 95% CI were calculated based on LS means from the ANOVA model.","D014098","Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain",FALSE,268,"anova",2,NA,NA,1.83151725073539
"3254","cc81a82dcf2540946cb05cb38bd778c1","NCT01559259",0.033,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Intensity Difference on 4-Point Categorical Scale (PID4)","SECONDARY","0.25 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,120,"anova",2,NA,NA,1.15004036115805
"3255","cc8ee7a82db02e60eb02bfc3b8f08706","NCT04833777",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Post-operative Pain","PRIMARY",NA,"D002349","Does a Different Local Anesthetic Improve Pain After Carpal Tunnel Release?",TRUE,139,"mann_whitney",NA,NA,NA,1.75124288073831
"3256","cc9eb2d7ec278d174d6f0b9943ff5f09","NCT01783860",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change of Total Severity Score Between Baseline and 31 Days Later","OTHER_PRE_SPECIFIED",NA,"D001762; D000080343","Oral Azithromycin Versus Doxycycline in Posterior Blepharitis",FALSE,100,"t-test",NA,NA,NA,1.23952993364171
"3257","cca1a8f313eedea1c736cf31007964d6","NCT02528188",0.0196,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 8: \>=50% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,2.93505894522506
"3258","cca538f5596a5c13089d8c35dd7f8c72","NCT05263791",0.05,"One-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Analysis to Compare the Influence of Subjects to Variated Breath Rates on Respiratory Rate Monitoring in Bpm as Measured by Airmod, Manual-scored and Capnostream™35","SECONDARY","Hypothesis: airRR-mancRR ≦ -2, In the target of p\<0.05 indicates significance.",NA,"Evaluating the Non-Inferiority of Airmod to Capnostream™35",TRUE,255,"t-test",NA,NA,NA,2.35710609207859
"3259","cca591a41b7d2e318b48acbe24376d23","NCT00099359",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Risk Factors for Perinatal HIV-1 Transmission","SECONDARY",NA,"D015658; D000163","Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission",FALSE,1591,"logistic_regression",NA,NA,NA,5.85055688345237
"3260","ccad4da9f4e91d48ef4a19fc43c915c5","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient-Reported Outcomes Measurement Information System (PROMIS Short Forms 8a - Pediatrics v. 2.0) is a Set of Person-centered Measures That Evaluates and Monitors Physical, Mental, and Social Health in Children and Adolescents.","SECONDARY","We hypothesized that adolescents randomized to the intervention would have lower scores on Emotional Distress - Depressive symptoms compared to controls at 12 months post baseline.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,126,"t-test",NA,NA,NA,1.66971913113983
"3261","ccb5a06c473461cf2b06e963a5925c7e","NCT04994691",0.023,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Who Completed Well Child Check Visit","PRIMARY",NA,NA,"Effect of Varied Outreach Methods on Appointment Scheduling and Appointment Completion Using MyChart",FALSE,630,"logistic_regression",NA,NA,NA,1.90162606114926
"3262","ccbc27d5cd593da91c40647bc2148e5a","NCT02528253",0.0274,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 32, \>=30%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1011,"logistic_regression",NA,NA,NA,2.79837757885718
"3263","ccc037edec203c51c11a21d3fd8bfbf0","NCT00270998",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Satisfaction With Treatment at 3 Months","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",FALSE,295,"logistic_regression",NA,NA,NA,1.64349226220842
"3264","ccebc2478d3283e3ab676ee89062d5ef","NCT00201201",0.0431,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Satisfaction With the PEP-NG","SECONDARY",NA,"D006973; D002318; D006331","Reducing Adverse Self-Medication Behaviors in Older Adults With Hypertension",FALSE,135,"t-test",NA,NA,NA,1.52508969053607
"3265","ccf688ca424d1c44b99bc3e8a83cd82d","NCT02539394",0.042,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Patient Reported Swallowing Difficulty Over 1 Year","SECONDARY","The distribution of POD1 modified Eat-10 is the same across the 2 arms","D007405; D055959; D003680; D013118","Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion",FALSE,109,"mann_whitney",NA,NA,NA,1.34587003352236
"3266","cd0d3d8a75e49f0cdcefe2127a8d9eb0","NCT02816736",0.035,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Tolerability - Hyperkalemia","SECONDARY",NA,"D006333","EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)",FALSE,335,"logistic_regression",NA,NA,NA,1.9959343488673
"3267","cd10038c9aea63fcd88b9c511630fd99","NCT05807828",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Medical Students Surgical Skills Differences Between VR and Control Group.","PRIMARY","The median difference between the cup angle of the Control Group for Cup Training and the cup angle of VR Group for Cup Training.","D015207","VR Simulation and Basic Skills in THA",TRUE,101,"mann_whitney",NA,NA,NA,1.50057440421219
"3268","cd177ebca24fba57bf56991147c1ad51","NCT01112267",0.0395,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Short Form (SF)-36 Score at Day 29","SECONDARY",NA,"D001416; D017116","An Efficacy and Safety Study of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen in Participants With Chronic Low-Back Pain",FALSE,175,"mann_whitney",NA,NA,NA,1.6078347660619
"3269","cd1a2476b708c1723bdd70f7061ab43f","NCT00453999",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change in Amount of Influenza Virus in Nose and Throat (Influenza A and B Combined)","SECONDARY","Change from Baseline at 48 hours","D007251","Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza",FALSE,112,"mann_whitney",NA,NA,NA,1.57722881888439
"3270","cd344e00bf765e5cc552175ab61a699f","NCT03789474",0.047,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Femoral Artery Velocity at T6","PRIMARY",NA,NA,"Does Fluid Requirement Decrease With the Use of Pneumatic Compression Device on Lower Limbs",FALSE,60,"t-test",NA,NA,NA,1.11333082815352
"3271","cd38dd57581d46f19568a3c0bd45bd91","NCT01459653",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Modeling CIN/FN-related Chemotherapy Disturbance: Cycle Level","SECONDARY","Center type: academic-affiliated vs non-academic as center-level predictor for CIN/FN-related chemotherapy disturbance","D009101; D009503; D064147; D000084462; D005334","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",FALSE,1045,"logistic_regression",NA,NA,NA,1.17540453489891
"3272","cd4c9957dc4b1d441479ac12c60d51f5","NCT02528188",0.0122,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 8: \>=90% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1989,"logistic_regression",NA,NA,NA,1.93186901273227
"3273","cd611532a35898fe2e6327dbd268f16b","NCT01056718",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Exercise Duration","PRIMARY","Nebivolol treatment group refers to 50 patients that completed 10 weeks of open label nebivolol treatment. Results were compared using paired T-tests in a pre - post study design before and after 10 weeks of his/her treatment. Each subject served as own control.","D006973; D054160","Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function",TRUE,50,"t-test",NA,NA,NA,1.07648023860356
"3274","cd8869fc925f2e514373d747a1642347","NCT03547531",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Baseline Plaque Level","PRIMARY","Null hypothesis: the mean of plaque index between groups are not different","D003773; D009066","Comparison of Modified Circular and Natural Tooth Brushing Methods in Effectiveness of Dental Plaque Removal",FALSE,124,"t-test",NA,NA,NA,1.6568216953838
"3275","cd8ac10fb67c650802a2da5d6a855c56","NCT00245219",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mental Health (as Measured With the SF-36) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the peer support condition and control condition at Time 2, among both late and early stage patients. The full regression model consisted of 3 steps: The 1st step contained the baseline measure of the dependent variable. The 2nd step contained two dummy coded variables contrasting each condition with control. The 3rd step contained the interaction between the peer support condition and cancer stage. Patients in the education condition were excluded from this analysis.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"linear_regression",NA,NA,NA,1.79957957739554
"3276","cdacb8a52f0c26e9607351b638187dc7","NCT02307682",0.0183,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Average Change From Baseline in CSFTtot Over the Period Week 36 Through Week 48 - Study Eye","SECONDARY",NA,"D008268; D057135; D020256; D009389","Efficacy and Safety of RTH258 Versus Aflibercept - Study 1",FALSE,718,"anova",2,NA,NA,1.66281440405555
"3277","cdb98e2121415ed618a503a0764bb80a","NCT02214186",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Platelets in Restrictive Fluid Management of Severe Preeclampsia","SECONDARY",NA,"D004461; D011225","Restrictive Fluid Therapy in Severe Preeclampsia",FALSE,46,"anova",2,NA,NA,1.03597838019194
"3278","cdb997e3f4a6085da9ad49e127891b16","NCT03201419",0.048,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Responder Rate in Nocturnal Voids at Week 1","SECONDARY",NA,"D011141; D053158","A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults",FALSE,104,"logistic_regression",NA,NA,NA,1.47108541860204
"3279","cdc00e5d8e2c4e26706c93b2cb68bc02","NCT00261443",0.018,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Baseline and Adjusted Mean Change From Baseline in the CGI-BP Severity of Illness (Overall) Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 24 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,1.10955294329597
"3280","cdc692fde87bc1c8eb3b85824c8fb3e4","NCT00094302",0.01,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Depression Symptoms, as Measured by Patient Health Questionnaire.","SECONDARY","Since the p-value for the preceding test (Statistical Analysis 1) was not significant at the 0.05 level, another generalized linear model was fit, omitting the interaction between treatment group and month of visit. This tests whether the value of the post-baseline quality of life parameter differs by treatment group, taking into account that measurements in the same subject over time may be correlated.","D006333; D002318; D006331","Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function",FALSE,1477,"linear_regression",NA,NA,NA,1.39609899161573
"3281","cdd71bd3f125900041960f1925469297","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Environment)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1735,"linear_regression",NA,NA,NA,6.10897489711546
"3282","cde3f7a9d5273b05b19d0459a30a463c","NCT04231318",0.0406,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score","PRIMARY",NA,"D010003; D020370","Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain",FALSE,198,"anova",2,NA,NA,1.74788170461504
"3283","ce0587999ce058164d089218e12ceb13","NCT05955560",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Performance of the PureWick MEC Against an Established Comparator","PRIMARY",NA,NA,"Male External Catheters' Comparison of Comfort and Efficacy",FALSE,118,"t-test",NA,NA,NA,1.34214946960672
"3284","ce0c13971df9f2478b771cdc35a394a2","NCT03192176",0.0432,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 11","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.20956993194601
"3285","ce0ed1ce3e74b7a30bad5f0a423cfbd7","NCT02214186",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Proteinuria in Severe Pre-eclampsia Submitted to Cesarean Section Under Different Regimes of Hydration","SECONDARY",NA,"D004461; D011225","Restrictive Fluid Therapy in Severe Preeclampsia",TRUE,46,"mann_whitney",NA,NA,NA,1.03597838019194
"3286","ce19a9e91fa2ebf4d1d8d2616703ba35","NCT01332851",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Child Engagement/Exploration","SECONDARY",NA,NA,"Supporting Parents Program: Intervention for Families in CPS",FALSE,247,"linear_regression",NA,NA,NA,2.32040326199209
"3287","ce5357ea2fb11102b5551fbbc2d09d6f","NCT00110812",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"CD4+ Cell Count 2 Years Post-study","POST_HOC",NA,"D007239","Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People",FALSE,221,"anova",2,NA,NA,2.19689065872099
"3288","ce60ae468bc829830229d9c2d79c41be","NCT03258645",0.026,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Patients With History of or Predisposition to Bleeding According to Dabigatran Initiation Time Period","SECONDARY","Multivariate linear regression with the continuous dependent variable of time-to-initiation for dabigatran in days and independent variable of age, Diastolic blood pressure (DBP), CHA2DS2-VASc, HAS-BLED, and History/Predisposition To Bleeding at index date was applied.","D001281","This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke",FALSE,1240,"linear_regression",NA,NA,NA,2.96068986319267
"3289","ce6f9dc5005de589f6db9f4f76c3d78a","NCT00245219",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mental Health (as Measured With the SF-36) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the education condition and the control condition at Time 3. The full regression model included 2 dummy coded variables, 1 contrasting the education and control condition, and 1 contrasting the peer support and control condition. The baseline measure of the outcome variable was included, in order to examine changes in the outcomes over time. This model tested the main effects of the conditions among patients with early stage cancer, late stage patients were excluded.","D001943","Understanding Shared Psychobiological Pathways",FALSE,131,"linear_regression",NA,NA,NA,1.70153588988359
"3290","ce87cbeb065881483b3dd20771cbdb22","NCT00006170",0.046,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Smoking Abstinence","PRIMARY",NA,"D014029","Bupropion and Weight Control for Smoking Cessation - 1",FALSE,74,"logistic_regression",NA,NA,NA,1.20700004663968
"3291","cea768e03a499da0ab9111e6d53fe3dc","NCT03192176",0.0429,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 2 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 1","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,87,"logistic_regression",NA,NA,NA,1.22979110385601
"3292","ceb3b754243879b1828d0e168558326d","NCT01539070",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Children´s Consumption of Foods From Baseline to 3 Months by Intervention Assignment","PRIMARY","In intent-to-treat analyses, we used unadjusted and adjusted multivariate regression models, to examine differences from baseline to 3 months between the intervention and usual care groups. For continuous outcomes, we used linear regression models, and for dichotomous outcomes, we used logistic regression models. To account for clustering by practices, we performed generalized linear mixed models. The Estimator (Est) and Confidence Interval 95% (95% CI)are reported.","D009765; D063766","Intervention for the Prevention of Obesity in Preschool",TRUE,306,"linear_regression",NA,NA,NA,2.5788408992482
"3293","cebeea685008c8a7afa7b0b95b71d3e1","NCT03962738",0.036,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With 48-Hour Sustained Pain Freedom","SECONDARY",NA,"D008881","A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine",FALSE,420,"logistic_regression",NA,NA,NA,2.2860139836418
"3294","ced86dd9567c989c85049efa4fdf45e0","NCT02353871",0.0441,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"The Proportion of Responders at Each Post-treatment Visit to the Study Centre (Except Day 29) as Measured by the ILA at Maximum Frown.","SECONDARY","Comparison of ILA at Day 183 (End of Study) - BTX-A-HAC NG solution (50 U) versus placebo",NA,"Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines",FALSE,184,"logistic_regression",NA,NA,NA,1.80781015277692
"3295","cef90b318cb0cadad2a39b36579657c4","NCT00114530",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,1,0,"Change From Baseline to Month 54 in Modified Rodnan Skin Score (mRSS) (ITT)","SECONDARY","This analysis is stratified by EFS status.","D012595; D045743; D001327; D012598","Scleroderma: Cyclophosphamide or Transplantation",FALSE,75,"mann_whitney",NA,NA,NA,1.301639172202
"3296","cf01f49396352158e372d2e0848451e2","NCT01070550",0.0223,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for age per 10 years. The logistic regression analysis for relapse 24 weeks after EOT was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,227,"logistic_regression",NA,NA,NA,1.11948098484303
"3297","cf08fce9784b165486c519828a13fdeb","NCT02609828",0.0405,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Cumulative Reduction of >=30, 50, 70 and 90 Percent (%) From Baseline in Daily Average Pain Intensity NRS Score in the Index Bone Metastasis Cancer Pain Site at Weeks 1, 2, 4, 6, 8, 12, 16 and 24","SECONDARY","Week 8 Reduction \>=50%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","D009362; D001859; D001855; D000072716","Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy",FALSE,144,"logistic_regression",NA,NA,NA,1.49342462107172
"3298","cf3c6a2cde542dfd920cf83a47f91472","NCT01515696",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Feeding Tolerance- Full Enteral Feedings","SECONDARY",NA,"D000074270; D001835; D001724","Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants",FALSE,78,"mann_whitney",NA,NA,NA,1.32610986002301
"3299","cf4cf0816f2ee86101def9121db39c73","NCT03978871",0.037,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Mean Difference in Emotion Regulation Strategies on the Emotion Regulation Strategy Scale","PRIMARY","We are reporting the p-value for the group effect (Growth Mindset vs. Brain Education) for the ERS emotion regulation proactive engagement subscale post psycho-educational lesson. This is a test of between-subjects effect.",NA,"Effect of Emotion Mindsets on Emotion Processing",FALSE,157,"anova",2,NA,NA,1.443068644725
"3300","cf5b0580e75a4a1e9ed51c9d5196870d","NCT04876482",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Tongue Depression Muscle Strength","PRIMARY","We hypothesized that the improvements in the tongue depression muscle strength would be more in patients who underwent TORS combined with OPR than in those who underwent only TORS and those who received conservative treatment (controls).","D001049; D012891; D020181","Myofunctional Training for Obstructive Sleep Apnea Patients After Transoral Robotic Surgery",TRUE,74,"linear_regression",NA,NA,NA,1.2933799900503
"3301","cf5c4a353e0ff573303abeaa697da4c9","NCT01011465",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Systolic Blood Pressure Change From Baseline to Second Stress Task Experience - Autonomic Stress Response Measure","PRIMARY","The null hypothesis is that both groups will have similar rise in SBP in response to stress.",NA,"The Biology of Resilience",FALSE,109,"t-test",NA,NA,NA,1.01271017194322
"3302","cf855ffdc92374fe4679121e16b4542d","NCT01236053",0.0474,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,183.224893212667
"3303","cf86b698023e9a23340424a6fb6196a5","NCT00847587",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Time to Lactogenesis Stage II","PRIMARY","It was assumed that both groups would have a mean of 54 hours to lactogenesis with a common standard deviation of 12 hours based on previous reports of lactogenesis in women with uncomplicated vaginal deliveries. Setting the noninferiority margin at 8 additional hours, using an alpha 0.05 level comparison, to achieve 80% power a sample size of n=34 evaluable subjects was required in each group. The calculation was performed using N Solution 2007 Professional Software.",NA,"Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant",TRUE,69,"t-test",NA,NA,NA,1.25127183253256
"3304","cf9448ecb0ede5e53b52471c65897664","NCT02413008",0.043,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Variation in Plasma Levels of Estriol","SECONDARY","Change from baseline to week 1 in plasma levels of estriol","D001284","A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting",FALSE,61,"mann_whitney",NA,NA,NA,1.04216964614346
"3305","cfa1c3653b41bdb7af045c910eee4de6","NCT01183689",0.02,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Insulin Resistance","SECONDARY","Analysis of variance was used to compare mean differences in changes from baseline to 2 years among the 3 groups.","D015430","Study of Novel Approaches for Prevention",FALSE,317,"anova",2,NA,NA,1.19966191848258
"3306","cfb423744309d113f4898d0e3bdea344","NCT02596126",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Efficacy Endpoints","SECONDARY","Patient satisfaction is measured at visit 1 (6 months) and visit 3 (2 years) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument comprising of four domains: effectiveness (questions 1 to 3), side effects (questions 4 to 8), convenience (questions 9 to 11) and global satisfaction (questions 12 to 14).","D009362; D002318; D009203; D007238","Secondary Prevention of Cardiovascular Disease in the Elderly Trial",TRUE,2466,"t-test",NA,NA,NA,7.28069129722027
"3307","cfcf106d63271259bb35a92dbcef0f48","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Urinary Daidzein","SECONDARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,98,"anova",2,NA,NA,1.47898140162831
"3308","cfff63ca057b104cd4251d9fcc161e74","NCT01559259",0.031,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Time-weighted Sum of Pain Relief Rating (TOTPAR) Over 2, 6, 8, 12 Hours Post-Dose","SECONDARY","0-2 hours: Treatment difference (Ibuprofen 200 mg + Acetaminophen 500 mg - Ibuprofen 400 mg) and corresponding 95% CI were calculated based on LSM from the ANOVA model.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,182,"anova",2,NA,NA,1.33416400439747
"3309","d005d85a59ac7d5b407d9e8d5e407905","NCT02986282",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Difference Between ABI (Ankle - Brachial Index) Before Electrical Cardioversion Using Two Methods (Doppler and Oscillometric).","PRIMARY","It was calculated that the study sample size of 79 subjects would be needed to detect a difference of 0.1 in the ABI measured in sinus rhythm and during atrial fibrillation, with a two-tailed α of 0.05 and a (1-β) of 0.90. Our initial estimate of sample size of 115 patients incorporated an assumption of dropout. Intra-observer variability was calculated using intra-class correlation coefficient.","D001281","Ankle - Brachial Index Measurement in Atrial Fibrillation",TRUE,99,"mann_whitney",NA,NA,NA,1.48621381452241
"3310","d0191c566b856e9bc69b038c67b31bb9","NCT04833777",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Post-operative Pain","PRIMARY",NA,"D002349","Does a Different Local Anesthetic Improve Pain After Carpal Tunnel Release?",TRUE,139,"mann_whitney",NA,NA,NA,1.75124288073831
"3311","d023b0362242213b52976fa771f7da80","NCT02697773",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >= 30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 16 \>=30%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,463,"logistic_regression",NA,NA,NA,1.44594153392838
"3312","d03ee5806f9e38d5e2309a3a9893e613","NCT01234649",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Aspartate Aminotransferase (AST)","SECONDARY","Factorial repeated measures ANOVA","D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",FALSE,72,"anova",2,NA,NA,1.27670232702116
"3313","d04cc8317e6eae4686af99954b502323","NCT03022370",0.041,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Problem Alcohol Use","SECONDARY",NA,NA,"Stepping Stones and Creating Futures Intervention Trial",FALSE,505,"linear_regression",NA,NA,NA,2.7966057150501
"3314","d04f52d8da258326d270c34bac66008d","NCT00420927",0.026,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Number of Subjects With DAS28 Remission (DAS28 Less Than 2.6) at Week 78","SECONDARY",NA,"D001168; D001172","Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis",FALSE,217,"logistic_regression",NA,NA,NA,1.25026890740279
"3315","d0619f705578cdcbc6dc9b9ab5158c44","NCT01552343",0.0463,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Construct Validity For the Nocturia Impact (NI) Total Scores and Overall Impact Question (Q12) for Participants With High/Low Number of Nocturnal Voids","SECONDARY","Overall Impact Question (Q12): Screening","D053158","Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary",FALSE,56,"t-test",NA,NA,NA,1.06481909812353
"3316","d063a543bd6dafaf891835d5ef83152f","NCT01894230",0.0429,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Brief Pain Inventory (BPI) Score - Pain Interference at Month 3 and Month 8","SECONDARY",NA,"D006937","Genetically Guided Statin Therapy",FALSE,144,"linear_regression",NA,NA,NA,1.56748325235291
"3317","d0695dd093626025c7f5f3fecfc5c808","NCT00474175",0.047,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Pain Relief Combined With Pain Intensity Difference (PRID) Scores","SECONDARY","30 minutes: P-value was calculated using ANOVA which was adjusted for treatment, site and baseline DPS. Treatment difference (Benzocaine 20% - Placebo) and corresponding 95% C.I. were calculated based on least-squares means from the ANOVA model with treatment, site, and baseline DPS effects.","D014098","Benzocaine Gel Toothache Dose-Response Study",FALSE,343,"anova",2,NA,NA,2.59068486736714
"3318","d076cfa212f345ca2a7fb5eba2411986","NCT02118766",0.038,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29","PRIMARY",NA,"D003876; D003872; D004485","Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis",FALSE,759,"logistic_regression",NA,NA,NA,3.21017607372089
"3319","d079be781cd1357c93bad9d22fb9c6a0","NCT00884221",0.047,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Endocrine Profile (Prolactin), Intention-to-treat (ITT) Analysis Set","SECONDARY","Prolactin","D007246","MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer",FALSE,749,"linear_regression",NA,NA,NA,3.81640550361774
"3320","d08170aed3659320491793417f70170a","NCT00669214",0.0435,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Mean Change in a Visual Analog Scale (VAS) of Scalp Itch at 12 Weeks","SECONDARY",NA,"D011565","A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp",FALSE,76,"t-test",NA,NA,NA,1.16678172279702
"3321","d089b3880a1396c0acf2d82b82e13f7f","NCT00190684",0.026,"Wilcoxon","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to 5 Year Endpoint in Conners' Parent Rating Scale-Revised: Short Form (CPRS-R:S) Subscale Scores","SECONDARY","Tested was the null hypothesis that there would be no statistically significant difference between baseline and endpoint.","D006948; D001289","Long-Term, Open Label Atomoxetine Study",FALSE,1059,"wilcoxon",NA,NA,NA,2.73702264619
"3322","d0a4b87c115950adca7c99cea8823d2e","NCT00707447",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Physical Exercise","SECONDARY",NA,"D003920","Evaluation of a Primary Type 2 Diabetes Prevention Programme",TRUE,166,"t-test",NA,NA,NA,1.90948799930043
"3323","d0aa9f836e0f9f943c8eb772c5e19385","NCT04233008",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Time to Delivery","PRIMARY",NA,NA,"Length of Cook Catheter Placement and Induction of Labor",FALSE,177,"mann_whitney",NA,NA,NA,1.63402696792663
"3324","d0af9d21142d07df23719369abba8b2b","NCT03192176",0.0412,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 3 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 9","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.18236895924251
"3325","d0b9a30914f9ade1bc61ae6685ea3d39","NCT00441116",0.0319,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline Hair Growth Assessed by Macrophotographic Technique (Hair Count) in the Vertex at 6 Months.","PRIMARY","Month 6 - Baseline","D000505; D000506","A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia",FALSE,148,"t-test",NA,NA,NA,1.23643004091158
"3326","d0ca18e380826309fd64aa8ba65b0e77","NCT02570022",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Pain Levels","PRIMARY","Our hypothesis was that in patients undergoing shoulder arthroplasty, treatment with LB would lead to no significant differences in average daily pain scores. A power analysis was performed prior to the study to assess the primary hypothesis that a significant difference in average daily pain of 13mm on VAS will not be found between the INB and LB groups. With a power of 80% (beta level = 0.80, alpha level = 0.05), a sample size of 25 patients per group was obtained",NA,"Liposomal Bupivacaine in Total Shoulder Arthroplasty",TRUE,57,"t-test",NA,NA,NA,1.1439569152679
"3327","d0fb405af5d35d518c2275e222e36be8","NCT02672176",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Perceived Stress Measured by PSS","SECONDARY",NA,"D003920","Improving Health in Diabetes Project",FALSE,287,"mann_whitney",NA,NA,NA,2.49853393660761
"3328","d0fca5c25a866354be21ec45c4d126c4","NCT01312909",0.0335,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 24 and Week 52","SECONDARY","Week 9 through Week 24: Odds ratios and p-values were obtained from a logistic regression model including the main effects of treatment, pooled center, age strata and body weight strata.",NA,"Smoking Cessation Study In Healthy Adolescent Smokers",FALSE,203,"logistic_regression",NA,NA,NA,1.50337844041892
"3329","d10d44bae2ec0ae59ce597c9cb07f18e","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Diastolic Blood Pressure at Screening/Visit 1, Visit 2, and Visit 3","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"3330","d12a24f54d66b890d894bbc3cc5eb499","NCT00829244",0.037,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Number of Oocytes Retrieved Per Participant","PRIMARY","The null hypothesis was that the difference between the mean number of oocytes \[CONSORT calculator dosing - Standard dosing\] was less than or equal to \[=\<\] (-3). The alternate hypothesis was that the difference was greater than \[\>\] (-3).","D007246","CONSORT Randomized Controlled Trial in Assisted Reproductive Technology",FALSE,179,"anova",2,NA,NA,1.53824018100297
"3331","d145fe610d612666c51dd209210bd196","NCT01638000",0.045,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Improvement in HRQoL Scales as Assessed by the OAB-q: ≥10 Points Improvement in OAB-q at Week 12 and Final Visit","SECONDARY","Final visit Odds Ratio vs. Mirabegron","D053201; D014570; D001745","A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.",FALSE,1833,"logistic_regression",NA,NA,NA,5.74673036144443
"3332","d14e960c0cfd49a4b1fd06dc7c897899","NCT05502081",0.035,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,1,"Albumin at Day 7","SECONDARY",NA,"D000086382","Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients",FALSE,123,"kruskal_wallis",2,NA,NA,1.2233272806057
"3333","d154b268ab32c859868fb7529e1a6ac1","NCT02980276",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Neonatal Height","SECONDARY",NA,"D016640; D003920","RCT Metformin for Reduction of Gestational Diabetes Mellitus Effects",FALSE,524,"t-test",NA,NA,NA,1.53720010503454
"3334","d158214225c2b5b51c45bbe8d7997ace","NCT02954848",0.0129,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Severity of Symptoms of Heartburn in Subgroup Stratified by Response (Improved or Not Improved) at Week 2","SECONDARY","Statistical analysis for criteria 2, improved response","D005764; D004942","Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)",FALSE,483,"mann_whitney",NA,NA,NA,1.00503516534162
"3335","d1738ea0ae2e098dc732820e636790b3","NCT01236053",0.008,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,20382,"logistic_regression",NA,NA,NA,4.24032164916455
"3336","d1746bb8ff88682d35aa17438da9314d","NCT00205348",0.0332,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Swallowing Quality of Life","PRIMARY","The statistical significance of the difference between pre-and post-operative scores for Communication was tested with the Wilcoxon signed-rank test.","D007037","Swallowing Function Before and After Surgery for Thyroid Goiter",FALSE,116,"mann_whitney",NA,NA,NA,1.13726519455192
"3337","d18116cd8ab802163032b3a1847d4b48","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Price)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1735,"linear_regression",NA,NA,NA,6.10897489711546
"3338","d1aa77d5c25fae4991e4a4fb8ea4f9aa","NCT00725101",0.05,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Odds Ratios From Stepwise Logistic Regression Model of Longitudinal Adherence to Duloxetine Treatment for Fibromyalgia (FM) Over 12 Months: Generalized Anxiety Disorder-7 (GAD-7) Score, Pregabalin Use, and Non-Steroidal Anti-Inflammatory Drug (NSAID) Use","PRIMARY",NA,"D005356; D009209","Fibromyalgia Health Outcome Study on Cost of Treatments",FALSE,212,"logistic_regression",NA,NA,NA,2.15248668480022
"3339","d1b714fdf1f2586f86520ec3ceee4882","NCT00442936",0.021,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Total Migraine Freedom (TMF) at 2 to 24 Hours Post-Dose","SECONDARY",NA,"D008881","Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)",FALSE,643,"logistic_regression",NA,NA,NA,1.77503179253386
"3340","d1c5cada5df669f20040dbfd6e4566eb","NCT03011775",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Thickness of the Intima-media Complex","SECONDARY",NA,"D006331; D050197; D003327; D003324; D017202; D007333; D024821; D018450","Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease",TRUE,43,"mann_whitney",NA,NA,NA,1.00454908915455
"3341","d1d8d61ab2923f19d3db135351da7925","NCT03855228",0.02,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Total Nasal Symptom Score (Assessed by Participant)","PRIMARY","This analysis compares Change From Baseline values.","D012220; D065631; D006255","Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)",FALSE,340,"anova",2,NA,NA,1.24170354272197
"3342","d1de0fb435bbd4bd0d3f2b56e6e25118","NCT05030467",0.011,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Patients With Well-controlled Blood Pressure","SECONDARY","Outcomes were evaluated using generalized estimating equations with a log link and Poisson-distributed errors, adjusting for clinic-level clustering.","D006973","Leveraging Electronic Health Record (EHR) Tools to Reduce Health Disparities for Patients With Uncontrolled Hypertension",FALSE,49210,"logistic_regression",NA,NA,NA,8.75244521905107
"3343","d1e48b65a7293c772fb5663145394ef9","NCT00583778",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Change in FEV-1 % Predicted Over Time","PRIMARY","Data were analyzed using STATA 10 SE.Categorical variables were described using frequencies and relative frequencies. Distribution of continuous variables were evaluated for normality using the Shapiro-Walk test and graphically using histograms and box plots. Because most data were non-parametric, they were described using the median and 25th and 75th percentiles (interquartile range) and then compared using Wilcoxon rank sum test.","D001249","A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation",TRUE,141,"mann_whitney",NA,NA,NA,1.76345107862741
"3344","d1eb8d9653260f123732e4e231cd6e96","NCT03534063",0.047,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Opioid Utilization","PRIMARY",NA,"D010149","Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery",FALSE,194,"mann_whitney",NA,NA,NA,1.9569817368126
"3345","d21f81b401278ea5d12960db1a73a70d","NCT01945034",0.042,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Participant Assessment of Normal Function and Activity at Day 3 and 10","SECONDARY","Day 3: The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline participant assessment of Normal Function/Activity terms. Upper limit of 95% CI \< 0 for Ibuprofen treatment significantly better than combined Placebo.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,219,"anova",2,NA,NA,1.88961833905716
"3346","d225eb06774e247b7ec33aacc277d39e","NCT00408876",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in 36-Item Short-Form Health Survey (SF36) - Physical Functioning","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,155,"t-test",NA,NA,NA,1.53169711141017
"3347","d24fc525e7f431228186a213737f45cf","NCT00651820",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Differences in Scar Viscoelasticity Between Wounds Treated With Collagenase Santyl and Its Vehicle","SECONDARY","Energy Absorption: Paired t-test and Wilcoxon signed rank test were used for testing any significant differences (Sig. diff.) between the two treatments","D002921","Effect of Collagenase on Healing and Scarring",TRUE,56,"t-test",NA,NA,NA,1.13456029943022
"3348","d2653057aa3718620a178769b2a471f9","NCT00673660",0.034,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Available Lipid Profiles of Compliant and Non-compliant Participants","SECONDARY","Triglycerides","D050171","Observational Study On Compliance Of Statin Treatment Of Patients With High Blood Cholesterol Levels",FALSE,263,"t-test",NA,NA,NA,1.72852785580976
"3349","d27de607dc96d1bdd23a3fc2d1a863d6","NCT01843842",0.0283,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,1,0,"Severity of Clinical Manifestations of Acute Respiratory Infection (ARI) by Total Symptom Score on Day 3 of Observation (Based on the Results of Pediatrician's Examination) and on Days 2, 3, 4 and 5 of Observation (Based on Patient Diary Data)","SECONDARY","Fever (Day 3, doctor's examination)","D007239; D003141; D012141","Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children",FALSE,293,"kruskal_wallis",2,NA,NA,1.55806528042035
"3350","d2809bb918580ea167802a81879894fd","NCT00002651",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"High Libido","PRIMARY",NA,"D011471","SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer",FALSE,113,"t-test",NA,NA,NA,1.31444539200497
"3351","d28c22ab6983555867bcdb5333dc4190","NCT03726489",0.0412,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Duration of Treatment Response During Observation Period","SECONDARY","Analysis for Phototypes III/IV","D011565","Light Treatment Effectiveness (LITE) Study",FALSE,273,"linear_regression",NA,NA,NA,2.07193784562784
"3352","d29a1b210749a03850c81d923949892b","NCT00571038",0.0438,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Change in Health Status","SECONDARY",NA,"D006973","Working With Veterans Organizations to Improve Blood Pressure",FALSE,374,"kruskal_wallis",2,NA,NA,2.54831883545233
"3353","d2a850c33de62b8f25cab96b086afbcc","NCT00147199",0.037,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Quality of Life (Minnesota Living With Heart Failure)","SECONDARY","Physical Dimension","D006976; D000081029; D006973","Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)",FALSE,235,"mann_whitney",NA,NA,NA,1.75741342756885
"3354","d2b2eee1e5c703db3478a706956dba80","NCT02709486",0.0271,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 8, \>=90%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,565,"logistic_regression",NA,NA,NA,2.07616193802565
"3355","d2b95a3d6a7598f1e0b77a3f452f2875","NCT00860470",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Still Birth Rates","SECONDARY",NA,"D047928; D066087; D001724; D066088","Antenatal Micronutrient Supplementation and Infant Survival",FALSE,29880,"logistic_regression",NA,NA,NA,11.5491941570185
"3356","d2d7ce13b24b93b8d77f695a0d625931","NCT01779362",0.05,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"ß-cell Response Measured by Hyperglycemic Clamp","PRIMARY","Seemingly unrelated regression was used to compare treatment arms on the combination of insulin sensitivity (M/I as calculated from the hyperglycemic clamp) and insulin secretion (steady-state C-peptide and ACPRmax as co-primary; ACPRg as major secondary,). See statistical analysis plan for further details and R code.","D011236","RISE Adult Medication Study",FALSE,232,"linear_regression",NA,NA,NA,2.24997314719514
"3357","d2f63aebe216fe9246d3ad0b0aaa827f","NCT01474876",0.0164,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Predictors of Maintained Treatment Response and Remission in Participants With Ankylosing Spondylitis","SECONDARY","Treatment response and participant age","D013166; D001168; D015535; D025241; D013167","Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis",FALSE,361,"logistic_regression",NA,NA,NA,1.07538648592825
"3358","d2fcdce674dd640cadd40b78deb34e27","NCT00773175",0.0325,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Mean Total Volume of Fluid Administered at a Single Infusion Site, From the Start to the Cessation of Fluid Administration, for All Randomized Participants","PRIMARY",NA,"D003681","Subcutaneous Rehydration Compared to Intravenous Rehydration",FALSE,148,"anova",2,NA,NA,1.25619669054344
"3359","d31413103f9e174a4294599019840657","NCT02477020",0.036,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Responders Based on CGI-I Ratings Score","SECONDARY","Week 2","D012559","A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia",FALSE,156,"logistic_regression",NA,NA,NA,1.40560661794007
"3360","d331b856d99210c3aba58b096211d551","NCT00433290",0.023,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Statisically Significant Change From Baseline to 13 Week Endpoint in Laboratory Analytes","SECONDARY",NA,"D010003; D020370","Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain",FALSE,256,"anova",2,NA,NA,1.21948776123183
"3361","d332f4e2ab285bdbcf959240d9c0036a","NCT01796236",0.042,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Abbreviated Profile of Hearing Aid Benefit (APHAB)","OTHER_PRE_SPECIFIED","Baseline: Global (Benefit)","D034381; D003638; D006314; D046089","Clinical and Health Economic Evaluation With a New Baha® Abutment Combined With a Minimally Invasive Surgical Technique",FALSE,103,"mann_whitney",NA,NA,NA,1.30974989899619
"3362","d333a323c6277a797e1cbd48a7967414","NCT01513343",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Children's BMI Percentiles","PRIMARY",NA,"D009765","Promoting The Self-Regulation Of Energy Intake",TRUE,147,"logistic_regression",NA,NA,NA,1.79957957739554
"3363","d341252c9fae8b96cbb39c8e7189ffbb","NCT02709486",0.0253,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 16, \>=70%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,565,"logistic_regression",NA,NA,NA,1.95662962365181
"3364","d35ccdd9f2c873292d0a1fc82acc4ad6","NCT02344290",0.04,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"For Mechanistic Substudy: Change in Non-Calcified Plaque (NCP) Volume From Baseline to Year 2","SECONDARY",NA,"D002318","Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults",FALSE,587,"linear_regression",NA,NA,NA,2.95105538093415
"3365","d3745a499ab9c55c54c39633792b7e66","NCT03192176",0.0423,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 4 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 4","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.20872438164849
"3366","d3869297e65a2d7297d55f8353346e09","NCT01707693",0.033,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Self-Efficacy","OTHER_PRE_SPECIFIED",NA,"D006331; D003327; D003324; D017202","A Lifestyle Physical Activity Intervention for Older Sedentary Women",FALSE,121,"mann_whitney",NA,NA,NA,1.15464149832376
"3367","d39445dac8c58fbafab30b10a1e31bd0","NCT01717872",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Percent of Glottic Opening With the Miller Blade Lifting the Epiglottis and Tongue","SECONDARY",NA,NA,"Comparing the Laryngoscopy View Using Miller and Macintosh Laryngoscopy Blades in Infants Under Two Years of Age",FALSE,50,"mann_whitney",NA,NA,NA,1.07648023860356
"3368","d39d1a74a6d81f9aeb3675ba51c57f2d","NCT01340027",0.047,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With 50% Reduction in Incontinence Episodes","SECONDARY",NA,"D053201; D014570; D001745; D020924","A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder",FALSE,59,"logistic_regression",NA,NA,NA,1.10462948081554
"3369","d3c7e0006d0ff0b8d475c30571b87aff","NCT04036058",0.0435,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Hospital-onset C. Difficile Infection (HO-CDI) Rates","SECONDARY",NA,"D003015","Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infection) in VA",FALSE,9781,"t-test",NA,NA,NA,12.8890045301154
"3370","d3d7b3bbb4bdec05536e12b4775aaa44","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Ambulatory Nighttime Brachial Rate-pressure Product","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"3371","d3e749f73aa2dc5114018a48f305c6d5","NCT05870956",0.02,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"Total All-cause Medical Costs","PRIMARY",NA,"D011658; D054990; D005355","Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients",FALSE,971,"anova",2,NA,NA,2.08757432514987
"3372","d3e74fa16e8dd7ab489a521b6abe3ebe","NCT00551135",0.0342,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Baseline and Change From Baseline in Anxiety Visual Analog Scale (VAS) Score","SECONDARY","Day 2 PS; LS Means from ANOVA model with terms of treatment, pooled center, baseline VAS score and baseline PCS score (for baseline visit ANOVA model with terms of treatment and pooled center). Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,200,"anova",2,NA,NA,1.51896877202793
"3373","d3fe5fefd351f890ce59a9c04382ef3f","NCT02856594",0.029,"Logistic regression","INTERVENTIONAL",0,0,1,1,0,"Incidence of Delirium","PRIMARY",NA,"D000071257","Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep",FALSE,364,"logistic_regression",NA,NA,NA,1.77060119012811
"3374","d45c0322e68167a7aa6ea2034e5cecec","NCT00405821",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"HIV-1 Viral Load Difference Between Arms","SECONDARY","Null hypothesis is no difference in annual rate of change in log10 viral load by arm.","D006558","Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda",FALSE,440,"t-test",NA,NA,NA,3.08645519783843
"3375","d475e42b1b492ee6079f7718c664569b","NCT01081301",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Non-Death Revised Grief Experience Inventory","SECONDARY","Generalized estimating equations were used to determine change in patterns of Non Death Revised Grief Experience Inventory scores over time (Day 7, 14 and 3, 6, and 12 months) compared to baseline. The advantage of utilizing general estimating equations was that it effectively increases the sample size (increasing power) and estimated more robust standard errors by taking into account the repeated measures and adjusting for covariates.","D009369","Living With Hope Program for Rural Women Caregivers",FALSE,58,"anova",2,NA,NA,1.15327776573523
"3376","d47683c0d736daf0eef07bd7553cb9cd","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Potassium Count at Baseline and After Treatment Completion","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"3377","d4c6809463ca089a7a343e76d10f9cd8","NCT00147199",0.027,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Quality of Life (Minnesota Living With Heart Failure)","SECONDARY","Global Score","D006976; D000081029; D006973","Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)",FALSE,235,"mann_whitney",NA,NA,NA,1.34284866619335
"3378","d4cd8455e4cafaf4516d72fb19664d0f","NCT00755131",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"High Mobility Group Box-1 (HMGB1)Levels at Baseline and 6 Months","PRIMARY","Sample size determination was based on a t-test assuming a normal distribution with non-equal variance with the mean and standard deviation for the experimental group (postinfarction patients) of HMGB1 levels equal to 15 ± 7 and 2 ± 1 ng/dl for the control group derived from a previous study, respectively. The required sample size was calculated to be 30 subjects per group to detect on the size of one SD with α value of 0.05 (two-sided) and power (1 - β) of 0.8.","D009203; D007238","Effects of Cardiac Rehabilitation on High Mobility Group Box-1 Levels After Acute Myocardial Infarction",TRUE,75,"t-test",NA,NA,NA,1.301639172202
"3379","d4cf0cb44d77ae318de70dab850e69b0","NCT01070550",0.0123,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for ALT ratio at BL (\<=1 vs \> 3). The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including total cumulative dose of peginterferon and ribavirin), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,2981,"logistic_regression",NA,NA,NA,2.38096552981154
"3380","d4e2a2cfd7f69e6318635bd8ba1a10e5","NCT00395850",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Retention","SECONDARY",NA,"D019970","Disulfiram for Cocaine Abuse",TRUE,107,"t-test",NA,NA,NA,1.54285677868397
"3381","d52ee141e211f24399d68fd96a8ec4b1","NCT01945034",0.029,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","SECONDARY","At Rest Day 5 Mid-day: The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms. Upper limit of 95% CI \< 0 for Ibuprofen treatment significantly better than combined Placebo.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,219,"anova",2,NA,NA,1.37935240606094
"3382","d544586a747afee509a27c53605b31f0","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Specific Perceived Healthfulness","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1752,"linear_regression",NA,NA,NA,6.13876469477842
"3383","d5493f67f32c9b317223c48870302b0c","NCT02528253",0.0387,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 4, \>=30%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1009,"logistic_regression",NA,NA,NA,3.75647640359296
"3384","d56eb33803c8c361844b102dde94e681","NCT02814565",0.033,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Physician's Clinical Global Assessment on Days 7 and 15 of Treatment","SECONDARY","Day 7. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.","D013035; D001416; D019547; D017116","Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin",FALSE,180,"mann_whitney",NA,NA,NA,1.39964132911301
"3385","d5766de237eebddf68ce215fa584f45b","NCT01787461",0.049,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Trans-Epidermal Water Loss (TEWL) at Week 6, 12, 18 and 24","SECONDARY","Change at Week 18, Left Cheek: Analysis was performed using ANOVA model with treatment, Glogau classification of photoaging, site, baseline and treatment-by-baseline interaction (if applicable) terms.",NA,"A Study to Assess the Effects of an Oral Dietary Supplement on Overall Facial Appearance Among Healthy Adult Women With Existing Skin Damage From Sun Exposure",FALSE,190,"anova",2,NA,NA,2.00578148695719
"3386","d58d8abff50ea7c577712d0f87a4a3b6","NCT00767806",0.039,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to 12 Week Endpoint in Aspartate Aminotransferase","SECONDARY","Tested was the null hypothesis that there is no difference between placebo and duloxetine groups in change of aspartate aminotransferase during 12 weeks of treatment.","D001416; D017116","A Study for Patient With Chronic Low Back Pain",FALSE,384,"anova",2,NA,NA,2.34066604064766
"3387","d5a95a83d03ccb32d2ecff81532fa4b5","NCT00567489",0.03,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline of Metabolic Control Determined by Lipoproteins at Month 3 and 6","SECONDARY","Estimate of Least Square Means Comparing Treatment Groups for Apo B-Month 6",NA,"IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients",FALSE,239,"anova",2,NA,NA,1.4820669901068
"3388","d5bbcca3e894b3639d2ba17e010f4d22","NCT00416572",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mental Health (Measured With the SF-36) at Baseline, Post-intervention (4-months Post-intervention) and Final Follow-up (13-months Post-intervention)","PRIMARY","Comparison between nutrition education intervention and the control condition at final follow-up (13 months post-intervention). The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome.","D001943","Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer",FALSE,154,"linear_regression",NA,NA,NA,1.84083479148392
"3389","d5c7cbcb6230c6e63d71c083c3fa6a4d","NCT01496066",0.0318,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Percent Absolute Reduction in Manifest Refraction Spherical Equivalent (MRSE) for Eyes With <0.75 D Cylinder Postoperatively","SECONDARY",NA,"D002386; D001251","Calhoun Vision Light Adjustable Lens (LAL) in Subjects With Pre-Existing Corneal Astigmatism",FALSE,153,"t-test",NA,NA,NA,1.25314767073569
"3390","d5db867317cf3e6cf0759b507537db97","NCT01878214",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Changes in Motivation to Quit Smoking and Thinking About Quitting Smoking","SECONDARY","Thinking about quitting",NA,"Promoting Smoking Cessation in Carpenters",FALSE,288,"logistic_regression",NA,NA,NA,2.07479149107725
"3391","d5e8cf83c63bd33e822556707bcdf208","NCT05127304",0.039,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"COPD-related Health Care Resource Utilization","PRIMARY","Inpatient visits","D029424","A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",FALSE,11316,"linear_regression",NA,NA,NA,12.6384148617557
"3392","d5f7fa383ac957f333856f6a82159155","NCT01187498",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change in Urgency Severity","SECONDARY","Standard regression methods adjusting for baseline values","D053201","Behavioral Treatment of Overactive Bladder in Men",FALSE,121,"t-test",NA,NA,NA,1.63728545358366
"3393","d605a826f661ba725d6ed8fb7a8ff8bf","NCT02528188",0.0105,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 4: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline PGA of OA scale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade, NSAID and treatment.","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,1.69311988088598
"3394","d614ee3b0cfda99dad3345cedde74100","NCT01658514",0.0474,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Cmax of Plasma Metformin","PRIMARY","For the Normal Renal Function Cohort. Met XR is the denominator for the % ratio of LS means and the comparator for the p-values.","D051437","Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction",FALSE,68,"anova",2,NA,NA,1.18897637924974
"3395","d6177bba8dd8c25c2f3cad52a2902bbe","NCT00255190",0.026,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Change From Baseline to Month 12 for Platelet Count Values","PRIMARY",NA,"D005764","Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn",FALSE,312,"anova",2,NA,NA,1.49396627207357
"3396","d624acb76be755a753dc35450500c1b4","NCT00645801",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Endoscopist Evaluation of Colon Cleanliness in the Lubiprostone Group vs the Placebo Group","PRIMARY","Based on the assumption that 70% of patients using PEG plus placebo (group 2) will have good results, by allocating 100 cases in each group, we will have 84% power to detect a difference of 18% or more in the effectiveness of PEG plus lubiprostone combination (group 1) (eg, 70% in group 2 vs. 88% in group 1) at the alpha level of significancelevel of significance.",NA,"Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation",FALSE,123,"t-test",NA,NA,NA,1.65033525744316
"3397","d627aa3a606264e8ae11cb6a350df566","NCT05182840",0.0342,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Last Observation on Treatment Carried Forward","SECONDARY","The odds ratio, 95% confidence interval, and p-value were calculated based on logistic regression of binary outcome adjusting for treatment, and stratification factors as covariates.

Randomisation stratification was used, which is based on estimated glomerular filtration rate (eGFR) and urine albumin creatinine ratio (UACR) levels at screening.","D007674; D051436","A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease",FALSE,127,"logistic_regression",NA,NA,NA,1.21824468739663
"3398","d62aca380807bd2fbbc1162dde867ad5","NCT00442546",0.0441,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Interference With Enjoyment of Life as Measured by the m-BPI-sf","SECONDARY","Month 6","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,160,"anova",2,NA,NA,1.68857876697354
"3399","d647843b88caaa7f904cf1c538d61ef7","NCT01972789",0.034,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"The Number of Times a Participant Needs to Return to Monthly Treatments During the 24 Months.","SECONDARY",NA,"D008268; D020256; D009389","Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)",FALSE,345,"logistic_regression",NA,NA,NA,1.97572276311821
"3400","d65084fc72596149a2be4df4b35ff290","NCT00927472",0.049,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Proportion of Index Subjects Lice-free 2 Weeks After Their Last Treatment","PRIMARY",NA,"D010373","Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice",FALSE,95,"t-test",NA,NA,NA,1.43283996080388
"3401","d653fc3ade346e71d2b57930c1f35d7f","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Environment)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1750,"linear_regression",NA,NA,NA,6.13526752012651
"3402","d65bf594c219014696853fd49d87a474","NCT02182440",0.045,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants Meeting at Least One MAKE 60 Criteria","OTHER_PRE_SPECIFIED",NA,"D058186","A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI",FALSE,227,"logistic_regression",NA,NA,NA,2.03807733802775
"3403","d67d09f8100198f5070c2987817b50f7","NCT01067768",0.016,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Catheter Days","SECONDARY","Null hypothesis: On average catheterization are the same in patients with daily review of the indication and control group patients","D007239; D003141; D014552","Reduction of Catheter-associated Urinary Tract Infection With a Daily Nursing Review of the Indication",FALSE,1209,"mann_whitney",NA,NA,NA,1.91503756206142
"3404","d69108297cfb663ad1dd285d6a4f561f","NCT00455533",0.0399,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]) to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR/RCB1","SECONDARY","GTSE1 204317_at","D001943","Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer",FALSE,295,"logistic_regression",NA,NA,NA,2.09505101992067
"3405","d6abf8238c00dd9aa7c7ed125d52d0fc","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Albumin Value at Baseline and After Treatment Completion","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"3406","d6bea825e67ba6d85d0f0c66ee0f645a","NCT03192176",0.0376,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 2 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 6","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.09504392037789
"3407","d6bebda90dadb184f72c99f19f8e7923","NCT00591253",0.018,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg","SECONDARY",NA,"D006973; D000075222","Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension",FALSE,267,"logistic_regression",NA,NA,NA,1.00604766183987
"3408","d6d7136b7b2652f2261199f22e84033d","NCT00536471",0.033,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Statistically Significant Changes in Baseline to 9 Month Endpoint Laboratory Values - Alkaline Phosphatase","SECONDARY",NA,"D003866; D003863; D003865","A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients",FALSE,268,"anova",2,NA,NA,1.70077638191706
"3409","d6ec14ce8a3bf2a3b69de121e2c3d3de","NCT02214186",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Activated Partial Thromboplastin Time in Restrictive Fluid Management of Severe Preeclampsia During Cesarean Section","SECONDARY",NA,"D004461; D011225","Restrictive Fluid Therapy in Severe Preeclampsia",TRUE,46,"anova",2,NA,NA,1.03597838019194
"3410","d6f145cb4ef59771da9e4c201253aece","NCT03428100",0.031,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving EASI50","SECONDARY",NA,"D003876; D003872; D004485","A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable",FALSE,185,"logistic_regression",NA,NA,NA,1.34483611906822
"3411","d6fb6f96a69e022c5d26dbbaf0fa9f63","NCT02519777",0.03,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change in CD8+ T-cell Count","SECONDARY","Under the null hypothesis, it was assumed there was no difference between Arm B: DTG and placebo MVC and Arm C: MVC and DTG in change in CD8+ T-cell count at Week 24 from baseline","D015658","Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)",FALSE,127,"mann_whitney",NA,NA,NA,1.08979318580368
"3412","d6fbcd903c8184ea8f6731be5baaf27e","NCT00949884",0.0476,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Participants Achieving Blood Pressure Goals at Week 8","OTHER_PRE_SPECIFIED","Percentage of participants achieving blood pressure goal of \<120/80 mmHg","D006973","Olmesartan Comparison to Losartan in Hypertensive Subjects",FALSE,810,"logistic_regression",NA,NA,NA,4.0104883381177
"3413","d71092c0db2459bc6b8f5f79e579a7c0","NCT01532986",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Percentage With a Patient Healthcare Questionnaire-2 (PHQ-2) Score ≥ 3","SECONDARY",NA,"D010300","Randomized Trial to Test the ""Coordinated Care for Health Promotion and Activities in Parkinson's Disease"" Intervention in the VA",TRUE,328,"t-test",NA,NA,NA,2.66881159065383
"3414","d711501953eeead3cba06e69afb5db25","NCT01444651",0.05,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Baseline to 3-month Change in Matsuda Disposition Index","SECONDARY","Linear regression was used to model the change in Matsuda disposition index (3-month minus baseline), comparing tadalafil to placebo groups after adjusting for baseline value.","D002318; D007333; D018149","A Trial of Tadalafil and Glycemic Traits",FALSE,53,"linear_regression",NA,NA,NA,1.10589694869732
"3415","d720f5acf23e8e0f7841569c3c3062cd","NCT00653133",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Complications of Peripheral Nerve Block","PRIMARY","Null hypothesis: There is no difference in reported complications associated with the placement of continuous peripheral nerve block catheters between ultrasound imaging guided placement and nerve stimulator guided placement.","D010149","Multicenter Continuous Peripheral Nerve Block Surveillance Study",TRUE,1821,"t-test",NA,NA,NA,6.25822060188009
"3416","d72fd4e2e6e157e6f5578bf2417a4bf1","NCT02709486",0.018,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >=30%, >=50%, >=70% and >=90% Response","SECONDARY","Week 12, \>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,563,"logistic_regression",NA,NA,NA,1.45286168891767
"3417","d738f4be0c7b71c93096f2ec41cd2010","NCT01198977",0.049,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Physical Activity (Behavioral Target)","OTHER_PRE_SPECIFIED",NA,"D009103; D012598; D005221","Telehealth-Based Exercise Program to Treat Fatigue in MS",FALSE,63,"anova",2,NA,NA,1.17897751993381
"3418","d7511d580b107a90be3880bd9469f369","NCT02634151",0.0359,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants Achieving LDL-C Reduction of ≥10%","SECONDARY","Week 12","D006937","A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins",FALSE,105,"logistic_regression",NA,NA,NA,1.15837382534082
"3419","d75b3baee18e04e7efca5f36d58bb6de","NCT03828019",0.029,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Corticosteroid-sparing Treatment Success Within the First 6 Months After Randomization","PRIMARY","The sample size estimation: Adalimumab was estimated to be successful in 75% of patients. The overall success rate with conventional immunosuppression was estimated to be 51%. A sample size of 222 (111 per treatment group) provided 90% power to detect a difference in cumulative percent of 75% versus 51%","D014605","Adalimumab vs. Conventional Immunosuppression for Uveitis Trial",FALSE,217,"logistic_regression",NA,NA,NA,1.3731773005723
"3420","d766044cc869724b7e83257f609d5cdf","NCT01283139",0.049,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With a Cutaneous Lupus Erythematosus Disease Activity and Severity Index (CLASI) Activity Score Greater Than or Equal to (>=) 10 at Baseline Who Achieved a >= 4-point Reduction","SECONDARY",NA,"D008180","A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus",FALSE,61,"logistic_regression",NA,NA,NA,1.16128313184243
"3421","d767c40fe42f4988951b9a2290a8bcfd","NCT02528188",0.0336,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 8: \>=30% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,4.67677824273464
"3422","d7755caff3aa17634f1fbc3d1cec726f","NCT01908829",0.012,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With a Mean of at Least 8 Micturitions Per 24 Hours at Baseline and Less Than 8 Micturitions Per 24 Hours Postbaseline","SECONDARY","Week 12 odds ratios, 95% Two sided CIs for Odds ratios and p-values were from a logistic regression model including treatment group, sex, age group (\<65, \>=65 years), 4-week incontinence episode reduction group, geographic region as factors and baseline value as covariate.","D014570; D001745; D053201","A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)",FALSE,1412,"logistic_regression",NA,NA,NA,1.60509247842272
"3423","d782bbd87f69a507d262c71a53559f03","NCT03499600",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Treatment Response","SECONDARY","Testes the effects of the moderation of language of service delivery and condition on treatment response.","D000066553","Improving Satisfaction, Engagement and Outcomes Among Traditionally Underserved Children Through Cultural Formulation",TRUE,89,"logistic_regression",NA,NA,NA,1.41222998379373
"3424","d7893dc79c9b9a56a76f4994b1dae798","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Specific Perceived Environmental Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1750,"linear_regression",NA,NA,NA,6.13526752012651
"3425","d78d113617e3ae2cd023634695542f4c","NCT01270958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Hemoglobin Values at Baseline and After Treatment Completion","PRIMARY",NA,"D012220; D065631; D012221","A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"3426","d79bf45d0880edd84db868b29073edb8","NCT00437125",0.0263,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline to 12 Weeks on the UKU (Udvalg for Kliniske Undersogelser: Committee for Clinical Investigations) Side Effect Rating Scale","SECONDARY","Tested was the null hypothesis that there would be no change on the global assessment by doctor subscale score from baseline to 12-week endpoint.","D010300; D003866; D003865","Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease",FALSE,151,"t-test",NA,NA,NA,1.05854108467949
"3427","d79c84743bda0dea93a9a72455c2e937","NCT02912650",0.045,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (PRID4)","OTHER_PRE_SPECIFIED","7 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,221,"anova",2,NA,NA,2.01144534307581
"3428","d7c3f599ed511345472558ec26186185","NCT04876482",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Tongue Protrusion Muscle Strength","PRIMARY","We hypothesized that the improvements in the tongue protrusion muscle strength would be more in patients who underwent TORS combined with OPR than in those who underwent only TORS and those who received conservative treatment (controls).","D001049; D012891; D020181","Myofunctional Training for Obstructive Sleep Apnea Patients After Transoral Robotic Surgery",TRUE,74,"linear_regression",NA,NA,NA,1.2933799900503
"3429","d7cb996df2f7c21b1ff5191520347d4b","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Postprandial C-peptide (AUC)","SECONDARY","Difference in treatment effect between the 2 groups","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",TRUE,50,"t-test",NA,NA,NA,1.07648023860356
"3430","d7ccb9c03e74cd4793224cf1b59efa8e","NCT02634151",0.0464,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants Achieving LDL-C Reduction of ≥10%","SECONDARY","Week 4","D006937","A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins",FALSE,105,"logistic_regression",NA,NA,NA,1.43672180675648
"3431","d7d8312b6ff1a0bd9f4d66a26cf3c954","NCT01876732",0.047,"Wilcoxon","INTERVENTIONAL",0,0,0,0,0,"Change in Quality of Life","SECONDARY",NA,"D014806","Impact of Vitamin B12 Replacement on Epogen Dosing and Improvement of Quality of Life in Hemodialysis Patients",FALSE,57,"wilcoxon",NA,NA,NA,1.08702005139635
"3432","d7e1ba02429d908f6e1f2b4e1328bd58","NCT00375973",0.05,"Linear regression","INTERVENTIONAL",0,0,1,1,0,"Change From Baseline in Brief Pain Inventory (BPI) --Average Pain Severity Score","SECONDARY",NA,"D015673; D013577; D005221","Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome",FALSE,57,"linear_regression",NA,NA,NA,1.1439569152679
"3433","d7f5ed45dae1db7f511f773ac36b114e","NCT04772755",0.0273,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Mean Injection-site Pain Scores on the Wong-Baker Faces Pain Scale© at (Approximately) 10 Minutes Following Vaccination.","SECONDARY",NA,"D013575; D019462","Presyncope (Syncope) Prevention Study",FALSE,332,"mann_whitney",NA,NA,NA,1.60646430601164
"3434","d80c1390fec9e868f61425812a7f4a38","NCT03435081",0.033,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement","SECONDARY",NA,"D003876; D003872; D004485","A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis",FALSE,294,"logistic_regression",NA,NA,NA,1.78003178544863
"3435","d82d845bb417fabf34be1b562cdeb035","NCT05407064",0.0429,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores","SECONDARY","Change from baseline in total CGI-S scores determined by the difference in means and difference between treatment and placebo (p-value determined from two-sample t-test).","D001008","A Dose-Finding Study of MM-120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms",FALSE,70,"t-test",NA,NA,NA,1.10944451679675
"3436","d832664bf94e8e959e78b61f7279f292","NCT00468845",0.0354,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Non-opioid Rescue Medication - Paracetamol","SECONDARY","1st Week PS","D010149","Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy",FALSE,302,"anova",2,NA,NA,1.91487557199802
"3437","d833e9d2db5ef9609eeb39d95e38680d","NCT05129592",0.037,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Change in Inferential Beliefs Regarding Smokeless Tobacco","PRIMARY","Unadjusted logistic regression showing the effect of condition (Nicotine corrective with reason for misperception compared to the Nicotine corrective with both components of coherence (reference group)) on smokeless tobacco relative harm beliefs",NA,"Can Exposure to Brief Messages Correct Misperceptions?",FALSE,98,"logistic_regression",NA,NA,NA,1.14966874144251
"3438","d83dd7e19b089807d47411c87c484ffa","NCT02912650",0.019,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Relief Rating (PRR) Score","OTHER_PRE_SPECIFIED","9 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,340,"anova",2,NA,NA,1.18744685865681
"3439","d840c0afa8e1e093e551c4c137097e59","NCT01580098",0.025,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"HbA1c","PRIMARY",NA,"D003920; D003924","Medium-term Health Coaching and Life-long Monitoring in Diabetes Mellitus",FALSE,162,"mann_whitney",NA,NA,NA,1.04850033988674
"3440","d8419ccefc0b36e68519c6743a693ac2","NCT02439320",0.035,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Used Rescue Medication","SECONDARY",NA,"D008881","Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:",FALSE,810,"logistic_regression",NA,NA,NA,3.09155280146082
"3441","d84788397e1cfe22baccade76887eff1","NCT02528253",0.0407,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 2, \>=70%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,810,"logistic_regression",NA,NA,NA,3.51440939392643
"3442","d8496fb766be0980eed10d193356c9e2","NCT04359758",0.039,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Completing Genetic Testing","PRIMARY","Because education and marital status have been associated with genetic testing participation in prior research, we conducted a follow-up analysis in which we adjusted for education and marital status.","D011471","Streamlined Genetic Testing in Prostate Cancer",FALSE,107,"logistic_regression",NA,NA,NA,1.25343935117704
"3443","d84b93c7221fb7c61da8adc286925b23","NCT00261443",0.043,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Median Baseline, Change From Baseline, and Highest Value of Change in Creatine Kinase, Phase 3 Safety Sample","SECONDARY","Treatment Comparison Baseline Creatine Kinase","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"mann_whitney",NA,NA,NA,2.34439862375478
"3444","d85e29f3c9c391af5841a2576545ce65","NCT03192176",0.0407,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 10","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,85,"logistic_regression",NA,NA,NA,1.1638489043191
"3445","d870808bcfa93edd59dfa49b19262d1a","NCT00094302",0.01,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Serum Creatinine","SECONDARY","Since the p-value for the preceding test (Statistical Analysis 1) was not significant at the 0.05 level, another generalized linear model was fit, omitting the interaction between treatment group and month of visit. This tests whether the value of the post-baseline laboratory parameter differs by treatment group, taking into account that measurements in the same subject over time may be correlated.","D006333; D002318; D006331","Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function",TRUE,3445,"linear_regression",NA,NA,NA,2.12942984619502
"3446","d876c79b3d51b7f76dcffd2e75257702","NCT00947882",0.049,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Odds Ratio (as Compared to Placebo) of Treatment Response in IPSS","SECONDARY",NA,"D011470; D006965; D059411","A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)",FALSE,200,"logistic_regression",NA,NA,NA,2.05683930419665
"3447","d87c4f8858e3952be09ddd5bd4af7191","NCT04634409",0.021,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants Demonstrating Symptom Improvement","SECONDARY",NA,"D000086382","A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness",FALSE,312,"logistic_regression",NA,NA,NA,1.24189936267887
"3448","d893a62240f23c44c4baf349118a0639","NCT05003791",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"State Hopelessness","PRIMARY",NA,"D006331; D017202; D003324; D007511","Perceived Social Support, Heart Rate Variability, and Hopelessness in Patients With Ischemic Heart Disease",TRUE,45,"linear_regression",NA,NA,NA,1.02560707988412
"3449","d896f9d1127ddb5d140ba36fa97ecbcd","NCT04003155",0.019,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate, and Severe VMS From Baseline to Each Study Week Up to Week 12","SECONDARY","Week 9","D019584","A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause",FALSE,349,"logistic_regression",NA,NA,NA,1.20280944066557
"3450","d8ad26be18269111ac8e1cf2a9d5fa2e","NCT03192176",0.0453,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 4 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 12","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,85,"logistic_regression",NA,NA,NA,1.27275131064248
"3451","d8c423f8d6ed9bc499628e2cd831d731","NCT00301262",0.0321,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Percentage of Occasions of Ejaculation and/or Orgasm (Event Log)","SECONDARY",NA,"D007172","Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied",FALSE,161,"t-test",NA,NA,NA,1.29484690940951
"3452","d8d9956488902d7ae4b07ffb88e3e0a3","NCT04697264",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Correlation Between Circulating Levels of These Markers and Demographic Characteristics.","PRIMARY","The influence of age on IGF1 and 2 levels were analysed by dividing the population into binary groups (\<60years and \>/=60years) to facilitate comparison.","D016889; D009765","Adipocytokines in Endometrial Cancer",FALSE,50,"linear_regression",NA,NA,NA,1.07648023860356
"3453","d90eff5a4d43cf9fc088236249fcb891","NCT01283139",0.031,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Achieving a Response in Systemic Lupus Erythematosus Responder Index 4 (SRI [4])","PRIMARY",NA,"D008180","A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus",FALSE,215,"logistic_regression",NA,NA,NA,1.44724034290976
"3454","d91b7f75ecca906c094931b8ad67718f","NCT03855189",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Response To Therapy At Day 15 (Physician-Evaluated)","SECONDARY","Pairwise treatment comparison based on t-test from an analysis of variance (ANOVA).","D012220; D065631; D006255","Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)",FALSE,219,"anova",2,NA,NA,2.18710096911154
"3455","d920c09ed2e77312d4a6cf1a55ef08f9","NCT03073603",0.036,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Total Number of New T2 Lesions on MRI","OTHER_PRE_SPECIFIED",NA,"D009103; D012598","Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)",FALSE,259,"mann_whitney",NA,NA,NA,1.80101488004476
"3456","d924b24dc7ae28d85897692fb9827959","NCT00511173",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"In Patients Receiving Warfarin, a Pharmacogenetic Algorithm Dose Was Compared to Clinician Dosing (mg/wk).","PRIMARY","Null hypothesis: there is no difference in warfarin dose (mg/wk) between pharmacist dosing and algorithm dosing. In order to gather all SNP groups, the power analysis resulted in \> 100 patients enrolled into each group.","D011655; D001281; D013927; D004617; D020246","Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm",TRUE,204,"t-test",NA,NA,NA,2.11223351769391
"3457","d9285c24411d7c203fd988e7ba1850ea","NCT00270998",0.0492,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"No Bothersome Stress Incontinence Symptoms at 12 Months.","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",TRUE,295,"logistic_regression",NA,NA,NA,2.49873946067788
"3458","d948a68af036b74ec4c92881d5211208","NCT03064113",0.046,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Peak Expiratory Flow Rate (PEFR) From 25% to 75% of Vital Capacity (FEF25-75), as Related to FEV1","SECONDARY","Tx Difference of LS Mean 12 hr","D008171; D008173; D029424","Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",FALSE,64,"t-test",NA,NA,NA,1.1272155956894
"3459","d94a81500cb745e37509d2b918cde133","NCT01234649",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Alanine Aminotransferase (ALT) Levels","SECONDARY","Factorial repeated measures ANOVA","D016640; D003920; D003924; D024821; D018149","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",FALSE,72,"anova",2,NA,NA,1.27670232702116
"3460","d9547c4d250542d60f066cacca36d27e","NCT04593940",0.0228,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Clinical Status for Day 28 Using an 8 Point Ordinal Scale","SECONDARY",NA,"D000086382","Immune Modulators for Treating COVID-19",FALSE,980,"logistic_regression",NA,NA,NA,2.3503907233095
"3461","d95abc61cabb7ae2c401b2c28c038d5d","NCT00791999",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,1,0,"American College of Rheumatology 20% (ACR20) Response at Week 24","SECONDARY",NA,"D001168; D001172","Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)",TRUE,316,"logistic_regression",NA,NA,NA,2.62011956983714
"3462","d969fe3aba5b330fd83052a915e4b3dc","NCT04003155",0.032,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate, and Severe VMS From Baseline to Each Study Week Up to Week 12","SECONDARY","Week 5","D019584","A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause",FALSE,348,"logistic_regression",NA,NA,NA,1.88411802496466
"3463","d96bc1e213bd0bec01e86eb3e0039e7b","NCT03718832",0.0390797,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Body Mass Index","SECONDARY","Adjusted mean difference for full controls, 6 months after trial enrollment",NA,"Fresh Food Farmacy: A Randomized Controlled Trial",FALSE,400,"linear_regression",NA,NA,NA,2.39253678446631
"3464","d970afbcfc1fddc13f885a095519a060","NCT03907683",0.037,"Two-sample t-test","INTERVENTIONAL",0,1,0,0,0,"Change in Moderate (or Higher) Physical Activity Duration Following Message Receipt","PRIMARY","Null hypothesis was that the mean steady state response to weekday move more messages would not differ from zero",NA,"Random Assignment of Intervention Messages for Developing Personalized Decision Rules to Promote Physical Activity",FALSE,80,"t-test",NA,NA,NA,1.04393530908943
"3465","d99fb45eabece74a91ea5730b59460b7","NCT00591721",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in Subscale Scores of the Fatigue Impact Scale","PRIMARY","Hypothesis: Individuals who participate in the program will report significantly reduced fatigue impact immediately post-intervention compared to individuals allocated to the wait-list control group.","D009103; D012598; D005221","Teleconference Fatigue Management for People With Multiple Sclerosis",TRUE,181,"t-test",NA,NA,NA,1.99198348802485
"3466","d9c89210e337be105a3638bf92942be9","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Daytime Central Diastolic Pressure","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"3467","da076434c0abd00284067b27d3d3dbe8","NCT02528188",0.0235,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 24: \>=70% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1989,"logistic_regression",NA,NA,NA,3.43289144898605
"3468","da33145dc7fd6419325768ed48007f80","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Postprandial Glucagon (AUC)","SECONDARY","Difference in treatment effect between the 2 groups","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",FALSE,50,"t-test",NA,NA,NA,1.07648023860356
"3469","da3d3d25f170b1527259735772b48797","NCT02757950",0.0155,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Subjects Reporting Pregnancy-related Hypertension, Pre-eclampsia, Eclampsia, and HELLP Syndrome","PRIMARY","The analysis contained only the subjects with vaccination date in the Exposed cohort and subjects from the Unexposed cohort.","D004165","A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.",FALSE,2458,"logistic_regression",NA,NA,NA,2.65217454158202
"3470","da42f662056b60d9f7d1332b9879d059","NCT02279043",0.02,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mean Change in Attitude About Hormonal IUC as Method for Women in General Between Pre-survey and Post-survey","SECONDARY","Multivariate analysis adjusting for cluster, as association was significant in bivariate test.",NA,"Online Peer Influence on IUD Behaviors and Attitudes",FALSE,330,"linear_regression",NA,NA,NA,1.22360198034379
"3471","da54a458903262aba8f3f2a9805a23f2","NCT02537678",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Child Behavior Checklist Externalizing Symptoms","SECONDARY",NA,"D013313","Stepped Care for Children After Trauma: Optimizing Treatment",FALSE,183,"t-test",NA,NA,NA,1.30077972312385
"3472","da5b4d8ae8f220dd08687f1123ccd292","NCT03399318",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Seizure Severity","PRIMARY","Seizure occurrence defined as a three-level ordinal variable was analyzed using a 223 multinomial logistic regression model because there was evidence that the proportional odds 224 assumption did not hold. This model included treatment group as the factor of interest and 225 country and disease severity as stratification factors. The adjusted treatment group odds ratio, 226 and its associated 95% confidence interval were derived from this model.","D008288; D018512; D012640; D005334; D000084462","Aggressive Antipyretics for Fever Reduction in CNS Malaria",TRUE,255,"logistic_regression",NA,NA,NA,2.35710609207859
"3473","da6bff51c431248a99f90b926be840b9","NCT00270998",0.048,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Satisfaction With Treatment at 3 Months","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",FALSE,299,"logistic_regression",NA,NA,NA,2.46395374770415
"3474","da8a7133ee10f376a4725d3a22a8c5af","NCT00390949",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Self-reported Urethral or Genital Discharge","SECONDARY",NA,"D015658","Scientific Evaluation of Peer Education and STD Treatment to Reduce the Spread of HIV in Zimbabwe",TRUE,4946,"logistic_regression",NA,NA,NA,10.3070296593889
"3475","da8d2de5b2cb0ea0f3b87bc53d534df9","NCT01028014",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Difference (Pre - Post) in Urethral Sensation (Milliamps) as Measured by Current Perception Threshold Testing.","OTHER_PRE_SPECIFIED","Using difference in EMG amplitude as primary outcome, assuming standard deviation of 6, we had greater than 80% power to detect a 10-microvolt change in urethral muscle activity with sample size of 9 participants per group. Due to non-normality and small sample sizes, non-parametric tests were used and data presented as median (IQR). Kruskal-Wallis p-values are reported to compare median scores across groups. Wilcoxon sign-test p-values are reported to evaluate 2-week change within groups.",NA,"Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters",FALSE,48,"mann_whitney",NA,NA,NA,1.05642048349345
"3476","daaaee897ee07b1bf5136b02981d481d","NCT00112151",0.05,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Lower Body Muscle Strength (1-RM, kg)","SECONDARY","As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in average lower body strength with any T to placebo in subjects assigned to no PRT.",NA,"TEAM: Testosterone Supplementation and Exercise in Elderly Men",TRUE,72,"linear_regression",NA,NA,NA,1.27670232702116
"3477","daae76804a7ea6d6595d611bb06be361","NCT00708097",0.0373,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Percentage SMHR of Demineralized Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste(1450ppmF) and Placebo Toothpaste (0ppmF)","SECONDARY","Null hypothesis considered population means of the treatments in comparison, to be equal with respect to percent SMH. Statistical tests were 2-sided with a significance level of 0.05.",NA,"In Situ Caries Efficacy of Fluoride Toothpastes",FALSE,105,"anova",2,NA,NA,1.19637999360086
"3478","dacda915b5cf84ff46ffbc7ccb0e2336","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient-Reported Outcomes Measurement Information System (PROMIS Short Forms 8a - Pediatrics v. 2.0) is a Set of Person-centered Measures That Evaluates and Monitors Physical, Mental, and Social Health in Children and Adolescents.","SECONDARY","This analysis is for the outcome Emotional distress - depressive symptoms. We hypothesized that adolescent in the intervention would have lower depressive symptoms compared to controls at 3, 6, and 12 month outcomes. The following are the baseline comparisons between control and intervention which were controlled for in the 3, 6, and 12 month analysis of outcomes.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,126,"t-test",NA,NA,NA,1.66971913113983
"3479","dadbe42f0c32c1af17067f4b90072da7","NCT02559609",0.027,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Percent Alcohol Negative Breath Tests","PRIMARY","Group A/C (contrast -1) compared to Group B/D (contrast 1)",NA,"Interventions for Unemployed Hazardous Drinkers",FALSE,234,"mann_whitney",NA,NA,NA,1.34004808601141
"3480","daf83693861d0e49a72b5527ae296618","NCT01216163",0.03,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Intensity Difference (PID)","SECONDARY","2 hours: Treatment difference (Ibuprofen sodium - Acetaminophen) and corresponding 95% CI were calculated based on LS means from the ANOVA model.","D014098","Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain",FALSE,173,"anova",2,NA,NA,1.2656810351766
"3481","dafa050693f440c23cbea31b977b7b56","NCT00977106",0.043,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Synovitis Score During the Double-Blind Treatment Period Assessed Using Power Doppler Ultrasound","SECONDARY","Change at Week 4","D001168; D001172","TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF",FALSE,103,"mann_whitney",NA,NA,NA,1.3358182470884
"3482","db016b55efbeb029309613cf4e107be3","NCT00417027",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Total Bupivicaine in Milligrams Administered Per Hour of Labor for Analgesia.","PRIMARY",NA,"D048949","Programmed Intermittent Epidural Bolus Time Interval and Injection Volume",FALSE,126,"mann_whitney",NA,NA,NA,1.66971913113983
"3483","db0642236f35d7715f69765f034661e6","NCT01462370",0.019,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With a Global Evaluation of Study Medication of Good, Very Good, or Excellent at 24 Hours After the Initial Dose","SECONDARY",NA,"D004412","Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)",FALSE,258,"logistic_regression",NA,NA,NA,1.03705387097622
"3484","db0770d26720bca8f9e5a901679cc536","NCT00105989",0.019,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hematocrit - Acute Phase","SECONDARY",NA,"D012008; D003866; D003863; D003865","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",FALSE,416,"t-test",NA,NA,NA,1.31153375946586
"3485","db14e0ad374da65e4b67f4da5dea4eb5","NCT02697773",0.0411,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >= 30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 16, \>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,463,"logistic_regression",NA,NA,NA,2.68431423964428
"3486","db226155900154b13b8d6c595f8927e7","NCT00778648",0.023,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Number of Days With at Least Moderate (i.e. Moderate or Severe) Common Cold Symptoms.","PRIMARY",NA,"D003139","Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms",FALSE,543,"anova",2,NA,NA,1.76660798751418
"3487","db36289e27b7d7c845bcf159c2ece011","NCT02528188",0.0076,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants Who Withdrew Due to Lack of Efficacy","SECONDARY","OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline diary average pain, baseline WOMAC pain score, classification variables index joint, highest Kellgren-Lawrence grade, NSAID and treatment.","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1998,"logistic_regression",NA,NA,NA,1.27002998195102
"3488","db4ceb89b03929a4d3af58b342bf15a5","NCT00303979",0.048,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Observe the Relative Change Between Baseline of Cohort A and 18 Months of Cohort C in Performance Measures and Composite Score for the Aggregate Practices.","SECONDARY","Performance Measure #2: the relative change of Cohort C (18 months) compared with Cohort A at baseline in beta-blockers for the aggregate practices.","D006333; D009203; D018754; D018487; D007238","IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting",FALSE,24818,"t-test",NA,NA,NA,22.3035991090671
"3489","db6c4c34f3d9e242aff698e5100e44d6","NCT01011556",0.047,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Percent Change From Baseline in Procollagen Type 1 N-Terminal Propeptide (P1NP)","SECONDARY",NA,"D010024","A Study for the Transdermal Application of Teriparatide",FALSE,114,"mann_whitney",NA,NA,NA,1.51090575578702
"3490","db6dedcb83b52f0961dcfe8bfb9e03aa","NCT03235024",0.0456,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change in Visual Analog Scale (VAS) Score for Pruritus Between the Active and Vehicle Group","OTHER_PRE_SPECIFIED",NA,"D003876; D003872; D004485","Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis",FALSE,107,"t-test",NA,NA,NA,1.42894142223146
"3491","db93ebb42c81c0b615574ef7797135ac","NCT01328743",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Number of Alcoholic Drinks Consumed","PRIMARY",NA,NA,"Brief Alcohol Intervention for HIV-Infected Men Who Have Sex With Men (MSM) in a Primary Care Setting",FALSE,82,"t-test",NA,NA,NA,1.12765035734601
"3492","db9cfb8574628aa7bea8e7ddd898be99","NCT02307682",0.0331,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Subjects With Disease Activity Present (q8 Treatment Need = ""Yes"") at Week 16 - Study Eye","SECONDARY",NA,"D008268; D057135; D020256; D009389","Efficacy and Safety of RTH258 Versus Aflibercept - Study 1",FALSE,697,"logistic_regression",NA,NA,NA,2.73559854934579
"3493","dbc142eaf76b041877f90c726c056843","NCT01559259",0.027,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Intensity Difference on 11-Point Numerical Scale (PID11)","SECONDARY","0.5 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, baseline numerical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,181,"anova",2,NA,NA,1.18217212846261
"3494","dbc5be0aaf62cb24f65ec3e27dafa278","NCT02041923",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Infant Growth","SECONDARY",NA,"D047928","Feeding and Transition to Home for Preterms at Social Risk",TRUE,73,"t-test",NA,NA,NA,1.28506804726186
"3495","dbe07651e573beb1482103a4d40efb51","NCT02746107",0.024,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Who Prescribed Oral Anticoagulants (OAC) According to the CHA2D2s-VASC Risk Score","OTHER_PRE_SPECIFIED","CHA2D2S-VASC risk score 1 was the reference","D020521; D001281","Intention to Prescribe/Take OAC Depending on the Number of Risk Diagrams , and Period for the Estimation of the Risk.",FALSE,384,"logistic_regression",NA,NA,NA,1.54440496324657
"3496","dbeda562a60ed0795a5d35893f1e276f","NCT02973815",0.047,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Home Availability of Vegetables","SECONDARY","Adjusted for: baseline HFI Vegetable value, and economic assistance status","D063766","New Ulm at HOME (Healthy Offerings Via the Mealtime Environment), NU-HOME",FALSE,94,"linear_regression",NA,NA,NA,1.37704410598008
"3497","dbf80ab187908e2f8e9a47e82ed5ce54","NCT02986282",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Difference Between ABI Measured Before and After Electrical Cardioversion Using Doppler Method.","SECONDARY",NA,"D001281","Ankle - Brachial Index Measurement in Atrial Fibrillation",TRUE,99,"mann_whitney",NA,NA,NA,1.48621381452241
"3498","dc0f30539cee8291e1af9ba08e812f18","NCT03320057",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Difference in Pharmacists' Mean Knowledge Score Related to Medication Abortion","SECONDARY","Medication abortion knowledge scores were based on a set of 15 items. We first assessed the internal consistency reliability of the 15 knowledge items and considered a Cronbach's alpha coefficient above .70 to be acceptable to examine the items as a combined score.",NA,"Medication Abortion Via Pharmacy Dispensing",TRUE,53,"linear_regression",NA,NA,NA,1.10589694869732
"3499","dc19f1c24f566b11199a45534c6203bc","NCT01559259",0.036,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Intensity Difference on 4-Point Categorical Scale (PID4)","SECONDARY","0.25 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,182,"anova",2,NA,NA,1.5151750544204
"3500","dc1efd9b792f14a970d8edd0dc5019ba","NCT00261443",0.027,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Median Baseline, Change From Baseline, and Highest Value of Change in PR, Phase 3 Safety Sample","SECONDARY","Treatment Comparison, Change from Baseline in PR at Week 52 (LOCF)","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,278,"mann_whitney",NA,NA,NA,1.45819806202238
"3501","dc4c446e5bd9c8e15c12eeb98259bbdb","NCT01620528",0.023,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Responders at Month 1 Based on Daily Assessment of NMPP","SECONDARY",NA,"D004715","A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain",FALSE,617,"logistic_regression",NA,NA,NA,1.88206649326584
"3502","dc592345dd9ffe393979b491dd037fdb","NCT00552669",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Differences in Costs Between Two Revascularization Strategies for de Novo Coronary Lesions.","PRIMARY","We used One way annalysis of a variance for means and standard deviation.","D006331; D003327; D003324; D017202; D023903","Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents",TRUE,200,"anova",2,NA,NA,2.09181669397075
"3503","dc6573fbe37eade71e369bcc5b991ac6","NCT05013008",0.044,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Mean Change in Plasma Biomarker Levels After 36 Months of Treatment Versus 4 Months of Treatment in a Set of 27 Pre-defined Biomarkers","PRIMARY","The NPX difference (corresponding to log-transformed ratio to baseline) of TGF beta-1 proprotein (P01137) was analyzed.","D007674; D051436; D003924","An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants",FALSE,921,"t-test",NA,NA,NA,4.00142832243753
"3504","dc96c6ea7524bc5e3d69d969a5176ab1","NCT00684060",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"End Systolic Volume Index","SECONDARY","Comparison of change in the active group minus change in the control group.","D018754; D018487","Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)",TRUE,81,"t-test",NA,NA,NA,1.3501394396673
"3505","dc9aae73b150f2caafef2dc930d5bbd7","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Saturated Fat","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1740,"linear_regression",NA,NA,NA,6.11775166016043
"3506","dcc0b5c0bcebf5438a479ef1eede5101","NCT01029262",0.047,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain at Week 12 and 24","SECONDARY","Week 24","D011289; D000740; D009190","A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q",FALSE,189,"anova",2,NA,NA,1.93211796571355
"3507","dcd564a70bbfafed385e6c2944bea449","NCT00552786",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Temporary Threshold Changes Measurement by Distortion Product Otoacoustic Emissions (DPOAE) (A Total of Four Hearing Assessments Were Completed for Each Formulation Period on the 1st Day Pre- and Post-shift, and the 14th Day Pre- and Post-shift)","SECONDARY",NA,"D034381; D003638; D006317","Antioxidation Medication for Noise-induced Hearing Loss",TRUE,106,"anova",2,NA,NA,1.53589031932405
"3508","dcd5f4856df791b277036d3d752de845","NCT05870956",0.021,"ANOVA","OBSERVATIONAL",0,0,0,0,0,"Total IPF-related Medical Costs","SECONDARY",NA,"D011658; D054990; D005355","Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients",FALSE,971,"anova",2,NA,NA,2.17822430811006
"3509","dcdac135e5c9d993ef6e624fc65cea5c","NCT03192176",0.0477,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 4 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 10","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.313605621787
"3510","dcebe1abade61cece087180382ef0811","NCT01559259",0.046,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Intensity Difference on 11-Point Numerical Scale (PID11)","SECONDARY","12 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, baseline numerical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,123,"anova",2,NA,NA,1.53953479542566
"3511","dcf2de85e0e6a1fb7d5f35f083c1eb5f","NCT03022370",0.019,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Past Year Severe Sexual and/or Physical Intimate Partner Violence Perpetration (Men) and Experience (Women)","PRIMARY",NA,NA,"Stepping Stones and Creating Futures Intervention Trial",FALSE,505,"logistic_regression",NA,NA,NA,1.44335244156062
"3512","dcf3fc83c10db8f780cabfda1555e4a1","NCT00245219",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Depressive Symptoms (as Measured With the CES-D) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the education condition and the control condition at Time 2. The full regression model included 2 dummy coded variables, 1 contrasting the education and control condition, and 1 contrasting the peer support and control condition. The baseline measure of the outcome variable was included, in order to examine changes in the outcomes over time. This model tested the main effects of the conditions among patients with early stage cancer, late stage patients were excluded.","D001943","Understanding Shared Psychobiological Pathways",FALSE,131,"logistic_regression",NA,NA,NA,1.70153588988359
"3513","dd1b5458ce2541c102d328966a6c2fff","NCT03246724",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Surgical Complication Rates","OTHER_PRE_SPECIFIED","Null hypothesis: The total surgical complications for oral triazolam will be statistically significant in comparison to total surgical complications for IV midazolam during all cataracts, retina, cornea, and glaucoma ocular procedures.

Alternate hypothesis: The total surgical complications for oral triazolam will not be statistically significant in comparison to total surgical complications for IV midazolam during all cataracts, retina, cornea, and glaucoma ocular procedures.",NA,"Oral Versus Intravenous Sedation for Ocular Procedures",TRUE,282,"t-test",NA,NA,NA,2.47696797709172
"3514","dd6e769caa9714a95a26e0d890969cb3","NCT02072174",0.0233,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,1,"Assessment of the Severity of Influenza Virus / Acute Respiratory Viral Infection Using the ""Area Under the Curve"" for an Overall Symptom Assessment","SECONDARY","Days 1, 3, 5 and 7 (doctor's examination)","D007239; D003141; D007251; D014777","Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children",FALSE,498,"kruskal_wallis",2,NA,NA,1.71166604495255
"3515","dd889954a3fac25015b8438e65dedd0a","NCT00322465",0.032,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Clinical, Behavioral, and Demographic Predictors of Mycoplasma Genitalium in Men With Non-gonococcal Urethritis","SECONDARY","The null hypothesis is that the odds ratio for age (per 5 years) is 1 versus the alternative that the odds ratio is greater than or less than 1.","D014526","NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)",FALSE,292,"logistic_regression",NA,NA,NA,1.72806551621735
"3516","dda41364d9f6a6024bf6b18c3a56f086","NCT00402987",0.036,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Who Still Had Perceptible Relief at 12 and 24 Hours Post-First Dose","OTHER_PRE_SPECIFIED",NA,"D010612","Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat",FALSE,133,"logistic_regression",NA,NA,NA,1.30102538480414
"3517","dda42ba490c739445bebe3074743d5a8","NCT00962585",0.0475,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Percentage Change From Baseline in Menopause Rating Scale (MRS) - Sum of 3 Symptoms (Irritability, Dry Vagina, Joint/Muscular Discomfort)","POST_HOC",NA,NA,"Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients",FALSE,84,"mann_whitney",NA,NA,NA,1.31652072546107
"3518","ddba9c3d80958bce1b4f4cbf09d199b0","NCT04003155",0.027,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate, and Severe VMS From Baseline to Each Study Week Up to Week 12","SECONDARY","Week 10","D019584","A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause",FALSE,349,"logistic_regression",NA,NA,NA,1.63090869895814
"3519","ddbf8a724c1b73be8bc7a813939fb2e2","NCT02528188",0.0301,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Progression of Osteoarthritis in the Index Knee (Kellgren-Lawrence Grade 2 or 3) According to Bland and Altman Method at Weeks 56 and 80","SECONDARY","Decrease in medial JSW at Week 80: Logistic regression model included treatment, and baseline JSW as covariate.","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1346,"logistic_regression",NA,NA,NA,3.49875628692297
"3520","ddc40b06b1c7645f9316d397f1cfb45a","NCT04218864",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"The Positive Affect and Well-being Scale (PAW)","SECONDARY","Statistical analysis strategy is identical to that for the primary outcome.",NA,"Strength for U in Relationship Empowerment",FALSE,121,"linear_regression",NA,NA,NA,1.63728545358366
"3521","ddf3c1f7c6eb6887f833b2789478453c","NCT03953508",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Average Daily Craving From Smoking","SECONDARY",NA,NA,"Perceptions of Cigarette Smoking in Young Adults",FALSE,124,"t-test",NA,NA,NA,1.6568216953838
"3522","ddf40f1addf30dd590087307102e955a","NCT02287883",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"PHQ-4","PRIMARY",NA,"D002318","Impact of Patient Activation and Engagement on Patient-Centered Outcomes of Care in ACOs",FALSE,1291,"t-test",NA,NA,NA,5.27165612963332
"3523","ddfbfe31243134b9b9233fcb290a051e","NCT01329029",0.0209,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Rate of COPD Exacerbations Per Patient Per Year All Categories","SECONDARY","Leading to Hospitalisation","D008171; D008173; D029424","Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)",FALSE,1935,"linear_regression",NA,NA,NA,3.05797827464668
"3524","de07b467779589ec9ff1bf31f3c43008","NCT01236053",0.0269,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,2067,"logistic_regression",NA,NA,NA,3.93339322126135
"3525","de0b3bdfb224ecc190331a4a2b8f653c","NCT01265056",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Opioid Consumption Between the Treatment and the Control Groups (Morphine Equivalents)","PRIMARY",NA,"D002056","The Effect of Neurontin on Pain Management in the Acutely Burned Patient",TRUE,53,"t-test",NA,NA,NA,1.10589694869732
"3526","de18e75b80f733a6543316caacec7d46","NCT04688320",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Death From All Causes","PRIMARY",NA,"D011655; D004617","Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE",TRUE,291,"t-test",NA,NA,NA,2.51565364388184
"3527","de2b0bac610d95b93ce73da0f9a9d469","NCT02528188",0.0207,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 8: \>=90% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,3.07822618025298
"3528","de35dd150320873dafe3f9879d4b0e41","NCT00369343",0.034,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Discontinuation-Emergent Signs and Symptoms (DESS) Total Score","SECONDARY","200mg vs. Placebo (0mg) post taper","D003863; D003866; D003865","Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women",FALSE,216,"t-test",NA,NA,NA,1.56939724671756
"3529","de43728b723d307e825fe1ed6c3a12c6","NCT01529385",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Microcirculation for Dorsum of Foot","PRIMARY",NA,"D004487","Mild Compression Sock for Control of Lower Extremity Edema in Individuals With Diabetes",FALSE,77,"anova",2,NA,NA,1.31800316623017
"3530","de538de3acc84c9df09753bfc81e509e","NCT05714696",0.029,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Self-efficacy for Weight Control Behavior","PRIMARY",NA,NA,"Weight Discrimination and Poor Cardiovascular Health",FALSE,135,"t-test",NA,NA,NA,1.09033883714494
"3531","de89bff23c9de8f130e803d07fcc9923","NCT03130257",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Comparative Performance of Clinic, Home, and Kiosk","PRIMARY","We used linear regression models to estimate the mean difference in BP between diagnostic measurement and daytime average 24-hr BP for each randomization group. Models were estimated using generalized estimating equations with robust standard errors, and adjusted for age, sex, BMI, education, and baseline systolic and diastolic BP. Separate models estimated mean differences (diagnostic protocol - 24-hr BP) between groups for systolic and diastolic BP.","D006973","Blood Pressure Checks for Diagnosing Hypertension (BP-CHECK)",TRUE,434,"linear_regression",NA,NA,NA,3.06552394865376
"3532","de90899ed6fad56027f5dde162603cbe","NCT01635218",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in 17-item Hamilton Rating Scale for Depression at 6 Weeks.","PRIMARY",NA,"D003863; D003866","Homeopathic Treatment for Depression in Peri- and Postmenopausal Women",TRUE,89,"anova",2,NA,NA,1.41222998379373
"3533","de962f7bf0cd50f495dae58619738bd5","NCT01432236",0.0205,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With >=30% and >=50% Pain Reduction Based on Daily Pain Diary.","SECONDARY","Statistical analysis presented above is for 50% responders. Analysis was conducted using a logistic regression model using sequence, period, and treatment as fixed factors and participant within sequence and within participant error as random factors. Logit link transformation was used for the model.","D005356; D009209; D003863","A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression",FALSE,352,"logistic_regression",NA,NA,NA,1.29051129248324
"3534","de9ef208ca416b39bea701c64aa29594","NCT02697773",0.031,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >= 30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 4, \>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,463,"logistic_regression",NA,NA,NA,2.111517743279
"3535","dec117074179b939e03a518b6d47d04d","NCT00911768",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Stimulated Salivary Flow Rates","SECONDARY",NA,"D014987","Effect of Korean Red Ginseng (KRG) on Dry Mouth",TRUE,90,"t-test",NA,NA,NA,1.41980120127578
"3536","dec453a15a31f100031d25514590eabd","NCT04537078",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"the Difference Between the Follicular Phase and the Luteal Phase of the Progestin Primed Double Stimulation Protocol Regarding the Fertilization Rate.","SECONDARY",NA,"D007246; D007247","Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders",FALSE,82,"mann_whitney",NA,NA,NA,1.12765035734601
"3537","dec466bd59889cbf243edfe86c6d46f5","NCT02528253",0.0273,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 8, \>=30%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1011,"logistic_regression",NA,NA,NA,2.78957210738833
"3538","decf181f7f3f004df15795338d52cd3a","NCT03670810",0.014,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Migraine Quality of Life Questionnaire (MQoLQ) Score at 24 Hours Post First Dose of Study During First Attack","SECONDARY","Feeling/Concerns 100 mg","D008881","A Study of Lasmiditan (LY573144) Over Four Migraine Attacks",FALSE,582,"anova",2,NA,NA,1.18453577625382
"3539","def75ff921e6174003c7253a830b5d4c","NCT01416194",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Hypertriglyceridemia","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",TRUE,7777,"logistic_regression",NA,NA,NA,3.19773018380892
"3540","defe252896773489be0a868eefa0ed61","NCT01532986",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient Assessement of Care for Chronic Conditions (PACIC)","SECONDARY",NA,"D010300","Randomized Trial to Test the ""Coordinated Care for Health Promotion and Activities in Parkinson's Disease"" Intervention in the VA",FALSE,328,"t-test",NA,NA,NA,2.66881159065383
"3541","df1b19ffc254e8e4d8352a536d65767e","NCT05143047",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Reported Dosing Accuracy","SECONDARY",NA,NA,"Discharge Medication Counseling in Hospitalized Children",FALSE,143,"t-test",NA,NA,NA,1.47289208003976
"3542","df27b6987b799002102c9b06737c1752","NCT01945034",0.032,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","SECONDARY","At Rest 1 hour Day 1: The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,152,"anova",2,NA,NA,1.25585729060319
"3543","df32509cc16f8310641f614e50c1cf91","NCT00645099",0.0272,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to End Point in Converted Insulin","SECONDARY",NA,"D012559","A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia",FALSE,391,"mann_whitney",NA,NA,NA,1.73595241984099
"3544","df48ac6706ea3f90331778a47f1b652d","NCT01066793",0.0306,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for cumulative ribavirin dose per 10000 mg, first 12 weeks. The logistic regression analysis for relapse was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Wk 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,518,"logistic_regression",NA,NA,NA,2.20751720057721
"3545","df74a228c17ef750f46c6eed7c859b2c","NCT02528188",0.0068,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 4: \>=50% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,1.14827382129998
"3546","df763c265587618fe24561f7e893ff9f","NCT03192176",0.0469,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 2","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,85,"logistic_regression",NA,NA,NA,1.31005443569427
"3547","df9ae40b84d484a1a6ce4fa439eeae36","NCT00442546",0.0258,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain-Related Sleep Interference Post Surgery","SECONDARY","96 hours","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,167,"anova",2,NA,NA,1.09328706960039
"3548","dfb0c44d92646b6b323918c9fa2dae6c","NCT01266161",0.036,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Intensity Difference (PID) Scores","SECONDARY","Ibuprofen versus placebo at 44 hours.","D014098","Multiple Dose Dental Pain Study Of Ibuprofen Extended Release",FALSE,106,"anova",2,NA,NA,1.16638390709256
"3549","dfc9b96c2b71ca4847f4f3854519e01e","NCT01639339",0.0245,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Double-blind Period: Percentage of Participants With PERR at Week 52","SECONDARY",NA,"D009393; D008181","Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis",FALSE,446,"logistic_regression",NA,NA,NA,1.69280772754227
"3550","dfdb17a68f4dbc912c328b85c5ac0814","NCT00576472",0.0428,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by The Conners' Parent Rating Scale (CPRS) Hyperactivity Scale.","SECONDARY",NA,"D054198; D007945; D001932","Learning Impairments Among Survivors of Childhood Cancer",FALSE,240,"t-test",NA,NA,NA,2.00817408852433
"3551","dfde66a64204a63a23d4388e74ab53ca","NCT05530603",0.033,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Health Beliefs","SECONDARY",NA,"D001943","Intervention to Promote Breast Cancer Screening Among American Indian Women",FALSE,122,"anova",2,NA,NA,1.15922442846015
"3552","dfed5782cf40f49a287429fae34da8c2","NCT02528253",0.0251,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants Who Responded for Chronic Low Back Pain Responder Index at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56","SECONDARY","Week 24: OR and 95% CI estimated from logistic regression model. Logistic regression model included treatment as fixed effect and baseline average LBPI, baseline PGA, and baseline RMDQ as covariates.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1009,"logistic_regression",NA,NA,NA,2.59181073763976
"3553","e005e10f0513be5839a68bbc185c5922","NCT02867709",0.0285,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose","PRIMARY",NA,"D008881","Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine",FALSE,891,"logistic_regression",NA,NA,NA,2.71850540621737
"3554","e017da18437f921c7e4d6056ea6e8ba9","NCT05302414",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Resuscitation Knowledge Scale","SECONDARY","For the pretest at week 0.",NA,"The Learning Outcome of Resuscitation Teamwork Training in Postgraduate Year Doctors and Nurses",TRUE,64,"kruskal_wallis",2,NA,NA,1.20770700959599
"3555","e01f152e6d96574b0e249a668083d409","NCT01340027",0.02,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Major Improvement in PPBC","SECONDARY",NA,"D053201; D014570; D001745; D020924","A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder",FALSE,283,"logistic_regression",NA,NA,NA,1.13466548909851
"3556","e02193565af370a5e3be98a4de0ab03a","NCT03740919",0.025,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Documented Hypoglycemic Events","SECONDARY","≤70 mg/dL","D003920; D003922","A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes",FALSE,436,"logistic_regression",NA,NA,NA,1.70342233455318
"3557","e0327d62310e247c6e885d97368edaa7","NCT00494806",0.05,"Two-sample t-test","INTERVENTIONAL",1,0,0,0,0,"Time to First Postoperative Flatus in Days Was the End of Postoperative Ileus (POI) Indicator.","PRIMARY","No differences in time to first flatus between the rocking and non rocking groups is the null hypothesis.

Sample size calculations by setting the criterion for significance at .05, two-tailed test (an effect in either directions was accepted), and power at .80. A total sample of 54 participants was determined necessary to yield statistically significant results (27 in Group A and 27 in Group B).","D045823","Effects of Rocking on Postoperative Ileus Duration Study",TRUE,66,"t-test",NA,NA,NA,1.2253174109698
"3558","e03f501e5543819bb82f9f15415bd60b","NCT01662635",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"FISH, IHC, RT-qPCR Comparison","PRIMARY","Continuous variables were summarized as arithmetic means, medians and standard deviations; and categorical variables were reported as proportions with 95% confidence intervals. Inferential comparisons were performed using Student's t test. The x2 or Fisher's exact tests were used to assess significance among categorical variables.","D008175; D002289","Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK)",TRUE,311,"t-test",NA,NA,NA,2.59956214364198
"3559","e0409832b1f211d2d1b0bd647e42e385","NCT00442546",0.0248,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain-Related Sleep Interference Post Surgery","SECONDARY","72 hours","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,167,"anova",2,NA,NA,1.0567321980057
"3560","e04eebedec4c3736e6f74d4a86221e98","NCT03879772",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Total Nasal Symptom Score (TNSS) [Average of Morning (AM)/Evening (PM) Score] Averaged Over Days 16 to 29 as Assessed by Participant","SECONDARY","Pairwise comparisons were performed using least square means from two-way ANOVA.","D012220; D065631; D006255","Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)",FALSE,271,"anova",2,NA,NA,2.42884919407747
"3561","e053063f1c4529e9af2953ff1812619f","NCT02374346",0.024,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Factors Associated With Postoperative Headache","SECONDARY","Female gender as a factor for developing postoperative headache","D006261; D013375","Postoperative Headache in Elective Surgery Patients",FALSE,446,"t-test",NA,NA,NA,1.6628861448926
"3562","e0530eaae15faf7398c43050a4362de9","NCT01203046",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,1,0,"Surgical Site Infection","PRIMARY",NA,"D013530; D000007","Early Short-term Antibiotic Therapy in Penetrating Abdominal Trauma, 3 vs 7 Days",TRUE,56,"logistic_regression",NA,NA,NA,1.13456029943022
"3563","e05878ee2c6a6bee25f6878a1d46e83d","NCT04507776",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Absolute Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Baseline and Last Visit: Participants Adherent and Not Adherent to Treatment","OTHER_PRE_SPECIFIED","Year 1 Adherence: Year 1 (Month 12)","D025242","Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel",TRUE,763,"t-test",NA,NA,NA,4.05689111055728
"3564","e07510ae1ede6c0c53cb9f7844f9db7b","NCT02572401",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Proportion Condom-protected Intercourse","SECONDARY","This analysis tested the efficacy of the text messaging intervention by comparing the HIV Risk Reduction and Text Messaging and Text Messaging Only Arms to the HIV Risk Reduction Only and No-Intervention No Text Message Control Arms. This is a test of the text messaging main effect.","D000163; D015658; D012749; D007153","Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men",TRUE,194,"linear_regression",NA,NA,NA,2.06081252830146
"3565","e08d942d7f94f2a327cfce7e2efc73f9","NCT02255474",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Association of Peripheral Defocus to Myopic Progression","SECONDARY","This analysis looks at the three-year change in spherical equivalent refractive error for different eccentricities of peripheral defocus measured with contact lenses in place","D012030","Bifocal Lenses In Nearsighted Kids",FALSE,292,"linear_regression",NA,NA,NA,2.51991540428951
"3566","e09dc29998e809a035965d359a689140","NCT03218397",0.022,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Time to First Gram-negative Antibiotic Escalation","SECONDARY",NA,"D016470; D004198","Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia",FALSE,448,"t-test",NA,NA,NA,1.54551745874435
"3567","e0a30ea8146dd1a7cd9b1143a04be2ea","NCT00408876",0.036,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Brief Pain Inventory Interference (BPI-I) Score - Mood","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,163,"t-test",NA,NA,NA,1.43592728170872
"3568","e0a6f581806590f7bd43067684728467","NCT01462162",0.044,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Regression Coefficient Between Change in Fatigue Score as Measured by the FACIT-F at Week 12 and 24 With Change in Disease Activity Parameters at Week 12 and 24","SECONDARY","change in fatigue score at Week 24 versus change in degree of pain Week 24","D001168; D001172","A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis",FALSE,84,"linear_regression",NA,NA,NA,1.23525039816419
"3569","e0e30a38494d9d1a76103690a0d65581","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in Total Cholesterol","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,109,"anova",2,NA,NA,1.55669642807029
"3570","e0e72f0674ad4b34dcb6194a206aadfb","NCT00956384",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"BreastQ Quality of Life and Satisfaction Questionnaire","PRIMARY","For the comparison of mean BREAST-Q subdomain score at each timepoint, Mann-Whitney U test was used for skewed data, while independent t-test was used for not skewed data. We investigated the possibly variable effects of the treatment group differences across multiple time-points, namely 2 weeks after mastectomy, at 6 months and at 12 months following the reconstruction procedure. A linear regression model was used to account for the correlation between the three time-points within each patient",NA,"One-stage Breast Reconstruction Using Dermal Matrix/Implant Versus Two-stage Expander/Implant Procedure",FALSE,164,"t-test",NA,NA,NA,1.8982180321277
"3571","e0ee1e9a55440027dac4cfa8a239ef5b","NCT01649375",0.0471,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving ASAS Partial Remission at Week 16","SECONDARY",NA,"D013166; D025241; D013167","16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis",FALSE,146,"logistic_regression",NA,NA,NA,1.70641783449631
"3572","e120327fca457b42212ea1ad20121a12","NCT01910116",0.049,"Mann-Whitney","INTERVENTIONAL",0,0,1,1,0,"Patient Global Assessment, Change From Baseline","SECONDARY",NA,"D010003","Efficacy of Shinabro in Hand Osteoarthritis",FALSE,215,"mann_whitney",NA,NA,NA,2.13113538707406
"3573","e125714499572ffc99430453d0ae0e79","NCT00261443",0.047,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Mean Baseline and Adjusted Mean Change From Baseline in Young-Mania Rating Scale (Y-MRS) Total Score Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 12 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,2.52642598430683
"3574","e129576d878b4b9e7081c245df367a19","NCT02373813",0.045,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in SDAI Score at All Measured Timepoints","SECONDARY","Change at Week 12","D001168; D001172","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",FALSE,202,"t-test",NA,NA,NA,1.92468288800521
"3575","e135961a30dcdd7977f9f150889b4036","NCT01434680",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup C 28 Days After Vaccination","PRIMARY","The study would be considered a success if the two-sided 95% confidence intervals (CIs) for the hSBA GMT ratios comparing MenC-CRM LIQ to MenC-CRM EMV at 28 days after a single vaccination were both within the equivalence interval (0.5, 2.0).","D008589; D008585; D008581","Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers",TRUE,564,"anova",2,NA,NA,3.49105249064812
"3576","e1402ffdd96b2119638aaee8a241ad97","NCT03192176",0.045,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 5","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,85,"logistic_regression",NA,NA,NA,1.26572480775938
"3577","e143357ffdfed7844948efe6767b5383","NCT01694485",0.03,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Remission at Week 8","PRIMARY","Comparisons between treatment groups were made using remission rates from a logistic regression model adjusted for baseline total Mayo Score and stratification factors (prior vs no prior TNF antagonist use and enrollment pre- vs post-protocol amendment).","D003092; D003093; D014456","Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis",FALSE,195,"logistic_regression",NA,NA,NA,1.34168832397415
"3578","e15428c7a230d742010e3151ead581c5","NCT00468845",0.0422,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Treatment Satisfaction Scale (PTSS): Satisfaction With Current Pain Medication","SECONDARY","Medication Subscale at Day 28","D010149","Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy",FALSE,277,"anova",2,NA,NA,2.12947652749234
"3579","e15c7509c43752878bccd8aece3448c4","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"ACRPP: 24-hour Ambulatory Central Rate-pressure Product (Also Called TTI, CTTI)","PRIMARY","Sequential analysis: if the first analysis (paired t-test to determine superiority of nebivolol/valsartan over valsartan ) reached p\< 0.05, the superiority of nebivolol over valsartan was tested (paired-t test); if the second comparison reached p \< 0.05, the superiority of nebivolol/valsartan over nebivolol was tested (paired-t test)","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"3580","e16474e79871f83270b24a4918e39940","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Burger Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1738,"linear_regression",NA,NA,NA,6.11424246677302
"3581","e164ceb33c02881be2d82dba4df4e9f3","NCT01163266",0.044,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With a MADRS Response at Week 8","SECONDARY",NA,"D003866; D003863; D003865","Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder",FALSE,303,"logistic_regression",NA,NA,NA,2.3054583329141
"3582","e17a86e848ec5b53b7bc65535311c0dc","NCT03953508",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Quantity of Past 30-day Tobacco Product Use","SECONDARY",NA,NA,"Perceptions of Cigarette Smoking in Young Adults",TRUE,55,"t-test",NA,NA,NA,1.12508606526115
"3583","e18dd5ab6694b4c04f608d3ead35172c","NCT01064167",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Postoperative Chest Tube Drainage","SECONDARY",NA,NA,"Tranexamic Acid in Off-pump Coronary Surgery",TRUE,231,"t-test",NA,NA,NA,2.24519929671403
"3584","e1a305d124062b3d4c33ac2ff4e290cb","NCT01066793",0.0092,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for HCV RNA at BL in log10 (IU/mL). The logistic regression analysis for relapse was performed for association between treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,960,"logistic_regression",NA,NA,NA,1.04624539778613
"3585","e1a37245bd3178d86023ceba92e4a6cd","NCT03252587",0.0434,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants Who Meet Response Criteria for Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] at Week 48","SECONDARY","BMS-986165 6 mg vs Placebo","D008180","An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus",FALSE,183,"logistic_regression",NA,NA,NA,1.77893236890958
"3586","e1a4e7dd6e47a1788f14502d2d2ff8d2","NCT02416934",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Swallowing Difficulty","PRIMARY","Comparing Bazaz between Dexamethasone and Saline at 6 months post-op","D003680","Dysphagia Following Anterior Cervical Spine Surgery; Steroid vs Saline",TRUE,64,"t-test",NA,NA,NA,1.20770700959599
"3587","e1d74fdb0b3f4fa36c1ef75d75353961","NCT03687762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in Physical Function","SECONDARY",NA,"D059350","Back on Track to Healthy Living Study",FALSE,302,"anova",3,NA,NA,1.03237942189705
"3588","e1e868975bb252a6011ba47554246448","NCT00438464",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Comparison of Biomarkers Between Treatment Arms: Percentage Change of Tumor Cells Exhibiting Detectable Staining Within Gleason Grade 4 (GG4) Biomarker Subgroup at Prostatectomy","PRIMARY","Androgen receptor (AR), Within GG4","D011471","Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery",FALSE,130,"mann_whitney",NA,NA,NA,1.40642013465706
"3589","e1f550bae8e7c1dbef3d44c64d475472","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Satisfaction Questionnaire","OTHER_PRE_SPECIFIED","Family member negative worded score comparing intervention to TAU.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,234,"t-test",NA,NA,NA,2.25949060683958
"3590","e1f5d9f6db8e90e16f83959a49ac76fd","NCT00539240",0.04,"Linear regression","INTERVENTIONAL",0,0,1,1,0,"Acid Regurgitation, Number of Days in Week Symptoms Intensity Score < 3 (Better)","PRIMARY",NA,"D005764","Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI",FALSE,101,"linear_regression",NA,NA,NA,1.24545208094669
"3591","e20c22cc3e3b72e3d6f995bc17929974","NCT01416194",0.01,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Cumulative Incidence of Clinical Fractures","SECONDARY","The hazard ratio from Cox proportional hazard regression models was used for comparison of event rates of the primary and secondary endpoints in each treatment group. Statistical two-sided tests was used with a significance level of 0.05.","D010024; D015663","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",FALSE,3831,"logistic_regression",NA,NA,NA,2.24534283552016
"3592","e224d932dc33a8403e4304a0dc542192","NCT05224453",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Muscle Cross Sectional Area","SECONDARY",NA,"D055948","Integrated Physical Training With Protein Diet in Older Adults With Sarcopenia Symptoms.",TRUE,71,"t-test",NA,NA,NA,1.26828177971868
"3593","e22d1e6a5f9c5190676e749e7b6cc06c","NCT02696785",0.041,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving ASDAS Inactive Disease","SECONDARY",NA,"D013166; D025241; D000089183","A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis",FALSE,170,"logistic_regression",NA,NA,NA,1.63586901306376
"3594","e23f24a4187469fa14864e19881c0171","NCT02224560",0.0439,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Subject/Caregiver Global Impression Of Change (S/CGIC) Assessment","SECONDARY",NA,"D012640; D065768; D013577","Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults",FALSE,150,"logistic_regression",NA,NA,NA,1.63011475658557
"3595","e24bed8d8894302c54e4ac9472ba37c4","NCT00265941",0.016,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Quality of Life as Measured by Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-HN) at 12 Months","SECONDARY",NA,"D006258","Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer",FALSE,455,"t-test",NA,NA,NA,1.17949742976261
"3596","e2602fe136fb064e228d3d88d749d873","NCT05018689",0.006,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in University of Michigan Depression Center Peer-to-Peer Depression Awareness Assessment Perceptions of School Culture Scores From Baseline (1 of 8)","SECONDARY","I would try to stay away from the new student",NA,"Evaluation of the Aevidum Curriculum and Club",FALSE,2557,"linear_regression",NA,NA,NA,1.16139296334341
"3597","e26fadbcda446a8d369e2f2afce2ae6a","NCT03192176",0.0345,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 4","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,85,"logistic_regression",NA,NA,NA,1.01282384511258
"3598","e28c37c36a9f3cb235a331c1f0ca7fde","NCT00468845",0.0183,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Current Pain - Pain With Movement Caused by Peak Expiratory (PEF) Test","SECONDARY","96 hours PS","D010149","Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy",FALSE,294,"anova",2,NA,NA,1.0699991319064
"3599","e295cec6bf709ed1fca0bc6e3a4bcd72","NCT01570036",0.02,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Percent Ejection Fraction - A Measure of Cardiac Toxicity","SECONDARY",NA,"D001943","Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax",FALSE,273,"anova",2,NA,NA,1.11482849465442
"3600","e2a7fd1279c3bec583533cff3a9acbd2","NCT00510146",0.049,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in Glucose and Lipids (Cholesterol, Triglycerides, HDL Cholesterol, LDL Cholesterol) (Open-Label Phase)","SECONDARY",NA,"D001714","Olanzapine Treatment of Patients With Bipolar I Disorder",FALSE,380,"t-test",NA,NA,NA,2.82217593412509
"3601","e2b2c25691d6a7a818b5bca70453b0f3","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient-Reported Outcomes Measurement Information System (PROMIS Short Forms 8a - Pediatrics v. 2.0) is a Set of Person-centered Measures That Evaluates and Monitors Physical, Mental, and Social Health in Children and Adolescents.","SECONDARY","We hypothesize that Emotional Distress - Depressive symptoms would be lower in intervention adolescents compared to controls at 6 months post intervention.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,126,"t-test",NA,NA,NA,1.66971913113983
"3602","e2c2108d66e50eca391bb0bb9e2649c6","NCT01047501",0.017,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Very Low-density Lipoprotein Cholesterol Levels","SECONDARY",NA,"D015228","Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)",FALSE,459,"mann_whitney",NA,NA,NA,1.2492500363209
"3603","e2c387bed6a7f58704accbd7ca8837ff","NCT02516982",0.024,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Time Needed to Complete the Whooley Questions and the EPDS According to Survey Layout","SECONDARY",NA,"D003863","mHealth for Antenatal Mental Health",FALSE,530,"mann_whitney",NA,NA,NA,1.81108940805388
"3604","e2c4c7ea962c4e5ed0d759e53273eb35","NCT02672176",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Depression Severity Measured by PHQ-9","SECONDARY",NA,"D003920","Improving Health in Diabetes Project",FALSE,280,"mann_whitney",NA,NA,NA,2.4682888545649
"3605","e2cbe5789fce9a89434b512b3fda3c1a","NCT00707447",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Waist Circumference","PRIMARY","independent t-tests for between group comparisons, dependent t-tests for within group comparisons","D003920","Evaluation of a Primary Type 2 Diabetes Prevention Programme",TRUE,166,"t-test",NA,NA,NA,1.90948799930043
"3606","e2dcffc5268617f9ed1a4ea81e69553b","NCT01874431",0.0462,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline to Day 90 in eGFR","SECONDARY",NA,"D007674; D003928; D003920; D003924","Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy",FALSE,177,"t-test",NA,NA,NA,1.84440735061578
"3607","e2f65570a80f0ad18156f4ef2681e345","NCT02891798",0.038,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"SF-MPQ2 Intermittent Pain Subscore Difference From Baseline","PRIMARY","Comparison of SF-MPQ2 Intermittent Pain Subscore Difference From Baseline between the 4-drug nerve block group and the bupivacaine only group",NA,"4-drug Nerve Block Versus Plain Local Anesthetic for Knee and Hip Arthroplasty Analgesia in Veterans",FALSE,78,"t-test",NA,NA,NA,1.05489330053711
"3608","e33fff3d316ab02f38727f0a293e06f4","NCT01410240",0.049,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in SF-36 Scores at Postoperative Weeks 1, 2, and 6","SECONDARY","Change Week 2: Bodily Pain","D010003","Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty",FALSE,97,"mann_whitney",NA,NA,NA,1.44723516937544
"3609","e34d746dd6722dfc44bd236b8b6cdd9e","NCT02475655",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change in Aspartate Aminotransferase (AST) (SGOT) Values From Entry","SECONDARY","Null hypothesis: There is no difference between the two arms in the change in Aspartate Aminotransferase (AST) (SGOT) values from Entry to Week 1/2.","D015658","Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults",FALSE,60,"t-test",NA,NA,NA,1.17169922891753
"3610","e3594a33a99e17b8fe939a12d51fddf2","NCT01631747",0.02,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Gestational Weight Gain (GWG)","PRIMARY",NA,"D015430","Maternal-Offspring Metabolics:Family Intervention Trial",FALSE,280,"linear_regression",NA,NA,NA,1.12875096791111
"3611","e381041a801873cfade4fe4281723bc4","NCT01236053",0.0063,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,2067,"logistic_regression",NA,NA,NA,1.09146218028265
"3612","e38dd45243e3b64677a4124ea10323c0","NCT02528253",0.0166,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 4, \>=50%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,810,"logistic_regression",NA,NA,NA,1.62088130283527
"3613","e3a5fdd61958ff7866d39b6030884124","NCT05302414",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Interprofessional Collaboration Scale","SECONDARY","For the pretest at week 0.",NA,"The Learning Outcome of Resuscitation Teamwork Training in Postgraduate Year Doctors and Nurses",TRUE,64,"kruskal_wallis",2,NA,NA,1.20770700959599
"3614","e3a6f428e74ed17529e15b1e327aab31","NCT00346164",0.0228,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Incidence of Distant Metastasis","SECONDARY","The logistic regression model was used to evaluate prognostic impact of histologic (POG) grade after accounting for the effects of disease extent (non-metastatic; metastatic), site of the primary tumor (body wall; extremity; head/neck; visceral), tumor size (\<=5cm; \>5cm), tumor depth (deep; superficial), tumor invasiveness (invasive; non-invasive), and extent of resection of the primary tumor (less than total resection; margin -; margin +) .","D012509; D012516; D007890; D008080; D002813; D013584; D006394; D005354; D018234; D051642; D006393; D054364; D018219; D051677; D018319; D018223; D008637","Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma",FALSE,494,"logistic_regression",NA,NA,NA,1.67309458531212
"3615","e3a8b706a9cc9fe78ab8bbaeb646c86c","NCT02528253",0.0326,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 40, \>=30%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1012,"logistic_regression",NA,NA,NA,3.25036223807713
"3616","e3afac1c5a28a87e6362fa8769bcdcd3","NCT02148874",0.04,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Maternal HAI Antibody Titers","PRIMARY","Statistical analysis for influenza strain B/Massachusetts",NA,"Immune Responses to the Flu Shot During Pregnancy",FALSE,260,"logistic_regression",NA,NA,NA,1.97291044957837
"3617","e3b113c59209ea5339f4faaf39b8f59f","NCT02912650",0.034,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Relief Rating (PRR) Score","OTHER_PRE_SPECIFIED","0.25 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,347,"anova",2,NA,NA,1.98136682823727
"3618","e3b3f999aa72aa4249a3a3d19c019d8f","NCT02603120",0.031,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in CD4+ Cell Count at Week 48","SECONDARY",NA,NA,"Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed",FALSE,532,"anova",2,NA,NA,2.26191885440493
"3619","e3d2ab3bd1dd54684e5e89f8856d11eb","NCT02605174",0.008,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Phonophobia Free","OTHER_PRE_SPECIFIED",NA,"D008881","Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",FALSE,1174,"logistic_regression",NA,NA,NA,1.02055274190717
"3620","e3d418194095090d2a625e73356ab095","NCT02672176",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Depression Severity Measured by PHQ-9","SECONDARY",NA,"D003920","Improving Health in Diabetes Project",FALSE,287,"mann_whitney",NA,NA,NA,2.49853393660761
"3621","e3d856b6e64f9cb85cc046ecf3504127","NCT01058356",0.05,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Presence of Bowel Habit Change (Watery Stools More Than 2 Times Per Day for at Least 2 Days)","SECONDARY","Null hypothesis: The efficay of the probiotic Lactobacilli (Lacidofil cap®) for the prevention of AAD in adults is not different form the placebo group in multi-center, randomized, placebo-controlled, double-blind trial.

Power calculation:

The assumption of sample size calculation:

difference 18% (8% : 26%) α: 0.05, statistical power: 90%, two sided difference: 18% Compliance: 80%

- Unadjusted sample size (N=200) 180 + 10(%) drop out = 180 + 180/ (1-0.1)2 = 222.2 Total 220 subjects","D004761; D003092; D003967","Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea",TRUE,214,"logistic_regression",NA,NA,NA,2.16243298173887
"3622","e3f5753ff05661595e91c14835f5fc60","NCT01532986",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Consumer Assessment of Healthcare Providers and Systems (CAHPS)","SECONDARY",NA,"D010300","Randomized Trial to Test the ""Coordinated Care for Health Promotion and Activities in Parkinson's Disease"" Intervention in the VA",FALSE,328,"t-test",NA,NA,NA,2.66881159065383
"3623","e3f8df807433352626710cfc4a4ca39b","NCT01183689",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Mean Change in Fasting Glucose From Baseline to 2 Years","SECONDARY","Analysis of variance was used to compare mean differences in changes from baseline to 2 years among the 3 groups.","D015430","Study of Novel Approaches for Prevention",FALSE,317,"anova",2,NA,NA,2.62421173601415
"3624","e42413c0bb01fae7d3c224fc0962487c","NCT01037985",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Participants Observer Scar Assessment Score at Week 12 and 24: Part B","SECONDARY","Week 12, Overall Opinion: Comparison within the participant between EXC 001 and placebo.",NA,"Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty",FALSE,64,"t-test",NA,NA,NA,1.00345743424713
"3625","e439f16639c9720e622b823f833b0537","NCT02726971",0.05,"Two-sample t-test","INTERVENTIONAL",0,1,1,0,0,"the AFS Score at Second-look Hysteroscopy","PRIMARY",NA,"D006175; D000267","Comparison of Different Doses of Oestrogen Therapy for Preventing Intrauterine Adhesion",FALSE,121,"t-test",NA,NA,NA,1.63728545358366
"3626","e43acc0c72956285c8dac8255abe782b","NCT00487084",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Verbal Rating Score (0 to 10) for Pain (VRPS)","SECONDARY",NA,"D000377","Effect of Timing on Efficacy of Morphine Analgesia After 2-chloroprocaine Anesthesia",TRUE,57,"kruskal_wallis",2,NA,NA,1.1439569152679
"3627","e449a75c4c78312bd73fa3f1e8620d18","NCT01005719",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"The Difference in the Onset of Action Based on Median pH Values Between the Two Active Treatments Compared to No Treatment on Day 1 and Day 7","SECONDARY",NA,NA,"Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)",TRUE,118,"mann_whitney",NA,NA,NA,1.61751378500378
"3628","e449c36ca11f4edd71c1c196085b6d36","NCT00262080",0.044,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hours Post-dose","SECONDARY","The analysis compared the change from baseline in MSCS score at 4 hours post-dosing for patients treated with ecallantide and placebo. Treatment effect was assessed by the non-parametric Wilcoxon Rank Sum test because of an assumed non-normal distribution.","D000799; D054179","Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)",FALSE,72,"mann_whitney",NA,NA,NA,1.1482312650823
"3629","e45200908814744b671dc6bec679f4e0","NCT02730260",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Smoking Abstinence for 7 Days at Last Contact","PRIMARY","Odds ratio for PriorQuit, from the logistic regression model representing the a priori hypothesis, which specified income, race, and intervention as independent and interacting variables, and smoking cessation at last contact as the dependent variable. This variable, PriorQuit (0-=none in the past year, 1=at least one in the past year) was added to the a priori model because it was not balanced after randomization.",NA,"Worksite Phone Counseling for Smoking Cessation",TRUE,361,"logistic_regression",NA,NA,NA,1.81541741349544
"3630","e45b185641616156d40a190c6bfe05e6","NCT01003184",0.0497,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Patients Achieving HbA1c ≤7.4% at Endpoint","SECONDARY","Logistic regression model includes independent variables treatment group, use of SU (yes/no), and baseline HbA1c.","D003920; D003924","Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes",FALSE,216,"logistic_regression",NA,NA,NA,2.16144966889392
"3631","e45fdfe31883b983277ab7f857169497","NCT01606189",0.04,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Mean McGill Pain Questionnaire Part 1 Score for 'Total Pain Intensity' at the End of Each Treatment Period (Each Lasting 14-20 Days)","SECONDARY","Total pain intensity scores were compared between treatment groups using ANOVA. The model included factors for patient, treatment and period. The significance of the overall treatment effect was assessed using the F-test from the ANOVA. The model used was as follows: Total Pain Intensity Score = Patient + Treatment + Period",NA,"A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain",FALSE,94,"anova",2,NA,NA,1.20338768890662
"3632","e46514401c18f2fd80f530b1ee59ab20","NCT05293314",0.05,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"The Ability of the Breath Test Model to Distinguish Bronchiectasis From Healthy People","PRIMARY","Evaluate the ability of the breath test model to distinguish bronchiectasis from healthy individuals by measuring the area under the receiver operating characteristic (ROC) curves. The maximum value in the area below the receiver is 1. The closer the value is to 1, the higher the prediction accuracy of the model.","D001987","Assessment of an Exhaled Breath Test to Detect Bronchiectasis",TRUE,289,"mann_whitney",NA,NA,NA,2.50710839765318
"3633","e46ac664266f1c6b2657c18bdcef5d08","NCT01062971",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Number of Adverse Events","SECONDARY",NA,"D005901; D005902; D009798; D006973","Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide",FALSE,112,"t-test",NA,NA,NA,1.57722881888439
"3634","e476fd8c3b764bf4e5d1e9d5e0a75a11","NCT06281171",0.03,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"PROMIS Depression Scale T-Scores","SECONDARY",NA,"D001321; D000067877","Evaluation of SkillTalk for Autistic Young Adults",FALSE,115,"linear_regression",NA,NA,NA,1.03903783307274
"3635","e47eba8268e5d095b5df0a721398fe7f","NCT05018689",0.04,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in University of Michigan Depression Center Peer-to-Peer Depression Awareness Assessment Perceptions of School Culture Scores From Baseline (1 of 8)","SECONDARY","I would help the new student even if I did not know him or her well",NA,"Evaluation of the Aevidum Curriculum and Club",FALSE,1560,"linear_regression",NA,NA,NA,4.80006827728457
"3636","e49dcde4c0868aca69d933cc9679858e","NCT02912650",0.048,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (PRID4)","OTHER_PRE_SPECIFIED","0.25 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,231,"anova",2,NA,NA,2.1698956477919
"3637","e4f4dac1de24129c1866b431fbe6b73a","NCT00442546",0.0255,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Interference Index Score as Measured by the m-BPI-sf","SECONDARY","Month 6","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,166,"anova",2,NA,NA,1.0791992650671
"3638","e4fbd67d8414311fd523c83ec8bcd858","NCT01064401",0.0176,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With a ≥ 7.5 Point Worsening From Baseline in the Multiple Sclerosis Impact Scale (MSIS-29) Physical Impact Score at 96 Weeks","SECONDARY",NA,"D009103; D020529; D012598","Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis",FALSE,1818,"logistic_regression",NA,NA,NA,2.55111337622526
"3639","e4fea471375a7cdd4c9e646c40e376aa","NCT02508116",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"The Number (Percentage) of Participants Receiving Prasugrel/Ticagrelor","PRIMARY","The sample size calculation was based on two factors: 1) the rate of pre-study prasugrel/ticagrelor use (\~20%) and 2) anticipated increase in prasugrel/ticagrelor prescribing based on the frequency CYP2C19 LOF variants (\~30-35%). We estimated a 15% difference in the use of prasugrel/ticagrelor in the two groups (35% in the genotyped group and 20% in the control group). A sample size of 138 per group (a total of 276) would provide 80% power at an alpha level of 0.05 to detect this difference.","D002318; D054058","Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention",FALSE,504,"logistic_regression",NA,NA,NA,2.1410876070102
"3640","e50a8fbf5cd6ed3164deb5ce17d31dcb","NCT01357564",0.03,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"12-item Zarit Burden Short Form Measuring Caregiver Burden","SECONDARY","Sample size calculation was based on the main study hypothesis tested at 80% power for a 2-sided alternative hypothesis using a t-test comparing the treatment groups on 4-month values. Based on previous trials, we sought a medium effect size of 0.50 using a type I error rate of .05.","D003704","Tailored Activity Program-Veterans Affairs",FALSE,322,"t-test",NA,NA,NA,1.71590770547382
"3641","e5299f5c62ad82e9495dc73592da6cbd","NCT01559259",0.031,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Intensity Difference on 4-Point Categorical Scale (PID4)","SECONDARY","12 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,122,"anova",2,NA,NA,1.09921766730189
"3642","e52d5236e02630e7fffd579a9195f1db","NCT05302414",0.05,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,0,"Interprofessional Collaboration Scale","SECONDARY","For follow-up test at the 16 weeks.",NA,"The Learning Outcome of Resuscitation Teamwork Training in Postgraduate Year Doctors and Nurses",FALSE,64,"kruskal_wallis",2,NA,NA,1.20770700959599
"3643","e537e9bf9cbba7f13ffd1153348c2feb","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Health)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1751,"linear_regression",NA,NA,NA,6.13701635655789
"3644","e5416f14ee49474b00816e0a6eb25ae0","NCT02276807",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in Quality of Life at 12 Weeks","SECONDARY",NA,"D003863; D003866","Improving Mood in Veterans in Primary Care",TRUE,118,"anova",2,NA,NA,1.61751378500378
"3645","e544a0b4c3f3fdde04c2665a010569fd","NCT01251757",0.019,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Post Intervention Low Density Lipoprotein (LDL) Level","SECONDARY","We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR+ versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline LDL level subgroups.","D002318","Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies",FALSE,9166,"linear_regression",NA,NA,NA,6.11760371198543
"3646","e54e4edc3d3d630a0516e5cdeb779453","NCT02899988",0.041,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With a Static Physician Global Assessment (sPGA) 0 and 0/1","SECONDARY","sPGA (0)","D011565","A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis",FALSE,103,"logistic_regression",NA,NA,NA,1.28354908721569
"3647","e559f9ea2c1c70fe277b4209f7aedfe0","NCT00956384",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants With Short Term Surgical Complications","SECONDARY","We assessed the effect of the surgical method on the occurrences of any complications versus none via logistic regression, and results were expressed as odds ratios with 95% CIs.",NA,"One-stage Breast Reconstruction Using Dermal Matrix/Implant Versus Two-stage Expander/Implant Procedure",TRUE,164,"logistic_regression",NA,NA,NA,1.8982180321277
"3648","e571ea439c3f644e3d3a7d1e2f13b5f7","NCT01766310",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Changes of Homocysteine Level","PRIMARY",NA,"D020138","Effect of Folic Acid Supplementation on Plasma Homocysteine Level in Obese Children",FALSE,46,"t-test",NA,NA,NA,1.03597838019194
"3649","e576e15af8a17a9c06feb235c5fae40f","NCT00535405",0.026,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Patients Who Achieved LDL-C <100 mg/dL at Week 12","SECONDARY",NA,"D006331; D003327; D003324; D017202; D006937","A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)",FALSE,470,"logistic_regression",NA,NA,NA,1.82874380703411
"3650","e57e904b32573b56c381bf0e9e78c471","NCT00551135",0.0348,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Numeric Rating Scale (NRS): Current Pain With Movement - Walking","SECONDARY","1 h PS; LS Means from ANOVA model with terms of treatment, pooled center and baseline pain from walking (for baseline visit ANOVA model with terms of treatment and pooled center). Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,202,"anova",2,NA,NA,1.54910944654498
"3651","e5b052c2e106b26cd15ef162448e3c36","NCT02889796",0.043,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 2, 4, 12, and 24","SECONDARY","Filgotinib 100 mg vs Placebo at Week 2.","D001168; D001172","Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate",FALSE,955,"logistic_regression",NA,NA,NA,3.99601972168552
"3652","e5b4af1cb60a323d8df17002a5f0917d","NCT01783041",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,1,0,"Neurodevelopment Indices in Infants Who Receive L-carnitine Supplementation Compared to Controls (NNNS)","PRIMARY",NA,"D047928; D065886","Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants",TRUE,119,"mann_whitney",NA,NA,NA,1.62413102595047
"3653","e5c8d6e5344089bb121a5e395dfcb47d","NCT02259127",0.024,"Linear regression","INTERVENTIONAL",0,0,1,1,0,"Mean Change in Weight From Baseline","OTHER_PRE_SPECIFIED","Statistical Analysis Title: Adjusted Difference (ODYSSEY A \>=14kg)

Statistical analysis description: Linear regression of weight at week 96, adjusting for randomised arm, baseline weight and stratification factors. Presenting mean difference between arms.

Number of subjects included in analysis: 311

Analysis Specification: Pre-specified","D007239; D015658; D000163","ODYSSEY (PENTA 20)",FALSE,311,"linear_regression",NA,NA,NA,1.39204093708557
"3654","e5cfe9631154d8725dd07543c8232622","NCT02539394",0.042,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Degree of Dysphagia Patients Experience (Communication)","PRIMARY","The distribution of POD2 SWAL-QOL - Communication is the same across the 2 arms","D007405; D055959; D003680; D013118","Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion",FALSE,109,"mann_whitney",NA,NA,NA,1.34587003352236
"3655","e5d0763a862669d834f2798b05652f6e","NCT01131299",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Lipoprotein Insulin Resistance Index (LIRI) After 12-14 Weeks Intervention, Compared to Baseline for Alpha-cyclodextrin (a-CD) and Placebo Groups After 12-14 Weeks, Compared to Baseline","SECONDARY",NA,"D002318","Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol",FALSE,150,"t-test",NA,NA,NA,1.5074733457683
"3656","e5d980c7e574762475aafb24d9250a4b","NCT03192176",0.0366,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 2 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 14","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.07048322283367
"3657","e5dba0f95ad7e9fe72f904f2a6130be2","NCT01033851",0.0366,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Clinical Global Impression of Severity (CGIS) of Anxiety Symptoms.","SECONDARY","A repeated measure ANOVA, with time as the repeated measure, treatment arm as between-subjects factor and CGI-S score as the dependent variable, found a main effect of time (F(1,84)=62.19, p\<0.001) and a significant treatment arm X time interaction (F(1,84)=4.51, p=0.0366).","D001008","Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects",FALSE,89,"anova",2,NA,NA,1.08806238771461
"3658","e5dd04965e8d98f9a26653292fe5972e","NCT02066896",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"The Xerostomia Inventory","PRIMARY",NA,"D012859; D014987; D007637; D007638; D015352; D013577","Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome",FALSE,66,"anova",2,NA,NA,1.2253174109698
"3659","e5e1e71aa59b43c9ba85ca95d934b64c","NCT03843541",0.022,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Day 3 and to Day 7 of Mean Sputum Volume of NAC and Placebo","SECONDARY",NA,"D012140","A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions",FALSE,218,"mann_whitney",NA,NA,NA,1.0847902392781
"3660","e5e7cbed993c1d5bd2a465e485b61ce4","NCT02697773",0.0312,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants Who Took Rescue Medication During Weeks 2, 4, 8, 12 and 16","SECONDARY","Week 2: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,465,"logistic_regression",NA,NA,NA,2.12771341049807
"3661","e5f3c6cb86043b020f07a677e3317ebb","NCT01462370",0.019,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Peak Pain Relief (Peak PR) During the 6 Hours After the Initial Dose","SECONDARY",NA,"D004412","Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)",FALSE,260,"anova",2,NA,NA,1.04098032105498
"3662","e5fa18d8902d4f780d375cf645ed55df","NCT05502081",0.036,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,1,"Platelets at Day 3","SECONDARY",NA,"D000086382","Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients",FALSE,159,"kruskal_wallis",2,NA,NA,1.41868041253474
"3663","e5fbc358105e88437dacff1dc55a17f1","NCT00434759",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in Social Interaction Anxiety Scale (SIAS)","PRIMARY",NA,"D010698; D000072861","Social Phobia Intervention Study of Mannheim",TRUE,89,"anova",2,NA,NA,1.41222998379373
"3664","e601fe137f442f42b2a077116a19b107","NCT00245219",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mental Health (as Measured With the SF-36) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the peer support condition and control condition at Time 3, among both late and early stage patients. The full regression model consisted of 3 steps: The 1st step contained the baseline measure of the dependent variable. The 2nd step contained two dummy coded variables contrasting each condition with control. The 3rd step contained the interaction between the peer support condition and cancer stage. Patients in the education condition were excluded from this analysis.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"linear_regression",NA,NA,NA,1.79957957739554
"3665","e61ae3695a2b74e6bbbe18d56198ca7e","NCT02988622",0.0492,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Scar Pain","PRIMARY",NA,NA,"Comparison of Lasers in the Treatment of Scars",FALSE,200,"t-test",NA,NA,NA,2.06384733124865
"3666","e6359b2b537006a8b8bfb7093f79d26e","NCT04243577",0.05,"Two-sample t-test","INTERVENTIONAL",1,0,0,0,0,"Signal to Noise Ratio (Signal Quality Parameter)","PRIMARY","For Iteration 1 testing, we hypothesized that Signal to Noise Ratio (SNR) obtained using the experimental sensors will not be inferior to the Signal to Noise Ratio (SNR) obtained using the conventional sensors. Alpha level was set to .025 to correct for multiple comparisons.","D003680","Wearable Monitoring Systems for Swallowing Function and Disorders",TRUE,80,"t-test",NA,NA,NA,1.34217713699512
"3667","e63967e1a749f858dec868e3692f310c","NCT00256750",0.0211,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire","SECONDARY","General Health, Month 36","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,424,"anova",2,NA,NA,1.45046131532407
"3668","e652d5bad07fecd3e66b07674019fa4d","NCT00458406",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Minutes of Use Per Night From Month 1 to Month 3","PRIMARY","Two-sided t-test. We hypothesized that Bi-Flex would result in improved adherence but similar effi cacy to CPAP.

The study sample size of 45 in the Bi-Flex group and 15 in the CPAP group had 80% power to detect an effect size ≥ 0.85 with a 0.05 two-sided significance level. In addition, with this sample size, the 95% CI for the difference between the 2 means had a range of 1.282 SD.","D001049; D012891; D020181","Evaluation of Adherence and Therapeutic Effectiveness of Bi-Flex Versus CPAP in Children With OSA",FALSE,56,"t-test",NA,NA,NA,1.13456029943022
"3669","e66cfa1d7c7bf39c12a9225e86b2502f","NCT03693989",0.045,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Intraocular Pressure","SECONDARY",NA,"D002386; D007249","Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification",FALSE,171,"t-test",NA,NA,NA,1.77404532051997
"3670","e66d802ba76b768a80a1c8a8dda4497b","NCT01107496",0.0474,"Mann-Whitney","INTERVENTIONAL",0,1,1,0,0,"Global Clinical Impression-Improvement (CGI-I) Score at Week 1, Week 2, Week 3, Week 4, Week 5, and Week 6","SECONDARY","Analysis pertains to Week 6 data","D006948; D001289","Evaluation of Immediate-Release Viloxazine in Adults With ADHD",FALSE,51,"mann_whitney",NA,NA,NA,1.03965283515826
"3671","e687f133829fae39368778e90ddcd25e","NCT00105196",0.037,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Mean Change in SDS Item Score (Family Life)","SECONDARY",NA,"D003866; D003863; D003865","A Study of Aripiprazole in Patients With Major Depressive Disorder",FALSE,320,"t-test",NA,NA,NA,2.04572479281769
"3672","e6966bb579c8fc65a9da4af9e9cdcdc1","NCT02469870",0.045,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Consumer Satisfaction Questionnaire","SECONDARY","Two-sample t-test","D001321","ASD Parent Trainer: Online Coaching for Parents of Children With Autism",FALSE,156,"t-test",NA,NA,NA,1.69636631714579
"3673","e6ae2be317032ba6f5ad71ec6338fb87","NCT01390415",0.0374,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Systolic Blood Pressure (SBP)","SECONDARY","Between-group comparison of Change from Baseline at Month 6","D006973","A Study to Evaluate Whether Losartan Protects the Kidney in Hypertensive Diabetic Participants With Microalbuminuria (MK0954-365 AM1)",FALSE,136,"t-test",NA,NA,NA,1.35825741036043
"3674","e6aec0f4129f0cd15f367c23720b69d4","NCT04196803",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Changes of Cytosine Modification in TMPRSS2 (5-mC at cg16371860) by Magnesium Treatment Versus Placebo","PRIMARY",NA,"D015179","Ancillary Study of Methylation Biomarkers in a Randomized Controlled Trial of a Personalized Prevention of Colorectal Cancer",TRUE,239,"linear_regression",NA,NA,NA,2.28311078024125
"3675","e6b21403e796b4077ae8982e7a64748d","NCT01649596",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient Satisfaction","SECONDARY",NA,"D007035","Impact of Expanded Peri Operative Warming",TRUE,94,"t-test",NA,NA,NA,1.44969222080406
"3676","e6b523b0dcca69fd2843387245d46b1f","NCT02748096",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Radiological Assessment of Component Positioning","PRIMARY","The sample size was calculated from a previous study that used similar radiological assessments to compare OUKAs performed using conventional instrumentation and computer navigation. In this study, the standard deviation of the tibia varus/valgus angle for the control group was 3.6°. Assuming a minimum clinically important difference of 3°, the SMD would be 0.8. Hence with a power of 0.8 and significance level of 0.05, a total sample size of 44 patients (22 in each group) was required.","D001168","The Assessment of Patient Specific Instrumentation for Unicompartmental Knee Replacement",TRUE,45,"t-test",NA,NA,NA,1.02560707988412
"3677","e6c7ed397499c5b8f841ae189c9e6157","NCT01462435",0.029,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"VASSPID-8. The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale (VASSPID) From 0 to 8 Hours After Trial Entry.","SECONDARY",NA,"D010149","Study of Diclofenac Capsules to Treat Pain Following Bunionectomy",FALSE,215,"t-test",NA,NA,NA,1.36697432851969
"3678","e6e5780a436718d9151b01e7af31579a","NCT01765920",0.037,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,1,0,"Dynamics of Acute URTI Symptoms Severity According to the Daily Wisconsin Upper Respiratory Symptom Survey - 21 (WURSS-21) Assessment of the Patient (Including the Total WURSS-21 Score, ""Symptoms"" Domain Score, and ""Ability"" Domain Score).","SECONDARY",NA,"D007239; D003141; D012141","Clinical Trial of Safety and Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adults",FALSE,333,"kruskal_wallis",2,NA,NA,2.08631119297495
"3679","e6f007cf9483441e8c56aca94b739ce1","NCT01236053",0.0257,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,1710950,"logistic_regression",NA,NA,NA,108.661327993302
"3680","e70c5fc6b9c47de9d6fdea0e99b4caae","NCT01929681",0.049,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Long Term Change: Montgomery-Åsberg Depression Rating Scale (MADRS)","PRIMARY",NA,"D003863; D003866; D001714","Multiple Treatment Study Using Low Field Magnetic Stimulation for Bipolar Depression",TRUE,50,"linear_regression",NA,NA,NA,1.05874945721546
"3681","e719bbbe4f96d2b329ecae4058d413e7","NCT00551135",0.0345,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Total Cumulative Dose of Opioids and Tramadol Used During and After Surgery","SECONDARY","Day 5 PS; LS Means from ANOVA model with terms of treatment, pooled center. Centers with fewer than 8 treated subjects were combined into pooled centers.","D006547; D010149; D006552","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",FALSE,202,"anova",2,NA,NA,1.53775201627097
"3682","e71bd8afaf9204116b00b4e903725d21","NCT02653664",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change From Pre-Treatment in Average Pain Intensity on a 0-10 Numerical Rating Scale 3 Months Following End of Treatment","OTHER_PRE_SPECIFIED",NA,"D059350","Chronic Pain Skills Study",FALSE,328,"anova",3,NA,NA,1.06842561169747
"3683","e726a3f9c2b72da3495298ad208225a7","NCT00791921",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"American College of Rheumatology 20% (ACR20) Response at Week 12","PRIMARY","For ACR20 responder rate at Week 12, comparison between the CDP870 200 mg group and the placebo group was performed.","D001168; D001172","Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)",TRUE,230,"logistic_regression",NA,NA,NA,2.24041528002211
"3684","e74918735cfaacc56b8491f881b681d2","NCT00442546",0.0476,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Daily and Weekly Worst Pain During the Hospital Stay and Post Discharge Assessed by the Pain Numerical Rating Scale (NRS)","SECONDARY","12 hours","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,156,"anova",2,NA,NA,1.77798149821528
"3685","e74b42eb281f19efe141fd0586214913","NCT04350788",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Healthcare Utilization Extracted From Electronic Medical Record","SECONDARY",NA,"D011471","Enhancing Survivorship Care Planning for Patients With Localized Prostate Cancer Using A Couple-focused Web-based Tailored Symptom Self-management Program",FALSE,62,"linear_regression",NA,NA,NA,1.18983814919554
"3686","e7affd7a2ccc144b66b29f3a9d2029c0","NCT01368185",0.01,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Serum Uric Acid (SUA) Level","PRIMARY","Comparison between Month 3 and Baseline","D006973","Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)",TRUE,1705,"t-test",NA,NA,NA,1.49953882648572
"3687","e7b15fadd5953c4a2d55597dbcea8cb8","NCT03476460",0.042,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Serum Creatinine at 24h From Baseline","SECONDARY",NA,"D051437; D007676; D058186","Sodium Chloride and Contrast Nephropathy",FALSE,252,"t-test",NA,NA,NA,2.02448878185049
"3688","e7bbcdd2dc75baccebf31eff96bdcf7d","NCT05714696",0.049,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Positive Affect","PRIMARY",NA,NA,"Weight Discrimination and Poor Cardiovascular Health",FALSE,135,"t-test",NA,NA,NA,1.69776718821639
"3689","e7d9e1b0d0f473e3ae3a1e15a19c33d2","NCT00331773",0.028,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Assessment of Anxiety and Depression Using the HSCL-25","SECONDARY","The distribution of HSCL-25 at 60 months (5 years) was calculated, and Wilcoxon test statistics were used to test the null hypothesis that responses are the same across the two treatment arms versus the alternative hypothesis that they are different. Significance level = 0.0125, two-sided test.","D011471","Radiation Therapy in Treating Patients With Stage II Prostate Cancer",FALSE,634,"mann_whitney",NA,NA,NA,2.2609800978287
"3690","e7e466233fdb607ec084e0b31c73ec6a","NCT01066793",0.0386,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for mode of infection (other vs injection drug U). The logistic regression analysis for relapse was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including total cumulative dose of peginterferon and ribavirin), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,960,"logistic_regression",NA,NA,NA,3.65648497246593
"3691","e7e5f7f59fcc7b46701f6c76733131a4","NCT03463993",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Amount of Blood Transfused","SECONDARY",NA,"D006473; D006470","Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section",TRUE,451,"mann_whitney",NA,NA,NA,3.12446504498784
"3692","e7f5a20299df014909504e0a4b4c6a33","NCT01066793",0.0443,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for aspartate aminotransferase (AST) ratio at BL (\> 1.5 vs \<=1.5). The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Wk 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,427,"logistic_regression",NA,NA,NA,2.747203080234
"3693","e804822affba73d75df556ab88e06945","NCT02189954",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Postoperative Pharyngolaryngeal Morbidity at Postoperative 24.Hour","SECONDARY",NA,NA,"Effect of Laryngeal Mask Cuff Pressure in Geriatric Patients",TRUE,90,"mann_whitney",NA,NA,NA,1.41980120127578
"3694","e813413cc3fab8d343b0a90093a56062","NCT00913458",0.0397,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Number of Participants That Met Sustained Remission at Week 76 and Week 91 Based on DAS28 Score","PRIMARY","The hypothesis of primary interest was the superiority of E25+MTX compared with PBO.","D001168; D001172","Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis",FALSE,130,"linear_regression",NA,NA,NA,1.39753363426033
"3695","e81879109fbae6cf3846c547073d6cf4","NCT02449291",0.029,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Evolution Score of Nausea (0-30 Mins)","SECONDARY",NA,"D009325; D014839; D020250","Study of APD421 as PONV Treatment (no Prior Prophylaxis)",FALSE,372,"mann_whitney",NA,NA,NA,1.78970052376175
"3696","e8267aa93e1df7fb2fd83d4d0f1ef3f1","NCT03982368",0.039,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Quality of Life (Impact of Dry Eye on Everyday Life (IDEEL) Questionnaire vs Different Timepoints - Full Analysis Set","SECONDARY","Symptom Bother - change from baseline to week 12","D015352; D007638","A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye",FALSE,166,"anova",2,NA,NA,1.55021568557853
"3697","e8487f01a5fe4837705423b9cccd2601","NCT01010009",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Modulation of Deoxygenated Levels of Haemoglobin","PRIMARY","An omnibus ANOVA was carried out with a priori planned comparisons using the mean squares error term from this ANOVA.",NA,"The Cognitive and Cerebral Blood Flow Effects of Resveratrol",TRUE,44,"anova",2,NA,NA,1.01513168983373
"3698","e86a099ac7f6b0b18f103ed420323a8a","NCT01626118",0.041,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"VASSPID-8. The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale (VASSPID) From 0 to 8 Hours After Trial Entry.","SECONDARY",NA,"D010149","Study of Indomethacin Capsules to Treat Pain Following Bunionectomy",FALSE,187,"t-test",NA,NA,NA,1.71379923005537
"3699","e86ff5603db496a1e3590580927addce","NCT05137041",0.035,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Time Course of PID","SECONDARY","Change from Baseline at Day 2 Morning","D001416; D017116","Efficacy and Safety of FIRTECH in Patients With Mild to Moderate Acute Low Back Pain",FALSE,181,"t-test",NA,NA,NA,1.47541666595669
"3700","e8737bae259106ab8029d1aa78997a86","NCT01236053",0.0248,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,20382,"logistic_regression",NA,NA,NA,11.5009367071124
"3701","e878c4e8354fc819775094b3eecaca72","NCT00967668",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Weight","PRIMARY","All participants were included in outcomes analyses using intention-to-treat principles. A linear mixed-effects model with baseline, 3- and 12-month outcome values modeled as dependent variables was used.This statistical approach allows the use of data from all participants as long as the dependent variable is available for at least one time point. Each subject was included as a random intercept to adjust for within-person correlations.",NA,"Coaching Veterans to Healthy Weights and Wellness",TRUE,481,"linear_regression",NA,NA,NA,3.22585304433708
"3702","e88a51b99bcd2e323ee98d629b4deeff","NCT02912650",0.046,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (PRID4)","OTHER_PRE_SPECIFIED","0.25 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,340,"anova",2,NA,NA,2.53332042609264
"3703","e88bd27f44811e598029bd26a8ac730d","NCT02419612",0.044,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 52","SECONDARY",NA,"D003920","A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone",FALSE,443,"logistic_regression",NA,NA,NA,2.78175631910699
"3704","e8965c541ab34561ee1b924cdc893190","NCT00089674",0.0125,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With a New Vertebral Fracture Through Month 36","SECONDARY",NA,"D011471","AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer",FALSE,1352,"logistic_regression",NA,NA,NA,1.62858405517142
"3705","e89e04aa55382e5a4ebf5f837819c558","NCT05457647",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Corrected Distance Visual Acuity","OTHER_PRE_SPECIFIED","Assessment of change of CDVA value at 12-months follow-up visit.","D007640","Theranostic Guided Riboflavin/UV-A Corneal Cross-linking",TRUE,47,"mann_whitney",NA,NA,NA,1.04624856756472
"3706","e8a782358d9af82ddb823872c1087cd7","NCT03114969",0.038,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants Making at Least One Critical Error at Visit 2-Primary Device Comparisons","SECONDARY",NA,"D008171; D029424","Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs",FALSE,97,"logistic_regression",NA,NA,NA,1.1700368461578
"3707","e8a9e96351b7ee71d49b1f2922d80c22","NCT00939107",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Disability","PRIMARY",NA,"D001416; D017116","The McKenzie Method Versus Manipulation for Patients With Chronic Low Back Pain",FALSE,350,"t-test",NA,NA,NA,2.7558473550607
"3708","e8aad77b087aa1ab155b3e4c7ba46e84","NCT01945034",0.021,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Sum of Pain Intensity Difference Scores at Rest and on Weight Bearing Over 7 Days","SECONDARY","At Rest Over 7 days: The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms. Upper limit of 95% CI \< 0 for Ibuprofen treatment significantly better than combined Placebo.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,219,"anova",2,NA,NA,1.0442525046957
"3709","e8c5bfea8b76fb847a8b6afee11b1c8e","NCT01010009",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Modulation of Deoxygenated Levels of Haemoglobin","PRIMARY","An omnibus ANOVA was carried out with a priori planned comparisons using the mean squares error term from this ANOVA.",NA,"The Cognitive and Cerebral Blood Flow Effects of Resveratrol",TRUE,44,"anova",2,NA,NA,1.01513168983373
"3710","e8c5e9339c2f46998f094dbe8bac84f7","NCT02476032",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Schiff Air Test: Mean Reduction in Sensitivity Between Groups","PRIMARY","Within group comparisons: t-tests comparing the mean change to 0 were utilized. P-values less than 0.05 were considered statistically significant. SAS V9.3 (SAS Institute Inc., Cary, NC) was used for analysis. The sample size of 20 participants per group was based on having 90% power to detect a one standard deviation difference between the DO-strip groups and the placebo group means using ANOVA with a 0.05 level of significance.","D003807; D006967","An Evaluation of the Efficacy of Oral-B New Product Sensi-Stop on Dentinal Hypersensitivity",FALSE,60,"t-test",NA,NA,NA,1.17169922891753
"3711","e8d53d1278f8fc0f51d0f7491ced9d38","NCT00335153",0.023,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Average Daily Normalized ""On"" Time With Troublesome Dyskinesia at Endpoint","SECONDARY",NA,"D010300","Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease",FALSE,307,"t-test",NA,NA,NA,1.3332093471745
"3712","e8d5a3354e748a8117d6909c26e025c8","NCT03718832",0.0417413,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Number of Outpatient Visits Claimed by Insurance","SECONDARY","Unadjusted mean difference, 6 months after trial enrollment",NA,"Fresh Food Farmacy: A Randomized Controlled Trial",FALSE,465,"t-test",NA,NA,NA,2.72548060598053
"3713","e8f3be833ffe259a166ab803c8feb73f","NCT05556148",0.0416,"One-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Each of the WURSS-21 Symptom Domains Score: Hoarseness","PRIMARY","Change from Baseline at Day 2","D003139","Otrivine: Quality of Life (QoL) Impact in a Real-World Setting",FALSE,102,"t-test",NA,NA,NA,1.29321850892188
"3714","e9085d1303505f7ca079ab5eaf822716","NCT01378299",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Percent Change in Bone Turnover Markers According the Presence of Diabetes Mellitus","SECONDARY","Analysis by intention to treat with the last value carry forward.","D007006","CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy",TRUE,78,"anova",2,NA,NA,1.32610986002301
"3715","e90d02baec4a91fa6ccd2fb223fbde84","NCT02528253",0.0257,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 40, \>=70%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1012,"logistic_regression",NA,NA,NA,2.64919365109635
"3716","e91e1ad00b82b675b93f1209e57c411a","NCT02469246",0.026,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in CD4 Cell Count at Week 48","SECONDARY",NA,NA,"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC",FALSE,503,"anova",2,NA,NA,1.89120108929073
"3717","e92e524caca9d73765f037a66a2716a2","NCT03726489",0.0213,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Number of Phototherapy Treatments Received","SECONDARY","Analysis for Phototypes V/VI","D011565","Light Treatment Effectiveness (LITE) Study",FALSE,541,"linear_regression",NA,NA,NA,1.64966286401113
"3718","e932dc6890d9099e4cc070f0f30afe60","NCT04828707",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Reduction in Migraine Days","PRIMARY","The Intent-To-Treat (ITT) dataset was used for primary outcome. To overcome impact of missing data, statistical analysis was conducted using the Last Observation Carried Forward (LOCF) as an imputation method.

The data of each variable collected from the daily diary was normalized to 28 days for every period (weeks 1-4, weeks 5-8, and weeks 9-12).

Participants' data who entered the treatment phase but dropped out during weeks 5-8 were carried forward and analyzed as their data at weeks 9-12.","D008881","Assessment of Safety and Efficacy of Nerivio for the Migraine Prevention",TRUE,248,"t-test",NA,NA,NA,2.32502278592711
"3719","e936d2a60cbcebd81edf4a4d5f5cb778","NCT00087490",0.016,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Duration of Hospital Stay for mITT Population","SECONDARY","Null hypothesis was that there was no difference in the length of hospital stay between the treatment groups.","D007239; D003141; D013203; D018461","Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)",FALSE,640,"mann_whitney",NA,NA,NA,1.39630649165275
"3720","e93c7a55fdffcf19d1fd57a100189122","NCT02973425",0.03,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Self-Efficacy at the End of the 6 Months","SECONDARY","For hypothesis 3, we compared the mean score on the SEQ-12 and its subscales at 6 months, adjusting for baseline.",NA,"Take a Break (TAB): mHealth-assisted Skills Building Challenge for Unmotivated Smokers",FALSE,160,"linear_regression",NA,NA,NA,1.21854475433189
"3721","e93c9688345b3ddf797412ec18cd8797","NCT02321462",0.0382,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean BBPS Score by Segment and Globally (ITT Population)","SECONDARY","Treatment difference for Transverse Colon BBPS Score.",NA,"Efficacy, Safety and Tolerability of Eziclen in Adult Subjects Undergoing Colonoscopy",FALSE,282,"anova",2,NA,NA,1.97491123804353
"3722","e946e59b024af8756fa89f08149c1900","NCT02696031",0.0197,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response at Week 16","PRIMARY","week 16","D013166; D025241; D000089183","Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis",FALSE,335,"logistic_regression",NA,NA,NA,1.21657492374847
"3723","e9472fe48536270eb687d01514f9b82c","NCT04167085",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Duration of Epistaxis","PRIMARY",NA,"D004844","NOrth American Study for the Treatment of Recurrent epIstaxis With DoxycycLine: The NOSTRIL Trial",FALSE,44,"mann_whitney",NA,NA,NA,1.01513168983373
"3724","e9605334a5a133c04dfff4465392291d","NCT01420536",0.044,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Kinesiographic Parameters -- (4.a) Upper Denture Base Movement, Vertical Axis","SECONDARY","For the kinesiographic assessment, the Kolmogorov-Smirnov test was used to evaluate whether the variables had normal distribution, which was positive in the majority of cases. A comparison between the values obtained for both groups was performed by means of the paired sample t-test.","D007575; D009066","Canine Guidance vs Bilateral Balanced Occlusion in Complete Denture",FALSE,78,"t-test",NA,NA,NA,1.19253001716793
"3725","e9837f1a6324b2a76724a02b5300458e","NCT01221597",0.0268,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Severity of Peyronie's Disease Physical and Psychological Symptoms","SECONDARY",NA,"D010411","Study of AA4500 in the Treatment of Peyronie's Disease",FALSE,303,"anova",2,NA,NA,1.51154676822128
"3726","e99339cbf1a26fb31b19f58fa1698081","NCT00139776",0.0102,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Total Rescue Medication Taken (Mean)","SECONDARY",NA,"D010003; D020370; D015207","Study Of ""Continuous Use"" Of Celecoxib Vs. ""Usual or Intermittent Use""",FALSE,858,"anova",2,NA,NA,1.08473240012041
"3727","e99a492a73ef7a752120ae591b3d83a0","NCT05182840",0.0418,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Last Observation on Treatment Carried Forward (LOCF)","SECONDARY","The odds ratio, 95% confidence interval, and p-value were calculated based on logistic regression of binary outcome adjusting for treatment, and stratification factors as covariates.

Randomisation stratification was used, which is based on estimated glomerular filtration rate (eGFR) and urine albumin creatinine ratio (UACR) levels at screening.","D007674; D051436","A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease",FALSE,261,"logistic_regression",NA,NA,NA,2.05146769585197
"3728","e9aea321becc92a2ad0c421b5a63f7fe","NCT03136861",0.0466,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With a Bath Ankylosing Spondylitis Disease Activity Index Score Below 4 at Week 8 (Treatment Period 1)","SECONDARY","BASDAI Score \<4 at Week 8","D013166; D025241; D000089183","SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis",FALSE,372,"logistic_regression",NA,NA,NA,2.67749842573903
"3729","e9b65424d0cf5defe10b5a6771f8ccc6","NCT00102063",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change in Positive and Negative Syndrome Scale (PANSS) Total Score","PRIMARY",NA,"D012559","Aripiprazole in Adolescents With Schizophrenia",FALSE,197,"t-test",NA,NA,NA,2.07637243500742
"3730","e9bbe65f7bd1ac25924e83755158ce7d","NCT00355147",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Medication (Statins) for Secondary Stroke Prevention Risk Factor Management","SECONDARY","Between Group Intervention Pre Post Comparison Compliance with Statin Medication","D020521; D000083242; D002546; D007511","Adapting Tools to Implement Stroke Risk Management to Veterans",FALSE,143,"logistic_regression",NA,NA,NA,1.77557547026144
"3731","e9d1d3550de2238893c46d785d5021ac","NCT00315328",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Stereoacuity Measured by the Randot Preschool Test at 17 or 19 Weeks- Participants With All Causes of Moderate Amblyopia","SECONDARY","To evaluate WITHIN each treatment group whether stereoacuity changed from baseline to outcome a Wilcoxon sign-rank test was performed to evaluate whether the distribution of change from baseline was zero","D000550","Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds",FALSE,88,"mann_whitney",NA,NA,NA,1.16613092430307
"3732","e9d3de96c61c3a80d3b65ebdd7e554c5","NCT01236053",0.0284,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,102836,"logistic_regression",NA,NA,NA,29.0395480962809
"3733","e9d71652b54c4fcb24ee4d0abf396c69","NCT00331773",0.009,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Frequency of Patients With GU and GI Acute and Late Toxicity","SECONDARY","Late GU toxicity rates were tabulated and dichotomized as \< grade 2 vs ≥ grade 2. To evaluate the differences by treatment arm, 2 X 2 subtables were formed and relative risk (RR) estimates with 95% CIs were computed.","D011471","Radiation Therapy in Treating Patients With Stage II Prostate Cancer",FALSE,1079,"logistic_regression",NA,NA,NA,1.08724090557538
"3734","e9f71ad02137831c518fd19d1a61718f","NCT00464204",0.037,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Amount of Study Drug Required to Achieve Initial Hemodynamic Stabilization","PRIMARY","Null-hypothesis: The amount of study drug required to achieve initial hemodynamic stabilization in patients treated with Voluven® is higher than or equal to this amount in patients treated with NaCl.

Alternative hypothesis: The amount of study drug required to achieve initial hemodynamic stabilization is lower in patients treated with Voluven® than in patients treated with NaCl.","D018805; D014115","Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis",FALSE,174,"t-test",NA,NA,NA,1.51713390356973
"3735","ea0357ffe312994c82a51011ef09367c","NCT02312154",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Hydration Level","PRIMARY","The change in each of the biophysical parameters was calculated as the pretreatment value minus the posttreatment value for each visit, and these pre- vs posttreatment changes were used in the statistical analysis to minimize the intraindividual variation between the two cheeks. The Wilcoxon rank-sum test was performed to compare the week-by-week changes in parameters of the right and left cheeks (i.e., treated vs untreated).",NA,"Changing in Skin Physiology After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces",TRUE,48,"mann_whitney",NA,NA,NA,1.05642048349345
"3736","ea226b8efeb0c9b65c0482d93e6f594a","NCT02391363",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Health Service Use at 9 Months","SECONDARY","We expected to reject the null hypothesis of no treatment group difference in 9 month health service use, controlling for baseline health service use.

Race/ethnicity and ERS-expectancies significantly differed between groups at baseline and were included as covariates.

A total of 134 participants allowed for 80% power to detect moderate group differences (d=.49) in primary and secondary outcomes given a 2-tailed type 1 error rate",NA,"Calmer Life: Treating Worry Among Older Adults In Underserved, Low-income, Minority Communities",FALSE,134,"logistic_regression",NA,NA,NA,1.42720213865968
"3737","ea25b77f3a8695c4591e0679e21bdfeb","NCT03458702",0.042,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Root Mean Square of Successive Differences (RMSSD) Assessed at Baseline, Post-Condition and Post-Exposure","PRIMARY","ANOVA: CONDITION X TIME INTERACTION","D001008","The Effects of Emotional Exposure on State Anxiety",FALSE,80,"anova",2,NA,NA,1.1609704438077
"3738","ea53d222bf858dac1e0171fc9c3125b0","NCT00736996",0.05,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Change in Insulin Resistance","SECONDARY","The mean change with PIO was compared with the mean change with Placebo in a linear regression conditioned on the stratification categories (MCI subtype and number of APOE ε4 alleles) and the baseline level of the outcome variable.","D060825","Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)",TRUE,49,"linear_regression",NA,NA,NA,1.06649684228356
"3739","ea66770ba3dc6ced6067c13326271e7e","NCT00540514",0.036,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment, by Histology","OTHER_PRE_SPECIFIED",NA,"D008175; D002289","Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer",FALSE,521,"logistic_regression",NA,NA,NA,2.54350377482168
"3740","ea6b9f553003aa8e43d2e321dee91276","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Urinary Genistein","SECONDARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,98,"anova",2,NA,NA,1.47898140162831
"3741","ea81f666b6de325045c6fbe6c798abd1","NCT03801382",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Scores Digital (ISC) Tests","PRIMARY",NA,NA,"Psychometric Properties of IntelliSpace Cognition",FALSE,300,"t-test",NA,NA,NA,2.55375355277734
"3742","ea8ffe9daab6707551c89513facfb20d","NCT00576472",0.019,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by Social Skills Rating System - Teacher (SSRS-T) - Social Skill.","SECONDARY",NA,"D054198; D007945; D001932","Learning Impairments Among Survivors of Childhood Cancer",FALSE,240,"t-test",NA,NA,NA,1.0010237084945
"3743","ea9c535dbc9c3d1b3f46d145e0163f9e","NCT00390949",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Attending a Peer Education or Other Programme Meeting","SECONDARY",NA,"D015658","Scientific Evaluation of Peer Education and STD Treatment to Reduce the Spread of HIV in Zimbabwe",TRUE,5098,"logistic_regression",NA,NA,NA,10.4640873618474
"3744","eaa3c1ed30a6d440401002778a4c0c28","NCT03064113",0.045,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Forced Expiratory Flow From 25% to 75% of Vital Capacity (FEF25-75), as Related to FEV1","SECONDARY","Tx Difference of LS Mean 12 hr","D008171; D008173; D029424","Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",FALSE,63,"t-test",NA,NA,NA,1.09871528226224
"3745","eaa6f5568568142c121f6ca53d5d1b9d","NCT02528253",0.0358,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 56, \>=50%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1011,"logistic_regression",NA,NA,NA,3.51916559647356
"3746","eab2e42b8cb7419496e201c1b6ba2dbc","NCT01144182",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Role Physical","SECONDARY",NA,"D006333","Veterans Affairs Lowering Readmission in Heart Failure",FALSE,95,"mann_whitney",NA,NA,NA,1.45706951885776
"3747","eab6019e09e1ee88fc5e12134e36864d","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Cognitive Elaboration (Price)","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1756,"linear_regression",NA,NA,NA,6.1457530740539
"3748","eab7617dcdc6aec289329003253f7223","NCT02081846",0.047,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants With Any Occurrence of Unplanned Re-hospitalization and/or Any Emergency/Urgent Care Visits Within 30 Days of Hospital Discharge","PRIMARY",NA,NA,"Hospital to Home Outcomes",FALSE,1498,"logistic_regression",NA,NA,NA,5.39010959060926
"3749","eaba8dd604da4fdabf59c225be309bb3","NCT00619957",0.0187,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Percent Change From Baseline in Femoral Neck BMD, 24 Months/Endpoint, ITT Population.","SECONDARY","A total of 210 patients will be randomized to 35 mg once a week risedronate and placebo groups in 2:1 ratio. Sample size will allow detection of a difference of at least 3% in lumbar spine BMD percent change from Baseline at 24 months between risedronate and placebo with at least 90% power. This calculation is based on the assumptions that the common within-group standard deviation (SD) would be below 5%, and the dropout rate within 2 years is about 35%.","D010024","Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis",FALSE,275,"anova",2,NA,NA,1.05523293090696
"3750","eac78a78a06493c1e9afbcf1223d6996","NCT01008410",0.0324,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Who Achieved Remission","PRIMARY","The logistic regression test was used to test for a difference in the percentages between the 2 treatment arms after adjusting for analysis center (country).","D011349; D011350; D014456","Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis",FALSE,265,"logistic_regression",NA,NA,NA,1.66512144952801
"3751","eaca9d85af9b22905fabc2d5d88808a2","NCT02374346",0.041,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Factors Associated With Postoperative Headache","SECONDARY","Association of caffeine consumption and postoperative headache","D006261; D013375","Postoperative Headache in Elective Surgery Patients",FALSE,218,"t-test",NA,NA,NA,1.84747178465323
"3752","eacca442910f88abd7819ff6a502470a","NCT02863198",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Measurement of Uterine Artery Pulsatility Index","PRIMARY",NA,"D007246","Endometrial Injury for Unexplained Infertility",TRUE,120,"t-test",NA,NA,NA,1.63072147479452
"3753","ead1ced08b2ae1f5be20c89787cf67f4","NCT02528188",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 2: \>=50% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,1.62119639165769
"3754","ead61d586e8145562d2d0139df93c651","NCT00406848",0.04,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Laboratory Values - Chloride and Fasting Glucose","SECONDARY",NA,"D003866; D003865","A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients",FALSE,342,"anova",2,NA,NA,2.25833896654624
"3755","ead9172045e7a588ea14a547b7bfc71e","NCT02658149",0.036,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Pain Score at 3 Hours","PRIMARY",NA,"D010003","Psoas Compartment Block Versus Periarticular Local Anesthetic for Total Hip Arthroplasty",FALSE,99,"mann_whitney",NA,NA,NA,1.12886782161459
"3756","eae2fa1d8d9a3198362ecb58ed215574","NCT01251757",0.022,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Adherence to Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs)","PRIMARY","We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline adherence level groups.","D002318","Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies",FALSE,8700,"linear_regression",NA,NA,NA,6.77302713289836
"3757","eaee0eb05c6034fe8408381cfed7a255","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Intention to Reduce","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1753,"linear_regression",NA,NA,NA,6.14051253521365
"3758","eaf5d6dc4a43c904e7d59b98cf4392b6","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Sodium","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1765,"linear_regression",NA,NA,NA,6.1614479472587
"3759","eb062769f3dc86a7fbbf909b0cecdff8","NCT01340027",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Improvement in PPBC","SECONDARY",NA,"D053201; D014570; D001745; D020924","A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder",FALSE,290,"logistic_regression",NA,NA,NA,2.51138465397077
"3760","eb15fcec225099d43d95c3c70293df89","NCT02037776",0.034,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in Global Overall Symptom (GOS)","SECONDARY",NA,"D004415","The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia",FALSE,125,"mann_whitney",NA,NA,NA,1.2029582117709
"3761","eb2ae50c798433b5c9d0e3ccf1eea4b6","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Sodium","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1757,"linear_regression",NA,NA,NA,6.14749892759128
"3762","eb3c747e48bdf474696d7a0a2db81cc9","NCT01070550",0.0069,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Genotype in Modified All-Treated Population","PRIMARY","The statistical analysis is presented for aspartate aminotransferase (AST) ratio at BL (\> 1.5 vs \<=1.5). The logistic regression analysis for mSVR was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,2981,"logistic_regression",NA,NA,NA,1.42165605633074
"3763","eb424c5ad8e8c887b7472e5968898273","NCT04109703",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Pain Rating","PRIMARY","Demographic and clinical characteristics were tabulated by randomization group. The primary outcome was change in pain score from baseline to 30 minutes after treatment ended. Linear regression was used to compare differences in primary outcome between treatment and control groups adjusting for initial pain level. Unadjusted comparisons are also presented. Change in pain scores at each other post baseline time point were similarly analyzed.","D001416; D017116; D059350","High Level Pulsed Heat Versus Low Level Steady Heat in Subjects With Chronic Low Back Pain",TRUE,100,"linear_regression",NA,NA,NA,1.49341131573029
"3764","eb467a24edc8e0c491f73fff358c8b4e","NCT04003142",0.028,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate, and Severe VMS From Baseline to Each Study Week Up to Week 12","SECONDARY","Week 5","D019584","A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2",FALSE,333,"logistic_regression",NA,NA,NA,1.64425416289548
"3765","eb5d8d6e7c6fd5e7cde95baeefb42335","NCT04653454",0.038,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"CGM Recorded Duration of Hyperglycemic Episodes","SECONDARY",NA,"D003920","Continuous Glucose Monitoring in Hospitalized Patients With Diabetes Mellitus",FALSE,101,"mann_whitney",NA,NA,NA,1.19286880324878
"3766","eb662fae38f7af51df1eb0888d338361","NCT04128228",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Frequency of Alcohol Use (Percentage)","SECONDARY",NA,"D000437; D014947; D000428","Neurobiological Responses in Alcoholism and Early Trauma",TRUE,54,"t-test",NA,NA,NA,1.11553228437488
"3767","eb67059c881cf5a889bbe571afacffa0","NCT01972841",0.044,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants for Micturition Frequency Normalization at Weeks 4, 8, 12 and EoT","SECONDARY","Odds ratio from a logistic regression model including treatment group, sex, age group (\<65, \>=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate.","D053201; D014570; D001745","This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",FALSE,1242,"logistic_regression",NA,NA,NA,4.64407079503056
"3768","eb70cd7dd41d484985bec33afec158aa","NCT00216476",0.0446,"Wilcoxon","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Endpoint in Clinical Global Impression Scale (CGI) Score","SECONDARY","Within-group comparison of the change from baseline to endpoint in CGI-S score. The endpoint of the study was based on the LOCF principle.","D012008; D012559; D011618","A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder",FALSE,326,"wilcoxon",NA,NA,NA,2.41762313343987
"3769","eb7e09204615d379d611609b3aca401f","NCT03953508",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Past 30-day Cigarette Smoking Frequency","PRIMARY",NA,NA,"Perceptions of Cigarette Smoking in Young Adults",TRUE,55,"t-test",NA,NA,NA,1.12508606526115
"3770","eb894a8a62b912ff92d1f6fc834a8428","NCT05481216",0.012,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Chronic Obstructive Pulmonary Disease","PRIMARY","Conditional logistic regression models accounting for case-control matching will be used to identify risk factors for advanced immunodeficiency associated with COVID-19. Odds ratio (OR), and the 95% confidence intervals of the OR will be calculated","D000086382; D060085","HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV",FALSE,1492,"logistic_regression",NA,NA,NA,1.64973840138337
"3771","eb90df01705c2f9c79e7db9613a0a184","NCT02649634",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Importance for Change Ratings After the Second Motivational Interview or Attention Control Interview, Week 12","SECONDARY","Importance of Change ratings were analyzed via an independent sample t-test comparing the groups on mean Importance of Change ratings on the 11-point visual analogue scales","D009765; D050177; D015431","Does Motivational Interviewing Improve Behavioral Weight Loss Outcomes for Obesity?",FALSE,129,"t-test",NA,NA,NA,1.68888097915129
"3772","eb93d3b92c620c7413172fd25c66d238","NCT03638258",0.034,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Baseline Worst Itch-Numeric Rating Scale (WI-NRS) Pruritus Score ≥6 Who Experienced a 4-point Reduction","SECONDARY","Difference from vehicle cream at Week 6","D011565","The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis",FALSE,135,"logistic_regression",NA,NA,NA,1.24848704737645
"3773","ebcce881f38b0cabb913e39bbcaab286","NCT02502461",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Sore Throat","PRIMARY",NA,NA,"Tracheal Palpation of Sliding Cuff to Assess Endotracheal Tube Location",FALSE,90,"t-test",NA,NA,NA,1.17868007673095
"3774","ebe32d7b4fb030114e9842cef499cbc9","NCT05127304",0.037,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"COPD and/or Pneumonia-related Health Care Resource Utilization: Pharmacy Fills","PRIMARY",NA,"D029424","A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",FALSE,11316,"linear_regression",NA,NA,NA,12.0850943643871
"3775","ebfcd1ad3450da293359f1ff4559ef80","NCT00495469",0.043,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants Who Were Fasting Plasma Glucose (FPG) Responders at Week 12","SECONDARY","Placebo vs GSK189075 250 mg QD: Responders (\<7.8 mmol/L)","D003920; D003924","Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive",FALSE,66,"logistic_regression",NA,NA,NA,1.08128708938898
"3776","ec00c7a1dcfde6c69781053f8b40c183","NCT03638258",0.038,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' Plus a 2-Grade Improvement From Baseline","SECONDARY","Difference from vehicle cream at Week 6","D011565","The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis",FALSE,218,"logistic_regression",NA,NA,NA,1.73257778918138
"3777","ec0d6c9dc555d1d0944b490e5e091c67","NCT00069823",0.04,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Pulmonary Function: Change in PC20","SECONDARY",NA,"D001249; D008171; D008173","Study of Acid Reflux in Asthma",FALSE,78,"linear_regression",NA,NA,NA,1.10125434205372
"3778","ec1c565de01e47f2e6c9721196aa3e53","NCT02407132",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Change in Probability of Performing Diabetes Self-care Behaviors From Baseline to 12 Months Post-intervention: Check Blood Glucose Daily","SECONDARY","To facilitate interpretation of regression coefficients, estimates obtained in the logit scale (log odds) were transformed into probability scale.","D003920","Family Model of Diabetes Self-Management Education in the Marshallese Community",FALSE,221,"logistic_regression",NA,NA,NA,1.8215390618374
"3779","ec1e51be10e2a67de14044afa2f8cc90","NCT01183013",0.0254,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Occurrence of Cumulative Treat to Target Efficacy Response, of HbA1c Under Treatment of < 7.0% After 30 Weeks of Treatment","SECONDARY","Treatment comparisons are for fixed dose combination versus monotherapy.","D003924","30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks",FALSE,250,"logistic_regression",NA,NA,NA,1.31326965482724
"3780","ec3ec012391f588d9b4b43482570e9f5","NCT00672737",0.05,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Experimental Cold-induced Pain - IGFBP-1","PRIMARY","Beta for IGFBP-1: for every 1-pg/mL increase in its serum level the cold pain threshold will additionally increase by 0.0025 seconds for every 1-mcg/mL increase in the plasma level of remifentanil.","D001049; D012891; D020181","Study of Pain Processing in Subjects Suffering From Obstructive Sleep Apnea",TRUE,48,"linear_regression",NA,NA,NA,1.05642048349345
"3781","ec488e4cf1e698148c6607889f973717","NCT01340027",0.048,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Improvement in PPBC","SECONDARY",NA,"D053201; D014570; D001745; D020924","A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder",FALSE,151,"logistic_regression",NA,NA,NA,1.76225447529525
"3782","ec4e15a00bf5529f4bf1f92148bbf464","NCT04452318",0.046,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Cohort B: Percentage of Participants With Asymptomatic Infection Who Develop Signs and Symptoms (CDC Definition) Within 14 Days of a Positive RT-qPCR at Baseline or During the EAP","SECONDARY",NA,"D000086382","COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay",FALSE,204,"logistic_regression",NA,NA,NA,1.9699764251461
"3783","ec7b328320c9b96c09c7d3c71ab3026a","NCT01441245",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Evaluation of Renal Function in Terms of GFR Values at Discharge","PRIMARY","Continuous variables are expressed as mean ± standard deviation (SD) and compared with t test for independent groups. p values \<0.05 were considered significant","D006333","Loop Diuretics Administration and Acute Heart Failure",FALSE,57,"t-test",NA,NA,NA,1.1439569152679
"3784","ec8d7f550791b94ea114958ddb97a45b","NCT01639443",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Advanced Adenoma Detection/Cecal Intubation Rates","SECONDARY","We calculated this measure on the patient level, but were hampered by a large sampling ratio (more than 50:1). Our null hypothesis is that the number of polyps detected will not differ between groups. We are powered to detect a 0.25 SD difference in polyp count per patient (Type I error rate = 5%; Power = 80%).","D003110","Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy",FALSE,4897,"t-test",NA,NA,NA,10.2558865801173
"3785","ec945fcfe402a52c8663647a69363edf","NCT00261443",0.038,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Baseline and Adjusted Mean Change From Baseline in the CGI-BP Severity of Illness (Overall) Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 40 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,2.11179944378023
"3786","eca193d4e389a5a14b58f376a962dfdd","NCT05481216",0.009,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"HIV Viral Load","PRIMARY","Conditional logistic regression models accounting for case-control matching will be used to identify risk factors for advanced immunodeficiency associated with COVID-19.","D000086382; D060085","HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV",FALSE,1492,"logistic_regression",NA,NA,NA,1.277377875623
"3787","ecad463f7d2c012a697d150c8a22a243","NCT02548650",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Maximal Platelet Aggregation in DM","PRIMARY","The primary end point of our study was the comparison of CAT-induced MPA measured by LTA between triple (vorapaxar plus DAPT) and dual (vorapaxar plus clopidogrel) therapy. We hypothesized that dual therapy would be non-inferior to triple therapy after 30±5 days of treatment","D009203; D058729; D016491; D003920; D007238","Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus",FALSE,60,"anova",2,NA,NA,1.17169922891753
"3788","ecee074a0bdde3f642a748291c90cc6d","NCT01194830",0.0352,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Occurrence of Absolute Efficacy Response (HbA1c < 6.5%) After 24 Weeks","SECONDARY",NA,"D003920; D003924","Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study",FALSE,208,"logistic_regression",NA,NA,NA,1.5867813300434
"3789","ecf450d591cccd8d729ee965fed0dc28","NCT02693665",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Satisfaction Questionnaire","OTHER_PRE_SPECIFIED","Adolescent positive score comparing intervention with TAU.","D003643","Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer",TRUE,234,"t-test",NA,NA,NA,2.25949060683958
"3790","ecf7dc66105ade3464ced1dbd6414baa","NCT02465567",0.0103,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Subjects Achieving a MCID of 4 Units or More in SGRQ Total Score","SECONDARY",NA,NA,"Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)",FALSE,4224,"logistic_regression",NA,NA,NA,2.4203635306986
"3791","ecff6093c53c89ac5dc5e7ae33222fd3","NCT03192176",0.0424,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 7","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.21111299172055
"3792","ed01abdfe8ad30e6c843b68b7d9551a8","NCT00390949",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Self-reported Genital Ulcers","SECONDARY",NA,"D015658","Scientific Evaluation of Peer Education and STD Treatment to Reduce the Spread of HIV in Zimbabwe",TRUE,4932,"logistic_regression",NA,NA,NA,10.2924432826191
"3793","ed2e74cfc3a1c86882b6fb868dab6365","NCT03192176",0.0495,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 2 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 6","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,83,"logistic_regression",NA,NA,NA,1.35459887642502
"3794","ed3cd1a645c7ed1135b960e94e99326e","NCT00087490",0.022,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Duration of Hospital Stay for PP Population","SECONDARY","Null hypothesis was that there was no difference in the length of hospital stay between the treatment groups.","D007239; D003141; D013203; D018461","Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)",FALSE,439,"mann_whitney",NA,NA,NA,1.53009817005066
"3795","ed60d1b8e2ea837836e234eadcb9e5d1","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Specific Perceived Environmental Risk","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1734,"linear_regression",NA,NA,NA,6.10721803093741
"3796","ed64820be4c5eaa08c52e7725394d371","NCT04428411",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Month 12","PRIMARY",NA,"D011565","Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).",TRUE,422,"t-test",NA,NA,NA,3.02322680112393
"3797","ed6564e46be7ff4e44b355b758ac872f","NCT03676465",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Family Communication Inventory Questionnaire","PRIMARY",NA,"D003920; D003922; D002908","CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management",FALSE,43,"t-test",NA,NA,NA,1.00454908915455
"3798","ed695fc0007222504c117a3930a61e18","NCT00507819",0.05,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Mean Respiratory Rate (Breaths/Min) at 6 Weeks","SECONDARY",NA,"D018636; D018785","Sildenafil After the Fontan Operation",FALSE,55,"linear_regression",NA,NA,NA,1.12508606526115
"3799","ed788d59cfc7c142355752e53263449e","NCT01620528",0.031,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Responders at Month 2 Based on Daily Assessment of NMPP","SECONDARY",NA,"D004715","A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain",FALSE,621,"logistic_regression",NA,NA,NA,2.44227641540333
"3800","ed8330b1809a34ec9e24b62fc54c7281","NCT01475461",0.0322,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Fasting Plasma Glucose at Week 1, 2, 4, 8, 12 and 14","SECONDARY","Week 8: Treatment difference and 80% CI were based on LS mean. MMRM analysis was performed with treatment, time and treatment-by-time interaction as fixed effects, baseline as the covariate, time was repeated for participant.","D003920; D003924","Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes",FALSE,112,"t-test",NA,NA,NA,1.08961262493301
"3801","ed86bb538227beee6149df0a510829db","NCT00673387",0.0464,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Least Squares (LS) Mean Absolute Change From Baseline to Week 28 in Percent of Body Fat - Evaluable Population","SECONDARY","Based on a general linear model general linear model that includes baseline value and factors for treatment group, sex, baseline BMI category (\<35 kg/m2, 35 to \<40 kg/m2, ≥40 kg/m2).","D050177; D001835","Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects",FALSE,76,"t-test",NA,NA,NA,1.23116234955249
"3802","ed98b4aae3973358dc79cfda6cac02f9","NCT01317160",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Venous Thromboembolic Events (VTE)","PRIMARY",NA,"D014946; D013530; D013927; D013923; D054556; D020246; D012421; D000072836","Compression Treatment Effects on Complications and Healing of Achilles Tendon Rupture",TRUE,138,"logistic_regression",NA,NA,NA,1.74510680710624
"3803","ed9e842c26654476b97b9ad24388a7dc","NCT03480022",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Total Cholesterol Levels","SECONDARY","Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect","D011085; D011236; D013577; D001835","Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS",FALSE,67,"anova",2,NA,NA,1.23402909436682
"3804","edb543a62f95019010341e936cea0d11","NCT02528253",0.0238,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 16, \>=70%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,810,"logistic_regression",NA,NA,NA,2.21908895427767
"3805","eddc5865352f2f55d10ead74b7213f52","NCT03891329",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Cor Family-related Serious Adverse Device Effect (SADE)-Free Rate Until 3-month Follow-up","PRIMARY","Serious Adverse Device Effects (SADE) possibly or securely related to the Cor Family devices until the 3- month follow-up are counted for this primary endpoint.

The following hypothesis has been defined:

Ho: SADE-free rate through 3 months post-implant ≤ 90.0% Ha: SADE-free rate through 3 months post-implant \> 90.0%","D013610","Master Study of the Acticor/Rivacor ICDs/CRT-Ds and the Plexa ProMRI S DX Lead",FALSE,123,"t-test",NA,NA,NA,1.65033525744316
"3806","ede69cb7de9b4c374c95c17b7863429d","NCT00384085",0.0313,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - ITT Population With All Sites) (Sensitivity Analysis)","PRIMARY",NA,"D003924","Insulin Glargine ""All to Target"" Trial",FALSE,392,"logistic_regression",NA,NA,NA,1.96075260292449
"3807","edfb06c28a534e40a0f74facb4857fe7","NCT00261443",0.046,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Mean Baseline and Adjusted Mean Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 32 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,2.48123941518757
"3808","ee17a65443fb3364fe8eff2e768cf935","NCT03258645",0.016,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Age of Patients According to Dabigatran Initiation Time Period","SECONDARY","Multivariate linear regression with the continuous dependent variable of time-to-initiation for dabigatran in days and independent variable of age, Diastolic blood pressure (DBP), CHA2DS2-VASc, HAS-BLED, and History/Predisposition To Bleeding at index date was applied.","D001281","This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke",FALSE,1240,"linear_regression",NA,NA,NA,1.93931757253316
"3809","ee2cd0c97be58743b64440d35fac8dd4","NCT00937326",0.034,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in PPG and PPI Levels at Day 28","SECONDARY","Placebo versus SRT2104 2.0 g/day for change from Baseline in PPI at 30 minutes.","D003924","Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects",FALSE,91,"anova",2,NA,NA,1.03331692544236
"3810","ee2e849701029a5ad12142128f6ab8f4","NCT02730260",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Smoking Abstinence for 7 Days at Last Contact","PRIMARY","Odds ratio based on the parameter estimate for the variable, IncomeAboveMedian (0=false, 1=true), from the logistic regression model representing the a priori hypothesis, which specified income, race, and intervention as independent and interacting variables, and smoking cessation at last contact as the dependent variable. An unbalanced variable, PriorQuit (0-=none in the past year, 1=at least one in the past year) was added to the a priori model.",NA,"Worksite Phone Counseling for Smoking Cessation",TRUE,361,"logistic_regression",NA,NA,NA,1.81541741349544
"3811","ee45db9fec10c3c509be85c11d420db5","NCT00261443",0.017,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Baseline and Adjusted Mean Change From Baseline in Clinical Global Impression Scale for Bipolar Disorder (CGI-BP) Severity of Illness Score (Mania) Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 36 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,1.0554830773903
"3812","ee47cc17d2cf3200dd15d8b5a853dae7","NCT00402987",0.023,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Subjects With >= 50% Total Pain Relief (TOTPAR) at 6 Hours Post-First Dose","OTHER_PRE_SPECIFIED",NA,"D010612","Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat",FALSE,179,"logistic_regression",NA,NA,NA,1.02416486228569
"3813","ee5ccfd7ed00528c53d5cec7ca5a2786","NCT00442546",0.0359,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Interference With Relations With People as Measured by the m-BPI-sf","SECONDARY","Discharge","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,166,"anova",2,NA,NA,1.44531640441444
"3814","ee6498a5ea4917cb77691c8baea013a2","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Urinary Daidzein","SECONDARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,102,"anova",2,NA,NA,1.50770356720122
"3815","ee8c3ff00f4581656191bcbcdab2cb70","NCT01437995",0.027,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,1,"Change in Pulmonary Function: FEV1 and FVC","SECONDARY","Comparing change in pre-bronchodilator FEV1","D001249","Long-acting Beta Agonist Step Down Study",FALSE,297,"kruskal_wallis",2,NA,NA,1.50635714270425
"3816","eeae5879375698692df5928627e39acb","NCT00416572",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Depressive Symptoms (Measured With an Abbreviated 10-item CES-D) at Baseline, Post-intervention (4-months Post-intervention) and Final Follow-up (13-months Post-intervention).","PRIMARY","Comparison between nutrition education intervention and the control condition at 4 months post-intervention. The full regression model contained 2 dummy-coded variables (education intervention vs. control condition and nutrition education intervention vs. control condition), and the baseline measure of the outcome.","D001943","Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer",FALSE,154,"linear_regression",NA,NA,NA,1.84083479148392
"3817","eec7a54cb28e2815a280348a1f9be879","NCT04196777",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Cases Who Were Re-admitted to the Hospital or Presented to an Emergency Department or an Urgent Care Clinic","SECONDARY","To model this secondary outcome across all sites, we used a logistic regression model and a set of four explanatory variables: time, a binary indicator for an observation occurring within the intervention phase, an interaction term between these two main effects (time and intervention), and a binary indicator for the primary outcome.","D014570; D064420","Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists",TRUE,1797,"logistic_regression",NA,NA,NA,1.53931074268959
"3818","eedf0b4bcc7acf9c5eaed66926a2d123","NCT01708902",0.0474,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG","SECONDARY","Comparison of 'APG: Linagliptin 2.5mg / Metformin 1000mg BID' / 'APG: Linagliptin 5mg QD'.

The logistic regression includes treatment and continuous baseline HbA1c.","D003924","Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients",FALSE,138,"logistic_regression",NA,NA,NA,1.66913176044797
"3819","eef2b1ff167b5d19d7551521a4b10386","NCT00270998",0.0492,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"""Much Better"" or ""Very Much Better"" on PGI-I at 12 Months","SECONDARY",NA,"D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",TRUE,295,"logistic_regression",NA,NA,NA,2.49873946067788
"3820","ef0747a783e8547614ac154ef5809448","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Burger Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1746,"linear_regression",NA,NA,NA,6.1282671837603
"3821","ef0baa89f585d6e30d0e6f8d5950c7d2","NCT01881373",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Change in Prevalence of Overweight and Obesity Using Body Mass Index Percentile for Age and Sex","PRIMARY",NA,"D000052; D009765; D056128","Children's Healthy Living Community Randomized Trial",FALSE,5645,"logistic_regression",NA,NA,NA,5.02183234305821
"3822","ef260f3255705d8e930c4d784e609ecb","NCT02867709",0.0129,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose","SECONDARY",NA,"D008881","Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine",FALSE,920,"logistic_regression",NA,NA,NA,1.38286973265799
"3823","ef32df42461f4233ed24564185d37aef","NCT01434680",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Geometric Mean hSBA Titers Against N Meningitidis Serogroup C 28 Days After Vaccination","SECONDARY","The secondary objective was to be assessed only if both primary objectives were met. Because of this, no adjustment for multiplicity was required. MenC-CRM liquid would be declared equivalent to MenC-CRM ROS if the two-sided 95% CI for the ratio of the hSBA GMTs at approximately 28 days following vaccination was within the equivalence interval (0.5, 2.0).","D008589; D008585; D008581","Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers",TRUE,542,"anova",2,NA,NA,3.42276043954353
"3824","ef41ee912d53329cb855839bd5dad8f1","NCT03875664",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Number of Patients With Adverse Events","SECONDARY",NA,"D010149","Extended Release Local Anesthetic for Postsurgical Pain After Posterior Colporrhaphy and Perineorrhaphy",TRUE,72,"mann_whitney",NA,NA,NA,1.27670232702116
"3825","ef445b5268db07b35353ddb86ca0782c","NCT00718549",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With CR or PR Assessed According to the NCI Revised Guidelines for the Diagnosis and Treatment of CLL According to Clinical and Biochemical Factors at Week 29","SECONDARY","Univariate Comparison: ZAP-70 Expression Negative versus Positive","D007938; D007945; D015451","A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)",FALSE,97,"logistic_regression",NA,NA,NA,1.2215919295291
"3826","ef4eab6ecc1b024171082170efdefcbd","NCT04079933",0.0333,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Summary Statistics of Percent Change From Baseline for Carboxyhemoglobin (%) (Per-Protocol Population)","SECONDARY","Null hypothesis = Test and Control groups will have equivalent levels of percent change from baseline to end of study in carboxyhemoglobin; Alternate hypothesis = Test and Control groups will NOT have equivalent levels of percent change from baseline to end of study in carboxyhemoglobin",NA,"A Study to Evaluate Changes in Smokers Using An Oral Tobacco-Derived Nicotine Product",FALSE,142,"t-test",NA,NA,NA,1.25699117653855
"3827","ef66fa7f97bc1c158157cc3d5bc03724","NCT02219932",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of Participants Achieving a Mean Improvement From Baseline of ≥ 15% in Timed Up and Go (TUG) Speed Over 24 Weeks","SECONDARY","Based on logistic regression, adjusting for baseline TUG speed, screening EDSS score and prior aminopyridine. Missing data were handled using multiple imputation.","D009103; D012598","Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis",FALSE,633,"logistic_regression",NA,NA,NA,2.39721802252388
"3828","ef761b880070b230949f59256b1af9ec","NCT03965754",0.005,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Enrollment (7 Days)","PRIMARY","We conducted a logistic regression with the two experimental conditions as dummy variables with the standard email as the reference group (among employees who previously enrolled in the program).",NA,"Assessing the Impact of myHealth Rewards Enrollment Emails",FALSE,2850,"logistic_regression",NA,NA,NA,1.03997867274304
"3829","ef77698f8b38570921ac0ca748da0c1b","NCT00120627",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Clinician Administered Posttraumatic Stress Disorder (PTSD) Scale (CAPS) From DSM-IVTR","PRIMARY","2 group (treatment vs. control) by 2 time (pre-intervention and post-intervention) one-way ANOVA","D013313","Mantram Repetition to Manage PTSD in Veterans",TRUE,146,"anova",2,NA,NA,1.79360862376457
"3830","ef778567788bf494f2fda69ff6561311","NCT00443872",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Unified Parkinson's Disease Rating Scale (UPDRS) Scores","SECONDARY",NA,"D010300","Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists",TRUE,60,"mann_whitney",NA,NA,NA,1.17169922891753
"3831","ef9cf0a167c277c832cbb26ecff7b7ee","NCT00176423",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Overall Cognitive Improvement Z-score","PRIMARY",NA,"D012559; D060825; D011618","Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia",TRUE,73,"mann_whitney",NA,NA,NA,1.28506804726186
"3832","ef9e177142d510cf7dfb31c679ef785e","NCT03556761",0.03,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Persistently Elevated Blood Pressures 7 Days Postpartum","PRIMARY",NA,"D046110; D006973","Furosemide for Accelerated Recovery of Blood Pressure Postpartum",FALSE,331,"linear_regression",NA,NA,NA,1.73937664451004
"3833","efa8badbb4bab9ef8abb994aee85542b","NCT01423812",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change in Total Cholesterol From Baseline to 48 Weeks","SECONDARY","p value",NA,"DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects",TRUE,60,"t-test",NA,NA,NA,1.17169922891753
"3834","efac1f8a1d1e9dbff5b906c9c816a20d","NCT02458365",0.013,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants Perpetrating Physical Peer Violence During Follow-up","OTHER_PRE_SPECIFIED",NA,"D058445","A Stage-Based Expert System for Teen Dating Violence Prevention",FALSE,681,"logistic_regression",NA,NA,NA,1.19932110551438
"3835","efb90b043c1d557e0d7a6ffbc8848432","NCT02209181",0.035,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Intensity Difference From Baseline (PID) Scores at 1 Hour Post Dose","SECONDARY","The null hypothesis was no difference between groups. The alternative hypothesis was a difference between groups.","D014098","A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine",FALSE,136,"anova",2,NA,NA,1.28413126179354
"3836","efbc599a0038628fb1746f2c0952839b","NCT00127062",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Spirometry, Percentage Change in FEV1 From Baseline","PRIMARY",NA,"D001249","Health Effects of Diesel Exhaust in Asthmatic Patients: A Real-world Study in a London Street",TRUE,58,"t-test",NA,NA,NA,1.15327776573523
"3837","efc8c63c45af4a4614d82031c9345409","NCT04833777",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Post-operative Pain","PRIMARY",NA,"D002349","Does a Different Local Anesthetic Improve Pain After Carpal Tunnel Release?",TRUE,139,"mann_whitney",NA,NA,NA,1.75124288073831
"3838","efd06c093b3c67451e6e9ef96ad7d7c4","NCT02820051",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient Comfort Assessed Using a Satisfaction Questionnaire","SECONDARY",NA,NA,"Non-anesthesiologist-administered Propofol During the Flexible Bronchoscopy",TRUE,91,"t-test",NA,NA,NA,1.42733241699876
"3839","efde5b9bf4c91875d49aaa088dc2e9d1","NCT04332614",0.0055,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Email Opened: Control vs. Less-is-better vs. Social Proof vs. Endowment","SECONDARY",NA,NA,"Email Campaign to Increase Uptake of myGeisinger",FALSE,4191,"logistic_regression",NA,NA,NA,1.37389590849306
"3840","efe727ec1e0087b04b9bdb30a07fb8fd","NCT02528253",0.0342,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 12, \>=50%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,810,"logistic_regression",NA,NA,NA,3.03116408302206
"3841","eff74bd3a9066e7ef35d066747be27d2","NCT00810199",0.0245,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Disease Activity Score 28 (DAS28) Remission","SECONDARY",NA,"D001168; D001172","A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment",FALSE,553,"logistic_regression",NA,NA,NA,1.88289539113282
"3842","f00499794822949d6feca1df0015ca3d","NCT02709486",0.0212,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >=30%, >=50%, >=70% and >=90% Response","SECONDARY","Week 16, \>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,563,"logistic_regression",NA,NA,NA,1.67567818324116
"3843","f00ec4a4843f37702ebb7167e63a35c6","NCT02634983",0.0486,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Regional Ventilated Lung Volume","SECONDARY","Lung, Left Upper Lobe Ventilation","D008173; D029424","QVA Mechanistic Efficacy Study (Receptor Effects, Etc)",FALSE,59,"t-test",NA,NA,NA,1.13560933554231
"3844","f030eb9d2f545f392247f5238a79eb9b","NCT03953508",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Cigarettes Per Day","SECONDARY",NA,NA,"Perceptions of Cigarette Smoking in Young Adults",FALSE,124,"t-test",NA,NA,NA,1.6568216953838
"3845","f0376e5ed2a700cb72064e122cc9c3b7","NCT00536471",0.022,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Chloride, Urea Nitrogen, Cholesterol, Sodium","SECONDARY",NA,"D003866; D003863; D003865","A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients",FALSE,250,"anova",2,NA,NA,1.15989504317983
"3846","f0468f579c5ad2c52fd840d5b57acf50","NCT02123797",0.0263,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Overall Concordance Rate Using a Hierarchy of Initial Conference Recommendations, MD vs SC (Conference)","PRIMARY",NA,NA,"Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology",FALSE,252,"logistic_regression",NA,NA,NA,1.35854637006175
"3847","f0887a40af1e17158e2e8f6453e7bb52","NCT03952338",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Difference Between Intervention and Control Groups in the Odds of Experiencing Household Food Insecurity at 16 Weeks Post-intervention (26-31 Weeks)","SECONDARY",NA,NA,"Impact of BC Farmers' Market Nutrition Coupon Program on Diet Quality and Psychosocial Well-being of Low-income Adults",FALSE,285,"logistic_regression",NA,NA,NA,2.0641160951678
"3848","f0922063121edb2ae69c9783782ae61f","NCT02449044",0.0412,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Mean Change From Baseline in SF-12 (Health Survey) Physical Component Summary (PCS)","SECONDARY","Statistical analysis at Week 106","D007010","International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia",FALSE,111,"t-test",NA,NA,NA,1.33596514976513
"3849","f0b5ac6ebf79b32c483b766c57449a8c","NCT04267614",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Clinical Disease Activity Index (CDAI) Score at Month 12","PRIMARY",NA,"D001168; D001172","This Study is to Investigate the Effect of Etanercept in Early Versus Delayed Referral for Management of Rheumatoid Arthritis Patients.",TRUE,979,"t-test",NA,NA,NA,4.59283895163754
"3850","f0b66d0fe0c54de560ae236a44e84ab0","NCT01945034",0.032,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","SECONDARY","At Rest Day 4(AM): The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,152,"anova",2,NA,NA,1.25585729060319
"3851","f0b932ae583c284378009378be4a2e1d","NCT02347124",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"7 Day Point Prevalent Smoking Abstinence (PPA)","SECONDARY",NA,"D009059","Promoting Oral Health Among Smokers Randomized Trial",FALSE,571,"logistic_regression",NA,NA,NA,2.91085173252245
"3852","f0c2815ab0226f1c156310b7eba4e849","NCT02217475",0.0388,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage and Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 1","SECONDARY",NA,"D005234; D008103; D065626","Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis",FALSE,289,"logistic_regression",NA,NA,NA,2.02546402048968
"3853","f0c422a7059680d21a23cfcfb628ef50","NCT00408876",0.043,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Week 13 Endpoint in Beck Depression Inventory-II Total Score","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,222,"t-test",NA,NA,NA,1.94033668288512
"3854","f0c7bd1e773976ed6b19018781f2e506","NCT00707447",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Emotional Well-being/ Depression (CES-D)","SECONDARY",NA,"D003920","Evaluation of a Primary Type 2 Diabetes Prevention Programme",TRUE,166,"t-test",NA,NA,NA,1.90948799930043
"3855","f0cdd967504c2e711317eaea36db999b","NCT04242446",0.041,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Worst Skin Pain Response at Week 16","SECONDARY",NA,"D017497; D016575","A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa",FALSE,236,"logistic_regression",NA,NA,NA,1.92082723734999
"3856","f0d6b68a08217c379b3891c953868806","NCT01203046",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,1,0,"Other Complications","PRIMARY",NA,"D013530; D000007","Early Short-term Antibiotic Therapy in Penetrating Abdominal Trauma, 3 vs 7 Days",TRUE,56,"logistic_regression",NA,NA,NA,1.13456029943022
"3857","f0dc8183087230b092d9df7db7184dcb","NCT01066793",0.0421,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Modified Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population","PRIMARY","The statistical analysis is presented for on-treatment response (cEVR vs No RVR/EVR). The logistic regression analysis for mSVR was performed for association between on-treatment response and baseline factors available in at least 90% of participants, in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",FALSE,427,"logistic_regression",NA,NA,NA,2.63172559844598
"3858","f0f302d9a17cdd1fe6870b7e76b5ed11","NCT05037513",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Initiating PrEP","PRIMARY",NA,NA,"Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky",TRUE,77,"logistic_regression",NA,NA,NA,1.31800316623017
"3859","f0fca8972c8f339f7de0dded5dc4a041","NCT05170841",0.031,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Total Pain Relief (TOTPAR) at 6h After the First Dose - Single Dose Phase - Dexketoprofen/Tramadol vs Placebo","SECONDARY",NA,"D001416; D017116","Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain",FALSE,204,"t-test",NA,NA,NA,1.41055464310129
"3860","f1028449e2132d06c430f3a85c8256d2","NCT02528188",0.0135,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 16: \>=50% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1989,"logistic_regression",NA,NA,NA,2.11285061597202
"3861","f10b01ec7cc15429ace2988983957c4a","NCT01706952",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"To Estimate the Change in Bleeding Category (Surgical Field Improvement) as Measured on a Six-point Scale, Measured From 0 (Best Case) to 5 (Worst Case).","PRIMARY","Data analysis was performed using SPSS version 13 for Windows (SPSS Inc, Chicago, IL). A power study was per formed with a power of 80% and a clinically significant difference in bleeding between the sides of 20% with a significance level of 5% (p \< 0.05).","D012852","Comparison of Topical Vasoconstriction in Endoscopic Sinus Surgery",FALSE,74,"t-test",NA,NA,NA,1.2933799900503
"3862","f114dc8a3d3cbe9070189e6708d23e69","NCT01421342",0.043,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Rate of Protocol Response Measured as a Change in Clinical Global Impression (CGI) - Improvement Scale","SECONDARY",NA,"D003863; D003866; D003865","VA Augmentation and Switching Treatments for Improving Depression Outcomes",FALSE,1011,"logistic_regression",NA,NA,NA,4.11102326552003
"3863","f124515849212591317018b4ab9e7e93","NCT03418701",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Weight Loss","PRIMARY",NA,"D015431","Health-Smart for Weight Loss at UF Jax Clinics",TRUE,356,"t-test",NA,NA,NA,2.77911147251385
"3864","f141d6596649f470cd74bdc3ea06ea89","NCT02528253",0.0332,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 4, \>=30%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1010,"logistic_regression",NA,NA,NA,3.29821070255138
"3865","f1524174056d0ab3f1e8e38074eb58e5","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Nighttime Brachial Diastolic Pressure","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"3866","f172e528573f1de8a17a7c0397d2af5c","NCT02732600",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Average Total Number of Services Provided-Adjusted (First Year Only and Across Both Years)","SECONDARY",NA,"D001523","Evaluation of Peer Specialists on VA PACTs",FALSE,899,"t-test",NA,NA,NA,2.00913494561587
"3867","f173b07d83b2669eb85a4e001af3327c","NCT03247556",0.0349,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Effect of SPN-812 Assessed by 50% Responder Rate Per the Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5)","SECONDARY",NA,NA,"Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD",FALSE,195,"logistic_regression",NA,NA,NA,1.5263506492859
"3868","f1782d6cc97570c536554eb146993ea5","NCT00487240",0.023,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Insulin Dose Per Body Weight (Total and By Component [Basal and Bolus])","SECONDARY",NA,"D003920; D003922","Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes",FALSE,381,"anova",2,NA,NA,1.48279667011391
"3869","f18b7463db43b21371b7556178131b75","NCT02528253",0.0101,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 2, \>=70%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,811,"logistic_regression",NA,NA,NA,1.04563768369256
"3870","f1a74a6ef0baa08eb4733331b04b3453","NCT02867709",0.0129,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose","PRIMARY",NA,"D008881","Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine",FALSE,920,"logistic_regression",NA,NA,NA,1.38286973265799
"3871","f1ad7d989ee9baec1c14ce0ffc518fd3","NCT01939002",0.0391,"One-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Summary of FLS-VAS During the 48 Weeks of Treatment Compared to 4-Week Run-In Period: Satisfaction With FLS Treatment","SECONDARY",NA,"D009103; D012598","Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)",FALSE,194,"t-test",NA,NA,NA,1.67638675513345
"3872","f1bf5d8bf439a7a2d9ffa016d0afb7dd","NCT03718832",0.0222222,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Number of Outpatient Visits Claimed by Insurance","SECONDARY","Adjusted mean difference for full controls, 6 months after trial enrollment",NA,"Fresh Food Farmacy: A Randomized Controlled Trial",FALSE,465,"linear_regression",NA,NA,NA,1.58802149369903
"3873","f1e6b8f5acf543df531ecdc58f3e094e","NCT04949165",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Haemoglobin Level","PRIMARY",NA,"D018798; D000090463","Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study",FALSE,130,"t-test",NA,NA,NA,1.69522022135929
"3874","f1ff3997f29ae22ffefa9a5f26a2f2fb","NCT00635492",0.0138,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Higher Value of Low Density Lipoprotein Cholesterol Associated With Treatment Choice at Baseline","SECONDARY","LDL cholesterol - 1 mmol/L higher at baseline","D003920; D003924","CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy",FALSE,2492,"logistic_regression",NA,NA,NA,2.41056702540571
"3875","f21d4b0b89a83d729bc69e2d5d317ae2","NCT01098747",0.04,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Relief Rating (PRR)","SECONDARY","7 hours: Treatment difference \[Ibuprofen sodium - Ibuprofen (Advil + Motrin IB)\] and corresponding 95% CI were calculated based on LS mean from the ANOVA model.","D014098","Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain",FALSE,268,"anova",2,NA,NA,2.00254802853272
"3876","f226b7010147c2cddaa019739e61034e","NCT00485173",0.017,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Arm Pain Success Rate","SECONDARY","Superiority analysis was performed if non-inferiority was demonstrated.","D055959","INFUSE® Bone Graft/ PEEK Interbody Spacer/ Anterior Cervical Plate Pivotal Clinical Trial",FALSE,588,"logistic_regression",NA,NA,NA,1.4120187588499
"3877","f246130fbff6389873d542c4eb6a1cb8","NCT00567398",0.03,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline of Metabolic Control Determined by Lipoproteins at Month 3 and 6","SECONDARY","Estimate of Least Square Means Comparing Treatment Groups for Apo B-Month 6",NA,"IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients",FALSE,239,"anova",2,NA,NA,1.4820669901068
"3878","f2546fc21ba9cf774af44d5a6a294fa6","NCT00245219",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Mental Health (as Measured With the SF-36) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the peer support condition and the control condition at Time 2. The full regression model included 2 dummy coded variables, 1 contrasting the education and control condition, and 1 contrasting the peer support and control condition. The baseline measure of the outcome variable was included, in order to examine changes in the outcomes over time. This model tested the main effects of the conditions among patients with early stage cancer, late stage patients were excluded.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"linear_regression",NA,NA,NA,1.79957957739554
"3879","f26f7a89d977f077fa208f7dcd1aa91d","NCT03468868",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Quality of Life in Neurological Disorders (Neuro-QOL) Survey","SECONDARY","NeuroQOL Lower Extremity Function Domain","D009103; D012598","Comparative Effectiveness Study Telerehab Versus Conventional",FALSE,379,"t-test",NA,NA,NA,1.30991282530445
"3880","f279ca2a341e3235d8ce8feacb63d36e","NCT01283139",0.038,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Achieving a Positive Response in SRI (4) in 4-Gene Interferon Test High Participants","PRIMARY",NA,"D008180","A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus",FALSE,175,"logistic_regression",NA,NA,NA,1.55609887158017
"3881","f29b5cd35aed5a81f17c4d6f69422d87","NCT01056718",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Peak Stress Diastolic BP","SECONDARY","Nebivolol treatment group refers to 50 patients that completed 10 weeks of open label nebivolol treatment. Results were compared using paired T-tests in a pre - post study design before and after 10 weeks of his/her treatment. Each subject served as own control.","D006973; D054160","Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function",TRUE,50,"t-test",NA,NA,NA,1.07648023860356
"3882","f2a37ed88e809d5b68df933ce3d857ba","NCT04833777",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Post-operative Pain","PRIMARY",NA,"D002349","Does a Different Local Anesthetic Improve Pain After Carpal Tunnel Release?",TRUE,139,"mann_whitney",NA,NA,NA,1.75124288073831
"3883","f2a5712432ee10dcfcc52692e6b2c579","NCT00962039",0.046,"Two-sample t-test","INTERVENTIONAL",0,0,1,1,0,"Children's Global Assessment Scale (C-GAS)","SECONDARY",NA,"D015746; D001008","Anxiety and Recurrent Abdominal Pain in Children",FALSE,81,"t-test",NA,NA,NA,1.25986565189607
"3884","f2d67e708b88ce8e935774ce6e9d09f9","NCT02306122",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Probability of Resolution of Nonadherence Within 30 Days","PRIMARY",NA,"D006937","Pharmacy Home Adherence Reporting and Monitoring Outcomes Study",TRUE,956,"logistic_regression",NA,NA,NA,1.12457005606209
"3885","f2e870505ba822d92b35758c343f99d1","NCT01052545",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Patient Level Analysis of Inappropriate Antibiotic Use","SECONDARY",NA,"D001437","Asymptomatic Bacteriuria Guideline Implementation Study",TRUE,1598,"logistic_regression",NA,NA,NA,5.8633822399763
"3886","f2eb09a69d5d34d4156ec4afef642cb1","NCT02986958",0.046,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Ratio of Psychosocial and Socio-emotional Statements Relative to Biomedical Talk and Orientation Statements (Patient-Centered Communication)","PRIMARY",NA,"D060825","Involving Family to Improve Communication in Primary Care",FALSE,93,"t-test",NA,NA,NA,1.34569275143357
"3887","f2ef3da8263c049ec5568dc3106c8762","NCT03235050",0.032,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Achieving Weight Loss of ≥5% and ≥10%","SECONDARY","weight loss \>=10% at Week 54","D003920; D050177; D003924","A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes",FALSE,368,"logistic_regression",NA,NA,NA,1.93680744635688
"3888","f30467c02ba9917738959841cab312e4","NCT00245219",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Depressive Symptoms (as Measured With the CES-D) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the peer support condition and control condition at Time 2, among both late and early stage patients. The full regression model consisted of 3 steps: The 1st step contained the baseline measure of the dependent variable. The 2nd step contained two dummy coded variables contrasting each condition with control. The 3rd step contained the interaction between the peer support condition and cancer stage. Patients in the education condition were excluded from this analysis.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"logistic_regression",NA,NA,NA,1.79957957739554
"3889","f317ed14510333e5f066d36d42ff8175","NCT05493787",0.003,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Number of Patients Who Self-scheduled a Flu Shot","PRIMARY","Null hypothesis: Flu shot self-scheduling does not differ between those sent a Protect Yourself - Rare message and those not sent a message (i.e., those in the Passive Control group); Alternative hypothesis: Sending a Protect Yourself - Rare Message increases self-scheduling compared with sending no message. Analysis combines across November and December send dates.",NA,"Nudging Flu Vaccination by Making it Easy for Patients to Schedule a Flu Shot",FALSE,46468,"linear_regression",NA,NA,NA,2.63694266266651
"3890","f329302dcb3cd12994ea1b1915557b89","NCT02323204",0.0325,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Peer Relationship Problems (SDQ Subscale) Through the First and Last Survey Administered Post-Baseline","PRIMARY","A Generalized Linear Mixed Model (GLMM) with log link and gamma distribution was fit to five imputed data sets. Obtained estimates and standard errors were adjusted accordingly.

A comparison of intervention efficacy was made through the intervention-time interaction effect included in the model. Statistical significance of the interaction effect is indicative of a difference in effect between interventions over time.","D014947; D000067073","PCORI-1306-02918 Evaluation of Parent-based Programs to Support Children After Traumatic Injury",FALSE,247,"t-test",NA,NA,NA,1.61282274641117
"3891","f35db23e840ff4bb5555922a5f9d99da","NCT00337727",0.01,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Patients Who Reported No Vomiting","PRIMARY",NA,"D009325; D014839","Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)",TRUE,831,"logistic_regression",NA,NA,NA,1.04902243141389
"3892","f361dc640932ea05a6c7a6140aa97449","NCT03855189",0.03,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Response To Therapy At Day 15 (Participant-Evaluated)","SECONDARY","Pairwise treatment comparison based on t-test from an analysis of variance (ANOVA).","D012220; D065631; D006255","Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)",FALSE,218,"anova",2,NA,NA,1.41680245031822
"3893","f395a3e3f5bf27423221ad7895bdf595","NCT00481195",0.0439,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"The Mean Change From Baseline to Endpoint (Week 8 or Last Observation After Baseline) in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30)","PRIMARY","Least square (LS) mean and standard error of the LS mean for each treatment group and the p-value for the treatment comparison is from an analysis of variance (ANOVA) with treatment ands concurrent treatment for bipolar disorders as factors. A significant treatment-by baseline interaction was observed in the total score that violates the assumption of parallelism on which an ANCOVA is based, so the data was analyzed using ANOVA without baseline as a covariate rather than ANCOVA.","D003863; D003866","Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder",FALSE,247,"anova",2,NA,NA,2.0807152357505
"3894","f399b7f36d67c6d4911e245e964f3c66","NCT02528253",0.029,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants Who Responded for Chronic Low Back Pain Responder Index at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56","SECONDARY","Week 4: OR and 95% CI estimated from logistic regression model. Logistic regression model included treatment as fixed effect and baseline average LBPI, baseline PGA, and baseline RMDQ as covariates.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1009,"logistic_regression",NA,NA,NA,2.93560435440696
"3895","f3a39e35d5630a678b11a619155c3d7a","NCT01392300",0.021,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Flexed Wrist","SECONDARY",NA,"D009128; D020521","Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke",FALSE,259,"logistic_regression",NA,NA,NA,1.13348986029584
"3896","f3b01cd27d5319f2acf9b8b71fe5b4a0","NCT01945034",0.028,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","SECONDARY","At Rest Day 6(PM): The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms. Upper limit of 95% CI \< 0 for Ibuprofen treatment significantly better than combined Placebo.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,219,"anova",2,NA,NA,1.33846728133383
"3897","f3b3180e735414ad383e1deb8f1ae9fd","NCT00256750",0.0191,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Mean Value of Physical and Mental Components Using SF-36 Questionnaire","SECONDARY","Physical Component Score; Month 36","D051437; D007676","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",FALSE,421,"anova",2,NA,NA,1.32534271017239
"3898","f3b5c4aa42d42b2450dd3cd3d2721e87","NCT01332149",0.0431,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Clinical Global Impression of Change (CGIC) at Endpoint","SECONDARY","Analysis performed using a general linear model with treatment and center as factors.","D010523; D003929; D010146","Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy",FALSE,589,"anova",2,NA,NA,3.14857053122865
"3899","f3b6d1c24c63733a7501417a7f342238","NCT01945034",0.032,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points","SECONDARY","At Rest Day 3(AM): The ANOVA model was used which contains treatment, baseline categorical pain severity rating, pooled site block, and baseline pain intensity at rest terms.","D013180; D016512","5% Topical Ibuprofen (IBU) for Ankle Sprain",FALSE,152,"anova",2,NA,NA,1.25585729060319
"3900","f3ca7d53599eff73e92b2c5ff043d2d0","NCT01258738",0.037,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Euro Quality of Life (EQ)-5D VAS Score Time Points","SECONDARY","With the exception of change from Baseline in the placebo group at Week 12, within group comparisons to baseline for all other treatment groups and time points were \<0.001, from paired t-test.","D013166; D025241; D013167","Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes",FALSE,186,"t-test",NA,NA,NA,1.56731211647585
"3901","f411905a962b91c984cb9a1f8f078ab4","NCT02216214",0.034,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Percentage of Participants With ≥ 10-Point Improvement From Baseline in OAB-q HRQL Subscales","SECONDARY","HRQL Subscale - Coping. Odds Ratio: Logistic regression was performed with treatment group, sex, age group (\<75, \>=75 years), and country as fixed factors and baseline value as a covariate.","D053201","Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)",FALSE,867,"logistic_regression",NA,NA,NA,3.11977101047417
"3902","f41b855aa671b44bf9796b4169281348","NCT00707447",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Psychological Well-being (WHO-5)","SECONDARY",NA,"D003920","Evaluation of a Primary Type 2 Diabetes Prevention Programme",TRUE,166,"t-test",NA,NA,NA,1.90948799930043
"3903","f4452d3c1c635a31ed14fe77eaf7e112","NCT01236053",0.0066,"Conditional logistic regression","OBSERVATIONAL",0,0,0,0,0,"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin","PRIMARY",NA,"D010190; D001749; D002292; D001005; D007680; D013274; D010386; D009423; D010412; D010195; D050500; D009437","Cancer in Patients With Gabapentin (GPRD)",FALSE,20382,"logistic_regression",NA,NA,NA,3.5680634312401
"3904","f44af8be416677c8c9d8ae4f88cc13e2","NCT02373813",0.039,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Clinical Disease Activity Index (CDAI) at All Measured Timepoints","SECONDARY","Week 36","D001168; D001172","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",FALSE,152,"t-test",NA,NA,NA,1.48516000324995
"3905","f469d3da8fb1251c3958b061a408437c","NCT02934347",0.05,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"The Time Between the Beginning of Laryngoscopy and Detection of Carbon Dioxide on the End-tidal Carbon Dioxide Monitor","SECONDARY",NA,NA,"Comparison of Glottic Views and Intubation Times in the Supine and 25 Degree Back-up Positions",TRUE,781,"mann_whitney",NA,NA,NA,4.10422727486405
"3906","f478774879a5188a4123298c72b66953","NCT00927368",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Opioid Consumption","PRIMARY","The primary analysis for opioid was a linear regression model comparing stimulating catheter to stimulating needle on the log of cumulative opioid consumption score for a patient in the first 48 hours.",NA,"Comparison of 3 Techniques for Ultrasound-guided Femoral Nerve Catheter Insertion",FALSE,290,"t-test",NA,NA,NA,2.08187802365606
"3907","f484528c532580a5c2ffac413b82ba6a","NCT02217475",0.0234,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 1","SECONDARY",NA,"D005234; D008103; D065626","Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis",FALSE,289,"logistic_regression",NA,NA,NA,1.31366605005841
"3908","f492813062649704794e6bf0505ca4a9","NCT03084796",0.045,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Transition Dyspnea Index (TDI) Response (Focal Score ≥1) at Week 3 and Week 6","SECONDARY","Week 6

Comparison treatment groups for this analysis were:

Treatment D (CHF 5259 pMDI 100 μg TDD) versus Treatment A (CHF 5259 pMDI 12.5 μg TDD).

Statistical analysis was performed as described for the statistical analysis 1 of this outcome measure.","D008171; D008173; D029424","A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease",FALSE,244,"logistic_regression",NA,NA,NA,2.11171259387865
"3909","f493a9fea70ac090b798b0e20459dc9c","NCT00469092",0.029,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Glycosylated Haemoglobin A1c (HbA1c)","PRIMARY","HbA1c was compared between the treatment groups by fitting a linear regression model (ANCOVA) with treatment and country as factors and the baseline values as a continuous covariate. Mean and SE are estimated from the model.","D003920; D003924","Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes",FALSE,457,"linear_regression",NA,NA,NA,1.98129603498012
"3910","f49936f2d5dba52200b40517011444c1","NCT03843541",0.027,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Day 3 and to Day 7 in Mean Sputum Color Score of Ambroxol Hydrochloride and Placebo","SECONDARY",NA,"D012140","A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions",FALSE,220,"mann_whitney",NA,NA,NA,1.30020733809561
"3911","f4a9e30bae57bd9d8e7f63aeff90329b","NCT03739762",0.033,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in SystolicBlood Pressure at 6 Months","PRIMARY",NA,NA,"Healthy Aging Resources to Thrive (HART)",FALSE,254,"linear_regression",NA,NA,NA,1.65653146626916
"3912","f4b0e5d203e0fb83cafac45667b65482","NCT00112151",0.05,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Fat Mass (kg)","SECONDARY","As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in fat mass measured by dual x-ray absorptiometry (DXA) with any T to placebo in subjects assigned to PRT.",NA,"TEAM: Testosterone Supplementation and Exercise in Elderly Men",TRUE,71,"linear_regression",NA,NA,NA,1.26828177971868
"3913","f4d4630f29ce75fad507c5fd10a10678","NCT00324168",0.03,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Subgroup Analysis Predicting 3 Month Best Spectacle-corrected Visual Acuity (BSCVA) by Visual Acuity Group","SECONDARY","CF or worse","D001424; D003320; D015817; D015818; D014456","Steroids for Corneal Ulcers Trial",FALSE,442,"linear_regression",NA,NA,NA,2.00638796126048
"3914","f4d802bb1265fd9a995c90ccd1233ebf","NCT03987919",0.023,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving an HbA1c Target Value of <7%","SECONDARY",NA,"D003920; D003924","A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes",FALSE,922,"logistic_regression",NA,NA,NA,2.29750311871084
"3915","f50ecde4678fabd6acb3c8cc41b025ef","NCT02123797",0.0499,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Concordance Rate for Any Conference Recommendation, MD vs SC (Conference)","PRIMARY",NA,NA,"Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology",FALSE,252,"logistic_regression",NA,NA,NA,2.33949525924937
"3916","f51e72be866aaa734e37899bc76ba3d7","NCT04003155",0.035,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate, and Severe VMS From Baseline to Each Study Week Up to Week 12","SECONDARY","Week 6","D019584","A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause",FALSE,349,"logistic_regression",NA,NA,NA,2.03667145827837
"3917","f51eac011d4899a9c8a49ad35d9681ab","NCT02431247",0.033,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48","SECONDARY",NA,"D007153","A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects",FALSE,661,"mann_whitney",NA,NA,NA,2.65760649180258
"3918","f52e99aaef1d91114c2fa17349466dbd","NCT01814878",0.0404,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID)","SECONDARY",NA,"D010149","A Study Comparing the Effectiveness and Safety of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen With Immediate Release (IR) Tramadol HCl/Acetaminophen in Participants With Moderate to Severe Postoperative Pain",FALSE,312,"t-test",NA,NA,NA,2.17652779246383
"3919","f568e6535d2d03332aad48bce17f823e","NCT01176968",0.0293,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change in Serum Levels of Biomarkers (PIIINP, Galectin 3, and PINP) at 6 Months Post-randomization.","SECONDARY","For Biomarker- Galecting 3, Wilconxon rank-sum test for between treatment difference at Month 6 was used to derive p-value.","D009203; D007238","Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction",FALSE,526,"mann_whitney",NA,NA,NA,2.14301948014617
"3920","f56bf47c6c2ac5989aa23ea150b118c4","NCT03035916",0.046,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Hemodynamic Parameters: Heart Rate.","PRIMARY","The Heart rate was measured from baseline to 48hours after surgery. The row ""Baseline"" is the preoperative level as the blank control.This Statistical Analysis applied to ""Before induction"" row.",NA,"Transversus Abdominis Plane Block on Stress Response",FALSE,59,"t-test",NA,NA,NA,1.08514521502874
"3921","f572ad7730e98fa34728b939ae313b19","NCT05170841",0.045,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Percentage of Maximum TOTPAR (%Max TOTPAR) at 24 Hours After the First Dose- Multiple Dose Phase - Dexketoprofen/Tramadol vs Tramadol","SECONDARY",NA,"D001416; D017116","Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain",FALSE,494,"t-test",NA,NA,NA,2.99221959645013
"3922","f57a211375df75a678b0bfae034760cb","NCT03676465",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Family Conflict Scale","SECONDARY",NA,"D003920; D003922; D002908","CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management",FALSE,43,"t-test",NA,NA,NA,1.00454908915455
"3923","f591b19cfeffbaee557455923d435cb9","NCT01387815",0.016,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"PASQ Total Score: Change From Baseline to Month 6","SECONDARY",NA,"D011565","Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis",FALSE,333,"t-test",NA,NA,NA,1.01141183959382
"3924","f59c375143f55226c2921ca7ffb7084f","NCT05502081",0.021,"Kruskal-Wallis","INTERVENTIONAL",0,0,0,0,1,"Number of Participants With Positive or Negative Polymerase Chain Reaction (PCR) Test Results at End of Hospital Visit","PRIMARY",NA,"D000086382","Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients",FALSE,212,"kruskal_wallis",2,NA,NA,1.02784066359136
"3925","f5daa53f468736ab4ba44ab40bcef709","NCT00576472",0.025,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Brain White Matter Volume for Treatment Intensity Groups and Sibling Controls","PRIMARY",NA,"D054198; D007945; D001932","Learning Impairments Among Survivors of Childhood Cancer",FALSE,240,"anova",2,NA,NA,1.26977890856384
"3926","f5eeea026c944ff136cc725d737aa89f","NCT00621140",0.0323,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Patients With HbA1c <6.5% at Week 24","SECONDARY","Linagliptin vs. Placebo

The odds-ratio is based on a logistic regression model including baseline HbA1c and previous antidiabetic medication.","D003924","Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control",FALSE,491,"logistic_regression",NA,NA,NA,2.251590931591
"3927","f5fdb6528f993533efe9c485bef64c65","NCT02709486",0.0203,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Osteoarthritis","SECONDARY","Week 16: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline patient global assessment of osteoarthritis scale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,563,"logistic_regression",NA,NA,NA,1.61360067281611
"3928","f6015a54a57d4a7672e8af96919c6da8","NCT01843023",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Treatment Retention","SECONDARY",NA,"D019966","Extended Release Naltrexone for Opioid-Dependent Youth",TRUE,218,"t-test",NA,NA,NA,2.18218966551193
"3929","f606ae4b9d73c28b0fe78676270f9093","NCT02633358",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Interleukin-6 - the Plasma Level of Participants","OTHER_PRE_SPECIFIED",NA,"D006323; D012770; D007035","Anti-inflammatory Effect of Therapeutic Hypothermia in Out-hospital Cardiac Arrest Patients With Cardiogenic Shock",TRUE,141,"t-test",NA,NA,NA,1.76345107862741
"3930","f607d7596c83ed43ecd9c575bc2ec40a","NCT02471339",0.042,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Interference Patient-Reported Outcomes Measurement Information System (PROMIS) II","SECONDARY",NA,"D017253; D009456; D009455; D018318; D059350","Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain",FALSE,62,"anova",2,NA,NA,1.02974738487734
"3931","f60e9585d0e0c319222f4d81211dce19","NCT03192176",0.035,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 3","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,85,"logistic_regression",NA,NA,NA,1.02519839260956
"3932","f61fddf1798103095ecfa4f445fbb3db","NCT00884065",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Pain in the Hand Behind Back Position After Intervention Minus Baseline","SECONDARY",NA,"D020069","Effectiveness of Diacutaneous Fibrolysis in Painful Shoulder",FALSE,50,"t-test",NA,NA,NA,1.07648023860356
"3933","f62c59a5a5c5af4a57fbfa61718832f4","NCT03928717",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Self-reported Medication Adherence","PRIMARY",NA,"D000163; D015658","A Text-Based Adherence Game for Young People Living With HIV in Ghana",TRUE,51,"anova",2,NA,NA,1.08637315449684
"3934","f6657b5d7aa7621bebbdeb2906311066","NCT04858802",0.048,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Inflammation Score in the Frontal Recess/FSO by Clinical Investigators","SECONDARY","Day 45","D000096825","A Clinical Evaluation of PROPEL® Contour Sinus Implant",FALSE,160,"t-test",NA,NA,NA,1.81269132930512
"3935","f66fe517c95d89d15a7c314b89e5dc81","NCT00321854",0.0489,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 15","SECONDARY",NA,"D010300","Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)",FALSE,409,"mann_whitney",NA,NA,NA,2.92182381378813
"3936","f6747062345199c46d1eed0df1d39de5","NCT00536471",0.036,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Path Analysis of BPOMS Total Score to Overall Improvement in HAMD-24 Item 7","SECONDARY",NA,"D003866; D003863; D003865","A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients",FALSE,330,"linear_regression",NA,NA,NA,2.02922974563456
"3937","f677804f749499817609a879f193c789","NCT03011775",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Lipid Metabolism 1","SECONDARY",NA,"D006331; D050197; D003327; D003324; D017202; D007333; D024821; D018450","Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease",TRUE,43,"mann_whitney",NA,NA,NA,1.00454908915455
"3938","f67b4de35292ddc30bea48e1083146c6","NCT00265096",0.015,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Total Radiographic Scores of the Hands and Feet at Week 24","PRIMARY","Null Hypothesis: There is no difference in change from baseline among 3 treatment groups. Sample size (n=396, 110 placebo, 286 combined golimumab) provided \>93% power to detect a significant difference (alpha=0.05) in change from baseline between treatment groups, assuming 50% of subjects received MTX at baseline, and mean change from baseline for combined golimumab of 0, and a mean increase for placebo of 0.1 in subjects who received MTX at baseline and 0.6 in subjects who did not receive MTX","D001168; D015535","A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis",FALSE,405,"anova",2,NA,NA,1.05233749180983
"3939","f6882049d1b20a4d15cb090ab24d3139","NCT00449696",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Short Form - 36 (SF-36)","SECONDARY",NA,"D010003; D020370","Gel-200 Versus Placebo in Osteoarthritis of the Knee",FALSE,375,"mann_whitney",NA,NA,NA,2.85152958765382
"3940","f6a1b65fcb0264138ff170528b277f5b","NCT04080544",0.039,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Relationship of Tau Burden to Working Memory","SECONDARY","Regression testing the interaction of temporal tau SUVR and amyloid SUVR in prediction of working memory.","D000544; D060825","Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study",FALSE,124,"linear_regression",NA,NA,NA,1.34566449713441
"3941","f6c1227766f94d90476301e4b908d927","NCT01694485",0.021,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Remission at Week 8","PRIMARY","Comparisons between treatment groups were made using remission rates estimated from a logistic regression model adjusted for baseline total Mayo Score and stratification factors (prior vs no prior TNF antagonist use and enrollment pre- vs post-protocol amendment).","D003092; D003093; D014456","Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis",FALSE,214,"logistic_regression",NA,NA,NA,1.03255634490692
"3942","f6c547986157e9c12a00f773f25bfef9","NCT00873288",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Patient Satisfaction in the 2 Interventions","PRIMARY",NA,"D011230","Activating Collaborative CIS Support Via Targeted Provider Mailing",FALSE,254,"t-test",NA,NA,NA,2.35254953828373
"3943","f6c997adfed3d131ddcef10caccaa6ce","NCT03528681",0.035,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of Normokalemic Patients at the End of RTP","SECONDARY",NA,"D006947","A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.",FALSE,118,"logistic_regression",NA,NA,NA,1.19912272919754
"3944","f6cdf017009db51a4d75b164cc80e195","NCT02149199",0.046,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"'Well-controlled Asthma Week' - a Derived Binary Variable (Yes/No)","PRIMARY",NA,"D001249","A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.",FALSE,2554,"logistic_regression",NA,NA,NA,6.90806983304928
"3945","f6eb02730cb66fcc951debd03cad7aab","NCT02649634",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Readiness for Change Ratings After the First Motivational Interview or Attention Control Interview, Week 1 -2","SECONDARY","Readiness for Change ratings were analyzed via an independent sample t-test comparing the groups on mean Readiness for Change ratings on the 11-point visual analogue scales","D009765; D050177; D015431","Does Motivational Interviewing Improve Behavioral Weight Loss Outcomes for Obesity?",FALSE,135,"t-test",NA,NA,NA,1.7265679672307
"3946","f7100f9cb1affe43825056b4d2564f4e","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Fasting Plasma Glucose","PRIMARY","Difference in treatment effects between the 2 groups","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",FALSE,50,"t-test",NA,NA,NA,1.07648023860356
"3947","f7215cb83bc247863563f1ea9fea80a0","NCT02528253",0.0108,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 2, \>=90%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1012,"logistic_regression",NA,NA,NA,1.23872923214541
"3948","f72737b9fce5865ad6e41b7305d1bf19","NCT01245439",0.05,"Wilcoxon","INTERVENTIONAL",0,0,0,1,0,"Disease Activity Score as Measured By DAS28 at Each Visit","SECONDARY","Change from Visit 4 to Visit 5","D001168; D001172","A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis",FALSE,60,"wilcoxon",NA,NA,NA,1.17169922891753
"3949","f72b278dc8468104a398bb32978dec84","NCT02867709",0.0129,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose","SECONDARY",NA,"D008881","Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine",FALSE,908,"logistic_regression",NA,NA,NA,1.37388242474223
"3950","f7417d06ff1b5a8ab3e26b843f16448b","NCT00424593",0.046,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Laboratory Assessments That Were Statistically Significantly Different Between Treatment Groups in Change From Baseline to Week 13 Endpoint: Bicarbonate","SECONDARY",NA,"D001416; D017116","Duloxetine Versus Placebo in Chronic Low Back Pain",FALSE,212,"anova",2,NA,NA,2.00749255689239
"3951","f745f597e71475b6435921022bd3972b","NCT00291499",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Consumption of Paracetamol","SECONDARY",NA,"D010003","Efficacy Study of Condrosulf in the Treatment of Symptomatic OA of the Hand",TRUE,154,"mann_whitney",NA,NA,NA,1.84083479148392
"3952","f74e6f8839c1b6f9ea83d62228f3c692","NCT01182103",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Brain-derived Neurotrophic Factor (BDNF) DNA Methylation of Major Depressive Disorder (MDD) Patients and Healthy Controls","PRIMARY",NA,"D003863; D003866; D003865","Epigenetic Regulation of BDNF in Major Depression",TRUE,101,"t-test",NA,NA,NA,1.50057440421219
"3953","f75336180fdda5de5bdd74a9055183e1","NCT04452318",0.026,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Cohort B: Number of Weeks of Symptomatic SARS-CoV-2 Infection (CDC Definition) Within 14 Days of a Positive RT-qPCR at Baseline or During the EAP","SECONDARY",NA,"D000086382","COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay",FALSE,204,"mann_whitney",NA,NA,NA,1.21312258110679
"3954","f7600977db2487dd3b75197d7aa40567","NCT01001429",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Adequate Sedation Via Bispectral Index Score (BIS)and University of Michigan Sedation Scale (UMSS)","PRIMARY",NA,"D012163","Dexmedetomidine Versus Propofol in Vitreoretinal Surgery",FALSE,76,"logistic_regression",NA,NA,NA,1.08781774095059
"3955","f7629ddf14b698395e5bf8b83c80706a","NCT00402987",0.038,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Subjects Who Achieved Their Own Level of 'Meaningful Relief' and 'Much Improvement' at 12 Hours Post-First Dose","OTHER_PRE_SPECIFIED",NA,"D010612","Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat",FALSE,89,"logistic_regression",NA,NA,NA,1.12298758249058
"3956","f76cd3bca3a2f61fa571dd537d9f179d","NCT02270671",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Depression Symptoms at 4-week Post-intervention and 12-week Follow-up","SECONDARY",NA,"D003863","Attention Bias Modification Training for Young People",FALSE,120,"anova",2,NA,NA,1.63072147479452
"3957","f772e54a2050cf8f0bc8ff06df5a6d07","NCT01559259",0.03,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Intensity Difference on 11-Point Numerical Scale (PID11)","SECONDARY","12 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, baseline numerical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,119,"anova",2,NA,NA,1.05622640959333
"3958","f774117a2354e6b0161f9e0d1622c882","NCT04452318",0.038,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Cohort B: Percentage of Participants Who Subsequently Develop Signs and Symptoms (Broad-Term) Within 14 Days of a Positive RT-qPCR at Baseline or During the EAP","PRIMARY",NA,"D000086382","COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay",FALSE,204,"logistic_regression",NA,NA,NA,1.67715756924528
"3959","f778a0f70c6e1ea83732caa1f42045f5","NCT03655951",0.02,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Attitudes Toward Sexual Communication - Child Report From Pretest to Posttest","SECONDARY",NA,NA,"Birds and Bees Research Study",FALSE,267,"linear_regression",NA,NA,NA,1.10275516908223
"3960","f7a246dab947700e83ed7a9af3c758c8","NCT04485637",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Who Measured Blood Pressure as Instructed (Assessed on Questionnaire)","PRIMARY","Enhanced table \> Basic table","D006973","Helping Hypertension Patients to Interpret Blood Pressure Readings and Motivate Blood Pressure Control",FALSE,542,"logistic_regression",NA,NA,NA,3.42276043954353
"3961","f7ad628bbce791b2b28e2248d6d409f5","NCT01258738",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed Due to Health Problems at Time Points","SECONDARY","Within group comparisons to baseline were \<0.05, from paired t-test.","D013166; D025241; D013167","Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes",TRUE,124,"t-test",NA,NA,NA,1.6568216953838
"3962","f7b0fc7393ad55e74886cee8dd75e60a","NCT03358030",0.05,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Percent Change From Baseline in Activated Partial Thromboplastin Time (aPTT)","OTHER_PRE_SPECIFIED","Day 15 through Day 232","D007674; D007676","A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis",TRUE,78,"anova",2,NA,NA,1.32610986002301
"3963","f7b34e092de7da959ebbfabd324f74ca","NCT00453999",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,1,0,0,"Change in Amount of Influenza Virus in Nose and Throat (Influenza A and B Combined)","SECONDARY","Change from Baseline at 24 hours","D007251","Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza",FALSE,112,"mann_whitney",NA,NA,NA,1.57722881888439
"3964","f7b4cc72ca3986d43309fe1d9e68673a","NCT02279043",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Number of Participants Reporting Informational Support (Receiving New Information From Birth Control Connect)","SECONDARY",NA,NA,"Online Peer Influence on IUD Behaviors and Attitudes",FALSE,354,"logistic_regression",NA,NA,NA,1.79796213415283
"3965","f7bf5183b9d915d48995b961efe79bff","NCT00935584",0.05,"Wilcoxon","INTERVENTIONAL",0,0,0,0,0,"Change in Patient Engagement","PRIMARY","The null hypothesis is that there is no significant change in patient engagement from pre to post visit.",NA,"Patient Centered Evaluation of Computerized Patient Records System",FALSE,125,"wilcoxon",NA,NA,NA,1.66328288934253
"3966","f7c2cbe696135c0e8eb5df6015c3f349","NCT00245219",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Depressive Symptoms (as Measured With the CES-D) at Baseline, Time 2 (2 Weeks Post-intervention) and Time 3 (6 Months Post-intervention)","PRIMARY","The comparison between the peer support condition and control condition at Time 3, among both late and early stage patients. The full regression model consisted of 3 steps: The 1st step contained the baseline measure of the dependent variable. The 2nd step contained two dummy coded variables contrasting each condition with control. The 3rd step contained the interaction between the peer support condition and cancer stage. Patients in the education condition were excluded from this analysis.","D001943","Understanding Shared Psychobiological Pathways",FALSE,147,"logistic_regression",NA,NA,NA,1.79957957739554
"3967","f7c623fdedbe4c8f0d57a71e2e78c2ea","NCT00790335",0.03,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Change in Leg Pain Severity","SECONDARY",NA,"D013927; D013923; D054556; D020246; D054070; D011186; D013577","Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis",FALSE,631,"linear_regression",NA,NA,NA,2.39345617138537
"3968","f7c87e21befd64a774425ea1e9603b43","NCT00798161",0.0445,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Use of Rescue Therapy","SECONDARY",NA,"D003924","Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design",FALSE,278,"logistic_regression",NA,NA,NA,2.23072795481816
"3969","f7d84b09e3c5bc844de2fa1b61f3e22c","NCT02596126",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Efficacy Endpoints","SECONDARY","Patient satisfaction is measured at visit 1 (6 months) and visit 3 (2 years) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument comprising of four domains: effectiveness (questions 1 to 3), side effects (questions 4 to 8), convenience (questions 9 to 11) and global satisfaction (questions 12 to 14).","D009362; D002318; D009203; D007238","Secondary Prevention of Cardiovascular Disease in the Elderly Trial",TRUE,2466,"t-test",NA,NA,NA,7.28069129722027
"3970","f7ebd052b6fbfc517766c918c149cc62","NCT00951912",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Percentage Change in Low Density Lipoprotein Cholesterol","PRIMARY",NA,"D003924","The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids",TRUE,110,"anova",2,NA,NA,1.56357043896758
"3971","f7f6056e00b616251d2f6f9be757cfb8","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Whole-body Glycolytic Disposal of Oral Glucose","PRIMARY","Difference in treatment effect between the 2 groups","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",FALSE,51,"t-test",NA,NA,NA,1.08637315449684
"3972","f810318262e94b9a071efbf3f9cc3736","NCT03372369",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Perceived Pregnancy Risk Score","PRIMARY","The null hypothesis is that the change in the perceived pregnancy risk score for the CDC poster between baseline and followup is 0.",NA,"Testing the Impact of Two Posters on Contraceptive Knowledge, Contraceptive Preferences, and Perceived Pregnancy Risk",FALSE,466,"t-test",NA,NA,NA,1.45056386784607
"3973","f81df1d78d194cbbb3bf895ee1d542cb","NCT03426787",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change in Decision Self-Efficacy Scale","PRIMARY",NA,"D006526; D006505; D007674; D051436","Helping Empower Liver and Kidney Patients",FALSE,110,"t-test",NA,NA,NA,1.56357043896758
"3974","f823ae0e01d2f95525e9b9fdf9a31c30","NCT03789396",0.03,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Patient-time Hyperoxic and Not on Room Air","PRIMARY","Comparison of patient odds of being hyperoxic and not on room air pre- versus post-intervention","D016638; D014947","Pilot Study of Targeted Normoxia in Critically Ill Trauma Patients",FALSE,572,"logistic_regression",NA,NA,NA,2.27969095208804
"3975","f8283adf9e81bfbe6853750ba016a2a2","NCT00310310",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,1,1,0,"Outcome Expectation","OTHER_PRE_SPECIFIED",NA,"D001049; D012891","Effect of Self-Management on Improving Sleep Apnea Outcomes",FALSE,190,"t-test",NA,NA,NA,1.69159088532404
"3976","f849406d013c7119e4c534a06f200767","NCT03480022",0.048,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Waist-to Height Ratio [WHtR])","SECONDARY","Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect","D011085; D011236; D013577; D001835","Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS",TRUE,67,"anova",2,NA,NA,1.19307303227173
"3977","f86cbcc56605af00e654c6ff2c954fde","NCT01462435",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"VASSPID-8. The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale (VASSPID) From 0 to 8 Hours After Trial Entry.","SECONDARY",NA,"D010149","Study of Diclofenac Capsules to Treat Pain Following Bunionectomy",FALSE,212,"t-test",NA,NA,NA,2.15248668480022
"3978","f86d14dec7865471f813616137e0db6a","NCT01882543",0.04,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Voiding Frequency as Recorded by Diary Over a 24 Hour Period","SECONDARY","Analyses of the secondary variable was based on observed data without imputation.","D003556; D018856; D013577","Efficacy and Safety of AQX-1125 in IC/BPS",FALSE,69,"anova",2,NA,NA,1.0394329659436
"3979","f882cc1a7e32b0982c20fcdfc5b1f4a0","NCT04672239",0.0429,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Use of Smoking Cessation Strategies","SECONDARY",NA,NA,"A Proof-of-concept RCT of Version 3.0 of the Smoking Cessation Smartphone App ""Smiling Instead of Smoking"" (SiS)",FALSE,128,"t-test",NA,NA,NA,1.48046913111533
"3980","f890b198d6d2af9d513f5f711b61a3d3","NCT02328326",0.048,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Change in Patient Activation, as Measured by Patient Activation Measure - 13","PRIMARY","The null hypothesis was that change (baseline to 12 months) in PAM is the same for CO-IMPACT (intervention) compared to PACT (control). The alternative hypothesis is that that COIMPACT will significantly increase patient participants' PAM score compared to patient participants in PACT.","D003920","Caring Others Increasing EngageMent in PACT",FALSE,239,"linear_regression",NA,NA,NA,2.20652463057901
"3981","f8b10e4d20eaef3c54f9d747cef17f6d","NCT00179621",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in the Functional Assessment of Cancer Therapy-Anemia (FACT-An) Endpoints at Week 12","SECONDARY",NA,"D011289; D009190; D000013; D013577","Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality",TRUE,97,"anova",2,NA,NA,1.47171356596352
"3982","f8d974a891c0d410ac279ece6a25b94d","NCT02697773",0.0172,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >= 30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 4, \>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee",FALSE,463,"logistic_regression",NA,NA,NA,1.26752696431024
"3983","f8e0728f16131ea9a1934dc8e895f4b0","NCT03676465",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Percent Time >180 mg/dL","SECONDARY",NA,"D003920; D003922; D002908","CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management",FALSE,43,"t-test",NA,NA,NA,1.00454908915455
"3984","f947215b75a5602c7ab6444614f7d685","NCT01553084",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Number of Participants With Initial Cessation in the First 7 Days Post-quit","SECONDARY",NA,"D014029","A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers",FALSE,662,"logistic_regression",NA,NA,NA,2.45111622240072
"3985","f9549c684df676a75256222c8c2a63c7","NCT02528253",0.0101,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 16, \>=30%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,810,"logistic_regression",NA,NA,NA,1.04499808857622
"3986","f9688623b60ead996dd728660ded5e59","NCT03114969",0.046,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants Making at Least One Critical Error at Visit 2-Dual Device Comparisons (Relvar Ellipta With or Without a LAMA DPI) Versus Any Other ICS/LABA DPI With or Without a LAMA DPI)","SECONDARY",NA,"D008171; D029424","Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs",FALSE,190,"logistic_regression",NA,NA,NA,1.90254542151046
"3987","f97bc83008332bd532806fe0e3b0e09d","NCT00657241",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Central Systolic Blood Pressure","SECONDARY","Statistical analysis performed on treatment groups (valsartan or carvedilol CR) at end of treatment period (4 weeks), not on the randomization arms in the crossover design (which controlled for carryover effects of the prior treatment arm).","D006973","Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril",FALSE,60,"t-test",NA,NA,NA,1.17169922891753
"3988","f98985707224ad6eb504bd03673bd617","NCT00924885",0.04,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Visual Analogue Scale","PRIMARY","The primary end-point was the 'overall pain experience', evaluated as described previously. Assuming the mean overall pain in the RN group to be 27 mm (value chosen after analysis of data from a previous study, Cerne et al., 2006) on VAS, with a standard deviation (SD) of 21.5 mm, 121 patients in each group would be needed to demonstrate a decrease in overall pain of 8 mm (30%) with 80% power and a significance level of 0.05 (two-tailed tests).","D007246","Experience of Pain During Oocyte Retrieval- a Comparison Between Two Aspiration Needles",FALSE,250,"mann_whitney",NA,NA,NA,1.9352256489868
"3989","f9a056ac31e25f22672763baf3a93578","NCT03982368",0.032,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Change From Baseline in Quality of Life (Impact of Dry Eye on Everyday Life (IDEEL) Questionnaire vs Different Timepoints - Full Analysis Set","SECONDARY","Daily Activity Limitations - change from baseline to week 4","D015352; D007638","A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye",FALSE,166,"anova",2,NA,NA,1.31074585866373
"3990","f9aaea47520217a3cc1c3d9c350bdde7","NCT03950167",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Gallbladder (GB) Ejection Fraction","PRIMARY",NA,"D006939","Gallbladder Functions & Serum Cholecystokinin Levels in Women Diagnosed With Hyperemesis Gravidarum",FALSE,46,"t-test",NA,NA,NA,1.03597838019194
"3991","f9d325c9a8fde0f33e826da437817365","NCT03614494",0.036,"Logistic regression","INTERVENTIONAL",0,0,1,1,0,"Pregnancy Rate","SECONDARY",NA,"D004630","Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception",FALSE,836,"logistic_regression",NA,NA,NA,3.21681529793142
"3992","f9d851a10cf25fbcf6258679560ca282","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Tax","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",TRUE,1752,"linear_regression",NA,NA,NA,6.13876469477842
"3993","f9dcdc6dff202924b9f68ad87741d468","NCT02963935",0.0311,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of Subjects Losing More Than 15% of Baseline Body Weight at Week 56","SECONDARY","Treatment policy estimand. Week 56 responses were analysed using a logistic regression model with treatment, BMI groups, and sex as factors and baseline body weight as covariate. Analysis of in-trial data with missing observations imputed from the placebo arm based on a jump to reference multiple (x100) imputation approach.","D009765; D009748","Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting",FALSE,282,"logistic_regression",NA,NA,NA,1.65777536956931
"3994","f9e5127cf3eb8bdd826a3e683924b7d1","NCT03192176",0.0461,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week","SECONDARY","Week 9","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.29865982603677
"3995","f9ff08373848bb518d92fa7494de14c1","NCT02528188",0.0121,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction of >=30%, >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 32: \>=90% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1989,"logistic_regression",NA,NA,NA,1.91783663692038
"3996","fa07f7eaeef5e25df961cea1e7204ea2","NCT03192176",0.039,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Absolute Reduction of 2 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week","SECONDARY","Week 3","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,86,"logistic_regression",NA,NA,NA,1.12920333910782
"3997","fa296be92af021ccc0d5986e6079e4f6","NCT01459653",0.017,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Modeling Composite Outcome (Any of CIN Grade 4, FN, CIN/FN-related Hospitalization, CIN/FN-related Chemotherapy Disturbance): Cycle Level","SECONDARY","History of CIN Grade 4 at enrollment as patient-level predictor for composite outcome (any of CIN Grade 4, FN, CIN/FN-related hospitalization, CIN/FN-related chemotherapy disturbance)","D009101; D009503; D064147; D000084462; D005334","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",FALSE,1529,"logistic_regression",NA,NA,NA,2.2701830694862
"3998","fa33f145b1266d108ae2ab676183a150","NCT00261443",0.046,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Median Baseline and Change From Baseline in Body Mass Index (BMI) During Phase 3","SECONDARY","Lowest Value Treatment Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,321,"anova",2,NA,NA,2.46237219193991
"3999","fa39f4abff22628b803ffed936955738","NCT01244815",0.042,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Total Y-MRS 50% Responders at Days 4, 7, 14 and 21","SECONDARY","Analysis is for asenapine versus placebo on Day 21 (LOCF)","D001714","Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)",FALSE,199,"logistic_regression",NA,NA,NA,1.80297895862058
"4000","fa46256312251308a370e1d2560ce796","NCT00293241",0.048,"Linear regression","INTERVENTIONAL",0,0,0,0,1,"Change in Left Ventricular Ejection Fraction (LVEF,%) Over 2 Years Time","SECONDARY",NA,"D002318","PreFER Managed Ventricular Pacing (MVP) For Elective Replacement",FALSE,605,"linear_regression",NA,NA,NA,3.49332034413697
"4001","fa4a0f715d41eb26480e04681eec68c2","NCT02259127",0.036,"Linear regression","INTERVENTIONAL",0,0,1,1,0,"Mean Change in BMI-for-age Z-score From Baseline","OTHER_PRE_SPECIFIED","Statistical Analysis Title: Adjusted Difference (\>=14kg)

Statistical analysis description: Linear regression of BMI-for-age at week 96, adjusting for randomised arm, baseline BMI-for-age and stratification factors. Presenting mean difference between arms.

Number of subjects included in analysis: 707

Analysis Specification: Pre-specified","D007239; D015658; D000163","ODYSSEY (PENTA 20)",FALSE,707,"linear_regression",NA,NA,NA,2.95965498809681
"4002","fa68f121ae2d582111428ffb9137928b","NCT02373813",0.021,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in CDAI at All Measured Timepoints","SECONDARY","Change at Week 48","D001168; D001172","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",FALSE,202,"t-test",NA,NA,NA,1.00393051424065
"4003","fa6f8ac954f227a16fb1f80581dbd25c","NCT01048866",0.0288,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Body Temperature at 2 Hours Post Initial Dose","SECONDARY",NA,"D010612","A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis",FALSE,198,"anova",2,NA,NA,1.30530747526941
"4004","fa98365ec5b72be6e67e948eb99d409e","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Ham Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1727,"linear_regression",NA,NA,NA,6.09490578810359
"4005","fadd4f52ee4d9d9185c2128777e64e72","NCT04412057",0.044,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Subjects Alive and Free of Respiratory Failure","PRIMARY","The sample size provided greater than 80% power to detect a difference of 0.25 in the proportion of subjects alive and free of respiratory failure using a Chi-square exact test at a one-sided significance level of 0.05. This calculation assumed that the proportion alive and free of respiratory failure will be 0.60 in the placebo group and 0.85 in the CERC-002 group.","D000086382; D011014; D055370; D055371; D014947","Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury",FALSE,62,"logistic_regression",NA,NA,NA,1.07036584478706
"4006","faeffeac1d5ec5612c9cf36eaebc34e1","NCT01199601",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Completion of 9 Month Measles-mumps-rubella Vaccination on Time.","SECONDARY",NA,"D006509","Blood-borne Infection Screening in an Afghan Antenatal Population",FALSE,697,"logistic_regression",NA,NA,NA,3.87838567678856
"4007","faf9150e684cafbdc69d0b90ef78f9ff","NCT00421304",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Motavizumab Concentration in Nasal Wash Aspirates at Day 1","PRIMARY",NA,NA,"A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness",FALSE,76,"mann_whitney",NA,NA,NA,1.30984657914153
"4008","faf9a13b16804bc78caf1e06afe71c56","NCT00330551",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Medication Adherence","PRIMARY",NA,"D012559","Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia",FALSE,83,"t-test",NA,NA,NA,1.36592548755136
"4009","fafca5ea224f97eb65a5c181f590cf30","NCT01811238",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"The Change in Quality of Life (EQ-5D) at Week 8 of Treatment With the Study Drug From Baseline","SECONDARY",NA,"D013122","An Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Spinal Disorders",TRUE,209,"t-test",NA,NA,NA,2.13748052036521
"4010","fb064c89de515d6034255ba122f0707e","NCT01191268",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at Weeks 26 and 52","SECONDARY",NA,"D003920; D003924","A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)",TRUE,555,"logistic_regression",NA,NA,NA,3.46327758726028
"4011","fb1493404ca6a437001b7e08099d674f","NCT05170061",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,1,0,"Daytime Brachial Systolic Pressure","SECONDARY","see primary dependent variable","D006973","24 Hour Ambulatory Cardiac Oxygen Consumption",FALSE,78,"t-test",NA,NA,NA,1.32610986002301
"4012","fb5a8d00e3fe29871a84c483018a01bb","NCT05274958",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Measurement of Symptomatology of Patients on Waitlist Via Patient Health Questionnaire (PHQ-9)","PRIMARY","Patient measures for both groups were first summarized descriptively with means and standard deviations. To compare the two groups, a t-test was used.","D001523","Effectiveness of Telepsychiatry With Randomized Waitlist Control Utilizing Patient Reported Outcome Measures",TRUE,91,"t-test",NA,NA,NA,1.42733241699876
"4013","fb602450f9c4dd1331c9d3935b2b711c","NCT00833638",0.038,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"Sexual Encounter Profile Diary Question 3, Daily Cumulative Percentage of Successful Intercourse Attempts","SECONDARY","Tested was the null-hypothesis that no differences in the precentage of successful intercourse attempts exists between participants who received placebo and participants who received tadalafil 2.5 mg, measured by a response of ""yes"" to the sexual encounter profile diary question number 3.","D007172","A Study in Erectile Dysfunction",FALSE,235,"logistic_regression",NA,NA,NA,1.79757996118908
"4014","fb618b3b66ffe8f6768597c060a772eb","NCT00408421",0.026,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Statistically Significant Change From Baseline to 13 Week Endpoint in Laboratory Data - Chemistry Analytes: Uric Acid","SECONDARY","An analysis of variance (ANOVA) model was used which contains the terms of treatment and investigator. Rank-transformed data will be used in the analysis given the view that the change scores for most of the laboratory analytes are not normally distributed. Type III sum-of-squares for the least-squares mean (LSMean) was used to test the null hypothesis that there is no treatment difference on the mean change from baseline to the endpoint of the outcome measure.","D010003; D020370","Duloxetine Versus Placebo for Osteoarthritis Knee Pain",FALSE,224,"anova",2,NA,NA,1.26982125575101
"4015","fba8a173c0df34a375a7eca4f377b291","NCT01251757",0.014,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Percentage With Good (>80%) ACEI/ARB Adherence","SECONDARY","We conducted separate primary analyses of each of IVR and IVR+ versus usual care at the .025 level of significance to assure a trial-wide error rate of .05. This analysis summary is for the IVR versus UC comparison only. Also, we only report results here for the full sample, and not also separately for the 3 baseline adherence level groups.","D002318","Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies",FALSE,8700,"logistic_regression",NA,NA,NA,4.55768348892865
"4016","fbae3d4db26ed221811d50b31ac4fba1","NCT03480022",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Total Testosterone Concentrations (T)","SECONDARY","Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect","D011085; D011236; D013577; D001835","Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS",FALSE,67,"anova",2,NA,NA,1.23402909436682
"4017","fbb5dc13c0ccf10c70ec4ff59da1c61a","NCT00684060",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"End Diastolic Volume Index","SECONDARY","Comparison of change in the active group minus change in global LVEF in the control group.","D018754; D018487","Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)",TRUE,81,"t-test",NA,NA,NA,1.3501394396673
"4018","fbba1ca7e4b0e1b614c94f0c727f2774","NCT03950167",0.05,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Gallbladder (GB) Ejection Fraction","PRIMARY",NA,"D006939","Gallbladder Functions & Serum Cholecystokinin Levels in Women Diagnosed With Hyperemesis Gravidarum",FALSE,46,"t-test",NA,NA,NA,1.03597838019194
"4019","fbc27ecc7c2efd3ab9e514291a64dd4e","NCT01315002",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Error Percentage in Antisaccade Task","PRIMARY","Null hypothesis is that there was no difference in change of error percentage in the antisaccade task between nicotine and placebo. An ANOVA model was used with treatment (nicotine, placebo) as a within-subjects factor. The test was performed with a significance level of 0.05 (two-sided). Results showed significantly better antisaccade performance (i.e. less antisaccade errors) in the nicotine condition.","D012559","Nicotine Effects on Endophenotypes of Schizophrenia",TRUE,222,"anova",2,NA,NA,2.2017691909032
"4020","fbc4338ca3b71fd7556d2d0690e56eb7","NCT02528253",0.0223,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving RMDQ Reduction of >=30%, >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 48, \>=90%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline RMDQ, baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1010,"logistic_regression",NA,NA,NA,2.34040859934138
"4021","fbe142839b3a9535b212530683f65bea","NCT00279201",0.021,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"MAINTENANCE: Rate of Self-reported Hypoglycemic Episodes","SECONDARY",NA,"D003920; D003924","The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)",FALSE,886,"anova",2,NA,NA,2.08124942296008
"4022","fbf7238cc84016e7da03defb4d446a96","NCT03296527",0.02,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Proportion of Subjects With Cycle Cancellation Due to Poor or Excessive Ovarian Response or Embryo Transfer Cancellation Due to Excessive Ovarian Response / OHSS Risk","SECONDARY","Proportion of participants with cycle cancellation due to poor or excessive response, or transfer cancellation due to excessive response/OHSS risk",NA,"Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women",FALSE,1009,"logistic_regression",NA,NA,NA,2.12780749724582
"4023","fc049ca30e470b5791b3f457dbdf47a3","NCT00377260",0.03,"Logistic regression","INTERVENTIONAL",0,0,0,0,1,"The Distribution of Children With Nasopharyngeal (NP) Colonization With AOM Pathogens at the Follow-up Visit According to Treatment Assignment","SECONDARY","Null hypothesis: There is no difference between the two groups regarding the proportion of culture results with Streptococcus pneumoniae present.","D010031; D010033","Acute Otitis Media (AOM) Therapy Trial in Young Children",FALSE,258,"logistic_regression",NA,NA,NA,1.53873431385305
"4024","fc275eeb79aea3e08d64dcc6a8d2e72e","NCT00459706",0.03,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Participant Satisfaction by Patient Activation Measure (PAM) Score for 2 Different Delivery Mechanisms for Etanercept","SECONDARY","All categories","D001168; D001172","Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept",FALSE,637,"linear_regression",NA,NA,NA,2.40472407218586
"4025","fc3fb3fa9e7026a3f875d9a0659784c8","NCT01532986",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Medical Outcomes Study (MOS)","SECONDARY",NA,"D010300","Randomized Trial to Test the ""Coordinated Care for Health Promotion and Activities in Parkinson's Disease"" Intervention in the VA",FALSE,328,"t-test",NA,NA,NA,2.66881159065383
"4026","fc40890db60e21d2a36e0f6734cdf724","NCT03882047",0.03,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline in Total Nasal Symptom Score Averaged Over Day 1 Through Day 15 (Based on Participant Diaries)","PRIMARY",NA,"D012220; D065631; D006255","Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)",FALSE,208,"anova",2,NA,NA,1.38464436495811
"4027","fc5f32ab23a515d447d44b7456299952","NCT00270998",0.0492,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"""Much Better"" or ""Very Much Better"" on PGI-I at 3 Months","PRIMARY","A priori, the combination treatment was considered superior (75% success rate) to either single-modality therapy (60% success rate) at 80% power with 150 participants per group.","D014549; D004775; D014550","ATLAS: Ambulatory Treatments for Leakage Associated With Stress",TRUE,295,"logistic_regression",NA,NA,NA,2.49873946067788
"4028","fc6dccfe5888ed9a8c7643d8e46d0249","NCT03292432",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Percentage of Days With Dose Taken Within Defined Acceptable Window (+/- 4 Hours) From Weeks 0-12, >12-24, >24-36 and >36-48","SECONDARY","Comparison of percentages of doses taken on time from Weeks \>24 - 36","D015658","Triggered Escalating Real-time Adherence (TERA) Intervention",FALSE,87,"mann_whitney",NA,NA,NA,1.39696496123414
"4029","fc8db73950e385b124437f5baa147d33","NCT00377858",0.022,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"30-Day Adjusted Rates of Self-Reported Hypoglycemic Episodes (Including Nocturnal and Non-Nocturnal)","SECONDARY",NA,"D003920; D003924","Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)",FALSE,479,"anova",2,NA,NA,1.59748985705784
"4030","fc989f521250c9471c5771ea4702847d","NCT04552041",0.0316,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change in Mean Montreal Сognitive Assessment (MoCA) Score","SECONDARY","This analysis applies to ∆ between baseline and 12 weeks row.","D003704; D015140; D001523; D000066553","Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.",FALSE,399,"mann_whitney",NA,NA,NA,1.99418742592053
"4031","fcb522cf0826275af6c51f232003e2dc","NCT02694640",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Min/Week Objectively Measured Moderate-to-vigorous Physical Activity","PRIMARY",NA,"D001943","Peers Promoting Exercise Adoption and Maintenance Among Cancer Survivors",TRUE,161,"linear_regression",NA,NA,NA,1.88118663862499
"4032","fcbac8af3c846ede94c4ae166ff5938b","NCT02658240",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Postoperative Pain Score With Movement","PRIMARY",NA,"D010149","Ultrasound-guided Fascia Iliaca Compartment Block Versus Periarticular Infiltration",FALSE,60,"anova",2,NA,NA,1.17169922891753
"4033","fccbfb8f7bf84a663a489787c16c9e91","NCT01283139",0.042,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants Achieving a Positive Response in SRI (4) in 4-Gene Interferon Test High Participants","PRIMARY",NA,"D008180","A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus",FALSE,175,"logistic_regression",NA,NA,NA,1.6931754957188
"4034","fcd2fe1090011031f64e36c10727a52e","NCT03051633",0.037,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Alcohol Intoxication Initiation","PRIMARY","Discrete time hazard represents the conditional probability that a student will experience first time alcohol initiation during a given measurement period, given that students did not become intoxicated in a previous measurement period. Thus, for each model, we tested the following hypothesis: controlling for age at first assessment, students attending BUYOI-assigned schools will have a lower risk of substance use uptake at the end of their eight grade year","D019966","Substance Use Prevention Campaign for American Indian Youth",FALSE,342,"logistic_regression",NA,NA,NA,2.11395320616153
"4035","fce7f7c6fd582a77a43ce34a8a241dbe","NCT03284853",0.05,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Mean Diurnal Intraocular Pressure by Goldmann Applanation Tonometry","PRIMARY","Assuming no difference between PG324 and Ganfort, a two-tailed alpha of 0.05 (2-sided 95% CI) at each of 9 time points, a common SD of 3.5 mmHg, and a correlation between time points of ≤ 0.60, 200 ITT subjects per arm were necessary to have 85% power to show clinical non-inferiority of PG324 to Ganfort in the mean change from baseline IOP.","D005901; D005902; D009798; D006973","Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension",TRUE,430,"linear_regression",NA,NA,NA,3.05149003252507
"4036","fcf4e6af8bfb3fb94f7822299937d683","NCT02303704",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,1,0,0,"Pharamacological Inotropic Support (Dobutamine)","SECONDARY",NA,NA,"Myocardial Protection With Multiport Antegrade Cold Blood Cardioplegia",TRUE,434,"t-test",NA,NA,NA,3.06552394865376
"4037","fcf5d45062ad1d69bc6432a75f94fae2","NCT00442546",0.0348,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Cumulative Total Amount of Opioids Used During the Entire Hospital Stay","SECONDARY","144 hours","D010003; D010149","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",FALSE,170,"anova",2,NA,NA,1.42407329169528
"4038","fcf611942da96f7d9c3491b316a5e449","NCT03676465",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,0,"Percent Time <70 mg/dL","SECONDARY",NA,"D003920; D003922; D002908","CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management",FALSE,43,"mann_whitney",NA,NA,NA,1.00454908915455
"4039","fd0d32264d1fbc5c55eb3577f2c56a42","NCT04003142",0.027,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Number of Participants With Percent Reduction of >=50% in the Mean Frequency of Moderate and Severe VMS From Baseline to Each Study Week Up to Week 12","SECONDARY","Week 9","D019584","A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2",FALSE,333,"logistic_regression",NA,NA,NA,1.59362181184444
"4040","fd167d0126351d50f990e9f1b898fbaf","NCT01533428",0.05,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With 30% Reduction in Average Daily Pain Score.","SECONDARY","Percentage of participants with 30% reduction in average daily pain score assessed in Weeks 2-12. The comparison of the odds ratio of capsaicin 8% to placebo for percent change from baseline was performed using a logistic regression model.","D010523; D003929","A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)",FALSE,369,"logistic_regression",NA,NA,NA,2.82886095271506
"4041","fd17e81dca1d6c4349483ba3237c32ad","NCT01559259",0.045,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Pain Intensity Difference on 11-Point Numerical Scale (PID11)","SECONDARY","11 hour: Treatment difference and 95% CI were based on LSM from ANOVA with treatment, baseline categorical PSR, baseline numerical PSR, gender and treatment-by-baseline categorical PSR terms used as covariates.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,120,"anova",2,NA,NA,1.49357182186547
"4042","fd1fd917bc78843fba3b9f6544b09fad","NCT04218123",0.05,"ANOVA","INTERVENTIONAL",0,0,1,1,0,"Number of Vertigo Episodes","PRIMARY",NA,"D008575","Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes",TRUE,80,"anova",2,NA,NA,1.34217713699512
"4043","fd38edf5323ffa5e07989c78560b67e7","NCT02528188",0.0248,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response at Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64","SECONDARY","Week 24: \>=70% reduction","D010003; D020370; D015207; D059350","Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee",FALSE,1994,"logistic_regression",NA,NA,NA,3.60136664149172
"4044","fd4c17b0b9644d7262fd3bda68e0a7ac","NCT01968434",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Change in Day Cough Score at End of Study (From D0 to D4)","SECONDARY",NA,"D007239; D012141; D003371","Comparison of Efficacy and Tolerability of Two Cough Syrups in Cough Due to Cold in Children.",TRUE,133,"t-test",NA,NA,NA,1.7140975432625
"4045","fd5c0579e83f948e769dafe741cc0ea3","NCT05970861",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Gut Microbiome","PRIMARY","Null Hypothesis: The freeze-dried mare's milk does not significantly influence the mean percentages of gut microbiota units.

Alternate Hypothesis: The freeze-dried mare's milk significantly influences the mean percentages of gut microbiota units.","D000086382","Effect of Natural Food on Gut Microbiome and Phospholipid Spectrum of Immune Cells in COVID-19 Patients",TRUE,60,"anova",2,NA,NA,1.17169922891753
"4046","fd647bdb62be91616de1209dc6e98821","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Total Sodium","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1753,"linear_regression",NA,NA,NA,6.14051253521365
"4047","fd6d2d15fda88313f91f0c9f42ea3756","NCT02297815",0.008,"Linear regression","OBSERVATIONAL",0,0,0,0,0,"Health Related Quality of Life Score","PRIMARY","Propensity-score based full matching performed using patient and physician-level characteristics. Average treatment effect weights calculated and applied to a weighted linear regression.","D007239; D012852; D010612; D010033","Comparative Effectiveness of Antibiotics for Respiratory Infections",FALSE,2430,"linear_regression",NA,NA,NA,1.46599376751479
"4048","fd78d248d9f70ee66bcdc14f71f4525b","NCT01559259",0.024,"ANOVA","INTERVENTIONAL",0,0,1,0,0,"Time-weighted Sum of Pain Intensity Difference on 11-Point Numerical Scale (SPID11) Over 2, 6, 8 and 12 Hours Post-Dose","SECONDARY","0-2 hours: Treatment difference (Ibuprofen 200 mg + Acetaminophen 500 mg - Ibuprofen 400 mg) and corresponding 95% CI were calculated based on LSM from the ANOVA model.","D014098","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",FALSE,182,"anova",2,NA,NA,1.07109701754967
"4049","fd8aa2d61bd10405c18551f0e39df03c","NCT02709486",0.016,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response","SECONDARY","Week 2, \>=30%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.","D010003; D020370; D015207","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",FALSE,565,"logistic_regression",NA,NA,NA,1.31273283645984
"4050","fd9e34110adfbd64eefd73dcbe57d207","NCT00762528",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"8-iso-prostaglandinF2α (8-iso-PGF2α)","PRIMARY","The null hypothesis states that there is no difference between groups.","D005891","Compare Anti-inflammatory Dentifrices",TRUE,49,"anova",2,NA,NA,1.06649684228356
"4051","fda43722c4cbc6dcf97d4a93236b422b","NCT01047501",0.017,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Apolipoprotein B Levels","SECONDARY",NA,"D015228","Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)",FALSE,446,"mann_whitney",NA,NA,NA,1.23165481147511
"4052","fdb39af0065b54b105e5a7a108de0c10","NCT03687762",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Change in Pain Interference (Macro-level Change)","PRIMARY",NA,"D059350","Back on Track to Healthy Living Study",FALSE,302,"anova",3,NA,NA,1.03237942189705
"4053","fdbb6673e7b61457882976090c7525ff","NCT02964234",0.03,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Changes in Psychosocial Facilitators of Screening Survey Measures","OTHER_PRE_SPECIFIED","Analyses were conducted using GEE with an exchangeable correlation structure and a gamma distribution with log link. All models included study arm, time, and the study arm\*time. Covariates included age, education, and mammography history. With 150 Latinas, alpha = 0.05, power = 0.80, ICC = 0.0-0.05, we expected to detect small/medium interaction effects.","D001943; D001941","Empowering Latinas to Obtain Breast Cancer Screenings",FALSE,110,"linear_regression",NA,NA,NA,1.01714525448484
"4054","fdc940788db89f5aaaadedafa64af953","NCT04271046",0.04,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Dementia Severity Rating Scale (DSRS) - Home Activities & Responsibilities","SECONDARY",NA,"D000544; D000084802","STAR Caregivers - Virtual Training and Follow-up",FALSE,67,"linear_regression",NA,NA,NA,1.02519287579014
"4055","fdd62bbd1e3581b7e5a2f549a368f289","NCT02063516",0.04,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Oropharyngeal Seal Pressure","PRIMARY","It was calculated that 80 adult patients randomized from different surgical department would have 80% power to detect a difference in 2 point in mean. Sampling size was determined using 2 sided t-test (alpha=0.05).",NA,"Comparison of Clinical Performance of the Guardian Laryngeal Mask With LMA Proseal",FALSE,80,"t-test",NA,NA,NA,1.11453001189074
"4056","fde78ae5d4fbde00b0e6261782b70842","NCT03083990",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"AUC0 - ∞","PRIMARY",NA,NA,"Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male",FALSE,98,"anova",2,NA,NA,1.47898140162831
"4057","fe06afa4a7e0689d596526749ed3e972","NCT03039621",0.046,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"ARVI Severity.","SECONDARY",NA,"D007239; D003141; D014777","Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children",FALSE,282,"mann_whitney",NA,NA,NA,2.30992687684497
"4058","fe152aa995c2bda5f4d8b68feb335c10","NCT03843541",0.022,"Mann-Whitney","INTERVENTIONAL",0,0,0,1,0,"Change From Baseline to Day 3 and to Day 7 in Mean Cough Severity Score of NAC and Placebo","SECONDARY",NA,"D012140","A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions",FALSE,218,"mann_whitney",NA,NA,NA,1.0847902392781
"4059","fe195e66fefb70daafa5679f197a7d71","NCT03458702",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"STAI-Y1 Score Assessed at Baseline, Post-Condition and Post-Exposure","PRIMARY",NA,"D001008","The Effects of Emotional Exposure on State Anxiety",FALSE,80,"t-test",NA,NA,NA,1.34217713699512
"4060","fe657db97a29b04b5509eedc48d3bc31","NCT01294644",0.021,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants With a CR-SMFRS 2-grade Response","SECONDARY",NA,NA,"Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat",FALSE,238,"logistic_regression",NA,NA,NA,1.08755266320396
"4061","fe7f0d2dfcdf1ed6bdcb622c672f969c","NCT01056718",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Resting Heart Rate","SECONDARY","Nebivolol treatment group refers to 50 patients that completed 10 weeks of open label nebivolol treatment. Results were compared using paired T-tests in a pre - post study design before and after 10 weeks of his/her treatment. Each subject served as own control.","D006973; D054160","Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function",TRUE,50,"t-test",NA,NA,NA,1.07648023860356
"4062","fe84626938a1922a61661e65bc8e32a6","NCT00759954",0.05,"ANOVA","INTERVENTIONAL",0,1,0,0,0,"Maximum Plasma Morphine Concentration","PRIMARY",NA,NA,"Comparison of One Morphine Sulfate Sustained-Release 200 mg Capsule With Two 100 mg KADIAN Capsules on Applesauce",TRUE,56,"anova",2,NA,NA,1.13456029943022
"4063","fe962ece2ff5f71ad33550593749aad9","NCT01276821",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,1,"Mean Change in Clinical Severity Score","PRIMARY","Null Hypothesis Efficacy of nebulised hypertonic saline (3%) with L-Epinephrine is not higer than as compared to L-Epinephrine given with 0.9% normal saline in the management of children aged 6 weeks to 24 months with mild to moderately severe bronchiolitis.

Alternate Hypothesis:

Nebulised hypertonic saline (3%) with L-Epinephrine is superior to 0.9% Normal saline with L-Epinephrine in the management of children aged 6 weeks to 24 months with mild to moderately severe bronchiolitis.","D001988","Efficacy of Nebulised Hypertonic Saline (3%) Among Children With Bronchiolitis.",TRUE,100,"t-test",NA,NA,NA,1.49341131573029
"4064","fea41330b71226ec99d5e5523705ecbf","NCT02528253",0.04,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Low Back Pain From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/ Last Observation CF (LOCF)","SECONDARY","Week 24: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline PGA of low back pain, baseline average LBPI, and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1010,"logistic_regression",NA,NA,NA,3.86514258477874
"4065","fed3bea0c851cb9b398c378a0dce7c92","NCT02027545",0.049,"Logistic regression","INTERVENTIONAL",0,0,0,0,0,"Concordance Between Screening Orders and Screening Benefit","SECONDARY",NA,"D015179","Promoting Veteran-Centered Colorectal Cancer Screening",FALSE,431,"logistic_regression",NA,NA,NA,3.00378522312531
"4066","fefbaf809ca4580ff2fc9fdda2b67ca2","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Perceived Cost of the Pizza Product.","SECONDARY",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1768,"linear_regression",NA,NA,NA,6.16667069503469
"4067","ff01453229ea0453f354b4ba248f4ae8","NCT01272921",0.05,"Mann-Whitney","INTERVENTIONAL",0,0,0,0,1,"Duration of Motor and Sensory Block of the Sciatic With 0.5% Bupivacaine and Ropivacaine After Ultrasound-guided Nerve-stimulator-Assisted Needle Positioning Beneath the CIEL","PRIMARY","The sample selected for this study,70 per drug group (or 10 in each of the 7 groups), achieves 88% power to detect a minimal difference of 4 hours in duration at a significance level (α) of 0.05 and a standard deviation of 3 hours using Williams test. We chose a difference of 4 hours as this was the interval used for assessment in the postoperative period at night. We sought to detect a difference that was equal to 1 observation period difference.",NA,"The Use of Bupivacaine and Ropivacaine for Sciatic Nerve Block",FALSE,69,"mann_whitney",NA,NA,NA,1.25127183253256
"4068","ff0c06cabaebee97263f1c8f89a3fd9e","NCT00094302",0.02,"Linear regression","INTERVENTIONAL",0,0,0,1,0,"Estimated Glomerular Filtration Rate (GFR)","SECONDARY","Since the p-value for the preceding test (Statistical Analysis 1) was not significant at the 0.05 level, another generalized linear model was fit, omitting the interaction between treatment group and month of visit. This tests whether the value of the post-baseline laboratory parameter differs by treatment group, taking into account that measurements in the same subject over time may be correlated.","D006333; D002318; D006331","Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function",FALSE,3445,"linear_regression",NA,NA,NA,3.92426019095056
"4069","ff1a4d2fdcf8b8864eb445345e99001e","NCT03055156",0.02,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Percentage of Time in Bed During Each Sleep Stage","PRIMARY","Analysis of Wake values","D012893; D020447","Effect of High Rebound Mattress Toppers on Sleep and Sleep-Related Symptoms",FALSE,412,"t-test",NA,NA,NA,1.3649697840912
"4070","ff3aa5e0e1b284a5b1d8fbd016aa809a","NCT03192176",0.0392,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week","SECONDARY","Week 3","D019584","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",FALSE,87,"logistic_regression",NA,NA,NA,1.14031245121406
"4071","ff42bcee42d42c5b1b488443bffb185b","NCT01225822",0.0401,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Number of Participants With VTE Events and All Cause Mortality","SECONDARY","BIBR 1048 150 mg bid vs. Enoxaparin 40 mg qd comparison. Secondary analysis, active control used as reference. The statistical model was a logistic regression which included treatment and centre.","D013923; D054556","BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery",FALSE,757,"logistic_regression",NA,NA,NA,3.35563333179277
"4072","ff4d3f1954371c47dd47e41cda89246a","NCT02122887",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,0,"Changes in Tension as a Function of Perspective-taking and Group","SECONDARY",NA,NA,"Peace-Building Interventions for Israeli and Palestinian Youth",FALSE,79,"anova",2,NA,NA,1.33416755946001
"4073","ff5c0d780aa972df51085d4510197f63","NCT03480022",0.05,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"High Density Lipoprotein Cholesterol (HDL-C)","SECONDARY","Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect","D011085; D011236; D013577; D001835","Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS",FALSE,67,"anova",2,NA,NA,1.23402909436682
"4074","ff603fe557d7b25a724696f5869b4e13","NCT01092663",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Postprandial Glucose (AUC)","PRIMARY","Difference in treatment effect between the 2 groups","D003920; D003924","The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus",FALSE,51,"t-test",NA,NA,NA,1.08637315449684
"4075","ff61f4a48098c809e78785d3f8d136e3","NCT00112151",0.05,"Linear regression","INTERVENTIONAL",0,0,1,0,0,"Lower Body Muscle Strength (1-RM, kg)","SECONDARY","As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in average lower body strength with any T to placebo in subjects assigned to PRT.",NA,"TEAM: Testosterone Supplementation and Exercise in Elderly Men",TRUE,71,"linear_regression",NA,NA,NA,1.26828177971868
"4076","ff66326392b2b3bada8be18c16e68349","NCT00261443",0.047,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Adjusted Mean Change in CGI-BP From Preceding Phase (Overall) Through Phase 3","SECONDARY","Aripiprazole - Placebo; Week 28 Comparison","D001714","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",FALSE,326,"anova",2,NA,NA,2.52642598430683
"4077","ff681288cc78e4cd4c470d1b72615c26","NCT00930943",0.05,"ANOVA","INTERVENTIONAL",0,0,0,0,1,"Spatial Working Memory (SWM) Test Strategy Score","SECONDARY",NA,"D059350","Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning",FALSE,60,"anova",2,NA,NA,1.17169922891753
"4078","ff6db07f5663c5c910eab6eedd0439af","NCT02964767",0.049,"Two-sample t-test","OBSERVATIONAL",0,0,0,0,0,"Comparing CD4+ T Cell Count in HIV-Tb. and HIV Cases.","SECONDARY",NA,"D060085","HIV-Tb Confections Among HIV Patients",TRUE,219,"t-test",NA,NA,NA,2.15051451578633
"4079","ff723cf0a50910ef7c00972f60761aef","NCT03645954",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Rate of Patients Satisfaction","SECONDARY",NA,NA,"Femoral Triangle and Adductor Canal Blocks Versus Femoral Nerve Block for Total Knee Arthroplasty",FALSE,77,"t-test",NA,NA,NA,1.31800316623017
"4080","ff8e130ca7b574f1607621dd53809b92","NCT04854707",0.032,"Mann-Whitney","OBSERVATIONAL",0,0,0,0,0,"Number of Oocytes Retrieved","PRIMARY",NA,"D005831; D007246","An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data",FALSE,2770,"mann_whitney",NA,NA,NA,5.28505432121515
"4081","ffa035ef88bf4de812b6121879781c67","NCT04716010",0.05,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Percentage of Participants Who Support Tax","OTHER_PRE_SPECIFIED",NA,"D003110; D012004","Developing and Evaluating Product Messaging",FALSE,1750,"linear_regression",NA,NA,NA,6.13526752012651
"4082","ffa3aa9ead84bbdb3339b5d9cf8c402d","NCT02912650",0.027,"ANOVA","INTERVENTIONAL",0,0,0,1,0,"Pain Intensity Difference on 4-Point Categorical Scale (PID4)","OTHER_PRE_SPECIFIED","8 hour: Treatment difference and 95% CI were based on LS Mean from ANOVA with treatment, gender and baseline categorical PSR.","D010149","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",FALSE,221,"anova",2,NA,NA,1.30309346199777
"4083","ffa59e207ca7a15db73c15bb9b267295","NCT02528253",0.0269,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Average LBPI Reduction of >=30 Percent(%), >=50%, >=70% and >=90% From Baseline at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/Last Observation Carried Forward (LOCF)","SECONDARY","Week 16, \>=30%: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline average LBPI and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1011,"logistic_regression",NA,NA,NA,2.75429261532183
"4084","ffc02955c6a618912ab727f27ececd05","NCT01240915",0.05,"Logistic regression","INTERVENTIONAL",0,0,1,0,0,"Percentage of Participants With Decrease From Baseline of at Least 1 Point in Rectal Bleeding Mayo Subscore at Weeks 4, 8, 12, and 16","SECONDARY","Pooled MultiStem versus Pooled Placebo (Week 4)","D003092; D003093; D014456","A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis",FALSE,88,"logistic_regression",NA,NA,NA,1.40461812327938
"4085","ffce8d4b48d205a524610cc637aea92d","NCT05009251",0.047,"Linear regression","INTERVENTIONAL",0,0,0,0,0,"Flu Vaccination at 2 Weeks After Final Outreach Date","PRIMARY","Null hypothesis: flu-shot messages that do not mention high-risk status do not increase vaccination relative to no messages; Alternative hypothesis: flu shot messages that do not mention high-risk status increase flu shots relative to no messages.","D007251","Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake",FALSE,16988,"linear_regression",NA,NA,NA,18.1297297434495
"4086","ffd15b6346b855e5741c3b0e0cf0f6dc","NCT01690117",0.05,"Two-sample t-test","INTERVENTIONAL",0,0,0,0,0,"Change From Baseline in Frequency of Problem Behavior on a German Version of the Frequency Subscale of the Revised Memory and Behavior Problem Checklist (RMBPC) - (5-point Scale) at Month 9","SECONDARY",NA,"D003704","German Adaptation of REACH II",TRUE,62,"t-test",NA,NA,NA,1.18983814919554
"4087","ffd44d5419eea6523d588f8696d952e3","NCT02528253",0.0207,"Logistic regression","INTERVENTIONAL",0,0,0,1,0,"Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Low Back Pain From Baseline at Weeks 2, 4, 8, 16, 24, 32, 40, 48 and 56: Mixed Baseline Observation Carried Forward (BOCF)/ Last Observation CF (LOCF)","SECONDARY","Week 16: OR and 95% CI estimated from logistic regression model. Logistic regression model included baseline PGA of low back pain, baseline average LBPI, and treatment.","D001416; D017116","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",FALSE,1010,"logistic_regression",NA,NA,NA,2.19364554777749
"4088","ffe1f8b980005132604e83a8c40a0a59","NCT01070550",0.0247,"Logistic regression","OBSERVATIONAL",0,0,0,0,0,"Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment","SECONDARY","The statistical analysis is presented for BMI in kg/m\^2. The logistic regression analysis for relapse 24 weeks after EOT was performed for association between treatment exposure and baseline factors available in at least 90% of participants (including cumulative dose of peginterferon and ribavirin up to Week 12), in naive HCV mono-infected mTRT participants receiving PEG-IFN alfa-2a.","D006506; D006526; D019698; D006505","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",FALSE,227,"logistic_regression",NA,NA,NA,1.22285507246175
